

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/12, 15/18, 15/52, C07K 14/47, 14/705, C12N 15/62, C07K 16/18, 16/28</b>		A2	(11) International Publication Number: <b>WO 99/14328</b>
(21) International Application Number: <b>PCT/US98/19330</b>		60/066,770	24 November 1997 (24.11.97) US
(22) International Filing Date:	16 September 1998 (16.09.98)	60/066,511	24 November 1997 (24.11.97) US
		60/066,453	24 November 1997 (24.11.97) US
		60/066,840	25 November 1997 (25.11.97) US
(30) Priority Data:			
60/059,115	17 September 1997 (17.09.97)	US	(71) Applicant (for all designated States except US): GENENTECH, INC. [US/US]; One DNA Way, South San Francisco, CA 94080 (US).
60/059,184	17 September 1997 (17.09.97)	US	
60/059,122	17 September 1997 (17.09.97)	US	
60/059,117	17 September 1997 (17.09.97)	US	
60/059,113	17 September 1997 (17.09.97)	US	
60/059,121	17 September 1997 (17.09.97)	US	
60/059,119	17 September 1997 (17.09.97)	US	
60/059,263	18 September 1997 (18.09.97)	US	
60/059,266	18 September 1997 (18.09.97)	US	
60/062,125	15 October 1997 (15.10.97)	US	
60/062,287	17 October 1997 (17.10.97)	US	
60/062,285	17 October 1997 (17.10.97)	US	
60/063,486	21 October 1997 (21.10.97)	US	
60/062,816	24 October 1997 (24.10.97)	US	
60/062,814	24 October 1997 (24.10.97)	US	
60/063,127	24 October 1997 (24.10.97)	US	
60/063,120	24 October 1997 (24.10.97)	US	
60/063,121	24 October 1997 (24.10.97)	US	
60/063,045	24 October 1997 (24.10.97)	US	
60/063,128	24 October 1997 (24.10.97)	US	
60/063,329	27 October 1997 (27.10.97)	US	
60/063,327	27 October 1997 (27.10.97)	US	
60/063,349	28 October 1997 (28.10.97)	US	
60/063,541	28 October 1997 (28.10.97)	US	
60/063,550	28 October 1997 (28.10.97)	US	
60/063,542	28 October 1997 (28.10.97)	US	
60/063,544	28 October 1997 (28.10.97)	US	
60/063,564	28 October 1997 (28.10.97)	US	
60/063,734	29 October 1997 (29.10.97)	US	
60/063,738	29 October 1997 (29.10.97)	US	
60/063,704	29 October 1997 (29.10.97)	US	
60/063,435	29 October 1997 (29.10.97)	US	
60/064,215	29 October 1997 (29.10.97)	US	
60/063,735	29 October 1997 (29.10.97)	US	
60/063,732	29 October 1997 (29.10.97)	US	
60/064,103	31 October 1997 (31.10.97)	US	
60/063,870	31 October 1997 (31.10.97)	US	
60/064,248	3 November 1997 (03.11.97)	US	
60/064,809	7 November 1997 (07.11.97)	US	
60/065,186	12 November 1997 (12.11.97)	US	
60/065,846	17 November 1997 (17.11.97)	US	
60/065,693	18 November 1997 (18.11.97)	US	
60/066,120	21 November 1997 (21.11.97)	US	
60/066,364	21 November 1997 (21.11.97)	US	
60/066,772	24 November 1997 (24.11.97)	US	
60/066,466	24 November 1997 (24.11.97)	US	

(54) Title: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

## (57) Abstract

The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptides molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

## Published

Without international search report and to be republished upon receipt of that report.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME****FIELD OF THE INVENTION**

The present invention relates generally to the identification and isolation of novel DNA and to the recombinant production of novel polypeptides encoded by that DNA.

5

**BACKGROUND OF THE INVENTION**

Extracellular and membrane-bound proteins play important roles in the formation, differentiation and maintenance of multicellular organisms. The fate of many individual cells, e.g., proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from other cells and/or 10 the immediate environment. This information is often transmitted by secreted polypeptides (for instance, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones) which are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins. These secreted polypeptides or signaling molecules normally pass through the cellular secretory pathway to reach their site of action in the extracellular environment, usually at a membrane-bound receptor protein.

15 Secreted proteins have various industrial applications, including use as pharmaceuticals, diagnostics, biosensors and bioreactors. In fact, most protein drugs available at present, such as thrombolytic agents, interferons, interleukins, erythropoietins, colony stimulating factors, and various other cytokines, are secretory proteins. Their receptors, which are membrane-bound proteins, also have potential as therapeutic or diagnostic agents. Receptor immunoadhesins, for instance, can be employed as therapeutic agents to block receptor-ligand interaction.  
20 Membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. Such membrane-bound proteins and cell receptors include, but are not limited to, cytokine receptors, receptor kinases, receptor phosphatases, receptors involved in cell-cell interactions, and cellular adhesin molecules like selectins and integrins. Transduction of signals that regulate cell growth and differentiation is regulated in part by phosphorylation of various cellular proteins. Protein tyrosine kinases, enzymes  
25 that catalyze that process, can also act as growth factor receptors. Examples include fibroblast growth factor receptor and nerve growth factor receptor.

Efforts are being undertaken by both industry and academia to identify new, native secreted and membrane-bound receptor proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted and membrane-bound receptor proteins. Examples of screening 30 methods and techniques are described in the literature [see, for example, Klein et al., *Proc. Natl. Acad. Sci.*, **93**:7108-7113 (1996); U.S. Patent No. 5,536,637].

We herein describe the identification and characterization of novel secreted and transmembrane polypeptides and novel nucleic acids encoding those polypeptides.

### 1. PRO211 and PRO217

Epidermal growth factor (EGF) is a conventional mitogenic factor that stimulates the proliferation of various types of cells including epithelial cells and fibroblasts. EGF binds to and activates the EGF receptor (EGFR), which initiates intracellular signaling and subsequent effects. The EGFR is expressed in neurons of the cerebral cortex, cerebellum, and hippocampus in addition to other regions of the central nervous system (CNS). In addition, EGF is 5 also expressed in various regions of the CNS. Therefore, EGF acts not only on mitotic cells, but also on postmitotic neurons. In fact, many studies have indicated that EGF has neurotrophic or neuromodulatory effects on various types of neurons in the CNS. For example, EGF acts directly on cultured cerebral cortical and cerebellar neurons, enhancing neurite outgrowth and survival. On the other hand, EGF also acts on other cell types, including septal cholinergic and mesencephalic dopaminergic neurons, indirectly through glial cells. Evidence of the effects of EGF 10 on neurons in the CNS is accumulating, but the mechanisms of action remain essentially unknown. EGF-induced signaling in mitotic cells is better understood than in postmitotic neurons. Studies of cloned pheochromocytoma PC12 cells and cultured cerebral cortical neurons have suggested that the EGF-induced neurotrophic actions are mediated by sustained activation of the EGFR and mitogen-activated protein kinase (MAPK) in response to EGF. The sustained intracellular signaling correlates with the decreased rate of EGFR down-regulation, which might determine 15 the response of neuronal cells to EGF. It is likely that EGF is a multi-potent growth factor that acts upon various types of cells including mitotic cells and postmitotic neurons.

EGF is produced by the salivary and Brunner's glands of the gastrointestinal system, kidney, pancreas, thyroid gland, pituitary gland, and the nervous system, and is found in body fluids such as saliva, blood, cerebrospinal fluid (CSF), urine, amniotic fluid, prostatic fluid, pancreatic juice, and breast milk, Plata-Salaman, 20 *Peptides* 12: 653-663 (1991).

EGF is mediated by its membrane specific receptor, which contains an intrinsic tyrosine kinase. Stoscheck *et al.*, *J. Cell Biochem.* 31: 135-152 (1986). EGF is believed to function by binding to the extracellular portion of its receptor which induces a transmembrane signal that activates the intrinsic tyrosine kinase.

Purification and sequence analysis of the EGF-like domain has revealed the presence of six conserved 25 cysteine residues which cross-bind to create three peptide loops, Savage *et al.*, *J. Biol. Chem.* 248: 7669-7672 (1979). It is now generally known that several other peptides can react with the EGF receptor which share the same generalized motif  $X_nCX_7CX_{4-5}CX_{10}CXCX_5GX_2CX_n$ , where X represents any non-cysteine amino acid, and n is a variable repeat number. Non isolated peptides having this motif include TGF- $\alpha$ , amphiregulin, schwannoma-derived growth factor (SDGF), heparin-binding EGF-like growth factors and certain virally encoded peptides (e.g., Vaccinia 30 virus, Reisner, *Nature* 313: 801-803 (1985), Shope fibroma virus, Chang *et al.*, *Mol Cell Biol.* 7: 535-540 (1987), Molluscum contagiosum, Porter and Archard, *J. Gen. Virol.* 68: 673-682 (1987), and Myxoma virus, Upton *et al.*, *J. Virol.* 61: 1271-1275 (1987), Prigent and Lemoine, *Prog. Growth Factor Res.* 4: 1-24 (1992).

EGF-like domains are not confined to growth factors but have been observed in a variety of cell-surface and extracellular proteins which have interesting properties in cell adhesion, protein-protein interaction and development, 35 Laurence and Gusterson, *Tumor Biol.* 11: 229-261 (1990). These proteins include blood coagulation factors (factors VI, IX, X, XII, protein C, protein S, protein Z, tissue plasminogen activator, urokinase), extracellular matrix components (laminin, cytотactин, entactin), cell surface receptors (LDL receptor, thrombomodulin receptor) and

immunity-related proteins (complement Clr, uromodulin).

Even more interesting, the general structure pattern of EGF-like precursors is preserved through lower organisms as well as in mammalian cells. A number of genes with developmental significance have been identified in invertebrates with EGF-like repeats. For example, the *notch* gene of *Drosophila* encodes 36 tandemly arranged 40 amino acid repeats which show homology to EGF, Wharton *et al.*, *Cell* 43: 557-581 (1985). Hydropathy plots indicate a putative membrane spanning domain, with the EGF-related sequences being located on the extracellular side of the membrane. Other homeotic genes with EGF-like repeats include Delta, 95F and 5ZD which were identified using probes based on Notch, and the nematode gene *Lin-12* which encodes a putative receptor for a developmental signal transmitted between two specified cells.

Specifically, EGF has been shown to have potential in the preservation and maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions, Konturek *et al.*, *Eur. J. Gastroenterol Hepatol.* 7 (10), 933-37 (1995), including the treatment of necrotizing enterocolitis, Zollinger-Ellison syndrome, gastrointestinal ulceration gastrointestinal ulcerations and congenital microvillus atrophy, Guglietta and Sullivan, *Eur. J. Gastroenterol Hepatol.* 7(10), 945-50 (1995). Additionally, EGF has been implicated in hair follicle differentiation; du Cros, *J. Invest. Dermatol.* 101 (1 Suppl.), 106S-113S (1993), Hillier, *Clin. Endocrinol.* 93(4), 427-28 (1990); kidney function, Hamm *et al.*, *Semin. Nephrol.* 13 (1): 109-15 (1993), Harris, *Am. J. Kidney Dis.* 17(6): 627-30 (1991); tear fluid, van Setten *et al.*, *Int. Ophthalmol.* 15(6): 359-62 (1991); vitamin K mediated blood coagulation, Stenflo *et al.*, *Blood* 78(7): 1637-51 (1991). EGF is also implicated various skin disease characterized by abnormal keratinocyte differentiation, e.g., psoriasis, epithelial cancers such as squamous cell carcinomas of the lung, epidermoid carcinoma of the vulva and gliomas. King *et al.*, *Am. J. Med. Sci.* 296: 154-158 (1988).

Of great interest is mounting evidence that genetic alterations in growth factors signaling pathways are closely linked to developmental abnormalities and to chronic diseases including cancer. Aaronson, *Science* 254: 1146-1153 (1991). For example, c-erb-2 (also known as HER-2), a proto-oncogene with close structural similarity to EGF receptor protein, is overexpressed in human breast cancer. King *et al.*, *Science* 229: 974-976 (1985); Gullick, *Hormones and their actions*, Cooke *et al.*, eds, Amsterdam, Elsevier, pp 349-360 (1986).

We herein describe the identification and characterization of novel polypeptides having homology to EGF, wherein those polypeptides are herein designated PRO211 and PRO217.

## 2. PRO230

Nephritis is a condition characterized by inflammation of the kidney affecting the structure and normal function of the kidney. This condition can be chronic or acute and is generally caused by infection, degenerative process or vascular disease. In all cases, early detection is desirable so that the patient with nephritis can begin treatment of the condition.

An approach to detecting nephritis is to determine the antigens associated with nephritis and antibodies thereto. In rabbit, a tubulointerstitial nephritis antigen (TIN-ag) has been reported in Nelson, T. R., et al., *J. Biol. Chem.*, 270(27):16265-70 (July 1995) (GENBANK/U24270). This study reports that the rabbit TIN-ag is a basement membrane glycoprotein having a predicted amino acid sequence which has a carboxyl-terminal region exhibiting 30% homology with human preprocathepsin B, a member of the cysteine proteinase family of proteins. It is also reported

that the rabbit TIN-ag has a domain in the amino-terminal region containing an epidermal growth factor-like motif that shares homology with laminin A and S chains, alpha 1 chain of type I collagen, von Willebrand's factor and mucin, indicating structural and functional similarities. Studies have also been conducted in mice. However, it is desirable to identify tubulointerstitial nephritis antigens in humans to aid in the development of early detection methods and treatment of nephritis.

5       Proteins which have homology to tubulointerstitial nephritis antigens are of particular interest to the medical and industrial communities. Often, proteins having homology to each other have similar function. It is also of interest when proteins having homology do not have similar functions, indicating that certain structural motifs identify information other than function, such as locality of function. We herein describe the identification and characterization of a novel polypeptide, designated hgerein as PRO230, which has homology to tubulointerstitial  
10     nephritis antigens.

### 3. PRO232

15     Stem cells are undifferentiated cells capable of (a) proliferation, (b) self maintenance, (c) the production of a large number of differentiated functional progeny, (d) regeneration of tissue after injury and/or (e) a flexibility in the use of these options. Stem cells often express cell surface antigens which are capable of serving as cell specific markers that can be exploited to identify stem cells, thereby providing a means for identifying and isolating specific stem cell populations.

Having possession of different stem cell populations will allow for a number of important applications. For example, possessing a specific stem cell population will allow for the identification of growth factors and other 20     proteins which are involved in their proliferation and differentiation. In addition, there may be as yet undiscovered proteins which are associated with (1) the early steps of dedication of the stem cell to a particular lineage, (2) prevention of such dedication, and (3) negative control of stem cell proliferation, all of which may be identified if one has possession of the stem cell population. Moreover, stem cells are important and ideal targets for gene therapy where the inserted genes promote the health of the individual into whom the stem cells are transplanted. Finally, stem 25     cells may play important roles in transplantation of organs or tissues, for example liver regeneration and skin grafting.

Given the importance of stem cells in various different applications, efforts are currently being undertaken by both industry and academia to identify new, native stem cell antigen proteins so as to provide specific cell surface markers for identifying stem cell populations as well as for providing insight into the functional roles played by stem 30     cell antigens in cell proliferation and differentiation. We herein describe the identification and characterization of novel polypeptides having homology to a stem cell antigen, wherein those polypeptides are herein designated as PRO232 polypeptides..

### 4. PRO187

35     Growth factors are molecular signals or mediators that enhance cell growth or proliferation, alone or in concert, by binding to specific cell surface receptors. However, there are other cellular reactions than only growth upon expression to growth factors. As a result, growth factors are better characterized as multifunctional and potent

cellular regulators. Their biological effects include proliferation, chemotaxis and stimulation of extracellular matrix production. Growth factors can have both stimulatory and inhibitory effects. For example, transforming growth factor (TGF- $\beta$ ) is highly pleiotropic and can stimulate proliferation in some cells, especially connective tissue, while being a potent inhibitor of proliferation in others, such as lymphocytes and epithelial cells.

The physiological effect of growth stimulation or inhibition by growth factors depends upon the state of development and differentiation of the target tissue. The mechanism of local cellular regulation by classical endocrine molecules involves comprehends autocrine (same cell), juxtacrine (neighbor cell), and paracrine (adjacent cells) pathways. Peptide growth factors are elements of a complex biological language, providing the basis for intercellular communication. They permit cells to convey information between each other, mediate interaction between cells and change gene expression. The effect of these multifunctional and pluripotent factors is dependent on the presence or absence of other peptides.

FGF-8 is a member of the fibroblast growth factors (FGFs) which are a family of heparin-binding, potent mitogens for both normal diploid fibroblasts and established cell lines, Gospodarowicz *et al.* (1984), *Proc. Natl. Acad. Sci. USA* **81**:6963. The FGF family comprises acidic FGF (FGF-1), basic FGF (FGF-2), INT-2 (FGF-3), K-FGF/HST (FGF-4), FGF-5, FGF-6, KGF (FGF-7), AIGF (FGF-8) among others. All FGFs have two conserved cysteine residues and share 30-50% sequence homology at the amino acid level. These factors are mitogenic for a wide variety of normal diploid mesoderm-derived and neural crest-derived cells, including granulosa cells, adrenal cortical cells, chondrocytes, myoblasts, corneal and vascular endothelial cells (bovine or human), vascular smooth muscle cells, lens, retina and prostatic epithelial cells, oligodendrocytes, astrocytes, chondrocytes, myoblasts and osteoblasts.

Fibroblast growth factors can also stimulate a large number of cell types in a non-mitogenic manner. These activities include promotion of cell migration into wound area (chemotaxis), initiation of new blood vessel formulation (angiogenesis), modulation of nerve regeneration and survival (neurotrophism), modulation of endocrine functions, and stimulation or suppression of specific cellular protein expression, extracellular matrix production and cell survival. Baird & Bohlen, *Handbook of Exp. Pharmacol.* **95**(1): 369-418, Springer, (1990). These properties provide a basis for using fibroblast growth factors in therapeutic approaches to accelerate wound healing, nerve repair, collateral blood vessel formation, and the like. For example, fibroblast growth factors have been suggested to minimize myocardium damage in heart disease and surgery (U.S.P. 4,378,347).

FGF-8, also known as androgen-induced growth factor (AIGF), is a 215 amino acid protein which shares 30-40% sequence homology with the other members of the FGF family. FGF-8 has been proposed to be under androgenic regulation and induction in the mouse mammary carcinoma cell line SC3. Tanaka *et al.*, *Proc. Natl. Acad. Sci. USA* **89**: 8928-8932 (1992); Sato *et al.*, *J. Steroid Biochem. Molec. Biol.* **47**: 91-98 (1993). As a result, FGF-8 may have a local role in the prostate, which is known to be an androgen-responsive organ. FGF-8 can also be oncogenic, as it displays transforming activity when transfected into NIH-3T3 fibroblasts. Kouhara *et al.*, *Oncogene* **9** 455-462 (1994). While FGF-8 has been detected in heart, brain, lung, kidney, testis, prostate and ovary, expression was also detected in the absence of exogenous androgens. Schmitt *et al.*, *J. Steroid Biochem. Mol. Biol.* **57** (3-4): 173-78 (1996).

FGF-8 shares the property with several other FGFs of being expressed at a variety of stages of murine embryogenesis, which supports the theory that the various FGFs have multiple and perhaps coordinated roles in differentiation and embryogenesis. Moreover, FGF-8 has also been identified as a protooncogene that cooperates with Wnt-1 in the process of mammary tumorigenesis (Shackleford *et al.*, *Proc. Natl. Acad. Sci. USA* **90**, 740-744 (1993); Heikinheimo *et al.*, *Mech. Dev.* **48**: 129-138 (1994)).

5 In contrast to the other FGFs, FGF-8 exists as three protein isoforms, as a result of alternative splicing of the primary transcript. Tanaka *et al.*, *supra*. Normal adult expression of FGF-8 is weak and confined to gonadal tissue, however northern blot analysis has indicated that FGF-8 mRNA is present from day 10 through day 12 or murine gestation, which suggests that FGF-8 is important to normal development. Heikinheimo *et al.*, *Mech Dev.* **48**(2): 129-38 (1994). Further *in situ* hybridization assays between day 8 and 16 of gestation indicated initial  
10 expression in the surface ectoderm of the first bronchial arches, the frontonasal process, the forebrain and the midbrain-hindbrain junction. At days 10-12, FGF-8 was expressed in the surface ectoderm of the forelimb and hindlimb buds, the nasal pits and nasopharynx, the infundibulum and in the telencephalon, diencephalon and metencephalon. Expression continues in the developing hindlimbs through day 13 of gestation, but is undetectable thereafter. The results suggest that FGF-8 has a unique temporal and spatial pattern in embryogenesis and suggests  
15 a role for this growth factor in multiple regions of ectodermal differentiation in the post-gastrulation embryo.

We herein describe the identification of novel polypeptides having homology to FGF-8, wherein those polypeptides are herein designated PRO187 polypeptides.

##### 5. PRO265

20 Protein-protein interactions include receptor and antigen complexes and signaling mechanisms. As more is known about the structural and functional mechanisms underlying protein-protein interactions, protein-protein interactions can be more easily manipulated to regulate the particular result of the protein-protein interaction. Thus, the underlying mechanisms of protein-protein interactions are of interest to the scientific and medical community.

All proteins containing leucine-rich repeats are thought to be involved in protein-protein interactions.  
25 Leucine-rich repeats are short sequence motifs present in a number of proteins with diverse functions and cellular locations. The crystal structure of ribonuclease inhibitor protein has revealed that leucine-rich repeats correspond to beta-alpha structural units. These units are arranged so that they form a parallel beta-sheet with one surface exposed to solvent, so that the protein acquires an unusual, nonglobular shape. These two features have been indicated as responsible for the protein-binding functions of proteins containing leucine-rich repeats. See, Kobe and  
30 Deisenhofer, *Trends Biochem. Sci.*, 19(10):415-421 (Oct. 1994).

A study has been reported on leucine-rich proteoglycans which serve as tissue organizers, orienting and ordering collagen fibrils during ontogeny and are involved in pathological processes such as wound healing, tissue repair, and tumor stroma formation. Iozzo, R. V., *Crit. Rev. Biochem. Mol. Biol.*, 32(2):141-174 (1997). Other studies implicating leucine rich proteins in wound healing and tissue repair are De La Salle, C., et al., *Vouv. Rev. Fr. Hematol.* (Germany), 37(4):215-222 (1995), reporting mutations in the leucine rich motif in a complex associated with the bleeding disorder Bernard-Soulier syndrome and Chlemetson, K. J., *Thromb. Haemost.* (Germany), 74(1):111-116 (July 1995), reporting that platelets have leucine rich repeats. Another protein of particular interest

which has been reported to have leucine-rich repeats is the SLIT protein which has been reported to be useful in treating neuro-degenerative diseases such as Alzheimer's disease, nerve damage such as in Parkinson's disease, and for diagnosis of cancer, see, Artavanistsakonas, S. and Rothberg, J. M., WO9210518-A1 by Yale University. Other studies reporting on the biological functions of proteins having leucine-rich repeats include: Tayar, N., et al., Mol. Cell Endocrinol., (Ireland), 125(1-2):65-70 (Dec. 1996) (gonadotropin receptor involvement); Miura, Y., et al., 5 Nippon Rinsho (Japan), 54(7):1784-1789 (July 1996) (apoptosis involvement); Harris, P. C., et al., J. Am. Soc. Nephrol., 6(4):1125-1133 (Oct. 1995) (kidney disease involvement); and Ruoslahti, E. I., et al., WO9110727-A by La Jolla Cancer Research Foundation (decorin binding to transforming growth factor- $\beta$  involvement for treatment for cancer, wound healing and scarring). Also of particular interest is fibromodulin and its use to prevent or reduce dermal scarring. A study of fibromodulin is found in U.S. Patent No. 5,654,270 to Ruoslahti, et al.

10 Efforts are therefore being undertaken by both industry and academia to identify new proteins having leucine rich repeats to better understand protein-protein interactions. Of particular interest are those proteins having leucine rich repeats and homology to known proteins having leucine rich repeats such as fibromodulin, the SLIT protein and platelet glycoprotein V. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted and membrane-bound proteins having leucine rich repeats. We 15 herein describe the identification and characterization of novel polypeptides having homology to fibromodulin, herein designated as PRO265 polypeptides.

#### 6. PRO219

Human matrilin-2 polypeptide is a member of the von Willebrand factor type A-like module superfamily. 20 von Willebrand factor is a protein which plays an important role in the maintenance of hemostasis. More specifically, von Willebrand factor is a protein which is known to participate in platelet-vessel wall interactions at the site of vascular injury via its ability to interact and form a complex with Factor VIII. The absence of von Willebrand factor in the blood causes an abnormality with the blood platelets that prevents platelet adhesion to the vascular wall at the site of the vascular injury. The result is the propensity for bruising, nose bleeds, intestinal bleeding, and the like 25 comprising von Willebrand's disease.

Given the physiological importance of the blood clotting factors, efforts are currently being undertaken by both industry and academia to identify new, native proteins which may be involved in the coagulation process. We herein describe the identification of a novel full-length polypeptide which possesses homology to the human matrilin-2 precursor polypeptide.

30

#### 7. PRO246

The cell surface protein HCAR is a membrane-bound protein that acts as a receptor for subgroup C of the adenoviruses and subgroup B of the coxsackieviruses. Thus, HCAR may provide a means for mediating viral infection of cells in that the presence of the HCAR receptor on the cellular surface provides a binding site for viral 35 particles, thereby facilitating viral infection.

In light of the physiological importance of membrane-bound proteins and specifically those which serve a cell surface receptor for viruses, efforts are currently being undertaken by both industry and academia to identify

new, native membrane-bound receptor proteins. Many of these efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel receptor proteins. We herein describe a novel membrane-bound polypeptide (designated herein as PRO246) having homology to the cell surface protein HCAR and to various tumor antigens including A33 and carcinoembryonic antigen, wherein this polypeptide may be a novel cell surface virus receptor or tumor antigen.

5

#### 8. PRO228

There are a number of known seven transmembrane proteins and within this family is a group which includes CD97 and EMR1. CD97 is a seven-span transmembrane receptor which has a cellular ligand, CD55, DAF. Hamann, et al., J. Exp. Med. (U.S.), 184(3):1189 (1996). Additionally, CD97 has been reported as being a dedifferentiation marker in human thyroid carcinomas and as associated with inflammation. Aust, et al., Cancer Res. (U.S.), 57(9):1798 (1997); Gray, et al., J. Immunol. (U.S.), 157(12):5438 (1996). CD97 has also been reported as being related to the secretin receptor superfamily, but unlike known members of that family, CD97 and EMR1 have extended extracellular regions that possess several EGF domains at the N-terminus. Hamann, et al., Genomics, 32(1):144 (1996); Harmann, et al., J. Immunol., 155(4):1942 (1995). EMR1 is further described in Lin, et al., Genomics, 41(3):301 (1997) and Baud, et al., Genomics, 26(2):334 (1995). While CD97 and EMR1 appear to be related to the secretin receptors, a known member of the secretin family of G protein-coupled receptors includes the alpha-latrotoxin receptor, latrophilin, which has been described as calcium independent and abundant among neuronal tissues. Lelianova, et al., J. Biol. Chem., 272(34), 21504 (1997); Davletov, et al., J. Biol. Chem. (U.S.), 271(38):23239 (1996). Both members of the secretin receptor superfamily and non-members which are related to the secretin receptor superfamily, or CRF and calcitonin receptors are of interest. In particular, new members of these families, identified by their homology to known proteins, are of interest.

Efforts are being undertaken by both industry and academia to identify new membrane-bound receptor proteins, particularly transmembrane proteins with EGF repeats and large N-terminuses which may belong to the family of seven-transmembrane proteins of which CD97 and EMR1 are members. We herein describe the identification and characterization of novel polypeptides having homology to CD97 and EMR1, designated herein as PRO228 polypeptides.

#### 9. PRO533

Growth factors are molecular signals or mediators that enhance cell growth or proliferation, alone or in concert, by binding to specific cell surface receptors. However, there are other cellular reactions than only growth upon expression to growth factors. As a result, growth factors are better characterized as multifunctional and potent cellular regulators. Their biological effects include proliferation, chemotaxis and stimulation of extracellular matrix production. Growth factors can have both stimulatory and inhibitory effects. For example, transforming growth factors (TGF- $\beta$ ) is highly pleiotropic and can stimulate proliferation in some cells, especially connective tissues, while being a potent inhibitor of proliferation in others, such as lymphocytes and epithelial cells.

The physiological effect of growth stimulation or inhibition by growth factors depends upon the state of development and differentiation of the target tissue. The mechanism of local cellular regulation by classical endocrine

molecules comprehends autocrine (same cell), juxtacrine (neighbor cell), and paracrine (adjacent cell) pathways. Peptide growth factors are elements of a complex biological language, providing the basis for intercellular communication. They permit cells to convey information between each other, mediate interaction between cells and change gene expression. the effect of these multifunctional and pluripotent factors is dependent on the presence or absence of other peptides.

5        Fibroblast growth factors (FGFs) are a family of heparin-binding, potent mitogens for both normal diploid fibroblasts and established cell lines, Godpodarowicz, D. et al. (1984), Proc. Natl. Acad. Sci. USA 81: 6983. the FGF family comprises acidic FGF (FGF-1), basic FGF (FGF-2), INT-2 (FGF-3), K-FGF/HST (FGF-4), FGF-5, FGF-6, KGF (FGF-7), AIGF (FGF-8) among others. All FGFs have two conserved cysteine residues and share 30-50% sequence homology at the amino acid level. These factors are mitogenic for a wide variety of normal diploid mesoderm-derived  
10      and neural crest-derived cells, inducing granulosa cells, adrenal cortical cells, chondrocytes, myoblasts, corneal and vascular endothelial cells (bovine or human), vascular smooth muscle cells, lens, retina and prostatic epithelial cells, oligodendrocytes, astrocytes, chondrocytes, myoblasts and osteoblasts.

Fibroblast growth factors can also stimulate a large number of cell types in a non-mitogenic manner. These activities include promotion of cell migration into a wound area (chemotaxis), initiation of new blood vessel formulation  
15      (angiogenesis), modulation of nerve regeneration and survival (neurotrophism), modulation of endocrine functions, and stimulation or suppression of specific cellular protein expression, extracellular matrix production and cell survival. Baird, A. & Bohlen, P., *Handbook of Exp. Pharmacol.* 95(1): 369-418 (1990). These properties provide a basis for using fibroblast growth factors in therapeutic approaches to accelerate wound healing, nerve repair, collateral blood vessel formation, and the like. For example, fibroblast growth factors, have been suggested to minimize myocardium  
20      damage in heart disease and surgery (U.S.P. 4,378,437).

We herein describe the identification and characterization of novel polypeptides having homology to FGF, herein designated PRO533 polypeptides.

#### 10. PRO245

25       Some of the most important proteins involved in the above described regulation and modulation of cellular processes are the enzymes which regulate levels of protein phosphorylation in the cell. For example, it is known that the transduction of signals that regulate cell growth and differentiation is regulated at least in part by phosphorylation and dephosphorylation of various cellular proteins. The enzymes that catalyze these processes include the protein kinases, which function to phosphorylate various cellular proteins, and the protein phosphatases, which function to  
30      remove phosphate residues from various cellular proteins. The balance of the level of protein phosphorylation in the cell is thus mediated by the relative activities of these two types of enzymes.

Although many protein kinase enzymes have been identified, the physiological role played by many of these catalytic proteins has yet to be elucidated. It is well known, however, that a number of the known protein kinases function to phosphorylate tyrosine residues in proteins, thereby leading to a variety of different effects. Perhaps most  
35      importantly, there has been a great deal of interest in the protein tyrosine kinases since the discovery that many oncogene products and growth factors possess intrinsic protein tyrosine kinase activity. There is, therefore, a desire to identify new members of the protein tyrosine kinase family.

Given the physiological importance of the protein kinases, efforts are being undertaken by both industry and academia to identify new, native kinase proteins. Many of these efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel kinase proteins. We herein describe the identification and characterization of novel polypeptides having homology to tyrosine kinase proteins, designated herein as PRO245 polypeptides.

5

11. **PRO220, PRO221 and PRO227**

Protein-protein interactions include receptor and antigen complexes and signaling mechanisms. As more is known about the structural and functional mechanisms underlying protein-protein interactions, protein-protein interactions can be more easily manipulated to regulate the particular result of the protein-protein interaction. Thus, 10 the underlying mechanisms of protein-protein interactions are of interest to the scientific and medical community.

All proteins containing leucine-rich repeats are thought to be involved in protein-protein interactions. Leucine-rich repeats are short sequence motifs present in a number of proteins with diverse functions and cellular locations. The crystal structure of ribonuclease inhibitor protein has revealed that leucine-rich repeats correspond to beta-alpha structural units. These units are arranged so that they form a parallel beta-sheet with one surface 15 exposed to solvent, so that the protein acquires an unusual, nonglobular shape. These two features have been indicated as responsible for the protein-binding functions of proteins containing leucine-rich repeats. See, Kobe and Deisenhofer, *Trends Biochem. Sci.*, 19(10):415-421 (Oct. 1994).

A study has been reported on leucine-rich proteoglycans which serve as tissue organizers, orienting and ordering collagen fibrils during ontogeny and are involved in pathological processes such as wound healing, tissue 20 repair, and tumor stroma formation. Iozzo, R. V., *Crit. Rev. Biochem. Mol. Biol.*, 32(2):141-174 (1997). Other studies implicating leucine rich proteins in wound healing and tissue repair are De La Salle, C., et al., *Vouv. Rev. Fr. Hematol.* (Germany), 37(4):215-222 (1995), reporting mutations in the leucine rich motif in a complex associated with the bleeding disorder Bernard-Soulier syndrome and Chiemetson, K. J., *Thromb. Haemost.* (Germany), 74(1):111-116 (July 1995), reporting that platelets have leucine rich repeats. Another protein of particular interest 25 which has been reported to have leucine-rich repeats is the SLIT protein which has been reported to be useful in treating neuro-degenerative diseases such as Alzheimer's disease, nerve damage such as in Parkinson's disease, and for diagnosis of cancer, see, Artavanistsakonas, S. and Rothberg, J. M., WO9210518-A1 by Yale University. Other studies reporting on the biological functions of proteins having leucine-rich repeats include: Tayar, N., et al., *Mol. Cell Endocrinol.*, 125(1-2):65-70 (Dec. 1996) (gonadotropin receptor involvement); Miura, Y., et al., 30 *Nippon Rinsho* (Japan), 54(7):1784-1789 (July 1996) (apoptosis involvement); Harris, P. C., et al., *J. Am. Soc. Nephrol.*, 6(4):1125-1133 (Oct. 1995) (kidney disease involvement); and Ruoslahti, E. I., et al., WO9110727-A by La Jolla Cancer Research Foundation (decorin binding to transforming growth factor $\beta$  involvement for treatment for cancer, wound healing and scarring).

Efforts are therefore being undertaken by both industry and academia to identify new proteins having leucine 35 rich repeats to better understand protein-protein interactions. Of particular interest are those proteins having leucine rich repeats and homology to known proteins having leucine rich repeats such as the SLIT protein and platelet glycoprotein V.

12. **PRO258**

Immunoglobulins are antibody molecules, the proteins that function both as receptors for antigen on the B-cell membrane and as the secreted products of the plasma cell. Like all antibody molecules, immunoglobulins perform two major functions: they bind specifically to an antigen and they participate in a limited number of biological effector functions. Therefore, new members of the Ig superfamily are always of interest. Molecules which 5 act as receptors by various viruses and those which act to regulate immune function are of particular interest. Also of particular interest are those molecules which have homology to known Ig family members which act as virus receptors or regulate immune function. Thus, molecules having homology to poliovirus receptors, CRTAM and CD166 (a ligand for lymphocyte antigen CD6) are of particular interest.

Extracellular and membrane-bound proteins play important roles in the formation, differentiation and 10 maintenance of multicellular organisms. The fate of many individual cells, e.g., proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from other cells and/or the immediate environment. This information is often transmitted by secreted polypeptides (for instance, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones) which are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins. These secreted polypeptides or 15 signaling molecules normally pass through the cellular secretory pathway to reach their site of action in the extracellular environment, usually at a membrane-bound receptor protein.

We herein describe the identification and characterization of novel polypeptides having homology to CRTAM, designated herein as PRO258 polypeptides.

20 13. **PRO266**

Protein-protein interactions include receptor and antigen complexes and signaling mechanisms. As more is known about the structural and functional mechanisms underlying protein-protein interactions, protein-protein interactions can be more easily manipulated to regulate the particular result of the protein-protein interaction. Thus, the underlying mechanisms of protein-protein interactions are of interest to the scientific and medical community.

25 All proteins containing leucine-rich repeats are thought to be involved in protein-protein interactions. Leucine-rich repeats are short sequence motifs present in a number of proteins with diverse functions and cellular locations. The crystal structure of ribonuclease inhibitor protein has revealed that leucine-rich repeats correspond to beta-alpha structural units. These units are arranged so that they form a parallel beta-sheet with one surface exposed to solvent, so that the protein acquires an unusual, nonglobular shape. These two features have been 30 indicated as responsible for the protein-binding functions of proteins containing leucine-rich repeats. See, Kobe and Deisenhofer, *Trends Biochem. Sci.*, 19(10):415-421 (Oct. 1994).

A study has been reported on leucine-rich proteoglycans which serve as tissue organizers, orienting and ordering collagen fibrils during ontogeny and are involved in pathological processes such as wound healing, tissue repair, and tumor stroma formation. Iozzo, R. V., *Crit. Rev. Biochem. Mol. Biol.*, 32(2):141-174 (1997). Others 35 studies implicating leucine rich proteins in wound healing and tissue repair are De La Salle, C., et al., *Vouv. Rev. Fr. Hematol.* (Germany), 37(4):215-222 (1995), reporting mutations in the leucine rich motif in a complex associated with the bleeding disorder Bernard-Soulier syndrome and Chlemetson, K. J., *Thromb. Haemost.* (Germany),

74(1):111-116 (July 1995), reporting that platelets have leucine rich repeats. Another protein of particular interest which has been reported to have leucine-rich repeats is the SLIT protein which has been reported to be useful in treating neuro-degenerative diseases such as Alzheimer's disease, nerve damage such as in Parkinson's disease, and for diagnosis of cancer, see, Artavanistsakonas, S. and Rothberg, J. M., WO9210518-A1 by Yale University. Other studies reporting on the biological functions of proteins having leucine-rich repeats include: Tayar, N., et al., Mol. Cell Endocrinol., (Ireland), 125(1-2):65-70 (Dec. 1996) (gonadotropin receptor involvement); Miura, Y., et al., Nippon Rinsho (Japan), 54(7):1784-1789 (July 1996) (apoptosis involvement); Harris, P. C., et al., J. Am. Soc. Nephrol., 6(4):1125-1133 (Oct. 1995) (kidney disease involvement); and Ruoslahti, E. I., et al., WO9110727-A by La Jolla Cancer Research Foundation (decorin binding to transforming growth factor $\beta$  involvement for treatment for cancer, wound healing and scarring).

10 Efforts are therefore being undertaken by both industry and academia to identify new proteins having leucine rich repeats to better understand protein-protein interactions, neuronal development and adhesin molecules. Of particular interest are those proteins having leucine rich repeats and homology to known proteins having leucine rich repeats such as the SLIT protein. We herein describe novel polypeptides having homology to SLIT, designated herein as PRO266 polypeptides.

15

#### 14. PRO269

Thrombomodulin binds to and regulates the activity of thrombin. It is important in the control of blood coagulation. Thrombomodulin functions as a natural anticoagulant by accelerating the activation of protein C by thrombin. Soluble thrombomodulin may have therapeutic use as an antithrombotic agent with reduced risk for hemorrhage as compared with heparin. Thrombomodulin is a cell surface trans-membrane glycoprotein, present on endothelial cells and platelets. A smaller, functionally active form of thrombomodulin circulates in the plasma and is also found in urine. (In Haeberli, A., Human Protein Data, VCH Oub., N.Y., 1992). Peptides having homology to thrombomodulin are particularly desirable.

20 We herein describe the identification and characterization of novel polypeptides having homology to thrombomodulin, designated herein as PRO269 polypeptides.

#### 15. PRO287

Procollagen C-proteinase enhancer protein binds to and enhances the activity of bone morphogenic protein "BMP1"/procollagen C-proteinase (PCP). It plays a role in extracellular matrix deposition. BMP1 proteins may be used to induce bone and/or cartilage formation and in wound healing and tissue repair. Therefore, procollagen C-proteinase enhancer protein, BMP1 and proteins having homology thereto, are of interest to the scientific and medical communities.

30 We herein describe the identification and characterization of novel polypeptides having homology to procollagen C-proteinase enhancer protein precursor and procollagen C-proteinase enhancer protein, designated herein as PRO287 polypeptides.

**16. PRO214**

Growth factors are molecular signals or mediators that enhances cell growth or proliferation, alone or in concert, by binding to specific cell surface receptors. However, there are other cellular reactions than only growth upon expression to growth factors. As a result, growth factors are better characterized as multifunctional and potent cellular regulators. Their biological effects include proliferation, chemotaxis and stimulation of extracellular matrix production. Growth factors can have both stimulatory and inhibitory effects. For example, transforming growth factor  $\beta$  (TGF- $\beta$ ) is highly pleiotropic and can stimulate proliferation in some cells, especially connective tissue, while being a potent inhibitor of proliferation in others, such as lymphocytes and epithelial cells.

The physiological effect of growth stimulation or inhibition by growth factors depends upon the state of development and differentiation of the target tissue. The mechanism of local cellular regulation by classical endocrine molecules involves comprehends autocrine (same cell), juxtacrine (neighbor cell), and paracrine (adjacent cells) pathways. Peptide growth factors are elements of a complex biological language, providing the basis for intercellular communication. They permit cells to convey information between each other, mediate interaction between cells and change gene expression. The effect of these multifunctional and pluripotent factors is dependent on the presence or absence of other peptides.

Epidermal growth factor (EGF) is a conventional mitogenic factor that stimulates the proliferation of various types of cells including epithelial cells and fibroblasts. EGF binds to and activates the EGF receptor (EGFR), which initiates intracellular signaling and subsequent effects. The EGFR is expressed in neurons of the cerebral cortex, cerebellum, and hippocampus in addition to other regions of the central nervous system (CNS). In addition, EGF is also expressed in various regions of the CNS. Therefore, EGF acts not only on mitotic cells, but also on postmitotic neurons. In fact, many studies have indicated that EGF has neurotrophic or neuromodulatory effects on various types of neurons in the CNS. For example, EGF acts directly on cultured cerebral cortical and cerebellar neurons, enhancing neurite outgrowth and survival. On the other hand, EGF also acts on other cell types, including septal cholinergic and mesencephalic dopaminergic neurons, indirectly through glial cells. Evidence of the effects of EGF on neurons in the CNS is accumulating, but the mechanisms of action remain essentially unknown. EGF-induced signaling in mitotic cells is better understood than in postmitotic neurons. Studies of cloned pheochromocytoma PC12 cells and cultured cerebral cortical neurons have suggested that the EGF-induced neurotrophic actions are mediated by sustained activation of the EGFR and mitogen-activated protein kinase (MAPK) in response to EGF. The sustained intracellular signaling correlates with the decreased rate of EGFR down-regulation, which might determine the response of neuronal cells to EGF. It is likely that EGF is a multi-potent growth factor that acts upon various types of cells including mitotic cells and postmitotic neurons.

EGF is produced by the salivary and Brunner's glands of the gastrointestinal system, kidney, pancreas, thyroid gland, pituitary gland, and the nervous system, and is found in body fluids such as saliva, blood, cerebrospinal fluid (CSF), urine, amniotic fluid, prostatic fluid, pancreatic juice, and breast milk, Plata-Salaman, CR *Peptides* 12: 653-663 (1991).

EGF is mediated by its membrane specific receptor, which contains an intrinsic tyrosine kinase. Stoscheck CM *et al.*, *J. Cell Biochem.* 31: 135-152 (1986). EGF is believed to function by binding to the extracellular portion of its receptor which induces a transmembrane signal that activates the intrinsic tyrosine kinase.

Purification and sequence analysis of the EGF-like domain has revealed the presence of six conserved cysteine residues which cross-bind to create three peptide loops, Savage CR *et al.*, *J. Biol. Chem.* **248**: 7669-7672 (1979). It is now generally known that several other peptides can react with the EGF receptor which share the same generalized motif X<sub>n</sub>CX<sub>2</sub>CX<sub>4/5</sub>CX<sub>10</sub>CXCX<sub>2</sub>GX<sub>2</sub>CX<sub>n</sub>, where X represents any non-cysteine amino acid, and n is a variable repeat number. Non isolated peptides having this motif include TGF-a, amphiregulin, schwannoma-derived growth factor (SDGF), heparin-binding EGF-like growth factors and certain virally encoded peptides (e.g., Vaccinia virus, Reisner AH, *Nature* **313**: 801-803 (1985), Shope fibroma virus, Chang W., et al., *Mol Cell Biol.* **7**: 535-540 (1987), Molluscum contagiosum, Porter CD & Archard LC, *J. Gen. Virol.* **68**: 673-682 (1987), and Myxoma virus, Upton C *et al.*, *J. Virol.* **61**: 1271-1275 (1987). Prigent SA & Lemoine N.R., *Prog. Growth Factor Res.* **4**: 1-24 (1992).

EGF-like domains are not confined to growth factors but have been observed in a variety of cell-surface and extracellular proteins which have interesting properties in cell adhesion, protein-protein interaction and development, Laurence DJR & Gusterson BA, *Tumor Biol.* **11**: 229-261 (1990). These proteins include blood coagulation factors (factors VI, IX, X, XII, protein C, protein S, protein Z, tissue plasminogen activator, urokinase), extracellular matrix components (laminin, cytотactин, entactin), cell surface receptors (LDL receptor, thrombomodulin receptor) and immunity-related proteins (complement C1r, uromodulin).

Even more interesting, the general structure pattern of EGF-like precursors is preserved through lower organisms as well as in mammalian cells. A number of genes with developmental significance have been identified in invertebrates with EGF-like repeats. For example, the *notch* gene of Drosophila encodes 36 tandemly arranged 40 amino acid repeats which show homology to EGF, Wharton W *et al.*, *Cell* **43**: 557-581 (1985). Hydropathy plots indicate a putative membrane spanning domain, with the EGF-related sequences being located on the extracellular side of the membrane. Other homeotic genes with EGF-like repeats include Delta, 95F and 5ZD which were identified using probes based on Notch, and the nematode gene *Lin-12* which encodes a putative receptor for a developmental signal transmitted between two specified cells.

Specifically, EGF has been shown to have potential in the preservation and maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions, Konturek, PC *et al.*, *Eur. J. Gastroenterol Hepatol.* **7** (10), 933-37 (1995), including the treatment of necrotizing enterocolitis, Zollinger-Ellison syndrome, gastrointestinal ulceration gastrointestinal ulcerations and congenital microvillus atrophy, A. Guglietta & PB Sullivan, *Eur. J. Gastroenterol Hepatol.* **7**(10), 945-50 (1995). Additionally, EGF has been implicated in hair follicle differentiation; C.L. du Cros, *J. Invest. Dermatol.* **101** (1 Suppl.), 106S-113S (1993), SG Hillier, *Clin. Endocrinol.* **33**(4), 427-28 (1990); kidney function, L.L. Hamm *et al.*, *Semin. Nephrol.* **13** (1): 109-15 (1993), RC Harris, *Am. J. Kidney Dis.* **17**(6): 627-30 (1991); tear fluid, GB van Setten *et al.*, *Int. Ophthalmol.* **15**(6): 359-62 (1991); vitamin K mediated blood coagulation, J. Stenflo *et al.*, *Blood* **78**(7): 1637-51 (1991). EGF is also implicated various skin disease characterized by abnormal keratinocyte differentiation, e.g., psoriasis, epithelial cancers such as squamous cell carcinomas of the lung, epidermoid carcinoma of the vulva and gliomas. King, LE *et al.*, *Am. J. Med. Sci.* **296**: 154-158 (1988).

Of great interest is mounting evidence that genetic alterations in growth factors signaling pathways are closely linked to developmental abnormalities and to chronic diseases including cancer. Aaronson SA, *Science* **254**:

1146-1153 (1991). For example, c-erb-2 (also known as HER-2), a proto-oncogene with close structural similarity to EGF receptor protein, is overexpressed in human breast cancer. King *et al.*, *Science* 229: 974-976 (1985); Gullick, WJ, *Hormones and their actions*, Cooke BA *et al.*, eds, Amsterdam, Elsevier, pp 349-360 (1986).

17. **PRO317**

- 5       The TGF- $\beta$  supergene family, or simply TGF- $\beta$  superfamily, a group of secreted proteins, includes a large number of related growth and differentiation factors expressed in virtually all phyla. Superfamily members bind to specific cell surface receptors that activate signal transduction mechanisms to elicit their multifunctional cytokine effects. Kolodziejczyk and Hall, *Biochem. Cell. Biol.*, 74: 299-314 (1996); Attisano and Wrana, *Cytokine Growth Factor Rev.*, 7: 327-339 (1996); and Hill, *Cellular Signaling*, 8: 533-544 (1996).
- 10      Members of this family include five distinct forms of TGF- $\beta$  (Sporn and Roberts, in *Peptide Growth Factors and Their Receptors*, Sporn and Roberts, eds. (Springer-Verlag: Berlin, 1990) pp. 419-472), as well as the differentiation factors vg1 (Weeks and Melton, *Cell*, 51: 861-867 (1987)) and DPP-C polypeptide (Padgett *et al.*, *Nature*, 325: 81-84 (1987)), the hormones activin and inhibin (Mason *et al.*, *Nature*, 318: 659-663 (1985); Mason *et al.*, *Growth Factors*, 1: 77-88 (1987)), the Mullerian-inhibiting substance (MIS) (Cate *et al.*, *Cell*, 45: 685-698 (1986)), the bone morphogenetic proteins (BMPs) (Wozney *et al.*, *Science*, 242: 1528-1534 (1988); PCT WO 88/00205 published January 14, 1988; U.S. 4,877,864 issued October 31, 1989), the developmentally regulated proteins Vgr-1 (Lyons *et al.*, *Proc. Natl. Acad. Sci. USA*, 86: 4554-4558 (1989)) and Vgr-2 (Jones *et al.*, *Molec. Endocrinol.*, 6: 1961-1968 (1992)), the mouse growth differentiation factor (GDF), such as GDF-3 and GDF-9 (Kingsley, *Genes Dev.*, 8: 133-146 (1994); McPherron and Lee, *J. Biol. Chem.*, 268: 3444-3449 (1993)), the mouse lefty/Stra1 (Meno *et al.*, *Nature*, 381: 151-155 (1996); Bouillet *et al.*, *Dev. Biol.*, 170: 420-433 (1995)), glial cell line-derived neurotrophic factor (GDNF) (Lin *et al.*, *Science*, 260: 1130-1132 (1993)), neurturin (Kotzbauer *et al.*, *Nature*, 384: 467-470 (1996)), and endometrial bleeding-associated factor (EBAF) (Kothapalli *et al.*, *J. Clin. Invest.*, 99: 2342-2350 (1997)). The subset BMP-2A and BMP-2B is approximately 75% homologous in sequence to DPP-C and may represent the mammalian equivalent of that protein.
- 25      The proteins of the TGF- $\beta$  superfamily are disulfide-linked homo- or heterodimers encoded by larger precursor polypeptide chains containing a hydrophobic signal sequence, a long and relatively poorly conserved N-terminal pro region of several hundred amino acids, a cleavage site (usually polybasic), and a shorter and more highly conserved C-terminal region. This C-terminal region corresponds to the processed mature protein and contains approximately 100 amino acids with a characteristic cysteine motif, *i.e.*, the conservation of seven of the nine cysteine residues of TGF- $\beta$  among all known family members. Although the position of the cleavage site between the mature and pro regions varies among the family members, the C-terminus of all of the proteins is in the identical position, ending in the sequence Cys-X-Cys-X, but differing in every case from the TGF- $\beta$  consensus C-terminus of Cys-Lys-Cys-Ser. Sporn and Roberts, 1990, *supra*.
- 30      There are at least five forms of TGF- $\beta$  currently identified, TGF- $\beta$ 1, TGF- $\beta$ 2, TGF- $\beta$ 3, TGF- $\beta$ 4, and TGF- $\beta$ 5. The activated form of TGF- $\beta$ 1 is a homodimer formed by dimerization of the carboxy-terminal 112 amino acids of a 390 amino acid precursor. Recombinant TGF- $\beta$ 1 has been cloned (Deryck *et al.*, *Nature*, 316:701-705 (1985)) and expressed in Chinese hamster ovary cells (Gentry *et al.*, *Mol. Cell. Biol.*, 7: 3418-3427 (1987)). Additionally,

recombinant human TGF- $\beta$ 2 (deMartin *et al.*, EMBO J., **6**: 3673 (1987)), as well as human and porcine TGF- $\beta$ 3 (Derynck *et al.*, EMBO J., **7**: 3737-3743 (1988); ten Dijke *et al.*, Proc. Natl. Acad. Sci. USA, **85**: 4715 (1988)) have been cloned. TGF- $\beta$ 2 has a precursor form of 414 amino acids and is also processed to a homodimer from the carboxy-terminal 112 amino acids that shares approximately 70% homology with the active form of TGF- $\beta$ 1 (Marquardt *et al.*, J. Biol. Chem., **262**: 12127 (1987)). See also EP 200,341; 169,016; 268,561; and 267,463; U.S.

- 5 Pat. No. 4,774,322; Cheifetz *et al.*, Cell, **48**: 409-415 (1987); Jakowlew *et al.*, Molecular Endocrin., **2**: 747-755 (1988); Derynck *et al.*, J. Biol. Chem., **261**: 4377-4379 (1986); Sharples *et al.*, DNA, **6**: 239-244 (1987); Derynck *et al.*, Nucl. Acids. Res., **15**: 3188-3189 (1987); Derynck *et al.*, Nucl. Acids. Res., **15**: 3187 (1987); Seyedin *et al.*, J. Biol. Chem., **261**: 5693-5695 (1986); Madisen *et al.*, DNA, **7**: 1-8 (1988); and Hanks *et al.*, Proc. Natl. Acad. Sci. (U.S.A.), **85**: 79-82 (1988).

- 10 TGF- $\beta$ 4 and TGF- $\beta$ 5 were cloned from a chicken chondrocyte cDNA library (Jakowlew *et al.*, Molec. Endocrinol., **2**: 1186-1195 (1988)) and from a frog oocyte cDNA library, respectively.

The pro region of TGF- $\beta$  associates non-covalently with the mature TGF- $\beta$  dimer (Wakefield *et al.*, J. Biol. Chem., **263**: 7646-7654 (1988); Wakefield *et al.*, Growth Factors, **1**: 203-218 (1989)), and the pro regions are found to be necessary for proper folding and secretion of the active mature dimers of both TGF- $\beta$  and activin (Gray and 15 Mason, Science, **247**: 1328-1330 (1990)). The association between the mature and pro regions of TGF- $\beta$  masks the biological activity of the mature dimer, resulting in formation of an inactive latent form. Latency is not a constant of the TGF- $\beta$  superfamily, since the presence of the pro region has no effect on activin or inhibin biological activity.

A unifying feature of the biology of the proteins from the TGF- $\beta$  superfamily is their ability to regulate developmental processes. TGF- $\beta$  has been shown to have numerous regulatory actions on a wide variety of both 20 normal and neoplastic cells. TGF- $\beta$  is multifunctional, as it can either stimulate or inhibit cell proliferation, differentiation, and other critical processes in cell function (Sporn and Roberts, *supra*).

One member of the TGF- $\beta$  superfamily, EBAF, is expressed in endometrium only in the late secretory phase and during abnormal endometrial bleeding. Kothapalli *et al.*, J. Clin. Invest., **99**: 2342-2350 (1997). Human endometrium is unique in that it is the only tissue in the body that bleeds at regular intervals. In addition, abnormal 25 endometrial bleeding is one of the most common manifestations of gynecological diseases, and is a prime indication for hysterectomy. *In situ* hybridization showed that the mRNA of EBAF was expressed in the stroma without any significant mRNA expression in the endometrial glands or endothelial cells.

The predicted protein sequence of EBAF showed a strong homology to the protein encoded by mouse *lefty/stra3* of the TGF- $\beta$  superfamily. A motif search revealed that the predicted EBAF protein contains most of the 30 cysteine residues which are conserved among the TGF- $\beta$ -related proteins and which are necessary for the formation of the cysteine knot structure. The EBAF sequence contains an additional cysteine residue, 12 amino acids upstream from the first conserved cysteine residue. The only other family members known to contain an additional cysteine residue are TGF- $\beta$ s, inhibins, and GDF-3. EBAF, similar to LEFTY, GDF-3/Vgr2, and GDF-9, lacks the cysteine residue that is known to form the intermolecular disulfide bond. Therefore, EBAF appears to be an additional 35 member of the TGF- $\beta$  superfamily with an unpaired cysteine residue that may not exist as a dimer. However, hydrophobic contacts between the two monomer subunits may promote dimer formation. Fluorescence *in situ* hybridization showed that the *egef* gene is located on human chromosome 1 at band q42.1.

Additional members of the TGF- $\beta$  superfamily, such as those related to EBAF, are being searched for by industry and academics. We herein describe the identification and characterization of novel polypeptides having homology to EBAF, designated herein as PRO317 polypeptides.

**18. PRO301**

- 5 The widespread occurrence of cancer has prompted the devotion of considerable resources and discovering new treatments of treatment. One particular method involves the creation of tumor or cancer specific monoclonal antibodies (mAbs) which are specific to tumor antigens. Such mAbs, which can distinguish between normal and cancerous cells are useful in the diagnosis, prognosis and treatment of the disease. Particular antigens are known to be associated with neoplastic diseases, such as colorectal cancer.
- 10 One particular antigen, the A33 antigen is expressed in more than 90% of primary or metastatic colon cancers as well as normal colon epithelium. Since colon cancer is a widespread disease, early diagnosis and treatment is an important medical goal. Diagnosis and treatment of colon cancer can be implemented using monoclonal antibodies (mAbs) specific therefore having fluorescent, nuclear magnetic or radioactive tags. Radioactive gene, toxins and/or drug tagged mAbs can be used for treatment *in situ* with minimal patient description.
- 15 mAbs can also be used to diagnose during the diagnosis and treatment of colon cancers. For example, when the serum levels of the A33 antigen are elevated in a patient, a drop of the levels after surgery would indicate the tumor resection was successful. On the other hand, a subsequent rise in serum A33 antigen levels after surgery would indicate that metastases of the original tumor may have formed or that new primary tumors may have appeared. Such monoclonal antibodies can be used in lieu of, or in conjunction with surgery and/or other chemotherapies. For 20 example, U.S.P. 4,579,827 and U.S.S.N. 424,991 (E.P. 199,141) are directed to therapeutic administration of monoclonal antibodies, the latter of which relates to the application of anti-A33 mAb.

Many cancers of epithelial origin have adenovirus receptors. In fact, adenovirus-derived vectors have been proposed as a means of inserting antisense nucleic acids into tumors (U.S.P. 5,518,885). Thus, the association of viral receptors with neoplastic tumors is not unexpected.

- 25 We herein describe the identification and characterization of novel polypeptides having homology to certain cancer-associated antigens, designated herein as PRO301 polypeptides.

**19. PRO224**

- Cholesterol uptake can have serious implications on one's health. Cholesterol uptake provides cells with 30 most of the cholesterol they require for membrane synthesis. If this uptake is blocked, cholesterol accumulates in the blood and can contribute to the formation of atherosclerotic plaques in blood vessel walls. Most cholesterol is transported in the blood bound to protein in the form of complexes known as low-density lipoproteins (LDLs). LDLs are endocytosed into cells via LDL receptor proteins. Therefore, LDL receptor proteins, and proteins having homology thereto, are of interest to the scientific and medical communities. Membrane-bound proteins and 35 receptors can play an important role in the formation, differentiation and maintenance of multicellular organisms. The LDL receptors are an example of membrane-bound proteins which are involved in the synthesis and formation of cell membranes, wherein the health of an individual is affected directly and indirectly by its function. Many

membrane-bound proteins act as receptors such as the LDL receptor. These receptors can function to endocytose substrates or they can function as a receptor for a channel. Other membrane-bound proteins function as signals or antigens.

Membrane-bound proteins and receptor molecules have various industrial applications, including as pharmaceutical and diagnostic agents. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule regulators of the relevant receptor/ligand interaction. In the case of the LDL receptor, it is desirable to find molecules which enhance endocytosis so as to lower blood cholesterol levels and plaque formation. It is also desirable to identify molecules which inhibit endocytosis so that these molecules can be avoided or regulated by individuals having high blood cholesterol. Polypeptides which are homologous to lipoprotein receptors but which do not function as lipoprotein receptors are also of interest in the determination of the function of the fragments which show homology.

The following studies report on previously known low density lipoprotein receptors and related proteins including apolipoproteins: Sawamura, et al., Nippon Chemiphar Co, Japan patent application J09098787; Novak, S., et al., *J. Biol. Chem.*, 271:(20)11732-6 (1996); Blaas, D., *J. Virol.*, 69(11)7244-7 (Nov. 1995); Scott, J., *J. Inherit. Metab. Dis. (UK)*, 9/Supp. 1 (3-16) (1986); Yamamoto, et al., *Cell*, 39:27-38 (1984); Rebecce, et al., *Neurobiol. Aging*, 15:5117 (1994); Novak, S., et al., *J. Biol. Chemistry*, 271:11732-11736 (1996); and Sestavel and Fruchart, *Cell Mol. Biol.*, 40(4):461-81 (June 1994). These publications and others published prior to the filing of this application provide further background to peptides already known in the art.

Efforts are being undertaken by both industry and academia to identify new, native membrane-bound receptor proteins, particularly those having homology to lipoprotein receptors. We herein describe the identification and characterization of novel polypeptides having homology to lipoprotein receptors, designated herein as PRO224 polypeptides.

#### 20. PRO222

Complement is a group of proteins found in the blood that are important in humoral immunity and inflammation. Complement proteins are sequentially activated by antigen-antibody complexes or by proteolytic enzymes. When activated, complement proteins kill bacteria and other microorganisms, affect vascular permeability, release histamine and attract white blood cells. Complement also enhances phagocytosis when bound to target cells. In order to prevent harm to autologous cells, the complement activation pathway is tightly regulated.

Deficiencies in the regulation of complement activation or in the complement proteins themselves may lead to immune-complex diseases, such as systemic lupus erythematosus, and may result in increased susceptibility to bacterial infection. In all cases, early detection of complement deficiency is desirable so that the patient can begin treatment. Thus, research efforts are currently directed toward identification of soluble and membrane proteins that regulate complement activation.

Proteins known to be important in regulating complement activation in humans include Factor H and Complement receptor type 1 (CR1). Factor H is a 150 kD soluble serum protein that interacts with complement protein C3b to accelerate the decay of C3 convertase and acts as a cofactor for Factor I-mediated cleavage of complement protein C4b. Complement receptor type 1 is a 190-280 kD membrane bound protein found in mast cells

and most blood cells. CR1 interacts with complement proteins C3b, C4b, and iC3b to accelerate dissociation of C3 convertases, acts as a cofactor for Factor I-mediated cleavage of C3b and C4b, and binds immune complexes and promotes their dissolution and phagocytosis.

Proteins which have homology to complement proteins are of particular interest to the medical and industrial communities. Often, proteins having homology to each other have similar function. It is also of interest when 5 proteins having homology do not have similar functions, indicating that certain structural motifs identify information other than function, such as locality of function.

Efforts are being undertaken by both industry and academia to identify new, native secreted and membrane-bound proteins, particularly those having homology to known proteins involved in the complement pathway. Proteins involved in the complement pathway were reviewed in Birmingham DJ (1995), Critical Reviews in Immunology, 15(2):133-154 and in Abbas AK, et al. (1994) Cellular and Molecular Immunology, 2nd Ed. W.B. 10 Saunders Company, Philadelphia, pp 295-315.

We herein describe the identification and characterization of novel polypeptides having homology to complement receptors, designated herein as PRO222 polypeptides.

15           21.       PRO234

The successful function of many systems within multicellular organisms is dependent on cell-cell interactions. Such interactions are affected by the alignment of particular ligands with particular receptors in a manner which allows for ligand-receptor binding and thus a cell-cell adhesion. While protein-protein interactions in cell recognition have been recognized for some time, only recently has the role of carbohydrates in physiologically 20 relevant recognition been widely considered (see B.K. Brandley *et al.*, *J. Leuk. Biol.* 40: 97 (1986) and N. Sharon *et al.*, *Science* 246: 227 (1989)). Oligosaccharides are well positioned to act as recognition novel lectins due to their cell surface location and structural diversity. Many oligosaccharide structures can be created through the differential activities of a smaller number of glycosyltransferases. The diverse structures of oligosaccharides can be generated by transcription of relatively few gene products, which suggests that the oligosaccharides are a plausible mechanism 25 by which is directed a wide range of cell-cell interactions. Examples of differential expression of cell surface carbohydrates and putative carbohydrate binding proteins (lectins) on interacting cells have been described (J. Dodd & T.M. Jessel, *J. Neurosci.* 5: 3278 (1985); L.J. Regan *et al.*, *Proc. Natl. Acad. Sci. USA* 83: 2248 (1986); M. Constantine-Paton *et al.*, *Nature* 324: 459 (1986); and M. Tiemeyer *et al.*, *J. Biol. Chem.* 263: 1671 (1989)). One interesting member of the lectin family are selectins.

30           The migration of leukocytes to sites of acute or chronic inflammation involves adhesive interactions between these cells and the endothelium. This specific adhesion is the initial event in the cascade that is initiated by inflammatory insults, and it is, therefore, of paramount importance to the regulated defense of the organism.

The types of cell adhesion molecules that are involved in the interaction between leukocytes and the endothelium during an inflammatory response currently stands at four: (1) selectins; (2) (carbohydrate and 35 glycoprotein) ligands for selectins; (3) integrins; and (4) integrin ligands, which are members of the immunoglobulin gene superfamily.

The selectins are cell adhesion molecules that are unified both structurally and functionally. Structurally, selectins are characterized by the inclusion of a domain with homology to a calcium-dependent lectin (C-lectins), an epidermal growth factor (egf)-like domain and several complement binding-like domains, Bevilacqua, M.P. *et al.*, *Science* **243**: 1160-1165 (1989); Johnston *et al.*, *Cell* **56**: 1033-1044 (1989); Lasky *et al.*, *Cell* **56**: 1045-1055 (1989); Siegalman, M. *et al.*, *Science* **243**: 1165-1172 (1989); Stoolman, L.M., *Cell* **56**: 907-910 (1989). Functionally, 5 selectins share the common property of their ability to mediate cell binding through interactions between their lectin domains and cell surface carbohydrate ligands (Brandley, B. *et al.*, *Cell* **63**, 861-863 (1990); Springer, T. and Lasky, L.A., *Nature* **349**, 19-197 (1991); Bevilacqua, M.P. and Nelson, R.M., *J. Clin. Invest.* **91** 379-387 (1993) and Tedder *et al.*, *J. Exp. Med.* **170**: 123-133 (1989).

There are three members identified so far in the selectin family of cell adhesion molecules: L-selectin (also 10 called peripheral lymph node homing receptor (pnHR), LEC-CAM-1, LAM-1, gp<sup>90<sup>MEL</sup></sup>, gp<sup>100<sup>MEL</sup></sup>, gp<sup>110<sup>MEL</sup></sup>, MEL-14 antigen, Leu-8 antigen, TQ-1 antigen, DREG antigen), E-selectin (LEC-CAM-2, LECAM-2, ELAM-1) and P-selectin (LEC-CAM-3, LECAM-3, GMP-140, PADGEM).

The identification of the C-lectin domain has led to an intense effort to define carbohydrate binding ligands 15 for proteins containing such domains. E-selectin is believed to recognize the carbohydrate sequence NeuNAc<sup>2</sup>-3Gal<sup>β</sup>1-4(Fuc<sup>α</sup>1-3)GlcNAc (sialyl-Lewis x, or sLe<sup>x</sup>) and related oligosaccharides, Berg *et al.*, *J. Biol. Chem.* **265**: 14869-14872 (1991); Lowe *et al.*, *Cell* **63**: 475-484 (1990); Phillips *et al.*, *Science* **250**: 1130-1132 (1990); Tiemeyer *et al.*, *Proc. Natl. Acad. Sci. USA* **88**: 1138-1142 (1991).

L-selectin, which comprises a lectin domain, performs its adhesive function by recognizing carbohydrate-containing ligands on endothelial cells. L-selectin is expressed on the surface of leukocytes, such as lymphocytes, 20 neutrophils, monocytes and eosinophils, and is involved with the trafficking of lymphocytes to peripheral lymphoid tissues (*Gallatin et al.*, *Nature* **303**: 30-34 (1983)) and with acute neutrophil-mediated inflammatory responses (Watson, S.R., *Nature* **349**: 164-167 (1991)). The amino acid sequence of L-selectin and the encoding nucleic acid sequence are, for example, disclosed in U.S. patent No. 5,098,833 issued 24 March 1992.

L-selectin (LECAM-1) is particularly interesting because of its ability to block neutrophil influx (Watson 25 *et al.*, *Nature* **349**: 164-167 (1991). It is expressed in chronic lymphocytic leukemia cells which bind to HEV (Spertini *et al.*, *Nature* **349**: 691-694 (1991)). It is also believed that HEV structures at sites of chronic inflammation are associated with the symptoms of diseases such as rheumatoid arthritis, psoriasis and multiple sclerosis.

E-selectin (ELAM-1), is particularly interesting because of its transient expression on endothelial cells in response to IL-1 or TNF. Bevilacqua *et al.*, *Science* **243**: 1160 (1989). The time course of this induced expression 30 (2-8 h) suggests a role for this receptor in initial neutrophil induced extravasation in response to infection and injury. It has further been reported that anti-ELAM-1 antibody blocks the influx of neutrophils in a primate asthma model and thus is beneficial for preventing airway obstruction resulting from the inflammatory response. Gundel *et al.*, *J. Clin. Invest.* **88**: 1407 (1991).

The adhesion of circulating neutrophils to stimulated vascular endothelium is a primary event of the 35 inflammatory response. P-selectin has been reported to recognize the Lewis x structure (Gal<sup>β</sup>1-4(Fuc<sup>α</sup>1-3) GlcNAc), Larsen *et al.*, *Cell* **63**: 467-474(1990). Others report that an additional terminal linked sialic acid is required for high affinity binding, Moore *et al.*, *J. Cell. Biol.* **112**: 491-499 (1991). P-selectin has been shown to be significant in acute

lung injury. Anti-P-selectin antibody has been shown to have strong protective effects in a rodent lung injury model. M.S. Mulligan *et al.*, *J. Clin. Invest.* 90: 1600 (1991).

We herein describe the identification and characterization of novel polypeptides having homology to lectin proteins, herein designated as PRO234 polypeptides.

5           22.       PRO231

Some of the most important proteins involved in the above described regulation and modulation of cellular processes are the enzymes which regulate levels of protein phosphorylation in the cell. For example, it is known that the transduction of signals that regulate cell growth and differentiation is regulated at least in part by phosphorylation and dephosphorylation of various cellular proteins. The enzymes that catalyze these processes include the protein 10 kinases, which function to phosphorylate various cellular proteins, and the protein phosphatases, which function to remove phosphate residues from various cellular proteins. The balance of the level of protein phosphorylation in the cell is thus mediated by the relative activities of these two types of enzymes.

Protein phosphatases represent a growing family of enzymes that are found in many diverse forms, including both membrane-bound and soluble forms. While many protein phosphatases have been described, the functions of 15 only a very few are beginning to be understood (Tonks, *Semin. Cell Biol.* 4:373-453 (1993) and Dixon, *Recent Prog. Horm. Res.* 51:405-414 (1996)). However, in general, it appears that many of the protein phosphatases function to modulate the positive or negative signals induced by various protein kinases. Therefore, it is likely that protein phosphatases play critical roles in numerous and diverse cellular processes.

Given the physiological importance of the protein phosphatases, efforts are being undertaken by both 20 industry and academia to identify new, native phosphatase proteins. Many of these efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel phosphatase proteins. Examples of screening methods and techniques are described in the literature [see, for example, Klein *et al.*, *Proc. Natl. Acad. Sci.*, 93:7108-7113 (1996); U.S. Patent No. 5,536,637)].

We herein describe the identification and characterization of novel polypeptides having homology to acid 25 phosphatases, designated herein as PRO231 polypeptides.

23.       PRO229

Scavenger receptors are known to protect IgG molecules from catabolic degradation. Riechmann and Hollinger, *Nature Biotechnology*, 15:617 (1997). In particular, studies of the CH2 and CH3 domains have shown 30 that specific sequences of these domains are important in determining the half-lives of antibodies. Ellerson, *et al.*, *J. Immunol.*, 116: 510 (1976); Yasmeen, *et al.*, *J. Immunol.* 116: 518 (1976); Pollock, *et al.*, *Eur. J. Immunol.*, 20: 2021 (1990). Scavenger receptor proteins and antibodies thereto are further reported in U.S. Patent No. 5,510,466 to Krieger, *et al.* Due to the ability of scavenger receptors to increase the half-life of polypeptides and their involvement in immune function, molecules having homology to scavenger receptors are of importance to the 35 scientific and medical community.

Efforts are being undertaken by both industry and academia to identify new, native secreted and membrane-bound receptor proteins, particularly those having homology to scavenger receptors. Many efforts are focused on

the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted and membrane-bound receptor proteins. Examples of screening methods and techniques are described in the literature [see, for example, Klein et al., *Proc. Natl. Acad. Sci.*, 93:7108-7113 (1996); U.S. Patent No. 5,536,637].

We herein describe the identification and characterization of novel polypeptides having homology to scavenger receptors, designated herein as PRO229 polypeptides.

5

#### 24. PRO238

Oxygen free radicals and antioxidants appear to play an important role in the central nervous system after cerebral ischemia and reperfusion. Moreover, cardiac injury, related to ischaemia and reperfusion has been reported to be caused by the action of free radicals. Additionally, studies have reported that the redox state of the cell is a pivotal determinant of the fate of the cells. Furthermore, reactive oxygen species have been reported to be cytotoxic, causing inflammatory disease, including tissue necrosis, organ failure, atherosclerosis, infertility, birth defects, premature aging, mutations and malignancy. Thus, the control of oxidation and reduction is important for a number of reasons including for control and prevention of strokes, heart attacks, oxidative stress and hypertension. In this regard, reductases, and particularly, oxidoreductases, are of interest. Publications further describing this subject matter include Kelsey, et al., *Br. J. Cancer*, 76(7):852-4 (1997); Friedrich and Weiss, *J. Theor. Biol.*, 187(4):529-40 (1997) and Pieulle, et al., *J. Bacteriol.*, 179(18):5684-92 (1997).

Efforts are being undertaken by both industry and academia to identify new, native secreted and membrane-bound receptor proteins, particularly secreted proteins which have homology to reductase. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted and membrane-bound receptor proteins. Examples of screening methods and techniques are described in the literature [see, for example, Klein et al., *Proc. Natl. Acad. Sci.*, 93:7108-7113 (1996); U.S. Patent No. 5,536,637].

We herein describe the identification and characterization of novel polypeptides having homology to reductase, designated herein as PRO238 polypeptides.

25

#### 25. PRO233

Studies have reported that the redox state of the cell is an important determinant of the fate of the cell. Furthermore, reactive oxygen species have been reported to be cytotoxic, causing inflammatory disease, including tissue necrosis, organ failure, atherosclerosis, infertility, birth defects, premature aging, mutations and malignancy. Thus, the control of oxidation and reduction is important for a number of reasons, including the control and prevention of strokes, heart attacks, oxidative stress and hypertension. Oxygen free radicals and antioxidants appear to play an important role in the central nervous system after cerebral ischemia and reperfusion. Moreover, cardiac injury, related to ischaemia and reperfusion has been reported to be caused by the action of free radicals. In this regard, reductases, and particularly, oxidoreductases, are of interest. In addition, the transcription factors, NF-kappa B and AP-1, are known to be regulated by redox state and to affect the expression of a large variety of genes thought to be involved in the pathogenesis of AIDS, cancer, atherosclerosis and diabetic complications. Publications further describing this subject matter include Kelsey, et al., *Br. J. Cancer*, 76(7):852-4 (1997); Friedrich and Weiss, *J. Theor. Biol.*, 187(4):529-40 (1997) and Pieulle, et al., *J. Bacteriol.*, 179(18):5684-92 (1997). Given the physiological

importance of redox reactions *in vivo*, efforts are currently being undertaken to identify new, native proteins which are involved in redox reactions. We describe herein the identification of novel polypeptides which have homology to reductase, designated herein as PRO233 polypeptides.

**26. PRO223**

5 The carboxypeptidase family of exopeptidases constitutes a diverse group of enzymes that hydrolyze carboxyl-terminal amide bonds in polypeptides, wherein a large number of mammalian tissues produce these enzymes. Many of the carboxypeptidase enzymes that have been identified to date exhibit rather strong cleavage specificities for certain amino acids in polypeptides. For example, carboxypeptidase enzymes have been identified which prefer lysine, arginine, serine or amino acids with either aromatic or branched aliphatic side chains as  
10 substrates at the carboxyl terminus of the polypeptide.

With regard to the serine carboxypeptidases, such amino acid specific enzymes have been identified from a variety of different mammalian and non-mammalian organisms. The mammalian serine carboxypeptidase enzymes play important roles in many different biological processes including, for example, protein digestion, activation, inactivation, or modulation of peptide hormone activity, and alteration of the physical properties of proteins and  
15 enzymes.

In light of the physiological importance of the serine carboxypeptidases, efforts are being undertaken by both industry and academia to identify new, native secreted and membrane-bound receptor proteins and specifically novel carboxypeptidases. Many of these efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted and membrane-bound receptor proteins. We describe herein novel  
20 polypeptides having homology to one or more serine carboxypeptidase polypeptides, designated herein as PRO223 polypeptides.

**27. PRO235**

Plexin was first identified in *Xenopus* tadpole nervous system as a membrane glycoprotein which was shown  
25 to mediate cell adhesion via a homophilic binding mechanism in the presence of calcium ions. Strong evolutionary conservation between *Xenopus*, mouse and human homologs of plexin has been observed. [Kaneyama et al., Biochem. And Biophys. Res. Comm. 226: 524-529 (1996)]. Given the physiological importance of cell adhesion mechanisms *in vivo*, efforts are currently being undertaken to identify new, native proteins which are involved in cell adhesion. We describe herein the identification of a novel polypeptide which has homology to plexin, designated  
30 herein as PRO235.

**28. PRO236 and PRO262**

$\beta$ -galactosidase is a well known enzymatic protein which functions to hydrolyze  $\beta$ -galactoside molecules.  $\beta$ -galactosidase has been employed for a variety of different applications, both *in vitro* and *in vivo* and has proven  
35 to be an extremely useful research tool. As such, there is an interest in obtaining novel polypeptides which exhibit homology to the  $\beta$ -galactosidase polypeptide.

Given the strong interest in obtaining novel polypeptides having homology to  $\beta$ -galactosidase, efforts are currently being undertaken by both industry and academia to identify new, native  $\beta$ -galactosidase homolog proteins. Many of these efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel  $\beta$ -galactosidase-like proteins. Examples of screening methods and techniques are described in the literature [see, for example, Klein et al., *Proc. Natl. Acad. Sci.*, 93:7108-7113 (1996); U.S. Patent No. 5,536,637)]. We herein describe novel polypeptides having significant homology to the  $\beta$ -galactosidase enzyme, designated herein as PRO236 and PRO262 polypeptides.

29. **PRO239**

Densin is a glycoprotein which has been isolated from the brain which has all the hallmarks of an adhesion molecule. It is highly concentrated at synaptic sites in the brain and is expressed prominently in dendritic processes in developing neurons. Densin has been characterized as a member of the O-linked sialoglycoproteins. Densin has relevance to medically important processes such as regeneration. Given the physiological importance of synaptic processes and cell adhesion mechanisms *in vivo*, efforts are currently being undertaken to identify new, native proteins which are involved in synaptic machinery and cell adhesion. We describe herein the identification of novel polypeptides which have homology to densin, designated herein as PRO239 polypeptides.

30. **PRO257**

Ebnerin is a cell surface protein associated with von Ebner glands in mammals. Efforts are being undertaken by both industry and academia to identify new, native cell surface receptor proteins and specifically those which possess sequence homology to cell surface proteins such as ebnerin. Many of these efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel receptor proteins. We herein describe the identification of novel polypeptides having significant homology to the von Ebner's gland-associated protein ebnerin, designated herein as PRO257 polypeptides.

25 31. **PRO260**

Fucosidases are enzymes that remove fucose residues from fucose containing proteoglycans. In some pathological conditions, such as cancer, rheumatoid arthritis, and diabetes, there is an abnormal fucosylation of serum proteins. Therefore, fucosidases, and proteins having homology to fucosidase, are of importance to the study and abrogation of these conditions. In particular, proteins having homology to the alpha-L-fucosidase precursor are of interest. Fucosidases and fucosidase inhibitors are further described in U.S. Patent Nos. 5,637,490, 5,382,709, 5,240,707, 5,153,325, 5,100,797, 5,096,909 and 5,017,704. Studies are also reported in Valk, et al., *J. Virol.*, 71(9):6796 (1997), Aktogu, et al., *Monaldi Arch. Chest Dis.* (Italy), 52(2):118 (1997) and Focarelli, et al., *Biochem. Biophys. Res. Commun.* (U.S.), 234(1):54 (1997).

Efforts are being undertaken by both industry and academia to identify new, native secreted and membrane-bound receptor proteins. Of particular interest are proteins having homology to the alpha-L-fucosidase precursor. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted and membrane-bound receptor proteins. Examples of screening methods and techniques are

described in the literature [see, for example, Klein et al., *Proc. Natl. Acad. Sci.*, 93:7108-7113 (1996); U.S. Patent No. 5,536,637)].

We herein describe the identification and characterization of novel polypeptides having homology to fucosidases, designated herein as PRO260 polypeptides.

5           32.       PRO263

CD44 is a cell surface adhesion molecule involved in cell-cell and cell-matrix interactions. Hyaluronic acid, a component of the extracellular matrix is a major ligand. Other ligands include collagen, fibronectin, laminin, chondroitin sulfate, mucosal addressin, serglycin and osteoponin. CD44 is also important in regulating cell traffic, lymph node homing, transmission of growth signals, and presentation of chemokines and growth factors to traveling 10 cells. CD44 surface proteins are associated with metastatic tumors and CD44 has been used as a marker for HIV infection. Certain splice variants are associated with metastasis and poor prognosis of cancer patients. Therefore, molecules having homology with CD44 are of particular interest, as their homology indicates that they may have functions related to those functions of CD44. CD44 is further described in U.S. Patent Nos. 5,506,119, 5,504,194 and 5,108,904; Gerberick, et al., *Toxicol. Appl. Pharmacol.*, 146(1):1 (1997); Wittig, et al., *Immunol. Letters* 15 (Netherlands), 57(1-3):217 (1997); and Oliveira and Odell, *Oral Oncol.* (England), 33(4):260 (1997).

Efforts are being undertaken by both industry and academia to identify new, native secreted and membrane-bound receptor proteins, particularly transmembrane proteins with homology to CD44 antigen. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted and membrane-bound receptor proteins. Examples of screening methods and techniques are described in 20 the literature [see, for example, Klein et al., *Proc. Natl. Acad. Sci.*, 93:7108-7113 (1996); U.S. Patent No. 5,536,637)].

We herein describe the identification and characterization of novel polypeptides having homology to CD44 antigen, designated herein as PRO263 polypeptides.

25           33.       PRO270

Thioredoxins effect reduction-oxidation (redox) state. Many diseases are potentially related to redox state and reactive oxygen species may play a role in many important biological processes. The transcription factors, NF-kappa B and AP-1, are regulated by redox state and are known to affect the expression of a large variety of genes thought to be involved in the pathogenesis of AIDS, cancer, atherosclerosis and diabetic complications. Such proteins may also 30 play a role in cellular antioxidant defense, and in pathological conditions involving oxidative stress such as stroke and inflammation in addition to having a role in apoptosis. Therefore, thioredoxins, and proteins having homology thereto, are of interest to the scientific and medical communities.

We herein describe the identification and characterization of novel polypeptides having homology to thioredoxin, designated herein as PRO270 polypeptides.

35

34. **PRO271**

The proteoglycan link protein is a protein which is intimately associated with various extracellular matrix proteins and more specifically with proteins such as collagen. For example, one primary component of collagen is a large proteoglycan called aggrecan. This molecule is retained by binding to the glycosaminoglycan hyaluronan through the amino terminal G1 globular domain of the core protein. This binding is stabilized by the proteoglycan link protein which is a protein that is also associated with other tissues containing hyaluronan binding proteoglycans such as versican.

Link protein has been identified as a potential target for autoimmune antibodies in individuals who suffer from juvenile rheumatoid arthritis (see Guerassimov et al., *J. Rheumatology* 24(5):959-964 (1997)). As such, there is strong interest in identifying novel proteins having homology to link protein. We herein describe the identification 10 and characterization of novel polypeptides having such homology, designated herein as PRO271 polypeptides.

35. **PRO272**

Reticulocalbin is an endoplasmic reticular protein which may be involved in protein transport and luminal protein processing. Reticulocalbin resides in the lumen of the endoplasmic reticulum, is known to bind calcium, 15 and may be involved in a luminal retention mechanism of the endoplasmic reticulum. It contains six domains of the EF-hand motif associated with high affinity calcium binding. We describe herein the identification and characterization of a novel polypeptide which has homology to the reticulocalbin protein, designated herein as PRO272.

20 36. **PRO294**

Collagen, a naturally occurring protein, finds wide application in industry. Chemically hydrolyzed natural collagen can be denatured and renatured by heating and cooling to produce gelatin, which is used in photographic and medical, among other applications. Collagen has important properties such as the ability to form interchain aggregates having a conformation designated as a triple helix. We herein describe the identification and 25 characterization of a novel polypeptide which has homology to portions of the collagen molecule, designated herein as PRO294.

37. **PRO295**

The integrins comprise a supergene family of cell-surface glycoprotein receptors that promote cellular 30 adhesion. Each cell has numerous receptors that define its cell adhesive capabilities. Integrins are involved in a wide variety of interaction between cells and other cells or matrix components. The integrins are of particular importance in regulating movement and function of immune system cells. The platelet IIb/IIIa integrin complex is of particular importance in regulating platelet aggregation. A member of the integrin family, integrin  $\beta$ -6, is expressed on epithelial cells and modulates epithelial inflammation. Another integrin, leucocyte-associated antigen-1 (LFA-1) is important 35 in the adhesion of lymphocytes during an immune response. The integrins are expressed as heterodimers of non-covalently associated alpha and beta subunits. Given the physiological importance of cell adhesion mechanisms *in vivo*, efforts are currently being undertaken to identify new, native proteins which are involved in cell adhesion. We

describe herein the identification and characterization of a novel polypeptide which has homology to integrin, designated herein as PRO295.

38. **PRO293**

5 Protein-protein interactions include receptor and antigen complexes and signaling mechanisms. As more is known about the structural and functional mechanisms underlying protein-protein interactions, protein-protein interactions can be more easily manipulated to regulate the particular result of the protein-protein interaction. Thus, the underlying mechanisms of protein-protein interactions are of interest to the scientific and medical community.

10 All proteins containing leucine-rich repeats are thought to be involved in protein-protein interactions. Leucine-rich repeats are short sequence motifs present in a number of proteins with diverse functions and cellular locations. The crystal structure of ribonuclease inhibitor protein has revealed that leucine-rich repeats correspond to beta-alpha structural units. These units are arranged so that they form a parallel beta-sheet with one surface exposed to solvent, so that the protein acquires an unusual, nonglobular shape. These two features have been indicated as responsible for the protein-binding functions of proteins containing leucine-rich repeats. See, Kobe and Deisenhofer, *Trends Biochem. Sci.*, 19(10):415-421 (Oct. 1994).

15 A study has been reported on leucine-rich proteoglycans which serve as tissue organizers, orienting and ordering collagen fibrils during ontogeny and are involved in pathological processes such as wound healing, tissue repair, and tumor stroma formation. Iozzo, R. V., *Crit. Rev. Biochem. Mol. Biol.*, 32(2):141-174 (1997). Other studies implicating leucine rich proteins in wound healing and tissue repair are De La Salle, C., et al., *Vouv. Rev. Fr. Hematol.* (Germany), 37(4):215-222 (1995), reporting mutations in the leucine rich motif in a complex associated 20 with the bleeding disorder Bernard-Soulier syndrome and Chlemetson, K. J., *Thromb. Haemost.* (Germany), 74(1):111-116 (July 1995), reporting that platelets have leucine rich repeats. Another protein of particular interest which has been reported to have leucine-rich repeats is the SLIT protein which has been reported to be useful in treating neuro-degenerative diseases such as Alzheimer's disease, nerve damage such as in Parkinson's disease, and for diagnosis of cancer, see, Artavanistsakonas, S. and Rothberg, J. M., WO9210518-A1 by Yale University. Other 25 studies reporting on the biological functions of proteins having leucine-rich repeats include: Tayar, N., et al., *Mol. Cell Endocrinol.*, (Ireland), 125(1-2):65-70 (Dec. 1996) (gonadotropin receptor involvement); Miura, Y., et al., *Nippon Rinsho* (Japan), 54(7):1784-1789 (July 1996) (apoptosis involvement); Harris, P. C., et al., *J. Am. Soc. Nephrol.*, 6(4):1125-1133 (Oct. 1995) (kidney disease involvement); and Ruoslahti, E. I., et al., WO9110727-A by La Jolla Cancer Research Foundation (decorin binding to transforming growth factor $\beta$  involvement for treatment for 30 cancer, wound healing and scarring).

Efforts are therefore being undertaken by both industry and academia to identify new proteins having leucine rich repeats to better understand protein-protein interactions. Of particular interest are those proteins having leucine rich repeats and homology to known neuronal leucine rich repeat proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted and membrane-bound 35 proteins having leucine rich repeats. Examples of screening methods and techniques are described in the literature [see, for example, Klein et al., *Proc. Natl. Acad. Sci.*, 93:7108-7113 (1996); U.S. Patent No. 5,536,637].

We describe herein the identification and characterization of a novel polypeptide which has homology to leucine rich repeat proteins, designated herein as PRO293.

39. **PRO247**

5 Protein-protein interactions include receptor and antigen complexes and signaling mechanisms. As more is known about the structural and functional mechanisms underlying protein-protein interactions, protein-protein interactions can be more easily manipulated to regulate the particular result of the protein-protein interaction. Thus, the underlying mechanisms of protein-protein interactions are of interest to the scientific and medical community.

10 All proteins containing leucine-rich repeats are thought to be involved in protein-protein interactions. Leucine-rich repeats are short sequence motifs present in a number of proteins with diverse functions and cellular locations. The crystal structure of ribonuclease inhibitor protein has revealed that leucine-rich repeats correspond to beta-alpha structural units. These units are arranged so that they form a parallel beta-sheet with one surface exposed to solvent, so that the protein acquires an unusual, nonglobular shape. These two features have been indicated as responsible for the protein-binding functions of proteins containing leucine-rich repeats. See, Kobe and Deisenhofer, *Trends Biochem. Sci.*, 19(10):415-421 (Oct. 1994).

15 A study has been reported on leucine-rich proteoglycans which serve as tissue organizers, orienting and ordering collagen fibrils during ontogeny and are involved in pathological processes such as wound healing, tissue repair, and tumor stroma formation. Iozzo, R. V., *Crit. Rev. Biochem. Mol. Biol.*, 32(2):141-174 (1997). Others studies implicating leucine rich proteins in wound healing and tissue repair are De La Salle, C., et al., *Vouv. Rev. Fr. Hematol.* (Germany), 37(4):215-222 (1995), reporting mutations in the leucine rich motif in a complex associated 20 with the bleeding disorder Bernard-Soulier syndrome and Chlemetson, K. J., *Thromb. Haemost.* (Germany), 74(1):111-116 (July 1995), reporting that platelets have leucine rich repeats. Another protein of particular interest which has been reported to have leucine-rich repeats is the SLIT protein which has been reported to be useful in treating neuro-degenerative diseases such as Alzheimer's disease, nerve damage such as in Parkinson's disease, and for diagnosis of cancer, see, Artavanistsakonas, S. and Rothberg, J. M., WO9210518-A1 by Yale University. Other 25 studies reporting on the biological functions of proteins having leucine-rich repeats include: Tayar, N., et al., *Mol. Cell Endocrinol.*, (Ireland), 125(1-2):65-70 (Dec. 1996) (gonadotropin receptor involvement); Miura, Y., et al., *Nippon Rinsho* (Japan), 54(7):1784-1789 (July 1996) (apoptosis involvement); Harris, P. C., et al., *J. Am. Soc. Nephrol.*, 6(4):1125-1133 (Oct. 1995) (kidney disease involvement); and Ruoslahti, E. I., et al., WO9110727-A by La Jolla Cancer Research Foundation (decorin binding to transforming growth factor $\beta$  involvement for treatment for 30 cancer, wound healing and scarring).

35 Densin is a glycoprotein which has been isolated from the brain which has all the hallmarks of an adhesion molecule. It is highly concentrated at synaptic sites in the brain and is expressed prominently in dendritic processes in developing neurons. Densin has been characterized as a member of the O-linked sialoglycoproteins. Densin has relevance to medically important processes such as regeneration. Given the physiological importance of synaptic processes and cell adhesion mechanisms *in vivo*, efforts are currently being undertaken to identify new, native proteins which are involved in synaptic machinery and cell adhesion. Densin is further described in Kennedy, M.B, *Trends Neurosci.* (England), 20(6):264 (1997) and Apperson, et al., *J. Neurosci.*, 16(21):6839 (1996).

Efforts are therefore being undertaken by both industry and academia to identify new proteins having leucine rich repeats to better understand protein-protein interactions. Of particular interest are those proteins having leucine rich repeats and homology to known proteins having leucine rich repeats such as KIAA0231 and densin. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted and membrane-bound proteins having leucine rich repeats. Examples of screening methods and 5 techniques are described in the literature [see, for example, Klein et al., *Proc. Natl. Acad. Sci.*, **93**:7108-7113 (1996); U.S. Patent No. 5,536,637)].

We describe herein the identification and characterization of a novel polypeptide which has homology to leucine rich repeat proteins, designated herein as PRO247.

10

#### 40. PRO302, PRO303, PRO304, PRO307 and PRO343

Proteases are enzymatic proteins which are involved in a large number of very important biological processes in mammalian and non-mammalian organisms. Numerous different protease enzymes from a variety of different mammalian and non-mammalian organisms have been both identified and characterized. The mammalian protease enzymes play important roles in many different biological processes including, for example, protein 15 digestion, activation, inactivation, or modulation of peptide hormone activity, and alteration of the physical properties of proteins and enzymes.

In light of the important physiological roles played by protease enzymes, efforts are currently being undertaken by both industry and academia to identify new, native protease homologs. Many of these efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel 20 secreted and membrane-bound receptor proteins. Examples of screening methods and techniques are described in the literature [see, for example, Klein et al., *Proc. Natl. Acad. Sci.*, **93**:7108-7113 (1996); U.S. Patent No. 5,536,637)]. We herein describe the identification of novel polypeptides having homology to various protease enzymes, designated herein as PRO302, PRO303, PRO304, PRO307 and PRO343 polypeptides.

25

#### 41. PRO328

The GLIP protein family has been characterized as comprising zinc-finger proteins which play important roles in embryogenesis. These proteins may function as transcriptional regulatory proteins and are known to be amplified in a subset of human tumors. Glioma pathogenesis protein is structurally related to a group of plant pathogenesis-related proteins. It is highly expressed in glioblastoma. See US Pat. Nos. 5,582,981 (issued Dec. 10, 30 1996) and 5,322,801 (issued June 21, 1996), Ellington, A.D. et al., *Nature*, **346**:818 (1990), Grindley, J.C. et al., *Dev. Biol.*, **188**(2):337 (1997), Marine, J.C. et al., *Mech. Dev.*, **63**(2):211 (1997). The CRISP or cysteine rich secretory protein family are a group of proteins which are also structurally related to a group of plant pathogenesis proteins. [Schwidetzky, U., *Biochem. J.*, **321**:325 (1997), Pfisterer, P., *Mol. Cell Biol.*, **16**(11):6160 (1996), Kratzschmar, J., *Eur. J. Biochem.*, **236**(3):827 (1996)]. We describe herein the identification of a novel polypeptide 35 which has homology to GLIP and CRISP, designated herein as PRO328 polypeptides.

42. PRO335, PRO331 and PRO326

Protein-protein interactions include receptor and antigen complexes and signaling mechanisms. As more is known about the structural and functional mechanisms underlying protein-protein interactions, protein-protein interactions can be more easily manipulated to regulate the particular result of the protein-protein interaction. Thus, the underlying mechanisms of protein-protein interactions are of interest to the scientific and medical community.

5 All proteins containing leucine-rich repeats are thought to be involved in protein-protein interactions. Leucine-rich repeats are short sequence motifs present in a number of proteins with diverse functions and cellular locations. The crystal structure of ribonuclease inhibitor protein has revealed that leucine-rich repeats correspond to beta-alpha structural units. These units are arranged so that they form a parallel beta-sheet with one surface exposed to solvent, so that the protein acquires an unusual, nonglobular shape. These two features have been  
10 indicated as responsible for the protein-binding functions of proteins containing leucine-rich repeats. See, Kobe and Deisenhofer, Trends Biochem. Sci., 19(10):415-421 (Oct. 1994).

A study has been reported on leucine-rich proteoglycans which serve as tissue organizers, orienting and ordering collagen fibrils during ontogeny and are involved in pathological processes such as wound healing, tissue repair, and tumor stroma formation. Iozzo, R. V., Crit. Rev. Biochem. Mol. Biol., 32(2):141-174 (1997). Other  
15 studies implicating leucine rich proteins in wound healing and tissue repair are De La Salle, C., et al., Voxv. Rev. Fr. Hematol. (Germany), 37(4):215-222 (1995), reporting mutations in the leucine rich motif in a complex associated with the bleeding disorder Bernard-Soulier syndrome, Chlebetson, K. J., Thromb. Haemost. (Germany), 74(1):111-116 (July 1995), reporting that platelets have leucine rich repeats and Ruoslahti, E. I., et al., WO9110727-A by La  
Jolla Cancer Research Foundation reporting that decorin binding to transforming growth factor $\beta$  has involvement in  
20 a treatment for cancer, wound healing and scarring. Related by function to this group of proteins is the insulin like growth factor (IGF), in that it is useful in wound-healing and associated therapies concerned with re-growth of tissue, such as connective tissue, skin and bone; in promoting body growth in humans and animals; and in stimulating other growth-related processes. The acid labile subunit of IGF (ALS) is also of interest in that it increases the half-life of IGF and is part of the IGF complex *in vivo*.

25 Another protein which has been reported to have leucine-rich repeats is the SLIT protein which has been reported to be useful in treating neuro-degenerative diseases such as Alzheimer's disease, nerve damage such as in Parkinson's disease, and for diagnosis of cancer, see, Artavanistsakonas, S. and Rothberg, J. M., WO9210518-A1 by Yale University. Of particular interest is LIG-1, a membrane glycoprotein that is expressed specifically in glial cells in the mouse brain, and has leucine rich repeats and immunoglobulin-like domains. Suzuki, et al., J. Biol. Chem. (U.S.), 271(37):22522 (1996). Other studies reporting on the biological functions of proteins having leucine rich repeats include: Tayar, N., et al., Mol. Cell Endocrinol., (Ireland), 125(1-2):65-70 (Dec. 1996) (gonadotropin receptor involvement); Miura, Y., et al., Nippon Rinsho (Japan), 54(7):1784-1789 (July 1996) (apoptosis involvement); Harris, P. C., et al., J. Am. Soc. Nephrol., 6(4):1125-1133 (Oct. 1995) (kidney disease involvement).

30 Efforts are therefore being undertaken by both industry and academia to identify new proteins having leucine rich repeats to better understand protein-protein interactions. Of particular interest are those proteins having leucine rich repeats and homology to known proteins having leucine rich repeats such as LIG-1, ALS and decorin. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for

novel secreted and membrane-bound proteins having leucine rich repeats. Examples of screening methods and techniques are described in the literature [see, for example, Klein et al., *Proc. Natl. Acad. Sci.*, **93**:7108-7113 (1996); U.S. Patent No. 5,536,637)].

We describe herein the identification and characterization of novel polypeptides which have homology to proteins of the leucine rich repeat superfamily, designated herein as PRO335, PRO331 and PRO326 polypeptides.

5

#### 43. PRO332

Secreted proteins comprising a repeat characterized by an arrangement of conserved leucine residues (leucine-rich repeat motif) have diverse biological roles. Certain proteoglycans, such as biglycan, fibromodulin and decorin, are, for example, characterized by the presence of a leucine-rich repeat of about 24 amino acids [Ruoslahti, 10 *Ann. Rev. Cell. Biol.* **4** 229-255 (1988); Oldberg *et al.*, *EMBO J.* **8**, 2601-2604 (1989)]. In general, proteoglycans are believed to play a role in regulating extracellular matrix, cartilage or bone function. The proteoglycan decorin binds to collagen type I and II and affects the rate of fibril formation. Fibromodulin also binds collagen and delays fibril formation. Both fibromodulin and decorin inhibit the activity of transforming growth factor beta (TGF- $\beta$ ) (U.S. Patent No. 5,583,103 issued December 10, 1996). TGF- $\beta$  is known to play a key role in the induction of 15 extracellular matrix and has been implicated in the development of fibrotic diseases, such as cancer and glomerulonephritis. Accordingly, proteoglycans have been proposed for the treatment of fibrotic cancer, based upon their ability to inhibit TGF- $\beta$ 's growth stimulating activity on the cancer cell. Proteoglycans have also been described as potentially useful in the treatment of other proliferative pathologies, including rheumatoid arthritis, arteriosclerosis, adult respiratory distress syndrome, cirrhosis of the liver, fibrosis of the lungs, post-myocardial infarction, cardiac 20 fibrosis, post-angioplasty restenosis, renal interstitial fibrosis and certain dermal fibrotic conditions, such as keloids and scarring, which might result from burn injuries, other invasive skin injuries, or cosmetic or reconstructive surgery (U.S. Patent No. 5,654,270, issued August 5, 1997).

We describe herein the identification and characterization of novel polypeptides which have homology to proteins of the leucine rich repeat superfamily, designated herein as PRO332 polypeptides.

25

#### 44. PRO334

Microfibril bundles and proteins found in association with these bundles, particularly attachment molecules, are of interest in the field of dermatology, particularly in the study of skin which has been damaged from aging, 30 injuries or the sun. Fibrillin microfibrils define the continuous elastic network of skin, and are present in dermis as microfibril bundles devoid of measurable elastin extending from the dermal-epithelial junction and as components of the thick elastic fibres present in the deep reticular dermis. Moreover, Marfan syndrome has been linked to mutations which interfere with multimerization of fibrillin monomers or other connective tissue elements.

Fibulin-1 is a modular glycoprotein with amino-terminal anaphylatoxin-like modules followed by nine epidermal growth factor (EGF)-like modules and, depending on alternative splicing, four possible carboxyl termini. 35 Fibulin-2 is a novel extracellular matrix protein frequently found in close association with microfibrils containing either fibronectin or fibrillin. Thus, fibrillin, fibulin, and molecules related thereto are of interest, particularly for the use of preventing skin from being damaged from aging, injuries or the sun, or for restoring skin damaged from

same. Moreover, these molecules are generally of interest in the study of connective tissue and attachment molecules and related mechanisms. Fibrillin, fibulin and related molecules are further described in Adams, et al., *J. Mol. Biol.*, 272(2):226-36 (1997); Kielty and Shuttleworth, *Microsc. Res. Tech.*, 38(4):413-27 (1997); and *Child. J. Card. Surg.*, 12(2Supp.):131-5 (1997).

5 Currently, efforts are being undertaken by both industry and academia to identify new, native secreted and membrane-bound receptor proteins, particularly secreted proteins which have homology to fibulin and fibrillin. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted and membrane-bound receptor proteins. Examples of screening methods and techniques are described in the literature [see, for example, Klein et al., *Proc. Natl. Acad. Sci.*, 93:7108-7113 (1996); U.S. Patent No. 5,536,637].

10 We herein describe the identification and characterization of novel polypeptides having homology to fibulin and fibrillin, designated herein as PRO334 polypeptides.

45. **PRO346**

15 The widespread occurrence of cancer has prompted the devotion of considerable resources and discovering new treatments of treatment. One particular method involves the creation of tumor or cancer specific monoclonal antibodies (mAbs) which are specific to tumor antigens. Such mAbs, which can distinguish between normal and cancerous cells are useful in the diagnosis, prognosis and treatment of the disease. Particular antigens are known to be associated with neoplastic diseases, such as colorectal and breast cancer. Since colon cancer is a widespread disease, early diagnosis and treatment is an important medical goal. Diagnosis and treatment of cancer can be 20 implemented using monoclonal antibodies (mAbs) specific therefore having fluorescent, nuclear magnetic or radioactive tags. Radioactive genes, toxins and/or drug tagged mAbs can be used for treatment *in situ* with minimal patient description.

25 Carcinoembryonic antigen (CEA) is a glycoprotein found in human colon cancer and the digestive organs of a 2-6 month human embryos. CEA is a known human tumor marker and is widely used in the diagnosis of neoplastic diseases, such as colon cancer. For example, when the serum levels of CEA are elevated in a patient, a drop of CEA levels after surgery would indicate the tumor resection was successful. On the other hand, a subsequent rise in serum CEA levels after surgery would indicate that metastases of the original tumor may have formed or that new primary tumors may have appeared. CEA may also be a target for mAb, antisense nucleotides

30 46. **PRO268**

35 Protein disulfide isomerase is an enzymatic protein which is involved in the promotion of correct refolding of proteins through the establishment of correct disulfide bond formation. Protein disulfide isomerase was initially identified based upon its ability to catalyze the renaturation of reduced denatured RNase (Goldberger et al., *J. Biol. Chem.* 239:1406-1410 (1964) and Epstein et al., *Cold Spring Harbor Symp. Quant. Biol.* 28:439-449 (1963)). Protein disulfide isomerase has been shown to be a resident enzyme of the endoplasmic reticulum which is retained in the endoplasmic reticulum via a -KDEL or -HDEL amino acid sequence at its C-terminus.

Given the importance of disulfide bond-forming enzymes and their potential uses in a number of different applications, for example in increasing the yield of correct refolding of recombinantly produced proteins, efforts are currently being undertaken by both industry and academia to identify new, native proteins having homology to protein disulfide isomerase. Many of these efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel protein disulfide isomerase homologs. We herein describe a novel 5 polypeptide having homology to protein disulfide isomerase, designated herein as PRO268.

**47. PRO330**

Prolyl 4-hydroxylase is an enzyme which functions to post-translationally hydroxylate proline residues at the Y position of the amino acid sequence Gly-X-Y, which is a repeating three amino acid sequence found in both 10 collagen and procollagen. Hydroxylation of proline residues at the Y position of the Gly-X-Y amino acid triplet to form 4-hydroxyproline residues at those positions is required before newly synthesized collagen polypeptide chains may fold into their proper three-dimensional triple-helical conformation. If hydroxylation does not occur, synthesized 15 collagen polypeptides remain non-helical, are poorly secreted by cells and cannot assemble into stable functional collagen fibrils. Vuorio et al., *Proc. Natl. Acad. Sci. USA* 89:7467-7470 (1992). Prolyl 4-hydroxylase is comprised of at least two different polypeptide subunits, alpha and beta.

Efforts are being undertaken by both industry and academia to identify new, native secreted and membrane-bound receptor proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted and membrane-bound receptor proteins. Examples of screening methods and techniques are described in the literature [see, for example, Klein et al., *Proc. Natl. Acad. Sci.*, 20 93:7108-7113 (1996); U.S. Patent No. 5,536,637)]. Based upon these efforts, Applicants have herein identified and describe a novel polypeptide having homology to the alpha subunit of prolyl 4-hydroxylase, designated herein as PRO330.

**48. PRO339 and PRO310**

Fringe is a protein which specifically blocks serrate-mediated activation of notch in the dorsal compartment 25 of the Drosophila wing imaginal disc. Fleming, et al., *Development*, 124(15):2973-81 (1997). Therefore, fringe is of interest for both its role in development as well as its ability to regulate serrate, particularly serrate's signaling abilities. Also of interest are novel polypeptides which may have a role in development and/or the regulation of 30 serrate-like molecules. Of particular interest are novel polypeptides having homology to fringe as identified and described herein, designated herein as PRO339 and PRO310 polypeptides.

**49. PRO244**

Lectins are a class of proteins comprising a region that binds carbohydrates specifically and non-covalently. Numerous lectins have been identified in higher animals, both membrane-bound and soluble, and have been 35 implicated in a variety of cell-recognition phenomena and tumor metastasis.

Most lectins can be classified as either C-type (calcium-dependent) or S-type (thiol-dependent).

Lectins are thought to play a role in regulating cellular events that are initiated at the level of the plasma membrane. For example, plasma membrane associated molecules are involved in the activation of various subsets of lymphoid cells, e.g. T-lymphocytes, and it is known that cell surface molecules are responsible for activation of these cells and consequently their response during an immune reaction.

A particular group of cell adhesion molecules, selectins, belong in the superfamily of C-type lectins. This 5 group includes L-selectin (peripheral lymph node homing receptor (pnHR), LEC-CAM-1, LAM-1, gp90<sup>MEL</sup>, gp100<sup>MEL</sup>, gp110<sup>MEL</sup>, MEL-14 antigen, Leu-8 antigen, TQ-1 antigen, DREG antigen), E-selectin (LEC-CAM-2, LECAM-2, ELAM-1), and P-selectin (LEC-CAM-3, LECAM-3, GMP-140, PADGEM). The structure of selectins consists of a C-type lectin (carbohydrate binding) domain, an epidermal growth factor-like (EGF-like) motif, and variable numbers of complement regulatory (CR) motifs. Selectins are associated with leukocyte adhesion, e.g. the 10 attachment of neutrophils to venular endothelial cells adjacent to inflammation (E-selectin), or with the trafficking of lymphocytes from blood to secondary lymphoid organs, e.g. lymph nodes and Peyer's patches (L-selectin).

Another exemplary lectin is the cell-associated macrophage antigen, Mac-2 that is believed to be involved in cell adhesion and immune responses. Macrophages also express a lectin that recognizes Tn Ag, a human carcinoma-associated epitope.

15 Another C-type lectin is CD95 (Fas antigen/APO-1) that is an important mediator of immunologically relevant regulated or programmed cell death (apoptosis). "Apoptosis" is a non-necrotic cell death that takes place in metazoan animal cells following activation of an intrinsic cell suicide program. The cloning of Fas antigen is described in PCT publication WO 91/10448, and European patent application EP510691. The mature Fas molecule consists of 319 amino acids of which 157 are extracellular, 17 constitute the transmembrane domain, and 145 are 20 intracellular. Increased levels of Fas expression at T cell surface have been associated with tumor cells and HIV-infected cells. Ligation of CD95 triggers apoptosis in the presence of interleukin-1 (IL-2).

C-type lectins also include receptors for oxidized low-density lipoprotein (LDL). This suggests a possible role in the pathogenesis of atherosclerosis.

We herein describe the identification and characterization of novel polypeptides having homology to C-type 25 lectins, designated herein as PRO244 polypeptides.

#### SUMMARY OF THE INVENTION

##### **1. PRO211 and PRO217**

Applicants have identified cDNA clones that encode novel polypeptides having homology to EGF, designated 30 in the present application as "PRO211" and "PRO217" polypeptides.

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO211 or PRO217 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding EGF-like homologue PRO211 and PRO217 polypeptides of Fig. 2 (SEQ ID NO:2) and/or 4 (SEQ ID NO:4) indicated in Fig. 1 (SEQ ID NO: 1) and/or Fig. 3 (SEQ ID NO:3), respectively, or is complementary to such encoding nucleic acid 35 sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO211 and PRO217 EGF-like homologue PRO211 and PRO217 polypeptides. In particular, the invention provides isolated native sequence PRO211 and PRO217 EGF-

like homologue polypeptides, which in one embodiment, includes an amino acid sequence comprising residues: 1 to 353 of Fig. 2 (SEQ ID NO:2) or (2) 1 to 379 of Fig. 4 (SEQ ID NO: 4).

## 2. PRO230

Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is 5 designated in the present application as "PRO230".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO230 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO230 polypeptide having amino acid residues 1 through 467 of Figure 6 (SEQ ID NO:12), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency 10 conditions.

In another embodiment, the invention provides isolated PRO230 polypeptide. In particular, the invention provides isolated native sequence PRO230 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 through 467 of Figure 6 (SEQ ID NO:12).

In another embodiment, the invention provides an expressed sequence tag (EST) comprising the nucleotide 15 sequence of SEQ ID NO:13 (Figure 7) which is herein designated as DNA20088.

## 3. PRO232

Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO232".

20 In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO232 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO232 polypeptide having amino acid residues 1 to 114 of Figure 9 (SEQ ID NO:18), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

25 In another embodiment, the invention provides isolated PRO232 polypeptide. In particular, the invention provides isolated native sequence PRO232 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 114 of Figure 9 (SEQ ID NO:18).

## 4. PRO187

30 Applicants have identified a cDNA clone that encodes a novel polypeptide, designated in the present application as "PRO187".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO187 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO187 polypeptide of Figure 11 (SEQ ID NO:23), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions. In another aspect, the invention 35 provides a nucleic acid comprising the coding sequence of Figure 10 (SEQ ID NO:22) or its complement. In another aspect, the invention provides a nucleic acid of the full length protein of clone DNA27864-1155, deposited with the ATCC under accession number ATCC 209375, alternatively the coding sequence of clone DNA27864-1155,

deposited under accession number ATCC 209375.

In yet another embodiment, the invention provides isolated PRO187 polypeptide. In particular, the invention provides isolated native sequence PRO187 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 205 of Figure 11 (SEQ ID NO:23). Alternatively, the invention provides a polypeptide encoded by the nucleic acid deposited under accession number ATCC 209375.

5

#### 5. **PRO265**

Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO265".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a 10 PRO265 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO265 polypeptide having amino acid residues 1 to 660 of Figure 13 (SEQ ID NO:28), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO265 polypeptide. In particular, the invention 15 provides isolated native sequence PRO265 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 660 of Figure 13 (SEQ ID NO:28). An additional embodiment of the present invention is directed to an isolated extracellular domain of a PRO265 polypeptide.

#### 6. **PRO219**

20 Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO219".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a 25 PRO219 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO219 polypeptide having amino acid residues 1 to 915 of Figure 15 (SEQ ID NO:34), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO219 polypeptide. In particular, the invention provides isolated native sequence PRO219 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 915 of Figure 15 (SEQ ID NO:34).

30

#### 7. **PRO246**

Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO246".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a 35 PRO246 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO246 polypeptide having amino acid residues 1 to 390 of Figure 17 (SEQ ID NO:39), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency

conditions.

In another embodiment, the invention provides isolated PRO246 polypeptide. In particular, the invention provides isolated native sequence PRO246 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 390 of Figure 17 (SEQ ID NO:39). An additional embodiment of the present invention is directed to an isolated extracellular domain of a PRO246 polypeptide.

5

8. **PRO228**

Applicants have identified a cDNA clone that encodes a novel polypeptide having homology to CD97, EMR1 and latrophilin, wherein the polypeptide is designated in the present application as "PRO228".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a 10 PRO228 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO228 polypeptide having amino acid residues 1 to 690 of Figure 19 (SEQ ID NO:49), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO228 polypeptide. In particular, the invention 15 provides isolated native sequence PRO228 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 690 of Figure 19 (SEQ ID NO:49). An additional embodiment of the present invention is directed to an isolated extracellular domain of a PRO228 polypeptide.

In another embodiment, the invention provides an expressed sequence tag (EST) comprising the nucleotide sequence of SEQ ID NO:50, designated herein as DNA21951.

20

9. **PRO533**

Applicants have identified a cDNA clone (DNA49435-1219) that encodes a novel polypeptide, designated in the present application as PRO533.

In one embodiment, the invention provides an isolated nucleic acid molecule having at least about 80% 25 sequence identity to (a) a DNA molecule encoding a PRO533 polypeptide comprising the sequence of amino acids 23 to 216 of Figure 22 (SEQ ID NO:59), or (b) the complement of the DNA molecule of (a). The sequence identity preferably is about 85%, more preferably about 90%, most preferably about 95%. In one aspect, the isolated nucleic acid has at least about 80%, preferably at least about 85%, more preferably at least about 90%, and most preferably 30 at least about 95% sequence identity with a polypeptide having amino acid residues 23 to 216 of Figure 22 (SEQ ID NO:59). Preferably, the highest degree of sequence identity occurs within the secreted portion (amino acids 23 to 216 of Figure 22, SEQ ID NO:59). In a further embodiment, the isolated nucleic acid molecule comprises DNA encoding a PRO533 polypeptide having amino acid residues 1 to 216 of Figure 22 (SEQ ID NO:59), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions. In another aspect, the invention provides a nucleic acid of the full length 35 protein of clone DNA49435-1219, deposited with the ATCC under accession number ATCC 209480.

In yet another embodiment, the invention provides isolated PRO533 polypeptide. In particular, the invention provides isolated native sequence PRO533 polypeptide, which in one embodiment, includes an amino acid sequence

comprising residues 23 to 216 of Figure 22 (SEQ ID NO:59). Native PRO533 polypeptides with or without the native signal sequence (amino acids 1 to 22 in Figure 22 (SEQ ID NO:59)), and with or without the initiating methionine are specifically included. Alternatively, the invention provides a PRO533 polypeptide encoded by the nucleic acid deposited under accession number ATCC 209480.

5

#### 10. PRO245

Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO245".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO245 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO245 polypeptide having amino acid residues 1 to 312 of Fig. 24 (SEQ ID NO:64), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO245 polypeptide. In particular, the invention provides isolated native sequence PRO245 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 312 of Figure 24 (SEQ ID NO:64).

15

#### 11. PRO220, PRO221 and PRO227

Applicants have identified cDNA clones that each encode novel polypeptides, all having leucine rich repeats. These polypeptides are designated in the present application as PRO220, PRO221 and PRO227.

In one embodiment, the invention provides isolated nucleic acid molecules comprising DNA respectively encoding PRO220, PRO221 and PRO227, respectively. In one aspect, provided herein is an isolated nucleic acid comprises DNA encoding the PRO220 polypeptide having amino acid residues 1 through 708 of Figure 26 (SEQ ID NO:69), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions. Also provided herein is an isolated nucleic acid comprises DNA encoding the PRO221 polypeptide having amino acid residues 1 through 259 of Figure 28 (SEQ ID NO:71), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions. Moreover, also provided herein is an isolated nucleic acid comprises DNA encoding the PRO227 polypeptide having amino acid residues 1 through 620 of Figure 30 (SEQ ID NO:73), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

30

In another embodiment, the invention provides isolated PRO220, PRO221 and PRO227 polypeptides. In particular, provided herein is the isolated native sequence for the PRO220 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 708 of Figure 26 (SEQ ID NO:69). Additionally provided herein is the isolated native sequence for the PRO221 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 259 of Figure 28 (SEQ ID NO:71). Moreover, provided herein is the isolated native sequence for the PRO227 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 620 of Figure 30 (SEQ ID NO:73).

**12. PRO258**

Applicants have identified a cDNA clone that encodes a novel polypeptide having homology to CRTAM and poliovirus receptor precursors, wherein the polypeptide is designated in the present application as "PRO258".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO258 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO258 polypeptide  
5 having amino acid residues 1 to 398 of Figure 32 (SEQ ID NO:84), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO258 polypeptide. In particular, the invention provides isolated native sequence PRO258 polypeptide, which in one embodiment, includes an amino acid sequence  
10 comprising residues 1 to 398 of Figure 32 (SEQ ID NO:84). An additional embodiment of the present invention is directed to an isolated extracellular domain of a PRO258 polypeptide.

**13. PRO266**

Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is  
15 designated in the present application as "PRO266".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO266 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO266 polypeptide having amino acid residues 1 to 696 of Figure 34 (SEQ ID NO:91), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency  
20 conditions.

In another embodiment, the invention provides isolated PRO266 polypeptide. In particular, the invention provides isolated native sequence PRO266 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 696 of Figure 34 (SEQ ID NO:91).

**25 14. PRO269**

Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as PRO269.

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO269 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO269 polypeptide  
30 having amino acid residues 1 to 490 of Fig. 36 (SEQ ID NO:96), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO269 polypeptide. In particular, the invention provides isolated native sequence PRO269 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 490 of Figure 36 (SEQ ID NO:96). An additional embodiment of the present invention is  
35 directed to an isolated extracellular domain of a PRO269 polypeptide.

**15. PRO287**

Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO287".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO287 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO287 polypeptide having amino acid residues 1 to 415 of Fig. 38 (SEQ ID NO:104), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO287 polypeptide. In particular, the invention provides isolated native sequence PRO287 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 415 of Figure 38 (SEQ ID NO:104).

10

**16. PRO214**

Applicants have identified a cDNA clone that encodes a novel polypeptide, designated in the present application as "PRO214".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO214 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO214 polypeptide of Fig. 40 (SEQ ID NO:109), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions. In another aspect, the invention provides a nucleic acid comprising the coding sequence of Fig. 39 (SEQ ID NO:108) or its complement. In another aspect, the invention provides a nucleic acid of the full length protein of clone DNA32286-1191, deposited with ATCC under accession number ATCC 209385.

In yet another embodiment, the invention provides isolated PRO214 polypeptide. In particular, the invention provides isolated native sequence PRO214 polypeptide, which in one embodiment, includes an amino acid sequence comprising the residues of Figure 40 (SEQ ID NO:109). Alternatively, the invention provides a polypeptide encoded by the nucleic acid deposited under accession number ATCC 209385.

25

**17. PRO317**

Applicants have identified a cDNA clone that encodes a novel polypeptide, designated in the present application as "PRO317".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding PRO317 polypeptide. In one aspect, the isolated nucleic acid comprises DNA (SEQ ID NO:113) encoding PRO317 polypeptide having amino acid residues 1 to 366 of Fig. 42, or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO317 polypeptide. In particular, the invention provides isolated native-sequence PRO317 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 366 of Figure 42 (SEQ ID NO:114).

In yet another embodiment, the invention supplies a method of detecting the presence of PRO317 in a sample, the method comprising:

- a) contacting a detectable anti-PRO317 antibody with a sample suspected of containing PRO317; and
- b) detecting binding of the antibody to the sample; wherein the sample is selected from the group consisting of a body fluid, a tissue sample, a cell extract, and a cell culture medium.

In a still further embodiment a method is provided for determining the presence of PRO317 mRNA in a sample, the method comprising:

- 5
  - a) contacting a sample suspected of containing PRO317 mRNA with a detectable nucleic acid probe that hybridizes under moderate to stringent conditions to PRO317 mRNA; and
  - b) detecting hybridization of the probe to the sample.

Preferably, in this method the sample is a tissue sample and the detecting step is by *in situ* hybridization, or the sample is a cell extract and detection is by Northern analysis.

- 10     Further, the invention provides a method for treating a PRO317-associated disorder comprising administering to a mammal an effective amount of the PRO317 polypeptide or a composition thereof containing a carrier, or with an effective amount of a PRO317 agonist or PRO317 antagonist, such as an antibody which binds specifically to PRO317.

15     **18. PRO301**

Applicants have identified a cDNA clone (DNA40628-1216) that encodes a novel polypeptide, designated in the present application as "PRO301".

- In one embodiment, the invention provides an isolated nucleic acid molecule having at least about 80% sequence identity to (a) a DNA molecule encoding a PRO301 polypeptide comprising the sequence of amino acids 20 28 to 258 of Fig. 44 (SEQ ID NO:119), or (b) the complement of the DNA molecule of (a). The sequence identity preferably is about 85%, more preferably about 90%, most preferably about 95%. In one aspect, the isolated nucleic acid has at least about 80%, preferably at least about 85%, more preferably at least about 90%, and most preferably at least about 95% sequence identity with a polypeptide having amino acid residues 28 to 258 of Fig. 44 (SEQ ID NO:119). Preferably, the highest degree of sequence identity occurs within the extracellular domains (amino acids 25 28 to 258 of Fig. 44, SEQ ID NO:119). In a further embodiment, the isolated nucleic acid molecule comprises DNA encoding a PRO301 polypeptide having amino acid residues 28 to 299 of Fig. 44 (SEQ ID NO:119), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions. In another aspect, the invention provides a nucleic acid of the full length protein of clone DNA40628-1216, deposited with the ATCC under accession number ATCC 209432, alternatively 30 the coding sequence of clone DNA40628-1216, deposited under accession number ATCC 209432.

- In yet another embodiment, the invention provides isolated PRO301 polypeptide. In particular, the invention provides isolated native sequence PRO301 polypeptide, which in one embodiment, includes an amino acid sequence comprising the extracellular domain residues 28 to 258 of Figure 44 (SEQ ID NO:119). Native PRO301 polypeptides with or without the native signal sequence (amino acids 1 to 27 in Figure 44 (SEQ ID NO:119), and with or without 35 the initiating methionine are specifically included. Additionally, the sequences of the invention may also comprise the transmembrane domain (residues 236 to about 258 in Figure 44; SEQ ID NO:119) and/or the intracellular domain (about residue 259 to 299 in Figure 44; SEQ ID NO:119). Alternatively, the invention provides a PRO301

polypeptide encoded by the nucleic acid deposited under accession number ATCC 209432.

19. **PRO224**

Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO224".

5 In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO224 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO224 polypeptide having amino acid residues 1 to 282 of Figure 46 (SEQ ID NO:127), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

10 In another embodiment, the invention provides isolated PRO224 polypeptide. In particular, the invention provides isolated native sequence PRO224 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 282 of Figure 46 (SEQ ID NO:127).

20. **PRO222**

15 Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO222".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO222 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO222 polypeptide having amino acid residues 1 to 490 of Fig. 48 (SEQ ID NO:132), or is complementary to such encoding nucleic acid 20 sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO222 polypeptide. In particular, the invention provides isolated native sequence PRO222 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 490 of Figure 48 (SEQ ID NO:132).

25 21. **PRO234**

Applicants have identified a cDNA clone that encodes a novel lectin polypeptide molecule, designated in the present application as "PRO234".

In one embodiment, the invention provides an isolated nucleic acid encoding a novel lectin comprising DNA 30 encoding a PRO234 polypeptide. In one aspect, the isolated nucleic acid comprises the DNA encoding PRO234 polypeptides having amino acid residues 1 to 382 of Fig. 50 (SEQ ID NO:137), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions. In another aspect, the invention provides an isolated nucleic acid molecule comprising the nucleotide sequence of Fig. 49 (SEQ ID NO:136).

In another embodiment, the invention provides isolated novel PRO234 polypeptides. In particular, the 35 invention provides isolated native sequence PRO234 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 382 of Figure 50 (SEQ ID NO:137).

In yet another embodiment, the invention provides oligonucleotide probes useful for isolating genomic and cDNA nucleotide sequences.

**22. PRO231**

Applicants have identified a cDNA clone that encodes a novel polypeptide having homology to a putative acid phosphatase, wherein the polypeptide is designated in the present application as "PRO231".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO231 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO231 polypeptide having amino acid residues 1 to 428 of Fig. 52 (SEQ ID NO:142), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO231 polypeptide. In particular, the invention provides isolated native sequence PRO231 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 428 of Figure 52 (SEQ ID NO:142).

**23. PRO229**

Applicants have identified a cDNA clone that encodes a novel polypeptide having homology to scavenger receptors wherein the polypeptide is designated in the present application as "PRO229".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO229 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO229 polypeptide having amino acid residues 1 to 347 of Figure 54 (SEQ ID NO:148), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO229 polypeptide. In particular, the invention provides isolated native sequence PRO229 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 347 of Figure 54 (SEQ ID NO:148).

25

**24. PRO238**

Applicants have identified a cDNA clone that encodes a novel polypeptide having homology to reductase, wherein the polypeptide is designated in the present application as "PRO238".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO238 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO238 polypeptide having amino acid residues 1 to 310 of Figure 56 (SEQ ID NO:153), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO238 polypeptide. In particular, the invention provides isolated native sequence PRO238 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 310 of Figure 56 (SEQ ID NO:153).

**25. PRO233**

Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO233".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO233 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO233 polypeptide having amino acid residues 1 to 300 of Figure 58 (SEQ ID NO:159), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

10 In another embodiment, the invention provides isolated PRO233 polypeptide. In particular, the invention provides isolated native sequence PRO233 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 300 of Figure 58 (SEQ ID NO:159).

**26. PRO223**

Applicants have identified a cDNA clone that encodes a novel polypeptide having homology to serine carboxypeptidase polypeptides, wherein the polypeptide is designated in the present application as "PRO223".

15 In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO223 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO223 polypeptide having amino acid residues 1 to 476 of Figure 60 (SEQ ID NO:164), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

20 In another embodiment, the invention provides isolated PRO223 polypeptide. In particular, the invention provides isolated native sequence PRO223 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 476 of Figure 60 (SEQ ID NO:164).

**27. PRO235**

25 Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO235".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO235 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO235 polypeptide having amino acid residues 1 to 552 of Figure 62 (SEQ ID NO:170), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

30 In another embodiment, the invention provides isolated PRO235 polypeptide. In particular, the invention provides isolated native sequence PRO235 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 552 of Figure 62 (SEQ ID NO:170).

28. **PRO236 and PRO262**

Applicants have identified cDNA clones that encode novel polypeptides having homology to  $\beta$ -galactosidase, wherein those polypeptides are designated in the present application as "PRO236" and "PRO262".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO236 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO236 polypeptide having amino acid residues 1 to 636 of Figure 64 (SEQ ID NO:175), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO262 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO262 polypeptide having amino acid residues 1 to 654 of Figure 66 (SEQ ID NO:177), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO236 polypeptide. In particular, the invention provides isolated native sequence PRO236 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 636 of Figure 64 (SEQ ID NO:175).

In another embodiment, the invention provides isolated PRO262 polypeptide. In particular, the invention provides isolated native sequence PRO262 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 654 of Figure 66 (SEQ ID NO:177).

20           **29. PRO239**

Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO239".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO239 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO239 polypeptide having amino acid residues 1 to 501 of Figure 68 (SEQ ID NO:185), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO239 polypeptide. In particular, the invention provides isolated native sequence PRO239 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 501 of Figure 68 (SEQ ID NO:185).

30.           **PRO257**

Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO257".

35           In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO257 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO257 polypeptide having amino acid residues 1 to 607 of Figure 70 (SEQ ID NO:190), or is complementary to such encoding nucleic

acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO257 polypeptide. In particular, the invention provides isolated native sequence PRO257 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 607 of Figure 70 (SEQ ID NO:190). An additional embodiment of the present invention  
5 is directed to an isolated extracellular domain of a PRO257 polypeptide.

### 31. PRO260

Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO260".

10 In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO260 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO260 polypeptide having amino acid residues 1 to 467 of Figure 72 (SEQ ID NO:195), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

15 In another embodiment, the invention provides isolated PRO260 polypeptide. In particular, the invention provides isolated native sequence PRO260 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 467 of Figure 72 (SEQ ID NO:195).

### 32. PRO263

20 Applicants have identified a cDNA clone that encodes a novel polypeptide having homology to CD44 antigen, wherein the polypeptide is designated in the present application as "PRO263".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO263 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO263 polypeptide having amino acid residues 1 to 322 of Figure 74 (SEQ ID NO:201), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.  
25

In another embodiment, the invention provides isolated PRO263 polypeptide. In particular, the invention provides isolated native sequence PRO263 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 322 of Figure 74 (SEQ ID NO:201). An additional embodiment of the present invention  
30 is directed to an isolated extracellular domain of a PRO263 polypeptide.

### 33. PRO270

Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO270".

35 In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO270 polypeptide. In one aspect, the isolated nucleic acid comprises DNA which includes the sequence encoding the PRO270 polypeptide having amino acid residues 1 to 296 of Fig. 76 (SEQ ID NO:207), or is complementary to

such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO270 polypeptide. In particular, the invention provides isolated native sequence PRO270 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 296 of Figure 76 (SEQ ID NO:207).

5

#### 34. PRO271

Applicants have identified a cDNA clone that encodes a novel polypeptide having homology to the proteoglycan link protein, wherein the polypeptide is designated in the present application as "PRO271".

10 In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO271 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO271 polypeptide having amino acid residues 1 to 360 of Figure 78 (SEQ ID NO:213), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

15 In another embodiment, the invention provides isolated PRO271 polypeptide. In particular, the invention provides isolated native sequence PRO271 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 360 of Figure 78 (SEQ ID NO:213).

#### 35. PRO272

20 Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO272".

25 In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO272 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO272 polypeptide having amino acid residues 1 to 328 of Figure 80 (SEQ ID NO:221), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO272 polypeptide. In particular, the invention provides isolated native sequence PRO272 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 328 of Figure 80 (SEQ ID NO:221).

30

#### 36. PRO294

Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO294".

35 In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO294 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO294 polypeptide having amino acid residues 1 to 550 of Figure 82 (SEQ ID NO:227), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO294 polypeptide. In particular, the invention provides isolated native sequence PRO294 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 550 of Figure 82 (SEQ ID NO:227).

37. **PRO295**

5 Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO295".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO295 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO295 polypeptide having amino acid residues 1 to 350 of Figure 84 (SEQ ID NO:236), or is complementary to such encoding nucleic 10 acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO295 polypeptide. In particular, the invention provides isolated native sequence PRO295 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 350 of Figure 84 (SEQ ID NO:236).

15

38. **PRO293**

Applicants have identified a cDNA clone that encodes a novel human neuronal leucine rich repeat polypeptide, wherein the polypeptide is designated in the present application as "PRO293".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a 20 PRO293 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO293 polypeptide having amino acid residues 1 to 713 of Figure 86 (SEQ ID NO:245), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO293 polypeptide. In particular, the invention 25 provides isolated native sequence PRO293 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 713 of Figure 86 (SEQ ID NO:245). An additional embodiment of the present invention is directed to an isolated extracellular domain of a PRO293 polypeptide.

39. **PRO247**

30 Applicants have identified a cDNA clone that encodes a novel polypeptide having leucine rich repeats wherein the polypeptide is designated in the present application as "PRO247".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO247 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO247 polypeptide having amino acid residues 1 to 546 of Figure 88 (SEQ ID NO:250), or is complementary to such encoding nucleic 35 acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO247 polypeptide. In particular, the invention provides isolated native sequence PRO247 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 546 of Figure 88 (SEQ ID NO:250). An additional embodiment of the present invention is directed to an isolated extracellular domain of a PRO247 polypeptide.

5        40.     PRO302, PRO303, PRO304, PRO307 and PRO343

Applicants have identified cDNA clones that encode novel polypeptides having homology to various proteases, wherein those polypeptide are designated in the present application as "PRO302", "PRO303", "PRO304", "PRO307" and "PRO343" polypeptides.

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a 10 PRO302 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO302 polypeptide having amino acid residues 1 to 452 of Figure 90 (SEQ ID NO:255), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a 15 PRO303 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO303 polypeptide having amino acid residues 1 to 314 of Figure 92 (SEQ ID NO:257), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In yet another embodiment, the invention provides an isolated nucleic acid molecule comprising DNA 20 encoding a PRO304 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO304 polypeptide having amino acid residues 1 to 556 of Figure 94 (SEQ ID NO:259), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding 25 a PRO307 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO307 polypeptide having amino acid residues 1 to 383 of Figure 96 (SEQ ID NO:261), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding 30 a PRO343 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO343 polypeptide having amino acid residues 1 to 317 of Figure 98 (SEQ ID NO:263), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO302 polypeptide. In particular, the invention 35 provides isolated native sequence PRO302 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 452 of Figure 90 (SEQ ID NO:255).

In another embodiment, the invention provides isolated PRO303 polypeptide. In particular, the invention provides isolated native sequence PRO303 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 314 of Figure 92 (SEQ ID NO:257).

5 In another embodiment, the invention provides isolated PRO304 polypeptide. In particular, the invention provides isolated native sequence PRO304 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 556 of Figure 94 (SEQ ID NO:259).

In another embodiment, the invention provides isolated PRO307 polypeptide. In particular, the invention provides isolated native sequence PRO307 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 383 of Figure 96 (SEQ ID NO:261).

10 In another embodiment, the invention provides isolated PRO343 polypeptide. In particular, the invention provides isolated native sequence PRO343 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 317 of Figure 98 (SEQ ID NO:263).

#### 41. PRO328

15 Applicants have identified a cDNA clone that encodes a novel polypeptide, wherein the polypeptide is designated in the present application as "PRO328".

20 In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO328 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO328 polypeptide having amino acid residues 1 to 463 of Figure 100 (SEQ ID NO:285), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

25 In another embodiment, the invention provides isolated PRO328 polypeptide. In particular, the invention provides isolated native sequence PRO328 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 463 of Figure 100 (SEQ ID NO:285). An additional embodiment of the present invention is directed to an isolated extracellular domain of a PRO306 polypeptide.

25

#### 42. PRO335, PRO331 and PRO326

Applicants have identified three cDNA clones that respectively encode three novel polypeptides, each having leucine rich repeats and homology to LIG-1 and ALS. These polypeptides are designated in the present application as PRO335, PRO331 and PRO326, respectively.

30 In one embodiment, the invention provides three isolated nucleic acid molecules comprising DNA respectively encoding PRO335, PRO331 and PRO326, respectively. In one aspect, herein is provided an isolated nucleic acid comprising DNA encoding the PRO335 polypeptide having amino acid residues 1 through 1059 of Figure 102 (SEQ ID NO:290), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions. Also provided herein is an isolated nucleic acid comprises DNA encoding the PRO331 polypeptide having amino acid residues 1 through 640 of Figure 104 (SEQ ID NO:292), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions. Additionally provided herein is an

isolated nucleic acid comprises DNA encoding the PRO326 polypeptide having amino acid residues 1 through 1119 of Figure 106 (SEQ ID NO:294), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO335, PRO331 and PRO326 polypeptides or extracellular domains thereof. In particular, the invention provides isolated native sequence for the PRO335 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 through 1059 of Figure 102 (SEQ ID NO:290). Also provided herein is the isolated native sequence for the PRO331 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 through 640 of Figure 104 (SEQ ID NO:292). Also provided herein is the isolated native sequence for the PRO326 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 through 1119 of Figure 106 (SEQ ID NO:294).

10

#### 43. PRO332

Applicants have identified a cDNA clone (DNA40982-1235) that encodes a novel polypeptide, designated in the present application as "PRO332."

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity to (a) a DNA molecule encoding a PRO358 polypeptide comprising the sequence of amino acids 49 to 642 of Fig. 108 (SEQ ID NO:310), or (b) the complement of the DNA molecule of (a). The sequence identity preferably is about 85%, more preferably about 90%, most preferably about 95%. In one aspect, the isolated nucleic acid has at least about 80%, preferably at least about 85%, more preferably at least about 90%, and most preferably at least about 95% sequence identity with a polypeptide having amino acid residues 1 to 642 of Fig. 108 (SEQ ID NO:310). Preferably, the highest degree of sequence identity occurs within the leucine-rich repeat domains (amino acids 116 to 624 of Fig. 108, SEQ ID NO:310). In a further embodiment, the isolated nucleic acid molecule comprises DNA encoding a PRO332 polypeptide having amino acid residues 49 to 642 of Fig. 108 (SEQ ID NO:310), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

25 In another embodiment, the invention provides isolated PRO332 polypeptides. In particular, the invention provides isolated native sequence PRO332 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 49 to 624 of Figure 108 (SEQ ID NO:310). Native PRO332 polypeptides with or without the native signal sequence (amino acids 1 to 48 in Figure 108, SEQ ID NO:310), and with or without the initiating methionine are specifically included.

30

#### 44. PRO334

Applicants have identified a cDNA clone that encodes a novel polypeptide having homology to fibulin and fibrillin, wherein the polypeptide is designated in the present application as "PRO334".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a 35 PRO334 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO334 polypeptide having amino acid residues 1 to 509 of Figure 110 (SEQ ID NO:315), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency

conditions.

In another embodiment, the invention provides isolated PRO334 polypeptide. In particular, the invention provides isolated native sequence PRO334 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 509 of Figure 110 (SEQ ID NO:315).

5

**45. PRO346**

Applicants have identified a cDNA clone (DNA44167-1243) that encodes a novel polypeptide, designated in the present application as "PRO346."

In one embodiment, the invention provides an isolated nucleic acid molecule having at least about 80% sequence identity to (a) a DNA molecule encoding a PRO346 polypeptide comprising the sequence of amino acids 10 19 to 339 of Fig. 112 (SEQ ID NO: 320), or (b) the complement of the DNA molecule of (a). The sequence identity preferably is about 85%, more preferably about 90%, most preferably about 95%. In one aspect, the isolated nucleic acid has at least about 80%, preferably at least about 85%, more preferably at least about 90%, and most preferably at least about 95% sequence identity with a polypeptide having amino acid residues 19 to 339 of Fig. 112 (SEQ ID NO:320). Preferably, the highest degree of sequence identity occurs within the extracellular domains (amino acids 15 19 to 339 of Fig. 112, SEQ ID NO:320). In alternative embodiments, the polypeptide by which the homology is measured comprises the residues 1-339, 19-360 or 19-450 of Fig. 112, SEQ ID NO:320). In a further embodiment, the isolated nucleic acid molecule comprises DNA encoding a PRO346 polypeptide having amino acid residues 19 to 339 of Fig. 112 (SEQ ID NO:320), alternatively residues 1-339, 19-360 or 19-450 of Fig. 112 (SEQ ID NO:320) or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, 20 and optionally, under high stringency conditions. In another aspect, the invention provides a nucleic acid of the full length protein of clone DNA44167-1243, deposited with the ATCC under accession number ATCC 209434, alternatively the coding sequence of clone DNA44167-1243, deposited under accession number ATCC 209434.

In yet another embodiment, the invention provides isolated PRO346 polypeptide. In particular, the invention provides isolated native sequence PRO346 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 19 to 339 of Figure 112 (SEQ ID NO:320). Native PRO346 polypeptides with or without the native signal sequence (residues 1 to 18 in Figure 112 (SEQ ID NO:320), with or without the initiating methionine, with or without the transmembrane domain (residues 340 to 360) and with or without the intracellular domain (residues 361 to 450) are specifically included. Alternatively, the invention provides a PRO346 polypeptide encoded by the nucleic acid deposited under accession number ATCC 209434.

30

**46. PRO268**

Applicants have identified a cDNA clone that encodes a novel polypeptide having homology to protein disulfide isomerase, wherein the polypeptide is designated in the present application as "PRO268".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a 35 PRO268 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO268 polypeptide having amino acid residues 1 to 280 of Figure 114 (SEQ ID NO:325), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency

conditions.

In another embodiment, the invention provides isolated PRO268 polypeptide. In particular, the invention provides isolated native sequence PRO268 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 280 of Figure 114 (SEQ ID NO:325). An additional embodiment of the present invention is directed to an isolated extracellular domain of a PRO268 polypeptide.

5

**47. PRO330**

Applicants have identified a cDNA clone that encodes a novel polypeptide having homology to the alpha subunit of prolyl 4-hydroxylase, wherein the polypeptide is designated in the present application as "PRO330".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a 10 PRO330 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO330 polypeptide having amino acid residues 1 to 533 of Figure 116 (SEQ ID NO:332), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO330 polypeptide. In particular, the invention 15 provides isolated native sequence PRO330 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 533 of Figure 116 (SEQ ID NO:332).

**48. PRO339 and PRO310**

Applicants have identified two cDNA clones wherein each clone encodes a novel polypeptide having 20 homology to fringe, wherein the polypeptides are designated in the present application as "PRO339" and "PRO310".

In one embodiment, the invention provides isolated nucleic acid molecules comprising DNA encoding a PRO339 and/or a PRO310 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding the PRO339 polypeptide having amino acid residues 1 to 772 of Figure 118 (SEQ ID NO:339), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under 25 high stringency conditions. In another aspect, the isolated nucleic acid comprises DNA encoding the PRO310 polypeptide having amino acid residues 1 to 318 of Figure 120 (SEQ ID NO:341), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

In another embodiment, the invention provides isolated PRO339 as well as isolated PRO310 polypeptides. 30 In particular, the invention provides isolated native sequence PRO339 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 772 of Figure 118 (SEQ ID NO:339). The invention further provides isolated native sequence PRO310 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 318 of Figure 120 (SEQ ID NO:341).

35

**49. PRO244**

Applicants have identified a cDNA clone that encodes a novel polypeptide, designated in the present application as "PRO244".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding PRO244 polypeptide. In one aspect, the isolated nucleic acid comprises DNA encoding PRO244 polypeptide having amino acid residues 1 to 219 of Fig. 122 (SEQ ID NO:377), or is complementary to such encoding nucleic acid sequence, and remains stably bound to it under at least moderate, and optionally, under high stringency conditions.

5 In another embodiment, the invention provides isolated PRO244 polypeptide. In particular, the invention provides isolated native sequence PRO244 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 219 of Figure 122 (SEQ ID NO:377).

#### **50. Additional Embodiments**

In other embodiments of the present invention, the invention provides vectors comprising DNA encoding 10 any of the above or below described polypeptides. A host cell comprising any such vector is also provided. By way of example, the host cells may be CHO cells, *E. coli*, or yeast. A process for producing any of the above or below described polypeptides is further provided and comprises culturing host cells under conditions suitable for expression of the desired polypeptide and recovering the desired polypeptide from the cell culture.

In other embodiments, the invention provides chimeric molecules comprising any of the above or below 15 described polypeptides fused to a heterologous polypeptide or amino acid sequence. An example of such a chimeric molecule comprises any of the above or below described polypeptides fused to an epitope tag sequence or a Fc region of an immunoglobulin.

In another embodiment, the invention provides an antibody which specifically binds to any of the above or below described polypeptides. Optionally, the antibody is a monoclonal antibody.

20 In yet other embodiments, the invention provides oligonucleotide probes useful for isolating genomic and cDNA nucleotide sequences, wherein those probes may be derived from any of the above or below described nucleotide sequences.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

25 Figure 1 shows a nucleotide sequence (SEQ ID NO:1) of a native sequence PRO211 cDNA, wherein SEQ ID NO:1 is a clone designated herein as "UNQ185" and/or "DNA32292-1131".

Figure 2 shows the amino acid sequence (SEQ ID NO:2) derived from the coding sequence of SEQ ID NO:1 shown in Figure 1.

30 Figure 3 shows a nucleotide sequence (SEQ ID NO:3) of a native sequence PRO217 cDNA, wherein SEQ ID NO:3 is a clone designated herein as "UNQ191" and/or "DNA33094-1131".

Figure 4 shows the amino acid sequence (SEQ ID NO:4) derived from the coding sequence of SEQ ID NO:3 shown in Figure 3.

Figure 5 shows a nucleotide sequence (SEQ ID NO:11) of a native sequence PRO230 cDNA, wherein SEQ ID NO:11 is a clone designated herein as "UNQ204" and/or "DNA33223-1136".

35 Figure 6 shows the amino acid sequence (SEQ ID NO:12) derived from the coding sequence of SEQ ID NO:11 shown in Figure 5.

Figure 7 shows a nucleotide sequence designated herein as DNA20088 (SEQ ID NO:13).

Figure 8 shows a nucleotide sequence (SEQ ID NO:17) of a native sequence PRO232 cDNA, wherein SEQ ID NO:17 is a clone designated herein as "UNQ206" and/or "DNA34435-1140".

Figure 9 shows the amino acid sequence (SEQ ID NO:18) derived from the coding sequence of SEQ ID NO:17 shown in Figure 8.

5 Figure 10 shows a nucleotide sequence (SEQ ID NO:22) of a native sequence PRO187 cDNA, wherein SEQ ID NO:22 is a clone designated herein as "UNQ161" and/or "DNA27864-1155".

Figure 11 shows the amino acid sequence (SEQ ID NO:23) derived from the coding sequence of SEQ ID NO:22 shown in Figure 10.

Figure 12 shows a nucleotide sequence (SEQ ID NO:27) of a native sequence PRO265 cDNA, wherein SEQ ID NO:27 is a clone designated herein as "UNQ232" and/or "DNA36350-1158".

10 Figure 13 shows the amino acid sequence (SEQ ID NO:28) derived from the coding sequence of SEQ ID NO:27 shown in Figure 12.

Figures 14A-B show a nucleotide sequence (SEQ ID NO:33) of a native sequence PRO219 cDNA, wherein SEQ ID NO:33 is a clone designated herein as "UNQ193" and/or "DNA32290-1164".

15 Figure 15 shows the amino acid sequence (SEQ ID NO:34) derived from the coding sequence of SEQ ID NO:33 shown in Figures 14A-B.

Figure 16 shows a nucleotide sequence (SEQ ID NO:38) of a native sequence PRO246 cDNA, wherein SEQ ID NO:38 is a clone designated herein as "UNQ220" and/or "DNA35639-1172".

Figure 17 shows the amino acid sequence (SEQ ID NO:39) derived from the coding sequence of SEQ ID NO:38 shown in Figure 16.

20 Figure 18 shows a nucleotide sequence (SEQ ID NO:48) of a native sequence PRO228 cDNA, wherein SEQ ID NO:48 is a clone designated herein as "UNQ202" and/or "DNA33092-1202".

Figure 19 shows the amino acid sequence (SEQ ID NO:49) derived from the coding sequence of SEQ ID NO:48 shown in Figure 18.

Figure 20 shows a nucleotide sequence designated herein as DNA21951 (SEQ ID NO:50).

25 Figure 21 shows a nucleotide sequence (SEQ ID NO:58) of a native sequence PRO533 cDNA, wherein SEQ ID NO:58 is a clone designated herein as "UNQ344" and/or "DNA49435-1219".

Figure 22 shows the amino acid sequence (SEQ ID NO:59) derived from the coding sequence of SEQ ID NO:58 shown in Figure 21.

30 Figure 23 shows a nucleotide sequence (SEQ ID NO:63) of a native sequence PRO245 cDNA, wherein SEQ ID NO:63 is a clone designated herein as "UNQ219" and/or "DNA35638-1141".

Figure 24 shows the amino acid sequence (SEQ ID NO:64) derived from the coding sequence of SEQ ID NO:63 shown in Figure 23.

Figure 25 shows a nucleotide sequence (SEQ ID NO:68) of a native sequence PRO220 cDNA, wherein SEQ ID NO:68 is a clone designated herein as "UNQ194" and/or "DNA32298-1132".

35 Figure 26 shows the amino acid sequence (SEQ ID NO:69) derived from the coding sequence of SEQ ID NO:68 shown in Figure 25.

Figure 27 shows a nucleotide sequence (SEQ ID NO:70) of a native sequence PRO221 cDNA, wherein SEQ ID NO:70 is a clone designated herein as "UNQ195" and/or "DNA33089-1132".

Figure 28 shows the amino acid sequence (SEQ ID NO:71) derived from the coding sequence of SEQ ID NO:70 shown in Figure 27.

Figure 29 shows a nucleotide sequence (SEQ ID NO:72) of a native sequence PRO227 cDNA, wherein SEQ 5 ID NO:72 is a clone designated herein as "UNQ201" and/or "DNA33786-1132".

Figure 30 shows the amino acid sequence (SEQ ID NO:73) derived from the coding sequence of SEQ ID NO:72 shown in Figure 29.

Figure 31 shows a nucleotide sequence (SEQ ID NO:83) of a native sequence PRO258 cDNA, wherein SEQ ID NO:83 is a clone designated herein as "UNQ225" and/or "DNA35918-1174".

10 Figure 32 shows the amino acid sequence (SEQ ID NO:84) derived from the coding sequence of SEQ ID NO:83 shown in Figure 31.

Figure 33 shows a nucleotide sequence (SEQ ID NO:90) of a native sequence PRO266 cDNA, wherein SEQ ID NO:90 is a clone designated herein as "UNQ233" and/or "DNA37150-1178".

15 Figure 34 shows the amino acid sequence (SEQ ID NO:91) derived from the coding sequence of SEQ ID NO:90 shown in Figure 33.

Figure 35 shows a nucleotide sequence (SEQ ID NO:95) of a native sequence PRO269 cDNA, wherein SEQ ID NO:95 is a clone designated herein as "UNQ236" and/or "DNA38260-1180".

Figure 36 shows the amino acid sequence (SEQ ID NO:96) derived from the coding sequence of SEQ ID NO:95 shown in Figure 35.

20 Figure 37 shows a nucleotide sequence (SEQ ID NO:103) of a native sequence PRO287 cDNA, wherein SEQ ID NO:103 is a clone designated herein as "UNQ250" and/or "DNA39969-1185".

Figure 38 shows the amino acid sequence (SEQ ID NO:104) derived from the coding sequence of SEQ ID NO:103 shown in Figure 37.

25 Figure 39 shows a nucleotide sequence (SEQ ID NO:108) of a native sequence PRO214 cDNA, wherein SEQ ID NO:108 is a clone designated herein as "UNQ188" and/or "DNA32286-1191".

Figure 40 shows the amino acid sequence (SEQ ID NO:109) derived from the coding sequence of SEQ ID NO:108 shown in Figure 39.

Figure 41 shows a nucleotide sequence (SEQ ID NO:113) of a native sequence PRO317 cDNA, wherein SEQ ID NO:113 is a clone designated herein as "UNQ278" and/or "DNA33461-1199".

30 Figure 42 shows the amino acid sequence (SEQ ID NO:114) derived from the coding sequence of SEQ ID NO:113 shown in Figure 41.

Figure 43 shows a nucleotide sequence (SEQ ID NO:118) of a native sequence PRO301 cDNA, wherein SEQ ID NO:118 is a clone designated herein as "UNQ264" and/or "DNA40628-1216".

35 Figure 44 shows the amino acid sequence (SEQ ID NO:119) derived from the coding sequence of SEQ ID NO:118 shown in Figure 43.

Figure 45 shows a nucleotide sequence (SEQ ID NO:126) of a native sequence PRO224 cDNA, wherein SEQ ID NO:126 is a clone designated herein as "UNQ198" and/or "DNA33221-1133".

Figure 46 shows the amino acid sequence (SEQ ID NO:127) derived from the coding sequence of SEQ ID NO:126 shown in Figure 45.

Figure 47 shows a nucleotide sequence (SEQ ID NO:131) of a native sequence PRO222 cDNA, wherein SEQ ID NO:131 is a clone designated herein as "UNQ196" and/or "DNA33107-1135".

Figure 48 shows the amino acid sequence (SEQ ID NO:132) derived from the coding sequence of SEQ ID NO:131 shown in Figure 47.

Figure 49 shows a nucleotide sequence (SEQ ID NO:136) of a native sequence PRO234 cDNA, wherein SEQ ID NO:136 is a clone designated herein as "UNQ208" and/or "DNA35557-1137".

Figure 50 shows the amino acid sequence (SEQ ID NO:137) derived from the coding sequence of SEQ ID NO:136 shown in Figure 49.

Figure 51 shows a nucleotide sequence (SEQ ID NO:141) of a native sequence PRO231 cDNA, wherein SEQ ID NO:141 is a clone designated herein as "UNQ205" and/or "DNA34434-1139".

Figure 52 shows the amino acid sequence (SEQ ID NO:142) derived from the coding sequence of SEQ ID NO:141 shown in Figure 51.

Figure 53 shows a nucleotide sequence (SEQ ID NO:147) of a native sequence PRO229 cDNA, wherein SEQ ID NO:147 is a clone designated herein as "UNQ203" and/or "DNA33100-1159".

Figure 54 shows the amino acid sequence (SEQ ID NO:148) derived from the coding sequence of SEQ ID NO:147 shown in Figure 53.

Figure 55 shows a nucleotide sequence (SEQ ID NO:152) of a native sequence PRO238 cDNA, wherein SEQ ID NO:152 is a clone designated herein as "UNQ212" and/or "DNA35600-1162".

Figure 56 shows the amino acid sequence (SEQ ID NO:153) derived from the coding sequence of SEQ ID NO:152 shown in Figure 55.

Figure 57 shows a nucleotide sequence (SEQ ID NO:158) of a native sequence PRO233 cDNA, wherein SEQ ID NO:158 is a clone designated herein as "UNQ207" and/or "DNA34436-1238".

Figure 58 shows the amino acid sequence (SEQ ID NO:159) derived from the coding sequence of SEQ ID NO:158 shown in Figure 57.

Figure 59 shows a nucleotide sequence (SEQ ID NO:163) of a native sequence PRO223 cDNA, wherein SEQ ID NO:163 is a clone designated herein as "UNQ197" and/or "DNA33206-1165".

Figure 60 shows the amino acid sequence (SEQ ID NO:164) derived from the coding sequence of SEQ ID NO:163 shown in Figure 59.

Figure 61 shows a nucleotide sequence (SEQ ID NO:169) of a native sequence PRO235 cDNA, wherein SEQ ID NO:169 is a clone designated herein as "UNQ209" and/or "DNA35558-1167".

Figure 62 shows the amino acid sequence (SEQ ID NO:170) derived from the coding sequence of SEQ ID NO:169 shown in Figure 61.

Figure 63 shows a nucleotide sequence (SEQ ID NO:174) of a native sequence PRO236 cDNA, wherein SEQ ID NO:174 is a clone designated herein as "UNQ210" and/or "DNA35599-1168".

Figure 64 shows the amino acid sequence (SEQ ID NO:175) derived from the coding sequence of SEQ ID NO:174 shown in Figure 63.

Figure 65 shows a nucleotide sequence (SEQ ID NO:176) of a native sequence PRO262 cDNA, wherein SEQ ID NO:176 is a clone designated herein as "UNQ229" and/or "DNA36992-1168".

Figure 66 shows the amino acid sequence (SEQ ID NO:177) derived from the coding sequence of SEQ ID NO:176 shown in Figure 65.

Figure 67 shows a nucleotide sequence (SEQ ID NO:184) of a native sequence PRO239 cDNA, wherein  
5 SEQ ID NO:184 is a clone designated herein as "UNQ213" and/or "DNA34407-1169".

Figure 68 shows the amino acid sequence (SEQ ID NO:185) derived from the coding sequence of SEQ ID NO:184 shown in Figure 67.

Figure 69 shows a nucleotide sequence (SEQ ID NO:189) of a native sequence PRO257 cDNA, wherein SEQ ID NO:189 is a clone designated herein as "UNQ224" and/or "DNA35841-1173".

10 Figure 70 shows the amino acid sequence (SEQ ID NO:190) derived from the coding sequence of SEQ ID NO:189 shown in Figure 69.

Figure 71 shows a nucleotide sequence (SEQ ID NO:194) of a native sequence PRO260 cDNA, wherein SEQ ID NO:194 is a clone designated herein as "UNQ227" and/or "DNA33470-1175".

15 Figure 72 shows the amino acid sequence (SEQ ID NO:195) derived from the coding sequence of SEQ ID NO:194 shown in Figure 71.

Figure 73 shows a nucleotide sequence (SEQ ID NO:200) of a native sequence PRO263 cDNA, wherein SEQ ID NO:200 is a clone designated herein as "UNQ230" and/or "DNA34431-1177".

Figure 74 shows the amino acid sequence (SEQ ID NO:201) derived from the coding sequence of SEQ ID NO:200 shown in Figure 73.

20 Figure 75 shows a nucleotide sequence (SEQ ID NO:206) of a native sequence PRO270 cDNA, wherein SEQ ID NO:206 is a clone designated herein as "UNQ237" and/or "DNA39510-1181".

Figure 76 shows the amino acid sequence (SEQ ID NO:207) derived from the coding sequence of SEQ ID NO:206 shown in Figure 75.

25 Figure 77 shows a nucleotide sequence (SEQ ID NO:212) of a native sequence PRO271 cDNA, wherein SEQ ID NO:212 is a clone designated herein as "UNQ238" and/or "DNA39423-1182".

Figure 78 shows the amino acid sequence (SEQ ID NO:213) derived from the coding sequence of SEQ ID NO:212 shown in Figure 77.

Figure 79 shows a nucleotide sequence (SEQ ID NO:220) of a native sequence PRO272 cDNA, wherein SEQ ID NO:220 is a clone designated herein as "UNQ239" and/or "DNA40620-1183".

30 Figure 80 shows the amino acid sequence (SEQ ID NO:221) derived from the coding sequence of SEQ ID NO:220 shown in Figure 79.

Figure 81 shows a nucleotide sequence (SEQ ID NO:226) of a native sequence PRO294 cDNA, wherein SEQ ID NO:226 is a clone designated herein as "UNQ257" and/or "DNA40604-1187".

35 Figure 82 shows the amino acid sequence (SEQ ID NO:227) derived from the coding sequence of SEQ ID NO:226 shown in Figure 81.

Figure 83 shows a nucleotide sequence (SEQ ID NO:235) of a native sequence PRO295 cDNA, wherein SEQ ID NO:235 is a clone designated herein as "UNQ258" and/or "DNA38268-1188".

Figure 84 shows the amino acid sequence (SEQ ID NO:236) derived from the coding sequence of SEQ ID NO:235 shown in Figure 83.

Figures 85A-B show a nucleotide sequence (SEQ ID NO:244) of a native sequence PRO293 cDNA, wherein SEQ ID NO:244 is a clone designated herein as "UNQ256" and/or "DNA37151-1193".

Figure 86 shows the amino acid sequence (SEQ ID NO:245) derived from the coding sequence of SEQ ID NO:244 shown in Figures 85A-B.

Figures 89A-B show a nucleotide sequence (SEQ ID NO:249) of a native sequence PRO247 cDNA, wherein SEQ ID NO:249 is a clone designated herein as "UNQ221" and/or "DNA35673-1201".

Figure 88 shows the amino acid sequence (SEQ ID NO:250) derived from the coding sequence of SEQ ID NO:249 shown in Figure 87.

Figure 89 shows a nucleotide sequence (SEQ ID NO:254) of a native sequence PRO302 cDNA, wherein SEQ ID NO:254 is a clone designated herein as "UNQ265" and/or "DNA40370-1217".

Figure 90 shows the amino acid sequence (SEQ ID NO:255) derived from the coding sequence of SEQ ID NO:254 shown in Figure 89.

Figure 91 shows a nucleotide sequence (SEQ ID NO:256) of a native sequence PRO303 cDNA, wherein SEQ ID NO:256 is a clone designated herein as "UNQ266" and/or "DNA42551-1217".

Figure 92 shows the amino acid sequence (SEQ ID NO:257) derived from the coding sequence of SEQ ID NO:256 shown in Figure 91.

Figure 93 shows a nucleotide sequence (SEQ ID NO:258) of a native sequence PRO304 cDNA, wherein SEQ ID NO:258 is a clone designated herein as "UNQ267" and/or "DNA39520-1217".

Figure 94 shows the amino acid sequence (SEQ ID NO:259) derived from the coding sequence of SEQ ID NO:258 shown in Figure 93.

Figure 95 shows a nucleotide sequence (SEQ ID NO:260) of a native sequence PRO307 cDNA, wherein SEQ ID NO:260 is a clone designated herein as "UNQ270" and/or "DNA41225-1217".

Figure 96 shows the amino acid sequence (SEQ ID NO:261) derived from the coding sequence of SEQ ID NO:260 shown in Figure 95.

Figure 97 shows a nucleotide sequence (SEQ ID NO:262) of a native sequence PRO343 cDNA, wherein SEQ ID NO:262 is a clone designated herein as "UNQ302" and/or "DNA43318-1217".

Figure 98 shows the amino acid sequence (SEQ ID NO:263) derived from the coding sequence of SEQ ID NO:262 shown in Figure 97.

Figure 99 shows a nucleotide sequence (SEQ ID NO:284) of a native sequence PRO328 cDNA, wherein SEQ ID NO:284 is a clone designated herein as "UNQ289" and/or "DNA40587-1231".

Figure 100 shows the amino acid sequence (SEQ ID NO:285) derived from the coding sequence of SEQ ID NO:284 shown in Figure 99.

Figures 101A-B show a nucleotide sequence (SEQ ID NO:289) of a native sequence PRO335 cDNA, wherein SEQ ID NO:289 is a clone designated herein as "UNQ287" and/or "DNA41388-1234".

Figure 102 shows the amino acid sequence (SEQ ID NO:290) derived from the coding sequence of SEQ ID NO:289 shown in Figures 103A-B.

Figure 103 shows a nucleotide sequence (SEQ ID NO:291) of a native sequence PRO331 cDNA, wherein SEQ ID NO:291 is a clone designated herein as "UNQ292" and/or "DNA40981-1234".

Figure 104 shows the amino acid sequence (SEQ ID NO:292) derived from the coding sequence of SEQ ID NO:291 shown in Figure 103.

Figures 105A-B show a nucleotide sequence (SEQ ID NO:293) of a native sequence PRO326 cDNA, 5 wherein SEQ ID NO:293 is a clone designated herein as "UNQ287" and/or "DNA37140-1234".

Figure 106 shows the amino acid sequence (SEQ ID NO:294) derived from the coding sequence of SEQ ID NO:293 shown in Figures 105A-B.

Figures 107A-B show a nucleotide sequence (SEQ ID NO:309) of a native sequence PRO332 cDNA, wherein SEQ ID NO:309 is a clone designated herein as "UNQ293" or "DNA40982-1235".

10 Figure 108 shows the amino acid sequence (SEQ ID NO:310) derived from the coding sequence of SEQ ID NO:309 shown in Figure 107.

Figure 109 shows a nucleotide sequence (SEQ ID NO:314) of a native sequence PRO334 cDNA, wherein SEQ ID NO:314 is a clone designated herein as "UNQ295" or "DNA41379-1236".

15 Figure 110 shows the amino acid sequence (SEQ ID NO:315) derived from the coding sequence of SEQ ID NO:314 shown in Figure 109.

Figure 111 shows a nucleotide sequence (SEQ ID NO:319) of a native sequence PRO346 cDNA, wherein SEQ ID NO:319 is a clone designated herein as "UNQ305" or "DNA44167-1243".

Figure 112 shows the amino acid sequence (SEQ ID NO:320) derived from the coding sequence of SEQ ID NO:319 shown in Figure 111.

20 Figure 113 shows a nucleotide sequence (SEQ ID NO:324) of a native sequence PRO268 cDNA, wherein SEQ ID NO:324 is a clone designated herein as "UNQ235" or "DNA39427-1179".

Figure 114 shows the amino acid sequence (SEQ ID NO:325) derived from the coding sequence of SEQ ID NO:324 shown in Figure 113.

25 Figure 115 shows a nucleotide sequence (SEQ ID NO:331) of a native sequence PRO330 cDNA, wherein SEQ ID NO:331 is a clone designated herein as "UNQ290" or "DNA40603-1232".

Figure 116 shows the amino acid sequence (SEQ ID NO:332) derived from the coding sequence of SEQ ID NO:331 shown in Figure 115.

Figure 117 shows a nucleotide sequence (SEQ ID NO:338) of a native sequence PRO339 cDNA, wherein SEQ ID NO:338 is a clone designated herein as "UNQ229" or "DNA43466-1225".

30 Figure 118 shows the amino acid sequence (SEQ ID NO:339) derived from the coding sequence of SEQ ID NO:338 shown in Figure 117.

Figure 119 shows a nucleotide sequence (SEQ ID NO:340) of a native sequence PRO310 cDNA, wherein SEQ ID NO:340 is a clone designated herein as "UNQ273" or "DNA43046-1225".

35 Figure 120 shows the amino acid sequence (SEQ ID NO:341) derived from the coding sequence of SEQ ID NO:340 shown in Figure 119.

Figure 121 shows a nucleotide sequence (SEQ ID NO:376) of a native sequence PRO244 cDNA, wherein SEQ ID NO:376 is a clone designated herein as "UNQ218" or "DNA35668-1171".

Figure 122 shows the amino acid sequence (SEQ ID NO:377) derived from the coding sequence of SEQ ID NO:376 shown in Figure 121.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

##### I. Definitions

5 The terms "PRO polypeptide" and "PRO" as used herein and when immediately followed by a numerical designation refer to various polypeptides, wherein the complete designation (i.e., PRO/number) refers to specific polypeptide sequences as described herein. The terms "PRO/number polypeptide" and "PRO/number" as used herein encompass native sequence polypeptides and polypeptide variants (which are further defined herein). The PRO polypeptides described herein may be isolated from a variety of sources, such as from human tissue types or from  
10 another source, or prepared by recombinant or synthetic methods.

A "native sequence PRO polypeptide" comprises a polypeptide having the same amino acid sequence as the corresponding PRO polypeptide derived from nature. Such native sequence PRO polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native sequence PRO polypeptide" specifically encompasses naturally-occurring truncated or secreted forms of the specific PRO polypeptide (e.g., an  
15 extracellular domain sequence), naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the polypeptide. In various embodiments of the invention, the native sequence PRO211 is a mature or full-length native sequence PRO211 polypeptide comprising amino acids 1 to 353 of Figure 2 (SEQ ID NO:2), the native sequence PRO217 is a mature or full-length native sequence PRO217 polypeptide comprising amino acids 1 to 379 of Figure 4 (SEQ ID NO:4), the native sequence PRO230 is a mature or full-length native  
20 sequence PRO230 polypeptide comprising amino acids 1 to 467 of Figure 6 (SEQ ID NO:12), the native sequence PRO232 polypeptide is a mature or full-length native sequence PRO232 polypeptide comprising amino acids 1 to 114 of Figure 9 (SEQ ID NO:18), the native sequence PRO187 is a mature or full-length native sequence PRO187 comprising amino acids 1 to 205 of Figure 11 (SEQ ID NO:23), the native sequence PRO265 polypeptide is a mature or full-length native sequence PRO265 polypeptide comprising amino acids 1 to 660 of Figure 13 (SEQ ID NO:28)  
25 or the native sequence PRO265 polypeptide is an extracellular domain of the full-length PRO265 protein, wherein the putative transmembrane domain of the full-length PRO265 protein is encoded by nucleotides beginning at nucleotide 1969 of SEQ ID NO:31, the native sequence PRO219 polypeptide is a mature or full-length native sequence PRO219 polypeptide comprising amino acids 1 to 915 of Figure 15 (SEQ ID NO:34), the native sequence PRO246 polypeptide is a mature or full-length native sequence PRO246 polypeptide comprising amino acids 1 to 390  
30 of Figure 17 (SEQ ID NO:39) or the native sequence PRO246 polypeptide is an extracellular domain of the full-length PRO246 protein, wherein the putative transmembrane domain of the full-length PRO246 protein is encoded by nucleotides beginning at nucleotide 855 as shown in Figure 16, the native sequence PRO228 polypeptide is a mature or full-length native sequence PRO228 polypeptide comprising amino acids 1 to 690 of Figure 19 (SEQ ID NO:49) or the native sequence PRO228 polypeptide is an extracellular domain of the full-length PRO228 protein, the native  
35 sequence PRO533 is a mature or full-length native sequence PRO533 comprising amino acids 1 to 216 of Figure 22 (SEQ ID NO:59), with or without the N-terminal signal sequence, and with or without the initiating methionine at position 1, the native sequence PRO245 polypeptide is a mature or full-length native sequence PRO245 polypeptide

comprising amino acids 1 to 312 of Figure 24 (SEQ ID NO:64), the native sequence of each PRO220, PRO221 and PRO227 polypeptides is a mature or full-length native sequence PRO220, PRO221 and PRO227 polypeptide comprising amino acids 1 through 708 of Figure 26 (SEQ ID NO:69), 1 through 259 of Figure 28 (SEQ ID NO:71), and 1 through 620 of Figure 30 (SEQ ID NO:73), the native sequence PRO258 polypeptide is a mature or full-length native sequence PRO258 polypeptide comprising amino acids 1 to 398 of Figure 32 (SEQ ID NO:84) or the native 5 sequence PRO258 polypeptide is an extracellular domain of the full-length PRO258 protein, wherein the putative transmembrane domain of the full-length PRO258 protein is encoded by nucleotides beginning at nucleotide 1134 of SEQ ID NO:83, the native sequence PRO266 polypeptide is a mature or full-length native sequence PRO266 polypeptide comprising amino acids 1 to 696 of Figure 34 (SEQ ID NO:91) or the native sequence PRO266 polypeptide is an extracellular domain of the full-length PRO266 protein, wherein the putative transmembrane domain 10 of the full-length PRO266 protein is encoded by nucleotides beginning at about nucleotide 2009 of SEQ ID NO:104, the native sequence PRO269 polypeptide is a mature or full-length native sequence PRO269 polypeptide comprising amino acids 1 to 490 of Figure 36 (SEQ ID NO:96) or the native sequence PRO269 polypeptide is an extracellular domain of the full-length PRO269 protein, wherein the putative transmembrane domain of the full-length PRO269 protein is encoded by nucleotides beginning at nucleotide 1502 as shown in Figure 35, the native sequence PRO287 15 polypeptide is a mature or full-length native sequence PRO287 polypeptide comprising amino acids 1 to 415 of Figure 38 (SEQ ID NO:104), the native sequence PRO214 is a mature or full-length native sequence PRO214 comprising amino acids 1 to 420 of Fig. 40 (SEQ ID NO:109), the native-sequence PRO317 is a full-length native-pre-sequence PRO317 comprising amino acids 1 to 366 of Fig. 42 (SEQ ID NO:114) or a mature native-sequence PRO317 comprising amino acids 19 to 366 of Fig. 42 (SEQ ID NO:114), the native sequence PRO301 is a mature or full- 20 length native sequence PRO301 comprising amino acids 1 to 299 of Fig. 44 (SEQ ID NO:119), with or without the N-terminal signal sequence, with or without the initiating methionine at position 1, with or without the potential transmembrane domain at position 236 to about 258, and with or without the intracellular domain at about position 259 to 299, the native sequence PRO224 polypeptide is a mature or full-length native sequence PRO224 polypeptide comprising amino acids 1 to 282 of Figure 46 (SEQ ID NO:127), the native sequence PRO222 polypeptide is a 25 mature or full-length native sequence PRO222 polypeptide comprising amino acids 1 to 490 of Figure 48 (SEQ ID NO:132), the native sequence PRO234 is a mature or full-length native sequence novel lectin comprising amino acids 1 to 382 of Fig. 50 (SEQ ID NO:137), the native sequence PRO231 polypeptide is a mature or full-length native sequence PRO231 polypeptide comprising amino acids 1 to 428 of Figure 52 (SEQ ID NO:142), the native sequence PRO229 polypeptide is a mature or full-length native sequence PRO229 polypeptide comprising amino acids 1 to 347 30 of Figure 54 (SEQ ID NO:148), the native sequence PRO238 polypeptide is a mature or full-length native sequence PRO238 polypeptide comprising amino acids 1 to 310 of Figure 56 (SEQ ID NO:153), the native sequence PRO233 polypeptide is a mature or full-length native sequence PRO233 polypeptide comprising amino acids 1 to 300 of Figure 58 (SEQ ID NO:159), the native sequence PRO223 polypeptide is a mature or full-length native sequence PRO223 polypeptide comprising amino acids 1 to 476 of Figure 60 (SEQ ID NO:164), the native sequence PRO235 35 polypeptide is a mature or full-length native sequence PRO235 polypeptide comprising amino acids 1 to 552 of Figure 62 (SEQ ID NO:170), the native sequence PRO236 polypeptide is a mature or full-length native sequence PRO236 polypeptide comprising amino acids 1 to 636 of Figure 64 (SEQ ID NO:175), the native sequence PRO262

polypeptide is a mature or full-length native sequence PRO262 polypeptide comprising amino acids 1 to 654 of Figure 66 (SEQ ID NO:177), the native sequence PRO239 polypeptide is a mature or full-length native sequence PRO239 polypeptide comprising amino acids 1 to 501 of Figure 68 (SEQ ID NO:185), the native sequence PRO257 polypeptide is a mature or full-length native sequence PRO257 polypeptide comprising amino acids 1 to 607 of Figure 70 (SEQ ID NO:190) or the native sequence PRO257 polypeptide is an extracellular domain of the full-length 5 PRO257 protein, wherein the putative transmembrane domain of the full-length PRO257 protein is encoded by nucleotides beginning at nucleotide 2668 as shown in Figure 69, the native sequence PRO260 polypeptide is a mature or full-length native sequence PRO260 polypeptide comprising amino acids 1 to 467 of Figure 72 (SEQ ID NO:195), the native sequence PRO263 polypeptide is a mature or full-length native sequence PRO263 polypeptide comprising amino acids 1 to 322 of Figure 74 (SEQ ID NO:201) or the native sequence PRO263 polypeptide is an extracellular 10 domain of the full-length PRO263 protein, wherein the putative transmembrane domain of the full-length PRO263 protein is encoded by nucleotides beginning at nucleotide 868 of SEQ ID NO:200, the native sequence PRO270 polypeptide is a mature or full-length native sequence PRO270 polypeptide comprising amino acids 1 to 296 of Figure 76 (SEQ ID NO:207), the native sequence PRO271 polypeptide is a mature or full-length native sequence PRO271 polypeptide comprising amino acids 1 to 360 of Figure 78 (SEQ ID NO:213), the native sequence PRO272 15 polypeptide is a mature or full-length native sequence PRO272 polypeptide comprising amino acids 1 to 328 of Figure 80 (SEQ ID NO:221), the native sequence PRO294 polypeptide is a mature or full-length native sequence PRO294 polypeptide comprising amino acids 1 to 550 of Figure 82 (SEQ ID NO:227), the native sequence PRO295 polypeptide is a mature or full-length native sequence PRO295 polypeptide comprising amino acids 1 to 350 of Figure 84 (SEQ ID NO:236), the native sequence PRO293 polypeptide is a mature or full-length native sequence PRO293 20 polypeptide comprising amino acids 1 to 713 of Figure 86 (SEQ ID NO:245) or the native sequence PRO293 polypeptide is an extracellular domain of the full-length PRO293 protein, wherein the putative transmembrane domain of the full-length PRO293 protein is encoded by nucleotides beginning at nucleotide 2771 of SEQ ID NO:244, the native sequence PRO247 polypeptide is a mature or full-length native sequence PRO247 polypeptide comprising amino acids 1 to 546 of Figure 88 (SEQ ID NO:250), the native sequence PRO302 polypeptide is a mature or full- 25 length native sequence PRO302 polypeptide comprising amino acids 1 to 452 of Figure 90 (SEQ ID NO:255), the native sequence PRO303 polypeptide is a mature or full-length native sequence PRO303 polypeptide comprising amino acids 1 to 314 of Figure 92 (SEQ ID NO:257), the native sequence PRO304 polypeptide is a mature or full-length native sequence PRO304 polypeptide comprising amino acids 1 to 556 of Figure 94 (SEQ ID NO:259), the native sequence PRO307 polypeptide is a mature or full-length native sequence PRO307 polypeptide comprising 30 amino acids 1 to 383 of Figure 96 (SEQ ID NO:261), the native sequence PRO343 polypeptide is a mature or full-length native sequence PRO343 polypeptide comprising amino acids 1 to 317 of Figure 98 (SEQ ID NO:263), the native sequence PRO328 polypeptide is a mature or full-length native sequence PRO328 polypeptide comprising amino acids 1 to 463 of Figure 100 (SEQ ID NO:285) or the native sequence PRO306 polypeptide is an extracellular domain of the full-length PRO306 protein, wherein the putative extracellular domain of the full-length PRO306 35 protein, the native sequence PRO335 polypeptide is a mature or full-length native sequence PRO335 polypeptide comprising amino acids 1 through 1059 of Figure 102 (SEQ ID NO:290), the native sequence PRO331 polypeptide is a mature or full-length native sequence PRO331 polypeptide comprising amino acids 1 through 640 of Figure 104

(SEQ ID NO:292), the native sequence PRO326 polypeptide is a mature or full-length native sequence PRO326 polypeptide comprising amino acids 1 through 1119 of Figure 106 (SEQ ID NO:294), wherein additional embodiments include wherein the transmembrane regions are deleted or the peptides are truncated, so as to not include the transmembrane regions for each of PRO335, PRO331, and PRO326, the native sequence PRO332 is a mature or full-length native sequence PRO332 comprising amino acids 49 to 642 of Fig. 180 (SEQ ID NO:310),  
5 without or without the N-terminal signal sequence, and with or without the initiating methionine at position 1, the native sequence PRO334 polypeptide is a mature or full-length native sequence PRO334 polypeptide comprising amino acids 1 to 509 of Figure 110 (SEQ ID NO:315), the native sequence PRO346 is a mature or full-length native sequence PRO346 comprising amino acids 19 to 339 of Fig. 112 (SEQ ID NO:320), with or without the N-terminal signal sequence, with or without the initiating methionine, with or without the transmembrane domain at positions  
10 340 to 360 and with or without the intracellular domain at positions 361 to 450, the native sequence PRO268 polypeptide is a mature or full-length native sequence PRO268 polypeptide comprising amino acids 1 to 280 of Figure 114 (SEQ ID NO:325) or the native sequence PRO268 polypeptide is an extracellular domain of the full-length PRO268 protein, wherein the putative transmembrane domain of the full-length PRO268 protein is encoded by nucleotides beginning at nucleotide 559 as shown in Figure 113, the native sequence PRO330 polypeptide is a mature or full-length native sequence PRO330 polypeptide comprising amino acids 1 to 533 of Figure 116 (SEQ ID NO:332), the native sequence PRO339 polypeptide is a mature or full-length native sequence PRO339 polypeptide comprising amino acids 1 to 772 of Figure 118 (SEQ ID NO:339), the native sequence PRO310 polypeptide is a mature or full-length native sequence PRO310 polypeptide comprising amino acids 1 to 318 of Figure 120 (SEQ ID NO:341) and the native sequence PRO244 is a mature or full-length native sequence PRO244 comprising amino acids 1 to 219 of  
15 Fig. 122 (SEQ ID NO:377), wherein the mature, full-length native-sequence PRO244 protein comprises a cytoplasmic domain (about amino acid positions 1 to 20), a transmembrane domain (about amino acid positions 21 to 46), and an extracellular domain (about amino acid positions 47 to 219). Within the extracellular domain, the C-lectin domain is between about amino acid position 55 and about amino acid position 206. Native sequence PRO244 as shown in Figure 122 maps to chromosome 12, bands p12-p13.

25 "PRO polypeptide variant" means an active PRO polypeptide as defined above or below having at least about 80% amino acid sequence identity with the full-length native sequence PRO polypeptide sequence as disclosed herein. Such PRO polypeptide variants include, for instance, PRO polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the full-length native amino acid sequence. Ordinarily, a PRO polypeptide variant will have at least about 80% amino acid sequence identity, more preferably at least about 90%  
30 amino acid sequence identity, and even more preferably at least about 95% amino acid sequence identity with the amino acid sequence of the full-length native amino acid sequence as disclosed herein.

35 "PRO317 variants" or "PRO317 sequence variants" as defined herein mean biologically active PRO317s as defined below having less than 100% sequence identity with the PRO317 isolated from recombinant cell culture or from mammalian fetal kidney tissue having the deduced sequence described in Figure 42. Ordinarily, a biologically active PRO317 variant will have an amino acid sequence having at least about 70% amino acid sequence identity with the PRO317 of Figure 42, preferably at least about 75%, more preferably at least about 80%, still more preferably at least about 85%, even more preferably at least about 90%, and most preferably at least about 95% (*i.e.*,

70-100%, 75-100%, 80-100%, 85-100%, 90-100%, and 95-100% sequence identity, respectively). These variants include covalently modified polypeptides, as well as PRO317 fragments and glycosylation variants thereof. PRO317 fragments have a consecutive sequence of at least 10, 15, 20, 25, 30, or 40 amino acid residues, preferably about 10-150 residues, that is identical to the sequence of the PRO317 shown in Figure 42. Other preferred PRO317 fragments include those produced as a result of chemical or enzymatic hydrolysis or digestion of the purified  
5 PRO317.

A "chimeric PRO317" is a polypeptide comprising full-length PRO317 or one or more fragments thereof fused or bonded to a second protein or one or more fragments thereof. The chimera will typically share at least one biological property in common with PRO317. The second protein will typically be a cytokine, growth factor, or hormone such as a neurotrophic or angiogenic factor such as GDNF or VEGF, or another member of the TGF-  
10 superfamily such as EBAF-1. Another exemplary preferred PRO317 chimera is a "domain chimera" that consists of the N-terminal residues substituted with one or more, but not all, of the residues of the human EBAF-1. In this embodiment, the PRO317 chimera would have individual or blocks of residues from the human EBAF-1 sequence added or substituted into the PRO317 sequence. For example, one or more of those segments of EBAF-1 that are  
15 not homologous could be substituted into the corresponding segments of PRO317. It is contemplated that this "PRO317-EBAF-1 domain chimera" will have an agonist biological activity.

"Percent (%) amino acid sequence identity" with respect to the PRO polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific PRO polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the  
20 sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, ALIGN or Megalign (DNASTAR) software. The preferred software alignment program is BLAST. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

25 "Percent (%) nucleic acid sequence identity" with respect to PRO-encoding nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the PRO nucleic acid sequence of interest, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available  
30 computer software such as BLAST, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

35 "Isolated," when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal

or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide *in situ* within recombinant cells, since at least one component of the PRO polypeptide natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.

An "isolated" PRO polypeptide nucleic acid is a nucleic acid molecule that is identified and separated from 5 at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the PRO polypeptide nucleic acid. An isolated PRO polypeptide nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated PRO polypeptide nucleic acid molecules therefore are distinguished from the specific PRO polypeptide nucleic acid molecule as it exists in natural cells. However, an isolated PRO polypeptide nucleic acid molecule includes PRO polypeptide nucleic acid molecules contained in cells that ordinarily express the 10 PRO polypeptide where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.

"Southern analysis" or "Southern blotting" is a method by which the presence of DNA sequences in a restriction endonuclease digest of DNA or a DNA-containing composition is confirmed by hybridization to a known, labeled oligonucleotide or DNA fragment. Southern analysis typically involves electrophoretic separation of DNA 15 digests on agarose gels, denaturation of the DNA after electrophoretic separation, and transfer of the DNA to nitrocellulose, nylon, or another suitable membrane support for analysis with a radiolabeled, biotinylated, or enzyme-labeled probe as described in sections 9.37-9.52 of Sambrook *et al.*, Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989).

"Northern analysis" or "Northern blotting" is a method used to identify RNA sequences that hybridize to 20 a known probe such as an oligonucleotide, DNA fragment, cDNA or fragment thereof, or RNA fragment. The probe is labeled with a radioisotope such as <sup>32</sup>P, or by biotinylation, or with an enzyme. The RNA to be analyzed is usually electrophoretically separated on an agarose or polyacrylamide gel, transferred to nitrocellulose, nylon, or other suitable membrane, and hybridized with the probe, using standard techniques well known in the art such as those described in sections 7.39-7.52 of Sambrook *et al.*, *supra*.

25 The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid 30 sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and 35 in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

The term "antibody" is used in the broadest sense and specifically covers single anti-PRO polypeptide monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies) and anti-PRO polypeptide antibody compositions with polyepitopic specificity. The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.

5 "Active" or "activity" for the purposes herein refers to form(s) of PRO polypeptide which retain the biologic and/or immunologic activities of the specific native or naturally-occurring PRO polypeptide. The activity of a PRO332 polypeptide preferably involves the regulation of extracellular matrix, cartilage, or bone function.

"PRO317-associated disorder" refers to a pathological condition or disease wherein PRO317 is over- or underexpressed. Such disorders include diseases of the female genital tract or of the endometrium of a mammal, 10 including hyperplasia, endometritis, endometriosis, wherein the patient is at risk for infertility due to endometrial factor, endometrioma, and endometrial cancer, especially those diseases involving abnormal bleeding such as a gynecological disease. They also include diseases involving angiogenesis, wherein the angiogenesis results in a pathological condition, such as cancer involving solid tumors (the therapy for the disorder would result in decreased vascularization and a decline in growth and metastasis of a variety of tumors). Alternatively, the angiogenesis may 15 be beneficial, such as for ischemia, especially coronary ischemia. Hence, these disorders include those found in patients whose hearts are functioning but who have a blocked blood supply due to atherosclerotic coronary artery disease, and those with a functioning but underperfused heart, including patients with coronary arterial disease who are not optimal candidates for angioplasty and coronary artery by-pass surgery. The disorders also include diseases involving the kidney or originating from the kidney tissue, such as polycystic kidney disease and chronic and acute 20 renal failure.

"Treatment" or "treating" refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in which the disorder is to be prevented.

"Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, 25 domestic and farm animals, and zoo, sports, or pet animals, such as sheep, dogs, horses, cats, cows, and the like. Preferably, the mammal herein is a human.

"Carriers" as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable 30 carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions 35 such as sodium; and/or nonionic surfactants such as TWEEN™, polyethylene glycol (PEG), and PLURONICS™.

The term "agonist" is used to refer to peptide and non-peptide analogs of the native PRO polypeptides (where native PRO polypeptide refers to pro-PRO polypeptide, pre-PRO polypeptide, prepro-PRO polypeptide, or

mature PRO polypeptide) of the present invention and to antibodies specifically binding such native PRO polypeptides, provided that they retain at least one biological activity of a native PRO polypeptide. Preferably, the agonists of the present invention retain the qualitative binding recognition properties and receptor activation properties of the native PRO polypeptide.

The term "antagonist" is used to refer to a molecule inhibiting a biological activity of a native PRO polypeptide of the present invention wherein native PRO polypeptide refers to pro-PRO polypeptide, pre-PRO polypeptide, prepro-PRO polypeptide, or mature PRO polypeptide. Preferably, the antagonists herein inhibit the binding of a native PRO polypeptide of the present invention. Preferred antagonists essentially completely block the binding of a native PRO317 polypeptide to a PRO317 polypeptide receptor to which it otherwise binds. Such receptors may include the Type I and Type II, and possibly Type III receptors identified for the TGF- superfamily.

5 Kolodziejczyk and Hall, *supra*. A PRO polypeptide "antagonist" is a molecule which prevents, or interferes with, a PRO antagonist effector function (*e.g.* a molecule which prevents or interferes with binding and/or activation of a PRO polypeptide receptor by PRO polypeptide). Such molecules can be screened for their ability to competitively inhibit PRO polypeptide receptor activation by monitoring binding of native PRO polypeptide in the presence and absence of the test antagonist molecule, for example. Examples of PRO317 polypeptide antagonists include

10 15 neutralizing antibodies against F-2. An antagonist of the invention also encompasses an antisense polynucleotide against the PRO polypeptide gene, which antisense polynucleotide blocks transcription or translation of the PRO polypeptide gene, thereby inhibiting its expression and biological activity.

"Stringent conditions" means (1) employing low ionic strength and high temperature for washing, for example, 0.015 sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C, or (2) employing 20 during hybridization a denaturing agent, such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 nM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C. Another example is use of 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6/8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 25 42°C in 0.2 x SSC and 0.1% SDS. Yet another example is hybridization using a buffer of 10% dextran sulfate, 2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

"Moderately stringent conditions" are described in Sambrook *et al.*, *supra*, and include the use of a washing solution and hybridization conditions (*e.g.*, temperature, ionic strength, and %SDS) less stringent than described 30 above. An example of moderately stringent conditions is a condition such as overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, *etc.*, as necessary to accommodate factors such as probe length and the like.

II. Compositions and Methods of the Invention1. Full-length PRO211 and PRO217 Polypeptides

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO211 and PRO217. In particular, Applicants have identified and isolated cDNA encoding PRO211 and PRO217 polypeptides, as disclosed in further detail in the Examples below. Using BLAST (FastA format) sequence alignment computer programs, Applicants found that cDNA sequences encoding full-length native sequence PRO211 and PRO217 have homologies to known proteins having EGF-like domains. Specifically, the cDNA sequence DNA32292-1131 (Figure 1, SEQ ID NO:1) has 36% identify and a Blast score of 209 with PAC6\_RAT and 31% identify and a Blast score of 206 with Fibulin-1, isoform c precursor. The cDNA sequence DNA33094-1131 (Figure 3, SEQ ID NO:3) has 36% identity and a Blast score of 336 with eastern newt tenascin, and 37% identity and a Blast score of 331 with human tenascin-X precursor. Accordingly, it is presently believed that PRO211 and PRO217 polypeptides disclosed in the present application are newly identified members of the EGF-like family and possesses properties typical of the EGF-like protein family.

2. Full-length PRO230 Polypeptides

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO230. In particular, Applicants have identified and isolated cDNA encoding a PRO230 polypeptide, as disclosed in further detail in the Examples below. Using known programs such as BLAST and FastA sequence alignment computer programs, Applicants found that a cDNA sequence encoding full-length native sequence PRO230 has 48% amino acid identity with the rabbit tubulointerstitial nephritis antigen precursor. Accordingly, it is presently believed that PRO230 polypeptide disclosed in the present application is a newly identified member of the tubulointerstitial nephritis antigen family and possesses the ability to be recognized by human autoantibodies in certain forms of tubulointerstitial nephritis.

3. Full-length PRO232 Polypeptides

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO232. In particular, Applicants have identified and isolated cDNA encoding a PRO232 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that a portion of the full-length native sequence PRO232 (shown in Figure 9 and SEQ ID NO:18) has 35% sequence identity with a stem cell surface antigen from Gallus gallus. Accordingly, it is presently believed that the PRO232 polypeptide disclosed in the present application may be a newly identified stem cell antigen.

4. Full-length PRO187 Polypeptides

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO187. In particular, Applicants have identified and isolated cDNA encoding a PRO187 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that a full-length native sequence PRO187 (shown in Figure

15) has 74% amino acid sequence identity and BLAST score of 310 with various androgen-induced growth factors and FGF-8. Accordingly, it is presently believed that PRO187 polypeptide disclosed in the present application is a newly identified member of the FGF-8 protein family and may possess identify activity or property typical of the FGF-8-like protein family.

5

#### **5. Full-length PRO265 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO265. In particular, Applicants have identified and isolated cDNA encoding a PRO265 polypeptide, as disclosed in further detail in the Examples below. Using programs such as BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO265 10 polypeptide have significant homology with the fibromodulin protein and fibromodulin precursor protein. Applicants have also found that the DNA encoding the PRO265 polypeptide has significant homology with platelet glycoprotein V, a member of the leucine rich related protein family involved in skin and wound repair. Accordingly, it is presently believed that PRO265 polypeptide disclosed in the present application is a newly identified member of the leucine rich repeat family and possesses protein protein binding capabilities, as well as be involved in skin and wound repair 15 as typical of this family.

15

#### **6. Full-length PRO219 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO219. In particular, Applicants have identified and isolated cDNA 20 encoding a PRO219 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO219 polypeptide have significant homology with the mouse and human matrilin-2 precursor polypeptides. Accordingly, it is presently believed that PRO219 polypeptide disclosed in the present application is related to the matrilin-2 precursor 25 polypeptide.

25

#### **7. Full-length PRO246 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO246. In particular, Applicants have identified and isolated cDNA 30 encoding a PRO246 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that a portion of the PRO246 polypeptide has significant homology with the human cell surface protein HCAR. Accordingly, it is presently believed that PRO246 polypeptide disclosed in the present application may be a newly identified membrane-bound virus receptor or tumor cell-specific antigen.

35

#### **8. Full-length PRO228 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO228. In particular, Applicants have identified and isolated cDNA

encoding a PRO228 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO228 polypeptide have significant homology with the EMR1 protein. Applicants have also found that the DNA encoding the PRO228 polypeptide has significant homology with latrophilin, macrophage-restricted cell surface glycoprotein, B0457.1 and leucocyte antigen CD97 precursor. Accordingly, it is presently believed that PRO228 polypeptide disclosed in the 5 present application is a newly identified member of the seven transmembrane superfamily and possesses characteristics and functional properties typical of this family. In particular, it is believed that PRO228 is a new member of the subgroup within this family to which CD97 and EMR1 belong.

**9. Full-length PRO533 Polypeptides**

10 The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO533. In particular, Applicants have identified and isolated cDNA encoding a PRO533 polypeptide, as disclosed in further detail in the Examples below. Using BLAST-2 and FastA sequence alignment computer programs, Applicants found that a full-length native sequence PRO533 (shown in Figure 22 and SEQ ID NO:59) has a Blast score of 509 and 53% amino acid sequence identity with fibroblast growth factor 15 (FGF). Accordingly, it is presently believed that PRO533 disclosed in the present application is a newly identified member of the fibroblast growth factor family and may possess activity typical of such polypeptides.

**10. Full-length PRO245 Polypeptides**

20 The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO245. In particular, Applicants have identified and isolated cDNA encoding a PRO245 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that a portion of the amino acid sequence of the PRO245 polypeptide has 60% amino acid identity with the human c-myb protein. Accordingly, it is presently believed that the PRO245 polypeptide disclosed in the present application may be a newly identified member of the transmembrane 25 protein tyrosine kinase family.

**11. Full-length PRO220, PRO221 and PRO227 Polypeptides**

30 The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO220, PRO221 and PRO227. In particular, Applicants have identified and isolated cDNAs encoding a PRO220, PRO221 and PRO227 polypeptide, respectively, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, PRO220 has amino acid identity with the amino acid sequence of a leucine rich protein wherein the identity is 87%. PRO220 additionally has amino acid identity with the neuronal leucine rich protein wherein the identity is 55%. The neuronal leucine rich protein is further described in Taguchi, *et al.*, Mol. Brain Res., 35:31-40 (1996).

35 PRO221 has amino acid identity with the SLIT protein precursor, wherein different portions of these two proteins have the respective percent identities of 39%, 38%, 34%, 31%, and 30%.

PRO227 has amino acid identity with the amino acid sequence of platelet glycoprotein V precursor. The same results were obtained for human glycoprotein V. Different portions of these two proteins show the following percent identities of 30%, 28%, 28%, 31%, 35%, 39% and 27%.

Accordingly, it is presently believed that PRO220, PRO221 and PRO227 polypeptides disclosed in the present application are newly identified members of the leucine rich repeat protein superfamily and that each 5 possesses protein-protein binding capabilities typical of the leucine rich repeat protein superfamily. It is also believed that they have capabilities similar to those of SLIT, the leucine rich repeat protein and human glycoprotein V.

#### **12. Full-length PRO258 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides 10 referred to in the present application as PRO258. In particular, Applicants have identified and isolated cDNA encoding a PRO258 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO258 polypeptide have significant homology with the CRTAM and poliovirus receptors. Accordingly, it is presently believed that PRO258 15 polypeptide disclosed in the present application is a newly identified member of the Ig superfamily and possesses virus receptor capabilities or regulates immune function as typical of this family.

#### **13. Full-length PRO266 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO266. In particular, Applicants have identified and isolated cDNA 20 encoding a PRO266 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO266 polypeptide have significant homology with the SLIT protein from Drosophila. Accordingly, it is presently believed that PRO266 25 polypeptide disclosed in the present application is a newly identified member of the leucine rich repeat family and possesses ligand-ligand binding activity and neuronal development typical of this family. SLIT has been shown to be useful in the study and treatment of Alzheimer's disease, *supra*, and thus, PRO266 may have involvement in the study and cure of this disease.

#### **14. Full-length PRO269 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides 30 referred to in the present application as PRO269. In particular, Applicants have identified and isolated cDNA encoding a PRO269 polypeptide, as disclosed in further detail in the Examples below. Using BLAST, FastA and sequence alignment computer programs, Applicants found that the amino acid sequence encoded by nucleotides 314 to 1783 of the full-length native sequence PRO269 (shown in Figure 35 and SEQ ID NO:95) has significant homology to human urinary thrombomodulin and various thrombomodulin analogues respectively, to which it was aligned. 35 Accordingly, it is presently believed that PRO269 polypeptide disclosed in the present application is a newly identified member of the thrombomodulin family.

15. **Full-length PRO287 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO287. In particular, Applicants have identified and isolated cDNA encoding a PRO287 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO287 polypeptide have 5 significant homology with the type 1 procollagen C-proteinase enhancer protein precursor and type 1 procollagen C-proteinase enhancer protein. Accordingly, it is presently believed that PRO287 polypeptide disclosed in the present application is a newly identified member of the C-proteinase enhancer protein family.

16. **Full-length PRO214 Polypeptides**

10 The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO214. In particular, Applicants have identified and isolated cDNA encoding a PRO214 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that a full-length native sequence PRO214 polypeptide (shown in Figure 40 and SEQ ID NO:109) has 49% amino acid sequence identity with HT protein, a known member 15 of the EGF-family. The comparison resulted in a BLAST score of 920, with 150 matching nucleotides. Accordingly, it is presently believed that the PRO214 polypeptide disclosed in the present application is a newly identified member of the family comprising EGF domains and may possess activities or properties typical of the EGF-domain containing family.

20 17. **Full-length PRO317 Polypeptides**

25 The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO317. In particular, cDNA encoding a PRO317 polypeptide has been identified and isolated, as disclosed in further detail in the Examples below. Using BLAST<sup>TM</sup> and FastA<sup>TM</sup> sequence alignment computer programs, it was found that a full-length native-sequence PRO317 (shown in Figure 42 and SEQ ID NO:114) has 92% amino acid sequence identity with EBAF-1. Further, it is closely aligned with many other members of the TGF- superfamily.

Accordingly, it is presently believed that PRO317 disclosed in the present application is a newly identified 30 member of the TGF- superfamily and may possess properties that are therapeutically useful in conditions of uterine bleeding, etc. Hence, PRO317 may be useful in diagnosing or treating abnormal bleeding involved in gynecological diseases, for example, to avoid or lessen the need for a hysterectomy.. PRO317 may also be useful as an agent that affects angiogenesis in general, so PRO317 may be useful in anti-tumor indications, or conversely, in treating coronary ischemic conditions.

35 Library sources reveal that ESTs used to obtain the consensus DNA for generating PRO317 primers and probes were found in normal tissues (uterus, prostate, colon, and pancreas), in several tumors (colon, brain (twice), pancreas, and mullerian cell), and in a heart with ischemia. PRO317 has shown up in several tissues as well, but it does look to have a greater concentration in uterus. Hence, PRO317 may have a broader use by the body than EBAF-1. It is contemplated that, at least for some indications, PRO317 may have opposite effects from EBAF-1.

**18. Full-length PRO301 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO301. In particular, Applicants have identified and isolated cDNA encoding a PRO301 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that a full-length native sequence PRO301 (shown in Figure 5 44 and SEQ ID NO:119) has a Blast score of 246 corresponding to 30% amino acid sequence identity with human A33 antigen precursor. Accordingly, it is presently believed that PRO301 disclosed in the present application is a newly identified member of the A33 antigen protein family and may be expressed in human neoplastic diseases such as colorectal cancer.

**10 19. Full-length PRO224 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO224. In particular, Applicants have identified and isolated cDNA encoding a PRO224 polypeptide, as disclosed in further detail in the Examples below. Using known programs such as BLAST and FastA sequence alignment computer programs, Applicants found that full-length native PRO224 (Figure 46, SEQ ID NO:127) has amino acid identity with apolipoprotein E receptor 2906 from homo sapiens. The alignments of different portions of these two polypeptides show amino acid identities of 37%, 36%, 30%, 44%, 44% and 28% respectively. Full-length native PRO224 (Figure 46, SEQ ID NO:127) also has amino acid identity with very low-density lipoprotein receptor precursor from gall. The alignments of different portions of these two polypeptides show amino acid identities of 38%, 37%, 42%, 33%, and 37% respectively. Additionally, full-length 15 native PRO224 (Figure 46, SEQ ID NO:127) has amino acid identity with the chicken oocyte receptor P95 from Gallus gallus. The alignments of different portions of these two polypeptides show amino acid identities of 38%, 37%, 42%, 33%, and 37% respectively. Moreover, full-length native PRO224 (Figure 46, SEQ ID NO:127) has amino acid identity with very low density lipoprotein receptor short form precursor from humans. The alignments of different portions of these two polypeptides show amino acid identities of 32%, 38%, 34%, 45%, and 31%, 20 respectively. Accordingly, it is presently believed that PRO224 polypeptide disclosed in the present application is a newly identified member of the low density lipoprotein receptor family and possesses the structural characteristics required to have the functional ability to recognize and endocytose low density lipoproteins typical of the low density lipoprotein receptor family. (The alignments described above used the following scoring parameters: T=7, S+65, 25 S2=36, Matrix: BLOSUM62.)

30

**20. Full-length PRO222 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO222. In particular, Applicants have identified and isolated cDNA encoding a PRO222 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that a sequence encoding full-length native sequence 35 PRO222 (shown in Figure 48 and SEQ ID NO:132) has 25-26% amino acid identity with mouse complement factor h precursor, has 27-29% amino acid identity with complement receptor, has 25-47% amino acid identity with mouse

complement C3b receptor type 2 long form precursor, has 40% amino acid identity with human hypothetical protein kiaa0247. Accordingly, it is presently believed that PRO222 polypeptide disclosed in the present application is a newly identified member of the complement receptor family and possesses activity typical of the complement receptor family.

5

#### **21. Full-length PRO234 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO234. In particular, Applicants have identified and isolated cDNA encoding a PRO234 polypeptide, as disclosed in further detail in the Examples below. Using BLAST (FastA-format) sequence alignment computer programs, Applicants found that a cDNA sequence encoding full-length native sequence

- 10 PRO234 has 31% identity and Blast score of 134 with E-selectin precursor. Accordingly, it is presently believed that the PRO234 polypeptides disclosed in the present application are newly identified members of the lectin/selectin family and possess activity typical of the lectin/selectin family.

#### **22. Full-length PRO231 Polypeptides**

15 The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO231. In particular, Applicants have identified and isolated cDNA encoding a PRO231 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that the full-length native sequence PRO231 polypeptide (shown in Figure 52 and SEQ ID NO:142) has 30 % and 31 % amino acid identity with human and rat prostatic acid

- 20 phosphatase precursor proteins, respectively. Accordingly, it is presently believed that the PRO231 polypeptide disclosed in the present application may be a newly identified member of the acid phosphatase protein family.

#### **23. Full-length PRO229 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO229. In particular, Applicants have identified and isolated cDNA encoding a PRO229 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO229 polypeptide have significant homology with antigen wc1.1, M130 antigen, T cell surface glycoprotein CD6 and CD6. It also is related to Sp-alpha. Accordingly, it is presently believed that PRO229 polypeptide disclosed in the present application is a

- 30 newly identified member of the family containing scavenger receptor homology, a sequence motif found in a number of proteins involved in immune function and thus possesses immune function and /or segments which resist degradation, typical of this family.

#### **24. Full-length PRO238 Polypeptides**

35 The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO238. In particular, Applicants have identified and isolated cDNA encoding a PRO238 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA

sequence alignment computer programs, Applicants found that various portions of the PRO238 polypeptide have significant homology with reductases, including oxidoreductase and fatty acyl-CoA reductase. Accordingly, it is presently believed that PRO238 polypeptide disclosed in the present application is a newly identified member of the reductase family and possesses reducing activity typical of the reductase family.

5

#### **25. Full-length PRO233 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO233. In particular, Applicants have identified and isolated cDNA encoding a PRO233 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO233 polypeptide have significant homology with the reductase protein. Applicants have also found that the DNA encoding the PRO233 polypeptide has significant homology with proteins from *Caenorhabditis elegans*. Accordingly, it is presently believed that PRO233 polypeptide disclosed in the present application is a newly identified member of the reductase family and possesses the ability to effect the redox state of the cell typical of the reductase family.

10

15

#### **26. Full-length PRO223 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO223. In particular, Applicants have identified and isolated cDNA encoding a PRO223 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that the PRO223 polypeptide has significant homology with various serine carboxypeptidase polypeptides. Accordingly, it is presently believed that PRO223 polypeptide disclosed in the present application is a newly identified serine carboxypeptidase.

20

25

30

#### **27. Full-length PRO235 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO235. In particular, Applicants have identified and isolated cDNA encoding a PRO235 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO235 polypeptide have significant homology with the various plexin proteins. Accordingly, it is presently believed that PRO235 polypeptide disclosed in the present application is a newly identified member of the plexin family and possesses cell adhesion properties typical of the plexin family.

35

#### **28. Full-length PRO236 and PRO262 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO236 and PRO262. In particular, Applicants have identified and isolated cDNA encoding PRO236 and PRO262 polypeptides, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO236 and PRO262 polypeptides have significant homology with various β-galactosidase and β-galactosidase precursor

polypeptides. Accordingly, it is presently believed that the PRO236 and PRO262 polypeptides disclosed in the present application are newly identified  $\beta$ -galactosidase homologs.

29. Full-length PRO239 Polypeptides

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO239. In particular, Applicants have identified and isolated cDNA encoding a PRO239 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO239 polypeptide have significant homology with densin proteins. Accordingly, it is presently believed that PRO239 polypeptide disclosed in the present application is a newly identified member of the densin family and possesses cell adhesion and the ability to effect synaptic processes as is typical of the densin family.

30. Full-length PRO257 Polypeptides

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO257. In particular, Applicants have identified and isolated cDNA encoding a PRO257 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO257 polypeptide have significant homology with the ebnerin precursor and ebnerin protein. Accordingly, it is presently believed that PRO257 polypeptide disclosed in the present application is a newly identified protein member which is related to the ebnerin protein.

20

31. Full-length PRO260 Polypeptides

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO260. In particular, Applicants have identified and isolated cDNA encoding a PRO260 polypeptide, as disclosed in further detail in the Examples below. Using programs such as BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO260 polypeptide have significant homology with the alpha-1-fucosidase precursor. Accordingly, it is presently believed that PRO260 polypeptide disclosed in the present application is a newly identified member of the fucosidase family and possesses enzymatic activity related to fucose residues typical of the fucosidase family.

30

32. Full-length PRO263 Polypeptides

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO263. In particular, Applicants have identified and isolated cDNA encoding a PRO263 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO263 polypeptide have significant homology with the CD44 antigen and related proteins. Accordingly, it is presently believed that PRO263 polypeptide disclosed in the present application is a newly identified member of the CD44 antigen family and possesses at least one of the properties associated with these antigens, i.e., cancer and HIV marker, cell-cell or cell-

matrix interactions, regulating cell traffic, lymph node homing, transmission of growth signals, and presentation of chemokines and growth factors to traveling cells.

33. **Full-length PRO270 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO270. In particular, Applicants have identified and isolated cDNA encoding a PRO270 polypeptide, as disclosed in further detail in the Examples below. Using BLAST, FastA and sequence alignment computer programs, Applicants found that various portions of the PRO270 polypeptide have significant homology with various thioredoxin proteins. Accordingly, it is presently believed that PRO270 polypeptide disclosed in the present application is a newly identified member of the thioredoxin family and possesses the ability to effect reduction-oxidation (redox) state typical of the thioredoxin family.

34. **Full-length PRO271 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO271. In particular, Applicants have identified and isolated cDNA encoding a PRO271 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that the PRO271 polypeptide has significant homology with various link proteins and precursors thereof. Accordingly, it is presently believed that PRO271 polypeptide disclosed in the present application is a newly identified link protein homolog.

20 35. **Full-length PRO272 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO272. In particular, Applicants have identified and isolated cDNA encoding a PRO272 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO272 polypeptide have significant homology with the human reticulocalbin protein and its precursors. Applicants have also found that the DNA encoding the PRO272 polypeptide has significant homology with the mouse reticulocalbin precursor protein. Accordingly, it is presently believed that PRO272 polypeptide disclosed in the present application is a newly identified member of the reticulocalbin family and possesses the ability to bind calcium typical of the reticulocalbin family.

30 36. **Full-length PRO294 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO294. In particular, Applicants have identified and isolated cDNA encoding a PRO294 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO294 polypeptide have significant homology with the various portions of a number of collagen proteins. Accordingly, it is presently believed that PRO294 polypeptide disclosed in the present application is a newly identified member of the collagen family.

**37. Full-length PRO295 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO295. In particular, Applicants have identified and isolated cDNA encoding a PRO295 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO295 polypeptide have significant homology with integrin proteins. Accordingly, it is presently believed that PRO295 polypeptide disclosed in the present application is a newly identified member of the integrin family and possesses cell adhesion typical of the integrin family.

**38. Full-length PRO293 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO293. In particular, Applicants have identified and isolated cDNA encoding a PRO293 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that portions of the PRO293 polypeptide have significant homology with the neuronal leucine rich repeat proteins 1 and 2, (NLRR-1 and NLRR-2), particularly NLRR-2. Accordingly, it is presently believed that PRO293 polypeptide disclosed in the present application is a newly identified member of the neuronal leucine rich repeat protein family and possesses ligand-ligand binding activity typical of the NRLL protein family.

**39. Full-length PRO247 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO247. In particular, Applicants have identified and isolated cDNA encoding a PRO247 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO247 polypeptide have significant homology with densin. Applicants have also found that the DNA encoding the PRO247 polypeptide has significant homology with a number of other proteins, including KIAA0231. Accordingly, it is presently believed that PRO247 polypeptide disclosed in the present application is a newly identified member of the leucine rich repeat family and possesses ligand binding abilities typical of this family.

**40. Full-length PRO302, PRO303, PRO304, PRO307 and PRO343 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO302, PRO303, PRO304, PRO307 and PRO343. In particular, Applicants have identified and isolated cDNA encoding PRO302, PRO303, PRO304, PRO307 and PRO343 polypeptides, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO302, PRO303, PRO304, PRO307 and PRO343 polypeptides have significant homology with various protease proteins. Accordingly, it is presently believed that the PRO302, PRO303, PRO304, PRO307 and PRO343 polypeptides disclosed in the present application are newly identified protease proteins.

**41. Full-length PRO328 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO328. In particular, Applicants have identified and isolated cDNA encoding a PRO328 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO328 polypeptide have significant homology with the human glioblastoma protein ("GLIP"). Further, Applicants found that various portions of the PRO328 polypeptide have significant homology with the cysteine rich secretory protein ("CRISP") as identified by BLAST homology [ECCRISP3\_1, S68683, and CRS3\_HUMAN]. Accordingly, it is presently believed that PRO328 polypeptide disclosed in the present application is a newly identified member of the GLIP or CRISP families and possesses transcriptional regulatory activity typical of the GLIP or CRISP families.

10

**42. Full-length PRO335, PRO331 and PRO326 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO335, PRO331 or PRO326. In particular, Applicants have identified and isolated cDNA encoding a PRO335, PRO331 or PRO326 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO335, PRO331 or PRO326 polypeptide have significant homology with LIG-1, ALS and in the case of PRO331, additionally, decorin. Accordingly, it is presently believed that the PRO335, PRO331 and PRO326 polypeptides disclosed in the present application are newly identified members of the leucine rich repeat superfamily, and particularly, are related to LIG-1 and possess the biological functions of this family as discussed and referenced herein.

20

**43. Full-length PRO332 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO332. In particular, Applicants have identified and isolated cDNA encoding PRO332 polypeptides, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that a full-length native sequence PRO332 (shown in Figure 108 and SEQ ID NO:310) has about 30-40% amino acid sequence identity with a series of known proteoglycan sequences, including, for example, fibromodulin and fibromodulin precursor sequences of various species (FMOD\_BOVIN, FMOD\_CHICK, FMOD\_RAT, FMOD\_MOUSE, FMOD\_HUMAN, P\_R36773), osteomodulin sequences (AB000114\_1, AB007848\_1), decorin sequences (CFU83141\_1, OCU03394\_1, P\_R42266, P\_R42267, P\_R42260, P\_R89439), keratan sulfate proteoglycans (BTU48360\_1, AF022890\_1), corneal proteoglycan (AF022256\_1), and bone/cartilage proteoglycans and proteoglycane precursors (PGS1\_BOVIN, PGS2\_MOUSE, PGS2\_HUMAN). Accordingly, it is presently believed that PRO332 disclosed in the present application is a new proteoglycan-type molecule, and may play a role in regulating extracellular matrix, cartilage, and/or bone function.

35

**44. Full-length PRO334 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO334. In particular, Applicants have identified and isolated cDNA encoding a PRO334 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO334 polypeptide have 5 significant homology with fibulin and fibrillin. Accordingly, it is presently believed that PRO334 polypeptide disclosed in the present application is a newly identified member of the epidermal growth factor family and possesses properties and activities typical of this family.

**45. Full-length PRO346 Polypeptides**

10 The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO346. In particular, Applicants have identified and isolated cDNA encoding a PRO346 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that a full-length native sequence PRO346 (shown in Figure 112 and SEQ ID NO:320) has 28 % amino acid sequence identity with carcinoembryonic antigen. Accordingly, it 15 is presently believed that PRO346 disclosed in the present application is a newly identified member of the carcinoembryonic protein family and may be expressed in association with neoplastic tissue disorders.

**46. Full-length PRO268 Polypeptides**

20 The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO268. In particular, Applicants have identified and isolated cDNA encoding a PRO268 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that portions of the PRO268 polypeptide have significant homology with the various protein disulfide isomerase proteins. Accordingly, it is presently believed that PRO268 25 polypeptide disclosed in the present application is a homolog of the protein disulfide isomerase p5 protein.

**47. Full-length PRO330 Polypeptides**

30 The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO330. In particular, Applicants have identified and isolated cDNA encoding a PRO330 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO330 polypeptide have significant homology with the murine prolyl 4-hydroxylase alpha-II subunit protein. Accordingly, it is presently believed that PRO330 polypeptide disclosed in the present application is a novel prolyl 4-hydroxylase subunit 35 polypeptide.

**48. Full-length PRO339 and PRO310 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO339 and PRO310. In particular, Applicants have identified and isolated

cDNA encoding a PRO339 polypeptide, as disclosed in further detail in the Examples below. Applicants have also identified and isolated cDNA encoding a PRO310 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that various portions of the PRO339 and PRO310 polypeptides have significant homology with small secreted proteins from *C. elegans* and are distantly related to fringe. PRO339 also shows homology to collagen-like polymers. Sequences which were used 5 to identify PRO310, designated herein as DNA40533 and DNA42267, also show homology to proteins from *C. elegans*. Accordingly, it is presently believed that the PRO339 and PRO310 polypeptides disclosed in the present application are newly identified member of the family of proteins involved in development, and which may have regulatory abilities similar to the capability of fringe to regulate serrate.

10           **49. Full Length PRO244 Polypeptides**

The present invention provides newly identified and isolated nucleotide sequences encoding C-type lectins referred to in the present application as PRO244. In particular, applicants have identified and isolated cDNA encoding PRO244 polypeptides, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that a full-length native sequence PRO244 (shown in Figure 15 122 and SEQ ID NO:377) has 43% amino acid sequence identity with the hepatic lectin gallus gallus (LECH-CHICK), and 42% amino acid sequence identity with an HIV gp120 binding C-type lectin (A46274). Accordingly, it is presently believed that PRO244 disclosed in the present application is a newly identified member of the C-lectin superfamily and may play a role in immune function, apoptosis, or in the pathogenesis of atherosclerosis. In addition, PRO244 may be useful in identifying tumor-associated epitopes.

20           **50. PRO Polypeptide Variants**

In addition to the full-length native sequence PRO polypeptides described herein, it is contemplated that PRO polypeptide variants can be prepared. PRO polypeptide variants can be prepared by introducing appropriate nucleotide changes into the PRO polypeptide DNA, or by synthesis of the desired PRO polypeptide. Those skilled 25 in the art will appreciate that amino acid changes may alter post-translational processes of the PRO polypeptides, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.

Variations in the native full-length sequence PRO polypeptides or in various domains of the PRO polypeptides described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a 30 substitution, deletion or insertion of one or more codons encoding the PRO polypeptide that results in a change in the amino acid sequence of the PRO polypeptide as compared with the native sequence PRO polypeptide. Optionally the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the PRO polypeptide. Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by comparing the sequence of the PRO polypeptide with 35 that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, i.e.,

conservative amino acid replacements. Insertions or deletions may optionally be in the range of 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity in the *in vitro* assay described in the Examples below.

The variations can be made using methods known in the art such as oligonucleotide-mediated (site-directed) 5 mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis [Carter et al., Nucl. Acids Res., 13:4331 (1986); Zoller et al., Nucl. Acids Res., 10:6487 (1987)], cassette mutagenesis [Wells et al., Gene, 34:315 (1985)], restriction selection mutagenesis [Wells et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)] or other known techniques can be performed on the cloned DNA to produce the desired PRO polypeptide variant DNA.

Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous 10 sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins, (W.H. Freeman & Co., N.Y.); Chothia, L 15 Mol. Biol., 150:1 (1976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.

### 51. Modifications of PRO Polypeptides

Covalent modifications of PRO polypeptides are included within the scope of this invention. One type of 20 covalent modification includes reacting targeted amino acid residues of the PRO polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues of the PRO polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking a PRO polypeptide to a water-insoluble support matrix or surface for use in the method for purifying anti-PRO polypeptide antibodies, and vice-versa. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, 25 N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate.

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding 30 glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the  $\alpha$ -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the PRO polypeptides included within the scope of this invention 35 comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in a native sequence PRO polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence PRO polypeptide.

Addition of glycosylation sites to the PRO polypeptide may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence PRO polypeptide (for O-linked glycosylation sites). The PRO polypeptide amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the PRO polypeptide at preselected bases such that codons are generated that will translate into the desired 5 amino acids.

Another means of increasing the number of carbohydrate moieties on the PRO polypeptide polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

10 Removal of carbohydrate moieties present on the PRO polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo- 15 glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of PRO polypeptides of the invention comprises linking the PRO polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

20 The PRO polypeptides of the present invention may also be modified in a way to form a chimeric molecule comprising a PRO polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of the PRO polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl- terminus of the PRO polypeptide. The presence of such epitope-tagged forms of the PRO 25 polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the PRO polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of the PRO polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule.

30 Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering, 3(6):547-553 (1990)]. Other tag 35 polypeptides include the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; an  $\alpha$ -tubulin epitope peptide [Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-

6397 (1990)].

**52. Modification of PRO317**

Amino acid sequence variants of PRO317 are prepared by introducing appropriate nucleotide changes into the PRO317 DNA, or by *in vitro* synthesis of the desired PRO317 polypeptide. Such variants include, for example, 5 deletions from, or insertions or substitutions of, residues within the amino acid sequence shown for human PRO317 in Figure 42. Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational processes of the PRO317, such as changing the number or position of glycosylation sites. Moreover, like most mammalian genes, PRO317 is presumably encoded by multi-exon genes. Alternative mRNA constructs 10 which may be attributed to different mRNA splicing events following transcription, and which share large regions of identity with the cDNAs claimed herein, are considered to be within the scope of the present invention.

For the design of amino acid sequence variants of PRO317, the location of the mutation site and the nature of the mutation will depend on the PRO317 characteristic(s) to be modified. For example, candidate PRO317 antagonists or agonists will be initially selected by locating sites that are identical or highly conserved among 15 PRO317, EBAF-1, LEFTY, and other members of the TGF- superfamily. The sites for mutation can be modified individually or in series, *e.g.*, by (1) substituting first with conservative amino acid choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue, or (3) inserting residues of the same or a different class adjacent to the located site, or combinations of options 1-3.

A useful method for identification of certain residues or regions of the PRO317 polypeptide that are 20 preferred locations for mutagenesis is called "alanine scanning mutagenesis," as described by Cunningham and Wells, *Science*, 244: 1081-1085 (1989). Here, a residue or group of target residues are identified (*e.g.*, charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Those domains demonstrating functional sensitivity to the substitutions then are refined by 25 introducing further or other variants at or for the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation *per se* need not be predetermined. For example, to optimize the performance of a mutation at a given site, alanine scanning or random mutagenesis is conducted at the target codon or region and the PRO317 variants produced are screened for the optimal combination of desired activity.

30 There are two principal variables in the construction of amino acid sequence variants: the location of the mutation site and the nature of the mutation. These are variants from the Figure 42 sequence, and may represent naturally occurring alleles (which will not require manipulation of the PRO317 DNA) or predetermined mutant forms made by mutating the DNA, either to arrive at an allele or a variant not found in nature. In general, the location and nature of the mutation chosen will depend upon the PRO317 characteristic to be modified.

35 Amino acid sequence deletions generally range from about 1 to 30 residues, more preferably about 1 to 10 residues, and typically are contiguous. Contiguous deletions ordinarily are made in even numbers of residues, but single or odd numbers of deletions are within the scope hereof. Deletions may be introduced into regions of low

homology among PRO317, EBAF-1, and other members of the TGF- superfamily which share the most sequence identity to the human PRO317 amino acid sequence to modify the activity of PRO317. Deletions from PRO317 in areas of substantial homology with one of the receptor binding sites of other members of the TGF- superfamily will be more likely to modify the biological activity of PRO317 more significantly. The number of consecutive deletions will be selected so as to preserve the tertiary structure of PRO317 in the affected domain, *e.g.*, beta-pleated sheet  
5 or alpha helix.

Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions (*i.e.*, insertions within the mature PRO317 sequence) may range generally from about 1 to 10 residues, more preferably 1 to 5, most preferably 1 to 3. Insertions are preferably  
10 made in even numbers of residues, but this is not required. Examples of terminal insertions include mature PRO317 with an N-terminal methionyl residue, an artifact of the direct production of mature PRO317 in recombinant cell culture, and fusion of a heterologous N-terminal signal sequence to the N-terminus of the mature PRO317 molecule to facilitate the secretion of mature PRO317 from recombinant hosts. Such signal sequences may be obtained from,  
15 and thus homologous to, the intended host cell species, but also may be from other members of the TGF- superfamily. Suitable sequences include STII or lpp for *E. coli*, alpha factor for yeast, and viral signals such as herpes gD or the native EBAF-1 sequence for mammalian cells.

Other insertional variants of the PRO317 molecule include the fusion to the N- or C-terminus of PRO317 of immunogenic polypeptides, *e.g.*, bacterial polypeptides such as beta-lactamase or an enzyme encoded by the *E. coli trp* locus, or yeast protein, and C-terminal fusions with proteins having a long half-life such as immunoglobulin  
20 constant regions (or other immunoglobulin regions), albumin, or ferritin, as described in WO 89/02922 published 6 April 1989.

A third group of variants are amino acid substitution variants. These variants have at least one amino acid residue in the PRO317 molecule removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include sites identified as the active site(s) of PRO317 and sites where the amino acids  
25 found in the known analogues are substantially different in terms of side-chain bulk, charge, or hydrophobicity, but where there is also a high degree of sequence identity at the selected site within various animal PRO317 species, or where the amino acids found in known members of the TGF- superfamily and novel PRO317 are substantially different in terms of side-chain bulk, charge, or hydrophobicity, but where there also is a high degree of sequence  
30 identity at the selected site within various animal analogues of such members (*e.g.*, among all the animal EBAF-1 molecules). This analysis will highlight residues that may be involved in the modulation of endometrial tissue or angiogenesis, and therefore, variations at these sites may affect such activities.

Other sites of interest are those in which particular residues of the PRO317 obtained from various species are identical among all animal species of PRO317 and other members of the TGF- superfamily, this degree of conservation suggesting importance in achieving biological activity common to these cytokines. These sites,  
35 especially those falling within a sequence of at least three other identically conserved sites, are substituted in a relatively conservative manner. Such conservative substitutions are shown in Table 1 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes,

denominated exemplary substitutions in Table 1, or as further described below in reference to amino acid classes, are introduced and the products screened.

Table 1

	<u>Original Residue</u>	<u>Exemplary Substitutions</u>	<u>Preferred Substitutions</u>
5	Ala (A)	val; leu; ile	val
	Arg (R)	lys; gln; asn	lys
10	Asn (N)	gln; his; lys; arg	gln
	Asp (D)	glu	glu
	Cys (C)	ser	ser
	Gln (Q)	asn	asn
	Glu (E)	asp	asp
15	Gly (G)	pro; ala	ala
	His (H)	asn; gln; lys; arg	arg
	Ile (I)	leu; val; met; ala; phe; norleucine	
	Leu (L)	norleucine; ile; val; met; ala; phe	leu
20	Lys (K)	arg; gln; asn	arg
	Met (M)	leu; phe; ile	leu
	Phe (F)	leu; val; ile; ala; tyr	leu
	Pro (P)	ala	ala
25	Ser (S)	thr	thr
	Thr (T)	ser	ser
	Trp (W)	tyr; phe	tyr
	Tyr (Y)	trp; phe; thr; ser	phe
30	Val (V)	ile; leu; met; phe; ala; norleucine	leu

Substantial modifications in function or immunological identity of the PRO317 are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophilic: cys, ser, thr;
- (3) acidic: asp, glu;
- 40 (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the 45 remaining (non-conserved) sites.

In one embodiment of the invention, it is desirable to inactivate one or more protease cleavage sites that are present in the molecule. These sites are identified by inspection of the encoded amino acid sequence, in the case of

trypsin, e.g., for an arginyl or lysinyl residue. When protease cleavage sites are identified, they are rendered inactive to proteolytic cleavage by substituting the targeted residue with another residue, preferably a basic residue such as glutamine or a hydrophilic residue such as serine; by deleting the residue; or by inserting a prolyl residue immediately after the residue.

5 In another embodiment, any methionyl residues other than the starting methionyl residue of the signal sequence, or any residue located within about three residues N- or C-terminal to each such methionyl residue, is substituted by another residue (preferably in accord with Table 1) or deleted. Alternatively, about 1-3 residues are inserted adjacent to such sites.

Any cysteine residues not involved in maintaining the proper conformation of PRO317 also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking.

10 Nucleic acid molecules encoding amino acid sequence variants of PRO317 are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of PRO317.

15 Oligonucleotide-mediated mutagenesis is a preferred method for preparing substitution, deletion, and insertion variants of PRO317 DNA. This technique is well known in the art as described by Adelman *et al.*, DNA, 2: 183 (1983). Briefly, PRO317 DNA is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of PRO317. After hybridization, a DNA polymerase is used to synthesize an 20 entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the PRO317 DNA.

25 Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea *et al.*, Proc. Natl. Acad. Sci. USA, 75: 5765 (1978).

The DNA template can be generated by those vectors that are either derived from bacteriophage M13 vectors (the commercially available M13mp18 and M13mp19 vectors are suitable), or those vectors that contain a single-stranded phage origin of replication as described by Viera *et al.* Meth. Enzymol., 153: 3 (1987). Thus, the 30 DNA that is to be mutated may be inserted into one of these vectors to generate single-stranded template. Production of the single-stranded template is described in Sections 4.21-4.41 of Sambrook *et al.*, *supra*.

Alternatively, single-stranded DNA template may be generated by denaturing double-stranded plasmid (or other) DNA using standard techniques.

For alteration of the native DNA sequence (to generate amino acid sequence variants, for example), the 35 oligonucleotide is hybridized to the single-stranded template under suitable hybridization conditions. A DNA polymerizing enzyme, usually the Klenow fragment of DNA polymerase I, is then added to synthesize the complementary strand of the template using the oligonucleotide as a primer for synthesis. A heteroduplex molecule

is thus formed such that one strand of DNA encodes the mutated form of PRO317, and the other strand (the original template) encodes the native, unaltered sequence of PRO317. This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote such as *E. coli* JM101. After the cells are grown, they are plated onto agarose plates and screened using the oligonucleotide primer radiolabeled with  $^{32}\text{P}$  to identify the bacterial colonies that contain the mutated DNA. The mutated region is then removed and placed in an appropriate vector for protein production, generally an expression vector of the type typically employed for transformation of an appropriate host.

The method described immediately above may be modified such that a homoduplex molecule is created wherein both strands of the plasmid contain the mutation(s). The modifications are as follows: The single-stranded oligonucleotide is annealed to the single-stranded template as described above. A mixture of three deoxyribonucleotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribothymidine (dTTP), is combined with a modified thio-deoxyribocytosine called dCTP-(aS) (which can be obtained from the Amersham Corporation). This mixture is added to the template-oligonucleotide complex. Upon addition of DNA polymerase to this mixture, a strand of DNA identical to the template except for the mutated bases is generated. In addition, this new strand of DNA will contain dCTP-(aS) instead of dCTP, which serves to protect it from restriction endonuclease digestion.

After the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme, the template strand can be digested with *ExoIII* nuclease or another appropriate nuclease past the region that contains the site(s) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is then formed using DNA polymerase in the presence of all four deoxyribonucleotide triphosphates, ATP, and DNA ligase. This homoduplex molecule can then be transformed into a suitable host cell such as *E. coli* JM101, as described above.

DNA encoding PRO317 mutants with more than one amino acid to be substituted may be generated in one of several ways. If the amino acids are located close together in the polypeptide chain, they may be mutated simultaneously using one oligonucleotide that codes for all of the desired amino acid substitutions. If, however, the amino acids are located some distance from each other (separated by more than about ten amino acids), it is more difficult to generate a single oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.

In the first method, a separate oligonucleotide is generated for each amino acid to be substituted. The oligonucleotides are then annealed to the single-stranded template DNA simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired amino acid substitutions.

The alternative method involves two or more rounds of mutagenesis to produce the desired mutant. The first round is as described for the single mutants: wild-type DNA is used for the template, an oligonucleotide encoding the first desired amino acid substitution(s) is annealed to this template, and the heteroduplex DNA molecule is then generated. The second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, this template already contains one or more mutations. The oligonucleotide encoding the additional desired amino acid substitution(s) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and second rounds of mutagenesis. This resultant DNA can be used as a template in a third round of mutagenesis, and so on.

PCR mutagenesis is also suitable for making amino acid variants of PRO317. While the following discussion refers to DNA, it is understood that the technique also finds application with RNA. The PCR technique generally refers to the following procedure (see Erlich, PCR Technology, (Stockton Press, NY, 1989), the chapter by R. Higuchi, p. 61-70): When small amounts of template DNA are used as starting material in a PCR, primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs from the template sequence only at the positions where the primers differ from the template. For introduction of a mutation into a plasmid DNA, one of the primers is designed to overlap the position of the mutation and to contain the mutation; the sequence of the other primer must be identical to a stretch of sequence of the opposite strand of the plasmid, but this sequence can be located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 200 nucleotides from that of the first, such that in the end the entire amplified region of DNA bounded by the primers can be easily sequenced. PCR amplification using a primer pair like the one just described results in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, as template copying is somewhat error-prone.

Another method for preparing variants, cassette mutagenesis, is based on the technique described by Wells *et al.*, Gene, 34: 315 (1985). The starting material is the plasmid (or other vector) comprising the PRO317 DNA to be mutated. The codon(s) in the PRO317 DNA to be mutated are identified. There must be a unique restriction endonuclease site on each side of the identified mutation site(s). If no such restriction sites exist, they may be generated using the above-described oligonucleotide-mediated mutagenesis method to introduce them at appropriate locations in the PRO317 DNA. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites to linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have 3' and 5' ends that are compatible with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid. This plasmid now contains the mutated PRO317 DNA sequence.

Covalent modifications of PRO317 are also included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of the PRO317 with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues of the PRO317. Derivatization with bifunctional agents is useful, for instance, for crosslinking PRO317 to a water-insoluble support matrix or surface for use in the method for purifying anti-PRO317 antibodies, and vice-versa. Commonly used crosslinking agents include, *e.g.*, 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis-(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane, and agents such as methyl-3-((p-azidophenyl)dithio)propioimidate.

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the "-amino groups of lysine, arginine, and histidine side chains (T.E.

Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the PRO317 polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native-sequence PRO 5 polypeptide, and/or adding one or more glycosylation sites that are not present in the native-sequence PRO polypeptide. The deduced amino acid sequence of PRO317 shown in Figure 42 (SEQ ID NO:114) has one predicted N-linked glycosylation site at residue 160.

Addition of glycosylation sites to the PRO317 polypeptide may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or 10 threonine residues to the native-sequence PRO317 (for O-linked glycosylation sites). The PRO317 amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the PRO317 polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the PRO317 polypeptide is by chemical 15 or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the PRO317 polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, 20 et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of PRO317 comprises linking the PRO317 polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the 25 manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

The PRO317 of the present invention may also be modified in a way to form a chimeric molecule comprising PRO317 fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of the PRO317 with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl- terminus of the PRO317. 30 The presence of such epitope-tagged forms of the PRO317 can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the PRO317 to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of the PRO317 with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region 35 of an IgG molecule.

Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5

(Field *et al.*, Mol. Cell. Biol., **8**:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7, and 9E10 antibodies thereto (Evan *et al.*, Molecular and Cellular Biology, **5**:3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky *et al.*, Protein Engineering, **3**(6):547-553 (1990)). Other tag polypeptides include the Flag-peptide (Hopp *et al.*, Bio/Technology, **6**:1204-1210 (1988)); the KT3 epitope peptide (Martin *et al.*, Science, **255**:192-194 (1992)); an "-tubulin epitope peptide (Skinner *et al.*, J. Biol. Chem., **266**:15163-15166 (1991)); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth *et al.*, Proc. Natl. Acad. Sci. USA, **87**:6393-6397 (1990)).

### 53. Preparation of PRO Polypeptides

The description below relates primarily to production of PRO polypeptides by culturing cells transformed or transfected with a vector containing the desired PRO polypeptide nucleic acid. It is, of course, contemplated that alternative methods, which are well known in the art, may be employed to prepare the PRO polypeptide. For instance, the PRO polypeptide sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques [see, e.g., Stewart *et al.*, Solid-Phase Peptide Synthesis, W.H. Freeman Co., San Francisco, CA (1969); Merrifield, J. Am. Chem. Soc., **85**:2149-2154 (1963)]. *In vitro* protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions of the desired PRO polypeptide may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length PRO polypeptide.

#### 20 A. Isolation of DNA Encoding PRO Polypeptides

DNA encoding PRO polypeptides may be obtained from a cDNA library prepared from tissue believed to possess the desired PRO polypeptide mRNA and to express it at a detectable level. Accordingly, human PRO polypeptide DNA can be conveniently obtained from a cDNA library prepared from human tissue, such as described in the Examples. The PRO polypeptide-encoding gene may also be obtained from a genomic library or by oligonucleotide synthesis.

25 Libraries can be screened with probes (such as antibodies to the desired PRO polypeptide or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook *et al.*, Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An alternative means to isolate the gene encoding the desired PRO polypeptide is to use PCR methodology [Sambrook *et al.*, *supra*; Dieffenbach *et al.*, PCR Primer:A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1995)].

30 The Examples below describe techniques for screening a cDNA library. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include the use of radiolabels like <sup>32</sup>P-labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are

provided in Sambrook et al., supra.

Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined through sequence alignment using computer software programs such as  
5 BLAST, ALIGN, DNAsstar, and INHERIT which employ various algorithms to measure homology.

Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.

10

#### B. Selection and Transformation of Host Cells

Host cells are transfected or transformed with expression or cloning vectors described herein for PRO polypeptide production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as  
15 media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook et al., supra.

20

Methods of transfection are known to the ordinarily skilled artisan, for example, CaPO<sub>4</sub> and electroporation.  
Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook et al., supra, or electroporation is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw et al., Gene, 23:315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate  
25 precipitation method of Graham and van der Eb, Virology, 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transformations have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen et al., J. Bact., 130:946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g.,  
30 polybrene, polyornithine, may also be used. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzymology, 185:527-537 (1990) and Mansour et al., Nature, 336:348-352 (1988).

Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as *E. coli*. Various *E. coli* strains are publicly  
35 available, such as *E. coli* K12 strain MM294 (ATCC 31,446); *E. coli* X1776 (ATCC 31,537); *E. coli* strain W3110 (ATCC 27,325) and K5 772 (ATCC 53,635). Other suitable prokaryotic host cells include Enterobacteriaceae such as *Escherichia*, e.g., *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, e.g., *Salmonella typhimurium*,

*Serratia*, e.g., *Serratia marcescens*, and *Shigella*, as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (e.g., *B. licheniformis* 41P disclosed in DD 266,710 published 12 April 1989), *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. Various *E. coli* strains are publicly available, such as *E. coli* K12 strain MM294 (ATCC 31,446); *E. coli* X1776 (ATCC 31,537); *E. coli* strain W3110 (ATCC 27,325); and K5 772 (ATCC 53,635). These examples are illustrative rather than limiting. Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including *E. coli* W3110 strain 1A2, which has the complete genotype *tonA*; *E. coli* W3110 strain 9E4, which has the complete genotype *tonA ptr3*; *E. coli* W3110 strain 27C7 (ATCC 55,244), which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP*; *ompT kan'*; *E. coli* W3110 strain 37D6, which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT rbs7 ilvG kan'*; *E. coli* W3110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant *degP* deletion mutation; and an *E. coli* strain having mutant periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990. Alternatively, *in vitro* methods of cloning, e.g., PCR or other nucleic acid polymerase reactions, are suitable.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for PRO polypeptide-encoding vectors. *Saccharomyces cerevisiae* is a commonly used lower eukaryotic host microorganism. Others include *Schizosaccharomyces pombe* (Beach and Nurse, *Nature*, 290: 140 [1981]; EP 139,383 published 2 May 1985); *Kluyveromyces* hosts (U.S. Patent No. 4,943,529; Fleer *et al.*, *Bio/Technology*, 9: 968-975 (1991)) such as, e.g., *K. lactis* (MW98-8C, CBS683, CBS4574; Louvencourt *et al.*, *J. Bacteriol.*, 737 [1983]), *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,045), *K. wickeramii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilae* (ATCC 36,906; Van den Berg *et al.*, *Bio/Technology*, 8: 135 (1990)), *K. thermotolerans*, and *K. marxianus*; *yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070; Sreekrishna *et al.*, *Basic Microbiol.*, 28: 265-278 [1988]); *Candida*; *Trichoderma reesiae* (EP 244,234); *Neurospora crassa* (Case *et al.*, *Proc. Natl. Acad. Sci. USA*, 76: 5259-5263 [1979]); *Schwanniomyces* such as *Schwanniomyces occidentalis* (EP 394,538 published 31 October 1990); and filamentous fungi such as, e.g., *Neurospora*, *Penicillium*, *Tolypocladium* (WO 91/00357 published 10 January 1991), and *Aspergillus* hosts such as *A. nidulans* (Ballance *et al.*, *Biochem. Biophys. Res. Commun.*, 112: 284-289 [1983]; Tilburn *et al.*, *Gene*, 26: 205-221 [1983]; Yelton *et al.*, *Proc. Natl. Acad. Sci. USA*, 81: 1470-1474 [1984]) and *A. niger* (Kelly and Hynes, *EMBO J.*, 4: 475-479 [1985]). Methylotropic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of *Hansenula*, *Candida*, *Kloeckera*, *Pichia*, *Saccharomyces*, *Torulopsis*, and *Rhodotorula*. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, *The Biochemistry of Methylotrophs*, 269 (1982).

Suitable host cells for the expression of glycosylated PRO polypeptides are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as *Drosophila S2* and *Spodoptera Sf9*, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham *et al.*, *J. Gen. Virol.*,

36:59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, *Proc. Natl. Acad. Sci. USA*, **77**:4216 (1980)); mouse sertoli cells (TM4, Mather, *Biol. Reprod.*, **23**:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51). The selection of the appropriate host cell is deemed to be within the skill in the art.

5

### C. Selection and Use of a Replicable Vector

The nucleic acid (*e.g.*, cDNA or genomic DNA) encoding a desired PRO polypeptide may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.

10 The PRO polypeptide of interest may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the PRO polypeptide DNA that is inserted into the vector. The signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, *e.g.*, the 15 yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces*  $\alpha$ -factor leaders, the latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In 20 mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.

25 Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the  $2\mu$  plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.

30 Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, *e.g.*, ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, *e.g.*, the gene encoding D-alanine racemase for *Bacilli*.

An example of suitable selectable markers for mammalian cells are those that enable the identification of 35 cells competent to take up the PRO polypeptide nucleic acid, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., *Proc. Natl. Acad. Sci. USA*, **77**:4216 (1980). A suitable selection gene

WO 99/14328

for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 [Stinchcomb et al., *Nature*, **282**:39 (1979); Kingsman et al., *Gene*, **7**:141 (1979); Tschemper et al., *Gene*, **10**:157 (1980)]. The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, *Genetics*, **85**:12 (1977)].

Expression and cloning vectors usually contain a promoter operably linked to the PRO polypeptide nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. 5 Promoters suitable for use with prokaryotic hosts include the β-lactamase and lactose promoter systems [Chang et al., *Nature*, **275**:615 (1978); Goeddel et al., *Nature*, **281**:544 (1979)], alkaline phosphatase, a tryptophan (*trp*) promoter system [Goeddel, *Nucleic Acids Res.*, **8**:4057 (1980); EP 36,776], and hybrid promoters such as the tac promoter [deBoer et al., *Proc. Natl. Acad. Sci. USA*, **80**:21-25 (1983)]. Promoters for use in bacterial systems also 10 will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the desired PRO polypeptide.

Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman et al., *J. Biol. Chem.*, **255**:2073 (1980)] or other glycolytic enzymes [Hess et al., *J. Adv. Enzyme Reg.*, **7**:149 (1968); Holland, *Biochemistry*, **17**:4900 (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 15 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for 20 use in yeast expression are further described in EP 73,657.

PRO polypeptide transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin 25 promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.

Transcription of a DNA encoding the desired PRO polypeptide by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from 30 mammalian genes (globin, elastase, albumin, α-fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the PRO polypeptide coding sequence, but is preferably located at a site 5' from the promoter.

35 Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated

regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding PRO polypeptides.

Still other methods, vectors, and host cells suitable for adaptation to the synthesis of PRO polypeptides in recombinant vertebrate cell culture are described in Gething et al., *Nature*, 293:620-625 (1981); Mantei et al., *Nature*, 281:40-46 (1979); EP 117,060; and EP 117,058.

5

#### D. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, *Proc. Natl. Acad. Sci. USA*, 77:5201-5205 (1980)], dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, 10 based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical 15 staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence PRO polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to a PRO polypeptide DNA and encoding a specific antibody epitope.

20

#### E. Purification of Polypeptide

Forms of PRO polypeptides may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (*e.g.* Triton-X 100) or by enzymatic cleavage. Cells employed in expression of PRO polypeptides can be disrupted by various physical or chemical 25 means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.

It may be desired to purify PRO polypeptides from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; 30 protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the PRO polypeptide. Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, *Methods in Enzymology*, 182 (1990); Scopes, *Protein Purification: Principles and Practice*, Springer-Verlag, New York (1982). The purification step(s) selected will depend, for example, on the nature of the production process used and the particular PRO polypeptide produced.

35

#### 54. Uses for PRO Polypeptides

Nucleotide sequences (or their complement) encoding the PRO polypeptides of the present invention have various applications in the art of molecular biology, including uses as hybridization probes, in chromosome and gene mapping and in the generation of anti-sense RNA and DNA. PRO polypeptide-encoding nucleic acid will also be useful for the preparation of PRO polypeptides by the recombinant techniques described herein.

5       The full-length native sequence PRO polypeptide-encoding nucleic acid or portions thereof, may be used as hybridization probes for a cDNA library to isolate the full-length PRO polypeptide gene or to isolate still other genes (for instance, those encoding naturally-occurring variants of the PRO polypeptide or PRO polypeptides from other species) which have a desired sequence identity to the PRO polypeptide nucleic acid sequences. Optionally, the length of the probes will be about 20 to about 50 bases. The hybridization probes may be derived from the  
10 nucleotide sequence of any of the DNA molecules disclosed herein or from genomic sequences including promoters, enhancer elements and introns of native sequence PRO polypeptide encoding DNA. By way of example, a screening method will comprise isolating the coding region of the PRO polypeptide gene using the known DNA sequence to synthesize a selected probe of about 40 bases. Hybridization probes may be labeled by a variety of labels, including radionucleotides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or enzymatic labels such as alkaline phosphatase coupled to the probe via  
15 avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of the specific PRO polypeptide gene of the present invention can be used to screen libraries of human cDNA, genomic DNA or mRNA to determine which members of such libraries the probe hybridizes to. Hybridization techniques are described in further detail in the Examples below.

20      The ESTs disclosed in the present application may similarly be employed as probes, using the methods disclosed herein.

The probes may also be employed in PCR techniques to generate a pool of sequences for identification of closely related PRO polypeptide sequences.

25      Nucleotide sequences encoding a PRO polypeptide can also be used to construct hybridization probes for mapping the gene which encodes that PRO polypeptide and for the genetic analysis of individuals with genetic disorders. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as *in situ* hybridization, linkage analysis against known chromosomal markers, and hybridization screening with libraries.

30      The PRO polypeptide can be used in assays to identify its ligands. Similarly, inhibitors of the receptor/ligand binding interaction can be identified. Proteins involved in such binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction. Screening assays can be designed to find lead compounds that mimic the biological activity of a native PRO polypeptide or a ligand for the PRO polypeptide. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. Small molecules contemplated include synthetic organic or inorganic compounds. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays and cell based assays, which are well characterized in the art.

Nucleic acids which encode a PRO polypeptide or its modified forms can also be used to generate either transgenic animals or "knock out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A transgenic animal (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A transgene is a DNA which is integrated into the genome of a cell from which a transgenic animal develops. In one embodiment, cDNA encoding a PRO polypeptide of interest can be used to clone genomic DNA encoding the PRO polypeptide in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express DNA encoding the PRO polypeptide. Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009. Typically, particular cells would be targeted for PRO polypeptide transgene incorporation with tissue-specific enhancers. Transgenic animals that include a copy of a transgene encoding a PRO polypeptide introduced into the germ line of the animal at an embryonic stage can be used to examine the effect of increased expression of DNA encoding the PRO polypeptide. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this facet of the invention, an animal is treated with the reagent and a reduced incidence of the pathological condition, compared to untreated animals bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition.

Alternatively, non-human homologues of PRO polypeptides can be used to construct a PRO polypeptide "knock out" animal which has a defective or altered gene encoding the PRO polypeptide of interest as a result of homologous recombination between the endogenous gene encoding the PRO polypeptide and altered genomic DNA encoding the PRO polypeptide introduced into an embryonic cell of the animal. For example, cDNA encoding a PRO polypeptide can be used to clone genomic DNA encoding the PRO polypeptide in accordance with established techniques. A portion of the genomic DNA encoding a PRO polypeptide can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see e.g., Thomas and Capecchi, *Cell*, 51:503 (1987) for a description of homologous recombination vectors]. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected [see e.g., Li et al., *Cell*, 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras [see e.g., Bradley, in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knockout animals can be characterized for instance, for their ability to defend against certain pathological conditions and for their development of pathological conditions due to absence of the PRO polypeptide.

With regard to the PRO211 and PRO217 polypeptide, therapeutic indications include disorders associated with the preservation and maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions

(e.g., enterocolitis, Zollinger-Ellison syndrome, gastrointestinal ulceration and congenital microvillus atrophy), skin diseases associated with abnormal keratinocyte differentiation (e.g., psoriasis, epithelial cancers such as lung squamous cell carcinoma, epidermoid carcinoma of the vulva and gliomas.

Since the PRO232 polypeptide and nucleic acid encoding it possess sequence homology to a cell surface stem cell antigen and its encoding nucleic acid, probes based upon the PRO232 nucleotide sequence may be employed to

5 identify other novel stem cell surface antigen proteins. Soluble forms of the PRO232 polypeptide may be employed as antagonists of membrane bound PRO232 activity both *in vitro* and *in vivo*. PRO232 polypeptides may be employed in screening assays designed to identify agonists or antagonists of the native PRO232 polypeptide, wherein such assays may take the form of any conventional cell-type or biochemical binding assay. Moreover, the PRO232 polypeptide may serve as a molecular marker for the tissues in which the polypeptide is specifically expressed.

10 With regard to the PRO187 polypeptides disclosed herein, FGF-8 has been implicated in cellular differentiation and embryogenesis, including the patterning which appears during limb formation. FGF-8 and the PRO187 molecules of the invention therefore are likely to have potent effects on cell growth and development. Diseases which relate to cellular growth and differentiation are therefore suitable targets for therapeutics based on functionality similar to FGF-8. For example, diseases related to growth or survival of nerve cells including  
15 Parkinson's disease, Alzheimer's disease, ALS, neuropathies. Additionally, disease related to uncontrolled cell growth, e.g., cancer, would also be expected therapeutic targets.

With regard to the PRO265 polypeptides disclosed herein, other methods for use with PRO265 are described in U.S. Patent 5,654,270 to Ruoslahti et al. In particular, PRO265 can be used in comparison with the fibromodulin disclosed therein to compare its effects on reducing dermal scarring and other properties of the fibromodulin  
20 described therein including where it is located and with what it binds and does not.

The PRO219 polypeptides of the present invention which play a regulatory role in the blood coagulation cascade may be employed *in vivo* for therapeutic purposes as well as for *in vitro* purposes. Those of ordinary skill in the art will well know how to employ PRO219 polypeptides for such uses.

25 The PRO246 polypeptides of the present invention which serve as cell surface receptors for one or more viruses will find other uses. For example, extracellular domains derived from these PRO246 polypeptides may be employed therapeutically *in vivo* for lessening the effects of viral infection. Those PRO246 polypeptides which serve as tumor specific antigens may be exploited as therapeutic targets for anti-tumor drugs, and the like. Those of ordinary skill in the art will well know how to employ PRO246 polypeptides for such uses.

Assays in which connective growth factor and other growth factors are usually used should be performed  
30 with PRO261. An assay to determine whether TGF beta induces PRO261, indicating a role in cancer is performed as known in the art. Wound repair and tissue growth assays are also performed with PRO261. The results are applied accordingly.

PRO228 polypeptides should be used in assays in which EMR1, CD97 and latrophilin would be used in to determine their relative activities. The results can be applied accordingly. For example, a competitive binding assay  
35 with PRO228 and CD97 can be performed with the ligand for CD97, CD55.

Native PRO533 is a 216 amino acid polypeptide of which residues 1-22 are the signal sequence. Residues 3 to 216 have a Blast score of 509, corresponding to 53% homology to fibroblast growth factor. At the nucleotide

level, DNA47412, the EST from which PCR oligos were generated to isolate the full length DNA49435-1219, has been observed to map to 11p15. Sequence homology to the 11p15 locus would indicate that PRO533 may have utility in the treatment of Usher Syndrome or Atrophy areata.

As mentioned previously, fibroblast growth factors can act upon cells in both a mitogenic and non-mitogenic manner. These factors are mitogenic for a wide variety of normal diploid mesoderm-derived and neural crest-derived 5 cells, inducing granulosa cells, adrenal cortical cells, chondrocytes, myoblasts, corneal and vascular endothelial cells (bovine or human), vascular smooth muscle cells, lens, retina and prostatic epithelial cells, oligodendrocytes, astrocytes, chondrocytes, myoblasts and osteoblasts.

Non-mitogenic actions of fibroblast growth factors include promotion of cell migration into a wound area (chemotaxis), initiation of new blood vessel formulation (angiogenesis), modulation of nerve regeneration and survival 10 (neurotrophism), modulation of endocrine functions, and stimulation or suppression of specific cellular protein expression, extracellular matrix production and cell survival. Baird, A. & Bohlen, P., *Handbook of Exp. Pharmacol.* 95(1): 369-418 (1990). These properties provide a basis for using fibroblast growth factors in therapeutic approaches to accelerate wound healing, nerve repair, collateral blood vessel formation, and the like. For example, fibroblast 15 growth factors, have been suggested to minimize myocardium damage in heart disease and surgery (U.S.P. 4,378,437).

Since the PRO245 polypeptide and nucleic acid encoding it possess sequence homology to a transmembrane protein tyrosine kinase protein and its encoding nucleic acid, probes based upon the PRO245 nucleotide sequence may be employed to identify other novel transmembrane tyrosine kinase proteins. Soluble forms of the PRO245 polypeptide may be employed as antagonists of membrane bound PRO245 activity both *in vitro* and *in vivo*. PRO245 20 polypeptides may be employed in screening assays designed to identify agonists or antagonists of the native PRO245 polypeptide, wherein such assays may take the form of any conventional cell-type or biochemical binding assay. Moreover, the PRO245 polypeptide may serve as a molecular marker for the tissues in which the polypeptide is specifically expressed.

PRO220, PRO221 and PRO227 all have leucine rich repeats. Additionally, PRO220 and PRO221 have 25 homology to SLIT and leucine rich repeat protein. Therefore, these proteins are useful in assays described in the literature, *supra*, wherein the SLIT and leucine rich repeat protein are used. Regarding the SLIT protein, PRO227 can be used in an assay to determine the affect of PRO227 on neurodegenerative disease. Additionally, PRO227 has homology to human glycoprotein V. In the case of PRO227, this polypeptide is used in an assay to determine its affect on bleeding, clotting, tissue repair and scarring.

30 The PRO266 polypeptide can be used in assays to determine if it has a role in neurodegenerative diseases or their reversal.

PRO269 polypeptides and portions thereof which effect the activity of thrombin may also be useful for *in vivo* therapeutic purposes, as well as for various *in vitro* applications. In addition, PRO269 polypeptides and portions thereof may have therapeutic use as an antithrombotic agent with reduced risk for hemorrhage as compared with 35 heparin. Peptides having homology to thrombomodulin are particularly desirable.

PRO287 polypeptides and portions thereof which effect the activity of bone morphogenic protein "BMP1"/procollagen C-proteinase (PCP) may also be useful for *in vivo* therapeutic purposes, as well as for various

*in vitro* applications. In addition, PRO287 polypeptides and portions thereof may have therapeutic applications in wound healing and tissue repair. Peptides having homology to procollagen C-proteinase enhancer protein and its precursor may also be used to induce bone and/or cartilage formation and are therefore of particular interest to the scientific and medical communities.

Therapeutic indications for PRO214 polypeptides include disorders associated with the preservation and  
5 maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions (e.g., enterocolitis, Zollinger-Ellison syndrome, gastrointestinal ulceration and congenital microvillus atrophy), skin diseases associated with abnormal keratinocyte differentiation (e.g., psoriasis, epithelial cancers such as lung squamous cell carcinoma, epidermoid carcinoma of the vulva and gliomas).

Studies on the generation and analysis of mice deficient in members of the TGF- superfamily are reported  
10 in Matzuk, Trends in Endocrinol. and Metabol., 6: 120-127 (1995).

The PRO317 polypeptide, as well as PRO317-specific antibodies, inhibitors, agonists, receptors, or their  
15 analogs, herein are useful in treating PRO317-associated disorders. Hence, for example, they may be employed in modulating endometrial bleeding angiogenesis, and may also have an effect on kidney tissue. Endometrial bleeding can occur in gynecological diseases such as endometrial cancer as abnormal bleeding. Thus, the compositions herein  
15 may find use in diagnosing and treating abnormal bleeding conditions in the endometrium, as by reducing or eliminating the need for a hysterectomy. The molecules herein may also find use in angiogenesis applications such as anti-tumor indications for which the antibody against vascular endothelial growth factor is used, or, conversely, ischemic indications for which vascular endothelial growth factor is employed.

Bioactive compositions comprising PRO317 or agonists or antagonists thereof may be administered in a  
20 suitable therapeutic dose determined by any of several methodologies including clinical studies on mammalian species to determine maximal tolerable dose and on normal human subjects to determine safe dose. Additionally, the bioactive agent may be complexed with a variety of well established compounds or compositions which enhance stability or pharmacological properties such as half-life. It is contemplated that the therapeutic, bioactive composition may be delivered by intravenous infusion into the bloodstream or any other effective means which could be used for  
25 treating problems of the kidney, uterus, endometrium, blood vessels, or related tissue, e.g., in the heart or genital tract.

Dosages and administration of PRO317, PRO317 agonist, or PRO317 antagonist in a pharmaceutical composition may be determined by one of ordinary skill in the art of clinical pharmacology or pharmacokinetics. See, for example, Mordini and Rescigno, Pharmaceutical Research, 9:17-25 (1992); Morenti *et al.*, Pharmaceutical  
30 Research, 8:1351-1359 (1991); and Mordini and Chappell, "The use of interspecies scaling in toxicokinetics" in Toxicokinetics and New Drug Development, Yacobi *et al.* (eds) (Pergamon Press: NY, 1989), pp. 42-96. An effective amount of PRO317, PRO317 agonist, or PRO317 antagonist to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the mammal. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of administration as  
35 required to obtain the optimal therapeutic effect. A typical daily dosage might range from about 10 ng/kg to up to 100 mg/kg of the mammal's body weight or more per day, preferably about 1  $\mu$ g/kg/day to 10 mg/kg/day. Typically, the clinician will administer PRO317, PRO317 agonist, or PRO317 antagonist, until a dosage is reached that achieves

the desired effect for treatment of the above mentioned disorders.

PRO317 or an PRO317 agonist or PRO317 antagonist may be administered alone or in combination with another to achieve the desired pharmacological effect. PRO317 itself, or agonists or antagonists of PRO317 can provide different effects when administered therapeutically. Such compounds for treatment will be formulated in a nontoxic, inert, pharmaceutically acceptable aqueous carrier medium preferably at a pH of about 5 to 8, more 5 preferably 6 to 8, although the pH may vary according to the characteristics of the PRO317, agonist, or antagonist being formulated and the condition to be treated. Characteristics of the treatment compounds include solubility of the molecule, half-life, and antigenicity/immunogenicity; these and other characteristics may aid in defining an effective carrier.

PRO317 or PRO317 agonists or PRO317 antagonists may be delivered by known routes of administration 10 including but not limited to topical creams and gels; transmucosal spray and aerosol, transdermal patch and bandage; injectable, intravenous, and lavage formulations; and orally administered liquids and pills, particularly formulated to resist stomach acid and enzymes. The particular formulation, exact dosage, and route of administration will be determined by the attending physician and will vary according to each specific situation.

Such determinations of administration are made by considering multiple variables such as the condition to 15 be treated, the type of mammal to be treated, the compound to be administered, and the pharmacokinetic profile of the particular treatment compound. Additional factors which may be taken into account include disease state (*e.g.* severity) of the patient, age, weight, gender, diet, time of administration, drug combination, reaction sensitivities, and tolerance/response to therapy. Long-acting treatment compound formulations (such as liposomally encapsulated PRO317 or PEGylated PRO317 or PRO317 polymeric microspheres, such as polylactic acid-based microspheres) 20 might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular treatment compound.

Normal dosage amounts may vary from about 10 ng/kg to up to 100 mg/kg of mammal body weight or more per day, preferably about 1  $\mu$ g/kg/day to 10 mg/kg/day, depending upon the route of administration. Guidance as 25 to particular dosages and methods of delivery is provided in the literature; see, for example, U.S. Pat. Nos. 4,657,760; 5,206,344; or 5,225,212. It is anticipated that different formulations will be effective for different treatment compounds and different disorders, that administration targeting the uterus, for example, may necessitate delivery in a manner different from that to another organ or tissue, such as cardiac tissue.

Where sustained-release administration of PRO317 is desired in a formulation with release characteristics suitable for the treatment of any disease or disorder requiring administration of PRO317, microencapsulation of 30 PRO317 is contemplated. Microencapsulation of recombinant proteins for sustained release has been successfully performed with human growth hormone (rhGH), interferon- (rhIFN- ), interleukin-2, and MN rgp120. Johnson *et al.*, Nat. Med., 2: 795-799 (1996); Yasuda, Biomed. Ther., 27: 1221-1223 (1993); Hora *et al.*, Bio/Technology, 8: 755-758 (1990); Cleland, "Design and Production of Single Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems," in Vaccine Design: The Subunit and Adjuvant Approach, Powell and Newman, eds, (Plenum Press: New York, 1995), pp. 439-462; WO 97/03692, WO 96/40072, WO 96/07399; and U.S Pat. No. 5,654,010.

The sustained-release formulations of these proteins were developed using poly-lactic-coglycolic acid (PLGA) polymer due to its biocompatibility and wide range of biodegradable properties. The degradation products

of PLGA, lactic and glycolic acids, can be cleared quickly within the human body. Moreover, the degradability of this polymer can be adjusted from months to years depending on its molecular weight and composition. Lewis, "Controlled release of bioactive agents from lactide/glycolide polymer," in: M. Chasin and R. Langer (Eds.), Biodegradable Polymers as Drug Delivery Systems (Marcel Dekker: New York, 1990), pp. 1-41.

- For example, for a formulation that can provide a dosing of approximately 80 g/kg/day in mammals with
- 5 a maximum body weight of 85 kg, the largest dosing would be approximately 6.8 mg PRO317 per day. In order to achieve this dosing level, a sustained- release formulation which contains a maximum possible protein loading (15-20 % w/w PRO317) with the lowest possible initial burst (<20%) is necessary. A continuous (zero-order) release of PRO317 from microparticles for 1-2 weeks is also desirable. In addition, the encapsulated protein to be released should maintain its integrity and stability over the desired release period.
- 10 It is contemplated that conditions or diseases of the uterus, endometrial tissue, or other genital tissues or cardiac tissues may precipitate damage that is treatable with PRO317 or PRO317 agonist where PRO317 expression is reduced in the diseased state; or with antibodies to PRO317 or other PRO317 antagonists where the expression of PRO317 is increased in the diseased state. These conditions or diseases may be specifically diagnosed by the probing tests discussed above for physiologic and pathologic problems which affect the function of the organ.
- 15 The PRO317, PRO317 agonist, or PRO317 antagonist may be administered to a mammal with another biologically active agent, either separately or in the same formulation to treat a common indication for which they are appropriate. For example, it is contemplated that PRO317 can be administered together with EBAF-1 for those indications on which they demonstrate the same qualitative biological effects. Alternatively, where they have opposite effects, EBAF-1 may be administered together with an antagonist to PRO317, such as an anti-PRO317 antibody.
- 20 Further, PRO317 may be administered together with VEGF for coronary ischemia where such indication is warranted, or with an anti-VEGF for cancer as warranted, or, conversely, an antagonist to PRO317 may be administered with VEGF for coronary ischemia or with anti-VEGF to treat cancer as warranted. These administrations would be in effective amounts for treating such disorders.

Native PRO301 (SEQ ID NO:119) has a Blast score of 246 and 30% homology at residues 24 to 282 of

25 Figure 44 with A33\_HUMAN, an A33 antigen precursor. A33 antigen precursor, as explained in the Background is a tumor-specific antigen, and as such, is a recognized marker and therapeutic target for the diagnosis and treatment of colon cancer. The expression of tumor-specific antigens is often associated with the progression of neoplastic tissue disorders. Native PRO301 (SEQ ID NO:119) and A33\_HUMAN also show a Blast score of 245 and 30% homology at residues 21 to 282 of Fig. 44 with A33\_HUMAN, the variation dependent upon how spaces are inserted

30 into the compared sequences. Native PRO301 (SEQ ID NO:119) also has a Blast score of 165 and 29% homology at residues 60 to 255 of Fig. 44 with HS46KDA\_1, a human coxsackie and adenovirus receptor protein, also known as cell surface protein HCAR. This region of PRO301 also shows a similar Blast score and homology with HSU90716\_1. Expression of such proteins is usually associated with viral infection and therapeutics for the prevention of such infection may be accordingly conceived. As mentioned in the Background, the expression of viral

35 receptors is often associated with neoplastic tumors.

Therapeutic uses for the PRO234 polypeptides of the invention includes treatments associated with leukocyte homing or the interaction between leukocytes and the endothelium during an inflammatory response. Examples

include asthma, rheumatoid arthritis, psoriasis and multiple sclerosis.

Since the PRO231 polypeptide and nucleic acid encoding it possess sequence homology to a putative acid

phosphatase and its encoding nucleic acid, probes based upon the PRO231 nucleotide sequence may be employed to identify other novel phosphatase proteins. Soluble forms of the PRO231 polypeptide may be employed as antagonists of membrane bound PRO231 activity both *in vitro* and *in vivo*. PRO231 polypeptides may be employed in screening

5 assays designed to identify agonists or antagonists of the native PRO231 polypeptide, wherein such assays may take the form of any conventional cell-type or biochemical binding assay. Moreover, the PRO231 polypeptide may serve as a molecular marker for the tissues in which the polypeptide is specifically expressed.

PRO229 polypeptides can be fused with peptides of interest to determine whether the fusion peptide has an increased half-life over the peptide of interest. The PRO229 polypeptides can be used accordingly to increase the 10 half-life of polypeptides of interest. Portions of PRO229 which cause the increase in half-life are an embodiment of the invention herein.

PRO238 can be used in assays which measure its ability to reduce substrates, including oxygen and Aceyl-CoA, and particularly, measure PRO238's ability to produce oxygen free radicals. This is done by using assays which have been previously described. PRO238 can further be used to assay for candidates which block, reduce 15 or reverse its reducing abilities. This is done by performing side by side assays where candidates are added in one assay having PRO238 and a substrate to reduce, and not added in another assay, being the same but for the lack of the presence of the candidate.

PRO233 polypeptides and portions thereof which have homology to reductase may also be useful for *in vivo* therapeutic purposes, as well as for various other applications. The identification of novel reductase proteins and 20 related molecules may be relevant to a number of human disorders such as inflammatory disease, organ failure, atherosclerosis, cardiac injury, infertility, birth defects, premature aging, AIDS, cancer, diabetic complications and mutations in general. Given that oxygen free radicals and antioxidants appear to play important roles in a number of disease processes, the identification of new reductase proteins and reductase-like molecules is of special importance in that such proteins may serve as potential therapeutics for a variety of different human disorders. Such polypeptides 25 may also play important roles in biotechnological and medical research, as well as various industrial applications. As a result, there is particular scientific and medical interest in new molecules, such as PRO233.

The PRO223 polypeptides of the present invention which exhibit serine carboxypeptidase activity may be employed *in vivo* for therapeutic purposes as well as for *in vitro* purposes. Those of ordinary skill in the art will well know how to employ PRO223 polypeptides for such uses.

30 PRO235 polypeptides and portions thereof which may be involved in cell adhesion are also useful *in vivo* for therapeutic purposes, as well as for various *in vitro* applications. In addition, PRO235 polypeptides *and which* may have therapeutic applications in disease states which involve cell adhesion. Given the *present scientific* of cell adhesion mechanisms *in vivo*, efforts are currently being undertaken to identify *various known β-* are involved in cell adhesion. Therefore, peptides having homology to plexin are *for use in conjugates of* and medical communities.

Because the PRO236 and PRO262 polypeptides disclosed galactosidase proteins, the PRO236 and PRO262 polypeptides

monoclonal antibodies and the polypeptide for specific killing of tumor cells by generation of active drug from a galactosylated prodrug (e.g., the generation of 5-fluorouridine from the prodrug  $\beta$ -D-galactosyl-5-fluorouridine). The PRO236 and PRO262 polypeptides disclosed herein may also find various uses both *in vivo* and *in vitro*, wherein those uses will be similar or identical to uses for which  $\beta$ -galactosidase proteins are now employed. Those of ordinary skill in the art will know how to employ PRO236 and PRO262 polypeptides for such uses.

5 PRO239 polypeptides and portions thereof which have homology to densin may also be useful for *in vivo* therapeutic purposes, as well as for various *in vitro* applications. In addition, PRO239 polypeptides and portions thereof may have therapeutic applications in disease states which involve synaptic mechanisms, regeneration or cell adhesion. Given the physiological importance of synaptic processes, regeneration and cell adhesion mechanisms *in vivo*, efforts are currently being undertaken to identify new, native proteins which are involved in synaptic machinery and cell  
10 adhesion. Therefore, peptides having homology to densin are of particular interest to the scientific and medical communities.

15 The PRO260 polypeptides described herein can be used in assays to determine their relation to fucosidase. In particular, the PRO260 polypeptides can be used in assays in determining their ability to remove fucose or other sugar residues from proteoglycans. The PRO260 polypeptides can be assayed to determine if they have any functional or locational similarities as fucosidase. The PRO260 polypeptides can then be used to regulate the systems in which they are integral.

PRO263 can be used in assays wherein CD44 antigen is generally used to determine PRO263 activity relative to that of CD44. The results can be used accordingly.

20 PRO270 polypeptides and portions thereof which effect reduction-oxidation (redox) state may also be useful for *in vivo* therapeutic purposes, as well as for various *in vitro* applications. More specifically, PRO270 polypeptides may affect the expression of a large variety of genes thought to be involved in the pathogenesis of AIDS, cancer, atherosclerosis, diabetic complications and in pathological conditions involving oxidative stress such as stroke and inflammation. In addition, PRO270 polypeptides and portions thereof may affect the expression of genes which have a role in apoptosis. Therefore, peptides having homology to thioredoxin are particularly desirable to the scientific and  
25 medical communities.

PRO272 polypeptides and portions thereof which possess the ability to bind calcium may also have numerous *in vivo* therapeutic uses, as well as various *in vitro* applications. Therefore, peptides having homology to reticulocalbin are particularly desirable. Those with ordinary skill in the art will know how to employ PRO272 polypeptides and portions thereof for such purposes.

30 PRO294 polypeptides and portions thereof which have homology to collagen may also be useful for *in vivo* therapeutic purposes, as well as for various other applications. The identification of novel collagens and collagen-like molecules may have relevance to a number of human disorders. Thus, the identification of new collagens and collagen-like molecules is of special importance in that such proteins may serve as potential therapeutics for a variety of different human disorders. Such polypeptides may also play important roles in biotechnological and medical  
35 research as well as various industrial applications. Given the large number of uses for collagen, there is substantial interest in polypeptides with homology to the collagen molecule.

PRO295 polypeptides and portions thereof which have homology to integrin may also be useful for *in vivo* therapeutic purposes, as well as for various other applications. The identification of novel integrins and integrin-like molecules may have relevance to a number of human disorders such as modulating the binding or activity of cells of the immune system. Thus, the identification of new integrins and integrin-like molecules is of special importance in that such proteins may serve as potential therapeutics for a variety of different human disorders. Such polypeptides 5 may also play important roles in biotechnological and medical research as well as various industrial applications. As a result, there is particular scientific and medical interest in new molecules, such as PRO295.

As the PRO293 polypeptide is clearly a leucine rich repeat polypeptide homologue, the peptide can be used in all applications that the known NLRR-1 and NLRR-2 polypeptides are used. The activity can be compared between these peptides and thus applied accordingly.

10 The PRO247 polypeptides described herein can be used in assays in which densin is used to determine the activity of PRO247 relative to densin or these other proteins. The results can be used accordingly in diagnostics and/or therapeutic applications with PRO247.

15 PRO302, PRO303, PRO304, PRO307 and PRO343 polypeptides of the present invention which possess protease activity may be employed both *in vivo* for therapeutic purposes and *in vitro*. Those of ordinary skill in the art will well know how to employ the PRO302, PRO303, PRO304, PRO307 and PRO343 polypeptides of the present invention for such purposes.

20 PRO328 polypeptides and portions thereof which have homology to GLIP and CRISP may also be useful for *in vivo* therapeutic purposes, as well as for various other applications. The identification of novel GLIP and CRISP-like molecules may have relevance to a number of human disorders which involve transcriptional regulation or are over expressed in human tumors. Thus, the identification of new GLIP and CRISP-like molecules is of special importance in that such proteins may serve as potential therapeutics for a variety of different human disorders. Such polypeptides may also play important roles in biotechnological and medical research as well as in various industrial applications. As a result, there is particular scientific and medical interest in new molecules, such as PRO328.

25 Uses for PRO335, PRO331 or PRO326 including uses in competitive assays with LIG-1, ALS and decorin to determine their relative activities. The results can be used accordingly. PRO335, PRO331 or PRO326 can also be used in assays where LIG-1 would be used to determine if the same effects are incurred.

30 PRO332 contains GAG repeat (GKEK) at amino acid positions 625-628 in Fig. 108 (SEQ ID NO:310). Slippage in such repeats can be associated with human disease. Accordingly, PRO332 can use useful for the treatment of such disease conditions by gene therapy, i.e. by introduction of a gene containing the correct GKEK sequence motif.

Other uses of PRO334 include use in assays in which fibrillin or fibulin would be used to determine the relative activity of PRO334 to fibrillin or fibulin. In particular, PRO334 can be used in assays which require the mechanisms imparted by epidermal growth factor repeats.

35 Native PRO346 (SEQ ID NO:320) has a Blast score of 230, corresponding to 27% homology between amino acid residues 21 to 343 with residues 35 to 1040 CGM6\_HUMAN, a carcinoembryonic antigen cgm6 precursor. This homology region includes nearly all but 2 N-terminal extracellular domain residues, including an immunoglobulin superfamily homology at residues 148 to 339 of PRO346 in addition to several transmembrane

residues (340-343). Carcinoembryonic antigen precursor, as explained in the Background is a tumor-specific antigen, and as such, is a recognized marker and therapeutic target for the diagnosis and treatment of colon cancer. The expression of tumor-specific antigens is often associated with the progression of neoplastic tissue disorders. Native PRO346 (SEQ ID NO:320) and P\_W06874, a human carcinoembryonic antigen CEA-d have a Blast score of 224 and homology of 28% between residues 2 to 343 and 67 to 342, respectively. This homology includes the entire 5 extracellular domain residues of native PRO346, minus the initiator methionine (residues 2 to 18) as well as several transmembrane residues (340-343).

PRO268 polypeptides which have protein disulfide isomerase activity will be useful for many applications where protein disulfide isomerase activity is desirable including, for example, for use in promoting proper disulfide bond formation in recombinantly produced proteins so as to increase the yield of correctly folded protein. Those of 10 ordinary skill in the art will readily know how to employ such PRO268 polypeptides for such purposes.

PRO330 polypeptides of the present invention which possess biological activity related to that of the prolyl 4-hydroxylase alpha subunit protein may be employed both *in vivo* for therapeutic purposes and *in vitro*. Those of ordinary skill in the art will well know how to employ the PRO330 polypeptides of the present invention for such purposes.

15

#### **55. Anti-PRO Polypeptide Antibodies**

The present invention further provides anti-PRO polypeptide antibodies. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.

20

#### **A. Polyclonal Antibodies**

The anti-PRO polypeptide antibodies may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent 25 may include the PRO polypeptide or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be 30 selected by one skilled in the art without undue experimentation.

#### **B. Monoclonal Antibodies**

The anti-PRO polypeptide antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, *Nature*, 256:495 (1975). 35 In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.

The immunizing agent will typically include the PRO polypeptide of interest or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, *Monoclonal Antibodies: Principles and Practice*, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are  
5 usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine  
10 ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Rockville,  
15 Maryland. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur *et al.*, *Monoclonal Antibody Production Techniques and Applications*, Marcel Dekker, Inc., New York, (1987) pp. 51-63].

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the PRO polypeptide of interest. Preferably, the binding specificity of  
20 monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, *Anal. Biochem.*, 107:220 (1980).

After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution procedures  
25 and grown by standard methods [Goding, *supra*]. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown *in vivo* as ascites in a mammal.

The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose,  
30 hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention  
35 serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the

recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences [U.S. Patent No. 4,816,567; Morrison et al., *supra*] or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-  
5 combining site of an antibody of the invention to create a chimeric bivalent antibody.

The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are  
10 deleted so as to prevent crosslinking.

*In vitro* methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art.

### C. Humanized Antibodies

15 The anti-PRO polypeptide antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region  
20 (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two,  
25 variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., *Nature*, 321: 522-525 (1986); Riechmann et al.,  
*Nature*, 332:323-329 (1988); and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992)].

30 Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., *Nature*, 321:  
522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeyen et al., *Science*, 239:1534-1536 (1988)],  
35 by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In

practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, *J. Mol. Biol.*, 227:381 (1991); Marks *et al.*, *J. Mol. Biol.*, 222:581 (1991)]. The techniques of Cole *et al.* and Boerner *et al.* are also available for the preparation of human monoclonal antibodies 5 (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, p. 77 (1985) and Boerner *et al.*, *J. Immunol.*, 147(1):86-95 (1991)).

#### D. Bispecific Antibodies

10 Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the PRO polypeptide, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.

15 Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities [Milstein and Cuello, *Nature*, 305:537-539 (1983)]. Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, *EMBO J.*, 10:3655-3659 (1991).

20 Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH<sub>2</sub>, and CH<sub>3</sub> regions. It is preferred to have the first heavy-chain constant region (CH<sub>1</sub>) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted 25 into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh *et al.*, *Methods in Enzymology*, 121:210 (1986).

#### E. Heteroconjugate Antibodies

30 Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of HIV infection [WO 91/00360; WO 92/200373; EP 03089]. It is contemplated that the antibodies may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins 35 may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptopbutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

### **56. Uses for Anti-Pro Polypeptide Antibodies**

The anti-PRO polypeptide antibodies of the invention have various utilities. For example, anti-PRO polypeptide antibodies may be used in diagnostic assays for a PRO polypeptide, e.g., detecting its expression in specific cells, tissues, or serum. Various diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either 5 heterogeneous or homogeneous phases [Zola, Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc. (1987) pp. 147-158]. The antibodies used in the diagnostic assays can be labeled with a detectable moiety. The detectable moiety should be capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , or  $^{125}\text{I}$ , a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, 10 beta-galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter *et al.*, *Nature*, 144:945 (1962); David *et al.*, *Biochemistry*, 13:1014 (1974); Pain *et al.*, *J. Immunol. Meth.*, 40:219 (1981); and Nygren, *J. Histochem. and Cytochem.*, 30:407 (1982).

Anti-PRO polypeptide antibodies also are useful for the affinity purification of PRO polypeptide from 15 recombinant cell culture or natural sources. In this process, the antibodies against the PRO polypeptide are immobilized on a suitable support, such as Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody then is contacted with a sample containing the PRO polypeptide to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the PRO polypeptide, which is bound to the immobilized antibody. Finally, the support is washed with another suitable 20 solvent that will release the PRO polypeptide from the antibody.

With regard to PRO211 and PRO217, therapeutic indications include disorders associated with the preservation and maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions (e.g., enterocolitis, Zollinger-Ellison syndrome, gastrointestinal ulceration and congenital microvillus atrophy), skin diseases associated with abnormal keratinocyte differentiation (e.g., psoriasis, epithelial cancers such as lung squamous cell 25 carcinoma, epidermoid carcinoma of the vulva and gliomas).

With regard to anti-PRO187 antibodies, FGF-8 has been implicated in cellular differentiation and embryogenesis, including the patterning which appears during limb formation. FGF-8 and the PRO187 molecules of the invention therefore are likely to have potent effects on cell growth and development. Diseases which relate to cellular growth and differentiation are therefore suitable targets for therapeutics based on functionality similar to 30 FGF-8. For example, diseases related to growth or survival of nerve cells including Parkinson's disease, Alzheimer's disease, ALS, neuropathies. Additionally, disease related to uncontrolled cell growth, e.g., cancer, would also be expected therapeutic targets.

Native PRO533 is a 216 amino acid polypeptide of which residues 1-22 are the signal sequence. Residues 3 to 216 have a Blast score of 509, corresponding to 53% homology to fibroblast growth factor. At the nucleotide 35 level, DNA47412, the EST from which PCR oligos were generated to isolate the full length DNA49435-1219, has been observed to map to 11p15. Sequence homology to the 11p15 locus would indicate that PRO533 may have utility in the treatment of Usher Syndrome or Atrophy areata.

As mentioned previously, fibroblast growth factors can act upon cells in both a mitogenic and non-mitogenic manner. These factors are mitogenic for a wide variety of normal diploid mesoderm-derived and neural crest-derived cells, inducing granulosa cells, adrenal cortical cells, chondrocytes, myoblasts, corneal and vascular endothelial cells (bovine or human), vascular smooth muscle cells, lens, retina and prostatic epithelial cells, oligodendrocytes, astrocytes, chondrocytes, myoblasts and osteoblasts. Antibodies to these factors can be generated to modulate such effects.

Non-mitogenic actions of fibroblast growth factors include promotion of cell migration into a wound area (chemotaxis), initiation of new blood vessel formulation (angiogenesis), modulation of nerve regeneration and survival (neurotrophism), modulation of endocrine functions, and stimulation or suppression of specific cellular protein expression, extracellular matrix production and cell survival. Baird, A. & Bohlen, P., *Handbook of Exp. Pharmacol.* 10 95(1): 369-418 (1990). These properties provide a basis for using fibroblast growth factors in therapeutic approaches to accelerate wound healing, nerve repair, collateral blood vessel formation, and the like. For example, fibroblast growth factors, have been suggested to minimize myocardium damage in heart disease and surgery (U.S.P. 4,378,437). Antibodies to these factors can be generated to modulate such effects.

Therapeutic indications for PRO214 polypeptides include disorders associated with the preservation and 15 maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions (e.g., enterocolitis, Zollinger-Ellison syndrome, gastrointestinal ulceration and congenital microvillus atrophy), skin diseases associated with abnormal keratinocyte differentiation (e.g., psoriasis, epithelial cancers such as lung squamous cell carcinoma, epidermoid carcinoma of the vulva and gliomas).

Anti-PRO317 antibodies find use in anti-tumor indications if they are angiostatic, or in coronary ischemic 20 indications if they are angiogenic.

Native PRO301 (SEQ ID NO:119) has a Blast score of 246 and 30% homology at residues 24 to 282 of Fig. 44 with A33\_HUMAN, an A33 antigen precursor. A33 antigen precursor, as explained in the Background is a tumor-specific antigen, and as such, is a recognized marker and therapeutic target for the diagnosis and treatment of colon cancer. The expression of tumor-specific antigens is often associated with the progression of neoplastic tissue 25 disorders. Native PRO301 (SEQ ID NO:119) and A33\_HUMAN also show a Blast score of 245 and 30% homology at residues 21 to 282 of Fig. 44 with A33\_HUMAN, the variation dependent upon how spaces are inserted into the compared sequences. Native PRO301 (SEQ ID NO:119) also has a Blast score of 165 and 29% homology at residues 60 to 255 of Fig. 44 with HS46KDA\_1, a human coxsackie and adenovirus receptor protein, also known as cell surface protein HCAR. This region of PRO301 also shows a similar Blast score and homology with HSU90716\_1. 30 Expression of such proteins is usually associated with viral infection and therapeutics for the prevention of such infection may be accordingly conceived. Accordingly, antibodies to the above identified antigens and receptors have therapeutic potential as diagnostic and treatment techniques.

Therapeutic uses for the PRO234 polypeptides of the invention includes treatments associated with leukocyte homing or the interaction between leukocytes and the endothelium during an inflammatory response. Examples 35 include asthma, rheumatoid arthritis, psoriasis and multiple sclerosis.

Cancer-associated or specific antigens permit the creation of tumor or cancer specific monoclonal antibodies (mAbs) which are specific to such tumor antigens. Such mAbs, which can distinguish between normal and cancerous

cells are useful in the diagnosis, prognosis and treatment of the disease.

Cancer specific monoclonal antibodies (mAbs) which are specific to tumor antigens. Such mAbs, which can distinguish between normal and cancerous cells are useful in the diagnosis, prognosis and treatment of the disease. Particular antigens are known to be associated with neoplastic diseases, such as colorectal and breast cancer. Since colon cancer is a widespread disease, early diagnosis and treatment is an important medical goal. Diagnosis and treatment of cancer can be implemented using monoclonal antibodies (mAbs) specific therefore having fluorescent, nuclear magnetic or radioactive tags. Radioactive genes, toxins and/or drug tagged mAbs can be used for treatment *in situ* with minimal patient description.

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.

#### EXAMPLES

Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Rockville, Maryland.

EXAMPLE 1: Extracellular Domain Homology Screening to Identify Novel Polypeptides and cDNA Encoding Therefor

The extracellular domain (ECD) sequences (including the secretion signal sequence, if any) from about 950 known secreted proteins from the Swiss-Prot public database were used to search EST databases. The EST databases included public databases (e.g., Dayhoff, GenBank), and proprietary databases (e.g. LIFESEQ™, Incyte Pharmaceuticals, Palo Alto, CA). The search was performed using the computer program BLAST or BLAST2 (Altschul, and Gish, *Methods in Enzymology* 266: 460-80 (1996); <http://blast.wustl.edu/blast/README.html>) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences. Those comparisons with a Blast score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA sequences with the program "phrap" (Phil Green, University of Washington, Seattle, WA; (<http://bozeman.mbt.washington.edu/phrap.docs/phrap.html>).

Using this extracellular domain homology screen, consensus DNA sequences were assembled relative to the other identified EST sequences. In addition, the consensus DNA sequences obtained were often (but not always) extended using repeated cycles of BLAST and phrap to extend the consensus sequence as far as possible using the sources of EST sequences discussed above.

Based upon the consensus sequences obtained as described above, oligonucleotides were then synthesized and used to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for a PRO polypeptide. Forward (.f) and reverse (.r) PCR primers generally range from 20 to 30 nucleotides and are often designed to give a PCR product of about 100-1000 bp in length. The probe (.p) sequences are typically 40-55 bp in length. In some cases, additional oligonucleotides are

synthesized when the consensus sequence is greater than about 1-1.5kbp. In order to screen several libraries for a full-length clone, DNA from the libraries was screened by PCR amplification, as per Ausubel et al., Current Protocols in Molecular Biology, with the PCR primer pair. A positive library was then used to isolate clones encoding the gene of interest using the probe oligonucleotide and one of the primer pairs.

The cDNA libraries used to isolate the cDNA clones were constructed by standard methods using  
5 commercially available reagents such as those from Invitrogen, San Diego, CA. The cDNA was primed with oligo dT containing a NotI site, linked with blunt to Sall hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the SfiI site; see, Holmes et al., Science, 253:1278-1280 (1991)) in the unique XhoI and NotI sites.

10

EXAMPLE 2: Isolation of cDNA Clones Encoding PRO211 and PRO217

Consensus DNA sequences were assembled as described in Example 1 above and were designated as DNA28730 and DNA28760, respectively. Based on these consensus sequences, oligonucleotides were synthesized and used to identify by PCR a cDNA library that contained the sequences of interest and for use as probes to isolate  
15 a clone of the full-length coding sequence for the PRO211 and PRO217 polypeptides. The libraries used to isolate DNA32292-1131 and DNA33094-1131 were fetal lung libraries.

cDNA clones were sequenced in their entirety. The entire nucleotide sequences of PRO211 (DNA32292-1131; UNQ185) and PRO217 (UNQ191; DNA33094-1131) are shown in Figure 1 (SEQ ID NO: 1) and Figure 3 (SEQ ID NO:3), respectively. The predicted polypeptides are 353 and 379 amino acid in length, respectively, with  
20 respective molecular weights of approximately 38,190 and 41,520 daltons.

The oligonucleotide sequences used in the above procedures were the following:

28730.p (OLI 516) (SEQ ID NO:5)

5'-AGGGAGCACGGACAGTGTGCAGATGTGGACGAGTGCTCACTAGCA-3'

28730.f (OLI 517) (SEQ ID NO:6)

25 5'-AGAGTGTATCTCTGGCTACGC-3'

28730.r (OLI 518) (SEQ ID NO:7)

5'-TAAGTCCGGCACATTACAGGTC-3'

28760.p (OLI 617) (SEQ ID NO:8)

5'-CCACCGATGTATGAATGGTGGACTTGTGACTCCTGGTTCTGCATC-3'

30 28760.f (OLI 618) (SEQ ID NO:9)

5'-AAAGACGCATCTGCGAGTGTCC-3'

28760.r (OLI 619) (SEQ ID NO:10)

5'-TGCTGATTTCACACTGCTCTCCC-3'

35 EXAMPLE 3: Isolation of cDNA Clones Encoding Human PRO230

A consensus DNA sequence was assembled relative to the other identified EST sequences as described in Example 1 above, wherein the consensus sequence is designated herein as DNA30857. An EST proprietary to

Genentech was employed in the consensus assembly. The EST is designated as DNA20088 and has the nucleotide sequence shown in Figure 7 (SEQ ID NO:13).

Based on the DNA30857 consensus sequence, oligonucleotides were synthesized to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for PRO230.

5 A pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-TTCGAGGCCTCTGAGAAGTGGCCC-3' (SEQ ID NO:14)

reverse PCR primer 5'-GGCGGTATCTCTGGCCTCCC-3' (SEQ ID NO:15)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30857 sequence which had the following nucleotide sequence

10 hybridization probe

5'-TTCTCCACAGCAGCTGTGGCATCCGATCGTGTCTCAATCCATTCTCTGGG-3' (SEQ ID NO:16)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO230 gene using the probe oligonucleotide and one of the PCR primers.

15 RNA for construction of the cDNA libraries was isolated from human fetal lung tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO230 (herein designated as UNQ204 (DNA33223-1136)) and the derived protein sequence for PRO230.

The entire nucleotide sequence of UNQ204 (DNA33223-1136) is shown in Figure 5 (SEQ ID NO:11).

Clone UNQ204 (DNA33223-1136) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 100-103 and ending at the stop codon at nucleotide positions 1501-1503 (Figure 5; SEQ ID NO:11). The predicted polypeptide precursor is 467 amino acids long (Figure 6).

EXAMPLE 4: Isolation of cDNA Clones Encoding Human PRO232

A consensus DNA sequence was assembled relative to the other identified EST sequences as described in Example 1 above, wherein the consensus sequence is designated herein as DNA30935. Based on the DNA30935 consensus sequence, oligonucleotides were synthesized to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for PRO232.

A pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-TGCTGTGCTACTCCTGCAAAGCCC-3' (SEQ ID NO:19)

30 reverse PCR primer 5'-TGCACAAGTCGGTGTACAGCACG-3' (SEQ ID NO:20)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30935 sequence which had the following nucleotide sequence

hybridization probe

5'-AGCAACGAGGACTGCCTGCAGGTGGAGAACTGCACCCAGCTGGG-3' (SEQ ID NO:21)

35 In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO232 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue.

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO232 [herein designated as UNQ206 (DNA34435-1140)] and the derived protein sequence for PRO232.

The entire nucleotide sequence of UNQ206 (DNA34435-1140) is shown in Figure 8 (SEQ ID NO:17). Clone UNQ206 (DNA34435-1140) contains a single open reading frame with an apparent translational initiation site 5 at nucleotide positions 17-19 and ending at the stop codon at nucleotide positions 359-361 (Fig. 8; SEQ ID NO:17). The predicted polypeptide precursor is 114 amino acids long (Fig. 9). Clone UNQ206 (DNA34435-1140) has been deposited with ATCC on September 16, 1997 and is assigned ATCC deposit no. ATCC 209250.

Analysis of the amino acid sequence of the full-length PRO232 suggests that it possesses 35% sequence identity with a stem cell surface antigen from *Gallus gallus*.

10

#### EXAMPLE 5: Isolation of cDNA Clones Encoding PRO187

A proprietary expressed sequence tag (EST) DNA database (LIFESEQ™, Incyte Pharmaceuticals, Palo Alto, CA) was searched and an EST (#843193) was identified which showed homology to fibroblast growth factor (FGF-8) also known as androgen-induced growth factor. mRNA was isolated from human fetal lung tissue using reagents and 15 protocols from Invitrogen, San Diego, CA (Fast Track 2). The cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents (e.g., Invitrogen, San Diego, CA, Life Technologies, Gaithersburg, MD). The cDNA was primed with oligo dT containing a NotI site, linked with blunt to SalI hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation into the cloning vector pRK5D using reagents and protocols from Life Technologies, Gaithersburg, MD 20 (Super Script Plasmid System). The double-stranded cDNA was sized to greater than 1000 bp and the SalI/NotI linker cDNA was cloned into XhoI/NotI cleaved vector. pRK5D is a cloning vector that has an sp6 transcription initiation site followed by an SfiI restriction enzyme site preceding the XhoI/NotI cDNA cloning sites.

Several libraries from various tissue sources were screened by PCR amplification with the following oligonucleotide probes:

25 IN843193.f (OLI315) (SEQ ID NO:24)  
5'-CAGTACGTGAGGGACCAGGGCGCCATGA-3'

IN843193.r (OLI 317) (SEQ ID NO:25)  
5'-CCGGTGACCTGCACGTGCTTGCCA-3'

30 A positive library was then used to isolate clones encoding the PRO187 gene using one of the above oligonucleotides and the following oligonucleotide probe:

IN843193.p (OLI 316) (SEQ ID NO:26)  
5'-GCGGATCTGCCGCCTGCTCANCTGGTCGGTCATGGCGCCCT-3'

35 A cDNA clone was sequenced in entirety. The entire nucleotide sequence of PRO187 (DNA27864-1155) is shown in Figure 10 (SEQ ID NO:22). Clone DNA27864-1155 contains a single open reading frame with an apparent translational initiation site at nucleotide position 1 (Figure 10; SEQ ID NO:22). The predicted polypeptide precursor is 205 amino acids long. Clone DNA27864-1155 has been deposited with the ATCC (designation: 40 DNA27864-1155) and is assigned ATCC deposit no. ATCC 209375.

Based on a BLAST and FastA sequence alignment analysis (using the ALIGN computer program) of the full-length sequence, the PRO187 polypeptide shows 74% amino acid sequence identity (Blast score 310) to human fibroblast growth factor-8 (androgen-induced growth factor).

**EXAMPLE 6: Isolation of cDNA Clones Encoding PRO265**

5 A consensus DNA sequence was assembled relative to other EST sequences as described in Example 1 above using phrap. This consensus sequence is herein designated DNA33679. Based on the DNA33679 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO265.

PCR primers (two forward and one reverse) were synthesized:

10 forward PCR primer A: 5'-CGGTCTACCTGTATGGCAACC-3' (SEQ ID NO:29);

forward PCR primer B: 5'-GCAGGACAACCAAGATAAACAC-3' (SEQ ID NO:30);

reverse PCR primer 5'-ACGCAGATTGAGAAGGCTGTC-3' (SEQ ID NO:31)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA33679 sequence which had the following nucleotide sequence

15 hybridization probe  
5'-TTCACGGGCTGCTCTGCCAGCTTGAAAGCTTGAAGAGCTGCAC-3' (SEQ ID NO:32)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with PCR primer pairs identified above. A positive library was then used to isolate clones encoding the PRO265 gene using the probe oligonucleotide and one of the PCR primers.

20 RNA for construction of the cDNA libraries was isolated from human a fetal brain library.

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO265 [herein designated as UNQ232 (DNA36350-1158) (SEQ ID NO:27) and the derived protein sequence for PRO265.

The entire nucleotide sequence of UNQ232 (DNA36350-1158) is shown in Figure 12 (SEQ ID NO:27). Clone UNQ232 (DNA36350-1158) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 352-354 and ending at the stop codon at positions 2332-2334 (Figure 12). The predicted polypeptide precursor is 660 amino acids long (Figure 13). Clone UNQ232 (DNA36350-1158) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209378.

Analysis of the amino acid sequence of the full-length PRO265 polypeptide suggests that portions of it possess significant homology to the fibromodulin and the fibromodulin precursor, thereby indicating that PRO265 may be a novel member of the leucine rich repeat family, particularly related to fibromodulin.

**EXAMPLE 7: Isolation of cDNA Clones Encoding Human PRO219**

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA28729. Based on the DNA28729 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO219.

A pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-GTGACCTGGTTGTGAATACTCC-3' (SEQ ID NO:35)

reverse PCR primer 5'-ACAGCCATGGTCTATAGCTTGG-3' (SEQ ID NO:36)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA28729 sequence which had the following nucleotide sequence

5 hybridization probe

5'-GCCTGTCAGTGTCCCTGAGGGACACGTGCTCCGCAGCGATGGGAAG-3' (SEQ ID NO:37)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO219 gene using the probe oligonucleotide and one of the PCR primers.

10 RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue.

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO219 [herein designated as UNQ193 (DNA32290-1164)] (SEQ ID NO:33) and the derived protein sequence for PRO219.

The entire nucleotide sequence of UNQ193 (DNA32290-1164) is shown in Figures 14A-B (SEQ ID NO:33).

Clone UNQ193 (DNA32290-1164) contains a single open reading frame with an apparent translational initiation site

15 at nucleotide positions 204-206 and ending at the stop codon at nucleotide positions 2949-2951 (Figures 14A-B). The predicted polypeptide precursor is 915 amino acids long (Figure 15). Clone UNQ193 (DNA32290-1164) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209384.

Analysis of the amino acid sequence of the full-length PRO219 polypeptide suggests that portions of it possess significant homology to the mouse and human matrilin-2 precursor polypeptides.

20

EXAMPLE 8: Isolation of cDNA Clones Encoding Human PRO246

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA30955. Based on the DNA30955 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO246.

A pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-AGGGTCTCCAGGAGAAAGACTC-3' (SEQ ID NO:40)

reverse PCR primer 5'-ATTGTGGGCCTTGCAGACATAGAC-3' (SEQ ID NO:41)

30 Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30955 sequence which had the following nucleotide sequence

hybridization probe

5'-GGCACAGCATAAAACCTTAGAACTCAATGTACTGGTCCTCCAGCTCC-3' (SEQ ID NO:42)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO246 gene using the probe oligonucleotide and one of the PCR primers.

35 RNA for construction of the cDNA libraries was isolated from human fetal liver tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO246 [herein designated as

UNQ220 (DNA35639-1172)] (SEQ ID NO:38) and the derived protein sequence for PRO246.

The entire nucleotide sequence of UNQ220 (DNA35639-1172) is shown in Figure 16 (SEQ ID NO:38). Clone UNQ220 (DNA35639-1172) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 126-128 and ending at the stop codon at nucleotide positions 1296-1298 (Figure 16). The predicted polypeptide precursor is 390 amino acids long (Figure 17). Clone UNQ220 (DNA35639-1172) has been 5 deposited with ATCC and is assigned ATCC deposit no. ATCC 209396.

Analysis of the amino acid sequence of the full-length PRO246 polypeptide suggests that it possess significant homology to the human cell surface protein HCAR, thereby indicating that PRO246 may be a novel cell surface virus receptor.

10 **EXAMPLE 9: Isolation of cDNA Clones Encoding Human PRO228**

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA28758. An EST proprietary to Genentech was employed in the consensus assembly. This EST is shown in Figure 20 (SEQ ID NO:50) and is herein designated as DNA21951.

15 Based on the DNA28758 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO228.

PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-GGTAATGAGCTCCATTACAG-3' (SEQ ID NO:51)

20 forward PCR primer 5'-GGAGTAGAAAGCGCATGG-3' (SEQ ID NO:52)

forward PCR primer 5'-CACCTGATACCATGAATGGCAG-3' (SEQ ID NO:53)

reverse PCR primer 5'-CGAGCTCGAATTAAATCG-3' (SEQ ID NO:54)

reverse PCR primer 5'-GGATCTCCTGAGCTCAGG-3' (SEQ ID NO:55)

reverse PCR primer 5'-CCTAGTTGAGTGATCCTTGTAAAG-3' (SEQ ID NO:56)

25 Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA28758 sequence which had the following nucleotide sequence

hybridization probe

5'-ATGAGACCCACACCTCATGCCGCTGTAATCACCTGACACATTGCAATT-3' (SEQ ID NO:57)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened 30 by PCR amplification with the PCR primer pairs identified above. A positive library was then used to isolate clones encoding the PRO228 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue.

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO228 [herein designated as UNQ202 (DNA33092-1202)] (SEQ ID NO:48) and the derived protein sequence for PRO228.

35 The entire nucleotide sequence of UNQ202 (DNA33092-1202) is shown in Figure 18 (SEQ ID NO:48). Clone UNQ202 (DNA33092-1202) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 24-26 of SEQ ID NO:48 and ending at the stop codon after nucleotide position 2093 of SEQ

ID NO:48. The predicted polypeptide precursor is 690 amino acids long (Figure 19). Clone UNQ202 (DNA33092-1202) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209420.

Analysis of the amino acid sequence of the full-length PRO228 polypeptide suggests that portions of it possess significant homology to the secretin-related proteins CD97 and EMR1 as well as the secretin member, latrophilin, thereby indicating that PRO228 may be a new member of the secretin related proteins.

5

EXAMPLE 10: Isolation of cDNA Clones Encoding Human PRO533

The EST sequence accession number AF007268, a murine fibroblast growth factor (FGF-15) was used to search various public EST databases (e.g., GenBank, Dayhoff, etc.). The search was performed using the computer program BLAST or BLAST2 [Altschul et al., *Methods in Enzymology*, 266:460-480 (1996); 10 <http://blast.wustl.edu/blast/README.html>] as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences. The search resulted in a hit with GenBank EST AA220994, which has been identified as stratagene NT2 neuronal precursor 937230.

Based on the Genbank EST AA220994 sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length 15 coding sequence. Forward and reverse PCR primers may range from 20 to 30 nucleotides (typically about 24), and are designed to give a PCR product of 100-1000 bp in length. The probe sequences are typically 40-55 bp (typically about 50) in length. In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification, as per Ausubel et al., *Current Protocols in Molecular Biology*, with the PCR 20 primer pair. A positive library was then used to isolate clones encoding the gene of interest using the probe oligonucleotide and one of the PCR primers.

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified below. A positive library was then used to isolate clones encoding the PRO533 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal retina. The cDNA libraries used 25 to isolated the cDNA clones were constructed by standard methods using commercially available reagents (e.g., Invitrogen, San Diego, CA; Clontech, etc.) The cDNA was primed with oligo dT containing a NotI site, linked with blunt to Sall hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRK8 or pRKD; pRK5B is a precursor of pRK5D that does not contain the SfiI site; see, Holmes et al., *Science*, 253:1278-1280 (1991)) in the unique XhoI and NotI sites.

30 A cDNA clone was sequenced in its entirety. The full length nucleotide sequence of PRO533 is shown in Figure 21 (SEQ ID NO:58). Clone DNA49435-1219 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 459-461 (Figure 21; SEQ ID NO:58). The predicted polypeptide precursor is 216 amino acids long. Clone DNA47412-1219 has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209480.

35 Based on a BLAST-2 and FastA sequence alignment analysis of the full-length sequence, PRO533 shows amino acid sequence identity to fibroblast growth factor (53%).

The oligonucleotide sequences used in the above procedure were the following:

FGF15.forward: 5'-ATCCGCCAGATGGCTACAATGTGTA-3' (SEQ ID NO:60);

FGF15.probe: 5'-GCCTCCCGGTCTCCCTGAGCAGTGCCAAACAGCGGCAGTGTGA-3' (SEQ ID NO:61);

FGF15.reverse: 5'-CCAGTCCGGTGACAAGCCCCAA-3' (SEQ ID NO:62).

5 **EXAMPLE 11: Isolation of cDNA Clones Encoding Human PRO245**

A consensus DNA sequence was assembled relative to the other identified EST sequences as described in Example 1 above, wherein the consensus sequence is designated herein as DNA30954.

Based on the DNA30954 consensus sequence, oligonucleotides were synthesized to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for PRO245.

10 A pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-ATCGTTGTGAAGTTAGTGCCCC-3' (SEQ ID NO:65)

reverse PCR primer 5'-ACCTGCGATATCCAACAGAATTG-3' (SEQ ID NO:66)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30954

15 sequence which had the following nucleotide sequence

hybridization probe

5'-GGAAGAGGATAACAGTCACTCTGGAAGTATTAGTGGCTCCAGCAGTTCC-3' (SEQ ID NO:67)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones

20 encoding the PRO245 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal liver tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO245 [herein designated as UNQ219 (DNA35638-1141)] and the derived protein sequence for PRO245.

25 The entire nucleotide sequence of UNQ219 (DNA35638-1141) is shown in Figure 23 (SEQ ID NO:63). Clone UNQ219 (DNA35638-1141) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 89-91 and ending at the stop codon at nucleotide positions 1025-1027 (Fig. 23; SEQ ID NO:63). The predicted polypeptide precursor is 312 amino acids long (Fig. 24). Clone UNQ219 (DNA35638-1141) has been deposited with ATCC on September 16, 1997 and is assigned ATCC deposit no. ATCC 209265.

30 Analysis of the amino acid sequence of the full-length PRO245 suggests that a portion of it possesses 60% amino acid identity with the human c-myb protein and, therefore, may be a new member of the transmembrane protein receptor tyrosine kinase family.

**EXAMPLE 12: Isolation of cDNA Clones Encoding Human PRO220, PRO221 and PRO227**

35 (a) **PRO220**

A consensus DNA sequence was assembled relative to the other identified EST sequences as described in Example 1 above, wherein the consensus sequence is designated herein as DNA28749. Based on the DNA28749 consensus sequence, oligonucleotides were synthesized to identify by PCR a cDNA library that contained the

sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for PRO220.

A pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-TCACCTGGAGCCTTATTGCC-3' (SEQ ID NO:74)

reverse PCR primer 5'-ATACCAGCTATAACCAGGCTGCG-3' (SEQ ID NO:75)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA28749

5 sequence which had the following nucleotide sequence:

hybridization probe

5'-CAACAGTAAGTGGTTGATGCTCTCCAAATCTAGAGATTCTGATGATTGGG-3' (SEQ ID NO:76).

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones

10 encoding the PRO220 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal lung tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO220 [herein designated as UNQ194 (DNA32298-1132) and the derived protein sequence for PRO220.

The entire nucleotide sequence of UNQ194 (DNA32298-1132) is shown in Figure 25 (SEQ ID NO:68).

15 Clone UNQ194 (DNA32298-1132) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 480-482 and ending at the stop codon at nucleotide positions 2604-2606 (Figure 25). The predicted polypeptide precursor is 708 amino acids long (Figure 26). Clone UNQ194 (DNA32298-1132) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209257.

20 Analysis of the amino acid sequence of the full-length PRO220 shows it has homology to member of the leucine rich repeat protein superfamily, including the leucine rich repeat protein and the neuronal leucine-rich repeat protein 1.

(b) PRO221

25 A consensus DNA sequence was assembled relative to the other identified EST sequences as described in Example 1 above, wherein the consensus sequence is designated herein as DNA28756. Based on the DNA28756 consensus sequence, oligonucleotides were synthesized to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for PRO221.

A pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-CCATGTGTCTCCTCACAAAG-3' (SEQ ID NO:77)

30 reverse PCR primer 5'-GGGAATAGATGTGATCTGATTGG-3' (SEQ ID NO:78)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA28756 sequence which had the following nucleotide sequence:

hybridization probe

5'-CACCTGTAGCAATGCAAATCTCAAGGAAATACCTAGAGATCTCCTCCTG-3' (SEQ ID NO:79)

35 In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO221 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal lung tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO221 [herein designated as UNQ195 (DNA33089-1132) and the derived protein sequence for PRO221.

The entire nucleotide sequence of UNQ195 (DNA33089-1132) is shown in Figure 27 (SEQ ID NO:70). Clone UNQ195 (DNA33089-1132) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 179-181 and ending at the stop codon at nucleotide positions 956-958 (Figure 27). The predicted polypeptide precursor is 259 amino acids long (Figure 28). PRO221 is believed to have a transmembrane region at amino acids 206-225. Clone UNQ195 (DNA33089-1132) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209262.

Analysis of the amino acid sequence of the full-length PRO221 shows it has homology to member of the leucine rich repeat protein superfamily, including the SLIT protein.

(c) PRO227

A consensus DNA sequence was assembled relative to the other identified EST sequences as described in Example 1 above, wherein the consensus sequence is designated herein as DNA28740. Based on the DNA28740 consensus sequence, oligonucleotides were synthesized to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for PRO227.

A pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-AGCAACCGCCTGAAGCTCATCC-3' (SEQ ID NO:80)

reverse PCR primer 5'-AAGGCGCGGTGAAAGATGTAGACG-3' (SEQ ID NO:81)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA28740 sequence which had the following nucleotide sequence:

hybridization probe

5'GACTACATGTTTCAGGACCTGTACAACCTCAAGTCACTGGAGGTTGGCGA-3' (SEQ ID NO:82).

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO227 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal lung tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO227 [herein designated as UNQ201 (DNA33786-1132) and the derived protein sequence for PRO227.

The entire nucleotide sequence of UNQ201 (DNA33786-1132) is shown in Figure 29 (SEQ ID NO:72). Clone UNQ201 (DNA33786-1132) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 117-119 and ending at the stop codon at nucleotide positions 1977-1979 (Figure 29). The predicted polypeptide precursor is 620 amino acids long (Figure 30). PRO227 is believed to have a transmembrane region. Clone UNQ201 (DNA33786-1132) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209253.

Analysis of the amino acid sequence of the full-length PRO221 shows it has homology to member of the leucine rich repeat protein superfamily, including the platelet glycoprotein V precursor and the human glycoprotein V.

**EXAMPLE 13: Isolation of cDNA Clones Encoding Human PRO258**

5 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA28746.

Based on the DNA28746 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO258.

10 PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-GCTAGGAATTCCACAGAACGCC-3' (SEQ ID NO:85)

reverse PCR primer 5'-AACCTGGAATGTCACCGAGCTG-3' (SEQ ID NO:86)

reverse PCR primer 5'-CCTAGCACAGTGACGAGGGACTTGGC-3' (SEQ ID NO:87)

Additionally, synthetic oligonucleotide hybridization probes were constructed from the consensus DNA28740

15 sequence which had the following nucleotide sequence:

hybridization probe

5'-AAGACACAGCCACCCTAAACTGTCAGTCTCTGGAGCAAGCCTGCAGCC-3' (SEQ ID NO:88)

5'-GCCCTGGCAGACGAGGGCGAGTACACCTGCTCAATCTCACTATGCCTGT-3' (SEQ ID NO:89)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened 20 by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO258 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal lung tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO258 [herein designated as UNQ225 (DNA35918-1174)] (SEQ ID NO:83) and the derived protein sequence for PRO258.

25 The entire nucleotide sequence of UNQ225 (DNA35918-1174) is shown in Figure 31 (SEQ ID NO:83). Clone UNQ225 (DNA35918-1174) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 147-149 of SEQ ID NO:83 and ending at the stop codon after nucleotide position 1340 of SEQ ID NO:83 (Figure 31). The predicted polypeptide precursor is 398 amino acids long (Figure 32). Clone UNQ225 (DNA35918-1174) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209402.

30 Analysis of the amino acid sequence of the full-length PRO258 polypeptide suggests that portions of it possess significant homology to the CRTAM and the poliovirus receptor and have an Ig domain, thereby indicating that PRO258 is a new member of the Ig superfamily.

**EXAMPLE 14: Isolation of cDNA Clones Encoding Human PRO266**

35 An expressed sequence tag database was searched for ESTs having homology to SLIT, resulting in the identification of a single EST sequence designated herein as T73996. Based on the T73996 EST sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and

2) for use as probes to isolate a clone of the full-length coding sequence for PRO266.

A pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-GTTGGATCTGGCAACAATAAC-3' (SEQ ID NO:92)

reverse PCR primer 5'-ATTGTTGTGCAGGCTGAGTTAAG-3' (SEQ ID NO:93)

Additionally, a synthetic oligonucleotide hybridization probe was constructed which had the following nucleotide

5 sequence

hybridization probe

5'-GGTGGCTATACATGGATAGCAATTACCTGGACACGCTGTCCCGGG-3' (SEQ ID NO:94)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones 10 encoding the PRO266 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal brain tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO266 [herein designated as UNQ233 (DNA37150-1178)] (SEQ ID NO:90) and the derived protein sequence for PRO266.

The entire nucleotide sequence of UNQ233 (DNA37150-1178) is shown in Figure 33 (SEQ ID NO:90).

15 Clone UNQ233 (DNA37150-1178) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 167-169 and ending at the stop codon after nucleotide position 2254 of SEQ ID NO:90. The predicted polypeptide precursor is 696 amino acids long (Figure 34). Clone UNQ233 (DNA37150-1178) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209401.

20 Analysis of the amino acid sequence of the full-length PRO266 polypeptide suggests that portions of it possess significant homology to the SLIT protein, thereby indicating that PRO266 may be a novel leucine rich repeat protein.

#### EXAMPLE 15: Isolation of cDNA Clones Encoding Human PRO269

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in 25 Example 1 above. This consensus sequence is herein designated DNA35705. Based on the DNA35705 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO269.

Forward and reverse PCR primers were synthesized:

forward PCR primer (.f1) 5'-TGGAAGGAGATGCGATGCCACCTG -3'

30 (SEQ ID NO:97)

forward PCR primer (.f2) 5'-TGACCAGTGGGAAGGACAG-3' (SEQ ID NO:98)

forward PCR primer (.f3) 5'-ACAGAGCAGAGGGTGCCTTG-3' (SEQ ID NO:99)

reverse PCR primer (.r1) 5'-TCAGGGACAAGTGGTGTCTCTCCC-3'

(SEQ ID NO:100)

35 reverse PCR primer (.r2) 5'-TCAGGGAAGGAGTGTGCAGTTCTG-3'

(SEQ ID NO:101)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA35705 sequence which had the following nucleotide sequence:

hybridization probe

5'-ACAGCTCCGATCTCAGTTACTGCATGCCGACGAAATCGGCCGCTCGCT-3' (SEQ ID NO:102)

- In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened  
5 by PCR amplification with the PCR primer pairs identified above. A positive library was then used to isolate clones encoding the PRO269 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue.

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO269 [herein designated as UNQ236 (DNA38260-1180)] (SEQ ID NO:95) and the derived protein sequence for PRO269.

- 10 The entire nucleotide sequence of UNQ236 (DNA38260-1180) is shown in Figure 35 (SEQ ID NO:95). Clone UNQ236 (DNA38260-1180) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 314-316 and ending at the stop codon at nucleotide positions 1784-1786 (Fig. 35; SEQ ID NO:95). The predicted polypeptide precursor is 490 amino acids long (Fig. 36). Clone UNQ236 (DNA38260-1180) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209397.

- 15 Analysis of the amino acid sequence of the full-length PRO269 suggests that portions of it possess significant homology to the human thrombomodulin proteins, thereby indicating that PRO269 may possess one or more thrombomodulin-like domains.

EXAMPLE 16: Isolation of cDNA Clones Encoding Human PRO287

- 20 A consensus DNA sequence encoding PRO287 was assembled relative to the other identified EST sequences as described in Example 1 above, wherein the consensus sequence is designated herein as DNA28728. Based on the DNA28728 consensus sequence, oligonucleotides were synthesized to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for PRO287.

A pair of PCR primers (forward and reverse) were synthesized:

- 25 forward PCR primer 5'-CCGATTAGACCTCGAGAGT-3' (SEQ ID NO:105)

reverse PCR primer 5'-GTCAAGGAGTCCTCCACAATAC-3' (SEQ ID NO:106)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA28728 sequence which had the following nucleotide sequence

hybridization probe

- 30 5'-GTGTACAATGGCCATGCCAATGGCCAGCGCATTGGCCGTTCTGT-3'  
(SEQ ID NO:107)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO287 gene using the probe oligonucleotide and one of the PCR primers.

- 35 RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue.

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO287 [herein designated as UNQ250 (DNA39969-1185), SEQ ID NO:103] and the derived protein sequence for PRO287.

The entire nucleotide sequence of UNQ250 (DNA39969-1185) is shown in Figure 37 (SEQ ID NO:103). Clone UNQ250 (DNA39969-1185) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 307-309 and ending at the stop codon at nucleotide positions 1552-1554 (Fig. 37; SEQ ID NO:103). The predicted polypeptide precursor is 415 amino acids long (Fig. 38). Clone UNQ250 (DNA39969-1185) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209400.

5 Analysis of the amino acid sequence of the full-length PRO287 suggests that it may possess one or more procollagen C-proteinase enhancer protein precursor or procollagen C-proteinase enhancer protein-like domains. Based on a BLAST and FastA sequence alignment analysis of the full-length sequence, PRO287 shows nucleic acid sequence identity to procollagen C-proteinase enhancer protein precursor and procollagen C-proteinase enhancer protein (47 and 54%, respectively).

10

**EXAMPLE 17: Isolation of cDNA Clones Encoding Human PRO214**

A consensus DNA sequence was assembled using phrap as described in Example 1 above. This consensus DNA sequence is designated herein as DNA28744. Based on this consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes 15 to isolate a clone of the full-length coding sequence.

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified below. A positive library was then used to isolate clones encoding the PRO214 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal lung tissue. A cDNA clone 20 was sequenced in its entirety. The full length nucleotide sequence of DNA32286-1191 is shown in Figure 39 (SEQ ID NO:108). DNA32286-1191 contains a single open reading frame with an apparent translational initiation site at nucleotide position 103 (Fig. 39; SEQ ID NO:108). The predicted polypeptide precursor is 420 amino acids long (SEQ ID NO:109).

Based on a BLAST and FastA sequence alignment analysis of the full-length sequence, PRO214 polypeptide 25 shows amino acid sequence identity to HT protein and/or Fibulin (49% and 38%, respectively).

The oligonucleotide sequences used in the above procedure were the following:

28744.p (OLI555)

5'-CCTGGCTATCAGCAGGTGGGCTCCAAGTGTCTCGATGTGGATGAGTGTGA-3' (SEQ ID NO:110)

28744.f (OLI556)

30 5'-ATTCTGCGTGAACACTGAGGGC-3' (SEQ ID NO:111)

28744.r (OLI557)

5'-ATCTGCTTGTAGCCCTCGGCAC-3' (SEQ ID NO:112)

**EXAMPLE 18: Isolation of cDNA Clones Encoding Human PRO317**

35 A consensus DNA sequence was assembled using phrap as described in Example 1 above, wherein the consensus sequence is herein designated as DNA28722. Based on this consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes

to isolate a clone of the full-length coding sequence. The forward and reverse PCR primers, respectively, synthesized for this purpose were:

5'-AGGACTGCCATAACTTGCCTG (OLI489) (SEQ ID NO:115) and

5'-ATAGGAGTTGAAGCAGCGCTGC (OLI490) (SEQ ID NO:116).

The probe synthesized for this purpose was:

5 5'-TGTGTGGACATAGACGAGTGCCGCTACCGCTACTGCCAGCACCGC (OLI488) (SEQ ID NO:117)

mRNA for construction of the cDNA libraries was isolated from human fetal kidney tissue.

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification, as per Ausubel *et al.*, *Current Protocols in Molecular Biology* (1989), with the PCR primer pair identified above. A positive library was then used to isolate clones containing the PRO317 gene using the probe

10 oligonucleotide identified above and one of the PCR primers.

A cDNA clone was sequenced in its entirety. The entire nucleotide sequence of DNA33461-1199 (encoding PRO317) is shown in Figure 41 (SEQ ID NO:113). Clone DNA33461-1199 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 68-70 (Fig. 41; SEQ ID NO:113). The predicted polypeptide precursor is 366 amino acids long. The predicted signal sequence is amino acids 1-18 of Figure 42 (SEQ

15 ID NO:114). There is one predicted N-linked glycosylation site at amino acid residue 160. Clone DNA33461-1199 has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209367.

Based on BLAST™ and FastA™ sequence alignment analysis (using the ALIGN™ computer program) of the full-length PRO317 sequence, PRO317 shows the most amino acid sequence identity to EBAF-1 (92%). The results also demonstrate a significant homology between human PRO317 and mouse LEFTY protein. The C-terminal 20 end of the PRO317 protein contains many conserved sequences consistent with the pattern expected of a member of the TGF- superfamily.

*In situ* expression analysis in human tissues performed as described below evidences that there is distinctly strong expression of the PRO317 polypeptide in pancreatic tissue.

25 **EXAMPLE 19: Isolation of cDNA clones Encoding Human PRO301**

A consensus DNA sequence designated herein as DNA35936 was assembled using phrap as described in Example 1 above. Based on this consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence.

30 In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified below. A positive library was then used to isolate clones encoding the PRO301 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal kidney.

A cDNA clone was sequenced in its entirety. The full length nucleotide sequence of native sequence 35 PRO301 is shown in Figure 43 (SEQ ID NO:118). Clone DNA40628-1216 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 52-54 (Fig. 43; SEQ ID NO:118). The predicted polypeptide precursor is 299 amino acids long with a predicted molecular weight of 32,583 daltons and pI of 8.29.

Clone DNA40628-1216 has been deposited with ATCC and is assigned ATCC deposit No. ATCC 209432.

Based on a BLAST and FastA sequence alignment analysis of the full-length sequence, PRO301 shows amino acid sequence identity to A33 antigen precursor (30%) and coxsackie and adenovirus receptor protein (29%).

The oligonucleotide sequences used in the above procedure were the following:

- 5 OLI2162 (35936.f1) 5'-TCGCGGAGCTGTGTTCTGTTCCC-3' (SEQ ID NO:120)  
OLI2163 (35936.p1)  
5'-TGATCGCGATGGGGACAAAGGCAGCAAGCTCGAGAGGAAACTGTTGTGCCT-3' (SEQ ID NO:121)  
OLI2164 (35936.f2)  
5'-ACACCTGGTCAAAGATGGG-3' (SEQ ID NO:122)
- 10 OLI2165 (35936.r1)  
5'-TAGGAAGAGAGTTGCTGAAGGCACGG-3' (SEQ ID NO:123)  
OLI2166 (35936.f3)  
5'-TTGCCCTTACTCAGGTGCTAC-3' (SEQ ID NO:124)  
OLI2167 (35936.r2)  
15 5'-ACTCAGCAGTGGTAGGAAAG-3' (SEQ ID NO:125)

EXAMPLE 20: Isolation of cDNA Clones Encoding Human PRO224

A consensus DNA sequence assembled relative to the other identified EST sequences as described in Example 1, wherein the consensus sequence is designated herein as DNA30845. Based on the DNA30845 consensus sequence, oligonucleotides were synthesized to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for PRO224.

A pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-AAGTTCCAGTGCCGCACCAGTGGC-3' (SEQ ID NO:128)

reverse PCR primer 5'-TTGGTTCCACAGCCGAGCTCGTCG-3' (SEQ ID NO:129)

25 Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30845 sequence which had the following nucleotide sequence

hybridization probe

5'-GAGGAGGAGTGCAGGATTGAGCCATGTACCCAGAAAGGGCAATGCCACC-3' (SEQ ID NO:130)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened 30 by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO224 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal liver tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO224 [herein designated as UNQ198 (DNA33221-1133)] and the derived protein sequence for PRO224.

35 The entire nucleotide sequence of UNQ198 (DNA33221-1133) is shown in Figure 45 (SEQ ID NO:126). Clone UNQ198 (DNA33221-1133) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 96-98 and ending at the stop codon at nucleotide positions 942-944 (Figure 45; SEQ ID NO:126). The start of a transmembrane region begins at nucleotide position 777. The predicted polypeptide precursor is 282 amino acids long (Figure 46). Clone UNQ198 (DNA33221-1133) has been deposited with ATCC 40 and is assigned ATCC deposit no. ATCC 209263.

Analysis of the amino acid sequence of the full-length PRO224 suggests that it has homology to very low-

density lipoprotein receptors, apolipoprotein E receptor and chicken oocyte receptors P95. Based on a BLAST and FastA sequence alignment analysis of the full-length sequence, PRO224 has amino acid identity to portions of these proteins in the range from 28% to 45%, and overall identity with these proteins in the range from 33% to 39%.

**EXAMPLE 21: Isolation of cDNA Clones Encoding Human PRO222**

5 A consensus DNA sequence was assembled relative to the other identified EST sequences as described in Example 1 above, wherein the consensus sequence is designated herein as DNA28771. Based on the DNA28771 consensus sequence, oligonucleotides were synthesized to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for PRO222.

A pair of PCR primers (forward and reverse) were synthesized:

10 forward PCR primer 5'-ATCTCCTATCGCTGCTTCCGG-3' (SEQ ID NO:133)  
reverse PCR primer 5'-AGCCAGGATCGCAGTAAACTCC-3' (SEQ ID NO:134)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA28771 sequence which had the following nucleotide sequence:

hybridization probe

15 5'-ATTTAAACTTGATGGGTCTGCGTATCTTGAGTGCTTACAAAACCTTATCT-3' (SEQ ID NO:135)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO222 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue.

20 DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO222 [herein designated as UNQ196 (DNA33107-1135)] and the derived protein sequence for PRO222.

The entire nucleotide sequence of UNQ196 (DNA33107-1135) is shown in Figure 47 (SEQ ID NO:131). Clone UNQ196 (DNA33107-1135) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 159-161 and ending at the stop codon at nucleotide positions 1629-1631 (Fig. 47; SEQ ID NO:131). The predicted polypeptide precursor is 490 amino acids long (Fig. 48). Clone UNQ196 (DNA33107-1135) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209251.

Based on a BLAST and FastA sequence alignment analysis of the full-length sequence, PRO222 shows amino acid sequence identity to mouse complement factor h precursor (25-26%), complement receptor (27-29%), mouse complement C3b receptor type 2 long form precursor (25-47%) and human hypothetical protein kiaa0247 (40%).

**EXAMPLE 22: Isolation of cDNA clones Encoding PRO234**

A consensus DNA sequence was assembled (DNA30926) using phrap as described in Example 1 above. Based on this consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence.

RNA for the construction of the cDNA libraries was isolated using standard isolation protocols, e.g., Ausubel *et al.*, *Current Protocols in Molecular Biology*, from tissue or cell line sources or it was purchased from

commercial sources (e.g., Clontech). The cDNA libraries used to isolate the cDNA clones were constructed by standard methods (e.g., Ausubel *et al.*) using commercially available reagents (e.g., Invitrogen). This library was derived from 22 week old fetal brain tissue.

A cDNA clone was sequenced in its entirety. The entire nucleotide sequence of PRO234 is shown in Figure 49 (SEQ ID NO:136). The predicted polypeptide precursor is 382 amino acids long and has a calculated molecular weight of approximately 43.1 kDa.

5 The oligonucleotide sequences used in the above procedure were the following:

30926.p (OLI826) (SEQ ID NO:138): 5'-GTTCATTGAAAACCTCTTGCCATCT

GATGGTGACTTCTGGATTGGCTCA-3'

30926.f (OLI827) (SEQ ID NO:139): 5'-AAGCCAAAGAAGCCTGCAGGAGGG-3'

10 30926.r (OLI828) (SEQ ID NO:140): 5'-CAGTCCAAGCATAAAGGTCTGGC-3'

**EXAMPLE 23: Isolation of cDNA Clones Encoding Human PRO231**

A consensus DNA sequence was assembled relative to the other identified EST sequences as described in Example 1 above, wherein the consensus sequence was designated herein as DNA30933. Based on the DNA30933 consensus sequence, oligonucleotides were synthesized to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for PRO231.

15 Three PCR primers (two forward and one reverse) were synthesized:

forward PCR primer 1 5'-CCAACTACCAAAGCTGCTGGAGCC-3' (SEQ ID NO:143)

forward PCR primer 2 5'-GCAGCTCTATTACCACGGGAAGGA-3' (SEQ ID NO:144)

20 reverse PCR primer 5'-TCCTTCCCCTGGTAATAGAGCTGC-3' (SEQ ID NO:145)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30933 sequence which had the following nucleotide sequence

hybridization probe

5'-GGCAGAGAACCAAGAGGCCGGAGGAGACTGCCTCTTACAGCCAGG-3' (SEQ ID NO:146)

25 In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pairs identified above. A positive library was then used to isolate clones encoding the PRO231 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal liver tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO231 [herein designated as 30 UNQ205 (DNA34434-1139)] and the derived protein sequence for PRO231.

The entire nucleotide sequence of UNQ205 (DNA34434-1139) is shown in Figure 51 (SEQ ID NO:141). Clone UNQ205 (DNA34434-1139) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 173-175 and ending at the stop codon at nucleotide positions 1457-1459 (Fig. 51; SEQ ID NO:141). The predicted polypeptide precursor is 428 amino acids long (Fig. 52). Clone UNQ205 (DNA34434-1139) 35 has been deposited with ATCC on September 16, 1997 and is assigned ATCC deposit no. ATCC 209252.

Analysis of the amino acid sequence of the full-length PRO231 suggests that it possesses 30% and 31% amino acid identity with the human and rat prostatic acid phosphatase precursor proteins, respectively.

**EXAMPLE 24: Isolation of cDNA Clones Encoding Human PRO229**

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA28762. Based on the DNA28762 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO229.

5 A pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-TTCAGCTCATCACCTCACCTGCC-3' (SEQ ID NO:149)

reverse PCR primer 5'-GGCTCATACAAAATACCACTAGGG-3' (SEQ ID NO:150)

10 Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA28762 sequence which had the following nucleotide sequence

hybridization probe

5'-GGGCCTCCACCGCTGTGAAGGGCGGGTGGAGGTGGAACAGAAAGGCCAGT-3' (SEQ ID NO:151)

15 In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO229 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal liver tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO229 [herein designated as UNQ203 (DNA33100-1159)] (SEQ ID NO:147) and the derived protein sequence for PRO229.

20 The entire nucleotide sequence of UNQ203 (DNA33100-1159) is shown in Figure 53 (SEQ ID NO:147). Clone UNQ203 (DNA33100-1159) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 98-100 and ending at the stop codon at nucleotide positions 1139-1141 (Figure 53). The predicted polypeptide precursor is 347 amino acids long (Figure 54). Clone UNQ203 (DNA33100-1159) has been deposited with ATCC and is assigned ATCC deposit no.ATCC 209377

25 Analysis of the amino acid sequence of the full-length PRO229 polypeptide suggests that portions of it possess significant homology to antigen wc1.1, M130 antigen and CD6.

**EXAMPLE 25: Isolation of cDNA Clones Encoding Human PRO238**

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described above in Example 1. This consensus sequence is herein designated DNA30908. Based on the DNA30908 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO238.

30 PCR primers (forward and reverse) were synthesized:

forward PCR primer 1 5'-GGTGCTAAACTGGTGCTCTGTGGC-3' (SEQ ID NO:154)

forward PCR primer 2 5'-CAGGGCAAGATGAGCATTCC-3' (SEQ ID NO:155)

35 reverse PCR primer 5'-TCATACTGTTCCATCTCGGCACGC-3' (SEQ ID NO:156)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30908 sequence which had the following nucleotide sequence

hybridization probe

5'-AATGGTGGGCCCTAGAAGAGCTCATCAGAGAACTCACCGCTTCATGC-3' (SEQ ID NO:157)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones 5 encoding the PRO238 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal liver tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO238 and the derived protein sequence for PRO238.

The entire nucleotide sequence of DNA35600-1162 is shown in Figure 55 (SEQ ID NO:152). Clone 10 DNA35600-1162 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 134-136 and ending prior to the stop codon at nucleotide positions 1064-1066 (Figure 55). The predicted polypeptide precursor is 310 amino acids long (Figure 56). Clone DNA35600-1162 has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209370.

Analysis of the amino acid sequence of the full-length PRO238 polypeptide suggests that portions of it 15 possess significant homology to reductase, particularly oxidoreductase, thereby indicating that PRO238 may be a novel reductase.

EXAMPLE 26: Isolation of cDNA Clones Encoding Human PRO233

The extracellular domain (ECD) sequences (including the secretion signal, if any) of from about 950 known 20 secreted proteins from the Swiss-Prot public protein database were used to search expressed sequence tag (EST) databases. The EST databases included public EST databases (e.g., GenBank) and a proprietary EST DNA database (LIFESEQ™, Incyte Pharmaceuticals, Palo Alto, CA). The search was performed using the computer program BLAST or BLAST2 (Altschul et al., *Methods in Enzymology* 266:460-480 (1996)) as a comparison of the ECD protein 25 sequences to a 6 frame translation of the EST sequence. Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA sequences with the program "phrap" (Phil Green, University of Washington, Seattle, Washington; <http://bozeman.mbt.washington.edu/phrap.docs/phrap.html>).

An expressed sequence tag (EST) was identified by the EST database search and a consensus DNA sequence 30 was assembled relative to other EST sequences using phrap. This consensus sequence is herein designated DNA30945. Based on the DNA30945 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO233.

Forward and reverse PCR primers were synthesized:

forward PCR primer 5'-GGTGAAGGCAGAAATTGGAGATG-3' (SEQ ID NO:160)

35 reverse PCR primer 5'-ATCCCATGCATCAGCCTGTTACC-3' (SEQ ID NO:161)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30945 sequence which had the following nucleotide sequence

hybridization probe

5'-GCTGGTGTAGTCTATACATCAGATTGTTGCTACACAAGATCCTCAG-3'

(SEQ ID NO:162)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened  
5 by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones  
encoding the PRO233 gene using the probe oligonucleotide.

RNA for construction of the cDNA libraries was isolated from human fetal brain tissue. DNA sequencing  
of the clones isolated as described above gave the full-length DNA sequence for PRO233 [herein designated as  
UNQ207 (DNA34436-1238)] (SEQ ID NO:158) and the derived protein sequence for PRO233.

10 The entire nucleotide sequence of UNQ207 (DNA34436-1238) is shown in Figure 57 (SEQ ID NO:158).  
Clone UNQ207 (DNA34436-1238) contains a single open reading frame with an apparent translational initiation site  
at nucleotide positions 101-103 and ending at the stop codon at nucleotide positions 1001-1003 (Figure 57). The predicted polypeptide precursor is 300 amino acids long (Figure 58). The full-length PRO233 protein shown in  
Figure 58 has an estimated molecular weight of about 32,964 daltons and a pI of about 9.52. Clone UNQ207  
15 (DNA34436-1238) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209523.

Analysis of the amino acid sequence of the full-length PRO233 polypeptide suggests that portions of it  
possess significant homology to reductase proteins, thereby indicating that PRO233 may be a novel reductase.

EXAMPLE 27: Isolation of cDNA Clones Encoding Human PRO223

20 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in  
Example 1 above. This consensus sequence is herein designated DNA30836. Based on the DNA30836 consensus  
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of  
interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO223.

PCR primer pairs (one forward and two reverse) were synthesized:

25 forward PCR primer 5'-TTCCATGCCACCTAACGGAGACTC-3' (SEQ ID NO:165)

reverse PCR primer 1 5'-TGGATGAGGTGTGCAATGGCTGGC-3' (SEQ ID NO:166)

reverse PCR primer 2 5'-AGCTCTCAGAGGCTGGTCATAGGG-3' (SEQ ID NO:167)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30836  
sequence which had the following nucleotide sequence

30 hybridization probe

5'-GTCGCCCTTCCCAGGACTGAACATGAAGAGTTATGCCGGCTTCCTCAC-3' (SEQ ID NO:168)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened  
by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones  
encoding the PRO223 gene using the probe oligonucleotide and one of the PCR primers.

35 RNA for construction of the cDNA libraries was isolated from human fetal liver tissue. DNA sequencing  
of the clones isolated as described above gave the full-length DNA sequence for PRO223 [herein designated as  
UNQ197 (DNA33206-1165)] (SEQ ID NO:163) and the derived protein sequence for PRO223.

The entire nucleotide sequence of UNQ197 (DNA33206-1165) is shown in Figure 59 (SEQ ID NO:163). Clone UNQ197 (DNA33206-1165) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 97-99 and ending at the stop codon at nucleotide positions 1525-1527 (Figure 59). The predicted polypeptide precursor is 476 amino acids long (Figure 60). Clone UNQ197 (DNA33206-1165) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209372.

5 Analysis of the amino acid sequence of the full-length PRO223 polypeptide suggests that it possesses significant homology to various serine carboxypeptidase proteins, thereby indicating that PRO223 may be a novel serine carboxypeptidase.

**EXAMPLE 28: Isolation of cDNA Clones Encoding Human PRO235**

10 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated "DNA30927". Based on the DNA30927 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO235.

A pair of PCR primers (forward and reverse) were synthesized:

15 forward PCR primer 5'-TGGAAATACCGCCTCCTGCAG-3' (SEQ ID NO:171)  
reverse PCR primer 5'-CTTCTGCCCTTGGAGAAGATGGC-3' (SEQ ID NO:172)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30927 sequence which had the following nucleotide sequence

hybridization probe

20 5'-GGACTCACTGGCCCAGGCCTTCAATATCACCAAGCCAGGACGAT-3' (SEQ ID NO:173)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO235 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal liver tissue. DNA sequencing 25 of the clones isolated as described above gave the full-length DNA sequence for PRO235 [herein designated as UNQ209 (DNA35558-1167)] (SEQ ID NO:169) and the derived protein sequence for PRO235.

The entire nucleotide sequence of UNQ209 (DNA35558-1167) is shown in Figure 61 (SEQ ID NO:169). Clone UNQ209 (DNA35558-1167) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 667-669 and ending at the stop codon at nucleotide positions 2323-2325 (Figure 61). The 30 predicted polypeptide precursor is 552 amino acids long (Figure 62). Clone UNQ209 (DNA35558-1167) has been deposited with ATCC and is assigned ATCC deposit no. 209374.

Analysis of the amino acid sequence of the full-length PRO235 polypeptide suggests that portions of it possess significant homology to the human, mouse and *Xenopus* plexin protein, thereby indicating that PRO235 may be a novel plexin protein.

EXAMPLE 29: Isolation of cDNA Clones Encoding Human PRO236 and Human PRO262

Consensus DNA sequences were assembled relative to other EST sequences using phrap as described in Example 1 above. These consensus sequences are herein designated DNA30901 and DNA30847. Based on the DNA30901 and DNA30847 consensus sequences, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO236 and PRO262, respectively.

Based upon the DNA30901 consensus sequence, a pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-TGGCTACTCCAAGACCCTGGCATG-3' (SEQ ID NO:178)

reverse PCR primer 5'-TGGACAAATCCCCTGCTCAGCCC-3' (SEQ ID NO:179)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30901 sequence which had the following nucleotide sequence

hybridization probe

5'-GGGCTTCACCGAAGCAGTGGACCTTATTGACCACCTGATGTCCAGGG-3' (SEQ ID NO:180)

Based upon the DNA30847 consensus sequence, a pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-CCAGCTATGACTATGATGCACC-3' (SEQ ID NO:181)

reverse PCR primer 5'-TGGCACCCAGAATGGTGTGGCTC-3' (SEQ ID NO:182)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30847 sequence which had the following nucleotide sequence

20 hybridization probe

5'-CGAGATGTCATCAGCAAGTTCCAGGAAGTTCTTGGGACCTTACCTCC-3' (SEQ ID NO:183)

In order to screen several libraries for a source of full-length clones, DNA from the libraries was screened by PCR amplification with the PCR primer pairs identified above. Positive libraries were then used to isolate clones encoding the PRO236 and PRO262 genes using the probe oligonucleotides and one of the PCR primers.

25 RNA for construction of the cDNA libraries was isolated from human fetal lung tissue for PRO236 and human fetal liver tissue for PRO262.

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO236 [herein designated as UNQ210 (DNA35599-1168)] (SEQ ID NO:174), the derived protein sequence for PRO236, the full-length DNA sequence for PRO262 [herein designated as UNQ229 (DNA36992-1168)] (SEQ ID NO:176) and 30 the derived protein sequence for PRO262.

The entire nucleotide sequence of UNQ210 (DNA35599-1168) is shown in Figure 63 (SEQ ID NO:174). Clone UNQ210 (DNA35599-1168) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 69-71 and ending at the stop codon at nucleotide positions 1977-1979 (Figure 63). The predicted polypeptide precursor is 636 amino acids long (Figure 64). Clone UNQ210 (DNA35599-1168) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209373.

The entire nucleotide sequence of UNQ229 (DNA36992-1168) is shown in Figure 65 (SEQ ID NO:176). Clone UNQ229 (DNA36992-1168) contains a single open reading frame with an apparent translational initiation site

at nucleotide positions 240-242 and ending at the stop codon at nucleotide positions 2202-2204 (Figure 65). The predicted polypeptide precursor is 654 amino acids long (Figure 66). Clone UNQ229 (DNA36992-1168) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209382.

Analysis of the amino acid sequence of the full-length PRO236 and PRO262 polypeptides suggests that portions of those polypeptides possess significant homology to  $\beta$ -galactosidase proteins derived from various sources,  
5 thereby indicating that PRO236 and PRO262 may be novel  $\beta$ -galactosidase homologs.

**EXAMPLE 30: Isolation of cDNA Clones Encoding Human PRO239**

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA30909. Based on the DNA30909 consensus  
10 sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO239.

A pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-CCTCCCTCTATTACCCATGTC-3' (SEQ ID NO:186)

reverse PCR primer 5'-GACCAACTTCTCTGGGAGTGAGG-3' (SEQ ID NO:187)

15 Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30909 sequence which had the following nucleotide sequence

hybridization probe

5'-GTCACTTTATTCTCTAACACAAGCTCGAATCCTTACCAAGTGGCAG-3'

(SEQ ID NO:188)

20 In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO239 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal lung tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO239 [herein designated as  
25 UNQ213 (DNA34407-1169)] (SEQ ID NO:184) and the derived protein sequence for PRO239.

The entire nucleotide sequence of UNQ213 (DNA34407-1169) is shown in Figure 67 (SEQ ID NO:184). Clone UNQ213 (DNA34407-1169) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 72-74 and ending at the stop codon at nucleotide positions 1575-1577 (Figure 67). The predicted polypeptide precursor is 501 amino acids long (Figure 68). Clone UNQ213 (DNA34407-1169) has been  
30 deposited with ATCC and is assigned ATCC deposit no. ATCC 209383.

Analysis of the amino acid sequence of the full-length PRO239 polypeptide suggests that portions of it possess significant homology to the densin protein, thereby indicating that PRO239 may be a novel molecule in the densin family.

35 **EXAMPLE 31: Isolation of cDNA Clones Encoding Human PRO257**

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA28731. Based on the DNA28731 consensus

sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO257.

A pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-TCTCTATTCCAAACTGTGGCG-3' (SEQ ID NO:191)

reverse PCR primer 5'-TTTGATGACGATTCGAAGGTGG-3' (SEQ ID NO:192)

- 5 Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA28731 sequence which had the following nucleotide sequence

hybridization probe

5'-GGAAGGATCCTCACCAAGCCCCATTACCCAAAGCCGCATCCTGAGC-3' (SEQ ID NO:193)

- In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened  
10 by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO257 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue.

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO257  
[herein designated as UNQ224 (DNA35841-1173) (SEQ ID NO:189) and the derived protein sequence for PRO257.

- 15 The entire nucleotide sequence of UNQ224 (DNA35841-1173) is shown in Figure 69 (SEQ ID NO:189). Clone UNQ224 (DNA35841-1173) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 964-966 and ending at the stop codon at nucleotide positions 2785-2787 (Figure 69). The predicted polypeptide precursor is 607 amino acids long (Figure 70). Clone UNQ224 (DNA35841-1173) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209403.

- 20 Analysis of the amino acid sequence of the full-length PRO257 polypeptide suggests that portions of it possess significant homology to the ebnerin protein, thereby indicating that PRO257 may be a novel protein member related to the ebnerin protein.

#### EXAMPLE 32: Isolation of cDNA Clones Encoding Human PRO260

- 25 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA30834. Based on the DNA30834 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO260.

PCR primers (forward and two reverse) were synthesized:

30 forward PCR primer: 5'-TGGTTTGACCAGGCCAAGTCGG-3' (SEQ ID NO:196);

reverse PCR primer A: 5'-GGATTCTCATCCTCAAGGAAGAGCGG-3' (SEQ ID NO:197); and

reverse PCR primer B: 5'AACTTGCAGCATCAGCCACTCTGC-3' (SEQ ID NO:198)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30834 sequence which had the following nucleotide sequence:

35 hybridization probe:

5'-TTCCGTGCCAGCTTCGGTAGCGAGTGGTCTGGTGGTATTGGCA-3' (SEQ ID NO:199)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO260 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue.

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO260  
5 [herein designated as UNQ227 (DNA33470-1175)] (SEQ ID NO:194) and the derived protein sequence for PRO260.

The entire nucleotide sequence of UNQ227 (DNA33470-1175) is shown in Figure 71 (SEQ ID NO:194).  
Clone UNQ227 (DNA33470-1175) contains a single open reading frame with an apparent translational initiation site  
10 at nucleotide positions 67-69 and ending at the stop codon 1468-1470 (see Figure 71). The predicted polypeptide  
precursor is 467 amino acids long (Figure 72). Clone UNQ227 (DNA33470-1175) has been deposited with ATCC  
and is assigned ATCC deposit no. ATCC 209398.

Analysis of the amino acid sequence of the full-length PRO260 polypeptide suggests that portions of it possess significant homology to the alpha-L-fucosidase precursor, thereby indicating that PRO260 may be a novel fucosidase.

15 **EXAMPLE 33: Isolation of cDNA Clones Encoding Human PRO263**

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA30914. Based on the DNA30914 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO263.

20 PCR primers (two forward and one reverse) were synthesized:

forward PCR primer 1: 5'-GAGCTTCCATCCAGGTGTACGC-3' (SEQ ID NO:202);

forward PCR primer 2: 5'-GTCAGTGACAGTACCTACTCGG-3' (SEQ ID NO:203); reverse PCR primer:  
5'-TGGAGCAGGAGGAGTAGTAGTAGG-3' (SEQ ID NO:204)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30914  
25 sequence which had the following nucleotide sequence:

hybridization probe:

5'-AGGAGGCCTGAGGCTGCTGGACTAAGTTGGCCGGCAAGGACCAAGTT-3' (SEQ ID NO:205)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones  
30 encoding the PRO263 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal liver tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO263 [herein designated as UNQ230 (DNA34431-1177)] (SEQ ID NO:200) and the derived protein sequence for PRO263.

The entire nucleotide sequence of UNQ230 (DNA34431-1177) is shown in Figure 73 (SEQ ID NO:200).  
35 Clone UNQ230 (DNA34431-1177) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 160-162 of SEQ ID NO:200 and ending at the stop codon after the nucleotide at position 1126-1128 of SEQ ID NO:200 (Figure 73). The predicted polypeptide precursor is 322 amino acids long (Figure 74).

Clone UNQ230 (DNA34431-1177) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209399.

Analysis of the amino acid sequence of the full-length PRO263 polypeptide suggests that portions of it possess significant homology to CD44 antigen, thereby indicating that PRO263 may be a novel cell surface adhesion molecule.

5    EXAMPLE 34: Isolation of cDNA Clones Encoding Human PRO270

A consensus DNA sequence was assembled relative to the other identified EST sequences as described in Example 1 above, wherein the consensus sequence was designated herein as DNA35712. Based on the DNA35712 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO270.

10    Forward and reverse PCR primers were synthesized:

forward PCR primer (.f1) 5'-GCTTGGATATCGCATGGCCTAC-3' (SEQ ID NO:208)

forward PCR primer (.f2) 5'-TGGAGACAATATCCCTGAGG-3' (SEQ ID NO:209)

reverse PCR primer (.r1) 5'-AACAGTTGCCACAGCATGGCAGG-3' (SEQ ID NO:210)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA35712 sequence which had the following nucleotide sequence

hybridization probe

5'-CCATTGATGAGGAACTAGAACGGGACAAGAGGGTCACTTGGATTGTGGAG-3'

(SEQ ID NO:211)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened 20 by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO270 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal lung tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO270 [herein designated as UNQ237, DNA39510-1181] (SEQ ID NO:206) and the derived protein sequence for PRO270.

25    The entire nucleotide sequence of UNQ237, DNA39510-1181 is shown in Figure 75 (SEQ ID NO:206). Clone UNQ237 (DNA39510-1181) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 3-5 and ending at the stop codon at nucleotide positions 891-893 (Fig. 75; SEQ ID NO:206). The predicted polypeptide precursor is 296 amino acids long (Fig. 76). Clone UNQ237 (DNA39510-1181) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209392.

30    Analysis of the amino acid sequence of the full-length PRO270 suggests that portions of it possess significant homology to the thioredoxin-protein, thereby indicating that the PRO270 protein may be a novel member of the thioredoxin family.

EXAMPLE 35: Isolation of cDNA Clones Encoding Human PRO271

35    A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA35737. Based on the DNA35737 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of

interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO271.

Forward and reverse PCR primers were synthesized:

forward PCR primer 1 5'-TGCTTCGCTACTGCCCTC-3' (SEQ ID NO:214)

forward PCR primer 2 5'-TTCCCTTGTGGGTTGGAG-3' (SEQ ID NO:215)

forward PCR primer 3 5'-AGGGCTGGAAGCCAGTTC-3' (SEQ ID NO:216)

5 reverse PCR primer 1 5'-AGCCAGTGAGGAAATGCG-3' (SEQ ID NO:217)

reverse PCR primer 2 5'-TGTCCAAAGTACACACACCTGAGG-3' (SEQ ID NO:218)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA35737 sequence which had the following nucleotide sequence

hybridization probe

10 5'-GATGCCACGATGCCAAGGTGGGACAGCTTTGCCGCCTGGAAG-3' (SEQ ID NO:219)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO271 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal brain tissue. DNA sequencing 15 of the clones isolated as described above gave the full-length DNA sequence for PRO271 [herein designated as UNQ238 (DNA39423-1182)] (SEQ ID NO:212) and the derived protein sequence for PRO271.

The entire nucleotide sequence of UNQ238 (DNA39423-1182) is shown in Figure 77 (SEQ ID NO:212). Clone UNQ238 (DNA39423-1182) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 101-103 and ending at the stop codon at nucleotide positions 1181-1183 (Figure 77). The 20 predicted polypeptide precursor is 360 amino acids long (Figure 78). Clone UNQ238 (DNA39423-1182) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209387.

Analysis of the amino acid sequence of the full-length PRO271 polypeptide suggests that it possess significant homology to the proteoglycan link protein, thereby indicating that PRO271 may be a link protein homolog.

25 **EXAMPLE 36: Isolation of cDNA Clones Encoding Human PRO272**

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA36460. Based on the DNA36460 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO272.

30 Forward and reverse PCR primers were synthesized:

forward PCR primer (.f1) 5'-CGCAGGCCCTCATGGCCAGG-3' (SEQ ID NO:222)

forward PCR primer (.f2) 5'-GAAATCCTGGTAATTGG-3' (SEQ ID NO:223)

reverse PCR primer 5'-GTGCGCGGTGCTCACAGCTCATC-3' (SEQ ID NO:224)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA36460 35 sequence which had the following nucleotide sequence

hybridization probe

5'-CCCCCTGAGCGACGCTCCCCATGATGACGCCACGGAACTTC-3' (SEQ ID NO:225)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pairs identified above. A positive library was then used to isolate clones encoding the PRO272 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal lung tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO272 [herein designated as 5 UNQ239 (DNA40620-1183)] (SEQ ID NO:220) and the derived protein sequence for PRO272.

The entire nucleotide sequence of UNQ239 (DNA40620-1183) is shown in Figure 79 (SEQ ID NO:220). Clone UNQ239 (DNA40620-1183) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 35-37 and ending at the stop codon at nucleotide positions 1019-1021 (Figure 79). The predicted polypeptide precursor is 328 amino acids long (Figure 80). Clone UNQ239 (DNA40620-1183) has been 10 deposited with ATCC and is assigned ATCC deposit no. ATCC 209388.

Analysis of the amino acid sequence of the full-length PRO272 polypeptide suggests that portions of it possess significant homology to the human and mouse reticulocalbin proteins, respectively, thereby indicating that PRO272 may be a novel reticulocalbin protein.

15 **EXAMPLE 37: Isolation of cDNA Clones Encoding Human PRO294**

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA35731. Based on the DNA35731 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO294.

20 Forward and reverse PCR primers were synthesized:

forward PCR primer (.f1) 5'-TGGTCTCGCACACCGATC-3' (SEQ ID NO:228)

forward PCR primer (.f2) 5'-CTGCTGTCCACAGGGGAG-3' (SEQ ID NO:229)

forward PCR primer (.f3) 5'-CCTTGAAGCATACTGCTC-3' (SEQ ID NO:230)

forward PCR primer (.f4) 5'-GAGATAGCAATTCCGCC-3' (SEQ ID NO:231)

25 reverse PCR primer (.r1) 5'-TTCCTCAAGAGGGCAGCC-3' (SEQ ID NO:232)

reverse PCR primer (.r2) 5'-CTTGGCACCAATGTCCGAGATTC-3'

(SEQ ID NO:233)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA35731 sequence which had the following nucleotide sequence

30 hybridization probe

5'-GCTCTGAGGAAGGTGACGCGCGGGGCCTCCGAACCCTTGGCCTTG-3'

(SEQ ID NO:234)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pairs identified above. A positive library was then used to isolate clones 35 encoding the PRO294 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal brain tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO294 [herein designated as

UNQ257 (DNA40604-1187)] (SEQ ID NO:226) and the derived protein sequence for PRO294.

The entire nucleotide sequence of UNQ257 (DNA40604-1187) is shown in Figure 81 (SEQ ID NO:226). Clone UNQ257 (DNA40604-1187) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 396-398 and ending at the stop codon at nucleotide positions 2046-2048 (Figure 81). The predicted polypeptide precursor is 550 amino acids long (Figure 82). Clone UNQ257 (DNA40604-1187) has been deposited with ATCC and is assigned ATCC deposit no. 209394.

Analysis of the amino acid sequence of the full-length PRO294 polypeptide suggests that portions of it possess significant homology to portions of various collagen proteins, thereby indicating that PRO294 may be collagen-like molecule.

10 **EXAMPLE 38: Isolation of cDNA Clones Encoding Human PRO295**

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA35814. Based on the DNA35814 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO295.

15 Forward and reverse PCR primers were synthesized:

forward PCR primer (.f1) 5'-GCAGAGCGGAGATGCAGCGGCTTG-3'

(SEQ ID NO:238)

forward PCR primer (.f2) 5'-CCCAGCATGTACTGCCAG-3' (SEQ ID NO:239)

forward PCR primer (.f3) 5'-TTGGCAGCTTCATGGAGG-3' (SEQ ID NO:240)

20 forward PCR primer (.f4) 5'-CCTGGGCAAAATGCAAC-3' (SEQ ID NO:241)

reverse PCR primer (r1) 5'-CTCCAGCTCCTGGCGCACCTCCTC-3' (SEQ ID NO:242)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA35814 sequence which had the following nucleotide sequence

hybridization probe

25 5'-GGCTCTCAGCTACCGCGCAGGAGCGAGGCCACCTCAATGAGATG-3'

(SEQ ID NO:243)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pairs identified above. A positive library was then used to isolate clones encoding the PRO295 gene using the probe oligonucleotide and one of the PCR primers.

30 RNA for construction of the cDNA libraries was isolated from human fetal lung tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO295 [herein designated as UNQ258 (DNA38268-1188)] (SEQ ID NO:235) and the derived protein sequence for PRO295.

The entire nucleotide sequence of UNQ258 (DNA38268-1188) is shown in Figure 83 (SEQ ID NO:235). Clone UNQ258 (DNA38268-1188) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 153-155 and ending at the stop codon at nucleotide positions 1202-1204 (Figure 83). The predicted polypeptide precursor is 350 amino acids long (Figure 84). Clone UNQ258 (DNA38268-1188) has been deposited with ATCC and is assigned ATCC deposit no. 209421.

Analysis of the amino acid sequence of the full-length PRO295 polypeptide suggests that portions of it possess significant homology to the integrin proteins, thereby indicating that PRO295 may be a novel integrin.

EXAMPLE 39: Isolation of cDNA Clones Encoding Human PRO293

The extracellular domain (ECD) sequences (including the secretion signal, if any) of from about 950 known 5 secreted proteins from the Swiss-Prot public protein database were used to search expressed sequence tag (EST) databases. The EST databases included public EST databases (e.g., GenBank) and a proprietary EST DNA database (LIFESEQ™, Incyte Pharmaceuticals, Palo Alto, CA). The search was performed using the computer program BLAST or BLAST2 (Altshul et al., *Methods in Enzymology* 266:460-480 (1996)) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequence. Those comparisons resulting in a BLAST score of 70 (or 10 in some cases 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA sequences with the program "phrap" (Phil Green, University of Washington, Seattle, Washington; <http://bozeman.mbt.washington.edu/phrap.docs/phrap.html>).

Based on an expression tag sequence designated herein as T08294 identified in the above analysis, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 15 2) for use as probes to isolate a clone of the full-length coding sequence for PRO293.

A pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-AACAAAGGTAAGATGCCATCCTG-3' (SEQ ID NO:246)

reverse PCR primer 5'-AAACTTGTCGATGGAGACCAGCTC-3' (SEQ ID NO:247)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the expression sequence tag which 20 had the following nucleotide sequence

hybridization probe

5'-AGGGGCTGCAAAGCCTGGAGAGCCTCTCCTTCTATGACAACCAGC-3' (SEQ ID NO:248)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones 25 encoding the PRO293 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal brain tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO293 [herein designated as UNQ256 (DNA37151-1193)] (SEQ ID NO:244) and the derived protein sequence for PRO293.

The entire nucleotide sequence of UNQ256 (DNA37151-1193) is shown in Figures 85A-B (SEQ ID 30 NO:244). Clone UNQ256 (DNA37151-1193) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 881-883 and ending at the stop codon after nucleotide position 3019 of SEQ ID NO:244, Figures 85A-B). The predicted polypeptide precursor is 713 amino acids long (Figure 86). Clone UNQ256 (DNA37151-1193) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209393.

Analysis of the amino acid sequence of the full-length PRO293 polypeptide suggests that portions of it 35 possess significant homology to the NLRR proteins, thereby indicating that PRO293 may be a novel NLRR protein.

EXAMPLE 40: Isolation of cDNA Clones Encoding Human PRO247

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA33480. Based on the DNA33480 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO247.

5 A pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-CAACAATGAGGGCACCAAGC-3' (SEQ ID NO:251)

reverse PCR primer 5'-GATGGCTAGGTTCTGGAGGTTCTG-3' (SEQ ID NO:252)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the DNA33480 expression sequence tag which had the following nucleotide sequence

10 hybridization probe

5'-AACCTGCAGGAGATTGACCTCAAGGACAACAAACCTCAAGACCATCG-3' (SEQ ID NO:253)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO247 gene using the probe oligonucleotide and one of the PCR primers.

15 RNA for construction of the cDNA libraries was isolated from human fetal brain tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO247 [herein designated as UNQ221 (DNA35673-1201)] (SEQ ID NO:249) and the derived protein sequence for PRO247.

20 The entire nucleotide sequence of UNQ221 (DNA35673-1201) is shown in Figures 89A-B (SEQ ID NO:249). Clone UNQ221 (DNA35673-1201) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 80-82 of SEQ ID NO:249 and ending at the stop codon after nucleotide position 1717 of SEQ ID NO:249 (Figures 89A-B). The predicted polypeptide precursor is 546 amino acids long (Figure 88). Clone UNQ221 (DNA35673-1201) has been deposited with ATCC and is assigned ATCC deposit no. 209418.

25 Analysis of the amino acid sequence of the full-length PRO247 polypeptide suggests that portions of it possess significant homology to the densin molecule and KIAA0231, thereby indicating that PRO247 may be a novel leucine rich repeat protein.

EXAMPLE 41: Isolation of cDNA Clones Encoding Human PRO302, PRO303, PRO304, PRO307 and PRO343

Consensus DNA sequences were assembled relative to other EST sequences using phrap as described in Example 1 above. These consensus sequences are herein designated DNA35953, DNA35955, DNA35958, 30 DNA37160 and DNA30895. Based on the DNA35953 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO302.

PCR primers (forward and reverse) were synthesized:

forward PCR primer 1 5'-GTCCGCAAGGATGCCTACATGTTC-3' (SEQ ID NO:264)

35 forward PCR primer 2 5'-GCAGAGGTGTCTAAGGTTG-3' (SEQ ID NO:265)

reverse PCR primer 5'-AGCTCTAGACCAATGCCAGCTTCC-3' (SEQ ID NO:266)

Also, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA35953 sequence which had the following nucleotide sequence

hybridization probe

5'-GCCACCAACTCCTGCAAGAACCTTCTCAGAACTGCCCTGGTCATG-3' (SEQ ID NO:267)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened  
5 by PCR amplification with the PCR primer pairs identified above. A positive library was then used to isolate clones encoding the PRO302 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue (LIB228).

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO302 [herein designated as UNQ265 (DNA40370-1217)] (SEQ ID NO:254) and the derived protein sequence for PRO302.

10 The entire nucleotide sequence of UNQ265 (DNA40370-1217) is shown in Figure 89 (SEQ ID NO:254). Clone UNQ265 (DNA40370-1217) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 34-36 and ending at the stop codon at nucleotide positions 1390-1392 (Figure 89). The predicted polypeptide precursor is 452 amino acids long (Figure 90). Various unique aspects of the PRO302 protein are shown in Figure 90. Clone UNQ265 (DNA40370-1217) has been deposited with the ATCC on November 21,  
15 1997 and is assigned ATCC deposit no. ATCC 209485.

Based on the DNA35955 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO303.

A pair of PCR primers (forward and reverse) were synthesized:

20 forward PCR primer 5'-GGGAATTCAACCCTATGACATTGCC-3' (SEQ ID NO:268)  
reverse PCR primer 5'-GAATGCCCTGCAAGCATCAACTGG-3' (SEQ ID NO:269)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA35955 sequence which had the following nucleotide sequence:

hybridization probe

25 5'-GCACCTGTCACCTACACTAACACATCCAGCCCATCTGTCTCCAGGCCTC-3' (SEQ ID NO:270)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pairs identified above. A positive library was then used to isolate clones encoding the PRO303 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal lung tissue (LIB25).

30 DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO303 [herein designated as UNQ266 (DNA42551-1217)] (SEQ ID NO:256) and the derived protein sequence for PRO303.

The entire nucleotide sequence of UNQ266 (DNA42551-1217) is shown in Figure 91 (SEQ ID NO:256). Clone UNQ266 (DNA42551-1217) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 20-22 and ending at the stop codon at nucleotide positions 962-964 (Figure 91). The predicted polypeptide precursor is 314 amino acids long (Figure 92). Various unique aspects of the PRO303 protein are shown in Figure 92. Clone UNQ266 (DNA42551-1217) has been deposited on November 21, 1997 with the ATCC and is assigned ATCC deposit no. ATCC 209483.

Based on the DNA35958 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO304.

Pairs of PCR primers (forward and reverse) were synthesized:

forward PCR primer 1 5'-GCGGAAGGGCAGAATGGGACTCCAAG-3' (SEQ ID NO:271)

5 forward PCR primer 2 5'-CAGCCCTGCCACATGTGC-3' (SEQ ID NO:272)

forward PCR primer 3 5'-TACTGGGTGGTCAGCAAC-3' (SEQ ID NO:273)

reverse PCR primer 5'-GGCGAAGAGCAGGGTGAGACCCCG-3' (SEQ ID NO:274)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA35958 sequence which had the following nucleotide sequence

10 hybridization probe

5'-GCCCTCATCCTCTGGCAAATGCAGTTACAGCCCCGGAGCCCCGAC-3' (SEQ ID NO:275)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pairs identified above. A positive library was then used to isolate clones encoding the PRO304 gene using the probe oligonucleotide and one of the PCR primers.

15 RNA for construction of the cDNA libraries was isolated from 22 week human fetal brain tissue (LIB153).

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO304 [herein designated as UNQ267 (DNA39520-1217)] (SEQ ID NO:258) and the derived protein sequence for PRO304.

The entire nucleotide sequence of UNQ267 (DNA39520-1217) is shown in Figure 93 (SEQ ID NO:258).

Clone UNQ267 (DNA39520-1217) contains a single open reading frame with an apparent translational initiation site 20 at nucleotide positions 34-36 and ending at the stop codon at nucleotide positions 1702-1704 (Figure 93). The predicted polypeptide precursor is 556 amino acids long (Figure 94). Various unique aspects of the PRO304 protein are shown in Figure 94. Clone UNQ267 (DNA39520-1217) has been deposited with ATCC on November 21, 1997 and is assigned ATCC deposit no. ATCC 209482.

Based on the DNA37160 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a 25 cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO307.

Pairs of PCR primers (forward and reverse) were synthesized:

forward PCR primer 1 5'-GGGCAGGGATTCCAGGGCTCC-3' (SEQ ID NO:276)

forward PCR primer 2 5'-GGCTATGACAGCAGGTTC-3' (SEQ ID NO:277)

30 forward PCR primer 3 5'-TGACAATGACCGACCAGG-3' (SEQ ID NO:278)

reverse PCR primer 5'-GCATCGCATTGCTGGTAGAGCAAG-3' (SEQ ID NO:279)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA37160 sequence which had the following nucleotide sequence

hybridization probe

35 5'-TTACAGTCCCCCTGGAAACCCACTTGGCCTGCATACCGCCTCCC-3' (SEQ ID NO:280)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pairs identified above. A positive library was then used to isolate clones

encoding the PRO307 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal liver tissue (LIB229).

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO307 [herein designated as UNQ270 (DNA41225-1217)] (SEQ ID NO:260) and the derived protein sequence for PRO307.

The entire nucleotide sequence of UNQ270 (DNA41225-1217) is shown in Figure 95 (SEQ ID NO:260).

5 Clone UNQ270 (DNA41225-1217) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 92-94 and ending at the stop codon at nucleotide positions 1241-1243 (Figure 95). The predicted polypeptide precursor is 383 amino acids long (Figure 96). Various unique aspects of the PRO307 protein are shown in Figure 96. Clone UNQ270 (DNA41225-1217) has been deposited with ATCC on November 21, 1997 and is assigned ATCC deposit no. ATCC 209491.

10 Based on the DNA30895 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO343.

A pair of PCR primers (forward and reverse) were synthesized:

forward PCR primer 5'-CGTCTCGAGCGCTCCATACAGTCCCTTGCCCCA-3' (SEQ ID NO:281)

15 reverse PCR primer

5'-TGGAGGGGAGCAGGGATGCTTGTCTGGCGACTCCGGGGGCC

CCCTCATGTGCCAGGTGGA-3' (SEQ ID NO:282)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30895 sequence which had the following nucleotide sequence

20 hybridization probe

5'-CCCTCAGACCCCTGCAGAACGCTGAAGGTTCCATCATCGAC

TCGGAAGTCTGCAGCCATCTGTACTGGCGGGAGCAGGACAGGGACCCATCACTGAGGACATGCTGT  
GTGCCGGCTACT-3' (SEQ ID NO:283)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened 25 by PCR amplification with the PCR primer pairs identified above. A positive library was then used to isolate clones encoding the PRO343 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal lung tissue (LIB26).

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO343 [herein designated as UNQ302 (DNA43318-1217)] (SEQ ID NO:262) and the derived protein sequence for PRO343.

30 The entire nucleotide sequence of UNQ302 (DNA43318-1217) is shown in Figure 97 (SEQ ID NO:262). Clone UNQ302 (DNA43318-1217) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 53-55 and ending at the stop codon at nucleotide positions 1004-1006 (Figure 97). The predicted polypeptide precursor is 317 amino acids long (Figure 98). Various unique aspects of the PRO343 protein are shown in Figure 98. Clone UNQ302 (DNA43318-1217) has been deposited with ATCC on November 21, 1997 35 and is assigned ATCC deposit no. ATCC 209481.

EXAMPLE 42: Isolation of cDNA Clones Encoding Human PRO328

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA35615. Based on the DNA35615 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO328.

5 Forward and reverse PCR primers were synthesized:

forward PCR primer 5'-TCCTGCAGTTCTGATGC-3' (SEQ ID NO:286)

reverse PCR primer 5'-CTCATATTGCACACCAGTAATCG-3' (SEQ ID NO:287)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA35615 sequence which had the following nucleotide sequence

10 hybridization probe

5'-ATGAGGAGAAACGTTGATGGTGGAGCTGCACAAACCTCTACCGGG-3'

(SEQ ID NO:288)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones 15 encoding the PRO328 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue.

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO328 [herein designated as UNQ289 (DNA40587-1231)] (SEQ ID NO:284) and the derived protein sequence for PRO328.

The entire nucleotide sequence of UNQ289 (DNA40587-1231) is shown in Figure 99 (SEQ ID NO:284).

20 Clone UNQ289 (DNA40587-1231) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 15-17 and ending at the stop codon at nucleotide positions 1404-1406 (Figure 99). The predicted polypeptide precursor is 463 amino acids long (Figure 100). Clone UNQ289 (DNA40587-1231) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209438.

25 Analysis of the amino acid sequence of the full-length PRO328 polypeptide suggests that portions of it possess significant homology to the human glioblastoma protein and to the cysteine rich secretory protein thereby indicating that PRO328 may be a novel glioblastoma protein or cysteine rich secretory protein.

EXAMPLE 43: Isolation of cDNA Clones Encoding Human PRO335, PRO331 or PRO326

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in 30 Example 1 above. This consensus sequence is herein designated DNA36685. Based on the DNA36685 consensus sequence, and Incyte EST sequence no. 2228990, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO335, PRO331 or PRO326.

Forward and reverse PCR primers were synthesized for the determination of PRO335:

35 forward PCR primer 5'-GGAACCGAATCTCAGCTA-3' (SEQ ID NO:295)

forward PCR primer 5'-CCTAAACTGAACTGGACCA-3' (SEQ ID NO:296)

forward PCR primer 5'-GGCTGGAGACACTAACCT-3' (SEQ ID NO:297)

forward PCR primer 5'-ACAGCTGCACAGCTCAGAACAGTG-3' (SEQ ID NO:298)  
reverse PCR primer 5'-CATTCCCAGTATAAAAATTTTC-3' (SEQ ID NO:299)  
reverse PCR primer 5'-GGGTCTTGGTGAATGAGG-3' (SEQ ID NO:300)  
reverse PCR primer 5'-GTGCCTCTCGGTTACCACCAATGG-3' (SEQ ID NO:301)

Additionally, a synthetic oligonucleotide hybridization probe was constructed for the determination of PRO335 which

5 had the following nucleotide sequence

hybridization probe

5'-GCGCCACTGTTGGACCGAACTGTAACCAAGGGAGAACAGCCGTCCTAC-3'  
(SEQ ID NO:302)

Forward and reverse PCR primers were synthesized for the determination of PRO331:

10 forward PCR primer 5'-GCCTTGACAACCTTCAGTCAGTAGTGG-3' (SEQ ID NO:303)  
reverse PCR primer 5'-CCCCATGTGTCCATGACTGTTCCC-3' (SEQ ID NO:304)

Additionally, a synthetic oligonucleotide hybridization probe was constructed for the determination of PRO331 which had the following nucleotide sequence

hybridization probe

15 5'-TACTGCCTCATGACCTCTTCACTCCCTGCATCATCTTAGAGCGG-3'  
(SEQ ID NO:305)

Forward and reverse PCR primers were synthesized for the determination of PRO326:

forward PCR primer 5'-ACTCCAAGGAAATCGGATCCGTTTC-3' (SEQ ID NO:306)  
reverse PCR primer 5'-TTAGCAGCTGAGGATGGGCACAAC-3' (SEQ ID NO:307)

20 Additionally, a synthetic oligonucleotide hybridization probe was constructed for the determination of PRO331 which had the following nucleotide sequence

hybridization probe

5'-GCCTTCACTGGTTGGATGCATTGGAGCATCTAGACCTGAGTGACAACGC-3'  
(SEQ ID NO:308)

25 In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pairs identified above. A positive library was then used to isolate clones encoding the PRO335, PRO331 or PRO326 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue (PRO335 and PRO326) and human fetal brain (PRO331).

30 DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO335, PRO331 or PRO326 [herein designated as SEQ ID NOS:289, 291 and 293, respectively; see Figures 103A-B, 105 and 107, respectively], and the derived protein sequence for PRO335, PRO331 or PRO326 (see Figures 104, 106 and 108, respectively; SEQ ID NOS:290, 292 and 294, respectively).

The entire nucleotide sequences are shown in Figures 103A-B, 105 and 107, deposited with the ATCC on  
35 June 2, 1998, November 7, 1997 and November 21, 1997, respectively.

Analysis of the amino acid sequence of the full-length PRO335, PRO331 or PRO326 polypeptide suggests that portions of it possess significant homology to the LIG-1 protein, thereby indicating that PRO335, PRO331 and

PRO326 may be a novel LIG-1-related protein.

**EXAMPLE 44: Isolation of cDNA clones Encoding Human PRO332**

Based upon an ECD homology search performed as described in Example 1 above, a consensus DNA sequence designated herein as DNA36688 was assembled. Based on the DNA36688 consensus sequence, 5 oligonucleotides were synthesized to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for PRO332.

A pair of PCR primers (forward and reverse) were synthesized:

5'-GCATTGGCCGCGAGACTTGCC-3' (SEQ ID NO:311)

5'-CGGCCACGGCTTGGAAATG-3' (SEQ ID NO:312)

10 A probe was also synthesized:

5'-TGGAGGAGCTAACCTCAGCTACAACCGCATCACCAAGCCCACAGG-3'

(SEQ ID NO:313)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones 15 encoding the PRO332 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from a human fetal liver library (LIB229).

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for DNA40982-1235 and the derived protein sequence for PRO332.

The entire nucleotide sequence of DNA40982-1235 is shown in Figures 109A-B (SEQ ID NO:309). Clone 20 DNA40982-1235 contains a single open reading frame (with an apparent translational initiation site at nucleotide positions 342-344, as indicated in Figures 109A-B). The predicted polypeptide precursor is 642 amino acids long, and has a calculated molecular weight of 72,067 (pI: 6.60). Clone DNA40982-1235 has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209433.

Based on a BLAST and FastA sequence alignment analysis of the full-length sequence, PRO332 shows about 25 30-40% amino acid sequence identity with a series of known proteoglycan sequences, including, for example, fibromodulin and fibromodulin precursor sequences of various species (FMOD\_BOVIN, FMOD\_CHICK, FMOD RAT, FMOD\_MOUSE, FMOD\_HUMAN, P\_R36773), osteomodulin sequences (AB000114\_1, AB007848\_1), decorin sequences (CFU83141\_1, OCU03394\_1, P\_R42266, P\_R42267, P\_R42260, P\_R89439), keratan sulfate proteoglycans (BTU48360\_1, AF022890\_1), corneal proteoglycan (AF022256\_1), and bone/cartilage proteoglycans and 30 proteoglycane precursors (PGS1\_BOVIN, PGS2\_MOUSE, PGS2\_HUMAN).

**EXAMPLE 45: Isolation of cDNA clones Encoding Human PRO334**

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. Based on the consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a 35 cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO334.

Forward and reverse PCR primers were synthesized for the determination of PRO334:

forward PCR primer 5'-GATGGTCCCTGCTCAAGTGCCCTG-3' (SEQ ID NO:316)

reverse PCR primer 5'-TTGCACTTGTAGGACCCACGTACG-3' (SEQ ID NO:317)

Additionally, a synthetic oligonucleotide hybridization probe was constructed for the determination of PRO334 which had the following nucleotide sequence

5 hybridization probe

5'-CTGATGGGAGGACCTGTGTAGATGTTGATGAATGTGCTACAGGAAGAGCC-3'

(SEQ ID NO:318)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones 10 encoding the PRO334 gene using the probe oligonucleotide and one of the PCR primers.

Human fetal kidney cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA.

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO334 [herein designated as DNA41379-1236] (SEQ ID NO:314) and the derived protein sequence for PRO334.

15 The entire nucleotide sequence of DNA41379-1236 (also referred to as UNQ295) is shown in Figure 109 (SEQ ID NO:314). Clone DNA41379-1236 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 203-205 and ending at the stop codon at nucleotide positions 1730-1732 (Figure 109). The predicted polypeptide precursor is 509 amino acids long (Figure 110). Clone DNA41379-1236 has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209488.

20 Analysis of the amino acid sequence of the full-length PRO334 polypeptide suggests that portions of it possess significant homology to the fibulin and fibrillin proteins, thereby indicating that PRO334 may be a novel member of the EGF protein family.

**EXAMPLE 46: Isolation of cDNA Clones Encoding Human PRO346**

25 A consensus DNA sequence was identified using phrap as described in Example 1 above. Specifically, this consensus sequence is herein designated DNA38240. Based on the DNA38240 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length PRO346 coding sequence.

RNA for construction of the cDNA libraries was isolated from human fetal liver. The cDNA libraries used 30 to isolate the cDNA clones were constructed by standard methods using commercially available reagents (e.g., Invitrogen, San Diego, CA; Clontech, etc.) The cDNA was primed with oligo dT containing a NotI site, linked with blunt to Sall hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the SfiI site; see, Holmes et al., *Science*, 253:1278-1280 (1991)) in the unique XhoI and NotI sites.

35 A cDNA clone was sequenced in entirety. The entire nucleotide sequence of DNA44167-1243 is shown in Figure 111 (SEQ ID NO:319). Clone DNA44167-1243 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 64-66 (Fig. 113; SEQ ID NO:319). The predicted polypeptide

precursor is 450 amino acids long. Clone DNA44167-1243 has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209434 (designation DNA44167-1243).

Based on a BLAST, BLAST-2 and FastA sequence alignment analysis (using the ALIGN computer program) of the full-length sequence, PRO346 shows amino acid sequence identity to carcinoembryonic antigen (28%).

The oligonucleotide sequences used in the above procedure were the following:

- 5 OLI2691 (38240.f1)  
5'-GATCCTGTCACAAAGCCAGTGGTGC-3' (SEQ ID NO:321)
- OLI2693 (38240.r1)  
5'-CACTGACAGGGTTCCCTACCCAGG-3' (SEQ ID NO:322)
- OLI2692 (38240.p1)  
10 5'-CTCCCTCTGGGCTGTGGAGTATGTGGGGACATGACCCTGACATG-3' (SEQ ID NO:323)

**EXAMPLE 47: Isolation of cDNA Clones Encoding Human PRO268**

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA35698. Based on the DNA35698 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO268.

Forward and reverse PCR primers were synthesized:

- forward PCR primer 1 5'-TGAGGTGGCAAGCGCGAAATG-3' (SEQ ID NO:326)
- forward PCR primer 2 5'-TATGTGGATCAGGACGTGCC-3' (SEQ ID NO:327)
- 20 forward PCR primer 3 5'-TGCAGGGTTCAGTCTAGATTG-3' (SEQ ID NO:328)
- reverse PCR primer 5'-TTGAAGGACAAAGGCAATCTGCCAC-3' (SEQ ID NO:329)
- Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA35698 sequence which had the following nucleotide sequence
- hybridization probe
- 25 5'-GGAGTCTTGCAGTTCCCCTGGCAGTCCTGGTGTGCTTGGG-3' (SEQ ID NO:330)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO268 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal lung tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO268 [herein designated as UNQ235 (DNA39427-1179)] (SEQ ID NO:324) and the derived protein sequence for PRO268.

The entire nucleotide sequence of UNQ235 (DNA39427-1179) is shown in Figure 113 (SEQ ID NO:324). Clone UNQ235 (DNA39427-1179) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 13-15 and ending at the stop codon at nucleotide positions 853-855 (Figure 113). The predicted polypeptide precursor is 280 amino acids long (Figure 114). Clone UNQ235 (DNA39427-1179) has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209395.

Analysis of the amino acid sequence of the full-length PRO268 polypeptide suggests that it possess significant homology to protein disulfide isomerase, thereby indicating that PRO268 may be a novel protein disulfide isomerase.

**EXAMPLE 48: Isolation of cDNA Clones Encoding Human PRO330**

5 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA35730. Based on the DNA35730 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO330.

Forward and reverse PCR primers were synthesized:

10 forward PCR primer 1 5'-CCAGGCACAATTCCAGA-3' (SEQ ID NO:333)  
forward PCR primer 2 5'-GGACCCTTCTGTGTGCCAG-3' (SEQ ID NO:334)  
reverse PCR primer 1 5'-GGTCTCAAGAACTCCTGTC-3' (SEQ ID NO:335)  
reverse PCR primer 2 5'-ACACTCAGCATTGCCTGGTACTTG-3' (SEQ ID NO:336)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus sequence which had  
15 the following nucleotide sequence

hybridization probe

5'-GGGCACATGACTGACCTGATTATGCAGAGAAAGAGCTGGTGCAG-3' (SEQ ID NO:337)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones  
20 encoding the PRO330 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal liver tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO330 [herein designated as UNQ290 (DNA40603-1232)] (SEQ ID NO:331) and the derived protein sequence for PRO330.

The entire nucleotide sequence of UNQ290 (DNA40603-1232) is shown in Figure 115 (SEQ ID NO:331).  
25 Clone UNQ290 (DNA40603-1232) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 167-169 and ending at the stop codon at nucleotide positions 1766-1768 (Figure 115). The predicted polypeptide precursor is 533 amino acids long (Figure 116). Clone UNQ290 (DNA40603-1232) has been deposited with ATCC and is assigned ATCC deposit no.ATCC 209486 on November 21, 1997.

30 Analysis of the amino acid sequence of the full-length PRO330 polypeptide suggests that portions of it possess significant homology to the mouse prolyl 4-hydroxylase alpha subunit protein, thereby indicating that PRO330 may be a novel prolyl 4-hydroxylase alpha subunit polypeptide.

**EXAMPLE 49: Isolation of cDNA Clones Encoding Human PRO310**

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in  
35 Example 1 above. This consensus sequence is herein designated DNA40553. Based on the DNA40553 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO310.

Forward and reverse PCR primers were synthesized:

forward PCR primer 1 5'-TCCCCAAGCCGTTCTAGACGCCG-3' (SEQ ID NO:342)

forward PCR primer 2 5'-CTGGTTCTTCCTTGACG-3' (SEQ ID NO:343)

reverse PCR primer 5'-GCCCAAATGCCCTAACCGCGTATAACCC-3' (SEQ ID NO:344)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus sequence which had

5 the following nucleotide sequence

hybridization probe

5'-GGGTGTGATGCTTGAAGCATTCTGTGCTTGATCACTATGCTAGGAC-3' (SEQ ID NO:345)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones

10 encoding the PRO310 gene using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal liver tissue. DNasequencing of the clones isolated as described above gave the full-length DNA sequence for PRO310 [herein designated as DNA43046-1225 (SEQ ID NO:340) and the derived protein sequence for PRO310 (SEQ ID NO:341).

The entire nucleotide sequence of DNA43046-1225 is shown in Figure 119 (SEQ ID NO:340). Clone  
15 DNA43046-1225 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 81-83 and ending at the stop codon at nucleotide positions 1035-1037 (Figure 119). The predicted polypeptide precursor is 318 amino acids long (Figure 120) and has a calculated molecular weight of approximately 36,382 daltons. Clone DNA43046-1225 has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209484.

20 Analysis of the amino acid sequence of the full-length PRO310 polypeptide suggests that portions of it possess homology to *C. elegans* proteins and to fringe, thereby indicating that PRO310 may be involved in development.

#### EXAMPLE 50: Isolation of cDNA clones Encoding Human PRO339

25 An expressed sequence tag (EST) DNA database (LIFESEQ™, Incyte Pharmaceuticals, Palo Alto, CA) was searched and ESTs were identified. An assembly of Incyte clones and a consensus sequence was formed using phrap as described in Example 1 above.

Forward and reverse PCR primers were synthesized based upon the assembly-created consensus sequence:

forward PCR primer 1 5'-GGGATGCAGGTGGTCTCATGGGG-3' (SEQ ID NO:346)

30 forward PCR primer 2 5'-CCCTCATGTACCGGCTCC-3' (SEQ ID NO:347)

forward PCR primer 3 5'-GTGTGACACAGCGTGGGC-3' (SEQ ID NO:43)

forward PCR primer 4 5'-GACCGGCAGGCTTCTGCG-3' (SEQ ID NO:44)

reverse PCR primer 1 5'-CAGCAGCTTCAGCCACCAGGAGTGG-3' (SEQ ID NO:45)

reverse PCR primer 2 5'-CTGAGCCGTGGCTGCAGTCTCGC-3' (SEQ ID NO:46)

35 Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus sequence which had the following nucleotide sequence

hybridization probe

5'-CCGACTACGACTGGTTCTTCATCATGCAGGATGACACATATGTGC-3' (SEQ ID NO:47)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pairs identified above. A positive library was then used to isolate clones encoding the PRO339 gene using the probe oligonucleotide and one of the PCR primers.

5 RNA for construction of the cDNA libraries was isolated from human fetal liver tissue. A cDNA clone was sequenced in entirety. The entire nucleotide sequence of DNA43466-1225 is shown in Figure 117 (SEQ ID NO:338). Clone DNA43466-1225 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 333-335 and ending at the stop codon found at nucleotide positions 2649-2651 (Figure 117; SEQ ID NO:338). The predicted polypeptide precursor is 772 amino acids long and has a calculated molecular weight of approximately 86,226 daltons. Clone DNA43466-1225 has been deposited with ATCC and is assigned ATCC deposit no. ATCC 209490.

10 Based on a BLAST and FastA sequence alignment analysis (using the ALIGN computer program) of the full-length sequence, PRO339 has homology to *C. elegans* proteins and collagen-like polymer sequences as well as to fringe, thereby indicating that PRO339 may be involved in development or tissue growth.

15

EXAMPLE 51: Isolation of cDNA Clones Encoding Human PRO244

A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. Based on this consensus sequence, oligonucleotides were synthesized to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding 20 sequence for PRO244.

A pair of PCR primers (forward and reverse) were synthesized:

5'-TTCAGCTTCTGGGATGTAGGG-3' (30923.f1) (SEQ ID NO:378)  
5'-TATTCTACCATTCACAAATCCG-3' (30923.r1) (SEQ ID NO:379)

A probe was also synthesized:

25 5'-GGAGGACTGTGCCACCATGAGAGACTCTCAAACCCAAGGCAAAATTGG-3' (30923.p1) (SEQ ID NO:380)

In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO244 gene using the probe oligonucleotide and one of the PCR primers.

30 RNA for construction of the cDNA libraries was isolated from a human fetal kidney library. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence and the derived protein sequence for PRO244.

The entire nucleotide sequence of PRO244 is shown in Figure 121 (SEQ ID NO:376). Clone DNA35668-1171 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 106-108 35 (Fig. 121). The predicted polypeptide precursor is 219 amino acids long. Clone DNA35668-1171 has been deposited with ATCC (designated as DNA35663-1171) and is assigned ATCC deposit no. ATCC209371. The protein has a cytoplasmic domain (aa 1-20), a transmembrane domain (aa 21-46), and an extracellular domain (aa 47-219), with

a C-lectin domain at aa 55-206.

Based on a BLAST and FastA sequence alignment analysis of the full-length sequence, PRO244 shows notable amino acid sequence identity to hepatic lectin gallus gallus (43 %), HIC hp120-binding C-type lectin (42 %), macrophage lectin 2 (HUMHML2-1, 41 %), and sequence PR32188 (44 %).

5    **EXAMPLE 52: Use of PRO Polypeptide-Encoding Nucleic Acid as Hybridization Probes**

The following method describes use of a nucleotide sequence encoding a PRO polypeptide as a hybridization probe.

DNA comprising the coding sequence of a PRO polypeptide of interest as disclosed herein may be employed as a probe or used as a basis from which to prepare probes to screen for homologous DNAs (such as those 10 encoding naturally-occurring variants of the PRO polypeptide) in human tissue cDNA libraries or human tissue genomic libraries.

Hybridization and washing of filters containing either library DNAs is performed under the following high stringency conditions. Hybridization of radiolabeled PRO polypeptide-encoding nucleic acid-derived probe to the filters is performed in a solution of 50% formamide, 5x SSC, 0.1% SDS, 0.1% sodium pyrophosphate, 50 mM 15 sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1x SSC and 0.1% SDS at 42°C.

DNAs having a desired sequence identity with the DNA encoding full-length native sequence PRO polypeptide can then be identified using standard techniques known in the art.

20    **EXAMPLE 53: Expression of PRO Polypeptides in *E. coli***

This example illustrates preparation of an unglycosylated form of a desired PRO polypeptide by recombinant expression in *E. coli*.

The DNA sequence encoding the desired PRO polypeptide is initially amplified using selected PCR primers. The primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected 25 expression vector. A variety of expression vectors may be employed. An example of a suitable vector is pBR322 (derived from *E. coli*; see Bolivar et al., *Gene*, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR amplified sequences are then ligated into the vector. The vector will preferably include sequences which encode for an antibiotic resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase 30 cleavage site), the specific PRO polypeptide coding region, lambda transcriptional terminator, and an argU gene.

The ligation mixture is then used to transform a selected *E. coli* strain using the methods described in Sambrook et al., *supra*. Transformants are identified by their ability to grow on LB plates and antibiotic resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.

Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with 35 antibiotics. The overnight culture may subsequently be used to inoculate a larger scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.

After culturing the cells for several more hours, the cells can be harvested by centrifugation. The cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the solubilized PRO polypeptide can then be purified using a metal chelating column under conditions that allow tight binding of the protein.

PRO187, PRO317, PRO301, PRO224 and PRO238 were successfully expressed in *E. coli* in a poly-His 5 tagged form, using the following procedure. The DNA encoding PRO187, PRO317, PRO301, PRO224 or PRO238 was initially amplified using selected PCR primers. The primers contained restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector, and other useful sequences providing for efficient and reliable translation initiation, rapid purification on a metal chelation column, and proteolytic removal with enterokinase. The PCR-amplified, poly-His tagged sequences were then ligated into an expression vector, which 10 was used to transform an *E. coli* host based on strain 52 (W3110 fuhA(tonA) lon galE rpoHts(htpRts) clpP(lacIq)). Transformants were first grown in LB containing 50 mg/ml carbenicillin at 30°C with shaking until an O.D.600 of 3-5 was reached. Cultures were then diluted 50-100 fold into CRAP media (prepared by mixing 3.57 g (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.71 g sodium citrate·2H<sub>2</sub>O, 1.07 g KCl, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 mL water, 15 as well as 110 mM MPOS, pH 7.3, 0.55% (w/v) glucose and 7 mM MgSO<sub>4</sub>) and grown for approximately 20-30 hours at 30°C with shaking. Samples were removed to verify expression by SDS-PAGE analysis, and the bulk culture is centrifuged to pellet the cells. Cell pellets were frozen until purification and refolding.

*E. coli* paste from 0.5 to 1 L fermentations (6-10 g pellets) was resuspended in 10 volumes (w/v) in 7 M guanidine, 20 mM Tris, pH 8 buffer. Solid sodium sulfite and sodium tetrathionate is added to make final concentrations of 0.1M and 0.02 M, respectively, and the solution was stirred overnight at 4°C. This step results 20 in a denatured protein with all cysteine residues blocked by sulfitolization. The solution was centrifuged at 40,000 rpm in a Beckman Ultracentrifuge for 30 min. The supernatant was diluted with 3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM Tris, pH 7.4) and filtered through 0.22 micron filters to clarify. Depending the clarified extract was loaded onto a 5 ml Qiagen Ni-NTA metal chelate column equilibrated in the metal chelate 25 column buffer. The column was washed with additional buffer containing 50 mM imidazole (Calbiochem, Utrol grade), pH 7.4. The protein was eluted with buffer containing 250 mM imidazole. Fractions containing the desired protein were pooled and stored at 4°C. Protein concentration was estimated by its absorbance at 280 nm using the calculated extinction coefficient based on its amino acid sequence.

The proteins were refolded by diluting sample slowly into freshly prepared refolding buffer consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCl, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM EDTA. Refolding 30 volumes were chosen so that the final protein concentration was between 50 to 100 micrograms/ml. The refolding solution was stirred gently at 4°C for 12-36 hours. The refolding reaction was quenched by the addition of TFA to a final concentration of 0.4% (pH of approximately 3). Before further purification of the protein, the solution was filtered through a 0.22 micron filter and acetonitrile was added to 2-10% final concentration. The refolded protein was chromatographed on a Poros R1/H reversed phase column using a mobile buffer of 0.1% TFA with elution with 35 a gradient of acetonitrile from 10 to 80%. Aliquots of fractions with A280 absorbance were analyzed on SDS polyacrylamide gels and fractions containing homogeneous refolded protein were pooled. Generally, the properly refolded species of most proteins are eluted at the lowest concentrations of acetonitrile since those species are the

most compact with their hydrophobic interiors shielded from interaction with the reversed phase resin. Aggregated species are usually eluted at higher acetonitrile concentrations. In addition to resolving misfolded forms of proteins from the desired form, the reversed phase step also removes endotoxin from the samples.

Fractions containing the desired folded PRO187, PRO317, PRO301, PRO224 and PRO238 proteins, respectively, were pooled and the acetonitrile removed using a gentle stream of nitrogen directed at the solution.

- 5 Proteins were formulated into 20 mM Hepes, pH 6.8 with 0.14 M sodium chloride and 4% mannitol by dialysis or by gel filtration using G25 Superfine (Pharmacia) resins equilibrated in the formulation buffer and sterile filtered.

**EXAMPLE 54: Expression of PRO Polypeptides in Mammalian Cells**

This example illustrates preparation of a glycosylated form of a desired PRO polypeptide by recombinant  
10 expression in mammalian cells.

The vector, pRK5 (see EP 307,247, published March 15, 1989), is employed as the expression vector. Optionally, the PRO polypeptide-encoding DNA is ligated into pRK5 with selected restriction enzymes to allow insertion of the PRO polypeptide DNA using ligation methods such as described in Sambrook et al., *supra*. The resulting vector is called pRK5-PRO polypeptide.

- 15 In one embodiment, the selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics. About 10 µg pRK5-PRO polypeptide DNA is mixed with about 1 µg DNA encoding the VA RNA gene [Thimmappaya et al., *Cell*, 31:543 (1982)] and dissolved in 500 µl of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M CaCl<sub>2</sub>. To this mixture is added, dropwise, 500 µl of 50 mM HEPES (pH 7.35),  
20 280 mM NaCl, 1.5 mM NaPO<sub>4</sub>, and a precipitate is allowed to form for 10 minutes at 25°C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37°C. The culture medium is aspirated off and 2 ml of 20% glycerol in PBS is added for 30 seconds. The 293 cells are then washed with serum free medium, fresh medium is added and the cells are incubated for about 5 days.

- 25 Approximately 24 hours after the transfections, the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200 µCi/ml <sup>35</sup>S-cysteine and 200 µCi/ml <sup>35</sup>S-methionine. After a 12 hour incubation, the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel. The processed gel may be dried and exposed to film for a selected period of time to reveal the presence of PRO polypeptide. The cultures containing transfected cells may undergo further incubation (in serum free medium) and the medium is tested in selected bioassays.

- 30 In an alternative technique, PRO polypeptide may be introduced into 293 cells transiently using the dextran sulfate method described by Sompanyrac et al., *Proc. Natl. Acad. Sci.*, 78:7575 (1981). 293 cells are grown to maximal density in a spinner flask and 700 µg pRK5-PRO polypeptide DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium,  
35 and re-introduced into the spinner flask containing tissue culture medium, 5 µg/ml bovine insulin and 0.1 µg/ml bovine transferrin. After about four days, the conditioned media is centrifuged and filtered to remove cells and debris. The sample containing expressed PRO polypeptide can then be concentrated and purified by any selected

method, such as dialysis and/or column chromatography.

In another embodiment, PRO polypeptides can be expressed in CHO cells. The pRK5-PRO polypeptide can be transfected into CHO cells using known reagents such as CaPO<sub>4</sub> or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as <sup>35</sup>S-methionine. After determining the presence of PRO polypeptide, the culture medium may be  
5 replaced with serum free medium. Preferably, the cultures are incubated for about 6 days, and then the conditioned medium is harvested. The medium containing the expressed PRO polypeptide can then be concentrated and purified by any selected method.

Epitope-tagged PRO polypeptide may also be expressed in host CHO cells. The PRO polypeptide may be subcloned out of the pRK5 vector. The subclone insert can undergo PCR to fuse in frame with a selected epitope  
10 tag such as a poly-his tag into a Baculovirus expression vector. The poly-his tagged PRO polypeptide insert can then be subcloned into a SV40 driven vector containing a selection marker such as DHFR for selection of stable clones. Finally, the CHO cells can be transfected (as described above) with the SV40 driven vector. Labeling may be performed, as described above, to verify expression. The culture medium containing the expressed poly-His tagged  
15 PRO polypeptide can then be concentrated and purified by any selected method, such as by Ni<sup>2+</sup>-chelate affinity chromatography.

PRO211, PRO217, PRO230, PRO219, PRO245, PRO221, PRO258, PRO301, PRO224, PRO222, PRO234, PRO229, PRO223, PRO328 and PRO332 were successfully expressed in CHO cells by both a transient and a stable expression procedure. In addition, PRO232, PRO265, PRO246, PRO228, PRO227, PRO220, PRO266, PRO269,  
20 PRO287, PRO214, PRO231, PRO233, PRO238, PRO244, PRO235, PRO236, PRO262, PRO239, PRO257, PRO260, PRO263, PRO270, PRO271, PRO272, PRO294, PRO295, PRO293, PRO247, PRO303 and PRO268 were successfully transiently expressed in CHO cells.

Stable expression in CHO cells was performed using the following procedure. The proteins were expressed as an IgG construct (immunoadhesin), in which the coding sequences for the soluble forms (e.g. extracellular domains) of the respective proteins were fused to an IgG1 constant region sequence containing the hinge, CH2 and  
25 CH2 domains and/or is a poly-His tagged form.

Following PCR amplification, the respective DNAs were subcloned in a CHO expression vector using standard techniques as described in Ausubel et al., *Current Protocols of Molecular Biology*, Unit 3.16, John Wiley and Sons (1997). CHO expression vectors are constructed to have compatible restriction sites 5' and 3' of the DNA of interest to allow the convenient shuttling of cDNA's. The vector used expression in CHO cells is as described  
30 in Lucas et al., *Nucl. Acids Res.* 24: 9 (1774-1779 (1996), and uses the SV40 early promoter/enhancer to drive expression of the cDNA of interest and dihydrofolate reductase (DHFR). DHFR expression permits selection for stable maintenance of the plasmid following transfection.

Twelve micrograms of the desired plasmid DNA were introduced into approximately 10 million CHO cells using commercially available transfection reagents Superfect® (Qiagen), Dosper® or Fugene® (Boehringer Mannheim).  
35 The cells were grown and described in Lucas et al., supra. Approximately 3 x 10<sup>7</sup> cells are frozen in an ampule for further growth and production as described below.

The ampules containing the plasmid DNA were thawed by placement into water bath and mixed by vortexing. The contents were pipetted into a centrifuge tube containing 10 mLs of media and centrifuged at 1000 rpm for 5 minutes. The supernatant was aspirated and the cells were resuspended in 10 mL of selective media (0.2  $\mu$ m filtered PS20 with 5% 0.2  $\mu$ m diafiltered fetal bovine serum). The cells were then aliquoted into a 100 mL spinner containing 90 mL of selective media. After 1-2 days, the cells were transferred into a 250 mL spinner filled with 5 150 mL selective growth medium and incubated at 37°C. After another 2-3 days, a 250 mL, 500 mL and 2000 mL spinners were seeded with  $3 \times 10^5$  cells/mL. The cell media was exchanged with fresh media by centrifugation and resuspension in production medium. Although any suitable CHO media may be employed, a production medium described in US Patent No. 5,122,469, issued June 16, 1992 was actually used. 3L production spinner is seeded at 10 1.2  $\times 10^6$  cells/mL. On day 0, the cell number pH were determined. On day 1, the spinner was sampled and sparging with filtered air was commenced. On day 2, the spinner was sampled, the temperature shifted to 33°C, and 30 mL of 500 g/L glucose and 0.6 mL of 10% antifoam (e.g., 35% polydimethylsiloxane emulsion, Dow Corning 365 Medical Grade Emulsion). Throughout the production, pH was adjusted as necessary to keep at around 7.2. After 10 days, or until viability dropped below 70%, the cell culture was harvested by centrifugation and filtering through a 0.22  $\mu$ m filter. The filtrate was either stored at 4°C or immediately loaded onto columns for purification.

15 For the poly-His tagged constructs, the proteins were purified using a Ni-NTA column (Qiagen). Before purification, imidazole was added to the conditioned media to a concentration of 5 mM. The conditioned media was pumped onto a 6 ml Ni-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min. at 4°C. After loading, the column was washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein was 20 subsequently desalting into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.

25 Immunoadhesin (Fc containing) constructs were purified from the conditioned media as follows. The conditioned medium was pumped onto a 5 ml Protein A column (Pharmacia) which had been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column was washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein was immediately neutralized by collecting 1 ml fractions into tubes containing 275  $\mu$ L of 1 M Tris buffer, pH 9. The highly purified protein was subsequently desalting into storage buffer as described above for the poly-His tagged proteins. The homogeneity was assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.

PRO211, PRO217, PRO230, PRO232, PRO187, PRO265, PRO219, PRO246, PRO228, PRO533, PRO245,  
30 PRO221, PRO227, PRO220, PRO258, PRO266, PRO269, PRO287, PRO214, PRO317, PRO301, PRO224,  
PRO222, PRO234, PRO231, PRO229, PRO233, PRO238, PRO223, PRO235, PRO236, PRO262, PRO239,  
PRO257, PRO260, PRO263, PRO270, PRO271, PRO272, PRO294, PRO295, PRO293, PRO247, PRO304,  
PRO302, PRO307, PRO303, PRO343, PRO328, PRO326, PRO331, PRO332, PRO334, PRO346, PRO268,  
PRO330, PRO310 and PRO339 were also successfully transiently expressed in COS cells.

35

EXAMPLE 55: Expression of PRO Polypeptides in Yeast

The following method describes recombinant expression of a desired PRO polypeptide in yeast.

First, yeast expression vectors are constructed for intracellular production or secretion of PRO polypeptides from the ADH2/GAPDH promoter. DNA encoding a desired PRO polypeptide, a selected signal peptide and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of 5 the PRO polypeptide. For secretion, DNA encoding the PRO polypeptide can be cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, the yeast alpha-factor secretory signal/leader sequence, and linker sequences (if needed) for expression of the PRO polypeptide.

Yeast cells, such as yeast strain AB110, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The transformed yeast supernatants can be analyzed by 10 precipitation with 10% trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.

Recombinant PRO polypeptide can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters. The concentrate containing the PRO polypeptide may further be purified using selected column chromatography resins.

15

EXAMPLE 56: Expression of PRO Polypeptides in Baculovirus-Infected Insect Cells

The following method describes recombinant expression of PRO polypeptides in Baculovirus-infected insect cells.

The desired PRO polypeptide is fused upstream of an epitope tag contained with a baculovirus expression 20 vector. Such epitope tags include poly-his tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen). Briefly, the PRO polypeptide or the desired portion of the PRO polypeptide (such as the sequence encoding the extracellular domain of a transmembrane protein) is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is 25 then digested with those selected restriction enzymes and subcloned into the expression vector.

Recombinant baculovirus is generated by co-transfected the above plasmid and BaculoGold™ virus DNA (Pharmingen) into *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from GIBCO-BRL). After 4-5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications. Viral infection and protein expression is performed as described by O'Reilley et al., Baculovirus 30 expression vectors: A laboratory Manual, Oxford: Oxford University Press (1994).

Expressed poly-his tagged PRO polypeptide can then be purified, for example, by Ni<sup>2+</sup>-chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert et al., *Nature*, 362:175-179 (1993). Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 mL Hepes, pH 7.9; 12.5 mM MgCl<sub>2</sub>; 0.1 mM EDTA; 10% Glycerol; 0.1% NP-40; 0.4 M KCl), and sonicated twice for 20 35 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10% Glycerol, pH 7.8) and filtered through a 0.45 μm filter. A Ni<sup>2+</sup>-NTA agarose column (commercially available from Qiagen) is prepared with a bed volume of 5 mL, washed with 25 mL

of water and equilibrated with 25 mL of loading buffer. The filtered cell extract is loaded onto the column at 0.5 mL per minute. The column is washed to baseline  $A_{280}$  with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% Glycerol, pH 6.0), which elutes nonspecifically bound protein. After reaching  $A_{280}$  baseline again, the column is developed with a 0 to 500 mM Imidazole gradient in the secondary wash buffer. One mL fractions are collected and analyzed by 5 SDS-PAGE and silver staining or western blot with  $Ni^{2+}$ -NTA-conjugated to alkaline phosphatase (Qiagen). Fractions containing the eluted His<sub>10</sub>-tagged PRO polypeptide are pooled and dialyzed against loading buffer.

Alternatively, purification of the IgG tagged (or Fc tagged) PRO polypeptide can be performed using known chromatography techniques, including for instance, Protein A or protein G column chromatography.

PRO211, PRO217, PRO230, PRO187, PRO265, PRO246, PRO228, PRO533, PRO245, PRO221, PRO220, 10 PRO258, PRO266, PRO269, PRO287, PRO214, PRO301, PRO224, PRO222, PRO234, PRO231, PRO229, PRO235, PRO239, PRO257, PRO272, PRO294, PRO295, PRO328, PRO326, PRO331, PRO334, PRO346 and PRO310 were successfully expressed in baculovirus infected Sf9 or high5 insect cells. While the expression was actually performed in a 0.5-2 L scale, it can be readily scaled up for larger (e.g. 8 L) preparations. The proteins were expressed as an IgG construct (immunoadhesin), in which the protein extracellular region was fused to an IgG1 15 constant region sequence containing the hinge, CH2 and CH3 domains and/or in poly-His tagged forms.

Following PCR amplification, the respective coding sequences were subcloned into a baculovirus expression vector (pb.PH.IgG for IgG fusions and pb.PH.His.c for poly-His tagged proteins), and the vector and Baculogold® baculovirus DNA (Pharmingen) were co-transfected into 105 *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711), using Lipofectin (Gibco BRL). pb.PH.IgG and pb.PH.His are modifications of the commercially available 20 baculovirus expression vector pVL1393 (Pharmingen), with modified polylinker regions to include the His or Fc tag sequences. The cells were grown in Hink's TNM-FH medium supplemented with 10% FBS (Hyclone). Cells were incubated for 5 days at 28°C. The supernatant was harvested and subsequently used for the first viral amplification by infecting Sf9 cells in Hink's TNM-FH medium supplemented with 10% FBS at an approximate multiplicity of infection (MOI) of 10. Cells were incubated for 3 days at 28°C. The supernatant was harvested and the expression 25 of the constructs in the baculovirus expression vector was determined by batch binding of 1 ml of supernatant to 25 mL of Ni-NTA beads (QIAGEN) for histidine tagged proteins or Protein-A Sepharose CL-4B beads (Pharmacia) for IgG tagged proteins followed by SDS-PAGE analysis comparing to a known concentration of protein standard by Coomassie blue staining.

The first viral amplification supernatant was used to infect a spinner culture (500 ml) of Sf9 cells grown in 30 ESF-921 medium (Expression Systems LLC) at an approximate MOI of 0.1. Cells were incubated for 3 days at 28°C. The supernatant was harvested and filtered. Batch binding and SDS-PAGE analysis was repeated, as necessary, until expression of the spinner culture was confirmed.

The conditioned medium from the transfected cells (0.5 to 3 L) was harvested by centrifugation to remove the cells and filtered through 0.22 micron filters. For the poly-His tagged constructs, the protein construct were 35 purified using a Ni-NTA column (Qiagen). Before purification, imidazole was added to the conditioned media to a concentration of 5 mM. The conditioned media were pumped onto a 6 mL Ni-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 mL/min. at 4°C. After

loading, the column was washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein was subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.

Immunoadhesin (Fc containing) constructs of proteins were purified from the conditioned media as follows.

- 5 The conditioned media were pumped onto a 5 ml Protein A column (Pharmacia) which had been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column was washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein was immediately neutralized by collecting 1 ml fractions into tubes containing 275 mL of 1 M Tris buffer, pH 9. The highly purified protein was subsequently desalted into storage buffer as described above for the poly-His tagged proteins. The homogeneity of the proteins was verified by
- 10 SDS polyacrylamide gel (PEG) electrophoresis and N-terminal amino acid sequencing by Edman degradation.

**EXAMPLE 57: Preparation of Antibodies that Bind to PRO Polypeptides**

This example illustrates preparation of monoclonal antibodies which can specifically bind to a PRO polypeptide.

- 15 Techniques for producing the monoclonal antibodies are known in the art and are described, for instance, in Goding, *supra*. Immunogens that may be employed include purified PRO polypeptide, fusion proteins containing the PRO polypeptide, and cells expressing recombinant PRO polypeptide on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.

Mice, such as Balb/c, are immunized with the PRO polypeptide immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms. Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA assays to detect anti-PRO polypeptide antibodies.

After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with a final intravenous injection of PRO polypeptide. Three to four days later, the mice are sacrificed and the spleen cells are harvested. The spleen cells are then fused (using 35% polyethylene glycol) to a selected murine myeloma cell line such as P3X63AgU.1, available from ATCC, No. CRL 1597. The fusions generate hybridoma cells which can then be plated in 96 well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.

The hybridoma cells will be screened in an ELISA for reactivity against the PRO polypeptide. Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against the PRO polypeptide is within the skill in the art.

- 35 The positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to produce ascites containing the anti-PRO polypeptide monoclonal antibodies. Alternatively, the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished

using ammonium sulfate precipitation, followed by gel exclusion chromatography. Alternatively, affinity chromatography based upon binding of antibody to protein A or protein G can be employed.

**EXAMPLE 58: Chimeric PRO Polypeptides**

PRO polypeptides may be expressed as chimeric proteins with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS™ extension/affinity purification system (Immunex Corp., Seattle Wash.). The inclusion of a cleavable linker sequence such as Factor XA or enterokinase (Invitrogen, San Diego Calif.) between the purification domain and the PRO polypeptide sequence may be useful to facilitate expression of DNA encoding the PRO polypeptide.

**EXAMPLE 59: Purification of PRO Polypeptides Using Specific Antibodies**

Native or recombinant PRO polypeptides may be purified by a variety of standard techniques in the art of protein purification. For example, pro-PRO polypeptide, mature PRO polypeptide, or pre-PRO polypeptide is purified by immunoaffinity chromatography using antibodies specific for the PRO polypeptide of interest. In general, an immunoaffinity column is constructed by covalently coupling the anti-PRO polypeptide antibody to an activated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway, N.J.). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated SEPHAROSE™ (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

Such an immunoaffinity column is utilized in the purification of PRO polypeptide by preparing a fraction from cells containing PRO polypeptide in a soluble form. This preparation is derived by solubilization of the whole cell or of a subcellular fraction obtained via differential centrifugation by the addition of detergent or by other methods well known in the art. Alternatively, soluble PRO polypeptide containing a signal sequence may be secreted in useful quantity into the medium in which the cells are grown.

A soluble PRO polypeptide-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PRO polypeptide (*e.g.*, high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt antibody/PRO polypeptide binding (*e.g.*, a low pH buffer such as approximately pH 2-3, or a high concentration of a chaotrope such as urea or thiocyanate ion), and PRO polypeptide is collected.

**35 EXAMPLE 60: Drug Screening**

This invention is particularly useful for screening compounds by using PRO polypeptides or binding fragment thereof in any of a variety of drug screening techniques. The PRO polypeptide or fragment employed in

such a test may either be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the PRO polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between PRO polypeptide or a fragment and the agent being tested. Alternatively, one can examine the diminution in complex formation between the PRO polypeptide and its target cell or target receptors caused by the agent being tested.

Thus, the present invention provides methods of screening for drugs or any other agents which can affect a PRO polypeptide-associated disease or disorder. These methods comprise contacting such an agent with an PRO polypeptide or fragment thereof and assaying (I) for the presence of a complex between the agent and the PRO polypeptide or fragment, or (ii) for the presence of a complex between the PRO polypeptide or fragment and the cell, by methods well known in the art. In such competitive binding assays, the PRO polypeptide or fragment is typically labeled. After suitable incubation, free PRO polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to PRO polypeptide or to interfere with the PRO polypeptide/cell complex.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to a polypeptide and is described in detail in WO 84/03564, published on September 13, 1984. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. As applied to a PRO polypeptide, the peptide test compounds are reacted with PRO polypeptide and washed. Bound PRO polypeptide is detected by methods well known in the art. Purified PRO polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies can be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding PRO polypeptide specifically compete with a test compound for binding to PRO polypeptide or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PRO polypeptide.

#### EXAMPLE 61: Rational Drug Design

The goal of rational drug design is to produce structural analogs of biologically active polypeptide of interest (*i.e.*, a PRO polypeptide) or of small molecules with which they interact, *e.g.*, agonists, antagonists, or inhibitors. Any of these examples can be used to fashion drugs which are more active or stable forms of the PRO polypeptide or which enhance or interfere with the function of the PRO polypeptide *in vivo* (*c.f.*, Hodgson, *Bio/Technology*, 9: 19-21 (1991)).

In one approach, the three-dimensional structure of the PRO polypeptide, or of an PRO polypeptide-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the PRO polypeptide must be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful information regarding the structure of the PRO polypeptide may be gained by modeling based on the structure of homologous proteins. In both cases, relevant

structural information is used to design analogous PRO polypeptide-like molecules or to identify efficient inhibitors. Useful examples of rational drug design may include molecules which have improved activity or stability as shown by Braxton and Wells, *Biochemistry*, 31:7796-7801 (1992) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda *et al.*, *J. Biochem.*, 113:742-746 (1993).

It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and  
5 then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids would be expected to be an analog of the original receptor. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides would then  
10 act as the pharmacore.

By virtue of the present invention, sufficient amounts of the PRO polypeptide may be made available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the PRO polypeptide amino acid sequence provided herein will provide guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.

15

#### EXAMPLE 62: Diagnostic Test Using PRO317 Polypeptide-Specific Antibodies

Particular anti-PRO317 polypeptide antibodies are useful for the diagnosis of prepathologic conditions, and chronic or acute diseases such as gynecological diseases or ischemic diseases which are characterized by differences in the amount or distribution of PRO317. PRO317 has been found to be expressed in human kidney and is thus likely  
20 to be associated with abnormalities or pathologies which affect this organ. Further, since it is so closely related to EBAF-1, it is likely to affect the endometrium and other genital tissues. Further, due to library sources of certain ESTs, it appears that PRO317 may be involved as well in forming blood vessels and hence to be a modulator of angiogenesis.

Diagnostic tests for PRO317 include methods utilizing the antibody and a label to detect PRO317 in human  
25 body fluids, tissues, or extracts of such tissues. The polypeptide and antibodies of the present invention may be used with or without modification. Frequently, the polypeptide and antibodies will be labeled by joining them, either covalently or noncovalently, with a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and have been reported extensively in both the scientific and patent literature. Suitable labels include radiomuclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent  
30 agents, magnetic particles, and the like. Patents teaching the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced as shown in U.S. Pat. No. 4,816,567.

A variety of protocols for measuring soluble or membrane-bound PRo317, using either polyclonal or monoclonal antibodies specific for that PRO317, are known in the art. Examples include enzyme-linked  
35 immunosorbent assay (ELISA), radioimmunoassay (RIA), radioreceptor assay (RRA), and fluorescent activated cell sorting (FACS). A two-site monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on PRO317 is preferred, but a competitive binding assay may be employed. These assays

are described, among other places, in Maddox *et al.* J. Exp. Med., 158:1211 (1983).

**EXAMPLE 63: Identification of PRO317 Receptors**

Purified PRO317 is useful for characterization and purification of specific cell surface receptors and other binding molecules. Cells which respond to PRO317 by metabolic changes or other specific responses are likely to express a receptor for PRO317. Such receptors include, but are not limited to, receptors associated with and activated by tyrosine and serine/threonine kinases. See Kolodziejczyk and Hall, *supra*, for a review on known receptors for the TGF- superfamily. Candidate receptors for this superfamily fall into two primary groups, termed type I and type II receptors. Both types are serine/threonine kinases. Upon activation by the appropriate ligand, type I and type II receptors physically interact to form hetero-oligomers and subsequently activate intracellular signaling cascades, ultimately regulating gene transcription and expression. In addition, TGF- binds to a third receptor class, type III, a membrane-anchored proteoglycan lacking the kinase activity typical of signal transducing molecules.

PRO317 receptors or other PRO317-binding molecules may be identified by interaction with radiolabeled PRO317. Radioactive labels may be incorporated into PRO317 by various methods known in the art. A preferred embodiment is the labeling of primary amino groups in PRO317 with <sup>125</sup>I Bolton-Hunter reagent (Bolton and Hunter, Biochem. J., 133:529 (1973)), which has been used to label other polypeptides without concomitant loss of biological activity (Hebert *et al.*, J. Biol. Chem., 266:18989 (1991); McColl *et al.*, J. Immunol., 150:4550-4555 (1993)). Receptor-bearing cells are incubated with labeled PRO317. The cells are then washed to remove unbound PRO317, and receptor-bound PRO317 is quantified. The data obtained using different concentrations of PRO317 are used to calculate values for the number and affinity of receptors.

Labeled PRO317 is useful as a reagent for purification of its specific receptor. In one embodiment of affinity purification, PRO317 is covalently coupled to a chromatography column. Receptor-bearing cells are extracted, and the extract is passed over the column. The receptor binds to the column by virtue of its biological affinity for PRO317. The receptor is recovered from the column and subjected to N-terminal protein sequencing. This amino acid sequence is then used to design degenerate oligonucleotide probes for cloning the receptor gene.

In an alternative method, mRNA is obtained from receptor-bearing cells and made into a cDNA library. The library is transfected into a population of cells, and those cells expressing the receptor are selected using fluorescently labeled PRO317. The receptor is identified by recovering and sequencing recombinant DNA from highly labeled cells.

In another alternative method, antibodies are raised against the surface of receptor bearing cells, specifically monoclonal antibodies. The monoclonal antibodies are screened to identify those which inhibit the binding of labeled PRO317. These monoclonal antibodies are then used in affinity purification or expression cloning of the receptor.

Soluble receptors or other soluble binding molecules are identified in a similar manner. Labeled PRO317 is incubated with extracts or other appropriate materials derived from the uterus. After incubation, PRO317 complexes larger than the size of purified PRO317 are identified by a sizing technique such as size-exclusion chromatography or density gradient centrifugation and are purified by methods known in the art. The soluble receptors or binding protein(s) are subjected to N-terminal sequencing to obtain information sufficient for database identification, if the soluble protein is known, or for cloning, if the soluble protein is unknown.

EXAMPLE 64: Determination of PRO317-Induced Cellular Response

The biological activity of PRO317 is measured, for example, by binding of an PRO317 of the invention to an PRO317 receptor. A test compound is screened as an antagonist for its ability to block binding of PRO317 to the receptor. A test compound is screened as an agonist of the PRO317 for its ability to bind an PRO317 receptor and influence the same physiological events as PRO317 using, for example, the KIRA-ELISA assay described by Sadick <sup>5</sup> et al., *Analytical Biochemistry*, 235:207-214 (1996) in which activation of a receptor tyrosine kinase is monitored by immuno-capture of the activated receptor and quantitation of the level of ligand-induced phosphorylation. The assay may be adapted to monitor PRO317-induced receptor activation through the use of an PRO317 receptor-specific antibody to capture the activated receptor. These techniques are also applicable to other PRO polypeptides described herein.

10

EXAMPLE 65: Use of PRO224 for Screening Compounds

PRO224 is expressed in a cell stripped of membrane proteins and capable of expressing PRO224. Low density lipoproteins having a detectable label are added to the cells and incubated for a sufficient time for endocytosis. The cells are washed. The cells are then analysed for label bound to the membrane and within the cell after cell lysis. <sup>15</sup> Detection of the low density lipoproteins within the cell determines that PRO224 is within the family of low density lipoprotein receptor proteins. Members found within this family are then used for screening compounds which affect these receptors, and particularly the uptake of cholesterol via these receptors.

20 EXAMPLE 66: Ability of PRO Polypeptides to Inhibit Vascular Endothelial Growth Factor (VEGF) Stimulated Proliferation of Endothelial Cell Growth

The ability of various PRO polypeptides to inhibit VEGF stimulated proliferation of endothelial cells was tested. Specifically, bovine adrenal cortical capillary endothelial (ACE) cells (from primary culture, maximum 12-14 passages) were plated on 96-well microtiter plates (Amersham Life Science) at a density of 500 cells/well per 100  $\mu$ L in low glucose DMEM, 10% calf serum, 2 mM glutamine, 1x pen/strept and fungizone, supplemented with 3 <sup>25</sup> ng/mL VEGF. Controls were plated the same way but some did not include VEGF. A test sample of the PRO polypeptide of interest was added in a 100  $\mu$ L volume for a 200  $\mu$ L final volume. Cells were incubated for 6-7 days at 37°C. The media was aspirated and the cells washed 1x with PBS. An acid phosphatase reaction mixture (100  $\mu$ L, 0.1M sodium acetate, pH 5.5, 0.1% Triton-100, 10 mM p-nitrophenyl phosphate) was added. After incubation for 2 hours at 37°C, the reaction was stopped by addition of 10  $\mu$ L 1N NaOH. OD was measured on microtiter plate reader at 405 nm. Controls were no cells, cells alone, cells + FGF (5 ng/mL), cells + VEGF (3 ng/mL), cells + <sup>30</sup> VEGF (3 ng/ml) + TGF- $\beta$  (1 ng/ml), and cells + VEGF (3ng/mL) + LIF (5 ng/mL). (TGF- $\beta$  at a 1 ng/ml concentration is known to block 70-90% of VEGF stimulated cell proliferation.)

The results were assessed by calculating the percentage inhibition of VEGF (3 ng/ml) stimulated cells proliferation, determined by measuring acid phosphatase activity at OD405 nm, (1) relative to cells without stimulation, and (2) relative to the reference TGF- $\beta$  inhibition of VEGF stimulated activity. The results, as shown in Table 2 below, are indicative of the utility of the PRO polypeptides in cancer therapy and specifically in inhibiting tumor angiogenesis. The numerical values (relative inhibition) shown in Table 2 are determined by calculating the

percent inhibition of VEGF stimulated proliferation by the PRO polypeptide relative to cells without stimulation and then dividing that percentage into the percent inhibition obtained by TGF- $\beta$  at 1 ng/ml which is known to block 70-90% of VEGF stimulated cell proliferation.

Table 2

	<u>PRO Name</u>	<u>PRO Concentration</u>	<u>Relative Inhibition</u>
5	PRO211	0.01 %	99.0
	PRO211	0.01 %	1.09
	PRO211	0.1 %	0.95
	PRO211	0.1 %	67.0
10	PRO211	1.0 %	0.27
	PRO211	1.0 %	20.0
	PRO217	0.01 %	1.06
	PRO217	0.1 %	0.84
	PRO217	1.0 %	0.39
15	PRO217	2.5 $\mu$ M	0.2
	PRO217	25 nM	0.88
	PRO217	250 nM	0.58
	PRO187	0.01 %	0.91
	PRO187	0.1 %	0.82
20	PRO187	1.0 %	0.44
	PRO219	5.7 $\mu$ M	0.61
	PRO219	57 nM	1.09
	PRO219	570 nM	0.97
	PRO246	0.01 %	1.04
25	PRO246	0.1 %	1.0
	PRO246	1.0 %	0.49
	PRO228	0.01 %	0.99
	PRO228	0.1 %	0.93
	PRO228	1.0 %	0.57
30	PRO228	0.01 %	0.95
	PRO228	0.01 %	0.98
	PRO228	0.1 %	0.77
	PRO228	0.1 %	0.88
	PRO228	1.0 %	0.16
35	PRO228	1.0 %	0.48
	PRO245	0.01 %	0.76
	PRO245	0.1 %	0.35
	PRO245	1.0 %	0.11
	PRO245	0.48 nM	1.03
40	PRO245	4.8 nM	0.95
	PRO245	48 nM	0.49
	PRO221	0.01 %	1.03
	PRO221	0.01 %	1.06
	PRO221	0.1 %	0.82
45	PRO221	0.1 %	0.93
	PRO221	1.0 %	0.31
	PRO221	1.0 %	0.43
	PRO258	0.01 %	0.98
	PRO258	0.01 %	1.06
50	PRO258	0.1 %	0.95
	PRO258	0.1 %	1.02
	PRO258	1.0 %	0.6
	PRO258	1.0 %	0.69

Table 2 cont'

<u>PRO Name</u>	<u>PRO Concentration</u>	<u>Relative Inhibition</u>
PRO301	7.0 $\mu$ M	1.02
PRO301	70 $\mu$ M	0.88
5 PRO301	700 $\mu$ M	0.44
PRO301	0.01%	0.92
PRO301	0.1%	0.85
PRO301	1.0%	0.68
10 PRO224	0.01%	101.0
PRO224	0.1%	65.0
PRO224	1.0%	23.0
PRO272	0.01%	0.95
PRO272	0.1%	0.57
15 PRO272	1.0%	0.18
PRO328	0.01%	0.98
PRO328	0.1%	0.96
PRO328	1.0%	0.6
PRO331	0.01%	0.88
PRO331	0.1%	0.82
20 PRO331	1.0%	0.56

EXAMPLE 67: Retinal Neuron Survival

This example demonstrates that PRO220 polypeptides have efficacy in enhancing the survival of retinal neuron cells.

25 Sprague Dawley rat pups at postnatal day 7 (mixed population: glia and retinal neuronal types) are killed by decapitation following CO<sub>2</sub> anesthesia and the eyes are removed under sterile conditions. The neural retina is dissected away from the pigment epithelium and other ocular tissue and then dissociated into a single cell suspension using 0.25% trypsin in Ca<sup>2+</sup>, Mg<sup>2+</sup>-free PBS. The retinas are incubated at 37°C for 7-10 minutes after which the trypsin is inactivated by adding 1 ml soybean trypsin inhibitor. The cells are plated at 100,000 cells per well in 96  
30 well plates in DMEM/F12 supplemented with N2 and with or without the specific test PRO polypeptide. Cells for all experiments are grown at 37°C in a water saturated atmosphere of 5% CO<sub>2</sub>. After 2-3 days in culture, cells are stained with calcein AM then fixed using 4% paraformaldehyde and stained with DAPI for determination of total cell count. The total cells (fluorescent) are quantified at 20X objective magnification using CCD camera and NIH image software for MacIntosh. Fields in the well are chosen at random.

35 The effect of various concentration of PRO220 polypeptides are reported in Table 3 below where percent survival is calculated by dividing the total number of calcein AM positive cells at 2-3 days in culture by the total number of DAPI-labeled cells at 2-3 days in culture. Anything above 30% survival is considered positive.

Table 3

	<u>PRO Name</u>	<u>PRO Concentration</u>	<u>Percent Survival</u>
40	PRO220	0.01%	2.4%
	PRO220	0.01%	4.1%
	PRO220	0.1%	3.0%
	PRO220	0.1%	3.1%
45	PRO220	1.0%	72.4%
	PRO220	1.0%	42.1%

EXAMPLE 68: Rod Photoreceptor Survival

This example demonstrates that PRO220 polypeptides have efficacy in enhancing the survival of rod photoreceptor cells.

Sprague Dawley rat pups at 7 day postnatal (mixed population: glia and retinal neuronal cell types) are killed by decapitation following CO<sub>2</sub> anesthesia and the eyes are removed under sterile conditions. The neural retina is dissected away from the pigment epithelium and other ocular tissue and then dissociated into a single cell suspension using 0.25% trypsin in Ca<sup>2+</sup>, Mg<sup>2+</sup>-free PBS. The retinas are incubated at 37°C for 7-10 minutes after which the trypsin is inactivated by adding 1 ml soybean trypsin inhibitor. The cells are plated at 100,000 cells per well in 96 well plates in DMEM/F12 supplemented with N2 and with or without the specific test PRO polypeptide. Cells for all experiments are grown at 37°C in a water saturated atmosphere of 5% CO<sub>2</sub>. After 2-3 days in culture, cells are fixed using 4% paraformaldehyde, and then stained using CellTracker Green CMFDA. Rho 4D2 (ascites or IgG 1:100), a monoclonal antibody directed towards the visual pigment rhodopsin is used to detect rod photoreceptor cells by indirect immunofluorescence. The results are reported as % survival: total number of calcein/CellTracker - rhodopsin positive cells at 2-3 days in culture, divided by the total number of rhodopsin positive cells at time 2-3 days in culture. The total cells (fluorescent) are quantified at 20x objective magnification using a CCD camera and NIH image software for MacIntosh. Fields in the well are chosen at random.

The effect of various concentration of PRO220 polypeptides are reported in Table 4 below. Anything above 10% survival is considered positive..

Table 4

	<u>PRO Name</u>	<u>PRO Concentration</u>	<u>Percent Survival</u>
	PRO220	0.01%	0.0%
	PRO220	0.1%	0.0%
	PRO220	2.0%	0.0%
	PRO220	10%	0.0%
25	PRO220	20%	66.9%
	PRO220	1.0%	56.9%

EXAMPLE 69: Induction of Endothelial Cell Apoptosis

The ability of PRO228 polypeptides to induce apoptosis in endothelial cells was tested in human venous umbilical vein endothelial cells (HUVEC, Cell Systems), using a 96-well format, in 0% serum media supplemented with 100 ng/ml VEGF. (As HUVEC cells are easily dislodged from the plating surface, all pipetting in the wells must be done as gently as practicable.)

The media was aspirated and the cells washed once with PBS. 5 ml of 1 x trypsin was added to the cells in a T-175 flask, and the cells were allowed to stand until they were released from the plate (about 5-10 minutes). Trypsinization was stopped by adding 5 ml of growth media. The cells were spun at 1000 rpm for 5 minutes at 4°C. The media was aspirated and the cells were resuspended in 10 ml of 10% serum complemented medium (Cell Systems), 1 x penn/strep.

The cells were plated on 96-well microtiter plates (Amersham Life Science, cytostar-T scintillating microplate, RPNQ160, sterile, tissue-culture treated, individually wrapped), in 10% serum (CSG-medium, Cell

Systems), at a density of  $2 \times 10^4$  cells per well in a total volume of 100  $\mu\text{l}$ . The PRO228 polypeptide was added in triplicate at dilutions of 1%, 0.33% and 0.11%. Wells without cells were used as a blank and wells with cells only as a negative control. As a positive control 1:3 serial dilutions of 50  $\mu\text{l}$  of a 3x stock of staurosporine were used. The ability of the PRO228 polypeptide to induce apoptosis was determined using Annexin V, a member of the calcium and phospholipid binding proteins, to detect apoptosis.

5        0.2 ml Annexin V - Biotin stock solution (100  $\mu\text{g}/\text{ml}$ ) were diluted in 4.6 ml 2 x  $\text{Ca}^{2+}$  binding buffer and 2.5% BSA (1:25 dilution). 50  $\mu\text{l}$ s of the diluted Annexin V - Biotin solution were added to each well (except controls) to a final concentration of 1.0  $\mu\text{g}/\text{ml}$ . The samples were incubated for 10-15 minutes with Annexin-Biotin prior to direct addition of  $^{35}\text{S}$ -Streptavidin.  $^{35}\text{S}$ -Streptavidin was diluted in 2x  $\text{Ca}^{2+}$  binding buffer, 2.5% BSA and was added to all wells at a final concentration of  $3 \times 10^4$  cpm/well. The plates were then sealed, centrifuged at 1000 rpm for 15 minutes and placed on orbital shaker for 2 hours. The analysis was performed on 1450 Microbeta Trilux (Wallac). The results are shown in Table 5 below where percent above background represents the percentage amount of counts per minute above the negative controls. Percents greater than or equal to 30% above background are considered positive.

15

Table 5

<u>PRO Name</u>	<u>PRO Concentration</u>	<u>Percent Above Background</u>
PRO228	0.11%	0.7%
PRO228	0.11%	47.6%
PRO228	0.33%	92.2%
20      PRO228	0.33%	123.7%
PRO228	1.0%	51.4%
PRO228	1.0%	95.3%

EXAMPLE 70: PDB12 Cell Inhibition

25        This example demonstrates that various PRO polypeptides have efficacy in inhibiting protein production by PDB12 pancreatic ductal cells.

PDB12 pancreatic ductal cells are plated on fibronectin coated 96 well plates at  $1.5 \times 10^3$  cells per well in 100  $\mu\text{L}/180 \mu\text{L}$  of growth media. 100  $\mu\text{L}$  of growth media with the PRO polypeptide test sample or negative control lacking the PRO polypeptide is then added to well, for a final volume of 200  $\mu\text{L}$ . Controls contain growth medium containing a protein shown to be inactive in this assay. Cells are incubated for 4 days at 37°C. 20  $\mu\text{L}$  of Alamar Blue Dye (AB) is then added to each well and the fluorescent reading is measured at 4 hours post addition of AB, on a microtiter plate reader at 530 nm excitation and 590 nm emission. The standard employed is cells without Bovine Pituitary Extract (BPE) and with various concentrations of BPE. Buffer or CM controls from unknowns are run 2 times on each 96 well plate.

35        The results from these assays are shown in Table 6 below wherein percent decrease in protein production is calculated by comparing the Alamar Blue Dye calculated protein concentration produced by the PRO polypeptide-treated cells with the Alamar Blue Dye calculated protein concentration produced by the negative control cells. A percent decrease in protein production of greater than or equal to 25% as compared to the negative control cells is considered positive.

Table 6

<u>PRO Name</u>	<u>PRO Concentration</u>	<u>Percent Decrease in Protein Production</u>
PRO211	0.1%	0.0%
PRO211	0.01%	0.6%
PRO211	1.0%	59.7%
5 PRO287	2.0%	22.3%
PRO287	10%	18.2%
PRO287	50%	67.5%
PRO287	2.0%	45.53%
PRO287	10%	57.3%
10 PRO287	50%	52.24%
PRO301	2.0%	0.0%
PRO301	10%	59.8%
PRO301	50%	65.6%
PRO293	2.0%	0.0%
15 PRO293	10%	40.4%
PRO293	50%	56.7%

EXAMPLE 71: Stimulation of Adult Heart Hypertrophy

This assay is designed to measure the ability of various PRO polypeptides to stimulate hypertrophy of adult heart.

Ventricular myocytes freshly isolated from adult (250g) Sprague Dawley rats are plated at 2000 cell/well in 180  $\mu$ l volume. Cells are isolated and plated on day 1, the PRO polypeptide-containing test samples or growth medium only (negative control) (20  $\mu$ l volume) is added on day 2 and the cells are then fixed and stained on day 5. After staining, cell size is visualized wherein cells showing no growth enhancement as compared to control cells are given a value of 0.0, cells showing small to moderate growth enhancement as compared to control cells are given a value of 1.0 and cells showing large growth enhancement as compared to control cells are given a value of 2.0. Any degree of growth enhancement as compared to the negative control cells is considered positive for the assay. The results are shown in Table 7 below.

30

Table 7

<u>PRO Name</u>	<u>PRO Concentration</u>	<u>Growth Enhancement Score</u>
PRO287	20%	1.0
PRO287	20%	1.0
PRO301	20%	1.0
35 PRO301	20%	1.0
PRO293	20%	1.0
PRO293	20%	1.0
PRO303	20%	1.0
PRO303	20%	1.0

40

EXAMPLE 72: PDB12 Cell Proliferation

This example demonstrates that various PRO polypeptides have efficacy in inducing proliferation of PDB12 pancreatic ductal cells.

PDB12 pancreatic ductal cells are plated on fibronectin coated 96 well plates at  $1.5 \times 10^3$  cells per well in 100  $\mu$ L/180  $\mu$ L of growth media. 100  $\mu$ L of growth media with the PRO polypeptide test sample or negative control

lacking the PRO polypeptide is then added to well, for a final volume of 200  $\mu$ L. Controls contain growth medium containing a protein shown to be inactive in this assay. Cells are incubated for 4 days at 37°C. 20  $\mu$ L of Alamar Blue Dye (AB) is then added to each well and the fluorescent reading is measured at 4 hours post addition of AB, on a microtiter plate reader at 530 nm excitation and 590 nm emission. The standard employed is cells without Bovine Pituitary Extract (BPE) and with various concentrations of BPE. Buffer or growth medium only controls from unknowns are run 2 times on each 96 well plate.

The results from these assays are shown in Table 8 below wherein percent increase in protein production is calculated by comparing the Alamar Blue Dye calculated protein concentration produced by the PRO polypeptide-treated cells with the Alamar Blue Dye calculated protein concentration produced by the negative control cells. A percent increase in protein production of greater than or equal to 25% as compared to the negative control cells is considered positive.

Table 8

<u>PRO Name</u>	<u>PRO Concentration</u>	<u>Percent Increase in Protein Production</u>
PRO301	2.0%	44.0%
PRO301	10%	67.4%
PRO301	50%	185.8%
PRO303	2.0%	27.9%
PRO303	10%	174.9%
PRO303	50%	193.1%

EXAMPLE 73: Enhancement of Heart Neonatal Hypertrophy Induced by PRO224

This assay is designed to measure the ability of PRO224 polypeptides to stimulate hypertrophy of neonatal heart.

Cardiac myocytes from 1-day old Harlan Sprague Dawley rats were obtained. Cells (180  $\mu$ l at  $7.5 \times 10^4$ /ml, serum <0.1%, freshly isolated) are added on day 1 to 96-well plates previously coated with DMEM/F12 + 4% FCS. Test samples containing the test PRO224 polypeptide or growth medium only (negative control) (20  $\mu$ l/well) are added directly to the wells on day 1. PGF (20  $\mu$ l/well) is then added on day 2 at final concentration of  $10^{-6}$  M. The cells are then stained on day 4 and visually scored on day 5, wherein cells showing no increase in size as compared to negative controls are scored 0.0, cells showing a small to moderate increase in size as compared to negative controls are scored 1.0 and cells showing a large increase in size as compared to negative controls are scored 2.0. The results are shown in Table 9 below.

Table 9

<u>PRO Name</u>	<u>PRO Concentration</u>	<u>Growth Enhancement Score</u>
PRO224	0.01%	0.0
PRO224	0.1%	0.0
PRO224	1.0%	1.0

EXAMPLE 74: In situ Hybridization

*In situ* hybridization is a powerful and versatile technique for the detection and localization of nucleic acid sequences within cell or tissue preparations. It may be useful, for example, to identify sites of gene expression,

analyze the tissue distribution of transcription, identify and localize viral infection, follow changes in specific mRNA synthesis and aid in chromosome mapping.

5 *In situ* hybridization was performed following an optimized version of the protocol by Lu and Gillett, Cell Vision 1:169-176 (1994), using PCR-generated  $^{33}\text{P}$ -labeled riboprobes. Briefly, formalin-fixed, paraffin-embedded human tissues were sectioned, deparaffinized, deproteinated in proteinase K (20 g/ml) for 15 minutes at 37°C, and further processed for *in situ* hybridization as described by Lu and Gillett, *supra*. A [ $^{33}\text{P}$ ] UTP-labeled antisense riboprobe was generated from a PCR product and hybridized at 55°C overnight. The slides were dipped in Kodak NTB2 nuclear track emulsion and exposed for 4 weeks.

#### $^{33}\text{P}$ -Riboprobe synthesis

10 6.0  $\mu\text{l}$  (125 mCi) of  $^{33}\text{P}$ -UTP (Amersham BF 1002, SA <2000 Ci/mmol) were speed vac dried. To each tube containing dried  $^{33}\text{P}$ -UTP, the following ingredients were added:

15 2.0  $\mu\text{l}$  5x transcription buffer  
1.0  $\mu\text{l}$  DTT (100 mM)  
2.0  $\mu\text{l}$  NTP mix (2.5 mM : 10  $\mu\text{l}$ ; each of 10 mM GTP, CTP & ATP + 10  $\mu\text{l}$  H<sub>2</sub>O)  
1.0  $\mu\text{l}$  UTP (50  $\mu\text{M}$ )  
1.0  $\mu\text{l}$  Rnasin  
1.0  $\mu\text{l}$  DNA template (1  $\mu\text{g}$ )  
1.0  $\mu\text{l}$  H<sub>2</sub>O  
1.0  $\mu\text{l}$  RNA polymerase (for PCR products T3 = AS, T7 = S, usually)

20 The tubes were incubated at 37°C for one hour. 1.0  $\mu\text{l}$  RQ1 DNase were added, followed by incubation at 37°C for 15 minutes. 90  $\mu\text{l}$  TE (10 mM Tris pH 7.6/1mM EDTA pH 8.0) were added, and the mixture was pipetted onto DE81 paper. The remaining solution was loaded in a Microcon-50 ultrafiltration unit, and spun using program 10 (6 minutes). The filtration unit was inverted over a second tube and spun using program 2 (3 minutes). After the final recovery spin, 100  $\mu\text{l}$  TE were added. 1  $\mu\text{l}$  of the final product was pipetted on DE81 paper and counted in 6 ml of Biofluor II.

25 The probe was run on a TBE/urea gel. 1-3  $\mu\text{l}$  of the probe or 5  $\mu\text{l}$  of RNA Mrk III were added to 3  $\mu\text{l}$  of loading buffer. After heating on a 95°C heat block for three minutes, the gel was immediately placed on ice. The wells of gel were flushed, the sample loaded, and run at 180-250 volts for 45 minutes. The gel was wrapped in saran wrap and exposed to XAR film with an intensifying screen in -70°C freezer one hour to overnight.

#### $^{33}\text{P}$ -Hybridization

30 A. Pretreatment of frozen sections

The slides were removed from the freezer, placed on aluminium trays and thawed at room temperature for 5 minutes. The trays were placed in 55°C incubator for five minutes to reduce condensation. The slides were fixed for 10 minutes in 4% paraformaldehyde on ice in the fume hood, and washed in 0.5 x SSC for 5 minutes, at room temperature (25 ml 20 x SSC + 975 ml SQ H<sub>2</sub>O). After deproteination in 0.5  $\mu\text{g}/\text{ml}$  proteinase K for 10 minutes 35 at 37°C (12.5  $\mu\text{l}$  of 10 mg/ml stock in 250 ml prewarmed RNase-free RNase buffer), the sections were washed in 0.5 x SSC for 10 minutes at room temperature. The sections were dehydrated in 70%, 95%, 100% ethanol, 2 minutes each.

5       B.     Pretreatment of paraffin-embedded sections

The slides were deparaffinized, placed in SQ H<sub>2</sub>O, and rinsed twice in 2 x SSC at room temperature, for 5 minutes each time. The sections were deproteinized in 20 µg/ml proteinase K (500 µl of 10 mg/ml in 250 ml RNase-free RNase buffer; 37°C, 15 minutes) - human embryo, or 8 x proteinase K (100 µl in 250 ml RNase buffer, 37°C, 30 minutes) - formalin tissues. Subsequent rinsing in 0.5 x SSC and dehydration were performed as described above.

5       C.     Prehybridization

The slides were laid out in a plastic box lined with Box buffer (4 x SSC, 50% formamide) - saturated filter paper. The tissue was covered with 50 µl of hybridization buffer (3.75g Dextran Sulfate + 6 ml SQ H<sub>2</sub>O), vortexed and heated in the microwave for 2 minutes with the cap loosened. After cooling on ice, 18.75 ml formamide, 3.75 ml 20 x SSC and 9 ml SQ H<sub>2</sub>O were added, the tissue was vortexed well, and incubated at 42°C for 1-4 hours.

10      D.     Hybridization

1.0 x 10<sup>6</sup> cpm probe and 1.0 µl tRNA (50 mg/ml stock) per slide were heated at 95°C for 3 minutes. The slides were cooled on ice, and 48 µl hybridization buffer were added per slide. After vortexing, 50 µl <sup>33</sup>P mix were added to 50 µl prehybridization on slide. The slides were incubated overnight at 55°C.

15      E.     Washes

Washing was done 2 x 10 minutes with 2xSSC, EDTA at room temperature (400 ml 20 x SSC + 16 ml 0.25M EDTA, V<sub>f</sub>=4L), followed by RNaseA treatment at 37°C for 30 minutes (500 µl of 10 mg/ml in 250 ml RNase buffer = 20 µg/ml). The slides were washed 2 x 10 minutes with 2 x SSC, EDTA at room temperature. The stringency wash conditions were as follows: 2 hours at 55°C, 0.1 x SSC, EDTA (20 ml 20 x SSC + 16 ml EDTA, V<sub>f</sub>=4L).

20      F.     Oligonucleotides

*In situ* analysis was performed on a variety of DNA sequences disclosed herein. The oligonucleotides employed for these analyses are as follows.

(1)     DNA33094-1131 (PRO217)

25    p1    5'-GGATTCTAACGACTCACTATAGGGCTCAGAAAAGCGAACAGAGAA-3' (SEQ ID NO:348)  
p2    5'-CTATGAAATTAAACCCTCACTAAAGGGATGTCTCCATGCCAACCTTC-3' (SEQ ID NO:349)

(2)     DNA33223-1136 (PRO230)

p1    5'-GGATTCTAACGACTCACTATAGGCAGCGATGTCCACTGGGCTAC-3' (SEQ ID NO:350)  
30    p2    5'-CTATGAAATTAAACCCTCACTAAAGGGACGAGGAAGATGGCGGATGGT-3' (SEQ ID NO:351)

(3)     DNA34435-1140 (PRO232)

p1    5'-GGATTCTAACGACTCACTATAGGCACCCACGCGTCCGGCTGCTT-3' (SEQ ID NO:352)  
p2    5'-CTATGAAATTAAACCCTCACTAAAGGGACGGGGACACCACGGACCAGA-3' (SEQ ID NO:353)

(4) DNA35639-1172 (PRO246)

p1 5'-GGATTCTAATACGACTCACTATAGGGCTTGCTGCCGTTTGTTCCTG-3' (SEQ ID NO:354)  
 p2 5'-CTATGAAATTAAACCCTCACTAAAGGGAGCTGCCATCCCCTGGTATT-3' (SEQ ID NO:355)

(5) DNA49435-1219 (PRO533)

5 p1 5'-GGATTCTAATACGACTCACTATAGGGCGGATCCTGGCCGGCCTCTG-3' (SEQ ID NO:356)  
 p2 5'-CTATGAAATTAAACCCTCACTAAAGGGAGCCGGCATGGTCTCAGTTA-3' (SEQ ID NO:357)

(6) DNA35638-1141 (PRO245)

10 p1 5'-GGATTCTAATACGACTCACTATAGGGCGGAAGATGGCGAGGAGGAG-3' (SEQ ID NO:358)  
 p2 5'-CTATGAAATTAAACCCTCACTAAAGGGACCAAGGCCACAAACGGAAATC-3' (SEQ ID NO:359)

(7) DNA33089-1132 (PRO221)

p1 5'-GGATTCTAATACGACTCACTATAGGGCTGTGCTTCATTCTGCCAGTA-3' (SEQ ID NO:360)  
 p2 5'-CTATGAAATTAAACCCTCACTAAAGGGAGGGTACAATTAAAGGGTGGAT-3' (SEQ ID NO:361)

15

(8) DNA35918-1174 (PRO258)

p1 5'-GGATTCTAATACGACTCACTATAGGGCCCGCCTCGCTCCTGCTCCTG-3' (SEQ ID NO:362)  
 p2 5'-CTATGAAATTAAACCCTCACTAAAGGGAGGATTGCCGACCCCTCACAG-3' (SEQ ID NO:363)

20 (9) DNA32286-1191 (PRO214)

p1 5'-GGATTCTAATACGACTCACTATAGGGCCCCCTCCTGCCTCCCTGTCC-3' (SEQ ID NO:364)  
 p2 5'-CTATGAAATTAAACCCTCACTAAAGGGAGTGGTGGCCGCGATTATCTGC-3' (SEQ ID NO:365)

(10) DNA33221-1133 (PRO224)

25 p1 5'-GGATTCTAATACGACTCACTATAGGGCGCAGCGATGGCAGCGATGAGG-3' (SEQ ID NO:366)  
 p2 5'-CTATGAAATTAAACCCTCACTAAAGGGACAGACGGGGCAGAGGGAGTG-3' (SEQ ID NO:367)

(11) DNA35557-1137 (PRO234)

p1 5'-GGATTCTAATACGACTCACTATAGGGCCAGGAGGCGTAGGGAGAAC-3' (SEQ ID NO:368)  
 30 p2 5'-CTATGAAATTAAACCCTCACTAAAGGGAAAGACATGTCATGGGAGTGG-3' (SEQ ID NO:369)

(12) DNA33100-1159 (PRO229)

p1 5'-GGATTCTAATACGACTCACTATAGGCCGGTGGAGGTGGAACAGAAA-3' (SEQ ID NO:370)  
 p2 5'-CTATGAAATTAAACCCTCACTAAAGGGACACAGACAGAGCCCCATACGC-3' (SEQ ID NO:371)

35

(13) DNA34431-1177 (PRO263)

- p1 5'-GGATTCTAATACGACTCACTATAGGCCAGGAAATCCGGATGTCTC-3' (SEQ ID NO:372)  
p2 5'-CTATGAAATTAAACCCTCACTAAAGGGAGTAAGGGATGCCACCGAGTA-3' (SEQ ID NO:373)

(14) DNA38268-1188 (PRO295)

- 5 p1 5'-GGATTCTAATACGACTCACTATAGGCCAGCTACCCGCAGGAGGAGG-3' (SEQ ID NO:374)  
p2 5'-CTATGAAATTAAACCCTCACTAAAGGGATCCCAGGTGATGAGGTCCAGA-3' (SEQ ID NO:375)

G. Results

10 *In situ* analysis was performed on a variety of DNA sequences disclosed herein. The results from these analyses are as follows.

(1) DNA33094-1131 (PRO217)

15 Highly distinctive expression pattern, that does not indicate an obvious biological function. In the human embryo it was expressed in outer smooth muscle layer of the GI tract, respiratory cartilage, branching respiratory epithelium, osteoblasts, tendons, gonad, in the optic nerve head and developing dermis. In the adult expression was observed in the epidermal pegs of the chimp tongue, the basal epithelial/myoepithelial cells of the prostate and urinary bladder. Also expressed in the alveolar lining cells of the adult lung, mesenchymal cells juxtaposed to erectile tissue in the penis and the cerebral cortex (probably glial cells). In the kidney, expression was only seen in disease, in cells surrounding thyroidized renal tubules.

20 Human fetal tissues examined (E12-E16 weeks) include: Placenta, umbilical cord, liver, kidney, adrenals, thyroid, lungs, heart, great vessels, oesophagus, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body wall, pelvis and lower limb.

Adult human tissues examined: Kidney (normal and end-stage), adrenal, myocardium, aorta, spleen, lymph node, gall bladder, pancreas, lung, skin, eye (inc. retina), prostate, bladder, liver (normal, cirrhotic, acute failure).

Non-human primate tissues examined:

- 25 (a) Chimp Tissues: Salivary gland, stomach, thyroid, parathyroid, skin, thymus, ovary, lymph node.  
(b) Rhesus Monkey Tissues: Cerebral cortex, hippocampus, cerebellum, penis.

(2) DNA33223-1136 (PRO230)

30 Sections show an intense signal associated with arterial and venous vessels in the fetus. In arteries the signal appeared to be confined to smooth-muscle/pericytic cells. The signal is also seen in capillary vessels and in glomeruli. It is not clear whether or not endothelial cells are expressing this mRNA. Expression is also observed in epithelial cells in the fetal lens. Strong expression was also seen in cells within placental trophoblastic villi, these cells lie between the trophoblast and the fibroblast-like cells that express HGF - uncertain histogenesis. In the adult, there was no evidence of expression and the wall of the aorta and most vessels appear to be negative. However, expression was seen over vascular channels in the normal prostate and in the epithelium lining the gallbladder. Insurers expression was seen in the vessels of the soft-tissue sarcoma and a renal cell carcinoma. In summary, this is a molecule that shows relatively specific vascular expression in the fetus as well as in some adult organs. Expression was also

observed in the fetal lens and the adult gallbladder.

In a secondary screen, vascular expression was observed, similar to that observed above, seen in fetal blocks. Expression is on vascular smooth muscle, rather than endothelium. Expression also seen in smooth muscle of the developing oesophagus, so as reported previously, this molecule is not vascular specific. Expression was examined in 4 lung and 4 breast carcinomas. Substantial expression was seen in vascular smooth muscle of at least 5 3/4 lung cancers and 2/4 breast cancers. In addition, in one breast carcinoma, expression was observed in peritumoral stromal cells of uncertain histogenesis (possibly myofibroblasts). No endothelial cell expression was observed in this study.

(3) DNA34435-1140 (PRO232)

10 Strong expression in prostatic epithelium and bladder epithelium, lower level of expression in bronchial epithelium. High background / low level expression seen in a number of sites, including among others, bone, blood, chondrosarcoma, adult heart and fetal liver. It is felt that this level of signal represents background, partly because signal at this level was seen over the blood. All other tissues negative.

15 Human fetal tissues examined (E12-E16 weeks) include: Placenta, umbilical cord, liver, kidney, adrenals, thyroid, lungs, heart, great vessels, oesophagus, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body wall, pelvis, testis and lower limb.

Adult human tissues examined: Kidney (normal and end-stage), adrenal, spleen, lymph node, pancreas, lung, eye (inc. retina), bladder, liver (normal, cirrhotic, acute failure).

Non-human primate tissues examined:

20 Chimp Tissues: adrenal

Rhesus Monkey Tissues: Cerebral cortex, hippocampus

In a secondary screen, expression was observed in the epithelium of the prostate, the superficial layers of the urethelium of the urinary bladder, the urethelium lining the renal pelvis and the urethelium of the ureter (1 out of 2 experiments). The urethra of a rhesus monkey was negative; it is unclear whether this represents a true lack of expression by the urethra, or if it is the result of a failure of the probe to cross react with rhesus tissue. The findings in the prostate and bladder are similar to those previously described using an isotopic detection technique. Expression of the mRNA for this antigen is NOT prostate epithelial specific. The antigen may serve as a useful marker for urethelial derived tissues. Expression in the superficial, post-mitotic cells, of the urinary tract epithelium also suggest that it is unlikely to represent a specific stem cell marker, as this would be expected to be expressed specifically in 25 basal epithelium.

(4) DNA35639-1172 (PRO246)

Strongly expressed in fetal vascular endothelium, including tissues of the CNS. Lower level of expression in adult vasculature, including the CNS. Not obviously expressed at higher levels in tumor vascular endothelium.

35 Signal also seen over bone matrix and adult spleen, not obviously cell associated, probably related to non-specific background at these sites.

Human fetal tissues examined (E12-E16 weeks) include: Placenta, umbilical cord, liver, kidney, adrenals, thyroid,

lungs, heart, great vessels, oesophagus, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body wall, pelvis, testis and lower limb.

Adult human tissues examined: Kidney (normal and end-stage), adrenal, spleen, lymph node, pancreas, lung, eye (inc. retina), bladder, liver (normal, cirrhotic, acute failure).

Non-human primate tissues examined:

5       Chimp Tissues: adrenal

Rhesus Monkey Tissues: Cerebral cortex, hippocampus

(5)      DNA49435-1219 (PRO533)

Moderate expression over cortical neurones in the fetal brain. Expression over the inner aspect of the fetal retina, possible expression in the developing lens. Expression over fetal skin, cartilage, small intestine, placental villi and umbilical cord. In adult tissues there is an extremely high level of expression over the gallbladder epithelium. Moderate expression over the adult kidney, gastric and colonic epithelia. Low-level expression was observed over many cell types in many tissues, this may be related to stickiness of the probe, these data should therefore be interpreted with a degree of caution.

10       Human fetal tissues examined (E12-E16 weeks) include: Placenta, umbilical cord, liver, kidney, adrenals, thyroid, lungs, heart, great vessels, oesophagus, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body wall, pelvis, testis and lower limb.

Adult human tissues examined: Kidney (normal and end-stage), adrenal, spleen, lymph node, pancreas, lung, eye (inc. retina), bladder, liver (normal, cirrhotic, acute failure).

15       Non-human primate tissues examined:

Chimp Tissues: adrenal

Rhesus Monkey Tissues: Cerebral cortex, hippocampus, cerebellum.

(6)      DNA35638-1141 (PRO245)

20       Expression observed in the endothelium lining a subset of fetal and placental vessels. Endothelial expression was confined to these tissue blocks. Expression also observed over intermediate trophoblast cells of placenta. All other tissues negative.

Fetal tissues examined (E12-E16 weeks) include: Placenta, umbilical cord, liver, kidney, adrenals, thyroid, lungs, heart, great vessels, oesophagus, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body wall, pelvis and lower limb.

Adult tissues examined: Liver, kidney, adrenal, myocardium, aorta, spleen, lymph node, pancreas, lung, skin, cerebral cortex (rm), hippocampus(rm), cerebellum(rm), penis, eye, bladder, stomach, gastric carcinoma, colon, colonic carcinoma, thyroid (chimp), parathyroid (chimp) ovary (chimp) and chondrosarcoma. Acetaminophen induced liver injury and hepatic

35       cirrhosis

(7) DNA33089-1132 (PRO221)

Specific expression over fetal cerebral white and grey matter, as well as over neurones in the spinal cord. Probe appears to cross react with rat. Low level of expression over cerebellar neurones in adult rhesus brain. All other tissues negative.

5 Fetal tissues examined (E12-E16 weeks) include: Placenta, umbilical cord, liver, kidney, adrenals, thyroid, lungs, heart, great vessels, oesophagus, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body wall, pelvis and lower limb.

Adult tissues examined: Liver, kidney, adrenal, myocardium, aorta, spleen, lymph node, pancreas, lung, skin, cerebral cortex (rm), hippocampus(rm), cerebellum(rm), penis, eye, bladder, stomach, gastric carcinoma, colon, colonic carcinoma and chondrosarcoma. Acetominophen induced liver injury and hepatic cirrhosis

10

(8) DNA35918-1174 (PRO258)

Strong expression in the nervous system. In the rhesus monkey brain expression is observed in cortical, hippocampal and cerebellar neurones. Expression over spinal neurones in the fetal spinal cord, the developing brain and the inner aspects of the fetal retina. Expression over developing dorsal root and autonomic ganglia as well as 15 enteric nerves. Expression observed over ganglion cells in the adult prostate. In the rat, there is strong expression over the developing hind brain and spinal cord. Strong expression over interstitial cells in the placental villi. All other tissues were negative.

Fetal tissues examined (E12-E16 weeks) include: Placenta, umbilical cord, liver, kidney, adrenals, thyroid, lungs, heart, great vessels, oesophagus, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body 20 wall, pelvis and lower limb.

Adult tissues examined: Liver, kidney, renal cell carcinoma, adrenal, aorta, spleen, lymph node, pancreas, lung, myocardium, skin, cerebral cortex (rm), hippocampus(rm), cerebellum(rm), bladder, prostate, stomach, gastric carcinoma, colon, colonic carcinoma, thyroid (chimp), parathyroid (chimp) ovary (chimp) and chondrosarcoma. Acetominophen induced liver injury and hepatic cirrhosis.

25

(9) DNA32286-1191 (PRO214)

Fetal tissue: Low level throughout mesenchyme. Moderate expression in placental stromal cells in membranous tissues and in thyroid. Low level expression in cortical neurones. Adult tissue: all negative.

Fetal tissues examined (E12-E16 weeks) include: Placenta, umbilical cord, liver, kidney, adrenals, thyroid, lungs, 30 heart, great vessels, oesophagus, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body wall, pelvis and lower limb.

Adult tissues examined include: Liver, kidney, adrenal, myocardium, aorta, spleen, lymph node, pancreas, lung and skin.

35 (10) DNA33221-1133 (PRO224)

Expression limited to vascular endothelium in fetal spleen, adult spleen, fetal liver, adult thyroid and adult lymph node (chimp). Additional site of expression is the developing

spinal ganglia. All other tissues negative.

Human fetal tissues examined (E12-E16 weeks) include: Placenta, umbilical cord, liver, kidney, adrenals, thyroid, lungs, heart, great vessels, oesophagus, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body wall, pelvis and lower limb.

Adult human tissues examined: Kidney (normal and end-stage), adrenal, myocardium, aorta, spleen, lymph node,

5      pancreas, lung, skin, eye (inc. retina), bladder, liver (normal, cirrhotic, acute failure).

Non-human primate tissues examined:

Chimp Tissues: Salivary gland, stomach, thyroid, parathyroid, skin, thymus, ovary, lymph node.

Rhesus Monkey Tissues: Cerebral cortex, hippocampus, cerebellum, penis.

10    (11)    **DNA35557-1137 (PRO234)**

Specific expression over developing motor neurones in ventral aspect of the fetal spinal cord (will develop into ventral horns of spinal cord). All other tissues negative. Possible role in growth, differentiation and/or development of spinal motor neurons.

Fetal tissues examined (E12-E16 weeks) include: Placenta, umbilical cord, liver, kidney, adrenals, thyroid, lungs,

15      heart, great vessels, oesophagus, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body wall, pelvis and lower limb.

Adult tissues examined: Liver, kidney, adrenal, myocardium, aorta, spleen, lymph node, pancreas, lung, skin, cerebral cortex (rm), hippocampus(rm), cerebellum(rm), penis, eye, bladder, stomach, gastric carcinoma, colon, colonic carcinoma and chondrosarcoma. Acetominophen induced liver injury and hepatic cirrhosis

20

(12)    **DNA33100-1159 (PRO229)**

Striking expression in mononuclear phagocytes (macrophages) of fetal and adult spleen, liver, lymph node and adult thymus (in tingible body macrophages). The highest expression is in the spleen. All other tissues negative.

Localisation and homology are entirely consistent with a role as a scavenger receptor for cells of the 25 reticuloendothelial system. Expression also observed in placental mononuclear cells.

Human fetal tissues examined (E12-E16 weeks) include: Placenta, umbilical cord, liver, kidney, adrenals, thyroid, lungs, heart, great vessels, oesophagus, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body wall, pelvis and lower limb.

Adult human tissues examined: Kidney (normal and end-stage), adrenal, myocardium, aorta, spleen, lymph node,

30      gall bladder, pancreas, lung, skin, eye (inc. retina), prostate, bladder, liver (normal, cirrhotic, acute failure).

Non-human primate tissues examined:

Chimp Tissues: Salivary gland, stomach, thyroid, parathyroid, skin, thymus, ovary, lymph node.

Rhesus Monkey Tissues: Cerebral cortex, hippocampus, cerebellum, penis.

35    (13)    **DNA34431-1177 (PRO263)**

Widespread expression in human fetal tissues and placenta over mononuclear cells, probably macrophages +/- lymphocytes. The cellular distribution follows a perivascular pattern in many tissues. Strong expression also seen

in epithelial cells of the fetal adrenal cortex. All adult tissues were negative.

Fetal tissues examined (E12-E16 weeks) include: Placenta, umbilical cord, liver, kidney, adrenals, thyroid, lungs, heart, great vessels, oesophagus, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body wall, pelvis and lower limb.

Adult tissues examined: Liver, kidney, adrenal, spleen, lymph node, pancreas, lung, skin, cerebral cortex (rm),

- 5 hippocampus(rm), cerebellum(rm), bladder, stomach, colon and colonic carcinoma. Acetominophen induced liver injury and hepatic cirrhosis.

A secondary screen evidenced expression over stromal mononuclear cells probably histiocytes.

(14) DNA38268-1188 (PRO295)

- 10 High expression over ganglion cells in human fetal spinal ganglia and over large neurones in the anterior horns of the developing spinal cord. In the adult there is expression in the chimp adrenal medulla (neural), neurones of the rhesus monkey brain (hippocampus [ + + + ] and cerebral cortex) and neurones in ganglia in the normal adult human prostate (the only section that contains ganglion cells, ie expression in this cell type is presumed NOT to be confined to the prostate). All other tissues negative.
- 15 Human fetal tissues examined (E12-E16 weeks) include: Placenta, umbilical cord, liver, kidney, adrenals, thyroid, lungs, great vessels, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body wall, pelvis, testis and lower limb.

Adult human tissues examined: Kidney (normal and end-stage), adrenal, spleen, lymph node, pancreas, lung, eye (inc. retina), bladder, liver (normal, cirrhotic, acute failure).

20 Non-human primate tissues examined:

Chimp Tissues: adrenal

Rhesus Monkey Tissues: Cerebral cortex, hippocampus, cerebellum.

Deposit of Material

- 25 The following materials have been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, USA (ATCC):

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
	DNA32292-1131	ATCC 209258	September 16, 1997
	DNA33094-1131	ATCC 209256	September 16, 1997
30	DNA33223-1136	ATCC 209264	September 16, 1997
	DNA34435-1140	ATCC 209250	September 16, 1997
	DNA27864-1155	ATCC 209375	October 16, 1997
	DNA36350-1158	ATCC 209378	October 16, 1997
	DNA32290-1164	ATCC 209384	October 16, 1997
35	DNA35639-1172	ATCC 209396	October 17, 1997
	DNA33092-1202	ATCC 209420	October 28, 1997
	DNA49435-1219	ATCC 209480	November 21, 1997
	DNA35638-1141	ATCC 209265	September 16, 1997
	DNA32298-1132	ATCC 209257	September 16, 1997
40	DNA33089-1132	ATCC 209262	September 16, 1997
	DNA33786-1132	ATCC 209253	September 16, 1997
	DNA35918-1174	ATCC 209402	October 17, 1997

	DNA37150-1178	ATCC 209401	October 17, 1997
	DNA38260-1180	ATCC 209397	October 17, 1997
	DNA39969-1185	ATCC 209400	October 17, 1997
	DNA32286-1191	ATCC 209385	October 16, 1997
	DNA33461-1199	ATCC 209367	October 15, 1997
5	DNA40628-1216	ATCC 209432	November 7, 1997
	DNA33221-1133	ATCC 209263	September 16, 1997
	DNA33107-1135	ATCC 209251	September 16, 1997
	DNA35557-1137	ATCC 209255	September 16, 1997
	DNA34434-1139	ATCC 209252	September 16, 1997
10	DNA33100-1159	ATCC 209373	October 16, 1997
	DNA35600-1162	ATCC 209370	October 16, 1997
	DNA34436-1238	ATCC 209523	December 10, 1997
	DNA33206-1165	ATCC 209372	October 16, 1997
	DNA35558-1167	ATCC 209374	October 16, 1997
15	DNA35599-1168	ATCC 209373	October 16, 1997
	DNA36992-1168	ATCC 209382	October 16, 1997
	DNA34407-1169	ATCC 209383	October 16, 1997
	DNA35841-1173	ATCC 209403	October 17, 1997
	DNA33470-1175	ATCC 209398	October 17, 1997
20	DNA34431-1177	ATCC 209399	October 17, 1997
	DNA39510-1181	ATCC 209392	October 17, 1997
	DNA39423-1182	ATCC 209387	October 17, 1997
	DNA40620-1183	ATCC 209388	October 17, 1997
	DNA40604-1187	ATCC 209394	October 17, 1997
25	DNA38268-1188	ATCC 209421	October 28, 1997
	DNA37151-1193	ATCC 209393	October 17, 1997
	DNA35673-1201	ATCC 209418	October 28, 1997
	DNA40370-1217	ATCC 209485	November 21, 1997
	DNA42551-1217	ATCC 209483	November 21, 1997
30	DNA39520-1217	ATCC 209482	November 21, 1997
	DNA41225-1217	ATCC 209491	November 21, 1997
	DNA43318-1217	ATCC 209481	November 21, 1997
	DNA40587-1231	ATCC 209438	November 7, 1997
	DNA41338-1234	ATCC 209927	June 2, 1998
35	DNA40981-1234	ATCC 209439	November 7, 1997
	DNA37140-1234	ATCC 209489	November 21, 1997
	DNA40982-1235	ATCC 209433	November 7, 1997
	DNA41379-1236	ATCC 209488	November 21, 1997
	DNA44167-1243	ATCC 209434	November 7, 1997
40	DNA39427-1179	ATCC 209395	October 17, 1997
	DNA40603-1232	ATCC 209486	November 21, 1997
	DNA43466-1225	ATCC 209490	November 21, 1997
	DNA43046-1225	ATCC 209484	November 21, 1997
	DNA35668-1171	ATCC 209371	October 16, 1997
45			

These deposit were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture of the deposit for 30 years from the date of deposit. The deposits will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the culture of the deposit to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined

by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC § 122 and the Commissioner's rules pursuant thereto (including 37 CFR § 1.14 with particular reference to 886 OG 638).

The assignee of the present application has agreed that if a culture of the materials on deposit should die or be lost or destroyed when cultivated under suitable conditions, the materials will be promptly replaced on notification with another of the same. Availability of the deposited material is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the construct deposited, since the deposited embodiment is intended as a single illustration of certain aspects of the invention and any constructs that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

WHAT IS CLAIMED IS:

1. Isolated nucleic acid having at least 80% sequence identity to a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:12), Figure 9 (SEQ ID NO:18), Figure 11 (SEQ ID NO:23), Figure 13 (SEQ ID NO:28), Figure 15 (SEQ ID NO:34), Figure 17 (SEQ ID NO:39),  
5 Figure 19 (SEQ ID NO:49), Figure 22 (SEQ ID NO:59), Figure 24 (SEQ ID NO:64), Figure 26 (SEQ ID NO:69), Figure 28 (SEQ ID NO:71), Figure 30 (SEQ ID NO:73), Figure 32 (SEQ ID NO:84), Figure 34 (SEQ ID NO:91), Figure 36 (SEQ ID NO:96), Figure 38 (SEQ ID NO:104), Figure 40 (SEQ ID NO:109), Figure 42 (SEQ ID NO:114), Figure 44 (SEQ ID NO:119), Figure 46 (SEQ ID NO:127), Figure 48 (SEQ ID NO:132), Figure 50 (SEQ ID NO:137), Figure 52 (SEQ ID NO:142), Figure 54 (SEQ ID NO:148), Figure 56 (SEQ ID NO:153), Figure 58  
10 (SEQ ID NO:159), Figure 60 (SEQ ID NO:164), Figure 62 (SEQ ID NO:170), Figure 64 (SEQ ID NO:175), Figure 66 (SEQ ID NO:177), Figure 68 (SEQ ID NO:185), Figure 70 (SEQ ID NO:190), Figure 72 (SEQ ID NO:195), Figure 74 (SEQ ID NO:201), Figure 76 (SEQ ID NO:207), Figure 78 (SEQ ID NO:213), Figure 80 (SEQ ID NO:221), Figure 82 (SEQ ID NO:227), Figure 84 (SEQ ID NO:236), Figure 86 (SEQ ID NO:245), Figure 88 (SEQ ID NO:250), Figure 90 (SEQ ID NO:255), Figure 92 (SEQ ID NO:257), Figure 94 (SEQ ID NO:259), Figure 96  
15 (SEQ ID NO:261), Figure 98 (SEQ ID NO:263), Figure 100 (SEQ ID NO:285), Figure 102 (SEQ ID NO:290), Figure 104 (SEQ ID NO:292), Figure 106 (SEQ ID NO:294), Figure 108 (SEQ ID NO:310), Figure 110 (SEQ ID NO:315), Figure 112 (SEQ ID NO:320), Figure 114 (SEQ ID NO:325), Figure 116 (SEQ ID NO:332), Figure 118 (SEQ ID NO:339), Figure 120 (SEQ ID NO:341) and Figure 122 (SEQ ID NO:377).
- 20 2. The nucleic acid of Claim 1, wherein said nucleotide sequence comprises a nucleotide sequence selected from the group consisting of the sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:11), Figure 8 (SEQ ID NO:17), Figure 10 (SEQ ID NO:22), Figure 12 (SEQ ID NO:27), Figure 14 (SEQ ID NO:33), Figure 16 (SEQ ID NO:38), Figure 18 (SEQ ID NO:48), Figure 21 (SEQ ID NO:58), Figure 23 (SEQ ID NO:63), Figure 25 (SEQ ID NO:68), Figure 27 (SEQ ID NO:70), Figure 29 (SEQ ID NO:72),  
25 Figure 31 (SEQ ID NO:83), Figure 33 (SEQ ID NO:90), Figure 35 (SEQ ID NO:95), Figure 37 (SEQ ID NO:103), Figure 39 (SEQ ID NO:108), Figure 41 (SEQ ID NO:113), Figure 43 (SEQ ID NO:118), Figure 45 (SEQ ID NO:126), Figure 47 (SEQ ID NO:131), Figure 49 (SEQ ID NO:136), Figure 51 (SEQ ID NO:141), Figure 53 (SEQ ID NO:147), Figure 55 (SEQ ID NO:152), Figure 57 (SEQ ID NO:158), Figure 59 (SEQ ID NO:163), Figure 61 (SEQ ID NO:169), Figure 63 (SEQ ID NO:174), Figure 65 (SEQ ID NO:176), Figure 67 (SEQ ID NO:184), Figure  
30 69 (SEQ ID NO:189), Figure 71 (SEQ ID NO:194), Figure 73 (SEQ ID NO:200), Figure 75 (SEQ ID NO:206), Figure 77 (SEQ ID NO:212), Figure 79 (SEQ ID NO:220), Figure 81 (SEQ ID NO:226), Figure 83 (SEQ ID NO:235), Figure 85 (SEQ ID NO:244), Figure 87 (SEQ ID NO:249), Figure 89 (SEQ ID NO:254), Figure 91 (SEQ ID NO:256), Figure 93 (SEQ ID NO:258), Figure 95 (SEQ ID NO:260), Figure 97 (SEQ ID NO:262), Figure 99 (SEQ ID NO:284), Figure 101 (SEQ ID NO:289), Figure 103 (SEQ ID NO:291), Figures 105A-B (SEQ ID NO:293),  
35 Figure 107 (SEQ ID NO:309), Figure 109 (SEQ ID NO:314), Figure 111 (SEQ ID NO:319), Figure 113 (SEQ ID NO:324), Figure 115 (SEQ ID NO:331), Figure 117 (SEQ ID NO:338), Figure 119 (SEQ ID NO:340) and Figure 121 (SEQ ID NO:376), or the complement thereof.

3. The nucleic acid of Claim 1, wherein said nucleotide sequence comprises a nucleotide sequence selected from the group consisting of the full-length coding sequence of the sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:11), Figure 8 (SEQ ID NO:17), Figure 10 (SEQ ID NO:22), Figure 12 (SEQ ID NO:27), Figure 14 (SEQ ID NO:33), Figure 16 (SEQ ID NO:38), Figure 18 (SEQ ID NO:48), Figure 21 (SEQ ID NO:58), Figure 23 (SEQ ID NO:63), Figure 25 (SEQ ID NO:68), Figure 27 (SEQ ID NO:70),  
5 Figure 29 (SEQ ID NO:72), Figure 31 (SEQ ID NO:83), Figure 33 (SEQ ID NO:90), Figure 35 (SEQ ID NO:95), Figure 37 (SEQ ID NO:103), Figure 39 (SEQ ID NO:108), Figure 41 (SEQ ID NO:113), Figure 43 (SEQ ID NO:118), Figure 45 (SEQ ID NO:126), Figure 47 (SEQ ID NO:131), Figure 49 (SEQ ID NO:136), Figure 51 (SEQ ID NO:141), Figure 53 (SEQ ID NO:147), Figure 55 (SEQ ID NO:152), Figure 57 (SEQ ID NO:158), Figure 59 (SEQ ID NO:163), Figure 61 (SEQ ID NO:169), Figure 63 (SEQ ID NO:174), Figure 65 (SEQ ID NO:176), Figure  
10 67 (SEQ ID NO:184), Figure 69 (SEQ ID NO:189), Figure 71 (SEQ ID NO:194), Figure 73 (SEQ ID NO:200), Figure 75 (SEQ ID NO:206), Figure 77 (SEQ ID NO:212), Figure 79 (SEQ ID NO:220), Figure 81 (SEQ ID NO:226), Figure 83 (SEQ ID NO:235), Figure 85 (SEQ ID NO:244), Figure 87 (SEQ ID NO:249), Figure 89 (SEQ ID NO:254), Figure 91 (SEQ ID NO:256), Figure 93 (SEQ ID NO:258), Figure 95 (SEQ ID NO:260), Figure 97 (SEQ ID NO:262), Figure 99 (SEQ ID NO:284), Figure 101 (SEQ ID NO:289), Figure 103 (SEQ ID NO:291),  
15 Figures 105A-B (SEQ ID NO:293), Figure 107 (SEQ ID NO:309), Figure 109 (SEQ ID NO:314), Figure 111 (SEQ ID NO:319), Figure 113 (SEQ ID NO:324), Figure 115 (SEQ ID NO:331), Figure 117 (SEQ ID NO:338), Figure 119 (SEQ ID NO:340) and Figure 121 (SEQ ID NO:376), or the complement thereof.

4. Isolated nucleic acid which comprises the full-length coding sequence of the DNA deposited under accession number ATCC 209258, ATCC 209256, ATCC 209264, ATCC 209250, ATCC 209375, ATCC 209378, ATCC 209384, ATCC 209396, ATCC 209420, ATCC 209480, ATCC 209265, ATCC 209257, ATCC 209262, ATCC 209253, ATCC 209402, ATCC 209401, ATCC 209397, ATCC 209400, ATCC 209385, ATCC 209367, ATCC 209432, ATCC 209263, ATCC 209251, ATCC 209255, ATCC 209252, ATCC 209373, ATCC 209370, ATCC 209523, ATCC 209372, ATCC 209374, ATCC 209373, ATCC 209382, ATCC 209383, ATCC 209403,  
25 ATCC 209398, ATCC 209399, ATCC 209392, ATCC 209387, ATCC 209388, ATCC 209394, ATCC 209421, ATCC 209393, ATCC 209418, ATCC 209485, ATCC 209483, ATCC 209482, ATCC 209491, ATCC 209481, ATCC 209438, ATCC 209927, ATCC 209439, ATCC 209489, ATCC 209433, ATCC 209488, ATCC 209434, ATCC 209395, ATCC 209486, ATCC 209490, ATCC 209484 or ATCC 209371.

30 5. A vector comprising the nucleic acid of Claim 1.

6. The vector of Claim 5 operably linked to control sequences recognized by a host cell transformed with the vector.

35 7. A host cell comprising the vector of Claim 5.

8. The host cell of Claim 7 wherein said cell is a CHO cell.

9. The host cell of Claim 7 wherein said cell is an *E. coli*.
10. The host cell of Claim 7 wherein said cell is a yeast cell.
11. A process for producing a PRO polypeptides comprising culturing the host cell of Claim 7 under conditions suitable for expression of said PRO polypeptide and recovering said PRO polypeptide from the cell culture.
  - 5
12. Isolated native sequence PRO polypeptide having at least 80% sequence identity to an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:12), Figure 9 (SEQ ID NO:18), Figure 11 (SEQ ID NO:23), Figure 13 (SEQ ID NO:28), Figure 15 (SEQ ID NO:34), Figure 17 (SEQ ID NO:39), Figure 19 (SEQ ID NO:49), Figure 22 (SEQ ID NO:59), Figure 24 (SEQ ID NO:64), Figure 26 (SEQ ID NO:69), Figure 28 (SEQ ID NO:71), Figure 30 (SEQ ID NO:73), Figure 32 (SEQ ID NO:84), Figure 34 (SEQ ID NO:91), Figure 36 (SEQ ID NO:96), Figure 38 (SEQ ID NO:104), Figure 40 (SEQ ID NO:109), Figure 42 (SEQ ID NO:114), Figure 44 (SEQ ID NO:119), Figure 46 (SEQ ID NO:127), Figure 48 (SEQ ID NO:132), Figure 50 (SEQ ID NO:137), Figure 52 (SEQ ID NO:142),
  - 10
15. Figure 54 (SEQ ID NO:148), Figure 56 (SEQ ID NO:153), Figure 58 (SEQ ID NO:159), Figure 60 (SEQ ID NO:164), Figure 62 (SEQ ID NO:170), Figure 64 (SEQ ID NO:175), Figure 66 (SEQ ID NO:177), Figure 68 (SEQ ID NO:185), Figure 70 (SEQ ID NO:190), Figure 72 (SEQ ID NO:195), Figure 74 (SEQ ID NO:201), Figure 76 (SEQ ID NO:207), Figure 78 (SEQ ID NO:213), Figure 80 (SEQ ID NO:221), Figure 82 (SEQ ID NO:227), Figure 84 (SEQ ID NO:236), Figure 86 (SEQ ID NO:245), Figure 88 (SEQ ID NO:250), Figure 90 (SEQ ID NO:255),
  - 20
20. Figure 92 (SEQ ID NO:257), Figure 94 (SEQ ID NO:259), Figure 96 (SEQ ID NO:261), Figure 98 (SEQ ID NO:263), Figure 100 (SEQ ID NO:285), Figure 102 (SEQ ID NO:290), Figure 104 (SEQ ID NO:292), Figure 106 (SEQ ID NO:294), Figure 108 (SEQ ID NO:310), Figure 110 (SEQ ID NO:315), Figure 112 (SEQ ID NO:320), Figure 114 (SEQ ID NO:325), Figure 116 (SEQ ID NO:332), Figure 118 (SEQ ID NO:339), Figure 120 (SEQ ID NO:341) and Figure 122 (SEQ ID NO:377).
  - 25
13. Isolated PRO polypeptide having at least 80% sequence identity to the amino acid sequence encoded by the nucleotide deposited under accession number ATCC 209258, ATCC 209256, ATCC 209264, ATCC 209250, ATCC 209375, ATCC 209378, ATCC 209384, ATCC 209396, ATCC 209420, ATCC 209480, ATCC 209265, ATCC 209257, ATCC 209262, ATCC 209253, ATCC 209402, ATCC 209401, ATCC 209397, ATCC 209400,
  - 30
30. ATCC 209385, ATCC 209367, ATCC 209432, ATCC 209263, ATCC 209251, ATCC 209255, ATCC 209252, ATCC 209373, ATCC 209370, ATCC 209523, ATCC 209372, ATCC 209374, ATCC 209373, ATCC 209382, ATCC 209383, ATCC 209403, ATCC 209398, ATCC 209399, ATCC 209392, ATCC 209387, ATCC 209388, ATCC 209394, ATCC 209421, ATCC 209393, ATCC 209418, ATCC 209485, ATCC 209483, ATCC 209482, ATCC 209491, ATCC 209481, ATCC 209438, ATCC 209927, ATCC 209439, ATCC 209489, ATCC 209433,
  - 35
35. ATCC 209488, ATCC 209434, ATCC 209395, ATCC 209486, ATCC 209490, ATCC 209484 or ATCC 209371.

14. A chimeric molecule comprising a polypeptide according to Claim 12 fused to a heterologous amino acid sequence.

15. The chimeric molecule of Claim 14 wherein said heterologous amino acid sequence is an epitope tag sequence.

5

16. The chimeric molecule of Claim 14 wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.

10

17. An antibody which specifically binds to a PRO polypeptide according to Claim 12.

15

18. The antibody of Claim 17 wherein said antibody is a monoclonal antibody.

19. Isolated nucleic acid having at least 80% sequence identity to a nucleotide sequence encoding a PRO228 polypeptide having amino acid residues 1 to 690 of Figure 19 (SEQ ID NO:49).

20

20. The nucleic acid of Claim 19, wherein said nucleotide sequence comprises the nucleotide sequence of Figure 18 (SEQ ID NO:48), or its complement.

25

21. The nucleic acid of Claim 19, wherein said nucleotide sequence comprises nucleotides 24-2093 of Figure 18 (SEQ ID NO:48), or its complement.

22. An isolated nucleic acid comprising the nucleotide sequence of the full-length coding sequence of clone UNQ202 (DNA33092-1202) deposited under accession number ATCC 209420.

25

23. An isolated nucleic acid encoding an extracellular domain of a PRO228 polypeptide.

24. A vector comprising the nucleic acid of any one of Claim 19 to 23.

30

25. The vector of Claim 24 operably linked to control sequences recognized by a host cell transformed with the vector.

26. A host cell comprising the vector of Claim 24.

27. The host cell of Claim 25 wherein said cell is a CHO cell.

35

28. The host cell of Claim 25 wherein said cell is an *E. coli*.

29. The host cell of Claim 25 wherein said cell is a yeast cell.

30. A process for producing a PRO228 polypeptide comprising culturing the host cell of Claim 25 under conditions suitable for expression of said PRO228 polypeptide and recovering said PRO228 polypeptide from the cell culture.

5

31. Isolated native sequence PRO228 polypeptide comprising amino acid residues 1 to 690 of Figure 19 (SEQ ID NO:49).

10 32. An isolated extracellular domain of a PRO228 polypeptide.

33. A chimeric molecule comprising a PRO228 polypeptide fused to a heterologous amino acid sequence.

15 34. The chimeric molecule of Claim 33 wherein said heterologous amino acid sequence is an epitope tag sequence.

35. The chimeric molecule of Claim 33 wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.

20 36. An antibody which specifically binds to a PRO228 polypeptide.

37. The antibody of Claim 36 wherein said antibody is a monoclonal antibody.

25 38. A method of inducing apoptosis of tumor cells, said method comprising:  
contacting said tumor cells with an apoptosis-inducing amount of a PRO228 polypeptide, wherein apoptosis of said tumor cells is induced.

39. The method according to Claim 38, wherein said contacting is *in vivo*.

**FIGURE 1**

GGCCGGAGCAGCACGCCGCAGGACCTGGAGCTCCGGCTCGTCTTCCGCAGCGCTACCCG  
CCATGCGCCTGCCGCCGGCGCTGGGCTCCTGCCGTTCTGCTGCTGCCGCC  
GCGCCGGAGGCCAAGAACGCGACGCCCTGCCACCGTGCCGGGCTGGTGGACAAGTT  
TAACCAGGGATGGTGGACACCGCAAAGAAGAACTTGGCGCGGAACACGGCTGGAGG  
AAAAGACGCTGTCCAAGTACGAGTCCAGCGAGATTGCCCTGCTGGAGATCCTGGAGGGCTG  
TGCAGAGCAGCAGTCGAATGCAATCAGATGCTAGAGGCCAGGAGGAGCACCTGGAGGC  
CTGGTGGCTGCAGCTGAAGAGCGAATATCCTGACTTATCGAGTGGTTGTGAAGACAC  
TGAAAGTGTGCTGCTCCAGAACCTACGGTCCCAGTGTCTGCATGCCAGGGCGGATCC  
CAGAGGCCCTGCAGCGGAATGCCACTGCAGCGAGATGGGAGCAGACAGGGCGACGGTC  
CTGCCGGTGCCACATGGGTACCAGGGCCGCTGTGCACTGACTGCATGGACGGCTACTTCA  
GCTCGCTCCGAAACGAGACCCACAGCATCTGCACAGCCTGTGACGAGTCCTGCAAGACGTGC  
TCGGGCTGACCAACAGAGACTGCCGAGTGTGAAGTGGCTGGGTGCTGGACGAGGGCGC  
CTGTGTGGATGTGGACGAGTGTGCGGCCAGGCCCTCCCTGCAGCGCTGCGCAGT  
TCTGTAAGAACGCAACGGCTCCTACACGTGCGAAGAGTGTGACTCCAGCTGTGAGGGCTGC  
ACAGGGGAAGGCCAGGAAACTGTAAAGAGTGTATCTGGTACGCGAGGAGCACGGACA  
GTGTGCAGATGTGGACGAGTGTGCACTAGCAGAAAAACCTGTGAGGAAAAACGAAA  
ACTGCTACAATACTCCAGGGAGCTACGTCTGTGTGTCCTGACGGCTTCGAAGAACGGAAGAT  
GCCTGTGTGCCGCCGGCAGAGGCTGAAGCCACAGAAGGAGAAAGCCGACACAGCTGCCCTC  
CCGCGAAGACCTGTAATGTGCCGACTTACCTTAAATTATTCAAGAAGGATGTCCGTGGA  
AAATGTGGCCCTGAGGATGCCGTCTCCTGCAGTGGACAGCGCGGGAGAGGCTGCCCTGCTC  
TCTAACGGTTGATTCTCATTGTCCCTAAACAGCTGCATTCTGGTTGTCTAAACAGA  
CTTGTATATTTGATACTAGTTGTAAATAAAATTGACCATTGTAGGTAATCAGGAGGAAA  
AAAAAA

## FIGURE 2

Met Arg Leu Pro Arg Arg Ala Ala Leu Gly Leu Leu Pro Leu Leu Leu  
Leu Leu Pro Pro Ala Pro Glu Ala Ala Lys Lys Pro Thr Pro Cys His  
Arg Cys Arg Gly Leu Val Asp Lys Phe Asn Gln Gly Met Val Asp Thr  
Ala Lys Lys Asn Phe Gly Gly Asn Thr Ala Trp Glu Glu Lys Thr  
Leu Ser Lys Tyr Glu Ser Ser Glu Ile Arg Leu Leu Glu Ile Leu Glu  
Gly Leu Cys Glu Ser Ser Asp Phe Glu Cys Asn Gln Met Leu Glu Ala  
Gln Glu Glu His Leu Glu Ala Trp Trp Leu Gln Leu Lys Ser Glu Tyr  
Pro Asp Leu Phe Glu Trp Phe Cys Val Lys Thr Leu Lys Val Cys Cys  
Ser Pro Gly Thr Tyr Gly Pro Asp Cys Leu Ala Cys Gln Gly Gly Ser  
Gln Arg Pro Cys Ser Gly Asn Gly His Cys Ser Gly Asp Gly Ser Arg  
Gln Gly Asp Gly Ser Cys Arg Cys His Met Gly Tyr Gln Gly Pro Leu  
Cys Thr Asp Cys Met Asp Gly Tyr Phe Ser Ser Leu Arg Asn Glu Thr  
His Ser Ile Cys Thr Ala Cys Asp Glu Ser Cys Lys Thr Cys Ser Gly  
Leu Thr Asn Arg Asp Cys Gly Glu Cys Glu Val Gly Trp Val Leu Asp  
Glu Gly Ala Cys Val Asp Val Asp Glu Cys Ala Ala Glu Pro Pro Pro  
Cys Ser Ala Ala Gln Phe Cys Lys Asn Ala Asn Gly Ser Tyr Thr Cys  
Glu Glu Cys Asp Ser Ser Cys Val Gly Cys Thr Gly Glu Gly Pro Gly  
Asn Cys Lys Glu Cys Ile Ser Gly Tyr Ala Arg Glu His Gly Gln Cys  
Ala Asp Val Asp Glu Cys Ser Leu Ala Glu Lys Thr Cys Val Arg Lys  
Asn Glu Asn Cys Tyr Asn Thr Pro Gly Ser Tyr Val Cys Val Cys Pro  
Asp Gly Phe Glu Glu Thr Glu Asp Ala Cys Val Pro Pro Ala Glu Ala  
Glu Ala Thr Glu Gly Glu Ser Pro Thr Gln Leu Pro Ser Arg Glu Asp  
Leu

## FIGURE 3

CCAGGCCGGGAGGCACCGCCCAGCGTCTAACGGAACAGCCCTGGCTGAGGGAGCTGC  
AGCGCAGCAGAGTATCTGACGGGCCAGGTTGCGTAGGTGCGCACGAGGAGTTCCCGGC  
AGCGAGGAGGTCCCTGAGCAGCATGGCCGGAGGAGCGCCTCCCTGCCCGCGCTCTGGCT  
CTGGAGCATCCTCCTGTGCCTGCTGGACTGCAGGGAGGCCGGCCGCAGGAGGAGA  
GCCTGTACCTATGGATCGATGCTCACCAAGGAAGAGTACTCATAGGATTGAAGAAGATATC  
CTGATTGTTCAGAGGGAAAATGGCACCTTACACATGATTTCAGAAAAGCGAACAGAG  
AATGCCAGCTATTCCCTGTCAATATCCATTCCATGAATTACCTGGCAAGCTGCAGGGCAGG  
CAGAATACTCTATGAATTCCCTGCTGGAACAGTGCGCTCACAGGCATCAGTTGTTCAAGTTGGTT  
ACCGTCAATGTCCCTTGCTGGAACAGTGCGCTCACAGGCATCAGTTGTTCAAGTTGGTT  
CCCATGTCTGGAAAACAGGATGGGTGGCAGCATTAAGTGGATGTGATTGTTATGAATT  
CTGAAGGCAACACCATTCTCAAACACCTCAAAATGCTATCTTCTTAAACATGTCAACAA  
GCTGAGTGCCAGGCGGGTGCCGAAATGGAGGCTTTGTAATGAAAGACGCATCTGCAGTG  
TCCTGATGGTTCCACGGACCTCACTGTGAGAAAGCCCTTGTACCCACGATGTATGAATG  
GTGGACTTGTGACTCCCTGGTTCTGCATCTGCCACCTGGATTCTATGGAGTGAACGT  
GACAAAGCAAATGCTCAACCACCTGCTTAATGGAGGGACCTGTTTACCCCTGGAAAATG  
TATTTGCCCTCAGGACTAGAGGGAGAGCAGTGTGAAATCAGCAAATGCCACAACCTGTC  
GAAATGGAGGTAAATGCATTGGAAAAGCAAATGTAAGTGTCCAAGGTTACCAAGGGAGAC  
CTCTGTTCAAAGCCTGTCTGCAGCCTGGCTGTGGTCACATGGAACCTGCCATGAACCAA  
CAAATGCCAATGTCAAGAAGGTTGGCATGGAAGACACTGCAATAAAAGGTACGAAGCCAGCC  
TCATACATGCCCTGAGGCCAGCAGCGCCAGCTCAGGCAGCACGCCCTCACTAAAAAG  
GCCGAGGAGCAGCGGGATCCACCTGAATCCAATTACATCTGGTAACCTCGACATCTGAAAC  
GTTTAAGTTACACCAAGTTACAGCCTTGTAAACCTTCATGTGTTGAATGTTCAAATAA  
TGTTCATTACACTTAAGAATACTGGCCTGAATTATTAGCTTCATTATAAATCACTGAGCT  
GATATTACTCTCCTTTAAGTTCTAAGTACGTCTGTAGCATGATGGTATAGATTCT  
TGTTTCAGTGCTTGGACAGATTATATTATGTCAATTGATCAGGTTAAATTTCAGTG  
TGTAGTTGGCAGATATTCAAAATTACAATGCATTATGGTGTCTGGGGCAGGGGAACAT  
CAGAAAGGTTAAATTGGCAAAATGCGTAAGTCACAAGAATTGGATGGTCAGTTAATGT  
TGAAGTTACAGCATTTCAGATTATTGTCAAGTATTAGATGTTGTTACATTAAAAA  
TTGCTCTTAATTTAAACTCTCAATACAATATATTGACCTTACCAATTCCAGAGATT  
CAGTATTAAAAAAAAAAATTACACTGTGGTAGTGGCATTAAACAATATAATATTCTA  
AACACAATGAAATAGGGAAATATAATGTATGAACCTTGCATTGGCTTGAAGCAATATAATA  
TATTGTAACAAAACACAGCTCTTACCTAATAACATTATACTGTTGTTATGTATAAAAT  
AAAGGTGCTGCTTAGTTGGAAAAA

**FIGURE 4**

Met Ala Arg Arg Ser Ala Phe Pro Ala Ala Ala Leu Trp Leu Trp Ser Ile Leu Leu Cys Leu Leu Ala Leu Arg Ala Glu Ala Gly ProPro Gln Glu Glu Ser Leu Tyr Leu Trp Ile Asp Ala His Gln Ala Arg Val Leu Ile Gly Phe Glu Glu Asp Ile Leu Ile Val Ser Glu Gly Lys Met Ala Pro Phe Thr His Asp Phe Arg Lys Ala Gln Gln Arg Met Pro Ala Ile Pro Val Asn Ile His Ser Met Asn Phe Thr Trp Gln Ala Ala Gly Gln Ala Glu Tyr Phe Tyr Glu Phe Leu Ser Leu Arg Ser Leu Asp Lys Gly Ile Met Ala Asp Pro Thr Val Asn Val Pro Leu Leu Gly Thr Val Pro His Lys Ala Ser Val Val Gln Val Gly Phe Pro Cys Leu Gly Lys Gln Asp Gly Val Ala Ala Phe Glu Val Asp Val Ile Val Met Asn Ser Glu Gly Asn Thr Ile Leu Gln Thr Pro Gln Asn Ala Ile Phe Phe Lys Thr Cys Gln Gln Ala Glu Cys Pro Gly Gly Cys Arg Asn Gly Gly Phe Cys Asn Glu Arg Arg Ile Cys Glu Cys Pro Asp Gly Phe His Gly Pro His Cys Glu Lys Ala Leu Cys Thr Pro Arg Cys Met Asn Gly Gly Leu Cys Val Thr Pro Gly Phe Cys Ile Cys Pro Pro Gly Phe Tyr Gly Val Asn Cys Asp Lys Ala Asn Cys Ser Thr Thr Cys Phe Asn Gly Gly Thr Cys Phe Tyr Pro Gly Lys Cys Ile Cys Pro Pro Gly Leu Glu Gly Glu Gln Cys Glu Ile Ser Lys Cys Pro Gln Pro Cys Arg Asn Gly Gly Lys Cys Ile Gly Lys Ser Lys Cys Lys Cys Ser Lys Gly Tyr Gln Gly Asp Leu Cys Ser Lys Pro Val Cys Glu Pro Gly Cys Gly Ala His Gly Thr Cys His Glu Pro Asn Lys Cys Gln Cys Gln Glu Gly Trp His Gly Arg His Cys Asn Lys Arg Tyr Glu Ala Ser Leu Ile His Ala Leu Arg Pro Ala Gly Ala Gln Leu Arg Gln His Thr Pro Ser Leu Lys Lys Ala Glu Glu Arg Arg Asp Pro Pro Glu Ser Asn Tyr Ile Trp

## FIGURE 5

CGGACCGCGTGGCGTCGGCGGTGCAGAGCCAGGAGGCGGAGGCAGCGCGCGGCCAGCCTGGG  
CCCCAGCCCACACCTCACCAAGGGCCAGGAGCCACCATGTGGCAGTGTCCACTGGGCTAC  
TGCTGTTGCTGCCGCTGGCACTTGCTCTGGTGCCTGGGACAGCAGGGCTGTGGGCGCCGG  
GAGCTAGCACCGGGCTGACCTGCGGGCATCGGGACGCAGGGAGGCCGTACTGCCAGGA  
GCAGGACCTGTGCTGCCGCGCCGTGCCGACGACTGTGCCACTGCCCTGACCTGGGCGCCATCT  
GTTACTGTGACCTCTTCTGCAACCGCACGGTCTCCACTGCTGCCCTGACTTCTGGGACTTC  
TGCCTCGCGTGCCACCCCTTTCCCCGATCCAAGGATGTATGCATGGAGGTCGTATCTA  
TCCAGTCTGGAACGTACTGGACAACGTAAACCGTTGCACCTGCCAGGAGAACAGGCAGT  
GGCAGTGTGACCAAGAACCATGCCTGGTGGATCCAGACATGATCAAAGCCATCAACCAGGGC  
AACTATGGCTGGCAGGCTGGGACACCACAGCGCCTCTGGGAGTACCCCTGGATGAGGGCAT  
TCGCTACCGCCTGGGACCCATCCGCCATCTCCTCGGTATGAACATGCATGAAATTATA  
CAGTGTGAAACCCAGGGAGGTGCTTCCCACAGCCTCGAGGCCTCTGAGAAGTGGCCCAAC  
CTGATTGATGAGCCTCTGACCAAGGCAACTGTGCAAGGCTCTGGGCTTCTCCACAGCAGC  
TGTGGCATCCGATCGTGTCTCAATCCTCTGGACACATGACGCCGTCTGTGCCCC  
AGAACCTGCTGCTTGTGACACCCACCAGCAGCAGGGCTGCCGCGTGGCGTCTGATGGT  
GCCTGGTGGTTCTCGCGTCGCCGAGGGGTGGTGTCTGACCACTGCTACCCCTCTGGGCCG  
TGAACGAGACGAGGCTGCCCTGCCACAGCTATGATGACAGCCGAGCCATGGGTCGGG  
GCAAGGCCAGGCCACTGCCACAGCTATGTTAATAACAATGACATCTACCAGGTC  
ACTCCTGTCTACCGCCTCGGCTCCAACGACAAGGAGATCATGAAGGAGCTGATGGAGAATGG  
CCCTGTCACGCCCTCATGGAGGTGCATGAGGACTCTTCCTATACAAGGGAGGCATCTACA  
GCCACACGCCAGTGAGCCTGGGAGGCCAGAGAGATACGCCGGCATGGGACCCACTCAGTC  
AAGATCACAGGATGGGAGAGGGAGACGCTGCCAGATGGAAGGACGCTAAATACTGGACTGC  
GGCCAACCTGGGCCAGCCTGGCGAGAGGGCACTCCGCATCGTGCAGCGCGTCA  
ATGAGTGCACATCGAGAGCTTGTGCTGGCGTCTGGGCGCGTGGCATGGAGGACATG  
GGTCATCACTGAGGCTGCCGCAACCGCGGGTCCGCTGACGCCAGGCTAAGGGCCGG  
CGGAAGAGGCCCAATGGGCGGTGACCCAGCCTGCCGACAGAGGCCGGCGCAGGCC  
GGGCCAGGGCGCTAATCCCGGCCGGTCCGCTGACGCCAGGCCCTGGAGGCCGG  
GGCAGGCGAGACTGGCGGAGGCCAGACCTCCAGTGGGACGGGCAGGGCTGGCCTGG  
GAAGAGCACAGCTGCAGATCCCAGGCCTCTGGGCCCACTCAAGACTACCAAAGCCAGGA  
CACCTCAAGTCTCCAGGCCCAATACCCACCCCAATCCGTATTCTTTTTTTTAGAC  
AGGGTCTTGTCTCGTTGCCAGGGTTGGAGTGCAGTGGCCCATCAGGGCTCACTGTAACCTCC  
GAECTCTGGGTTCAAGTGCACCTCCACCTCAGCCTCTCAAGTAGCTGGACTACAGGTGCA  
CCACCACACCTGGCTAATTTTGATTTTGATAGAGGGGGTCTCACTGTTGCCAG  
GCTGGTTTCGAACTCTGGCTCAAGCGGTCCACCTGCCTCCGCTCCAAAGTGTGGGAT  
TGCAGGCATGAGCCACTGCACCCAGCCCTGTATTCTTATTTCAGATATTATTTCTTT  
TCACTGTTAAAATAACCAAAGTATTGATAAAAAAAA

**FIGURE 6**

><ss.DNA33223  
><subunit 1 of 1, 467 aa, 1 stop  
><MW: 52387, pI: 6.95, NX(S/T): 2  
MWRCPLGLLLLLPLAGHLALGAQQGRGRRELAPGLHLRGIRDAAGGRYEQDLCRGRAD  
DCALPYLGAICYCDLFCNRTVSDCCPDFWDFCLGVPPPFPIQGCMHGGRIYPVLGTYWD  
NCNRCTCQENRQWQCDQEPCLVDPDMIKAINQGNYGWQAGNHSAFWGMTLDEGIRYRLGT  
IRPSSSVNMHEIYTVLNPGEVLPPTAFEAEEKWPNLIHEPLDQGNCAWSAFSTAASD  
RVSIHSLGHMTPVLSQPQNLSCDTHQQQGCRGGRLDGAWWFLLRRGVSDHCYPFSGRER  
DEAGPAPPMMHSRAMGRGKRQATAHCPNSYVNNNDIYQVTPVYRLGSNDKEIMKELMEN  
GPVQALMEVHEDFFLYKGGIYSHTPVSLGRPERYRRHGTHSVKITGWGEETLPDGRTLKY  
WTAANSWGPAPWGERGHFRIVRGVNECDIESFVLGVWGRVMEDMGHH

**FIGURE 7**

AGGCTCCTGGCCCTTTCCACAGCAAGCTTNTGCNATCCGATTGTTGTCTCAAATC  
CAATTCTCTGGGACACATNACGCCCTGTCCTTNGCCCCAGAACCTGCTGTCTTGACAC  
CCACCAGCAGCAGGGCTGCCCGNTGGCGTCTCGATGGTGCTGGTGGTCTGCGTCG  
CCGAGGGNTGGTGTCTGACCACTGCTACCCCTCTCGGGCCGTGAACGAGACGAGGCTGG  
CCCTGCGCCCCCTGTATGATGCACAGCCAGCCATGGTCGGGCAAGCGCCAGGCCAC  
TGCCCAC TGCCCCAACAGCTATGTTAATAACAATGACATCTACCAGGTCACTCCTGTCTA  
CCGCCTCGGCTCCAACGACAAGGAGATCATGAAGGAGCTGATGGAGAATGGCCCTGTCCA  
AGCCCTCATGGAGGTGCATGAGGACTTCTTCTATAACAAGGGAGGCATCTACAGGCCACAC  
GCCAGTGAGCCTGGGAGGCCAGAGAGATACCGCCGGCATGGGACCCACTCAG

**FIGURE 8**

GCTGCTTGCCTGTTGATGGCAGGCTGGCCCTGCAGCCAGGCAGTGCCTGCTGTGCTACT  
CCTGCAAAGCCCAGGTGAGCAACGAGGAAGTGCCTGCAGGTGGAGAACTGCACCCAGCTGGGG  
GAGCAGTGCTGGACCGCGCGCATCCGCGCAGTGGCCTCCTGACCGTCATCAGCAAAGGCTG  
CAGCTTGAAC TGCGTGGATGACTCACAGGACTACTACGTGGCAAGAAGAACATCAGTGCT  
GTGACACCGACTTGTGCAACGCCAGCGGGGCCATGCCCTGCAGCCGGCTGCCGCCATCCTT  
GCGCTGCTCCCTGCACTCGGCCTGCTGCTCTGGGACCCGGCCAGCTATAGGCTCTGGGGGG  
CCCCGCTGCAGCCCACACTGGGTGTGGTCCCCAGGCCTCTGTGCCACTCCTCACAGACCTG  
GCCCACTGGGAGCCTGTCCTGGTCCCTGAGGCACATCCTAACGCAAGTCTGACCATGTATGT  
CTGCACCCCTGTCCCCACCCCTGACCCCTCCATGGCCCTCTCCAGGACTCCCACCCGGCAGA  
TCAGCTCTAGTGACACAGATCCGCTGCAGATGGCCCTCCAACCCCTCTGCTGCTGTTCCAT  
GGCCCAGCATTCTCCACCCCTTAACCCCTGTGCTCAGGCACCTCTCCCCCAGGAAGCCTTCCC  
TGCCCACCCATCTATGACTTGAGCCAGGTCTGGTCCGTGGTCCCCGACCCAGCAGGG  
GACAGGCACTCAGGAGGGCCAGTAAAGGCTGAGATGAAGTGGACTGAGTAGAACTGGAGGA  
CAAGAGTCGACGTGAGTTCTGGAGTCTCCAGAGATGGGCCTGGAGGCCTGGAGGAAGGG  
GCCAGGCCTCACATTGTTGGCTCCCTGAATGGCAGCCTGAGCACAGCGTAGGCCCTTAAT  
AAACACCTGTTGGATAAGCCAAAAAAA

**FIGURE 9**

MAGLALQPGTALLCYSCKAQVSNEDCLQVENCTQLGEQCWTARIRAVGLTVISKGCSLNCV  
DDSQDYYVGKKNITCCDTDLNASGAHALQPAAAILALLPALGLLLWGPQQL

**FIGURE 10**

ATGGGAGCCGCCCGCCTGCTGCCAACCTCACTCTGTGCTTACAGCTGCTGATTCTCTGCTG  
TCAAACTCAGTACGTGAGGGACCAGGGGCCATGACCGACCAGCTGAGCAGGCAGATCC  
GCGAGTACCAACTCTACAGCAGGACCAGTGGCAAGCACGTGCAGGTACCGGGCGTCGCATC  
TCCGCCACCGCCGAGGAACGAAACAAGTTGCCAAGCTCATAGTGGAGACGGACACGTTGG  
CAGCCGGGTTCGCATCAAAGGGCTGAGAGTGAGAAGTACATCTGTATGAACAAGAGGGCA  
AGCTCATCGGAAGCCCAGCGGAAGAGCAAAGACTGCGTGTTCACGGAGATCGTGCCTGGAG  
AACAACTATACTGGCCTTCCAGAACGCCGGCACGAGGGCTGGTCATGGCCTCACGCCGA  
GGGGCGGCCCGCCAGGCTTCCCGCAGCCAGAACCGCGAGAAGCAGAAGCAGTTGAGTT  
GCCTCTACCAAGGCCAGCTGCCCTCCCCAACCACGCCGAGAAGCAGAAGCAGTTGAGTT  
GTGGGCTCCGCCCCCACCGCCGGACCAAGCGCACACGGCGCCAGCCCTCACGTAGTC  
TGGGAGGCAGGGGGCAGCAGCCCTGGGCCCTCCCCACCCCTTCCCTTAATCCAAG  
GAATGGGCTGGGTGGCGGGAGGGGAGCCAGATCCCCGAGGGAGGGACCTGAGGGCCCGA  
GCATCCGAGCCCCCAGCTGGAAAGGGCAGGCCGGTGCCTGGGCCAGGGCGGCTGGCACAGTG  
CCCTTCCCGACGGTGGCAGGCCCTGGAGAGGAAGTGTACCCCTGATCTCAGGCCAC  
CAGCCTTGCCGGCTCCCAGCCGGCTCTGAAGCCCGCTGAAAGGTCAAGCAGTGAAGGC  
CTTGCAGACAACCGTCTGGAGGTGGCTGTCTCAAAATCTGTTCTGGATCTCCCTCAGTC  
TGCCCCCAGCCCCAAACTCCTCTGGCTAGACTGTAGGAAGGGACTTTGTTGTTGTT  
GTTTCAGGAAAAAAGAAAGGGAGAGAGAGGAAAATAGAGGGTTGTCCACTCCTCACATTCCA  
CGACCCAGGCCTGCACCCACCCCCACTCCAGCCCCGGAATAAAACCATTTCTGC

## **FIGURE 11**

Met Gly Ala Ala Arg Leu Leu Pro Asn Leu Thr Leu Cys Leu Gln  
Leu Leu Ile Leu Cys Cys Gln Thr Gln Tyr Val Arg Asp Gln Gly  
Ala Met Thr Asp Gln Leu Ser Arg Arg Gln Ile Arg Glu Tyr Gln  
Leu Tyr Ser Arg Thr Ser Gly Lys His Val Gln Val Thr Gly Arg  
Arg Ile Ser Ala Thr Ala Glu Asp Gly Asn Lys Phe Ala Lys Leu  
Ile Val Glu Thr Asp Thr Phe Gly Ser Arg Val Arg Ile Lys Gly  
Ala Glu Ser Glu Lys Tyr Ile Cys Met Asn Lys Arg Gly Lys Leu  
Ile Gly Lys Pro Ser Gly Lys Ser Lys Asp Cys Val Phe Thr Glu  
Ile Val Leu Glu Asn Asn Tyr Thr Ala Phe Gln Asn Ala Arg His  
Glu Gly Trp Phe Met Ala Phe Thr Arg Gln Gly Arg Pro Arg Gln  
Ala Ser Arg Ser Arg Gln Asn Gln Arg Glu Ala His Phe Ile Lys  
Arg Leu Tyr Gln Gly Gln Leu Pro Phe Pro Asn His Ala Glu Lys  
Gln Lys Gln Phe Glu Phe Val Gly Ser Ala Pro Thr Arg Arg Thr  
Lys Arg Thr Arg Arg Pro Gln Pro Leu Thr

**FIGURE 12**

ACTTGCCATCACCTGTTGCCAGTGTGGAAAAATTCTCCCTGTTGAATTTCACATGGAG  
 GACAGCAGCAAAGAGGGCAACACAGGCTGATAAGACCAGAGACAGCAGGGAGATTATTTAC  
 CATA CGCCCTCAGGACGTTCCCTAGCTGGAGTTCTGGACTTCAACAGAACCCCATCCAGT  
 CATT TGATTTGCTGTTATTTTTCTTTCTTTCCCACACATTGTATTTAT  
 TTCCGTACTTCAGAAATGGGCCTACAGACCACAAAGTGGCCAGCCATGGGCTTTTCT  
 GAAGTCTGGCTTATCATTCCCTGGGCTACTCACAGGTGTCAAACACTCCTGGCCTGCC  
 CTAGTGTGTGCCGCTGCAGAGAACCTTGTCTACTGTAATGAGCGAAGCTTGACCTCAGTG  
 CCTCTGGGATCCGGAGGGCGTAACCGTACTCTACCTCCACAACAACAAATTAAATG  
 TGGATTCCTGCAGAACTGCACAATGTACAGTCGGTGACACCGGTCTACCTGTATGGCAACC  
 AACTGGACGAATTCCCCATGAACCTTCCAAGAATGTCAAGAGTCTCCATTGCAAGGAAAACAAT  
 ATTCA GACCATTTCACGGGCTGCTTGCCTGCCCAGCTTGAAGCTTGAAGAGCTGCACTGGA  
 TGACA ACTCCATATCCACAGTGGGGGTGGAAGACGGGCTCCGGGAGGCTATTAGCCTCA  
 AATTGTTGTTTGTCTAAGAATCACCTGAGCAGTGTGCCTGTTGGCTCTGTGGACTTG  
 CAAGAGCTGAGAGTGGATGAAAATCGAATTGCTGTCATATCCGACATGGCCTCCAGAATCT  
 CACGAGCTGGAGCGTCTTATTGTTGACGGAACCTCCTGACCAACAAGGGTATGCCGAGG  
 GCACCTTCAGCCATCTCACCAAGCTCAAGGAATTTCATTTGACTGTAATTGCTGTCCCAC  
 CCTCCTCCGATCTCCAGGTACGCATCTGATCAGGCTCTATTGCAAGGACAACCAGATAAA  
 CCACATTCCCTTGACAGCCTCTCAAATCTCGTAAGCTGGAACGGCTGGATATATCCAACA  
 ACCAACTGCGGATGCTGACTCAAGGGTTTTGATAATCTCTCCAACTGAAGCAGCTCACT  
 GCTCGGAATAACCCCTGGTTTGACTGCACTATTAAATGGGTACAGAATGGCTCAAATA  
 TATCCCTTCATCTCTCAACGTGCGGGTTTCACTGTCCTGCAAGGTCTGAACAAGTCCGGGG  
 TGGCGTCAGGGATTAAATATGAATCTTGTCTGCTCCACCACGACCCCCGGCTGCC  
 CTCTTCAACCCAGCCCCAAGTACAGCTCTCCGACCACTCAGCCTCCACCCTCTATTCC  
 AAACCCTAGCAGAAAGCTACACGCCTCCAACCTACCACATCGAAACTCCCACGATTCTG  
 ACTGGGATGGCAGAGAAAGAGTGAACCCACCTATTCTGAACGGATCCAGCTCTATCCAT  
 TTTGTAATGATACTTCAAGTCAGCTGGCTCTCTCTTCACTGACGCTGATGGCATACAA  
 ACTCACATGGGTAAAATGGCCACAGTTAGTAGGGGGCATCGTCAGGAGCGCATAGTCA  
 GCGGTGAGAAGCAACACCTGAGCCTGGTTAACTTAGAGCCCCGATCCACCTATCGGATTGT  
 TTAGTGCCTGGATGCTTTAACTACC CGCGGTAGAAGACACCATTGTCAGAGGCCAC  
 CACCCATGCCTCTATCTGAACAACGGCAGCAACACAGCGTCCAGCCATGAGCAGACGACT  
 CCCACAGCATGGGCTCCCCCTTCTGCTGGCGGGCTTGATGGGGGGCGCGGTGATATTGTG  
 CTGGTGGTCTTGCTCAGCGTCTTGCTGGCATATGCACAAAAAGGGCGCTACACCTCCA  
 GAAGTGGAAATACAACCGGGCCGGAAAGATGATTATTGCGAGGCAGGCACCAAGAAG  
 ACAACTCCATCCTGGAGATGACAGAAACCAGTTTCAAGATCGTCTCTTAAATAACGATCAA  
 CTCCTTAAAGGAGATTTCAGACTGCAGCCATTACACCCAAATGGGGCATTAATTACAC  
 AGACTGCCATATCCCCAACACATGCAGTACTGCAACAGCAGCGTGCAGACCTGGAGCACT  
 GCCATACGTGACAGCCAGAGGCCAGCGTATCAAGGCGGACAATTAGACTCTTGAGAACAC  
 ACTCGTGTGTGCACATAAAGACACGCAGATTACATTGATAATGTTACACAGATGCATTG  
 TGCATTGAATACTCTGTAATTATACGGTGTACTATATAATGGGATTAAAAAAAGTGCTA  
 TCTTTCTATTCAAGTTAATTACAAACAGTTGTAACTCTTGCTTTAAATCTT

**FIGURE 13**

><1158/ss.DNA36350  
><subunit 1 of 1, 660 aa, 1 stop  
><MW: 74049, pI: 8.09, NX(S/T): 7  
MGLQTTKWPSPHGAGFLKSWSLIIISLGLYSQVSQSKLLACPSVCRCDRNFVYCNERSLTSVPLGIPEGVTVLYLHNNQINNAGFPAELHNVQSVHTVYLYGNQLDEFPMNLPKNVRVLHLQENN  
IQTISRAALAQLLKLEELHLDNSISTVGVEDGAFREAIISLKLLFLSKNHLSVPVGLPV  
DLQELRVDENRIAVISDMAFQNLTSLERLIVDGNLLTNKGIAEGTFSHLTKLKEFSIVRN  
SLSHPPPDLPGTHLIRLYLQDNQINHIPLTAFSNLRKLERLDISNNQLRMLTQGVFDNLS  
NLKQLTARNNPWFCDCSIKWVTEWLKYIPSSLNVRGFMCGPEQVRGMARVELNMNLLSC  
PTTTPGLPLFTPAPSTASPTTQPPTLSIPNPNPSRSYTPPTPTTSLPTIPDWDGRERVTPP  
ISERIQLSIHVFNDTSIQVSWLSLFTVMAYKLTWVKMGHSLVGGIVQERIVSGEKQHLSL  
VNLEPRSTYRICLVPLDAFNRYRAVEDTICSEATTHASYLNNGSNTASSHEQTTSHSMGSP  
FLLAGLIGGAVIFVLVVLLSVFCWHMHKKGRYTSQWKYNRGRRKDDYCEAGTKKDNSIL  
EMTETSFQIVSLNNNDQLKGDFRLQPIYTPNGGINYTDCHIPNNMRYCNSSVPDLEHCHT

## **FIGURE 14A**

ACTTGGAGCAAGCGCGGCGGCGGAGACAGAGGCAGAGGCAGAAGCTGGGCTCCGTCTCG  
 CCTCCCACGAGCGATCCCCGAGGGAGAGCCGCGGCCCTCGCCTCGCTTCCAGGCGCCGGCTGCAGCCTTGCCCC  
 TCTTGCTCGCCTTGAAATGGAAAAGATGCTCGCAGGCTGCTTCTGCTGATCCTCGGACAG  
 ATCGTCCTCCTCCCTGCCAGGGAGCGGTACGTGGGAGGTCATCTCTAGGGGAG  
 ACACGCTCGGACCCACCCGCAGACGGCCCTCTGGAGAGTTCTGTGAGAACACAAGCGGGAG  
 ACCTGGTTTCATCATTGACAGCTCTCGCAGTGTCAACACCCATGACTATGCAAAGGTCAAG  
 GAGTTCATCGTGGACATCTGCAATTCTGGACATTGGCTCTGATGTCACCCGAGTGGGCT  
 GCTCCAATATGGCAGCACTGTCAAGAACATGAGTTCTCCCTCAAGACCTTAAGAGGAAGTCCG  
 AGGTGGAGCGTGTCAAGAGGATGCGGCATCTGTCACGGCACCATGACTGGCTGGCC  
 ATCCAGTATGCCCTGAACATCGCATTCTAGAACAGAGGGGGCCGGCCCTGAGGGAGAA  
 TGTGCCACGGGTATAATGATCGTACAGAGATGGGAGACCTCAGGACTCCGTGGCCAGGTGG  
 CTGCTAAGGCACGGACACGGGCATCCTAATCTTGCCATTGGTGTGGCCAGGTAGACTTC  
 AACACCTGAAGTCCATTGGAGTGAGCCCCATGAGGACCATGTCCTCCTGTGGCCAATT  
 CAGCCAGATTGAGACGCTGACCTCCGTGTCAGAACAGAGTTGTGCACGGCCACATGTCA  
 GCACCCCTGGAGCATAACTGTGCCACTTCTGCATCAACATCCCTGGCTCATACGTCTGCAGG  
 TGCAAACAAGGCTACATTCTCAACTCGGATCAGACGGACTTGCAAGAACAGGATCTGTGTGC  
 CATGGAGGACCACAACGTGAGCAGCTCTGTGAATGTGCCGGCTCCTCGTCTGCCAGT  
 GCTACAGTGGCTACGCCCTGGCTGAGGATGGGAAGAGGTGTGGCTGTGGACTACTGTGCC  
 TCAGAAAACCACGGATGTGAACATGAGTGTAAATGCTGATGGCTCTACCTTGCCAGTG  
 CCATGAAGGATTGCTCTAACCCAGATGAAAAAACGTGCACAAGGATCAACTACTGTGCAC  
 TGAACAAACCGGGCTGTGAGCATGAGTGCCTAACATGGAGGAGAGCTACTACTGCCGCTGC  
 CACCGTGGCTACACTCTGGACCCAACTGGCAAAACCTGCAGCCGAGTGGACCACTGTGCACA  
 GCAGGACCATGGCTGTGAGCAGCTGTGAACACAGGAGGATTCCCTCGTCTGCCAGTGCT  
 CAGAAGGCTCCTCATCAACGAGGACCTCAAGACCTGCTCCGGGTGATTACTGCCGCTGC  
 AGTGACCAGGGTTGTGAATACTCCTGTCAACATGGACAGATCCTTGCTGTCAAGTGCC  
 TGAGGGACACGTGCTCCGCAGCGATGGGAAGACGTGTGCAAATTGGACTCTTGCTGTCTGG  
 GGGACCACGGTTGTGAACATTGCTGTGAAGCAGTGAAGGATTGTTGTGCTGCCAGTGCTTT  
 GAAGGTTATATACTCCGTGAAGATGGAAAAACCTGCAGAACAGGAAAGATGTCTGCCAAGCTAT  
 AGACCAGGGCTGTGAACACATTGTGAACAGTGCACACTACACGTGCGAGTGCTTGG  
 AGGGATTCCGGCTCGCTGAGGATGGAAACGCTGCCGAAGGAAGGATGTCTGCAAATCAACC  
 CACCATGGCTCGAACACATTGTGTTATAATGGAAATTCTACATCTGCAAATGCTCAGA  
 GGGATTGTTCTAGCTGAGGACGGAAGACGGTCAAGAAATGCACTGAAGGCCAATTGACC  
 TGGCTTGATCGATGGATCCAAGAGTCTGGAGAAGAGAATTGAGGTGCTGAAGCAG  
 TTTGTCACTGGAATTATAGATTCCCTGACAATTCCCCAAAGCCGCTCGAGTGGGCTGCT  
 CCAGTATTCCACACAGGCCACACAGACTCACTCTGAGAACACTCAACTCAGCCAAAGACA  
 TGAAAAAAAGCCGTGGCCACATGAAATACATGGAAAGGGCTCTATGACTGGGCTGGCCCTG  
 AAACACATGTTGAGAGAAGTTTACCAAGGAGAACGGCCAGGCCCTTCCACAAGGGT  
 GCCCAGAGCAGCCATTGTTGTTACCGACGGACGGGCTCAGGATGACGTCTCGAGTGGGCA  
 GTAAAGCCAAGGCCAATGGTATCACTATGATGCTGTTGGGTAGGAAAAGCCATTGAGGAG  
 GAACTACAAGAGATTGCCCTGTGAGGCCACAAACAAGCATCTCTATGCCGAAGACTTCAG  
 CACAATGGATGAGATAAGTGAAGAAACTCAAGAACGGCATCTGTGAAGCTCTAGAACAGACTCCG  
 ATGGAAGACAGGACTCTCCAGCAGGGAACTGCCAAAAGGTCAAACGCCAACAGAACATCT  
 GAGCCAGTCACCATAAATATCCAAGACCTACTTCTGTTCTAATTGCAAGTGCAACACAG  
 ATATCTGTTGAAGAAGACAATCTTTACGGTCTACACAAAGCTTCCCATTCAACAAAC  
 CTTCAAGGAAGGCCATTGGAAGAAAAACAGATCAATGCAAATGTGAAAACCTTATAATGTT  
 CAGAACCTTGCAAACGAAGAAGTAAGAAAATTAAACACAGCGCTTAGAAGAAATGACACAGAG  
 AATGGAAGGCCATTGGAAGAACATGCGTGAAGATACAGATGAAGATTAGAAATCGCGACACATTG  
 AGTCATTGTATCACGGATTACAATGAACGAGTGCAGAGGCCAAAGCTCAGGCTATTGTTA  
 AATCAATAATGTTGTGAAGTAAACAATCAGTACTGAGAACCTGGTTGCCACAGAACAAA  
 GACAAGAAGTATACACTAACTTGTATAAATTATCTAGGAAAAAAATCCTTCAGAATTCTAA  
 GATGAATTTACCGGTGAGAATGAATAAGCTATGCAAGGTATTTGTAATATACTGTGGACA  
 CAACTGCTTCTGCCTCATCCTGCCCTAGTGTGCAATCTCATTTGACTATACGATAAGTT

**FIGURE 14B**

GCACAGTCTACTTCTGTAGAACACTGGCCATAGGAAATGCTGTTTTTGACTGGACTTT  
ACCTTGATATATGTATATGGATGTATGCATAAAATCATAGGACATATGTACTTGTGGAACAA  
GTTGGATTTTTATACAATATTAAAATTCAACCTTCAG

**FIGURE 15**

><1164/ss.DNA32290  
><subunit 1 of 1, 915 aa, 1 stop  
><MW: 102233, pI: 6.02, NX(S/T): 1  
MEKMLAGCFLLILGQIVLLPAEARERSRGRSISRGRHARTHQPQTALLESSCENKRADLVF  
IIDSSRSVNTHDYAKVKEFIVDILQFLDIGPDVTRVGLLQYGSTVKNEFSLKTFRKSEV  
ERAVKMRHLSTGTMTGLAIQYALNIAFSEAEGARPLRENVPRVIMIVTDGRPQDSVAEV  
AAKARDTGILIFAIGVGQVDFNTLKSIGSEPHEDHVFLVANFSQIETLTSVFQKKLCTAH  
MCSTLEHNCAHFCINIPGSYVCRCKQGYILNSDQTTCRIQDLCAMEDHNCEQLCVNVPGS  
FVCQCYSGYALAEDGKRCVAVDYCASENHGCEHECVNADGSYLCQCHEGFALNPDEKTCT  
RINYCALNKGCEHECVNMEESYYCRCHRGYTLDPNGKTCRVDHCAQQDHGCEQLCLNT  
EDSFVCQCSEGFLINEDLKTCSRVDYCLLSDHGCEYSCVNMDRSFACQCPEGHVLRSRGK  
TCAKLDSCALGDHGCEHSCVSSEDSFVCQCFEGYILREDGKTCRRKDVCQAIDHGCEHIC  
VNSDDSYTCECLEGFRLAEDGKRCRRKDVKSTHHGCEHICVNNGNSYICKCSEGFLVLAE  
DGRRKCKCTEGPIDLVFVIDGSKSLGEENFEVVQFVTGIIDSLTISPKAARVGLLQYST  
QVHTEFTLRNFNSAKDMKKAVAHMKYMGKGSMTGLALKHMFERSFTQGEGARPLSTRVPR  
AAIVFTDGRAQDDVSEWASKAKANGITMYAVGVGKAIEEELQEIASEPTNKHLFYAEDFS  
TMDEISEKLKKGICEALESDGRQDSPAGELPKTVQQPTESEPVTINIQDLLSCSNFAVQ  
HRYLFEDNLLRSTQKLSHSTKPSGSPLEEKHDQCKCENLIMFQNLANEEVRKLTQRLEE  
MTQRMEALENRLRYR

**FIGURE 16**

GGAGCCGCCCTGGGTGTCAGCGGCTCGGCTCCGCACGCTCCGGCGTCGCAGCCTCG  
GCACCTGCAGGTCCGTCCGCTCCGGCTGGCGCCCTGACTCCGTCCGGCCAGGGAGGGC  
CATGATTCCCTCCCAGGGCCCTGGTGACCAACTTGCTCGGGTTTGTCTGGGCTGA  
GTGCCCTCGGCCCTCGGGCCCAGCTGCAACTGCACTTGCCCACCGGTTGCAG  
GCGGTGGAGGGAGGGAAAGTGGTCTCCAGCGTGGTACACCTGCACGGGAGGGTCTTC  
ATCCCAGCCATGGGAGGTGCCCTTGTGATGTGGTCTTCAAACAGAAAGAAAAGGAGGATC  
AGGTGTTGTCCTACATCAATGGGTCACAACAAGCAAACCTGGAGTATCCTGGTCTACTCC  
ATGCCCTCCCGAACCTGCTCCGTGGAGGGTCTCCAGGAGAAAGACTCTGGCCCTA  
CAGCTGCTCCGTGAATGTGCAAGACAAACAAGGCAAATCTAGGGGCCACAGCATCAAAACCT  
TAGAACTCAATGTAUTGGTCTCCAGCTCCTCCATCCTGCCGTCTCCAGGGTGTGCCCAT  
GTGGGGCAAACGTGACCTGAGCTGCCAGTCTCCAAGGAGTAAGCCGCTGTCCAATACCA  
GTGGGATCGGAGCTTCATCCTCCAGACTTCTTGACCAGCATTAGATGTCATCCGTG  
GGTCTTAAGCCTCACCAACCTTCGTCTTCATGGCTGGAGTCTATGTCATGCCAGGCCCAC  
AATGAGGTGGGACTGCCAATGTAATGTGACGCTGGAAGTGAGCACAGGGCTGGAGCTGC  
AGTGGTTGCTGGAGCTGTTGGTACCTGGTGGACTGGGTTGCTGGCTGGCTGGTCC  
TCTTGTACCACCGCCGGGCAAGGCCCTGGAGGAGCCAGCCAATGATATCAAGGAGGATGCC  
ATTGCTCCCCGGACCCCTGCCCTGCCCAAGAGCTCAGACACAATCTCCAAGAATGGGACCT  
TTCCTCTGTCACCTCCGACGAGCCCTCCGGCACCCATGCCCTCCAGGCCTGGTGCAT  
TGACCCCCACGCCAGTCTCCAGCCAGGCCCTGCCCTCACCAAGACTGCCACGACAGAT  
GGGGCCCACCCCTCAACCAATATCCCCATCCCTGGTGGGTTCTCCTCTGGCTGAGCCG  
CATGGGTGCTGCTGATGGTGCCTGCCAGAGTCAAGCTGGCTCTGGTATGAC  
CCCACCACTATTGGCTAAAGGATTGGGCTCTCCTTATAAGGGTACCTCTAGCAC  
AGAGGCCTGAGTCATGGAAAGAGTCACACTCCTGACCCCTAGTACTCTGCCACCTCTC  
TTTACTGTGGAAAACCCTCAGTAAGACCTAAGTGTCCAGGAGACAGAAGGAGAAGAGGA  
AGTGGATCTGGAATTGGGAGGAGCCTCACCCACCCCTGACTCCTCCTATGAAGCCAGCTG  
CTGAAATTAGCTACTCACCAAGAGTGAGGGCAGAGACTTCCAGTCAGTGAGTCTCCAGGC  
CCCCTGATCTGTACCCACCCCTATCTAACACCACCTGGCTCCACTCCAGCTCCCTGT  
ATTGATATAACCTGTCAGGCTGGTTGGTAGGTTTACTGGGCAGAGGATAGGAAATCTC  
TTATTAAGGAACTAACATGAAATATGTGTTTTCAATTGCAAATTAAATAAGATACTAA  
TGTTGTATGAAAAA

**FIGURE 17**

><1172/ss.DNA35639  
><subunit 1 of 1, 390 aa, 1 stop  
><MW: 41176, pI: 9.61, NX(S/T): 5  
MISLPGPLVTNLLRFLFLGLSALAPPSRAQLQLHLPANRLQAVEGGEVVLPAWYTLHGEV  
SSSQPWEVPFVMWFFKQKEKDQVLSYINGVTTSKPGVSLVYSMPSRNLSLRLEGLQEKD  
SGPYSCSVNVQDKQGKSRGHSIKTLELNVLVPPAPPSCRLQGVPHVGANVTLSCQSPRSK  
PAVQYQWDRQLPSFQTFFAPALDVIRGSLSLTNLSSSMAGVYVCKAHNEVGTAQCNVTL  
VSTGPGAAVVAGAVVGTIVGLGLLAGLVLLYHRRGKALEEPANDIKEDAIAPRTLWPWPKS  
SDTISKNGTLSSVTSARALRPPHGPPRGALTPTPSLSSQALPSPRLPTTDGAHPQPISP  
IPGGVSSSGLSRMGAVPVMVPAQSQAGSLV

**FIGURE 18**

```

CGCCACCACTGCGGCCACCGCCA
><MET {trans=1-s, dir=f, res=1}>
ATGAAACGCCTCCGCTCCTAGTGGTTTTCACTTGTTGAATTGTTCTATACTCAA
AATTGCACCAAGACACCTTGTCTCCAAATGCAAATGCAATGGAATTGAA
GCCTGCTATTGCAACATGGGATTTCAAGGAAATGGTGTACAATTGTAAGAGATGATAAT
GAATGTGGAAATTAACTCAGTCTGTGGCGAAATGCTAATTGACTAACACAGAAGGA
AGTTATTATTGTATGTGTGACCTGGCTTCAGATCCAGCAGTAACCAAGACAGGTTATC
ACTAATGATGGAACCCTGTATAGAAAATGTGAATGCAAACGCCATTAGATAATGTC
TGTATAGCTGCAAATATTAACTTAAACAAAATCAGATCCATAAAAGAACCTGTG
GCTTGCTACAAGAAGTCTATAGAAATTCTGTGACAGATCTTCACCAACAGATATAATT
ACATATATAGAAATATTAGCTGAATCATCTCATTACTAGGTACAAGAACACTATC
TCAGCCAAGGACACCCTTCTAACACTCAACTCTTACTGAATTGTTAAAAACCGTGAATAAT
TTTGTCAAAGGGATACATTGTAGTTGGACAAGTTATCTGTGAATCATAGGAGAAC
CATCTACAAAACATGCACACTGTTGAACAAGCTACTTTAAGGATATCCCAGAGCTC
CAAAGACCACAGAGTTGATACAAATTCAACGGATAAGCTCTCAAAGTTTCTTTT
GATTCAATATAACATGAAACATATTCACTCCTCATATGAATATGGATGGAGACTACATAAT
ATATTCCAAGAGAAAAGCTGCATATGATTCAAATGGCAATGTTGCAGTTGCATT
TATTATAAGAGTATTGGCCTTGCTTCATCATCTGACAACCTCTTATTGAAACCTCAA
AATTATGATAATTCTGAAGAGGAGGAAAGAGTCATATCTCAGTAATTTCAGTCATG
AGCTCAAACCCACCCACATTATATGAACTTGAACAAATAACATTACATTAAGTCATCGA
AAGGTACAGATAGGTATAGGAGTCTATGTGCAATTGGAATTACTCACCTGATACCATG
AATGGCAGCTGGCTTCAGAGGGCTGTGAGCTGACACTCAATGAGAACCCACACCTCA
TGCGCTGTAATCACCTGACACATTGCAATTGATGTCCTCTGGCCTTCCATTGGT
ATTAAGAGTATTAAATATTCTTACAAGGATCACTCAACTAGGAATAATTATTCACTGATT
TGTCTGCCATATGCATTTCACCTTCTGGTCTTCAGTGAATTCAAAGCACCAGGACA
ACAATTCAACAAAATCTTGCTGTAGCCTATTCTGCTGAACATTGTTTCTGTTGGG
ATCAATACAACAAACTAATAAGCTCTCTGTCATCATTGCCGACTGCTACACTACTC
TTTTAGCTGCTTGCATGGATGTGCATTGAAGGCATACATCTCTATCTCATTGTTGTG
GGTGCATCTACAACAAGGGATTTGCACAAGAATTATCTTGGCTATCTAAC
CCAGCCGTGGTAGTTGGATTTCCGCAGCACTAGGATACAGATATTATGGCACAACCAA
GTATGTTGGCTAGCACCAGAAAACAACCTTATTGGAGTTTATAGGACCGCATGCCTA
ATCATCTTGTAAATCTCTGGCTTTGGAGTCATCATATAACAAAGTTTCTGTCACACT
GCAGGGTTGAAACCAGAAGTTAGTTGCTTGAGAACATAAGGTCTGCAAGAGGAGCC
CTCGCTTCTGTCCTCTGGCACCCACCTGGATCTTGGGTTCTCATGTTGTGCAC
GCATCAGTGGTACAGCTTACCTCTCACAGTCAGCAATGCTTCCAGGGATGTTCATT
TTTTATTCTGTGTTATCTAGAAAGATTCAAGAAGAATATTACAGATTGTTCAA
AATGCCCCCTGTTGGATTTAAGGTAACATAGAGAATGGTGATAATTACAAC
TGCACAAAATAAAATCCAAGCTGTGGATGACCAATGTATAAAATGACTCATCAAAT
TATCCAATTATAACTAGACAAAAAGTATTAAATCAGTTTCTGTTATGCTAT
AGGAACCTGTAGATAATAAGGAAAATTATGTATCATATAGATATACTATGTTTCTATG
TGAAATAGTTCTGTCAAAATAGTATTGCAGATATTGGAAAGTAATTGTTCTCAGGA
GTGATATCACTGCACCCAGGAAAGATTCTTCTAACACGAGAAGTATATGAATGTCC
TGAAGGAAACCACTGGCTTGATATTCTGTGACTCGTGTGCTTGAACACTAGTCCCCT
ACCACCTCGGTAAATGAGCTCCATTACAGAAAGTGGAACATAAGAGAATGAAGGGCAGAA
TATCAAACAGTGAAAAGGGAAATGATAAGATGTATTGAAATGAACTGTTTCTGAGA
CTAGCTGAGAAATTGTTGACATAAAATAAGAATTGAAGAACACATTACCTTACCAATTG
GAATTGTTCTGAACTAAATGTCCACTAAAACAACCTAGACTCTGTTGCTAAATCTGT
TTCTTTCTAATATTCTAAAAAAAAAGGTTACCTCCACAAATTGAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

```

**FIGURE 19**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA33092
><subunit 1 of 1, 690 aa, 0 stop
><MW: .77825, pI: 7.96, NX(S/T): 11
MKRLPLLVVFSTLLNCSYTQNCTKTPCLPNAKCEIRNGIEACYCNMGFSGNGVTICEEDDN
ECGNLTQSCGENANCTNTEGSYYCMCVPGRSSSNQDRFITNDGTVCIENVANCHLDNV
CIAANINKTLTKIRSIKEPVALLQEYVRNSVTDLSPTDIITYIEILAESSSLGYKNNTI
SAKDTLSNSTLTEFVKTVNNFVQRDTFVWDKLSVNHRRTHLTKLMHTVEQATLRISQSF
QKTTEFDTNSTDIALKVFFFDSYNMKHIHPHMNMDGDYINIFPKRKAAYDSNGNVAVAFL
YYKSIGPLLSSSDNFLLKPQNYDNSEEERVISSVISVSMSSNPPTLYELEKITFTLSHR
KVTDRYRSLCAFWNYS PDTMNGWSSEGCELTYSNETHTSCRNCNLTHFAILMSSGPSIG
IKDYNILTRITQLGIIISLICLAICIFTWFFSEIQSTRTTIHKNLCCSLFLAELVFLVG
INTNTNKLFCSSIAGLLHYFFLAFAWMCIEGIHLYLIVVGVINYKGFLHKNFYIFGYLS
PAVVVGFSaalGYRYYGTtkvcwlstennfiwsfigpacliilvnllafgviiykvfrht
AGLKPEVSCFENIRSCARGALALLFLLGTTWIFGVLVHVHASVVTAYLFTVSNAFQGMFI
FLFLCVLSRKIQQEEYYRLFKNVPCCFGCLR
```

**FIGURE 20**

ATAGGAGTCTATGTGGCATTGGAAACTCACCTGATAACCATGAATGGCAGCTGGTCTTCAGAGGGCTGTGAGCTGACATACTCAAATGAGACCCACACCTCATGCCGCTGTAATCACCTGACACATTGGCAATTTGATGTCCTCTGGTCCTCCATTGGTATTAAAGATTATAATATTCTTACAAGGATCACTCAACTAGGAATAATTATTCACTGATTGTCTGCCATATGCATTTTACCTTCTGGTTCTTCAGTGAAATTCAAAGCACCAGGA

**FIGURE 21**

CTCCCAGCCAAGAACCTCGGGGCCGCTGCGCGGTGGGAGGAGTTCCCCGAAACCCGGCCGC  
TAAGCGAGGCCTCCTCTCCCAGATCCGAACGGCCTGGCGGGGTCAACCCGGCTGGGAC  
AAGAAGCCGCCCTGCCCTGCCCGGGCCGGGGAGGGGGCTGGGGCTGGGGCCGGAGGCGGG  
GTGTGAGTGGGTGTGCGGGGGCGGAGGCTTGATGCACTCCCAGATAAGAAATGCTCGGGT  
GTCTGGGCACCTACCCGTGGGGCGTAAGGCCTACTATATAACGCTGCCGCCCTGAGC  
CGCCGAGCCGTCCGAGCAGGAGCGCTGCGTCCAGGATCTAGGGCACGACCATCCAACCCGG  
CATTCACAGCCCCGAGCGCATCCGGTCGCCGGCAGCTCCGCACCCATGCCGGAGCTG  
CGCCGAGAGCCCCAGGGAGGTGCCATGCGGAGCAGGGTGTGGTGGTCCACGTATGGATCCT  
GGCCGGCCTCTGGCTGGCGTGGCGGGCGCCCCCTCGCCTCTCGGACGCGGGCCCCACG  
TGCAC TACGGCTGGGGCGACCCATCCGCTGCGCACCTGTACACCTCCGGCCCCACGGG  
CTCTCCAGCTGCTTCTGCGCATCCGTGCCGACGGCGTCGTTGACTGCGCGGGGCCAGAG  
CGCGCACAGTTGCTGGAGATCAAGGCAGTCGCTCTGCGGACCGTGGCCATCAAGGGCGTGC  
ACAGCGTGCGGTACCTCTGCATGGCGCCGACGGCAAGATGCAGGGCTGCTCAGTACTCG  
GAGGAAGACTGTGCTTCGAGGAGGAGATCCGCCAGATGGCTACAATGTGTACCGATCCGA  
GAAGCACCGCCTCCGGTCTCCCTGAGCAGTGCCAAACAGCGGCAGCTGTACAAGAACAGAG  
GCTTCTCCACTCTCATTTCTGCCATGCTGCCATGGTCCCAGAGGAGGCTGAGGAC  
CTCAGGGGCCACTTGGAAATCTGACATGTTCTTCGCCCTGGAGACCGACAGCATGGACCC  
ATTGGGCTTGTCAACGGACTGGAGGCCGTGAGGAGTCCAGCTTGAGAAGTAAGTAACTGAGAC  
CATGCCCGGGCTTCACTGCTGCCAGGGCTGTGGTACCTGCAGCGTGGGGACGTGCTT  
CTACAAGAACAGTCTGAGTCCACGTTCTGTTAGCTTAGGAAGAACATCTAGAAGTGT  
ACATATTCAAGATTTCATTGGCAGTGCCAGTTCTAGCCAATAGACTTGTCTGATCATAA  
CATTGGAAAGCCTGTACTTGGCCAGCTGTTGCCTGGGCCCTGGGACCGTCTGAGG  
TGCTGGACAAGCTGCTGCACTGTCTCAGTTCTGCTGAATACCTCCATCGATGGGAACCTCA  
CTTCCCTTGGAAAAATTCTTATGTCAAGCTGAAATTCTCTAATTTCTCATCACTCCCCA  
GGAGCAGCCAGAAGACAGGAGTAGTTAATTTCAGGAACAGGTGATCCACTCTGAAAAC  
AGCAGGTAAATTTCACTCAACCCATGTGGGAATTGATCTATCTACTTCCAGGGACCA  
TTTGCCTTCCAAATCCCTCCAGGCCAGAACTGACTGGAGCAGGCATGGCCACCAGGCTT  
CAGAAGTAGGGGAAGCCTGGAGCCCCACTCCAGCCCTGGGACAACCTGAGAATTCCCCCTGA  
GGCCAGTTCTGTCATGGATGCTGCTGAGAATAACTTGCTGTCCCCTGTCACCTGCTTCC  
ATCTCCAGCCCACCAGCCCTGCCCACCTCACATGCCCTCCCATGGATTGGGGCTCCCA  
GGCCCCCACCCTATGTCAACCTGCACTTCTGTTCAAAAATCAGGAAAAGAAAAGATTGA  
AGACCCCAAGTCTTGTCAATAACTGCTGTGGAAGCAGCGGGGGAAAGACCTAGAACCTT  
TCCCCAGCACCTGGTTTCCAACATGATATTATGAGTAATTATTTGATATGTACATCTC  
TTATTTCTTACATTATTATGCCCAAATTATATTATGTATGTAAGTGAGGTTGTTTGT  
GTATATTAAAATGGAGTTGTTGT

**FIGURE 22**

Met Arg Ser Gly Cys Val Val Val His Val Trp Ile Leu Ala Gly  
Leu Trp Leu Ala Val Ala Gly Arg Pro Leu Ala Phe Ser Asp Ala  
Gly Pro His Val His Tyr Gly Trp Gly Asp Pro Ile Arg Leu Arg  
His Leu Tyr Thr Ser Gly Pro His Gly Leu Ser Ser Cys Phe Leu  
Arg Ile Arg Ala Asp Gly Val Val Asp Cys Ala Arg Gly Gln Ser  
Ala His Ser Leu Leu Glu Ile Lys Ala Val Ala Leu Arg Thr Val  
Ala Ile Lys Gly Val His Ser Val Arg Tyr Leu Cys Met Gly Ala  
Asp Gly Lys Met Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys  
Ala Phe Glu Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg  
Ser Glu Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln  
Arg Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe  
Leu Pro Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg  
Gly His Leu Glu Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp  
Ser Met Asp Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg  
Ser Pro Ser Phe Glu Lys

**FIGURE 23**

CCCGAGAAGTTCAAGGGCCCCGGCCTCCTGCGCTCCTGCCGCCGGGACCCCTGACCTCCTCA  
GAGCAGCCGGCTGCCGCCCCGGGAAGATGGCGAGGAGGAGCCGCCACCGCCTCCTGCTG  
CTGCTGCGCTACCTGGTGGTCGCCCTGGCTATCATAAGGCCTATGGGTTTCTGCCCAAA  
AGACCAACAAGTAGTCACAGCAGTAGAGTACCAAGAGGCTATTTAGCCTGCAAACCCCAA  
AGAAGACTGTTCCAGATTAGAGTGGAAGAAAAGGGTCGGAGTGTCTCCTTGTCTAC  
TATCAACAGACTCTCAAGGTGATTTAAAAATCGAGCTGAGATGATAGATTCAATATCCG  
GATCAAAAATGTGACAAGAAGTGTGATGCCGGAAATATCGTTGTGAAGTTAGTGCCTCATCTG  
AGCAAGGCCAACCTGGAAGAGGATACAGTCACTCTGGAAGTATTAGTGGCTCCAGCAGTT  
CCATCATGTGAAGTACCCCTCTGCTCTGAGTGGAACTGTGGTAGAGCTACGATGTCAAGA  
CAAAGAAGGGAAATCCAGCTCCTGAATAACACATGGTTAAGGATGGCATCCGTTGCTAGAAA  
ATCCCAGACTGGCTCCAAAGCACCAACAGCTCATACACAATGAATAACAAAAGTGGAACT  
CTGCAATTAAACTGTTCAAACGGACACTGGAGAATATTCTGTGAAGCCCGCAATTG  
TGTTGGATATCGCAGGTGTCCTGGAAACGAATGCAAGTAGATGATCTCAACATAAGTGGCA  
TCATAGCAGCCGTAGTAGTTGTGGCCTAGTGATTCCGTTGTGGCCTTGGTGTATGCTAT  
GCTCAGAGGAAAGGCTACTTTCAAAAGAAACCTCCTCCAGAAGAGTAATTCTCATCTAA  
AGCCACGACAATGAGTGAAATGTGCAGTGGCTACGCCTGTAATCCAGCACTTGGAGG  
CCGGCGGGCGGATCACGAGGTAGGAGTTCTAGACCAGTCTGGCCAATATGGTAAACCC  
CATCTCTACTAAAATACAAAATTAGCTGGCATGGTGGCATGTGCCTGCAGTCCAGCTGC  
TTGGGAGACAGGAGAATCACTGAACCCGGGAGGCGGAGGTTGCAGTGAGCTGAGATCACGC  
CACTGCAGTCCAGCCTGGTAACAGAGCAAGATTCCATCTAAAAAATAAAATAATA  
AATAAAATCTGGTTTACCTGTAGAATTCTTACAATAATAGCTTGATATTG

**FIGURE 24**

```
><ss.DNA35638
><subunit 1 of 1, 312 aa, 1 stop
><MW: 34554, pI: 9.39, NX(S/T): 4
MARRSRHRLLLLLRYLVVALGYHKAYGFSAPKDQQVVTAVEYQEAILACKTPKKT
VSSRLEWKKLGRSVSFVYYQQTLQGDFKNRAEMIDFNIRIKNVTRSDAGKYRCEVS
APSEQGQNLEEDTVTLEVVLVAPAVPSCEVPSSALSGTVVELRCQDKEGNPAPEYT
WFKDGI
RLLENPRLGSQSTNSSYT
MNTKTGTLQFNTVSKLDTGEYSCEARNSVGYRRCPGKRMQVDDLNISGI
IAAVVVVALVISVCGLGVCYAQRKGYFSKETSFQKSNSSSKATTMSENVQWLTPV
IPALWKAAAGGSRGQEF
```

## **FIGURE 25**

GACATCGGAGGTGGCTAGCACTGAAACTGCTTTCAAGACGAGGAAGAGGAGGAGAAAGAG  
 AAAGAAGAGGAAGATGTTGGCAACATTATTAACATGCTCCACAGCCGGACCCTGGCAT  
 CATGCTGCTATTCTGCAAATACTGAAGAACATGGATTAAATATTTACTCTAAATAA  
 ATGAATTACTCAATCTCCTATGACCATCTACATACACTCCACCTTCAAAAAGTACATCAATA  
 TTATATCATTAGGAAATAGTAACTCTCTTCTCCAATATGCATGACATTGGACAATG  
 CAATTGTGGACTGGCACTTATTTCAGTGAAGAAAACTTGTGGTTATGGCATTCA  
 TTTGACAAATGCAAGCATCTCCTTATCAATCAGCTCCTATTGAACTTACTAGCACTGACTG  
 TGGAATCCTTAAGGGCCCATTACATTCTGAAGAAGAAAGCTAAGATGAAGGACATGCCACT  
 CCGAATTCTATGTGCTACTTGGCCTAGCTATCACTACACTAGTACAAGCTGTAGATAAAAAG  
 TGGATTGTCCACGGTTATGTACGTGTGAAATCAGGCCCTGGTTACACCCAGATCCATTAT  
 ATGGAAGCATCTACAGTGGATTGTAATGATTAGGTCTTTAACCTTCCAGCAGATTGCC  
 AGCTAACACACAGATTCTCTCCTACAGACTAACAAATATTGCAAAAATTGAATACTCCACAG  
 ACTTTCCAGTAAACCTACTTGGCCTGGATTATCTCAAAACAATTATCTCAGTCACCAAT  
 ATTAATGAAAAAGATGCCCTCAGCTCCTTCTGTGTACCTAGAGGAAAACAAACTTACTGA  
 ACTGCTGAAAAATGCTGTCCGAUTGAGCAACTACAAGAACTCTATATTAAATCACAAC  
 TGCTTCTACAATTTCACCTGGAGCCTTATTGGCCTACATAATCTTCTCGACTTCATCTC  
 AATTCAAATAGATTGCAGATGATCAACAGTAAGTGGTTATGCTCTCCAAATCTAGAGAT  
 TCTGATGATTGGGAAAATCCAATTATCAGAATCAAAGACATGAACCTTAAGCCTTATCA  
 ATCTTCGCAGCCTGGTTAGCTGGTATAAACCTCACAGAAATACAGATAACGCCCTGGTT  
 GGACTGGAAAACCTAGAAAGCATCTCTTTACGATAACAGGGCTTAAAGTACCCCATGT  
 TGCTCTCAAAAAGTTGTAATCTCAAATTGGATCTAAATAAAAATCCTATTAAATAGAA  
 TACGAAGGGGTGATTAGCAATATGCTACACTAAAAGAGTTGGGATAAAATAATAGCCT  
 GAGCTGATTCCATCGATAGTCTGCTGTGGATAACCTGCCAGATTAAAGAAAATAGAAC  
 TACTAACAAACCTAGATTGTCTTACATTCCCCAATGCATTTCAGACTCCCCAAGCTGG  
 AATCACTCATGCTGAACAGCAATGCTCTCAGTGCCCTGTACCTGGTACATTGAGTCTCG  
 CCAAAACCTCAAGGAAATCAGCATACACAGTAACCCCATCAGGTGTGACTGTGTACCGTTG  
 GATGAACATGAACAAAACCAACATTGATTGATGGAGCCAGATTCACTGTTTGCCTGGACC  
 CACCTGAATTCCAAGGTGAGAATGTTGGCAAGTGCTTCAAGGGACATGATGGAAATTGT  
 CTCCCTTCTTATAGCTCTGAGAGCTTCCCTTAATCTAAATGTTAGAAGCTGGAGCTATGT  
 TTCCTTCACTGTAGAGCTACTGCAGAACACAGCCTGAAACTACTGGATAACACCTCTG  
 GTCAAAAACCTTGCCTAATACCCCTGACAGACAAGTTCTATGTCATTCTGAGGGAAACACTA  
 GATATAATGGCGTAACTCCAAAGAAGGGGTTATATACTTGATAGCAACTAACCTAGT  
 TGGCGCTGACTTGAAGTCTGTTATGATCAAAGTGGATGGATCTTCCACAAGATAACAATG  
 GCTCTTGAATATTAAAATAAGAGATATTCAAGGCCATTCAAGTTGGTGTCTGGAAAGCA  
 AGTTCTAAAATTCTCAAATCTAGTGTAAATGGACAGCCTTGTCAAGACTGAAAATTCTCA  
 TGCTGCGCAAAGTGTGCAATACCATCTGATGTCAAGGTATATAATCTTACTCATCTGAATC  
 CATCAACTGAGTATAAAATTGTATTGATATTCCCCACCATCTACAGAAAAACAGAAAAAAA  
 TGTGTAAATGTCACCACCAAGGTTGCACCCCTGATCAAAAAGAGTATGAAAAGAATAATAC  
 CACAACACTTATGGCCTGTCTGGAGGCCTTCTGGGGATTATTGGTGTGATATGTCTTATCA  
 GCTGCCCTCTCCAGAAATGAACGTGATGGTGACACAGCTATGTGAGGAATTACTACAG  
 AAACCAACCTTGCATTAGGTGAGCTTATCCTCCTGTATAAAATCTCTGGGAAGCAGGAAA  
 AGAAAAAAAGTACATCACTGAAAGTAAAGCAACTGTTAGGTTACCAACAAATATGTCTAA  
 AAACCACCAAGGAAACCTACTCCAAAATGAAC

**FIGURE 26**

MKDMPRLIHVLLGLAITTLVQAVDKVDCPRLCTCEIRPWFTPRTSIYMEASTVDCNDLG  
LLTFPARLPANTQILLQTNNIAKIEYSTDFPVNLTGDLSQNNLSSVTNINVKKMPQL  
LSVYLEENKLTELPEKCLSELSNLQELYINHNLLSTISPGAFIGLHNLLRLHLNSNRLQ  
MINSKWFDALPNLEILMIGENPIIRIKDMNFKPLINRSLVIAGINLTEIPDNALVGLE  
NLESISFYDNRLIKVPHVALQKVVLKFLDLNKNPINRIRRGDFSNMLHLKELGINNMP  
ELISIDSIAVDNLPDLRKIEATNNPRLSYIHPNAFFRLPKLESMLNSNALSALYHGTI  
ESLPNLKEISIHSNPIRCDCVIRWMNMNKTNIRFMEPDSDLFCVDPPEFQGQNVRQVHFR  
DMMEICLPLIAPESFPSNLNVEAGSYVSFHCRATAEPQPEIYWITPSGQKLLPNTLTDK  
FYVHSEGTLINGVTPKEGGLYTCIATNLVGADLKSVMIKVDGSPQDNNGSLNIKIRD  
IQANSVLVSWKASSKILKSSVKWTAFVKTENSAAQSARIPSDVKVYNLTHLNPSSTEYK  
ICIDIPTIYQKNRKKCVNVTTKGLHPDQKEYEKNNTTLMACLGGLGIIGVICLISCL  
SPEMNCDGGHSYVRNYLQKPTFALGELYPPLINLWEAGKEKSTSLKVATVIGLPTNMS

**FIGURE 27**

GCCCCGGACTGGCGCAAGGTGCCAAGCAAGGAAAGAAATAATGAAGAGACACATGTGTTAG  
CTGCAGCCTTTGAAACACGCAAGAAGGAAATCAATAGTGTGGACAGGGCTGGAACCTTAC  
CACGCTTGTGGAGTAGATGAGGAATGGGCTCGTATTGCTGACATTCCAGCATGAATCT  
GGTAGACCTGTGGTTAACCGTCCCTCCATGTGTCTCCTCCTACAAAGTTTGTCTTA  
TGATACTGTGCTTCATTCTGCCAGTATGTGTCCAAGGGCTGTCTTGTCTCCTCTGGG  
GGTTAAATGTCACCTGTAGCAATGCAAATCTCAAGGAAATACCTAGAGATCTCCTCCTGA  
AACAGTCTTACTGTATCTGGACTCCAATCAGATCACATCTATTCCAATGAAATTTTAAGG  
ACCTCCATCAACTGAGAGTTCTAACCTGTCCAAAATGGCATTGAGTTATCGATGAGCAT  
GCCTCAAAGGAGTAGCTGAAACCTTGCAGACTCTGGACTTGTCCGACAATGGATTCAAAG  
TGTGCACAAAATGCCTTCATAAACCTGAAGGCCAGGGCCAGAATTGCCAACAAACCCCTGGC  
ACTGCGACTGTACTCTACAGCAAGTTCTGAGGAGCATGGCGTCCAATCATGAGACAGCCCAC  
AACGTGATCTGTAAAACGTCCGTGTTGGATGAACATGCTGGCAGACCATTCTCAATGCTGC  
CAACGACGCTGACCTTGTAACCTCCCTAAAAAAACTACCGATTATGCCATGCTGGTCACCA  
TGTGGCTGGTCACTATGGTGTCTCATATGTGGTATATTATGTGAGGCAAAATCAGGAG  
GATGCCGGAGACACCTCGAATACTTGAAATCCCTGCCAAGCAGGCAGAAGAAAGCAGATGA  
ACCTGATGATATTAGCACTGTGGTATAGTGTCCAAACTGACTGTCAATTGAGAAAGAAAGAAA  
GTAGTTGCGATTGCAGTAGAAATAAGTGGTTACTTCTCCATCCATTGTAAACATTTGAA  
ACTTTGTATTCAGTTTTTGAAATTATGCCACTGCTGAACCTTAACAAACACTACAACA  
TAAATAATTGAGTTAGGTGATCCACCCCTTAATTGTACCCCGATGGTATATTCTGAGT  
AAGCTACTATCTGAACATTAGTTAGATCCATCTCACTATTTAATAATGAAATTATTTTT  
AATTAAAAGCAAATAAAAGCTTAACCTTGAACCAGGGAAAAAAAAAAAAAAACA

**FIGURE 28**

><ss.DNA33089  
><subunit 1 of 1, 259 aa, 1 stop  
><MW: 29275, pI: 6.92, NX(S/T): 2  
MNLVDLWLTRSLSMCLLQSFSVLMILCFHSASMC PKGCLSSSGGLNVTC SNANLKEIPR  
DLPPETVLLYLDNSNQITSIPNEIFKDLHQLRVLNLSKNGIEFIDEHAFKGVAETLQTL  
SDNRIQSVHKNAFNNLKARARIANNPWHCDCTLQQVLRSMASNHETAHNVIC KTSVLDEH  
AGRPF LN AANDADLCNLPKKTTDYAMLVTMFGWFTMVISYVVYYVRQNQEDARRHLEYLK  
SLPSRQKKADEPDDISTVV

**FIGURE 29**

ACCGAGCCGAGCGGACCGAAGGCAGCCCAGATGCAGGTGAGCAAGAGGATGCTGGCGGGG  
GGCGTGAGGAGCATGCCAGCCCCCTCCTGGCCTGTCAGGCAGCCCACCTCCTGCTGGTGC  
GGGCTCAGTGCCTGTCAGGCTCGGCCACGGCAAGTCTTGTGGCAGTCCCAGGGCATCCCCACCGAG  
ACCGCGCTGTGCTGTGCCACCGCAAGTCTTGTGGCAGTCCCAGGGCATCCCCACCGAG  
ACGCGCCTGCTGGACCTAGGCAAGAACCGCATAAAACGCTCAACCAGGACGAGTTCGCCAG  
CTTCCCACCTGGAGGAGCTGGAGCTCAACGAGAACATCGTAGCAGGCCGTGGAGGCCGGCG  
CCTTCAACAACCTCTCAACCTCCGGACGCTGGGCTCCGCAGCAACCGCCTGAAGCTCATC  
CCGCTAGGCCTTCACTGGCCTCAGCAACCTGACCAAGCAGGACATCAGCAGAACAAAGAT  
CGTTATCCTACTGGACTACATGTTCAAGGACCTGTACAACCTCAAGTCAGTCACTGGAGGTTGGCG  
ACAATGACCTCGTCTACATCTCACCGCGCTTCAGCGCCTCAACAGCCTGGAGCAGCTG  
ACGCTGGAGAAATGCAACCTGACCTCCATCCCCACCGAGGCGCTGTCCCACCTGCACGGCCT  
CATCGCCTGAGGCTCCGGCACCTCAACATCAATGCCATCCGGACTACTCCTCAAGAGGC  
TGTACCGACTCAAGGTCTGGAGATCTCCACTGGCCTACTTGGACACCATGACACCCAAC  
TGCCTCTACGGCCTCAACCTGACGTCCCTGTCCATCACACACTGCAATCTGACCGCTGTGCC  
CTACCTGGCGTCCGCCACCTAGTCTATCTCGCTCCTCAACCTCTCTACAACCCATCA  
GCACCATTGAGGGCTCCATGTTGCATGAGCTGCTCCGGCTGCAGGAGATCCAGCTGGTGGCG  
GGCAGCTGGCGTGGTGGAGCCCTATGCCTCCGGCGCTCAACTACCTGCGCGTGTCAA  
TGTCTCTGGCAACCAGCTGACCAACTGGAGGAATCAGTCTCCACTCGGTGGCAACCTGG  
AGACACTCATCCTGGACTCCAACCCGCTGGCCTGCGACTGTCGGCTCCTGTGGGTGTTCCGG  
CGCCGCTGGCGCTCAACTCAACCGCAGCAGCCACGTGCGCCACGCCAGTGGAGTTGTCAA  
GGCAAGGAGTTCAAGGACTTCCCTGATGTGCTACTGCCAACTACTTCACCTGCGCGCG  
CCCGCATCCGGGACCGCAAGGCCAGCAGGTGTTGTGGACGAGGCCACACGGTGCAGTTT  
GTGTGCCGGGCGATGGCAGCCGCCATCTGCTCTCACCCGAAAGCACCT  
GGTCTCAGCCAAGAGCAATGGCGGCTCACAGTCTCCCTGATGGCACGCTGGAGGTGCGCT  
ACGCCAGGTACAGGACAACGGCACGTACCTGTGCATCGCGCCAACCGCGGCGAACGAC  
TCCATGCCGCCACCTGCATGTGCGCAGCTACTGCCGACTGCCCATCAGCCCAAACAA  
GACCTCGCTTCATCTCAACCAGCCGGCGAGGGAGAGGCCAACAGCACCCGCGCACTG  
TGCCTTCCCTCGACATCAAGACCTCATCATGCCACCCATGGGCTTCATCTCTTTC  
CTGGCGTCCTCTGCCTGGTGCCTGTTCTGAGGCCGGCAAGGGCAACAC  
AAAGCACAAACATCGAGATCGAGTATGTGCCCGAAAGTCGGACGCAGGCATCAGCTCCGCG  
ACGCCCGCAAGTTCAACATGAAGATGATATGAGGCCGGGGCGGGGGAGGGACCCCCCG  
GGCGGCCGGGAGGGGAAGGGGCTGGCGCCACCTGCTCACTCCAGTCCTCCACCTC  
CTCCCTACCCCTCTACACAGTTCTCTTCTCCCTCCGCCCTCGTCCCTGCTGCCCG  
CCAGCCCTCACCACTGCCCTCTACAGGACCTCAGAACGCCAGACCTGGGACCCCA  
CCTACACAGGGCATTGACAGACTGGAGTTGAAAGCCGACGAACCGACACGCCAGAGTCA  
ATAATTCAATAAAAAAGTTACGAACCTTCTGTAACTTGGGTTCAATAATTATGGATT  
TATGAAAAACTTGAAATAATAAAAAAGAGAAAAAACTAAAAAAAAAAAAAA

**FIGURE 30**

><ss.DNA33786  
><subunit 1 of 1, 620 aa, 1 stop  
><MW: 69838, pI: 8.84, NX(S/T): 10  
MQVSKRMLAGGVRSMPSPLLACWQPILLVLGSVLGSATGCPPRCECSAQDRAVLCHRK  
CFVAVPEGIPTETRLLDLGKNRIKTLNQDEFASFPHLEELELNENIVSAVEPGAFNNLFN  
LRTLGLRSNRLKLIPLGVFTGLSNLTQDISENKIVILLDYMFQDLYNLKSLEVGDNDLV  
YISHRAFSGLNSLEQLTLEKCNLTSIPTEALSHLHGLIVLRLRHLNINAIRDYSFKRLYR  
LKVLEISHWPYLDTMTPNCLYGLNLTSLSITHCNLTAVPYLAVRHLVYLRFLNLSYNPIS  
TIEGSMLHELLRLQEIQLVGGQLAVVEPYAFRGLNYLRVLNVSGNQLTTLEESVFHSVGN  
LETLLILDSNPLACDCRLLWVFRRWRNLNFNRQQPTCATPEFVQGKEFKDFPDVLLPNYFT  
CRRARIRDRKAQQVFVDEGHTVQFVCRADGDPPPAILWLSPRKHLVSAKSNGRLTVFPDG  
TLEVRYAQVQDNGTYLCIAANAGGNDMSMPAHLHVRSYSPDWPHQPNKTFAFISNQPGEGE  
ANSTRATVPFPFDIKTLIIATTMGFISFLGVVLFCLVLLFLWSRGKGNTKHNIIEYVPR  
KSDAGISSADAPRKFNMKMI

**FIGURE 31**

CCCACCGCGTCCGCACCTCGGCCCCGGCTCCGAAGCGGCTCGGGGGCGCCCTTCGGTCAAC  
ATCGTAGTCCACCCCTCCCCATCCCCAGCCCCGGGATTCAAGGCTCGCCAGCGCCAGCC  
AGGGAGCCGGCGGGAAAGCGCGATGGGGGCCAGCCGCCTCGCTCCTGCTCCTGCTCCTGC  
TGTTCGCCTGCTGCTGGCGCCCGCGGGCCAACCTCTCCAGGACGACAGCCAGCCCTGG  
ACATCTGATGAAACAGTGGTGGCTGGCACCGTGGTGTCAAGTGCCAAGTGAAAGATCA  
CGAGGACTCATCCCTGCAATGGCTAACCTGCTCAGCAGACTCTACTTTGGGAGAAGA  
GAGCCCTTCGAGATAATCGAATTCACTGGTTACCTCTACGCCAACGAGCTCAGCATCAGC  
ATCAGCAATGTGGCCCTGGCAGACGAGGGCAGTACACCTGCTCAATCTTCACTATGCCCTGT  
GCGAACTGCCAAGTCCCTCGTCACTGTGCTAGGAATTCCACAGAACGCCATCATCACTGGTT  
ATAAAATCTTCAATTACGGAAAAAGACACAGCCACCCCTAAACTGTCAGTCTTCTGGGAGCAAG  
CCTGCAGCCCCGGCTCACCTGGAGAAAGGGTACCAAGAACACTCCACGGAGAACCAACCCGCAT  
ACAGGAAGATCCAATGGTAAAACCTTCACTGTCAGCAGCTCGGTGACATTCCAGGTTACCC  
GGGAGGATGATGGGCGAGCATCGTGTGCTCTGTGAACCATGAATCTCTAAAGGGAGCTGAC  
AGATCCACCTCTCAACGCATTGAAGTTTATACACACCAACTGCGATGATTAGGCCAGACCC  
TCCCCATCCTCGTGAGGGCCAGAACGCTGTGCTACACTGTGAGGGTCCGGCAATCCAGTCC  
CCCAGCAGTACCTATGGGAGAACGGAGGGCAGTGTGCCACCCCTGAAGATGACCCAGGAGAGT  
GCCCTGATCTTCCCTTCCTCAACAAGAGTGACAGTGGCACCTACGGCTGCACAGCCACCA  
CAACATGGCAGCTACAAGGCCTACTACACCCCTCAATGTTAATGACCCAGTCCGGTGCCT  
CCTCCTCCAGCACCTACCACGCCATCATCGTGGATCGTGGCTTCATTGTCTTCTGCTG  
CTCATCATGCTCATCTTCCCTGGCCACTACTTGATCCGGACAAAGGAACCTACCTGACACA  
TGAGGCAAAAGGCTCCGACGATGCTCCAGACGCCACGGCCATCATCAATGCAGAACGGCG  
GGCAGTCAGGAGGGACGACAAGAACGAAATTTCATCTAGAGGCGCTGCCACTTCCCTGC  
GCCCGCCAGGGCCCTGTGGGACTGCTGGGCCGTACCAACCCGGACTTGTACAGAGCAA  
CCGCAGGGCCGCCCTCCGCTTGCTCCCCAGCCACCCACCCCTGTACAGAACGCTGC  
TTTGGGTGGGTTTGACTCGGTTGGAATGGGGAGGGAGGAGGGGGGGGGAGGGAGGG  
TTGCCCTCAGCCCTTCCGTGGCTCTGCATTGGTTATTATTATTTGTAAACAATCC  
CAAATCAAATCTGTCTCCAGGCTGGAGAGGCAGGAGCCCTGGGTGAGAAAAGCAAAAAACA  
AACAAAAAACAA

**FIGURE 32**

MGAPAASLLLLLFAACCWAPGGANLSQDDSQWPWTSDETVVAGGTVVLKCQVKDHEDSS  
LQWSNPAQQTLYFGEKRALRDNRQLVTSTPHELSIISNVALADEGEYTCSIFTMPVR  
TAKSLVTVLGI PQKPI ITGYKSSLREKDTATLNCQSSGSKPAARLTWRKGDQELHGEPT  
RIQEDPNGKTFTVSSSVTFQVTREDDGASIVCSVNHESLKGADRSTSQRIEVLYTPTAM  
IRPDPPHPREGQKLLLHCEGRGNPVPQQYLWEKEGSVPPLKMTQESALIFPFLNKSDSG  
TYGCTATSNMGSYKAYTLNVNDPSPVPSSSSTYHAIIGGIVAFIVFLLLIMLIFLGHY  
LIRHKGTYLTHEAKGSDDAPDADTAIINAEGGQSGGDDKKEYFI

## FIGURE 33

GGGGGTTAGGGAGGAAGGAATCCACCCCCACCCCCCAAACCCCTTCTCCTTCTGG  
 CTTCGGACATTGGAGCACTAAATGAACTTGAATTGTGTCTGGCGAGCAGGATGGTCGCTG  
 TTACTTGTGATGAGATCGGGATGAATTGCTCGCTTAAAATGCTGCTTGGATTCTGTT  
 GCTGGAGACGCTCTTTGCGCTGAAACGTTACAGGGACGTTGCAAAGAGAAGA  
 TCTGTTCCCTGCAATGAGATAGAAGGGACCTACACGTAGACTGTAAAAAAGGGCTTCACA  
 AGTCTGCAGCGTTCACTGCCCGACTTCCAGTTACCATTTATTCATGGCAATT  
 CCTCACTCGACTTTCCCTAACATGAGTTCGCTAACCTTATAATGCGGTTAGTTGCACATGG  
 AAAACAATGGCTGATGAAATCGTCCGGGGCTTCTGGGCTGCAGCTGGTAAAAAGG  
 CTGCACATCAACAACAAGATCAAGTCTTCGAAAGCAGACTTTCTGGGCTGGACGA  
 TCTGGAATATCTCAGGCTGATTTAATTATTACAGAGATATAGACCCGGGGCTTCAGG  
 ACTTGAACAAGCTGGAGGTGCTCATTTAAATGACAATCTCATCAGCACCCCTACCTGCCAAC  
 GTGTTCCAGTATGTGCCATCACCCACCTCGACCTCCGGGTAACAGGCTGAAAACGCTGCC  
 CTATGAGGAGGTCTGGAGCAAATCCCTGGTATTGCGGAGATCCTGCTAGAGGATAACCCTT  
 GGGACTGCACCTGTGATCTGCTCCCTGAAAGAATGGCTGAAAACATTCCAAGAATGCC  
 CTGATCGGCCAGTGGCTCGGAAGCCCCACCAGACTGCAGGGTAAAGACCTAACATGAAAC  
 CACCGAACAGGACTTGTGCTTGGAAAACCGAGTGGATTCTAGTCTCCGGCGCCCCCTG  
 CCCAAGAACAGACCTTGCTCTGGACCCCTGCCAACCTTCAAGACAAATGGCAAGAG  
 GATCATGCCAACACCAGGGTCTGCTCAAACGGAGGTACAAGATCCCAGGCAACTGGCAGAT  
 CAAAATCAGACCCACAGCAGCGATAGCGACGGTAGCTCCAGGAACAAACCCCTAGCTAACAA  
 GTTACCCCTGCCCTGGGGCTGCAGCTGCGACCACATCCCAGGGTGGTTAAAGATGAAC  
 TGCAACAAACAGGAACGTGAGCAGCTGGCTGATTGAAGCCCAAGCTCTAACGTGCAGGA  
 GCTTTCCTACAGAGATAACAAGATCCACAGCATCCGAAAATCGACTTGTGGATTACAAGA  
 ACCTCATTCTGTTGGATCTGGCAACAATAACATCGCTACTGTAGAGAACAAACACTTCAAG  
 AACCTTTGGACCTCAGGTGGCTATACATGGATAGCAATTACCTGGACACGCTGTCCGGGA  
 GAAATTGCGGGGCTGCAAAACCTAGAGTACCTGAACGTGGAGTACAACGCTATCCAGCTCA  
 TCCTCCGGGCACTTCATGCCATGCCAAACTGAGGATCCTCATTCTAACAAACAACCTG  
 CTGAGGTCCCTGCCTGGACGTGTTGCTGGCTGGGCTCGCTCTAAACTCAGCCTGCACAA  
 CAATTACTCATGTACCTCCGGTGGCAGGGTGGCTGGACCAGTTAACCTCCATCATCCAGA  
 TAGACCTCCACGGAAACCCCTGGGAGTGCTCCTGACAATTGTGCCTTCAAGCAGTGGGCA  
 GAACGCTTGGGTTCCGAAGTGTGATGAGCGACCTCAAGTGTGAGACCCGGTGAACCTT  
 TAGAAAGGATTTCATGCTCCTCTCAATGACGAGATCTGCCCTCAGCTGTACGCTAGGATCT  
 CGCCACGTTAACCTCGCACAGTAAAACAGCACTGGGTTGGCGGAGACGGGACGCACTCC  
 AACTCCTACCTAGACACCAGCAGGGTGTCCATCTGGTGTGGTCCGGACTGCTGTGGT  
 GTTGTCACTCCGCCTCACCGTGGCATGCTGTTATCCTGAGGAACCGAAAGC  
 GGTCCAAGAGACGAGATGCCAACTCCTCCGCTCGAGATTAATTCCCTACAGACAGTCTGT  
 GACTCTCCTACTGGACAATGGCCTTACAACGCAAGATGGGCCCACAGAGTGTATGACTG  
 TGGCTCTCACTCGCTCTCAGACTAACGACCCAAACCCAAATAGGGAGGGCAGAGGGAAAGGCG  
 ATACATCCTCCCCACCGCAGGCACCCGGGGCTGGAGGGCGTGTACCCAAATCCCCGCG  
 CCATCAGCCTGGATGGGCATAAGTAGATAAAACTGTGAGCTCGCACACCGAAAGGGCCT  
 GACCCCTTACTAGCTCCCTCTTGAAACAAAGAGCAGACTGTGGAGAGCTGGAGAGCGCA  
 GCCAGCTCGCTTTGCTGAGAGCCCTTGTGACAGAAAGCCAGCACGACCTGCTGGAAG  
 AACTGACAGTGCCCTGCCCTCGGCCCCGGGGCTGTGGGGTTGGATGCCGGTTCTATAC  
 ATATATACATAATCCACATCTATATAGAGAGATAGATATCTATTTCCTGTGGATTAG  
 CCCCGTGTGATGGCTCCCTGTTGGCTACGCAGGGATGGCAGTTGCACGAAGGCATGAATGTAT  
 TGTAATAAGTAACCTTGACTTCTGAC

**FIGURE 34**

MLLWILLLETSLCFAAGNVTDVCKEKCSCNEIEGDLHVDCEKKGFTSLQRFTAPTSQ  
FYHLFLHGNSLTRLFPNEFANFYNNAVLHMENNGLHEIVPG AFLGLQLVKRLHINNNKI  
KSFRKQTFLGLDDLEYLQADFNLLRDIDPGAFQDLNKLEVILILNDNLISTLPANVFQYV  
PITHLDLRGNRKLTPYEEVLEQIPGIAEILLEDPWDCTCDLLSLKEWLENIPKNALI  
GRVVCEAPTRLQGKDLNETTEQDLCPLKNRVDSSLAPPQAETFAPGPLPTPKTNGQ  
EDHATPGSAPNGGTIPGNWQIKIRPTAAIATGSSRNKPLANSLPCPGGCSDHIPGSG  
LKMNCNNRNVSSLADLKPKLSNVQELFLRDNKIHSIRKSHFVDYKNLILDLGNNNIAT  
VENNTFKNLLDLRWLYMDSNYLDTLSREKFAGLQNLEYLNVEYNAIQLILPGTFNAMPK  
LRILILNNNLLRSLPVDFAGVSLSKLSLHNYYFMYLPVAGVLDQLTSIIQIDLHGNPW  
ECSCTIVPFKQWAERLGSEVLMSDLKCETPVNFFRKDFMLLSNDEICPQLYARISPLT  
SHSKNSTGLAETGTHNSYLDTSRVSISVLVPGLLVFVTSAFTVVGMLVFILRNRKRS  
KRRDANSSASEINSLQTVCDSSYWHNGPYNADGAHRVYDCGSHSLSD

**FIGURE 35**

AGTCGACTGCGTCCCCTGTACCCGGCGCCAGCTGTGTTCTGACCCCCAGAATAACTCAGG  
 GCTGCACCGGGCCTGGCAGCGCTCCGCACACATTCTGTGCGGGCTAAGGGAAACTGT  
 TGGCCGCTGGGCCGCGGGGGATTCTTGCAGTTGGGGTCCGTGGAGCGAGGGCG  
 GAGGGGAAGGGAGGGGAACCGGGTTGGGAAGCCAGCTGTAGAGGGCGGTGACC CGCCT  
 CCAGACACAGCTCTGCGCCTCGAGCGGGACAGATCCAAGTTGGGAGCAGCTTGCGTGC  
 GGGCCTCAGAGA  
 ><MET {trans=1-s, dir=f, res=1}  
 ATGAGGCCGGCGTTCGCCCTGTGCCCTCCTCTGGCAGGCCTCTGGCCCGGGCCGGCG  
 GGCACACCCCCACTGCGGACCGTGCTGGCTCGGCCCTGGGGCTGCTACAGCCTG  
 CACCA CGCTACCATGAAGCGGAGGCAGGGCGAGGAGGCCTGCATCCTGCGAGGTGGGGCG  
 CTCAGCACCGTGCCTGGCGCCGAGCTGCGCGCTGTGCTCGCGCTCCTGCGGGCAGGC  
 CCAGGGCCGGAGGGGCTCAAAGACCTGCTGTTCTGGGTGCACTGGAGCGCAGGC  
 TCCCCACTGCACCCCTGGAGAACGAGCCTTGCAGTGGGTGGAGGAGCCCCAACGCTCCTG  
 GCGGGTCTCGAAAGCAGACCGCTGAGTGGGTGGAGGAGCCCCAACGCTCCTG  
 CGGAGATGCGCGGTACTCCAGGCCACCGGTGGGTGAGCCCGCAGGCTGGAAGGAGATG  
 CGATGCCACCTGCGCGCAACGGTACCTGTGCAAGTACCAAGTTGAGGTCTTGTG  
 GCGCCCGCCCCGGGGCCCTCTAAC TTGAGCTATCGCGCCCTTCCAGCTGCACAGC  
 GCCGCTCTGGACTTCAGTCCACCTGGGACCGAGGTGAGTGCGCTCTGCCGGGACAGCTC  
 CCGATCTCAGTTACTTGCACTCGGGACGAAATCGCGCTCGTGGACAAACTCTCGGGC  
 GATGTGTTGTGCCCTGCCCGGGAGGTACCTCCGTGCTGGCAAATGCGCAGAGCTCC  
 AACTGCCTAGACGACTTGGGAGGCTTGCGATGTGCTACGGGCTTCGAGCTGGGG  
 AAGGACGGCCGCTTGTGACCAAGTGGGAAGGACAGCCGACCCCTGGGGGACCGGG  
 GTGCCACCAGCGCCGCCACTGCAACCAGCCCCGTGCCAGAGAACATGGCA  
 ATCAGGGTCGACGAGAACGACTGGGAGAGACACCAACTGTCCCTGAACAAGAACATT  
 ACATCTATTCTGAGATTCTCGATGGGATCACAGAGCACCGATGTCTACCCCTCAAATG  
 TCCCTCAAGCCGAGTCAAAGGCCACTATCACCCCATCAGGGAGCGTGATTCCAAGTT  
 AATTCTACGACTTCTGCACTCCTCAGGCTTGCAGTCCCTGCGACAGTACTGGGCTT  
 ATATTGTGAGCACAGCAGTAGTAGTGTTGGTGTGATCTTGACCATGACAGTACTGGG  
 GTCAAGCTCTGCTTCAAGAAAGCCCCTCTCCAGCCAAGGAAGGAGTCTATGGGCC  
 CGGGCCTGGAGAGTGATCCTGAGCCCGCTGCTTGGGCTCCAGTTCTGCACATTGACA  
 AACAAATGGGTGAAAGTCGGGACTGTGATCTGCGGGACAGAGCAGAGGGTGCCTG  
 GCGGAGTCCCTTGGCTCTAGTGATGCATAGGAAACAGGGACATGGCACCTGT  
 GAACAGTTTCACTTTGATGAAACGGGAACCAAGAGGAACCTACTTGTAAGTAC  
 AATTCTGCAGAAATCCCCCTCTAAATTCCCTTACTCCACTGAGGAGCTAAATCA  
 GAACTGCACACTCCTCCCTGATGATAGAGGAAGTGGAAAGTGCCTTGGATGGT  
 TGGGGACCGGGTAGTGCTGGGAGAGATATTCTTATGTTATTGGAGAATTGGAG  
 AAGTGATTGAACTTTCAAGACATTGAAACAAATAGAACACAATATAATTACATTAA  
 AAATAATTCTACCAAAATGGAAAGGAAATGTTCTATGTTGTCAGGCTAGGAGTATT  
 GGTCGAAATCCCAGGGAAAAAATAAAAAATAAAGGATTGTTGAT

**FIGURE 36**

MRPAFALCLLWQALWPGPGGGEHTADRAGCSASGACYSLHHATMKRQAAEEACILRGGA  
LSTVRAGAELRAVLALLRAGPGPGGGSKDLLFWVALERRSHCTLENEPLRGFSWLSSDP  
GGLESDTLQWVEEPQRSCTARRCAVLQATGGVEPAGWKEMRCHLRANGYLCKYQFEVLCP  
APRPGAASNLSYRAPFQLHSAALDFSPPGTEVSALCRGQLPISVTCIADEIGARWDKLSG  
DVLCPCPGRYLRAGKCAELPNCLDDLGGFACECATGFELGKDGRSCVTSGEGQPTLGGTG  
VPTRRPPATATSPVPQRTWPIRVDEKLGETPLVPEQDNSVTSIPEIPRWGSQSTMSTLQM  
SLQAESKATITPSGSVISKFNSTTSSATPOAFDSSSAVFIFVSTAVVVLVILTMVLGL  
VKLCFHESPSSQPRKESMGPPGLESDPPEPAALGSSSAHCTNNGVKVGDCDLRDRAEGALL  
AESPLGSSDA

## FIGURE 37

CGGACCGCGTGGGATTCAAGCAGTGGCCTGTGGCTGCCAGAGCAGCTCCCTCAGGGGAAACTA  
AGCGTCGAGTCAGACGGCACCATAATGCCCTTAAAAGTGCCTCCGCCCTGCCGGCGCG  
TATCCCCCGGCTACCTGGGCCGCCCCGCGGGTGCAGCGTGA  
AGCCGAGCGCCGGTGTGAGCCAGCGCTGCTGCCAGTGTGAGCGGCGGTGTGAGCGCGGTG  
GGTGCAGGGGGCGTGTGTGCCGGCGCGCCGTGGGGTGCAAACCCCGAGCGTCTAC  
GCTGCC  
><MET {trans=1-s, dir=f, res=1}  
ATGAGGGGCGCAACGCCCTGGCGCCACTCTGCCCTGCTGCTGGCTGCCGCCACCCAGCTC  
TCGCAGCAGTCCCCAGAGAGACCTGTTCACATGTGGTGGCATTCTTACTGGAGAG  
TCTGGATTATTGGCAGTGAAGGTTTCCTGGAGTGTACCCCTCCAAATAGCAAATGTACT  
TGGAAAATCACAGTCCCGAAGGAAAAGTAGTCGTTCTCAATTCCGATTCAAGACACTC  
GAGAGTGACAACCTGTGCCGCTATGACTTGTGGATGTGTACAATGGCATGCCAATGGC  
CAGCGCATTGGCCGCTCTGTGGCACTTCCGGCCTGGAGCCCTGTGTCCAGTGGCAAC  
AAGATGATGGTGCAGATGATTCTGATGCCAACACAGCTGGCAATGGCTTCATGCCATG  
TTCTCCGCTGCTGAACCAAACGAAAGAGGGGATCAGTATTGTGGAGGACTCCTTGACAGA  
CCTTCCGGCTCTTAAAACCCCCAAGTGGCCAGACGGGATTACCTGCAAGGAGTCACT  
TGTGTGTGGCACATTGTAGCCCCAAAGAATCAGTTAGAATTAAAGTTGAGAAGTT  
GATGTGGAGCGAGATAACTACTGCCGATATGATTATGTGGCTGTGTTAATGGCGGGAA  
GTCAACGATGCTAGAAGAATTGGAAAGTATTGTGGTGTAGTCCACCTGCCAATTGTG  
TCTGAGAGAAATGAACCTCTTATTCAAGTTTATCAGACTTAAGTTAAGTGCAGATGGG  
TTTATTGGTCACTACATATTCAAGGCCAAAAAAACTGCCCTACAACTACAGAACAGCCTGTC  
ACCACCACTCCCTGTAACCACGGGTTAAAACCCACCGTGGCCTGTGTCAACAAAAG  
TGTAGACGGACGGGACTCTGGAGGGCAATTATTGTCAAGTGA  
ACTTTGTATTAGCCGGC  
ACTGTTATCACAACCATCACTCGCGATGGGAGTTGCACGCCACAGTCTCGATCATCAAC  
ATCTACAAAGAGGGAAATTGGCGATTCAAGCAGGCCAGAACATGAGTGCAGGCTG  
ACTGTCGTCGCAAGCAGTGCCTCTCCTCAGAAGAGGTCTAAATTACATTATTATGGGC  
CAAGTAGGTGAAGATGGCGAGGCAAAATCATGCCAACAGCTTATCATGATGTTCAAG  
ACCAAGAATCAGAACGCTCTGGATGCCCTAAAAATAAGCAATGTTAACAGTGA  
ACTGTG  
TCCATTAAAGCTGTATTGCCATTGCCCTTGAAGAGATCTATGTTCTCAGTAGAAAAAA  
AAAATACTTATAAAATTACATATTCTGAAAGAGGATTCCGAAAGATGGGACTGGTTGACT  
CTTCACATGATGGAGGTATGAGGCCCTCGAGAGATAGCTGAGGGAGTTCTTGCCTGCTGT  
CAGAGGAGCAGCTATGATTGGAAACCTGCCACTAGTGCCTGTAGAGAAGCTAAA  
GTGTCAAGCGTTGACAGCTGGAAAGCGTTATTATACATCTGTAAAAGGATATT  
GAATTGAGTTGTGTGAAGATGTCAAAAAAGATTAGAAGTGC  
AATATTATAGGTTA  
TTGTTCACCTCAAGCCTTGCCCTGAGGTGTACAATCTGTCTGCCTTCTAAA  
TCAATGCTTAATAAAATTAAAGGAAAAAA

**FIGURE 38**

MRGANAWAPLCLLLAAATQLSRQQSPERPVFTCGGILTGESFIGSEGFPGVYPPNSKCT  
WKITVPEGKVVVLNFRFIDLESNDNLCRYDFVDVYNGHANGQRIGRFCGTFRPGALVSSGN  
KMMVQMIISDANTAGNGFMAMFSAAEPNERGDQYCGGLLDRPSGSFKTPNWPDYDYPAGVT  
CVWHIVAPKNQELKFEKFDVERDNYCRYDYVAVFNGGEVNDARRIGKYCGDSPPAPIV  
SERNELLIQFLSDLSLTADGFIGHYIFRPKKLPTTEQPVTTFPVTTGLKPTVALCQQK  
CRRTGTLEGNYCSSDFVLAGTVITTITRDGSLHATVSIINIYKEGNLAIQQAGKNMSARL  
TVVCKQCPLLRRGLNYIIMGQVGEDGRGKIMPNSFIMMFKTKNQKLLDALKNKQC

**FIGURE 39**

CGGACGCGTGGCGGACGCGTGGCGGCCACGGCGCCGCGGGCTGGGCAGTCGTTCTT  
CCTTCTCCGTGGCCTACGAGGGTCCCCAGCCTGGTAAAGATGGCCCCATGGCCCCGAAGG  
GCCTAGTCCCAGCTGTGCTCTGGGCCTCAGCCTCTCCTCAACCTCCCAGGACCTATCTGG  
CTCCAGCCCTCTCACCTCCCCAGTCTCTCCCCGCCTCAGCCCCATCCGTGTACACTG  
CCGGGGACTGGTGACAGCTTAACAAGGGCTGGAGAGAACCATCCGGACAACTTGGAG  
GTGGAAACACTGCCTGGGAGGAAGAGAATTGTCAAATACAAAGACAGTGTGAGACCCGCCTG  
GTAGAGGTGCTGGAGGGTGTGCAGCAAGTCAGACTCGAGTGCCACCGCCTGCTGGAGCT  
GAGTGAGGAGCTGGTGGAGAGCTGGTGGTTACAAGCAGCAGGAGGCCGGACCTCTCC  
AGTGGCTGTGCTCAGATTCCCTGAAGCTCTGCTGCCCGCAGGCACCTCGGGCCCTCCTGC  
CTTCCCTGTCTGGGAAACAGAGAGGCCCTGCGGTGGCTACGGCAGTGTGAAGGAGAAGG  
GACACGAGGGGGCAGCGGGCACTGTGACTGCCAAGCCGGCTACGGGGTGAGGCCTGTGGCC  
AGTGTGGCCTGGCTACTTGAGGCAGAACGCAACGCCAGCCATCTGGTATGTTGCAATGCAAGAAGGG  
CTGGGCCCTGCATCACCTCAAGTGTGTAGACATTGATGAGTGTGGCACAGAGGGAGCCA  
GTGGAGCTGACCAATTCTGCGTGAACACTGAGGGCTCCTATGAGTGCCGAGACTGTGCCAAG  
GCCTGCCTAGGCTGCATGGGGCAGGGCAGGTGCTGTAAGAAGTGTAGCCCTGGCTATCA  
GCAGGTGGCTCCAAGTGTCTCGATGTGGATGAGTGTGAGACAGAGGTGTCCGGAGAGA  
ACAAGCAGTGTAAAACACCGAGGGCGGTTATCGCTGCATCTGTGCCGAGGGCTACAAGCAG  
ATGGAAGGCATCTGTGTGAAGGAGCAGATCCCAGAGTCAGCAGGCTTCTCAGAGATGAC  
AGAAGACGAGTTGGTGGTGCAGCAGATGTTCTTGGCATCATCATCTGTGCACTGGCCA  
CGCTGGCTGCTAAGGGCACTGGTGTTCACCGCCATCTCATTGGGGCTGTGGCGGCCATG  
ACTGGCTACTGGTGTCAAGCGCAGTGACCGTGTGGCTGGAGGGCTTCATCAAGGGCAGATA  
ATCGCGGCCACCACCTGTAGGACCTCCTCCCACCCACGCTGCCCGGCCAGAGCTTGGCTGCC  
TCCTGCTGGACACTCAGGACAGCTGGTTATTTTGGAGAGTGGGTAAGCACCCCTACCTG  
CCTTACAGAGCAGCCCAGGTACCCAGGCCGGCAGACAAGGCCCTGGGTAAAAAGTAGC  
CCTGAAGGTGGATACCATGAGCTTCACTGGCGGGACTGGCAGGCTTACAATGTGTGA  
ATTTCAAAAGTTTCTTAATGGTGGCTGCTAGAGCTTGGCCCTGCTTAGGATTAGGTG  
GTCCTCACAGGGTGGGCCATCACAGCTCCCTGCCAGCTGCATGCTGCCAGTTCCGT  
TCTGTGTTACCCACATCCCCACACCCATTGCCACTTATTATTCATCTCAGGAAATAAAGA  
AAGGTCTGGAAAGTTAAAAAAAAAAAAAAAAAAAAAA

**FIGURE 40**

Met Ala Pro Trp Pro Pro Lys Gly Leu Val Pro Ala Val Leu Trp Gly  
Leu Ser Leu Phe Leu Asn Leu Pro Gly Pro Ile Trp Leu Gln Pro Ser  
Pro Pro Pro Gln Ser Ser Pro Pro Pro Gln Pro His Pro Cys His Thr  
Cys Arg Gly Leu Val Asp Ser Phe Asn Lys Gly Leu Glu Arg Thr Ile  
Arg Asp Asn Phe Gly Gly Asn Thr Ala Trp Glu Glu Glu Asn Leu  
Ser Lys Tyr Lys Asp Ser Glu Thr Arg Leu Val Glu Val Leu Glu Gly  
Val Cys Ser Lys Ser Asp Phe Glu Cys His Arg Leu Leu Glu Leu Ser  
Glu Glu Leu Val Glu Ser Trp Trp Phe His Lys Gln Gln Glu Ala Pro  
Asp Leu Phe Gln Trp Leu Cys Ser Asp Ser Leu Lys Leu Cys Cys Pro  
Ala Gly Thr Phe Gly Pro Ser Cys Leu Pro Cys Pro Gly Gly Thr Glu  
Arg Pro Cys Gly Gly Tyr Gly Gln Cys Glu Gly Glu Gly Thr Arg Gly  
Gly Ser Gly His Cys Asp Cys Gln Ala Gly Tyr Gly Glu Ala Cys  
Gly Gln Cys Gly Leu Gly Tyr Phe Glu Ala Glu Arg Asn Ala Ser His  
Leu Val Cys Ser Ala Cys Phe Gly Pro Cys Ala Arg Cys Ser Gly Pro  
Glu Glu Ser Asn Cys Leu Gln Cys Lys Lys Gly Trp Ala Leu His His  
Leu Lys Cys Val Asp Ile Asp Glu Cys Gly Thr Glu Gly Ala Asn Cys  
Gly Ala Asp Gln Phe Cys Val Asn Thr Glu Gly Ser Tyr Glu Cys Arg  
Asp Cys Ala Lys Ala Cys Leu Gly Cys Met Gly Ala Gly Pro Gly Arg  
Cys Lys Lys Cys Ser Pro Gly Tyr Gln Gln Val Gly Ser Lys Cys Leu  
Asp Val Asp Glu Cys Glu Thr Glu Val Cys Pro Gly Glu Asn Lys Gln  
Cys Glu Asn Thr Glu Gly Gly Tyr Arg Cys Ile Cys Ala Glu Gly Tyr  
Lys Gln Met Glu Gly Ile Cys Val Lys Glu Gln Ile Pro Glu Ser Ala  
Gly Phe Phe Ser Glu Met Thr Glu Asp Glu Leu Val Val Leu Gln Gln  
Met Phe Phe Gly Ile Ile Ile Cys Ala Leu Ala Thr Leu Ala Ala Lys  
Gly Asp Leu Val Phe Thr Ala Ile Phe Ile Gly Ala Val Ala Ala Met  
Thr Gly Tyr Trp Leu Ser Glu Arg Ser Asp Arg Val Leu Glu Gly Phe  
Ile Lys Gly Arg

**FIGURE 41**

TGAGACCCTCCTGCAGCCTCTCAAGGGACAGCCCCACTCTGCCTTTGCTCCTCCAGGG  
CAGCACC  
><MET {trans=1-s, dir=f, res=1}  
ATGCAGCCCCCTGTGGCTCTGCTGGGCACTCTGGGTGTTGCCCTGGCCAGCCCCGGGGCC  
GCCCTGACCGGGGAGCAGCTCCTGGCAGCCTGCTGCGCAGCTGCAGCTCAAAGAGGTG  
CCCACCCCTGGACAGGGCCGACATGGAGGAGCTGGTACATCCCCACCCACGTGAGGGCCCAG  
TACGTGGCCCTGCTGCAGCGCAGCCACGGGGACCGCTCCCGCGAAAGAGGTTCAGCCAG  
AGCTTCCGAGAGGTGGCCGGCAGGTTCTGGCGTTGGAGGCCAGCACACACCTGCTGGTG  
TTCGGCATGGAGCAGCGGCTGCCGCCAACAGCGAGCTGGTGCAGGCCGTGCTGCGGCTC  
TTCCAGGAGCCGGTCCCCAAGGCCCGCTGCACAGGCACGGCCGGCTGTCCCCGCGCAGC  
GCCCGGGCCCGGGTGACCGTCGAGTGGCTGCGCGTCCGACGGCTCCAACCGCACC  
TCCCTCATCGACTCCAGGCTGGTGTCCGTCCACGAGAGCGGCTGGAAGGCCTTCGACGTG  
ACCGAGGCCGTGAACCTCTGGCAGCAGCTGAGCCGGCCGGCAGCCGCTGCTGCTACAG  
GTGTGGTGCAGAGGGAGCATCTGGGCCCGCTGGCGTCCGGCCACAAGCTGGTCCGC  
TTTGCCTCGCAGGGGGGCCAGCCGGCTTGGGGAGCCCCAGCTGGAGCTGCACACCCCTG  
GACCTTGGGACTATGGAGCTCAGGGCAGTGTGACCTGAAGCACCAATGACCGAGGGC  
ACCCGCTGCTGCCGCCAGGAGATGTACATTGACCTGCAGGGATGAAGTGGGCCAGAAC  
TGGGTGCTGGAGCCCCCGGGCTTCTGGCTTATGAGTGTGTCGGCACCTGCCGCCAGGCC  
CCGGAGGCCCTGGCCTTCAAGTGGCGTTCTGGGGCTCGACAGTGCATGCCCTCGGAG  
ACTGACTCGCTGCCCATGATCGTCAGCATCAAGGAGGGAGGCAGGACCAGGCCAGGTG  
GTCAGCCTGCCAACATGAGGGTGCAGAAGTGCAGCTGTGCCTCGGATGGTGCCTCGTG  
CCAAGGAGGCTCCAGCCATAGGCGCTAGTGTAGCCATCGAGGGACTTGACTTGTGTG  
TTTCTGAAGTGGTGCAGGGTACCAAGGAGAGCTGGCGATGACTGAAC TGCTGATGGACAAA  
TGCTCTGTGCTCTCTAGTGAGCCCTGAATTGCTTCTCTGACAAGTTACCTCACCTAAT  
TTTGCTTCTCAGGAATGAGAATCTTGGCCACTGGAGAGGCCCTGCTCAGTTCTCTA  
TTCTTATTATTCACTGCACTATATTCTAACCTACATGTGGAGATACTGTAACCTGAG  
GGCAGAAAGCCCANTGTGTCATTGTTACTTGTCCGTCACTGGATCTGGCTAAAGTCC  
TCCACCAACCCTGGACCTAACGACCTGGGGTTAAGTGTGGGTGTGCATCCCCAATCCA  
GATAATAAGACTTGTAAAACATGAATAAAACACATTCTAAAA

**FIGURE 42**

MQPLWLCWALWVLPLASPGAAALTGEQLLGSSLRQLQLKEVPTLDRADMEELVIPTHVRAQ  
YVALLQRSHGDRSRGKRFQSFSREVAGRFLALEASTHLLVFGMEQRLPPNSELVQAVLRL  
FQEPPVKAALHRHGRLSPRSARARVTVEWLVRDDGSNRTSLIDSRLVSVHESGWKAFDV  
TEAVNFWQQLSRPRQPLLLQSVQREHLGPLASGAHKLVRFASQGAPAGLGEPQLELHTL  
DLGDYGAQGDCDPEAPMTEGTRCCRQEMYIDLQGMKWAENWVLEPPGFLAYECVGTCRQP  
PEALAFKWPFLGPRQCIASETDSLPMIVSIKEGGRTRPQVVSLPNMRVQKCSCASDGALV  
PRRLQP

**FIGURE 43**

GTCTGTTCCCAGGAGTCCTCGGGCTGTTGTCACTGGCCTGATCGCAGGGACAAA  
 GGCGCAAGTCGAGAGGAAACTGTTGTGCCTCTTATGGCGATCCTGTTGTGCTCCCTGG  
 CATTGGGCAGTGTACAGTGCACCTCTGAACCTGAAGTCAGAATTCTGAGAATAATCCT  
 GTGAAGTTGTCTGTGCCTACTCGGGCTTTCTTCTCCCCGTGTGGAGTGGAAAGTTGACCA  
 AGGAGACACCACCAAGACTCGTTGCTATAATAACAAGATCACAGCTTCTATGAGGACCGGG  
 TGACCTTCTGCCAACTGGTATCACCTCAAGTCCGTGACACGGGAAGACACTGGGACATAC  
 ACTTGATGGTCTCTGAGGAAGGCAGAACAGCTATGGGGAGGTCAAGGTCAAGCTCATCGT  
 GCTTGTGCCTCCATCCAAGCCTACAGTTAACATCCCCCTCTGCCACCATTGGAACCGGG  
 CAGTGCTGACATGCTCAGAACAGATGGTCCCCACCTCTGAATACACCTGGTCAAAGAT  
 GGGATAGTGATGCCTACGAATCCAAAAGCACCCGTGCCTCAGCAACTCTCCTATGTCC  
 GAATCCCACAAACAGGAGAGCTGGTCTTGATCCCCGTGACCCATGACTCAAATGCTGTGCGCATGGAAAGCT  
 GCTGTGAGGCACCGAATGGTATGGACACCCATGACTCAAATGCTGTGCGCATGGAAAGCT  
 GTGGAGCAGGAATGTGGGGTCATCGTGGCAGCCGTCTGTAACCCCTGATTCTCCTGGGAAT  
 CTTGGTTTTGGCATCTGGTTGCCTATAGCCGAGGCCACTTGACAGAACAAAGAAAGGGA  
 CTTCGAGTAAGAAGGTGATTACAGCCAGCCTAGTGCCTGAAGTGAAGGAGAACCAAACAG  
 ACCTCGTCATTCTGGTGTGAGCCTGGTCGGCTACCGCCTATCATCTGCATTGCCCTACT  
 CAGGTGCTACCGGACTCTGGCCCTGATGTCAGTTCACAGGATGCCATTGTCTTC  
 TACACCCACAGGGCCCCCTACTCTCGGATGTTAAATAATGTCAGCTATGTGCC  
 ATCCTCCTCATGCCCTCCCTCCCTTACCACTGCTGAGTGGCCTGGAACCTGTTAAA  
 GTGTTATTCCCCATTCTTGAGGGATCAGGAAGGAATCCTGGGTATGCCATTGACTTCCC  
 TTCTAAGTAGACAGCAAAATGGCGGGGTCGCAGGAATCTGCACTCAACTGCCACCTGGC  
 TGGCAGGGATCTTGAATAGGTATCTGAGCTGGTCTGGCTCTTCTGTACTGAC  
 GACCAGGGCCAGCTGTTAGAGCGGGATTAGAGGCTAGAGCGGCTGAAATGGTTGG  
 TGATGACACTGGGTCTTCCATCTCTGGGCCACTCTCTGTCTTCCATGGAAAGTG  
 CCACTGGATCCCTCTGCCCTGTCCCTGAATACAAGCTGACTGACATTGACTGTCTGT  
 GGAAAATGGGAGCTTGTGGAGAGCATAGTAAATTTCAGAGAACCTGAAGCCAAAAG  
 GATTTAAAACCGCTGCTCTAAAGAAAAGAAAATGGAGGCTGGCGCAGTGGCTACGCC  
 TAATCCCAGAGGCTGAGGCAGGGGATCACCTGAGGTCGGAGTCGGGATCAGCCTGACCA  
 ACATGGAGAAACCTACTGGAAATACAAAGTTAGCCAGGCATGGTGGTGCATGCC  
 CCAGCTGCTCAGGAGCCTGGCAACAAGAGCAAAACTCCAGCTCA

**FIGURE 44**

Met Gly Thr Lys Ala Gln Val Glu Arg Lys Leu Leu Cys Leu Phe Ile  
Leu Ala Ile Leu Leu Cys Ser Leu Ala Leu Gly Ser Val Thr Val His  
Ser Ser Glu Pro Glu Val Arg Ile Pro Glu Asn Asn Pro Val Lys Leu  
Ser Cys Ala Tyr Ser Gly Phe Ser Ser Pro Arg Val Glu Trp Lys Phe  
Asp Gln Gly Asp Thr Thr Arg Leu Val Cys Tyr Asn Asn Lys Ile Thr  
Ala Ser Tyr Glu Asp Arg Val Thr Phe Leu Pro Thr Gly Ile Thr Phe  
Lys Ser Val Thr Arg Glu Asp Thr Gly Thr Tyr Thr Cys Met Val Ser  
Glu Glu Gly Asn Ser Tyr Gly Glu Val Lys Val Lys Leu Ile Val  
Leu Val Pro Pro Ser Lys Pro Thr Val Asn Ile Pro Ser Ser Ala Thr  
Ile Gly Asn Arg Ala Val Leu Thr Cys Ser Glu Gln Asp Gly Ser Pro  
Pro Ser Glu Tyr Thr Trp Phe Lys Asp Gly Ile Val Met Pro Thr Asn  
Pro Lys Ser Thr Arg Ala Phe Ser Asn Ser Ser Tyr Val Leu Asn Pro  
Thr Thr Gly Glu Leu Val Phe Asp Pro Leu Ser Ala Ser Asp Thr Gly  
Glu Tyr Ser Cys Glu Ala Arg Asn Gly Tyr Gly Thr Pro Met Thr Ser  
Asn Ala Val Arg Met Glu Ala Val Glu Arg Asn Val Gly Val Ile Val  
Ala Ala Val Leu Val Thr Leu Ile Leu Leu Gly Ile Leu Val Phe Gly  
Ile Trp Phe Ala Tyr Ser Arg Gly His Phe Asp Arg Thr Lys Lys Gly  
Thr Ser Ser Lys Lys Val Ile Tyr Ser Gln Pro Ser Ala Arg Ser Glu  
Gly Glu Phe Lys Gln Thr Ser Ser Phe Leu Val

**FIGURE 45**

CAGCGCGTGGCCGGCGCCGCTGTGGGACAGCATGAGCGCGGTTGGATGGCGCAGGTTGGA  
GCGTGGCGAACAGGGCTCTGGGCCTGGCGCTGCTGCTGCTCGGCCTGGACTAGGCCT  
GGAGGCCGCCGAGCCCGTTCCACCCGACCTCTGCCAGGCCAGGCCAGCTCAG  
GCTCGTCCCACCCACCAAGTTCCAGTGCAGCACCAAGTGCTTATGCGTGCCCCCACCTGG  
CGCTGCGACAGGGACTTGGACTGCAGCGATGGCAGCGATGAGGAGGAGTGCAGGATTGAGCC  
ATGTACCCAGAAAGGGCAATGCCACCGCCCCCTGGCCTCCCTGCCCTGCACCGCGTCA  
GTGACTGCTCTGGGGAACTGACAAGAAACTGCGCAACTGCAGCCCTGGCCTGCCTAGCA  
GGCGAGCTCCGTTGCACGCTGAGCGATGACTGCATTCCACTCACGTGGCGCTGCACGGCA  
CCCAGACTGTCCCGACTCCAGCGACGAGCTGGCTGTGAACCAATGAGATCCTCCGGAAG  
GGGATGCCACAACCATTGGGCCCCCTGTGACCTGGAGAGTGTCACCTCTCAGGAATGCC  
ACAACCATGGGCCCCCTGTGACCTGGAGAGTGTCACCTCTGTGGAAATGCCACATCCTC  
CTCTGCCGGAGACCAGTCTGGAAGCCAATGCCCTATGGGTTATTGCAGCTGCTGCGGTGC  
TCAGTGCAAGCCTGGTACCGCCACCCCTCCTCTTGTCCCTGGCTCCGAGCCCAGGAGCGC  
CTCCGCCACTGGGTTACTGGTGGCCATGAAGGAGTCCCTGCTGTCAGAACAGAAC  
CTCGCTGCCCTGAGGACAAGCAACTGCCACCCGTCACTCACGCCCTGGCGTAGCCGGACA  
GGAGGAGAGCAGTGATGCGGATGGTACCCGGCACACCAGCCCTCAGAGACCTGAGTTCTT  
CTGGCACGTGGAACCTCGAACCCGAGCTCCTGCAGAAGTGGCCCTGGAGATTGAGGGTCCC  
TGGACACTCCCTATGGAGATCCGGGAGCTAGGATGGGAACTGCCACAGCCAGAAC  
GGGCTGGCCCCAGGCAGCTCCAGGGGTAGAACGCCCTGTGCTTAAGACACTCCCTGCTG  
CCCCGTCTGAGGGTGGCGATTAAAGTTGCTTC

**FIGURE 46**

```
><ss.DNA33221
><subunit 1 of 1, 282 aa, 1 stop
><MW: 28991, pI: 4.62, NX(S/T): 3
MSGGWMAQVGAWRTGALGLALLLGLGLEAAASPLSTPTSAQAAGPSSGSCPPTKFQ
CRTSGLCVPLTWRCRDLDCCSDGSDEEECRIEPCTQKGQC PPPGLPCPCTGVSDCSGGT
DKKLRNCSRLACLAGELRCTLSSLDCIPLTWRCDGHPDCPDSSDELCGTNEILPEGDATT
MGPPVTLESVTSRNATTMGPVTLESPVPSGNATSSSAGDQSGSPTAYGVIAAAAVLSA
SLVTATLLLLSWLRAQERLRPLGLLVAMKESLLLSEQKTSLP
```

**FIGURE 47**

CCACCGCGTCCGGTCTCGCTCGCTCGCGCAGCGCGGCAGCAGAGGTCGCGCACAGATGCGG  
GTTAGACTGGCGGGGGAGGAGGCGGAGGAGGAAGGAGCTGCATGCATGAGACCCACAGA  
CTCTTGCAAGCTGGATGCCCTCTGTGGATGAAAGATGTATCATGGAATGAACCCGAGCAATG  
GAGATGGATTCTAGAGCAGCAGCAGCAGCAGCAACCTCAGTCCCCCAGAGACTCTTG  
GCCGTGATCCTGTGGTTCAGCTGGCGCTGTGCTCGGCCCTGCACAGCTCACGGCGGGTT  
CGATGACCTCAAGTGTGCTGACCCGGCATTCCGAGAATGGCTTCAGGACCCCCAGCG  
GAGGGGTTTCTTGAAGGCTCTGTAGCCGATTCACTGCCAAGACGGATTCAAGCTGAAG  
GGCGCTACAAAGAGACTGTGTTGAAGCATTAAATGGAACCCTAGGCTGGATCCAAGTGA  
TAATTCCATCTGTGTGCAAGAAGATTGCCGTATCCCTCAAATCGAAGATGCTGAGATTATA  
ACAAGACATATAGACATGGAGAGAAGCTAACATCACTGTGATGAAGGATTCAAGATCCGG  
TACCCGACCTACACAATATGGTTCATTATGTCGCGATGATGGAACGTGGAATAATCTGCC  
CATCTGTCAAGGCTGCCGTGAGACCTCTAGCCTCTTAATGGCTATGTAAACATCTGAGC  
TCCAGACCTCCTCCCGTGGGACTGTGATCTCCTATCGCTGCTTCCGGATTTAAACTT  
GATGGGTCTGCGTATCTGAGTGCTTACAAAACCTTATCTGGTCGTCAGCCCACCCGGTG  
CCTTGCTCTGGAAGCCAAGTCTGTCCACTACCTCCAATGGTGAGTCACGGAGATTCGTCT  
GCCACCCGCGGCCCTGTGAGCGCTACAACCACGGAACGTGGTGGAGTTACTGCGATCCT  
GGCTACAGCCTCACCAAGCGACTACAAGTACATCACCTGCCAGTATGGAGAGTGGTTCCCT  
TTATCAAGTCTACTGCATCAAATCAGAGCAAACGTGGCCAGCACCCATGAGACCCCTCTGA  
CCACGTGGAAGATTGTGGCGTTACGGCAACCAGTGTGCTGGTGTGCTGCTCGTCATC  
CTGGCCAGGATGTTCCAGACCAAGTTCAAGGCCACTTCCCCCAGGGGCTCCCCGGAG  
TTCCAGCAGTGACCTGACTTGTGGTAGACGGCGTGGCTCATGCTCCGTCATG  
ACGAAGCTGTGAGTGGCGCTTGAGTGCCCTAGGCCCCGGTACATGGCCTCTGTGGCCAG  
GGCTGCCCTTACCCGTGGACGACCAGAGCCCCCAGCATAACCCGGCTCAGGGACACGGA  
CACAGGCCAGGGAGTCAGAAACCTGTGACAGCGTCTCAGGCTCTGTGAGCTGCCAAA  
GTCTGTATTCACCTCCAGGTGCCAAGAGAGCACCCACCCACCTGCTTGGACAACCCCTGACATA  
ATTGCCAGCACGGCAGAGGAGGTGGCATCCACCAGGCCAGGCATCCATCATGCCACTGGGT  
GTTGTTCTAAGAAACTGATTGATTAAAAAATTCCAAAGTGTCTGAAGTGTCTCTCAA  
ATACATGTTGATCTGTGGAGTTGATTCCCTTCTTGTGAGTGGTGGAGGGCTGGAAGCTGATCAAGTC  
CTGTTCTTCTTGACACAGACTGATTAAAAATTAAAAGNAAAAAA

**FIGURE 48**

><ss.DNA33107  
><subunit 1 of 1, 490 aa, 1 stop  
><MW: 53920, pI: 5.41, NX(S/T): 4  
MYHGMNPSNGDFLEQQQQQQQQSPQRLLAVILWFQLALCFGPAQLTGGFDDLQVCADP  
GIPENGFRTPSGGVFFEGSVARFHCQDGFKLKGATKRLCLKHFNGTLGWIPSNDNSICVQE  
DCRIPQIEDAEIHNKTYRHGEKLIITCHEGFKIRYPDLHNMVSLCRDDGTWNNLPICQGC  
LRPLASSNGYVNISELQTSFPVGTVISYRCFPGFKLDSAYLECLQNLIWSSSPRCLAL  
EAQVCPPLPMVSHGDFVCHPRPCERYNHGTVEFYCDPGYSLSDYKYITCQYGEWFPSY  
QVYCIKSEQTWYSTHETLLTTWKIVAFATSVLLVLLVILARMFQTKFKAHFPPRGPPR  
SSSSDPDFVVVDGVPVMLPSYDEAVSGGLSALGPGYMASVGQGCPLPVDDQSPPAYPGSG  
DTDTGPGESETCDSVGSSELLQSLYSPPRCQESTHPASDNPDIIASTAEVASTSPGIH  
HAHWVLFLRN

## **FIGURE 49**

CCCCACGGCGTCCGCTCCGCACCCCTCCCCCGCCTCCGTGCGGTCCGTCGGTAGAGA  
TGCTGCTGCCCGGGTTGCAGTTGTCGCGCACGCCCTGCCGCCAGCCCCTCACCGCCGT  
AGCGCCCGAGTGTGGGGCGCACCCGAGTCGGGCCATGAGGCCGGAACCGCGTACAGG  
CCGTGCTGCCGTGCTGGTGGGCTGCCGCCAGGGTCGCCTGCTGAGTGC  
TCGGATTGGACCTCAGAGGAGGGCAGCCAGTCTGCCGGGAGGGACACAGAGGCCTTGTAA  
TAAAGTCATTTACTTCCATGATACTTCTCGAAGACTGAACATTGAGGAAGCCAAGAACGCT  
GCAGGAGGGATGGAGGCCAGCTAGTCAGCATCGAGTCAGATGAACAGAAACTGATAGAA  
AAGTTCATTGAAAACCTTGCATCTGATGGTACTTCTGGATTGGCTCAGGAGGCAGTGA  
GGAGAAACAAAGCAATAGCACAGCCTGCCAGGACCTTATGCTGGACTGATGGCAGCATA  
CACAAATTAGGAACCTGGTATGTGGATGAGCCGTCCGCCAGCAGGAGGTCTGCGTGGTCATG  
TACCATCAGCCATCGGCACCCGCTGGCATCGGAGGCCCTACATGTTCCAGTGGAAATGATGA  
CCGGTCAACATGAAGAACAAATTCAATTGCAAATATTCTGATGAGAACACCAGCAGTCCCT  
CTAGAGAACGCTGAAGGTGAGGAAACAGAGCTGACAACACCTGTACTTCCAGAAGAACACAG  
GAAGAACGATGCCAAAAAAACATTAAAGAAAGTAGAGAACGCTGCCCTGAATCTGGCCTACAT  
CCTAATCCCCAGCATTCCCTCCTCCTTGTCACCACAGTTGTATGGGTT  
GGATCTGTAGAAAAAGAAAACGGGAGCAGCCAGACCTAGCACAAAGAACACACCATC  
TGGCCCTCTCCTCACCAAGGAAACAGCCGGACCTAGAGGTCTACAATGTCATAAGAAAACA  
AAGCGAACGCTGACTTAGCTGAGACCCGGCCAGACCTGAAGAATATTCAATTCCGAGTGTGTT  
CGGGAGAACCCACTCCGATGACATGTCAGTACTGACATGGCTGTGAACCCATCA  
GAAAGTGGTTGTGACTCTGGTGGAGAGTGGATTGTGACCAATGACATTTATGA  
GTTCTCCCCAGACCAAAATGGGAGGAGTAAGGAGCTGGATGGTGGAAAATGAAATATATG  
GTTATTAGGACATATAAAAAACTGAAACTGACAACAAATGGAAAAGAAATGATAAGCAAATC  
CTCTTATTTCTATAAGGAAAATACACAGAACGGTCTATGACAAGCTTAGATCAGGTCTGT  
GGATGAGCATGTGGTCCCCACGACCTCCTGGACCCCCACGTTGGCTGTATCCTTAT  
CCCAGCCAGTCATCCAGCTGACCTTATGAGAACGGTACCTGCCAGGTCTGGCACATAGTA  
GAGTCTCAATAATGTCACTGGTTGGTTGTATCTAACCTTAAGGGACAGAGCTTACCTG  
GCAGTGATAAAAGATGGCTGTGGAGCTTGGAAAACCACCTCTGTTCTGGCTATACAG  
CAGCACATATTACACAGAACAGAAAATCCAGAACCTTCAAAGCCCACATATGGTAGCA  
CAGGTTGGCCTGTGCATGGCAATTCTCATATCTGTTTTCAAAGAACATAAAATCAAATAA  
AGAGCAGGAAAAAA

**FIGURE 50**

Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Leu Ala Val Leu Leu Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Ala Ser Asp Leu Asp Leu Arg Gly Gly Gln Pro Val Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr Phe His Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala Cys Arg Arg Asp Gly Gly Gln Leu Val Ser Ile Glu Ser Glu Asp Glu Gln Lys Leu Ile Glu Lys Phe Ile Glu Asn Leu Leu Pro Ser Asp Gly Asp Phe Trp Ile Gly Leu Arg Arg Arg Glu Glu Lys Gln Ser Asn Ser Thr Ala Cys Gln Asp Leu Tyr Ala Trp Thr Asp Gly Ser Ile Ser Gln Phe Arg Asn Trp Tyr Val Asp Glu Pro Ser Cys Gly Ser Glu Val Cys Val Val Met Tyr His Gln Pro Ser Ala Pro Ala Gly Ile Gly Gly Pro Tyr Met Phe Gln Trp Asn Asp Asp Arg Cys Asn Met Lys Asn Asn Phe Ile Cys Lys Tyr Ser Asp Glu Lys Pro Ala Val Pro Ser Arg Glu Ala Glu Gly Glu Glu Thr Glu Leu Thr Thr Pro Val Leu Pro Glu Glu Thr Gln Glu Glu Asp Ala Lys Lys Thr Phe Lys Glu Ser Arg Glu Ala Ala Leu Asn Leu Ala Tyr Ile Leu Ile Pro Ser Ile Pro Leu Leu Leu Leu Val Val Thr Thr Val Val Cys Trp Val Trp Ile Cys Arg Lys Arg Lys Arg Glu Gln Pro Asp Pro Ser Thr Lys Lys Gln His Thr Ile Trp Pro Ser Pro His Gln Gly Asn Ser Pro Asp Leu Glu Val Tyr Asn Val Ile Arg Lys Gln Ser Glu Ala Asp Leu Ala Glu Thr Arg Pro Asp Leu Lys Asn Ile Ser Phe Arg Val Cys Ser Gly Glu Ala Thr Pro Asp Asp Met Ser Cys Asp Tyr Asp Asn Met Ala Val Asn Pro Ser Glu Ser Gly Phe Val Thr Leu Val Ser Val Glu Ser Gly Phe Val Thr Asn Asp Ile Tyr Glu Phe Ser Pro Asp Gln Met Gly Arg Ser Lys Glu Ser Gly Trp Val Glu Asn Glu Ile Tyr Gly Tyr

**FIGURE 51**

GGGGTCTCCCTCAGGGCCGGGAGGCACAGCGGTCCCTGCTGCTGAAGGGCTGGATGTACGC  
ATCCGCAGGTTCCCGCGGACTTGGGGCGCCCGCTGAGCCCCGGCGCCGCAGAACAGACTTGT  
GTTTGCCTCCTGCAGCCTCAACCCGGAGGGCAGCGAGGGCCTACCACCATGATCACTGGTGT  
GTTCAAGCATGCCTTGAGGACCCCAGTGGCGTCCTGACCTCGCTGGCGTACTGCCTGCACC  
AGCGGGCGGGTGGCCCTGGCGAGCTGCAGGAGGCCATGGCCAGTGTCCGGTCACCGCAGC  
CTGCTGAAGTTGAAAATGGTCAGGTCGTGTTCGACACGGGGCTGGAGTCCTCTCAAGCC  
GCTCCCGCTGGAGGAGCAGGTAGAGTGGAACCCCCAGCTATTAGAGGTCCCACCCAAACTC  
AGTTGATTACACAGTCACCAATCTAGCTGGTGGTCCGAAACCATATTCTCCTTACGACTCT  
CAATACCATGAGACCACCCCTGAAGGGGGCATGTTGCTGGCAGCTGACCAAGGTGGCAG  
GCAGCAAATGTTGCCTTGGAGAGAGACTGAGGAAGAACTATGTGGAAGACATTCCCTTC  
TTTCACCAACCTTCAACCCACAGGAGGTCTTATTGTTCCACTAACATTTTCCAATCTG  
GAGTCCACCCGTTGCTGGCTGGCTTTCCAGTGTCAAGAAAGAAGGACCATCATCAT  
CCACACTGATGAAGCAGATTCAAAGTCTGTATCCAACTACCAAAGCTGCTGGAGCCTGA  
GGCAGAGAACCAAGAGGCCGGAGGCAGACTGCCTCTTACAGCCAGGAATCTCAGAGGATTG  
AAAAAGGTGAAGGACAGGATGGCATTGACAGTAGTGATAAAGTGGACTTCTTCATCCTCCT  
GGACAACGTGGCTGCCGAGCAGGCACACAACCTCCAAGCTGCCATGCTGAAGAGATTG  
CACGGATGATCGAACAGAGAGCTGTGGACACATCCTGTACATACTGCCAAGGAAGACAGG  
GAAAGTCTTCAGATGGCAGTAGGCCATTCCCTCACATCCTAGAGAGCAACCTGCTGAAAGC  
CATGGACTCTGCCACTGCCCGACAAGATCAGAAAGCTGTATCTCTATGCGGCTCATGATG  
TGACCTTCATACCGCTTTAATGACCTGGGATTTGACCAAAATGGCCACCGTTGCT  
GTTGACCTGACCATGGAACCTTACCAAGCACCTGGAATCTAAGGAGTGGTTGTGCA  
TTACCAAGGAAGGAGCAGGTGCCAGAGGTTGCCCTGATGGCTCTGCCGCTGGACATGT  
TCTTGAAATGCCATGTCAGTTATACCTTAAGCCCAGAAAAATACCATGCACTCTGCTCTCAA  
ACTCAGGTGATGGAAGTTGGAAATGAAGAGTAAGTGTGATTATAAAAGCAGGATGTGTTGATT  
TTAAAATAAAGTGCCTTATACAAATG

**FIGURE 52**

```
><ss.DNA34434
><subunit 1 of 1, 428 aa, 1 stop
><MW: 48886, pI: 6.39, NX(S/T): 0
MITGVFSMRLWTPVGVLTSAYCLHQRRVALAELQEADGQCPVDRSLLKLKMVQVVFRHG
ARSPLKPLPLEEQVEWNPQLLEVPPQTQFDYTVTNLAGGPKPYSPYDSQYHETTLKGGMF
AGQLTKVGMQQMFALGERLRKNYVEDIPFLSPTFNPQEVFIRSTNIFRNLESTRCLLAGL
FQCQKEGPIIIHTDEADSEVLYPNYQSCWSLRQRTRGRRQTASLQPGISEDLKKVKDRMG
IDSSDKVDFFILLDNVAEQAHNLPSCPMLKRFARMIEQRAVDTSLYILPKEDRESLQMA
VGPFLHILESNLLKAMDSATAPDKIRKLYLYAAHDVTFIPLLMTLGIFDHKWPPFAVDLT
MELYQHLESKEWFVQLYYHGKEQVPRGCPDGLCPLDMFLNAMSVTLSPEKYHALCSQTQ
VMEVGNEE
```

**FIGURE 53**

CTCCTCTTAACATACTTGCAGCTAAAACATAATGGCTGGGACCTCCTCTAGCCT  
TAAATTTCAGCTCATCACCTCACCTGCCTTGGCATGGCTCTGCTATTCTCCTTGATCCTT  
GCCATTGCAACCAGACCTGGATTCCCTAGCGTCTCCATCTGGAGTGCAGCTGGTGGGGGCCT  
CCACCGCTGTGAAGGGCGGTGGAGGTGAAACAGAAAGGCCAGTGGGCAACCGTGTGATG  
ACGGCTGGACATTAAGGACGTGGCTGTGTTGCGGGAGCTGGCTGTGGAGCTGCCAGC  
GGAACCCCTAGTGGTATTTGTATGAGCCACCAGCAGAAAAAGAGCAAAGGTCTCATCCA  
ATCAGTCAGTTGCACAGGAACAGAAGATACTGGCTCAGTGTGAGCAAGAAGAAGTTATG  
ATTGTTACATGATGAAGATGCTGGGCATCGTGTGAGAACCCAGAGAGCTCTTCTCCCCA  
GTCCCAGAGGGTGTCAAGGCTGGCTGACGGCCCTGGCATTGCAAGGGACGCGTGGAAAGTGAA  
GCACCAAGAACAGTGGTATACCGTGTGCCAGACAGGCTGGAGCCTCCGGGCCGAAAGGTGG  
TGTGCCGGCAGCTGGATGTGGAGGGCTGTACTGACTCAAAACGCTGCAACAAGCATGCC  
TATGGCCGAAACCCATCTGGCTGAGCCAGATGTCATGCTCAGGACGAGAAGCAACCCCTCA  
GGATTGCCCTCTGGGCCTGGGGAAAGAACACCTGCAACCATGATGAAGACACGTGGTGC  
AATGTGAAGATCCCTTGACTTGAGACTAGTAGGAGGAGACAACCTCTGCTCTGGCGACTG  
GAGGTGGCTGCACAAGGGCGTATGGGCTCTGTCTGTGATGACAACCTGGGAGAAAGGAGGA  
CCAGGTGGTATGCAAGCAACTGGCTGTGGAAAGTCCCTCTCCCTCCTCAGAGACCGGA  
AATGCTATGCCCTGGGGTTGGCCGATCTGCTGGATAATGTTGTTGCTCAGGGAGGAG  
CAGTCCCTGGAGCAGTGCACAGATTGGGGTTTACGACTGCACCCACCAGGAAGA  
TGTGGCTGTCATCTGCTCAGTGTAGGTGGCATCATCTAATCTGTTGAGTGCCTGAATAGAA  
GAAAAACACAGAAGAAGGGAGCATTACTGTCTACATGACTGCATGGGATGAACACTGATCT  
TCTTCTGCCCTGGACTGGACTTATACTTGGTGCCTGATTCTCAGGCCTCAGAGTTGG  
ATCAGAACTTACAACATCAGGTCTAGTTCTCAGGCATCAGACATAGTTGGAACATACATCA  
CCACCTTCCTATGTCACATTGCACACAGCAGATTCCAGCCTCCATAATTGTGTGTAT  
CAACTACTTAAATACATTCTCACACACACACACACACACACACACACACACACACATA  
CACCAATTGTCCTGTTCTGAAGAACTCTGACAAAATACAGATTGGTACTGAAAGAGA  
TTCTAGAGGAACGGAATTAAAGGATAAATTCTGAATTGGTTATGGGTTCTGAAATTG  
GCTCTATAATTCTAATTAGATAAAATTCTGGTAACCTTATTACAATAATAAGATAGCAC  
TATGTGTTAAA

**FIGURE 54**

```
><ss.DNA33100
><subunit 1 of 1, 347 aa, 1 stop
><MW: 38130, pI: 5.40, NX(S/T): 0
MALLFSLILAICTRPGFLASPSGVRLVGGLHRCEGRVEVEQKGQWGTVCDDGWDIKDVA
LCRELGCGAASGTPSGILYEPPAEKEQKVLIQSVSCTGTEDTLAQCEQEEVYDCSHDEDA
GASCENPESSFSPVPEGVRLADGPGHCKGRVEVKHQNWYTCQTGWSLRAAKVVCRQLG
CGRAVLTQKRCNKHAYGRKPIWLSQLMSQMSCSGREATLQDCPSGPWGKNTCNHDEDTW
VECEDPFDLRLVGGDNLCSGRLEVHKGVWGSVCDDNWGEKEDQVVCKQLGCGKSLSPSF
RDRKC
YGPGVGRIWLDNVRCSCGEEQSLEQCQHRFWGFHDCTHQEDVAVICSV
```

**FIGURE 55**

ACTGCACTCGTTCTATCGATTGAATTCCCCGGGGATCCTCTAGAGATCCCTGACCTCGAC  
CCACCGCGTCCCGCGACCGTGGCGGACCGTGGGCCGGCTACCAGGAAGAGTCGCCGAAG  
GTGAAGGCCATGGACTTCATCACCTCCACAGCCATCCTGCCCTGCTGGCTGCCTGG  
CGTCTCGGCCTCTCCGGCTGCTGCAGTGGTGCGCGGAAGGCCTACCTGCCGAATGCTG  
TGGTGGTGATCACAGGCGCCACCTCAGGGCTGGCAAAGAATGTGAAAAGTCTTCTATGCT  
GCGGGTGCTAAACTGGTGCTCTGGCCGAATGGTGGGCCCTAGAACAGCTCATCAGAGA  
ACTTACCGCTTCTCATGCCACCAAGGTGCAGACACACAAGCCTACTTGGTACCTCGACC  
TCACAGACTCTGGGCCATAGTTGCAGCAGCTGAGATCCTGCAGTGCTTGGCTATGTC  
GACATACTGTCAACAATGCTGGATCAGCTACCGTGGTACCATCATGGACACCAAGTGG  
TGTGGACAAGAGGGTCAAGGAGACAAACTACTTGGCCCAGTGCTCTAACGAAAGCACTCC  
TGCCCTCCATGATCAAGAGGAGGCAAGGCCACATTGTCGCCATCAGCAGCATCCAGGGCAAG  
ATGAGCATTCTTTGATCAGCATATGCAGCCTCCAAGCACGCAACCCAGGCTTCTTGA  
CTGTCGTGCCAGATGAAACAGTATGAAATTGAGGTGACCGTCATCAGCCCCGGCTACA  
TCCACACCAACCTCTGTAAATGCCATACCGCGATGGATCTAGGTATGGAGTTATGGAC  
ACCACACAGGCCAGGGCGAAGCCCTGGAGGTGGCCAGGATGTTCTGCTGTGG  
GAAGAAGAAGAAAGATGTGATCCTGGCTACTTACTGCCTCCTGGCTGTTATCTCGAA  
CTCTGGCTCCTGGCTCTTCAGCCTCATGGCCTCCAGGCCAGAAAGAGCGGAAATCC  
AAGAACTCCTAGTACTCTGACCAGCCAGGGCAGGGCAGAGAACGAGCACTCTAGGCTTGC  
TTACTCTACAAGGGACAGTTGCATTGAGACTTAATGGAGATTGTCTCACAGTGG  
AAAGACTGAAGAAACACATCTCGTGCAGATCTGCTGGCAGAGGACAATCAAAACGACAACA  
AGCTTCTCCCAGGGTGAGGGAAACACTTAAGGAATAATGGAGCTGGGTTAACACT  
AAAAACTAGAAATAAACATCTCAAACAGTAAAAAAAAAAGGGCGGCCGACTCTAG  
AGTCGACCTGCAGAAGCTGGCCGCCATGGCCCAACTTGTATTGCAGCTTATAATGGTTAC

**FIGURE 56**

```
><ss.DNA35600
><subunit 1 of 1, 310 aa, 1 stop
><MW: 33524, pI: 9.55, NX(S/T): 1
MDFITSTAILPILLFGCLGVFGLFRLLQWVRGKAYLRNAVVIITGATSGLGKEAKVFYAA
GAKLVLCGRNGGALEELIRELTASHATKVQTHKPYLVTFDLTDGAIVAAAAEILQCFGY
VDILVNNAAGISYRGTIMDTTVDKRVMETNYFGPVALTKALLPSMIKRRQGHIVAISSI
QGKMSIPFRSAYAASKHATQAFFDCLRAEMEQYEIEVTVISPGYIHTNLSVNAITADGSR
YGVMDTTAQGRSPVEVAQDVLA AVGKKKDVLADLLPSLAVYLRTLAPGLFFSLMASR
ARKERKS KNS
```

## FIGURE 57

CCACCGCGTCCGCTGGTGTAGATCGAGCAACCCTCTAAAAGCAGTTAGAGTGGTAAAAAA  
AAAAAAAAACACACCAAACGCTCGCAGCCACAAAGGG  
><MET {trans=1-s, dir=f, res=1}>  
ATGAAATTCTCTGGACATCCTCCTGCTCTCCCGTTACTGATCGTCTGCTCCCTAGAGTC  
CTTCGTGAAGCTTTTATTCTTAAGAGGAGAAATCAGTCACCGGGCAAATCGTCTGATTA  
CAGGAGCTGGCATGGAATTGGGAGACTGACTGCCTATGAATTGCTAAACTAAAAGCAAG  
CTGGTCTCTGGATATAATAAGCATGGACTGGAGGAAACAGCTGCCAATGCAAGGGACT  
GGGTGCCAAGGTTCATACCTTGTTGAGACTGCAGCAACCGAGAAGATAATTACAGCTCTG  
CAAAGAAGGTGAAGGCAGAAATTGGAGATGTTAGTATTAGTAAATAATGCTGGTAGTC  
TATACATCAGATTGTTGCTACACAAGATCCTCAGATTGAAAAGACTTTGAAGTTAATGT  
ACTTGACATTTCTGGACTACAAAGGCATTCTGCATGACAGAAGATAACCATGGCC  
ATATTGTCAGTGTGGCTTCGGCAGCTGGACATGTCCTGGTCCCCTTACTGGCTTACTGT  
TCAAGCAAGTTGCTGCTGGATTTCATAAAACCTTGACAGATGAACTGGCTGCCTTACA  
AATAACTGGAGTCAAAACAACATGTCCTGCTTAATTGCTAAACACTGGCTTCATCAAAA  
ATCCAAGTACAAGTTGGGACCCACTCTGGAACCTGAGGAAGTGGAACAGGCTGATGCAT  
GGGATTCTGACTGAGCAGAAGATGATTTTATTCCATCTCTAGCTTTTAACAACATT  
GGAAAGGATCCTCCTGAGCGTTCTGGCAGTTAAAACGAAAATCAGTGTAAAGTTG  
ATGCAGTTATTGGATATAAAATGAAAGCGAATAAGCACCTAGTTCTGAAAATGATT  
CCAGGTTAGGTTGATGTCATCTAATAGTGCAGAATTAAATGTTGAACCTCTGTTTT  
CTAATTATCCCCATTCTCAATATCATTGAGGCTTGGCAGTCTCATTACTACCAC  
TTGTTCTTAGCCAAAAGCTGATTACATATGATATAAACAGAGAAACCTTAGAGGTGAC  
TTAAGGAAAATGAAGAAAAGAACCAAAATGACTTATTAAAATAATTCCAAGATT  
GTGGCTCACCTGAAGGCTTGCAAAATTGACCATACCGTTATTAAACATATATT  
TTTGATTGCACTTAAATTGATTAATTGTTCTTTCTGTTCTACATAAAATCAG  
AAACTCAAGCTCTAAATAAAATGAAGGACTATATCTAGTGGTATTCTACAAATGAATATC  
ATGAACTCTCAATGGTAGGTTCATCCTACCCATTGCCACTCTGTTCTGAGAGATACCT  
CACATTCAATGCCAACATTCTGCACAGGGAAGCTAGAGGGATACACGTGTTGCAAGT  
ATAAAAGCATCACTGGATTAAAGGAGAATTGAGAGAATGTACCCACAAATGGCAGCAATAA  
TAAATGGATCACACTTAAAAA  
AAA  
AAA

## FIGURE 58

> <subunit 1 of 1, 300 aa, 1 stop

> <MW: 32964, pI: 9.52

><signal peptide>

MKFLLDILLLPLLIVCSL

><start mature protein>

ESFVKLFIPKRRKSVTGEIVLITGAGHGIGRLTAYEFAKLKS KLVLWDINKHGLEETA AK  
CKGLGAKVHTFVVDCSNREDIYSSAKKVKA EIGDVSILVNNAGVVYTSDFATQDPQIEK  
TFEVNVLAHFWTTKAFLPAMTKNNGHIVTVASAAGHVSVFLLA

><putative oxidoreductase active site, by similarity to Y00P\_MYCTU and BUDC\_KLETE>  
YCSSKFAAVGFHKLTDELAALQITGVKTTCLCPNFVNTGFIKNPSTSLGPTLEPEEVVN  
RLMHGILTEQKMIFIPSSIAFLTLERILPERFLAVLKRKISVKFDAVIGYKMKAQ

**FIGURE 59**

CCCACGCGTCCCGGGACCGTGGTCGACTAGTTCTAGATCGCGAGCGGCCGCCGGCTC  
AGGGAGGAGCACCGACTGCGCCGCACCCCTGAGAGATGGTGGTGCCTGTGAAGGTGATTG  
TTTCGCTGGTCCTGTTGATGCCTGGCCCTGTGATGGCTGTTCGCTCCCTATACAGAACT  
GTTTCCATGCCACCTAACGGAGACTCAGGACAGCCATTATTCACCCCTAACATTGAAGC  
TGGGAAGATCCAAAAAGGAAGAGAATTGAGTTGGTCGGCCCTTCCAGGACTGAACATGA  
AGAGTTATGCCGGCTTCCTCACCGTGAATAAGACTTACAACAGCAACCTCTTCTGGTTC  
TTCCCAGCTCAGATAACGCCAGAAGATGCCAGTAGTTCTGGCTACAGGGTGGCCGGG  
AGGTTCATCCATGTTGGACTCTTGGAACATGGCCTTATGTTGTCACAAGTAACATGA  
CCTTGGCGTACAGAGACTTCCCTGGACCACAACGCTCTCCATGCTTACATTGACAATCCA  
GTGGGCACAGGCTTCAGTTACTGATGATAACCCACGGATATGCAGTCATGAGGACGATGT  
AGCACGGGATTTATACAGTGCACTAATTGAGTTCCAGATATTCCTGAATATAAAAATA  
ATGACTTTATGTCACTGGGAGTCTTATGCAGGGAAATATGTGCCAGCCATTGCACACCTC  
ATCCATTCCCTCAACCCGTGAGAGAGGTGAAGATCAACCTGAACGGAATTGCTATTGGAGA  
TGGATATTCTGATCCCGAATCAATTATAGGGGCTATGCAGAATTCCGTACCAAATTGGCT  
TGTTGGATGAGAAGCAAAAAAAAGTACTTCCAGAACCCAGTGCATGAATGCATAGAACACATC  
AGGAAGCAGAACTGGTTGAGGCCTTGAAATACTGGATAAAACTACTAGATGGCGACTAAC  
AAGTGATCCTTACTTCCAGAAATGTTACAGGATGTAGTAATTACTATAACTTTGCGGT  
GCACGGAACCTGAGGATCAGCTTACTATGTGAAATTGGTCACTCCAGAGGTGAGACAA  
GCCATCCACGTGGGAATCAGACTTTAATGATGGAACATAGTTGAAAAGTACTTGCAGA  
AGATAACAGTACAGTCAGTTAACCCATGGTAACTGAAATCATGAATAATTATAAGGTTCTGA  
TCTACAATGCCAACTGGACATCATCGTGGCAGCTGCCCTGACAGAGCGCTCCTGATGGC  
ATGGACTGAAAGGATCCCAGGAATACAAGAAGGCAGAAAAAAAGTTGGAAGATTTAA  
ATCTGACAGTGAAGTGGCTGGTTACATCCGGCAAGCGGGTACTTCATCAGGTAAATTATTC  
GAGGTGGAGGACATATTTACCCCTATGACCAGCCTCTGAGAGCTTGTACATGATTAATCGA  
TTCATTTATGAAAAGGATGGGATCCTTATGTTGATAAAACTACCTTCCAAAAGAGAACAT  
CAGAGGTTTCATTGCTGAAAAGAAAATCGTAAAACAGAAAATGTCATAGGAATAAAAAAA  
TTATCTTTCATATCTGCAAGATTTTCTCAATAAAATTATCCTGAAACAAGTGCAGTTG  
TTTGTGTTGGGGAGATGTTACTACAAATTAAACATGAGTACATGAGTAAGAATTACA  
TTATTTAACTAAAGGATGAAAGGTATGGATGATGTGACACTGAGACAGAAGATGTATAATGA  
AATTTAGGGCTTGAATAGGAAGTTAATTCTTAAGAGTAAGTGAAGGTTGAGCTTGAAGGT  
TAACAAACAAAGCTGTAACATCTTCTGCCAATAACAGAAGTTGGCATGCCGTGAAGGT  
GTTTGGAAATATTATTGGATAAGAATAGCTCAATTATCCAAATAATGGATGAAGCTATAA  
TAGTTTGGGAAAAGATTCTCAAATGTATAAAGTCTTAGAACAAAAGAATTCTTGAAATA  
AAAATATTATATAAAAGTAAAAAAAAAA

**FIGURE 60**

><ss.DNA33206  
><subunit 1 of 1, 476 aa, 1 stop  
><MW: 54164, pI: 5.52, NX(S/T): 4  
MVGAMWKVIVSLVLLMPGCDGLFRSLYRSVSMPKGDSQPLFLTPYIEAGKIQKGREL  
SLVGPFPGLNMKSYAGFLTVNKTYNSNLFFWFFPAQIQPEDAPVVLWLQGGPGGSSMFGL  
FVEHGPYVVTSNMTLRDRDFPWTTLSMLYIDNPVGTGFSFTDDTHGYAVNEDDVARDLY  
SALIQFFQIFPEYKNNDFYVTGESYAGKYVPAIAHLIHSLNPREVKINLNGIAIGDGYS  
DPESIIGGYAEFLYQIGLLDEKQKKYFQKQCHECIEHIRKQNWFIAFEILDKLLGDLTS  
DPSYFQNVTCGSYYNFLRCTEPEDQLYYVKFLSLPEVRQAIHVGQTFNDGTIVEKYLR  
EDTVQSVKPWLTIEMNNYKVLIYNGQLDIIVAAALTERSLMGMDWKGSQEYKKAEKKVWK  
IFKSDSEVAGYIRQAGDFHQVIIRGGGHILPYDQPLRAFDMINRFIYKGKWDPYVG

**FIGURE 61**

CGAGGGCTTTCCGGCTCCGAATGGCACATGTGGAATCCCAGTCTTGGCTACAACAT  
TTTCCTTCTAACAAAGTCTAACAGCTGTTAACAGCTAGTGATCAGGGTTCTTCTT  
GCTGGAGAAGAAAGGGCTGAGGGCAGAGCAGGGCACTCTCACTCAGGGTACCAAGCTCCTTG  
CCTCTGTGGATAACAGAGCATGAGAAAGTGAAGAGATGCAGCGGAGTGAGGTGATGGAAG  
TCTAAAATAGGAAGGAATTGTGTGCAATATCAGACTCTGGGAGCAGTGACCTGGAGAGC  
CTGGGGAGGGCTGCCTAACAAAGCTTCAAAAACAGGAGCGACTTCACTGGCTGGGAT  
AAGACGTGCCGGTAGGGAGACTGGGTTAGTCCTAATATCAAATTGACTGGCTGGG  
TGAACCTCAACAGCCTTAACCTCTGGGAGATGAAAACGATGGCTTAAGGGCCAGAAA  
TAGAGATGCTTGTAAAATAAAATTAAAAAGCAAGTATTATAGCATAAAGGCTAGA  
GACCAAAATAGATAACAGGATTCCCTGAACATTCTAACAGGGAGAAAAGTATGTTAAAATA  
GAAAAACCAAAATGCAGAAGGAGGAGACTCACAGAGCTAACACCAGGATGGGACCCCTGGGTC  
AGGCCAGCCTTTGCTCTCCCGAAATTATTTGGTCTGACCACTCTGCCTGTGTTT  
GCAGAATCATGTGAGGGCCAACCGGGGAAGGTGGAGCAGATGAGCACACACAGGAGCCGTCT  
CCTCACCGCCGCCCTCTCAGCATGGAACAGAGGCAGCCCTGGCCCCGGGCCCTGGAGGTGG  
ACAGCCGCTGTGGTCTGCTCAGTGGTCTGGGCTGCTGGCCCCCAGCAGCCGGC  
ATGCCTCAGTTAGCACCCTCACTCTGAGAATCGTGAUTGGACCTTCAACCACCTGACCGT  
CCACCAAGGGACGGGGCGTCTATGTGGGGCCATCAACCGGGTCTATAAGCTGACAGGCA  
ACCTGACCATCCAGGTGGCTCATAGACAGGGCAGAAGAGGACAACAAGTCTCGTTACCCG  
CCCCTCATCGTCAGCCCTGCAGCGAAGTGTCTCACCTCACCAACAATGTCACAAGCTGCT  
CATCATTGACTACTCTGAGAACCGCCTGCTGGCTGTGGAGCCTCTACCAAGGGTCTGCA  
AGCTGCTGCGGCTGGATGACCTCTCATCTGGTGGAGCCATCCCACAAGAAGGAGCACTAC  
CTGTCCAGTGTCAACAAAGACGGCACCATGTACGGGTGATTGTGCGCTCTGAGGGTGGAGGA  
TGGCAAGCTCTCATCGGCACGGCTGTGGATGGAAGCAGGATTACTTCCGACCCCTGTCCA  
GCCGGAAGCTGCCCGAGAACCTGAGTCCTCAGCCATGCTCGACTATGAGCTACACAGCGAT  
TTTGTCTCCTCTCATCAAGATCCCTCAGACACCCCTGGCCCTGGTCTCCACTTGACAT  
CTTCTACATCTACGGCTTGCTAGTGGGGCTTGTCTACTTCTCACTGTCCAGCCGAGA  
CCCCTGAGGGTGTGGCATCAACTCCGCTGGAGACCTCTACACCTCACGCTCGGG  
CTCTGCAAGGATGACCCAAGTCCACTCATCGTCCCTGCCCTCGCTGCACCCGGGC  
CGGGTGGAAATACGCCCTGCAGGCTGTTACCTGGCAAGCCTGGGACTCACTGGCC  
AGGCCTCAATATCACCAAGCCAGGACGATGTACTCTTGCCATCTTCTCAAAGGGCAGAAG  
CAGTATCACCAACCGCCGATGACTCTGCCCTGTGCTTCCCTATCCGGCCATCAACTT  
GCAGATCAAGGAGCGCCTGCAGTCTGCTACCAAGGGCAGGGCACCTGGAGCTCAACTGGC  
TGCTGGGAAGGACGTCAGTGCACGAAGGGCCTGTCCCCATCGATGATAACTCTGTGGA  
CTGGACATCAACCAGCCCTGGGAGGCTCAACTCCAGTGGAGGGCTGACCCCTGTACACCAC  
CAGCAGGGACCGCATGACCTCTGTGGCCTCTACGTTACAACGGCTACAGCGTGGTTTG  
TGGGGACTAAGAGTGGCAAGCTGAAAAGTAAGAGTCTATGAGTTAGTCAAGTCAACTGCC  
ATTCACCTCCTCAGCAAAGAGTCCTTGGAGGTAGTATTGGTGGAGATTAACTATAG  
GCAACTTATTTCTTGGGAACAAAGGTGAAATGGGGAGGTAAGAAGGGGTTAATTTGTG  
ACTTAGCTTCTAGCTACTTCCTCAGCCATCAGTCATTGGTATGTAAGGAATGCAAGCGTA  
TTCAATATTCCTCAAACCTTAAGAAAAACTTAAGAAGGTACATCTGCAAAAGCAAA

**FIGURE 62**

```
><ss.DNA35558
><subunit 1 of 1, 552 aa, 1 stop
><MW: 61674, pI: 6.95, NX(S/T): 4
MGTLGQASLFAPPGNYFWSDHSALCFAESCEGQPGKVEQMSTHRSRLLTAAPLSMEQRQP
WPRALEVDSRSVVLLSVVWVLLAPPAAGMPQFSTFHSENRDWTFNHLTVHQGTGAVYVGA
INRVYKLTGNLTIQVAHKTGPEEDNKSRYPPLIVQPCSEVLTLTNNVNKLLIIDYSENRL
LACGSLYQGVCKLLRLDDLFIΛVEPSHKKEHYLSSVNKTGTMGYVIVRSEGEDGKLFIGT
AVDGKQDYFPTLSSRKLPDRPESSAMLDYELHSDFVSSLIKIPSDTLALVSHFDIFYIYG
FASGGFVYFLTVQPETPEGVAINSAGDLFYTSRIVRLCKDDPKFHSYVSLPFGCTRAGVE
YRLLQAAYLAKPGDSLAQAFNITSQDDVLFAlFSKGQKQYHHPPDDSALCAFPIRAINLQ
IKERLQSCYQGEGNLELNWLLGKDVKQCTKAPVPIDDNFCGLDINQPLGGSTPVEGLTLYT
TSRDRMTSVASYVYNGYSVVFVGTKSGKLKKVRVYEFRCSNAIHLLSKESLLEGSYWWRF
NYRQLYFLGEQR
```

**FIGURE 63**

AGGCTCCCGCGCGCGGCTGAGTGC GG ACTGGAGTGGAACCCGGGTCCCCCGCGCTTAGAGAA  
 CACCGCGATGACCACGTGGAGCCTCCGGCGAGGCCGCCGCACGCTGGACTCCTGCTGCT  
 GGTGCTTGGCTTCCTGGTCTCGCAGGCTGGACTGGAGCACCCCTGGTCCCTCTGC CGC  
 TCCGCCATCGACAGCTGGGCTGCAGGCCAAGGGCTGGAACCTCATGCTGGAGGATTCCACC  
 TTCTGGATCTCGGGGCTCCATCCACTATTCCTGGTCTGCCCAGGGAGTACTGGAGGGACCG  
 CCTGCTGAAGATGAAGGCCTGTGGCTGAACACCCTCACCAACCTATGTTCCGTGGAACCTGC  
 ATGAGGCCAGAAAGAGGCAAATTGACTTCTCTGGAACCTGACCTGGAGGCCTCGTCCCTG  
 ATGGCCGAGAGATCGGGCTGTGGGTGATTCTGCGTCCAGGCCCTACATCTGCAGTGAGAT  
 GGACCTCGGGGCTTGCCCAGCTGGCTACTCCAAGACCCCTGGCATGAGGCTGAGGACAACCT  
 ACAAGGGCTTCACCGAACGAGCTGGACCTTATTGACCACTGATGTCAGGGTGGTGC  
 CTCCAGTACAAGCGTGGGGACCTATCATGCCCTACGTCAGAACAGGACTGGAGGACCGTGGCATTG  
 TAATAAGACCCCGATACATGCCCTACGTCAGAACAGGATGGCTGAGCAAGGGGATTGTCAGGGAGTCTG  
 AACTGCTCCTGACTTCAGACAACAAGGATGGCTGAGCAAGGGGATTGTCAGGGAGTCTG  
 GCCACCATCAACTGCACTGCAACACACGAGCTGCACTGACCACTTCTCTCAACGT  
 CCAGGGGACTCAGCCAAAGATGGTATGGAGTACTGGACGGGTGGTTGACTCGTGGGGAG  
 GCCCTCACAATATCTTGGATTCTCTGAGGTTTGAAAACCGTGTCTGCCATTGGACGCC  
 GGCTCCTCCATCAACCTCTACATGTTCCACGGAGGCACCAACTTGGCTTCATGAATGGAGC  
 CATGCACTTCCATGACTACAAGTCAGATGTCACCAAGCTATGACTATGATGCTGTGACAG  
 AAGCGCGATTACACGCCAAGTACATGAAGCTCGAGACTTCTCGGCTCCATCTCAGGC  
 ATCCCTCTCCCTCCCCACCTGACCTTCTCCAAAGATGCCGTATGAGCCCTTAACGCCAGT  
 CTTGTACCTGTCCTGTGGGACGCCCTCAAGTACCTGGGGAGGCCAATCAAGTCAGGTTACATTCTC  
 TATGAGACCAGCATCACCTCGTCTGGCATCCTCAGTGGCACGTGCATGATGGGGCAGGT  
 GTTGTGAACACAGTATCCATAGGATTCTGGACTACAAGACAACGAAGATTGCTGTCCCC  
 TGATCCAGGGTTACACCGTGTGAGGATCTGGTGGAGAATCGTGGCGAGTCAACTATGG  
 GAGAATATTGATGACCAGCGCAAAGGCTTAATTGAAATCTCTATCTGAATGATTCAACCC  
 GAAAAACTTCAGAATCTATAGCCTGGATATGAAGAAGAGCTCTTCAGAGGTTGGCCTGG  
 ACAAAATGGNGTTCCCTCCCAGAAACACCCACATTACCTGCTTCTTGGTAGCTTGTCC  
 ATCAGCTCCACGCCCTGTGACACCTTCTGAAGCTGGAGGGCTGGGAGAAGGGGTTGTATT  
 CATCAATGCCAGAACCTGGACGTTACTGGAACATTGGACCCAGAACAGCCTTACCTCC  
 CAGGTCCTGGTTGAGCAGCGGAATCAACCAAGGTCTCGTTTTGAGGGAGACGATGGCGGG  
 CCTGCATTACAGTTCA CGGAAACCCCCACCTGGGCAGGAACCAAGTACATTAAGTGAGCGGT  
 GGCACCCCTCCTGCTGGTGCCTGGAGACTGCCCTCCTTGAACCTGAAGCCTGGTG  
 GCTGCTGCCACCCCTCACTGCAAAAGCATCTCCTTAAGTAGCAACCTCAGGGACTGGGG  
 CTACAGTCTGCCCTGTCTCAGCTAAAACCTAAGCCTGCAGGGAAAGGTGGATGGCTCT  
 GGGCCTGGCTTGTGATGATGGCTTCCACAGCCCTGCTTGTGGCGAGGCTGTCGG  
 TGTCTCTAGGGTGGGAGCAGCTAACAGATGCCAGCCTTGGCCCTCAGAAAAAGTGTG  
 AACAGTGCCTTGCACCGGACGTCACAGCCCTGCGAGCATCTGCTGGACTCAGGCCTGCT  
 TTGCTGGTTCTGGAGGCTGGCCACATCCCTATGGCCCCATTATCCCCGAAATCTG  
 GGTGTGTCAACCAGTGTAGAGGGGGAGGGGTGTCTCACCTGAGCTGACTTGTCTTCC  
 TTCACAACCTCTGAGCCTCTTGGATTCTGGAGGAACCTGGCTGAGAACATGTGAC  
 TTCCCCCTTCCCTCCACTCGCTGCTTCCCACAGGGTGCAGGCTGGCTGGAGAACAGA  
 AATCCTCACCCCTGCGTCTCCAAAGTTAGCAGGTGCTCTGGTCTAGTGAGGAGGACATG  
 TGAGTCTGGCAGAACCCAGTGTGAGTCCTGGCAGAACGCCATGGCCATGTCTGCACATCC  
 CTCACATGTGAGTCCTGGCAGAACGCCATGGCCATGTCTGCACATCCAGGGAGGAGGACAGA  
 AGGCCAGCTCACATGTGAGTCCTGGCAGAACGCCATGGCCATGTCTGCACATCCAGGGAGG  
 AGGACAGAACGCCAGCTCACATGTGAGTCCTGGCAGAACGCCATGGCCATGTCTGCACATC  
 CAGGGAGGAGGACAGAACGCCAGCTCAGTGGCCCCGCTCCCCACCCCCACGCCGAACA  
 GCAGGGGGCAGAGCAGCCCTCCTCGAAGTGTGTCAGTCCGACATTGAGCCTGTTCTGG  
 GCCCAGCCAAACACCTGGCTTGGCTACTGTCCTGAGTTGCAAGTAAAGCTATAACCTTGAA  
 TCACAA

**FIGURE 64**

MTTWSLRRR PART LGLLLVVLGFLVRL RDWSTLVPLRLRHQLGLQAKGWNFMLED  
TFWIFGGSIHYFRVPREYWRDRLKMKACGLNTLTTYVPWNLHEPERGKFDFSGNLDLE  
AFVLMAAEIGLWVILRPGPYICSEMDLGGLPSWLLQDPGMRLRTTYKGFTEAVDLYFDH  
LMSRVVPLQYKRGGPIIAVQNEYGSYNKDPAYMPYVKKALEDRGIVELLLTSDNKDG  
LSKGIVQGVLATINLQSTHELQLLTTFLFNVQGTQPKMVMEYWTGWFD SWGGPHNILDS  
SEVLKTVAVIDAGSSINLYMFHGGTNFGFMNGAMHFHDYKSDVT SYDYDAVLTEAGDY  
TAKYMKLRDFFGSISGIPPLPPP DLPKMPYEPLTPVLYLSLWDALKYLGEPIKSEKPI  
NMENLPVNGGNGQSFGYI LYET SITSSGILSGHVHDRGQVFVNTVSIGFLDYKTTKIAV  
PLIQGYTVLRILVENRGRVNYGENIDDQRKGLIGNLYLNDSP LKNFRIYSLDMKKSFFQ  
RFGLDKWXSLPETPTLPAFFLGSLSI SSTPCDTFLKLEGWEKVV FINGQNLGRYWNIG  
PQKTL YLPGPWLS SGINQVIVFEETMAGPALQFTETPHLGRNQYIK

**FIGURE 65**

GGGGACGCGGAGCTGAGAGGCTCCGGCTAGCTAGGTGTAGGGTGGACGGTCCAGGACC  
 CTGGTGAGGGTTCTACTTGGCCTTCGGTGGGGTCAAGACGCAGGCACCTACGCCAAAGG  
 GGAGCAAAGCCGGCTCGGCCGAGGCCCGAGGACCTCCATCTCCAATGTTGGAGGAATC  
 CGACACGTGACGGTCTGTCGCCGTCAAGACTAGAGGAGCGCTGTAAACGCCATGGCTCC  
 AAGAAGCTGTCTGCCTCGTCCCTGCTGCTGCCGCTCAGGCTGACGCTACTGCTGCCCA  
 GGCAGACACTCGGTCGTTGTAAGGGTCATGACGGTTCTCCTAGACGGGCC  
 CGTCCGCTATGTGTCTGGCAGCCTGCACTACTTCGGTACCGCGGGTGTCTGGGCCAC  
 CGGCTTTGAAGATGCGATGGAGCGGCCTAACGCCATACAGTTTATGTGCCCTGGAAC  
 CCACGAGCCACAGCCTGGGTCTATAACTTAATGGCAGGCCGGACCTCATTGCCCTTCTGA  
 ATGAGGCAGCTCTAGCGAACCTGTTGGTCATACTGAGACCAGGACCTACATCTGTGCAGAG  
 TGGGAGATGGGGGTCTCCCATCCTGGTTGCTCGAAAACCTGAAATTCACTAAGAAC  
 AGATCCAGACTCCTGCCGCAGTGGACTCCTGGTCAAGGCTTGCTGCCAAGATATATC  
 CATGGCTTTATCACAATGGGGCAACATCATTAGCATTAGGTGGAGAATGAATATGGTAGC  
 TACAGAGCCTGTGACTTCAGCTACATGAGGCACGGCTGGCTGGCTTCCGTGCACTGCTAGG  
 AGAAAAGATCTGCTCTCACACAGATGGGCCTGAAGGACTCAAGTGTGGCTCCCTCCGG  
 GACTCTATACCACTGTAGATTTGGCCCAGCTGACAACATGACCAAAATCTTACCTGCTT  
 CGGAAGTATGAACCCCATGGCCATTGGTAAACTCTGAGTACTACACAGGCTGGCTGGATTA  
 CTGGGCCAGAACATCACTCCACACGGTCTGTGTCAGCTGTAACCAAAGGACTAGAGAACATGC  
 TCAAGTGGGAGCCAGTGTGAACATGTACATGTTCCATGGAGGTACCAACTTGGATATTGG  
 AATGGTGCCTGATAAGAAGGGACGCTTCCTCGATTACTACCAAGCTATGACTATGATGCACC  
 TATATCTGAAGCAGGGACCCCACACCTAACGTTTGCTCTGAGATGTCATCAGCAAGT  
 TCCAGGAAGTTCTTGGGACCTTACCTCCCCGAGCCCCAACATGATGCTTGGACCTGTG  
 ACTCTGCACCTGGTGGCATTACTGGCTTCTAGACTTGCTTGCCCCGTGGCCCAT  
 TCATTCAATCTGCCAATGACCTTGAGGCTGTCAGCAGGACCATGGCTTCTAGTTGTA  
 GAACCTATATGACCCATACCATTGGTGGCAACACCATTCTGGGTGCCAAATAATGGAGTC  
 CATGACCGTGCTATGTGATGGTGGATGGGTGTTCCAGGGTGTGGAGCGAAATATGAG  
 AGACAAACTATTTGACGGGAAACTGGGTCAAACACTGGATATCTTGGTGGAGAACATGG  
 GGAGGCTCAGCTTGGTCTAACAGCAGTGAACGGCTGTGAAGGCCACCAATTCTG  
 GGGCAAACAATCCTACCCAGTGGATGATGTTCCCTGTAACAAATTGATAACCTGTGAAGTG  
 GTGGTTCCCTCCAGTGCACAAATGCCATATCTCAAGCTCTGGCCCCACATTCT  
 ACTCCAAAACATTCCAATTAGGCTCAGTTGGGACACATTCTATATCTACCTGGATGG  
 ACCAAGGGCCAAGTCTGGATCAATGGTTAACCTGGCCGGTACTGGACAAAGCAGGGGCC  
 ACAACAGACCCCTACGTGCCAAGATTCTGCTGTTCTAGGGAGCCCTAACAAAATT  
 CATTGCTGGAACCTAGAAGATGTACCTCTCAGCCCCAAGTCCAATTGGATAAGCCTATC  
 CTCAATAGCACTAGTACTTGCACAGGACACATATCAATTCCCTTCAGCTGATACACTGAG  
 TGCTCTGAACCAATGGAGTTAAGTGGCACTGAAAGGTAGGCCGGCATGGTGGCTCATGC  
 CTGTAATCCCAGCAGTTGGAGGCTGAGACGGGTGGATTACCTGAGGTCAAGGACTTCAAGA  
 CCAGCCTGGCCAACATGGTGAACCCCGTCTCCACTAAAAAATACAAAATTAGCCGGCGTG  
 ATGGTGGGCACCTCTAACATCCCAGCTACTTGGAGGCTGAGGCAGGAGAATTGCTTGAATCC  
 AGGAGGCAGAGGTTGCAGTGAGTGGAGGTTGTACCACTGCACTCCAGCCTGGCTGACAGTGA  
 GACACTCCATCTCAAAAAAAAAAA

**FIGURE 66**

MRWSGLNAIQFYVPWNYHEPQPGVNFNGSRDLIAFLNEAALANLLVILRPGPYICA  
EMGGLPSWLLRKPEIHLRTSDPDFLAAVDSWFKVLLPKIYPWLYHNGGNIISIQVENEY  
GSYRACDFSYMRHLAGLFRAALLGEKILLFTTDGPEGLKCGSLRGLYTTVDFGPADNM  
TKIFTLLRKYEPMHGPLVNSEYYTGWLWQNHSTRVSATKGLENMLKLGASVNMYMFH  
GGTNFGYWGADKKGRFLPITTSYDYDAPISEAGDPTPKLFALRDVISKFQEVP  
LGPLPPSPKMMGLGPVTLHLVGHLLAFLDLLCPRGPIHSILPMTFEAVKQDHGFMLYRTYM  
THTIFEPTFWVPNNGVHDRAYVMVDGVFQGVVERNMRDKLFLTGKLGSKLDILVENM  
GRRLSFGSNSSDFKGLLKPPILGQTILTQWMMFPLKIDNLVKWWFPLQLPKWPYPQAPSG  
PTFYSKTFPILGSVGDTFLYLPGWTKGQVWINGFNLGRYWTQGPQQTLVPRFLLFPRG  
ALNKITLLELEDVPLQPQVQFLDKPILNSTSTLHRTHINSLSADTLSASEPMELSGH

**FIGURE 67**

GCTTTGAACACGTCTGCAAGCCAAAGTTGAGCATTGATTGGTTATGAGGTATTTGAGTGC  
 ACCCACAAATGGCTTACATGTTGAAAAGCTTCTCATCAGTTACATATCCATTATTTGTGT  
 TTATGGCTTATCTGCCTCTACACTCTTCTGGTTATTCAGGATACTTGAAGGAATATT  
 CTTTCGAAAAAGTCAGAGAAGAGCAGTTTAGTGACATTCCAGATGTCAAAAACGATTT  
 GCGTTCCTTCTTCACATGGTAGACCAGTATGACCAGCTATATTCCAAGCGTTGGTGTGTT  
 CTTGTCAGAAGTTAGTGAAAATAACTTAGGGAAATTAGTTGAACCATGAGTGGACATTTG  
 AAAAACTCAGGCAGCACATTCAACGCAACGCCAGGACAAGCAGGAGTTGCATCTGTTCATG  
 CTGTCGGGGGTGCCGATGCTGCTTGCACCTCACAGACCTGGATGTGCTAAAGCTTGAAC  
 AATTCCAGAAGCTAAAATTCTGCTAAGATTCTCAAATGACTAACCTCCAAGAGCTCCACC  
 TCTGCCACTGCCCTGCAAAAGTTGAACAGACTGCTTTAGCTTCTCGCGATCACTGAGA  
 TGCCTCACGTGAAGTTCACTGATGTGGCTGAAATTCTGCCTGGGTGTATTTGCTCAAAAA  
 CCTTCGAGAGTTGACTTAATAGGCAATTGAACTCTGAAAACAATAAGATGATAGGACTTG  
 AATCTCTCCGAGAGTTGCCACCTTAAGATTCTCCACGTGAAGAGCAATTGACCAAAGTT  
 CCCTCCAACATTACAGATGTGGCTCCACATCTTACAAAGTTAGTCATTCTAAATGACGGCAC  
 TAAACTCTGGTACTGAACAGCCTTAAGAAAATGATGAATGTCGCTGAGCTGGAACCTCAGA  
 ACTGTGAGCTAGAGAGAATCCCACATGCTATTTCAGCCTCTCTAATTACAGGAACCTGGAT  
 TTAAAGTCCAATAACATTGCACAATTGAGGAAATCATCAGTTCCAGCATTAAAACGACT  
 GACTTGTAAAATTATGGCATAACAAAATTGTTACTATTCCCTCTATTACCCATGTCA  
 AAAACTGGAGTCACTTTATTCTCTAACACAAGCTCGAACCTTACAGTGGCAGTATT  
 AGTTTACAGAAAATCAGATGCTTAGATGTGAGCTACAACAAACATTCAATGATTCAATAGA  
 AATAGGATTGCTTCAGAACCTGCAGCATTGCATATCACTGGGAACAAAGTGGACATTCTGC  
 CAAAACAATTGTTAAATGCATAAAGTTGAGGACTTGAATCTGGGACAGAACTGCATCACC  
 TCACTCCCAGAGAAAGTTGGTCAGCTCTCCAGCTCACTCAGCTGGAGCTGAAGGGAACTG  
 CTTGGACCGCCTGCCAGCCCAGCTGGCCAGTGTGGATGCTCAAGAAAAGCAGGGCTTGTG  
 TGGAAGATCACCTTTGATACCCCTGCCACTCGAAGTCAAAGAGGCATTGAATCAAGACATA  
 AATATTCCCTTGCAAATGGGATTAAACTAAGATAATATATGCACAGTGATGTGAGGAAC  
 AACCTCCTAGATTGCAAGTGCTCACGTACAAGTTATTACAAGATAATGCATTAGGAGTAG  
 ATACATCTTTAAAATAACAGAGAGGATGCATAGAAGGCTGATAGAAGACATAACTGAAT  
 GTTCAATGTTGTAGGTTAAAGTCATTCAATTCAAATCATTCTTTCTTTGGGG  
 AAAGGGAAGGAAAAATTATAATCACTAATCTGGTTCTTTAAATTGTTGTAACCTGGAT  
 GCTGCCGCTACTGAATGTTACAAATTGCTGCCTGCTAAAGTAAATGATTAAATTGACATT  
 TTCTTACTAAAAAAAAAAAAAA

**FIGURE 68**

```
><ss.DNA34407
><subunit 1 of 1, 501 aa, 1 stop
><MW: 57819, pI: 8.15, NX(S/T): 3
MAYMLKKLLISYISIICVYGFICLYTLFWLFRIPKEYSFEKVREESSFSDIPDVKNDF
FLLHMVDQYDQLYSKRGVFLSEVSENKLREISLNHEWTFEKLRQHISRNAQDKQELHL
MLSGVPDAVFDLTDLDVLKLELIPEAKIPAKISQMTNLQELHLCHCPAKVEQTAFSFLRD
HLRCLHVFKFTDVAEIPAWVYLLKNLRELYLIGNLNSENNKMICLGESLRELRLKILHVKS
NLTKVPSNITDVAPHLTKLVIHNDGTKLLVNSLKKMMNVAELELQNCELERIPHAI
FSLSNLQELDLKSNNIRTIEIIISFQHLKRLTCLKLWHNKIVTI
PPSITHVKNLESLYFSNNKLESLPVAVFSLQKLRCLDVSYNNISM
IPIEIGLLQNLQHLHITGNKVDILPKQLFKCIKLRTLNLGQNCITS
LPEKVGQLSQLTQLELKGNCLDRPAQLGQCRMLKKSGLVVEDHLFDT
LPLEVKEALNQDINIPFANGI
```

**FIGURE 69**

CCACCGCGTCGGCCTCTCTGGACTTGCATTCCATTCTTTGACAAACTGAC  
 TTTTTTATTCCTTTTCCATCTCTGGGCCAGCTGGGATCCTAGGCCCTGGGAAGA  
 CATTGTGTTTACACACATAAGGATCTGTGTTGGGTTCTTCTCCCTGACATTG  
 GCATTGCTTAGTGGTTGTGGGGAGGGAGACCACGTGGGCTCAGTGCTTGCTGCACATT  
 CTGCCTAGGTACATCGAACAGTCTTGACCTCCATACAGTGATTATGCCTGTCATCGCTGGTG  
 GTATCCTGGGGCCTGCTCCTGCTGATAGTTGTCGTGCTCTGCTTTACTTCAAAACAC  
 AACCGCTAAAAGCTGAAAGAACCTGAAGCTGTGGCTGTAAAAAATACAACAGCACAA  
 GGTGTGGTGGCCAAGAACAGCAGGCCAAACCATTGCCACGGAGTCTGTGCTGCCCTGC  
 AGTGCTGTGAAGGATAAGAATGTGTCAGTTGATTCCCTGCCACCTGCTGTTGCGAC  
 ATAAATGAGGGCCTCTGAGTTAGGAAAGGCTCCCTCTCAAAGCAGAGGCCCTGAAGACTTCA  
 ATGATGTCAATGAGGCCACCTGTTGTGATGTGCAAGGACAGAAGAAAGGCACAGCTCCCCA  
 TCAGTTCATGAAAATAACTCAGTGCTGGAAACCAGCTGCTGGAGATCCTACAGAG  
 AGCTTCACTGGGGCAACCCCTCCAGGAAGGAGTTGGGGAGAGAACCCCTACTGTGGG  
 AATGCTGATAAACCAAGTCACACAGCTGCTCTATTCTCACACAAATCTACCCCTGCGTGCT  
 GGAACGTGACGTTCCCTGGAGGTGTCAGAAAGCTGATGTAACACAGAGCCTATAAAAGCTG  
 TCGGTCTTAAGGCTGCCAGGCCCTGCCAAAATGGAGCTGTAAGAAGGCTCATGCCATT  
 GACCCCTTTAATTCTCTCCTGTTGGCGAGCTGACAATGGCGAGGCTGAAGGCAATGCAA  
 GCTGCACAGTCAGTCTAGGGGGTGCCTATGGCAGAGACCCACAAAGCCATGATCCTGCAA  
 CTCAATCCCAGTGAGAACTGCACCTGGACAATAGAAAGACCAGAAAACAAAAGCATCAGAAT  
 TATCTTTCTATGTCAGCTGATCCAGATGGAAGCTGTGAAAGTGAACAACTAAAGTCT  
 TTGACGGAACCTCCAGCAATGGCCTCTGCTAGGGCAAGTCTGAGTAAAAACGACTATGTT  
 CCTGTATTGAATCATCATCCAGTACATTGACGTTCAAATAGTTACTGACTCAGCAAGAAT  
 TCAAAGAACTGCTTTGCTTCTACTACTTCTCTCTAACATCTTCTAACTCTATTCAAACGTG  
 GCGGTTACCTGGATACCTTGGAGGATCCTCACCAGCCCCAATTACCCAAAGCCGATCCT  
 GAGCTGGCTATTGTGTTGGCACATACAAGTGGAGAAAGATTACAAGATAAAACTAAACCT  
 CAAAGAGATTTCTAGAAAATAGACAAACAGTGCCTTTGATTTCTGCCATCTATGATG  
 GCCCCTCCACCAACTCTGGCTGATTGGACAAGTCTGTGGCGTGTGACTCCACCTCGAA  
 TCGTCATCAAACCTCTGACTGTCGTGTTCTACAGATTATGCCAATTCTACCGGGGATT  
 TTCTGCTTCTACACCTCAATTATGCAAGAAAACATCAACACTACATCTTAACTTGCTCTT  
 CTGACAGGATGAGAGTTATTATAAGCAAATCCTACAGGCTTTAACTCTAATGGGAAT  
 AACTTGCAACTAAAAGACCCAACTTGCAGACCAAAATTATCAAATGTTGGAATTTCCTGT  
 CCCTCTTAATGGATGTGGTACAATCAGAAAGGTAGAAGATCAGTCAATTACTACACCAATA  
 TAATCACCTTCTGCATCCTCAACTCTGAACTGATCACCCGTCAAGAAACAACCTCCAGATT  
 ATTGTGAAGTGTGAAATGGGACATAATTCTACAGTGGAGATAATATAACATAACAGAAGATGA  
 TGTAATACAAAGTCAAAATGCACTGGCAAATATAACACCAGCATGGCTTTTGATTC  
 ATTCAATTGAAAAGACTATACTTGAATCACCATTATGTTGGAACCAACTCTTT  
 GTTCAAGTTAGTCTGCACACCTCAGATCCAAATTGGTGGTTCTGATACCTGTAGAGC  
 CTCTCCACCTCTGACTTGCATCTCAACCTACGGACCTAAATCAAGAGTGGATGTAGTCGAG  
 ATGAAACTTGTAAAGGTGATCCCTTATTGGACACTATGGGAGATTCCAGTTAATGCC  
 AAATTCTGAGAAGTATGAGCTCTGTGATCTGCAGTGTAAAGTTGATATGTGATAGCAG  
 TGACCAACAGTCTCGCTGCAATCAAGGTTGTCTCCAGAAGCAAACAGAGACATTCTCAT  
 ATAAATGGAAAACAGATTCCATCATAGGACCCATTGCTCTGAAAAGGGATGAAAGTGCAGT  
 GGCAATTCAAGGATTTCAAGCATGAAACACATGCGGAAGAAACTCCAAACCAGCCTTCAACAG  
 TGTGCATCTGTTCTCATGGTCTAGCTCTGAACTGTGGTACTGTAGCGACAATCACAG  
 TGAGGCATTGAAATCAACGGGCAGACTACAAATACCAGAAGCTGCAGAACTATTAACTA  
 ACAGGTCCAACCCCTAAGTGAGACATGTTCTCCAGGATGCCAAAGGAAATGCTACCTCGG  
 CTACACATATTGAATAATGAGGAAGGGCTGAAAGTGACACACAGGCTGCATGAAAAAAA

**FIGURE 70**

```
><ss.DNA35841
><subunit 1 of 1, 607 aa, 1 stop
><MW: 68153, pI: 6.39, NX(S/T): 9
MELVRRLMPLTLLLILSCLAE LTMAEAEGNASCTVSLGGANMAETHKAMILQLNPSENCTW
TIERPENKSIRII FSYVQLDPDGSCES ENIKVFDGTSSNGPLLGVCSKNDYVPVFESSS
STLTFQIVTDSARIQRTVVFYYFFSPNISIPNCGGYLDTLEGSFTSPNYPKPHPELAYC
VWHIQVEKDYKIKLNFKEIFLEIDKQCKFDLAIYDGPSTNSGLIGQVCGRVTPTFESSS
NSLTVVLSTDYANSYRGFSASYTSIYAENINTTSLTCSSDRMRVIISKSYLEAFNSNGNN
LQLKDPTCRPKLSNVVEFSVPLNGCGTIRKVEDQSITYTNIIITFSASSTSEVITRQKQLQ
IIVKCEMGHNSTVEI IYITEDDVIQSQNALGKYNTSMALFESNSFEKTIILESPYYVDLNQ
TLFVQVSLHTSDPNLVVFLDTCRASPTSDFASPTYDLIKSGCSRDETCKVYPLFGHYGRF
QFNAFKFLRSMSSVYLQCKVLICDSSDHQSRCNQGCVSRSKRD ISSYWKTDIIGPIRL
KRDRSASGNSGFQHETHAEETPNQPFNSVHLFSFMVLALNVVTVATITVRHFVNQRADYK
YQKLQNY
```

**FIGURE 71**

GACGGAAGAACAGCGCTCCCGAGGCCGCCGGAGCCTGCAGAGAGGACAGCCGGCTGCAGCG  
 GGACATGCGGCCAGGAGCTCCCCAGGCTCGCTTCCCCTGCTGCTGCTGCTGC  
 TGCTGCCGCCGCCGTGCCCTGCCACAGCGCACCGCCTCGACACCCACCTGGGAGTCC  
 CTGGACGCCGCCAGCTGCCGCCGTGGTTGACCAGGCCAAGTTCGGCATCTTCATCCACTG  
 GGGAGTGTTCCTCGTCCCCAGCTCGTAGCGAGTGGTCTGGTGGTATTGGAAAAGGAAA  
 AGATAACGAAGTATGTGAAATTATGAAAGATAATTACCCCTCTAGTTCAAATATGAAGAT  
 TTTGGACCACTATTTACAGCAAATTAAATGCCAACCAGTGGGAGATATTTCAGGC  
 CTCTGGTGCCAAATACATTGTCTTAACCTCCAAACATCATGAAGGCTTACCTTGTTGGGGT  
 CAGAATATTCTGTGAACTGGAATGCCATAGATGAGGGGCCAAGAGGGACATTGTCAAGGAA  
 CTTGAGGTAGCCATTAGGAACAGAACTGACCTGCGTTTGGACTGTACTATTCCCTTTG  
 ATGGTTTCATCCGCTTCTCTGAGGATGAATCCAGTTCATCCATAAGCGGCAATTCCAG  
 TTTCTAAGACATTGCCAGAGCTCTATGAGTTAGTGAACAACTATCAGCCTGAGGTTCTGTGG  
 TCGGATGGTGACGGAGGAGCACCCGATCAACTGGAACAGCACAGGCTTCTGGCCTGGT  
 ATATAATGAAAGCCCAGTTGGGCACAGTAGTCACCAATGATCGTTGGGAGCTGGTAGCA  
 TCTGTAAGCATGGTGGCTCTATACCTGCAGTGATCGTTATAACCCAGGACATCTTGCCA  
 CATAAAATGGAAAATGCAATGACAATAGACAAACTGTCCTGGGCTATAGGAGGAAAGCTGG  
 AATCTCTGACTATCTTACAATTGAAGAATTGGTGAAGCAACTTGTAGAGACAGTTCATGTG  
 GAGGAAATCTTGATGAATATTGGGCCACACTAGATGGCACCATTCTGTAGTTTGAG  
 GAGCGACTGAGGCAAGTGGGCTCTGGCTAAAAGTCATGGAGAAGCTATTATGAAACCTA  
 TACCTGGCGATCCCAGAATGACACTGTCACCCAGATGTGGTACACATCCAAGCCTAAAG  
 AAAAATTAGTCTATGCCATTCTAAATGGCCACATCAGGACAGCTGTTCTGGCCAT  
 CCCAAAGCTATTCTGGGGCAACAGAGGTGAAACTACTGGGCCATGGACAGCCACTTAAC  
 GATTTCTTGGAGCAAATGGCATTATGGTAGAACTGCCACAGCTAACCATTCAGATGC  
 CGTGTAAATGGGCTGGCTAGCCTAACTATGTGATCTAAAGTGCAGCAGAGTGGCTG  
 ATGCTGCAAGTTATGTCTAAGGCTAGGAACATCAGGTGTCTATAATTGTAGCACATGGAGA  
 AAGCAATGTAACGGATAAGAAAATTATTGGCAGTTCAAGCCCTTCCCTTTCCACTA  
 AATTTTCTTAAATTACCCATGTAACCATTTAACCTCCAGTGCACCTTGCCATTAAAGTC  
 TCTTCACATTGATTGTTCCATGTGACTCAGAGGTGAGAATTTCACATTAGTAG  
 CAAGGAATTGGTGGTATTATGGACCGAATGAAAATTATGTTGAAGCCATATCCCCATG  
 ATTATATAGTTATGCATCACTTAATATGGGATATTCTGGAAATGCATTGCTAGTCAT  
 TTTTTTGTGCCAACATCATAGAGTGTATTACAAATCCTAGATGGCATAGCCTACTACA  
 CACCTAATGTGTATGGTATAGACTGTTGCTCTAGGCTACAGACATATACAGCATGTTACTG  
 AATACTGTAGGCAATAGTAACAGTGGTATTGTATATGAAACATATGGAAACATAGAGAAG  
 GTACAGTAAAATACTGAAAATGGCAGCTGTATAGGGCACTTACCAAGAATGGAG  
 CTTACAGGACTGGAAGTTGCTCTGGGTGAGTCAGTGAAGTGAAGGCCTAGGACATTA  
 TTGAACACTGCCAGACGTTATAAAACTGTATGCTTAGGCTACACTACATTATAAAAAAA  
 GTTTTCTTCTCAATTATAAAATTAACATAAGTGTACTGTAACTTACAAACGTTAAATT  
 TTTAAACCTTTGGCTCTTGTAATAACACTTAGCTAAAACATAAAACTCATTGTGCAA  
 ATGTAA

**FIGURE 72**

MRPQELPRLAFPLLLLLLPPPCPAHSATRFDPTWESLDARQLPAWFDQAKFGIFI  
HWGVFSVPSFGSEFWWWYWQKEKIPKYVEFMKDNYPPSFKYEDFGPLFTAKFFNANQWA  
DIFQASGAKYIVLTSKHHEGFTLWGSEYSWNWNAIDEGPKRDIVKELEVAIRNRTDLRF  
GLYYSLFEWFHPLFLEDESSSFHKRQFPVSKTLPELYELVNYYQPEVLWSDGDGGAPDQ  
YWNSTGFLAWLYNESPVRGTVVTNDRGAGSICKHGGFYTCSDRYNPGHLLPHKWENCM  
TIDKLSWGYRREAGISDYLTIEELVKQLVETVSCGGNLLMNI GPTLDGTISVVFEERLR  
QVGSLWKVNGEAIYETYTWRSQNDTVTPDVWYTSKPKEKLVYAIFLKWPMSGQLFLGHP  
KAILGATEVKLLGHGQPLNWISLEQNGIMVELPQLTIHQMPCKWGWLALTNVI

**FIGURE 73**

AGCAGGGAAATCCGGATGTCTCGGTTATGAAGTGGAGCAGTGAGTGTGAGCCTAACATAGT  
 TCCAGAACTCTCCATCCGGACTAGTTATTGAGCATCTGCCTCTCATATCACCACTGGCCATC  
 TGAGGTGTTCCCTGGCTCTGAAGGGTAGGCACGATGGCCAGGTGCTTCAGCCTGGTGTG  
 CTTCTCACTCCATCTGGACCACGAGGCTCTGGTCCAAGGCCTTTGCGTGAGAAGAGCT  
 TTCCATCCAGGTGTCATGCAGAATTATGGGATCACCCCTGTGAGCAAAAGGCGAACCGC  
 AGCTGAATTTCACAGAAGCTAAGGAGGCCTGAGGCTGCTGGACTAAGTTGCCGGCAAG  
 GACCAAGTTGAAACAGCCTTGAAAGCTAGCTTCAAACCTTGAGCTATGGCTGGTTGGAGA  
 TGGATTGTGGTCATCTCTAGGATTAGCCAAACCCAAAGTGTGGAAAAATGGGTTGGTG  
 TCCTGATTGAAAGGTTCCAGTGAGCCGACAGTTGCAGCCTATTGTTACAACATCTGAT  
 ACTTGGACTAACTCGTCATTCCAGAATTATCACCACCAAGATCCCATATTCAACACTCA  
 AACGTCAACACAAACAGAATTATTGTCAGTGACAGTACCTACTCGTGGCATCCCCCT  
 ACTCTACAATACCTGCCCTACTACTACTCCTCCTGCTCCAGCTTCACTTCTATTCCACGG  
 AGAAAAAAATTGATTGTGTCAGAAGTTTTATGAAACTAGCACCATGTCAGAAAC  
 TGAACCATTGTTGAAAATAAGCAGCATTCAAGAATGAAGCTGCTGGTTGGAGGTGTC  
 CCACGGCTCTGCTAGTGCTCTCCTCTTGGTCTGAGCTGGCTTGGATTG  
 TATGTCAAAAGGTATGTGAAGGCCTCCCTTTACAAACAAGAATCAGCAGAAGGAAATGAT  
 CGAAACCAAAGTAGTAAAGGAGGAGAAGGCCATGATAGCAACCTAATGAGGAATCAAAGA  
 AAACGTATAAAACCCAGAAGAGTCCAAGAGTCCAAGCAAAACTACCGTGCATGCCTGGAA  
 GCTGAAGTTAGATGAGACAGAAATGAGGAGACACACCTGAGGCTGGTTCTTCATGCTCC  
 TTACCCCTGCCCAAGCTGGGAAATCAAAAGGCCAAAGAACCAAAGAACAGAAAGTCCACCCT  
 GGTTCTAACTGGAATCAGCTCAGGACTGCCATTGGACTATGGAGTGCAACAAAGAGAAC  
 CCTTCTCCTTATTGTAACCTGTCTGGATCCTATCCTCCTACCTCCAAAGCTCCCACGCC  
 TTTCTAGCCTGGCTATGCTTAATAATATCCCAGTGGGAAAGGAGTTTGCAAAGTGCAA  
 GGACCTAAAACATCTCATCAGTATCCAGTGGTAAAAGGCCCTGGCTGCTGAGGCTAGG  
 TGGGTTGAAAGCCAAGGAGTCAGTGAGACCAAGGCCCTCTACTGATTCCGAGCTCAGAC  
 CCTTCTCAGCTCTGAAAGAGAAACACGTATCCCACCTGACATGTCCTCTGAGGCCGGTA  
 AGAGCAAAAGAATGGCAGAAAAGTTAGGCCCTGAAAGGCCATGGAGATTCTCATAACTTGAG  
 ACCTAATCTCTGTAAGCTAAAATAAGAAATAGAACACAGGCTGAGGATACGACAGTACACT  
 GTCAGCAGGGACTGTAACACAGACAGGGCTAAAGTGTCTCTGAACACATGAGTTGGA  
 ATCACTGTTAGAACACACACTTACTTTCTGGTCTCTACCACTGCTGATATTTCTCT  
 AGGAAATATACTTTACAAGTAACAAAATAAAACTCTTATAAAATTCTATTGTTATCTGA  
 GTTACAGAAATGATTACTAAGGAAGATTACTCAGTAATTGTTAAAAGTAATAAAATTCA  
 ACAAACATTGCTGAATAGCTACTATATGTCAGTGCTGTGCAAGGTATTACACTCTGTAAT  
 TGAATATTATTCCCTAAAAATTGCACATAGTAGAACGCTATCTGGGAAGCTATTTTCA  
 GTTTGATATTCTAGCTTATCTACTTCCAAACTAATTGTTATTGCTGAGACTAATCTT  
 ATTCAATTCTCTAATATGCCAACCTTAAACCTTAATTATTAAACATAACCTAACAGAAG  
 TACATTGTTACCTCTATATACCAAAAGCACATTAAAAGGCCATTAAACAAATGTATCACTA  
 GCCCTCCTTTCCAACAAAGAAGGGACTGAGAGATGCAGAAATATTGTGACAAAAAAATTAA  
 AGCATTAGAAAATT

**FIGURE 74**

```
><ss.DNA34431
><subunit 1 of 1, 322 aa, 1 stop
><MW: 35213, pI: 8.71, NX(S/T): 3
MARCFSLVLLTSIWTTTRLLVQGSLRAEELSIQVSCRIMGITLVSKKANQQLNFTEAKEA
CRLLGLSLAGKDQVETALKASFETCSYGVGDGFVVISRISPNSPKCGKNGVGVLIWKPV
SRQFAAYCYNSSDTWTNSCIPEIITTKDPIFNTQTATQTTEFIVSDSTYSVASPYSTIPA
PTTTPPAPASTSIPRRKKLICVTEVFMETSTMSTETEPFVENKAAFKNEAAGFGGVPTAL
LVLALLFFGAAAGLGFCYVKRYVKAFPFTNKNQQKEMIETKVVKEEKANDSNPNEESKKT
DKNPEESKSPSKTTVRCLEAEV
```

**FIGURE 75**

AG

```
><MET {trans=1-s, dir=f, res=1}>
ATGGCGGTCTTGGCACCTCTAATTGCTCTCGTATTGGTGCCGCACTTCACGATGG
CTCGCCCAACCTTAACCTCTGTCGGCCCTGCTCTGCTGCCTCCTACTCGTGAGG
AAACTGCCGCCGCTCTGCCACGGTCTGCCACCCAACGCGAACGGTAACCGTGTGAC
TTGACTGGAGAGAAGTGGAGATCCTGATGTTCTCAGTGCCATTGTGATGATGAAGAAC
CGCAGATCCATCACTGTGGAGCAACATATAAGGCAACATTTCATGTTAGTAAAGTGGCC
AACACAATTCTTTCTTCCGTTGGATATTGCATGGGCCTACTTACATCACACTCTGC
ATAGTGTTCCTGATGACGTGCAAACCCCCCTATATATGGGCCCTGAGTATATCAAGTAC
TTCAATGATAAAACCATTGATGAGGAACCTAGAACGGGACAAGAGGGTCACTGGATTGTG
GAGTTCTTGCCAATTGGTCTAATGACTGCCAATCATTGCCCTATCTATGCTGACCTC
TCCCTAAATACAACGTACAGGGCTAAATTGGGAAGGTGGATGTTGGACGCTATACT
GATGTTAGTACCGCGGTACAAAGTGGACACATCACCCTCACCAAGCAACTCCCTACCTG
ATCCTGTTCCAAGGTGGCAAGGAGGCAATGCGCGGCCACAGATTGACAAGAAAGGACGG
GCTGTCATGGACCTCTGAGGAGAATGTGATCCGAGAATTAACTTAAATGAGCTA
TACAGCGGGCCAAGAAACTATCAAAGGCTGGAGACAATATCCCTGAGGAGCAGCCTGTG
GCTCAACCCCCACCACAGTGTCAAGTGGGAAAACAAGAAGGATAATAAGATCCTCAC
TTTGGCAGTGCTTCCTCCTGTCAATTCCAGGCTTTCCATAACCACAAGCCTGAGGC
TGCAGCCTTNATTNATGTTCCCTTGCTGNGACTGGNTGGGCAGCATGCAGCTTC
TGATTAAAGAGGCATCTAGGAAATTGTCAGGCACCCCTACAGGAAGGCCTGCCATGCTG
TGGCCAATGTTCACTGGAGCAAGAAAGAGATCTCATAGGACGGAGGGGGAAATGGTT
CCCTCCAAGCTGGTCAGTGTGTTAAGTGTCACTGCTTATCAGCTATTGACACATCTCCATGGTT
TCTCCATGAAACTCTGTGGTTCATCATTCTCTTAGTTGACCTGCACAGCTGGTTAG
ACCTAGATTAAACCTAACGGTAAGATGCTGGGTATAGAACGCTAACGAAATTTCACCCCAA
GGACTCTGCTCCTAACGCCCTCTGGCTCGTTATGGTCTTCATTAAAGTATAAGC
CTAACTTGTGCGTAGTCCTAACGGAGAACCTTAACCACAAAGTTTATCATTGAAGA
CAATATTGAACAAACCCCTATTTGTGGGATTGAGAACGGGTGAATAGAGGCTTGAGAC
TTCCCTTGTGGTAGGACTTGAGGAGAACCCCTGGACTTCACTAACCCCTGTGAC
ATACTCCCCACACCCAGTTGATGGCTTCCGTAATAAAAGATTGGGATTCCCTTTG
```

**FIGURE 76**

MAVLAPLIALVYSVPRLSRWLAQPYYLLSALLSAAFLLVRKLPPCHGLPTQREDGNPCD  
FDWREVEILMFLSAIVMMKNRRSITVEQHIGNIFMFSKVANTILFFRLDIRMGLLYITLC  
IVFLMTCKPPLYMGPEYIKYFNDKTIDEELERDKRVTWIVEFFANWSNDCQSFAPIYADL  
SLKYNTGLNGKVDVGRYTDVSTRYKVSTSPLTKQLPTLILFQGGKEAMRRPQIDKKGR  
AVSWTFSEENVIREFNLNELYQRACKLSKAGDNIPEEQPVASTPTTVSDGENKKDK

**FIGURE 77**

GGACAGCTCGCGCCCCCGAGAGCTCTAGCCGTCGAGGAGCTGCCTGGGACGTTGCCCTG  
GGGCCCGAGCCTGGCCCGGTCAACCTGGCATGAGGAGATGGGCCTGTTGCTCCTGGTCCA  
TTGCTCCTGCTGCCCGCTCCTACGGACTGCCCTCTACAACGGCTTACTACTCCAACAG  
CGCCAACGACCAGAACCTAGGCAACGGTCATGGCAAAGACCTCCTTAATGGAGTGAAGCTGG  
TGGTGGAGACACCCGAGGGAGACCCCTGTTCACCTACCAAGGGGCCAGTGTGATCCTGCCCTGC  
CGCTACCGCTACGAGCCGGCCCTGGTCTCCCCGCGCGTGTGCGTGTCAAATGGTGGAAAGCT  
GTCGGAGAACGGGGCCCCAGAGAAGGACGTGCTGGTGCCATCGGCTGAGGCACCGCTCCT  
TTGGGACTACCAAGGCCGCGTGCACCTGCGGCAGGACAAGAGCATGACGTCTCGCTGGAG  
ATCCAGGATCTCGGCTGGAGGACTATGGCGTTACCGCTGTGAGGTATTGACGGGCTGGAG  
GGATGAAAGCGGTCTGGTGGAGCTGGAGCTGGGGGTGTGGTCTTCCTTACCAAGTCCCCA  
ACGGGCGCTACCAGTTCAACTTCCACGAGGGCCAGCAGGTCTGTGAGAGCAGGCTGCCGTG  
GTGGCCTCCTTGAGCAGCTTCCGGGCTGGAGGGAGGGCTGGACTGGTGCAACGCCGG  
CTGGCTGCAGGATGCTACGGTGCAGTACCCCATCATGTTGCCCGGCAGCCCTGCCGTGG  
CAGGCCTGGCACCTGGCGTGCAGCTACGGCCCCGCCACGCCGCTGCACCGCTATGAT  
GTATTCTGCTTCGCTACTGCCCTCAAGGGCGGGTGTACTACCTGGAGCACCCGTAGAAGCT  
GACGCTGACAGAGGCAAGGGAGGCCTGCCAGGAAGATGATGCCACGATGCCAAGGTGGAGC  
AGCTCTTGCCGCCTGGAAGTTCCATGGCCTGGACCGCTGCCAGCTGGCTGGCTGGCAGAT  
GGCAGCGTCCGCTACCCCTGTGGTTACCCGCATCTAACTGTGGGCCAGAGCCTGGGGT  
CCGAAGCTTGGCTTCCCCGACCCGCAGAGCGCTGTACGGTGTACTGCTACCGCCAGC  
ACTAGGACCTGGGCCCTCCCCTGCCGATTCCCTCACTGGCTGTGTATTTATTGAGTGGTT  
CGTTTCCCTGTGGTTGGAGCCATTTAACTGTTTATACTTCTCAATTAAATTTCT  
TTAAACATTTTTACTATTTTGAAAGCAAACAGAACCCATGCCCTCCCTTGCTCCTG  
GATGCCCACTCCAGGAATCATGCTTGCTCCCTGGCCATTGCGGTTGTGGCTTCTG  
GAGGGTTCCCCGCATCCAGGCTGGCTCCCTCCCTTAAGGAGGTGGTGCCTAGGTGG  
GGTGGCCTGTCTAGAATGCCGCCGGAGTCCGGGCATGGTGGCACAGTCTCCCTGCC  
CAGCCTGGGGGAAGAAGAGGGCCTGGGGCCTCCGGAGCTGGCTTGGCCTCTGCC  
CACCTCTACTTCTGTGAAGCCGCTGCCAGTCTGCCACTGAGGGCTAGGGCTGGAA  
GCCAGTTCTAGGCTTCCAGGCAGAATCTGAGGGAGGAAGAAACTCCCTCCCCGTTCC  
TCCCTCTCGGTTCAAAGAACATCTGTTGTCAATTGTTCTCCTGTTCCCTGTGTGG  
GGAGGGGCCCTCAGGTGTGTACTTGGACAATAATGGTGTATGACTGCCCTCCGCCAA  
AAA  
AAA

**FIGURE 78**

```
><ss.DNA39423
><subunit 1 of 1, 360 aa, 1 stop
><MW: 40894, pI: 6.44, NX(S/T): 0
MGLLLVPLLLPGSYGLFYNGFYYNSNSANDQNLGNHGKDLLNGVKLVVETPEETLFT
YQGASVILPCRYRYEPALVSPRRVRVKWWKLSENGAPEKDVLVAIGLRHRSFGDYQGRVH
LRQDKEHDVSLEIQDLRLEDYGRYRCEVIDGLEDESGLVELELRGVVF PYQSPNGRYQFN
FHEGQQVCAEQAAVVASFEQLFRAWEELDWNCAGWLQDATVQYPIMLPRQPCGGPGLAP
GVRSYGPRHRLHRYDVFCFATALKGRVYYLEHPEKLTLEAREACQEDDATIAKVGQLF
AAWKFHGLDRCDAGWLADGSVRYPVVHPHPNCGPPEPGVRSFGFPDPQSRLYGVYCYRQH
```

**FIGURE 79**

GGAGAGCGGAGCGAAGCTGGATAACAGGGGACCG  
><MET {trans=1-s, dir=f, res=1}  
ATGATGTGGCGACCATCAGTTCTGCTGCTTCTGCTACTGAGGCACGGGCCAGGG  
AAGCCATCCCCAGACGCAGGCCCTCATGGCCAGGGAGGGTGCACCAGGCGGCCCCCTG  
AGCGACGCTCCCCATGATGACGCCACGGAACTTCCAGTACGACCATGAGGCTTCCTG  
GGACGGGAAGTGGCCAAGGAATTGACCAACTCACCCCAGAGGAAAGCCAGGCCGTCTG  
GGCGGGATCGTGGACCGCATGGACCGCGCGGGGACGGCGACGGCTGGGTGTCGCTGGCC  
GAGCTCGCGCGTGGATCGCGCACCGCAGCAGCGCACATACGGACTCGGTGAGCGCG  
GCCTGGGACACGTACGACACGGACCGCGACGGCGTGTGGTTGGAGGAGCTGCGAAC  
GCCACCTATGGCCACTACGCGCCCGGTGAAGAATTTCATGACGTGGAGGATGCAGAGACC  
TACAAAAAGATGCTGGCTCGGGACGAGCGCGTTCCGGGTGGCCGACCAGGATGGGAC  
TCGATGGCCACTCGAGAGGGAGCTGACAGCCTCCTGCACCCCGAGGAGTCCCTCACATG  
CGGGACATCGTATTGCTGAAACCCCTGGAGGACCTGGACAGAAACAAAGATGGCTATGTC  
CAGGTGGAGGAGTACATCGCGATCTGTACTCAGCCGAGCCTGGGAGGAGGAGCCGGCG  
TGGGTGCAGACGGAGAGGGCAGCAGTTCCGGACTTCCGGATCTGAACAAGGATGGGAC  
CTGGATGGGAGTGAGGTGGGCCACTGGGTGCTGCCCTGCCAGGACCAGCCCTGGTG  
GAAGCCAACCACCTGCTGCACGAGAGCGACACGGACAAGGATGGCGGCTGAGCAAAGCG  
GAAATCCTGGGTAAATTGGAACATGTTGTTGGCAGTCAGGCCACCAACTATGGCGAGGAC  
CTGACCCGGCACCACGATGAGCTGTGAGCACCAGCACCTGCCACAGCCTCAGAGGCCCG  
ACAATGACCGGGAGGAGGGCCGCTGTGGTCTGGCCCTCCCTGTCCAGGCCCGCAGG  
AGGCAGATGCAGTCCCAGGCATCCTCTGCCCTGGCTCTCAGGGACCCCTGGTCGG  
CTTCTGTCCCTGTACACCCCCAACCCAGGGAGGGCTGTCAAGTCCCAGAGGATAAG  
CAATAACCTATTCTGACTGAGTCTCCAGGCCAGACCCAGGGACCCCTGGCCCAAGCTC  
AGCTCTAAGAACCGCCCAACCCCTCCAGCTCCAAATCTGAGCCTCCACACATAGACTG  
AAACTCCCCTGGCCCCAGCCCTCTCCTGCCCTGGCCTGGACACCTCCTCTGCC  
AGGAGGCAATAAAAGCCAGCGCCGGACCTTGAaaaaaaaaaaaaaaaaaaaaaaa  
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaa

**FIGURE 80**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA40620
><subunit 1 of 1, 328 aa, 0 stop
><MW: 37493, pI: 4.77, NX(S/T): 1
MMWRPSVLLLLLRLHGAQGKPSPDAGPHGQGRVHQAAPLSDAPHDDAHGNFQYDHEAFL
GREVAKEFDQLTPEESQARLGRIVDRMDRAGDGWVSLAEIRAWIAHTQQRHIRDSVSA
AWDTYDTDGRVGWEELRNATYGHYAPGEEFHDVEDAETYKKMLARDERRFRVADQDGD
SMATREELTAFLHPEEFPHMRDIVIAETLEDLRNKDGYVQVEEYIADLYSAEPGEEEPA
WVQTERQQFRDFRDLNKGHDGSEVGHVLPPAQDQPLVEANHLLHESDTDKDGRLSKA
EILGNWNMFVGSQATNYGEDLTRHHDEL
```

**FIGURE 81**

GGGGCCTTGCCTTCCGCACTCGGGCGCAGCCGGTGGATCTCGAGCAGGTGCGGAGCCCC  
 GGGCAGCGGGCGCGGGTGCAGGGATCCCTGACGCCCTGTCCCTGTTCTTGCGCTC  
 CCAGCCTGTCTGTCGCTGTTGGCGCCCCCGCCTCCCGCGGTGCGGGGTTGCACACCG  
 ATCCTGGGCTTCGCTCGATTGCCGCCGAGGCGCCTCCAGACACTAGAGGGGCGCTGGCC  
 TGGAGCAGCGGGTCGTCTGTGTCCTCTCCTCTGCCGCCGCCGGGATCGAAGGGT  
 GCGGGGCTCTGAGGAGGTGACGCCGCCCTCCGCACCCCTGGCCTGCCGCATTCTC  
 CCTCTCTCCAGGTGTGAGCAGCCTATCAGTCACC  
 ><MET {trans=1-s, dir=f, res=1}  
 ATGTCCCGAGCCTGGATCCCGCTCTCGGCCTCGGTGTGTCTGCTGCTGCCGGGG  
 CCCGCGGGCAGCGAGGGAGGCCGCTCCCATTGCTATCACATGTTTACCATGAGGCTTGGAC  
 ATCAGGAAAGAGAAAGCAGATGTCCTCTGCCGCCAGGGGCTGCCCTTTGAGGAATTCTCT  
 GTGTATGGAACATAGTATATGCTTCTGTATCGAGCATATGTGGGCTGCTGTCACAGG  
 GGAGTAATCAGCAACTCAGGGGACCTGTACGAGTCTATGCCTACCTGGTCGAGAAAAC  
 TATTCTCAGTAGATGCCAATGGCATCCAGTCTCAAATGCTTCTAGATGGTCTGCTTCT  
 TTCACAGTAACAAAGGAAAAGTAGTACACAGGAGGCCACAGGACAAGCAGTGTCCACA  
 GCACATCCACCAACAGGTAAACGACTAAAGAAAACACCCGAGAAGAAAACGGCAATAAA  
 GATTGTAAGCAGACATTGCATTCTGATTGATGGAAGCTTTAATATTGGCAGCGCCGA  
 TTTAATTACAGAAGAATTGTTGGAAAAGTGGCTCTAATGTTGGGATTGGAACAGAA  
 GGACCACATGTTGGCCTTGTCAAGCAGTGAACATCCAAAATAGAATTCTACTTGAAA  
 AACTTACATCAGCAAAGATGTTTGTGCAAGCATACTGCTCAGAAATTCTCACGGTAGATGCT  
 GGAGTAAGAAAAGGGATCCCAAAGTGGTGGTGGTATTGATGGTGGCCTCTGAT  
 GACATCGAGGAAGCAGGATTGTGCCAGAGAGTTGGTGTCAATGTTATAGTTCT  
 GTGGCCAAGCCTATCCCTGAAGAACTGGGATGGTTCAGGATGTCACATTGTTGACAAG  
 GCTGCTGTCGAATAATGGCTTCTCTTACACATGCCAACTGGTTGGCACCACA  
 AAATACGTAAAGCCTCTGGTACAGAACAGCTGTGCACTCATGAACAAATGATGTGCAGCAAG  
 ACCTGTTATAACTCAGTGAACATTGCCCTCTAATTGATGGCTCCAGCAGTGGAGAT  
 AGCAATTCCGCCTCATGCTGAAATTGTTCCAACATAGCCAAGACTTTGAAATCTCG  
 GACATTGGTGCAGATAGCTGCTGTACAGTTACTTATGATCAGCGCACGGAGTTCACT  
 TTCACTGACTATAGCACCAAAGAGAACAGCTACTGGTGTGCACTCAGAAACATCCGCTATATG  
 AGTGGTGGAACAGCTACTGGTGTGCACTTCCCTCACTGTTAGAAATGTGTTGGCCT  
 ATAAGGGAGAGCCCCAACAGAACCTCCTAGTAATTGTCACAGATGGCAGTCCTATGAT  
 GATGTCGAAGGCCCTGCAGCTGTCACATGATGCAGGAATCACTATCTCTGTTGGT  
 GTGGCTTGGCACCTCTGGATGACCTGAAAGATATGGCTCTAAACCGAAGGAGTCTCAC  
 GCTTCTTCACAAGAGAGTTCACAGGATTAGAACCAATTGTTCTGATGTCATCAGAGGC  
 ATTGTTAGAGATTCTTAGAATCCCAGCAATAATGGTAACATTGACAACAGAAAGAAA  
 AAGTACAAGGGATCCAGTGTAAATTGTTCTCATATAACTGAAATGCTTACAGCATA  
 CTAGAACATGACAAAAACTATTAAGTATGTCACAGGCCATTAGGCAAATAAGCACTCC  
 TTTAAAGCCGCTGCCCTCTGGTTACAATTACAGTGTACTTTGTTAAAACACTGCTGAG  
 GCTTCATAATCATGGCTTCTAGAAACTCAGGAAAGAGGAGATAATGTGGATTAAAACCTT  
 AAGAGTTCTAACCATGCCTACTAAATGTACAGATATGCAAATTCCATAGCTCAATAAAAG  
 AATCTGATACTTAGACCAAAAAAA

**FIGURE 82**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA40604
><subunit 1 of 1, 550 aa, 0 stop
><MW: 59483, pI: 8.34, NX(S/T): 2
MSAAWIPALGLGVCLLLPGPAGSEGAAPIAITCFTRGLDIRKEKADVLCPGGCPLEEFS
VYGNIVYASVSSICGAAVHRGVISSNGGPVRVYSLPGRENYSSVDANGIQSQMLSRWSAS
FTVTKGKSSTQEATGQAVSTAHPPTGKRLKKTPEKKTGNKDCCKADIAFLIDGSFNIGQRR
FNLQKNFVGKVALMLGIGTEGPHVGLVQASEHPKIEFYLNFTSAKDVLFAIKEVGFRGG
NSNTGKALKHTAQKFFTVDAGVRKGIPKVVVFIDGWPSSDDIEEAGIVAREFGVNPFIVS
VAKPIPEELGMVQDVTFVDKAVCRNNNGFFSYHMPNWFGTTKYVKPLVQKLCTHEQMMCSK
TCYNSVNIAFLIDGSSSVGDSNFRMLEFVSNIAKTFEISDIGAKIAAVQFTYDQRTEFS
FTDYSTKENVLAVIRNIRYMSGGTATGDAISFTVRNVFGPIRESPNKNFLVIVTDGQSYD
DVQGPAAAHDAGITIFSVGVAWAPLDDLKDMASKPKESHAFFTREFTGLEPIVSDVIRG
ICRDFLESQQ
```

## FIGURE 83

```

CGCCCGCGCTCCCGACCCGGGCCCCGCCACCGCGCCGCTCCGCATCTGCACCCGCAGC
CCGGCGGCCTCCGGGGAGCGAGCAGATCCAGTCCGGCCCGCAGCGCAACTCGGTCCA
GTCGGGGCGGCGGCTGCGGGCGCAGAGCGAG
><MET .{trans=1-s, dir=f, res=1}
ATGCAGCGGTTGGGCCACCTGCTGTGCTGCTGGCGGGGGTCCCACGGCC
CCCGCGCCCGCTCCGACGGCGACCTCGGCTCCAGTCAGCAGCCGGCCGGCTCTCAGCTAC
CCGCAGGAGGAGGCCACCCCTCAATGAGATGTTCCCGAGGGTTGAGGAAGCTGATGGAGGAC
ACGCAGCACAAATTGCGCAGCGGGTGGAGAGATGGAGGCAGAAGAAAGCTGCTAA
GCATCATCAGAAAGTGAACCTGGCAAACCTAACCTCCAGCTATCACAAATGAGACCAACACA
GACACGAAGGTTGAAATAATACCATCCATGTGCACCGAGAAATTACAAGATAACCAAC
AACCAGACTGGACAAATGGCTTTCAAGAGACAGTTACATCTGTGGGAGACGAAGAA
GGCAGAAGGAGGCCACGAGTCATCATCGACGAGGAAGCTGTGGGCCAGCATGTAAGTGCAG
TTGCCAGCTCCAGTACACCTGCCAGCCATGCCAGGGCCAGAGGATGCTCTGCACCCGG
GACAGTGAGTGCTGTGGAGACCAAGCTGTGTCTGGGTCACTGCACCAAAATGGCACC
AGGGCAGCAATGGGACCATCTGTGACAACCAGAGGGACTGCCAGCCGGGCTGTGCTGT
GCCTTCCAGAGAGGCCTGCTGTTCCCTGTGTCACACCCCTGCCGTGGAGGGCGAGCTT
TGCCATGACCCGCCAGCCGGCTCTGGACCTCATCACCTGGGAGCTAGAGCCTGATGGA
GCCTTGGACCGATGCCCTGTGCCAGTGGCCTCTGCCAGCCCCACAGCCACAGCCTG
GTGTATGTGCAAGCCGACCTTCGTGGGAGCCGTGACCAAGATGGGAGATCCTGCTG
CCCAGAGAGGTCCCCGATGAGTATGAAGTGGCAGCTTCATGGAGGAGGTGCGCCAGGAG
CTGGAGGACCTGGAGAGGAGCCTGACTGAAGAGATGGCGCTGGGGAGCCTGCCGGCTGCC
GCCGCTGCACTGCTGGAGGGGAAGAGATTAGATCTGGACCAAGGCTGTGGTAGATGTG
CAATAGAAATAGCTAATTATTTCCCAGGTGTGCTTTAGGCGTGGCTGACAGCATGAGGTGTTGTG
TCTTCCTACATCTTCTCCAGTAAGTTCCTCTGGCTTGACAGCATGAGGTGTTGTG
CATTTGTTCAAGCTCCCCCAGGCTGTTCTCAGGCTTCACAGTCTGGTCTGGAGAGTC
AGGCAGGGTTAAACTGCAGGAGCAGTTGCCACCCCTGTCCAGATTATTGGCTGCTTTGC
CTCTACCAGTTGGCAGACAGCCGTTGTTCTACATGGCTTGTATAATTGTTGAGGGAG
GAGATGGAAACAATGTGGAGTCTCCCTCTGATTGGTTTGGGAAATGTGGAGAAAGAGTG
CCCTGCTTGCACATCAACCTGGCAAAATGCAACAAATGAATTTCACGCAGTTCT
TTCCATGGGCATAGGTAAAGCTGTGCTTCAGCTGTTGCAAGATGAAATGTTCTGTTCACCC
TGCATTACATGTGTTATTCACTCAGCAGTGTGCTCAGCTCCTACCTCTGTGCCAGGGC
AGCATTTCATATCCAAGATCAATTCCCTCTCAGCACAGCCTGGGGAGGGGTATTG
TTCTCCTCGTCCATCAGGGATCTCAGAGGCTCAGAGACTGCAAGCTGCTTGCCTGCCAAGTCA
CACAGCTAGTGAAGACCAGAGCAGTTCTGGTTGTGACTCTAAGCTCAGTGTCTCT
CCACTACCCACACCAGCCTGGGCCACAAAAGTGCTCCCCAAAAGGAAGGAGAATGG
GATTTTCTTGAGGCATGCACATCTGGAAATTAGGTCAAACTAATTCTCACATCCCTCTA
AAAGTAAACTACTGTTAGGAACAGCAGTGTCTCACAGTGTGGGGCAGCCGTCTTCTAA
TGAAGACAATGATATTGACACTGTCCTCTTGGCAGTTGCATTAGTAACATTGAAAGGT
ATATGACTGAGCGTAGCATAAGGTTAACCTGCAGAAACAGTACTTAGGTAAATTGTAGGG
CGAGGATTATAAATGAAATTGCAAATCACTTAGCAGCAACTGAAGACAATTATCAACC
ACGTGGAGAAAATCAAACCGAGCAGGGCTGTGTGAAACATGGTTGTAATATGCGACTGCG
AACACTGAACCTACGCCACTCCACAAATGATGTTTCAGGTGTATGGACTGTTGCCAC
CATGTATTCACTCCAGAGTTCTTAAAGTTAAAGTTGACATGATTGTATAAGCATGCTTT
CTTGAGTTTAAATTATGTATAAACATAAGTTGCATTAGAAATCAAGCATAAAACT
TCAACTGCAAAAAAAAAAAAAAA

```

**FIGURE 84**

MQRLGATLLCLLLAAAVPTAPAPAPTATSAPVKPGPALSYPQEEATLNEMFREVEELMED  
TQHKLRSAVEEMEAEEAAAKASSEVNLANLPPSYHNETNTDKVGNNTIHVHREIHKITN  
NQTGQMVFSETVITSVGDEEGRRSHECIIDEDCGPSMYCQFASFQYTCQPCRQQRMLCTR  
DSECCGDQLCVWGHCTKMATRGSGNTICDNQRDCQPGLCCAFQRGLFPVCTPLPVEGEL  
CHDPASRLLDLITWELEPDGALDRCPASCAGLLCQPHSHSLVYVCKPTFVGSRDQDGIEL  
PREVPDEYEVGSFMEEVRQELEDLERSLTEEMALGEPAAAAALLGGEI

**FIGURE 85A**

AAGGAGGGCTGGGAGGAAGAGGTAAGAAAGGTTAGAGAACCTACCTCACATCTCTGGGCT  
 CAGAAGGACTCTGAAGATAACAATAATTTCAGCCCACCTCTCCTCCCTCCAAACACA  
 CATGTGCATGTACACACACACATACACACATACACCTTCCTCCTCACTGAAGACTCA  
 CAGTCACACTCTGTGAGCAGGTACAGAAAAGGACACTAAAGCCTTAAGGACAGGCCTGG  
 CCATTACCTCTGCAGCTCTTGGCTTGTTGAGTAAAAACATGGGAGGGGCCAGGCACGG  
 TGACTCACACCTGTAATCCAGCATTTGGGAGACCGAGGTGAGCAGATCACTTGAGGTCA  
 GAGTTGAGACCAGCCTGGCCAACATGGAGAAACCCCCATCTCTACTAAAATACAAAAATT  
 AGCCAGGAGTGGTGGCAGGTGCTGTAATCCCAGCTACTCAGGTGGCTGAGCCAGGAGAATC  
 GCTTGAATCCAGGAGGCGGAGGATGCAGTCAGTCAGTGAGTCAGCACCCTGCACTCCAGCCTGGG  
 GACAGAATGAGACTCTGTCAAACAAACACAGGGAGGAGGGTAGATACTGCTTCTCT  
 GCAACCTCTTAACCTGCATCCTCTTCCAGGGCTGCCCTGATGGGCTGGCAATG  
 CTGAGCAGGCCAGCCCCAGAGGACAAGGAAGAGAAGGCATATTGAGGAGGGCAAGAAGTGA  
 CGCCCGGTGAGAATGACTGCCCTGGGAGGGTGGTCCCTGGGCCCTGGCAGGGTTGCTGAC  
 CCTTACCCCTGCAAAACACAAAGAGCAGGACTCCAGACTCTCCTTGTAATGGTCCCCTGCC  
 TGCAGCTCCACCATGAGGCTTCTCGTGGCCCCACTCTGCTAGCTGGTGGCTGGTGCAC  
 TGCCACTGTGCCGTGGTACCCCTGGCATGTTCCCTGCCCTCAGTGTGCCTGCCAGATCC  
 GGCCCTGGTATACGCCCGCTCGCTTACCGCGAGGCTACCACTGTGGACTGCAATGACCTA  
 TTCCTGACGGCAGTCCCCCGGACTCCCCGAGGACACAGACCCCTGCTCCTGCAGAGCAA  
 CAGCATTGTCCGTGTGGACCAGAGTGAAGCTGGCTACCTGGCAATCTCACAGAGCTGGACC  
 TGTCCCAGAACAGCTTTGGATGCCGAGACTGTGATTCCATGCCCTGCCAGCTGCTG  
 AGCCTGCACCTAGAGGAGAACCAAGAGCTGACCCGGCTGGAGGACACAGCTTGCAAGGGCTGGC  
 CAGCCTACAGGAACCTATCTCAACCACAAACAGCTTACCCGATGCCCTGCCAGGGCTTTT  
 CTGGCCTCAGCAACTTGTGCGGTGACCTCAACTCCAACCTCCTGAGGGCCATTGACAGC  
 CGCTGGTTGAAATGCTGCCAACTTGGAGATACTCATGATTGGCGGCAACAAAGGTAGATGC  
 CATCCTGGACATGAACTTCCGGCCCTGGCCAACCTGCGTAGCCTGGTCTAGCAGGCATGA  
 ACCTGCGGGAGATCTCGACTATGCCCTGGAGGGCTGCAAAGCCTGGAGAGGCCTCCTTC  
 TATGACAACCAGCTGGCCGGGTGCCAGGGGGCACTGGAACAGGTGCCGGGCTCAAGTT  
 CCTAGACCTCAACAAGAACCCGCTCCAGCGGGTAGGGCGGGGACTTGCCAAATGCTGC  
 ACCTTAAGGAGCTGGACTGAACAAACATGGAGGAGCTGGTCTCATGACAAGTTGCCCTG  
 GTGAACCTCCCCGAGCTGACCAAGCTGGACATCACCAATAACCCACGGCTGTCCTCATCCA  
 CCCCCCGCCTTCCACCACCTGCCCAAGATGGAGACCCCTATGCTCAACAACACGCTCTCA  
 GTGCCTTGCACCAGCAGACGGTGGAGTCCCTGCCAACCTGCAAGGAGGTAGGTCTCACGGC  
 AACCCCATCCGCTGTGACTGTGATCCGCTGGGCCATGCCACGGCACCCGTGTCGGCTT  
 CATCGAGCCGAATCCACCCCTGTGCGGAGCCTCCGGACCTCCAGCGCTCCGGTCCGTG  
 AGGTGCCCTTCCGGAGATGACGGACCAGTGTGTTGCCCTCATCTCCCACGAAGCTTCCCC  
 CCAAGCCTCCAGGTAGCCAGTGGAGAGAGCATGGTGTGATTGCCGGCACTGCCGAACC  
 CGAACCCGAGATCTACTGGTCACTCCAGCTGGCTCGACTGACACCTGCCATGCAGGCA  
 GGAGGTACCGGGTGTACCCCGAGGGGACCCCTGGAGCTGCGGAGGGTGACAGCAGAACAGGGCA  
 GGGCTATACACCTGTGTGGCCAGAACCTGGTGGGGCTGACACTAAGACGGTTAGTGTGGT  
 TGTGGGCCGTGCTCTCCAGCCAGGCAGGGACGAAGGACAGGGCTGGAGCTCCGGGTG  
 AGGAGACCCACCCCTATCACATCCTGCTATCTGGGTACCCACCAACACAGTGTCCACC  
 AACCTCACCTGGTCCAGTGCCTCCCTCCGGGGCAAGGGGGCACAGCTCTGCCCGCCT  
 GCCTCGGGGAACCCACAGCTACAAACATTACCCGCTCCCTCAGGCCACGGAGTACTGGCCT  
 GCCTGCAAGTGGCCTTGTGATGCCACACCCAGTTGGCTGTGATGGGCTTGTGAGTGGCC  
 GAGGCCACTTCTGCCACAGGCCCTAGGGATGTCCTGGCTATTGCCATCTGGCTCT  
 CGCTGTCTTCTCCTGGCAGCTGGCTAGCGGCCACCTGGCACAGGCCAACCCAGGAAGG  
 GTGTGGGTGGGAGGCGGCCTCTCCCTCCAGCCTGGCTTCTGGGCTGGAGTGGCC  
 GTCCGGGTTGTGCTGCTCCCTCGTCCCTGCCCTGGAATCCAGGGAGGAAGCTGCCAGATC  
 CTCAGAAGGGGAGACACTGTTGCCACCATGGTCTCAAATTCTGAAGCTCAGCCTGTTCTC  
 AGCAGTAGAGAAATCACTAGGACTACTTTTACCAAAAGAGAACAGCTGGGCCAGATGCC  
 CTGCCAGGAAAGGGACATGGACCCACGTGCTGAGGCCCTGGCAGCTGGCCAAGACAGATGG  
 GGCTTGTGCCCTGGGGTGCTTCTGCAGCCTGAAAAAGTGGCTTACCTCCTAGGGTC  
 ACCTCTGCTGCCATTCTGAGGAACATCTCCAAGGAACAGGAGGGACTTGGCTAGAGCCTCC

**FIGURE 85B**

TGCCTCCCCATCTTCTCTGCCAGAGGCTCCTGGCCTGGCTGTCCCACCTGT  
GTCCCCGGGCTGCACCCCTCCTCTCTCTGTACAGTCTCAGTTGCTTGTCTTGT  
GCCTCCTGGCAAGGGCTGAAGGAGGCCACTCCATTCACCTCGGGGGCTGCCCTAATGT  
GGGAGTGACCCCAGCCAGATCTGAAGGACATTGGGAGAGGGATGCCAGGAACGCCTCATC  
TCAGCAGCCTGGGCTCGGCATTCCAAGCTGACTTCTATAGGCAATTGTACCTTG  
AGAAATGTGTACCTCCCCAACCGATTCACTCTTCTCCTGTTGTAAAAAATAAAA  
TAAATAATAACAATAAAAAAA

**FIGURE 86**

MRLLVAPLLLAWVAGATATPVVPWHVPCPPQCACQIRPWYTPRSSYREATTVDNDLF  
LTAVPPALPAGTQTLLLQSNSIVRVDQSELGYLANLTELDSQNSFSDARDCDFHALPQ  
LLSLHLEENQLTRLEDHSFAGLASLQELYLNHNQLYRIAPRAFSGLSNLLRLHLNSNLL  
RAIDSRWFEMLPNLEILMIGGNKVDAILDMDNFRPLANLRSVLVAGMNLREISDYALEGL  
QSLESLSFYDNQLARVPRRALEQVPGLKFLDLNKNPQRVPGDFANMLHLKELGLNNM  
EELVSIDKFALVNLPELTKLDIRNNPRLSFIHPRAFHLPQMELMLNNNALSAHQQT  
VESLPNLQEVLHGNPIRCDCVIRWANATGTRVRFIEPQSTLCAEPPDLQRLPVREVPF  
REMTDHCLPLISPRSFPPLQVASGESMVLHCRALAEPEPEIYWVTPAGLRLTPAHAGR  
RYRVYPEGTLELRRVTAEEAGLYTCVAQNLVGADTKTVSVVGRALLQPGRDEGQGLEL  
RVQETHPYHILLSWTPPNTVSTNLTWSSASSLRGQGATALARLPRGTHSYNITRLLQA  
TEYWACLQVAFADAHTQLACVWARTKEATSCHRALGDRPGLIAILALAVLLAAGLAAH  
LGTGQPRKGVGRRPLPPAWFWGWSAPSRRVVSAPLVLWNPGRKLPSSSEGETLLPP  
LSQNS

**FIGURE 87A**

GCAAGCCAAGGCGCTGTTGAGAAGGTGAAGAAGTCCGGACCCATGTGGAGGAGGGGGA  
 CATTGTGTACCGCCTCTAC  
 ><MET {trans=1-s, dir=f, res=1}>  
 ATGCGGCAGACCATCATCAAGGTGATCAAGTTCATCCTCATCATCTGCTACACCGTCTAC  
 TACGTGCACAACATCAAGTTGACGTGGACTGCACCGTGGACATTGAGAGCCTGACGGGC  
 TACCGCACCTACCGCTGTGCCACCCCCCTGGCCACACTCTTCAGATCCTGGCGTCCTTC  
 TACATCAGCCTAGTCATCTTCTACGGCCTCATCTGCATGTACACACTGTGGTGGATGCTA  
 CGGCCTCCCTCAAGAAGTACTCGTTGAGTCGATCCGTGAGGAGAGCAGCTACAGCGAC  
 ATCCCCGACGTCAGAACGACTTCGCCCTCATGCTGCACCTCATTGACCAATACGACCCG  
 CTCTACTCCAAGCGCTTCGCCGTCTCCTGCGAGGTGAGTGAGAACAAAGCTGCGGAG  
 CTGAACCTCAACAACGAGTGGACGCTGGACAAGCTCCGGCAGCGCTACCAAGAACGCG  
 CAGGACAAGCTGGAGCTGCACCTGTTCATGCTCAGTGGCATTCCCTGACACTGTGTTGAC  
 CTGGTGGAGCTGGAGGTCTCAAGCTGGAGCTGATCCCCGACGTGACCACATCCC GCCCAGC  
 ATTGCCCAGCTCACGGCCTCAAGGAGCTGTGGCTTACACACAGCGCCAAGATTGAA  
 GCGCTCGCTGGCCTTCTGCGCGAGAACCTGCGGGCGCTGCACATCAAGTTCACCGAC  
 ATCAAGGAGATCCCGCTGTGGATCTATAGCCTGAAGACACTGGAGGAGCTGCACCTGACG  
 GGCAACCTGAGCGCGGAGAACAAACCGCTACATCGTATCGACGGGCTGCGGGAGCTCAA  
 CGCCTCAAGGTGCTGCGCTCAAGAGCAACCTAACGCAAGCTGCCACAGGTGGTACAGAT  
 GTGGCGTGCACCTGAGAACGCTGTCCATCAACAATGAGGGACCAAGCTCATCGTCCTC  
 AACAGCCTCAAGAAGATGGCGAACCTGACTGAGCTGGAGCTGATCCGCTGCGACCTGGAG  
 CGCATCCCCCCTCCATCTTCAGCCTCCACAACCTGAGGAGATTGACCTCAAGGACAAC  
 AACCTCAAGACCATCGAGGAGATCATCAGCTTCCAGCACCTGCACCGCCTCACCTGCCT  
 AAGCTGTGGTACAACCACATCGCTACATCCCCATCCAGATCGGCAACCTCACCAACCTG  
 GAGCGCCTCTACCTGAACCGAACAGATCGAGAACGATCCCCACCCAGCTCTTACTGC  
 CGCAAGCTGCGCTACCTGGACCTCAGCCACAACAACCTGACCTTCCCTGCCGACATC  
 GGCCTCTGAGAACCTCCAGAACCTAGCCATCACGCCAACCGGATCGAGACGCTCCCT  
 CCGGAGCTCTCCAGTGCCGGAGCTGCCGGCTGCACCTGGCAACAACGTGCTGCGAG  
 TCACTGCCCTCCAGGGTGGCGAGCTGACCAACCTGACGAGATCGAGCTGCCGGCAAC  
 CGGCTGGAGTGCCCTGCTGTGGAGCTGGCGAGTGCCACTGCTCAAGCGCAGCGGCTTG  
 GTGGTGGAGGAGGACCTGTTCAACACACTGCCACCCGAGGTGAAGGAGCGGCTGTGGAGG  
 GCTGACAAGGAGCAGGCCCTGAGCGAGGCCGCCAGCACAGCAAGCAGCAGGACCGCTGC  
 CCAGTCCTCAGGCCGGAGGGCAGGCCCTAGCTTCTCCAGAACCTCCGGACAGCCAGGA  
 CAGCCTCGCGGCTGGCAGGAGCTGGGGCCCTGTGAGTCAGGCCAGAGCGAGGAG  
 AGTATCTGTGGGGCTGGCCCTTTCTCCCTCTGAGACTCACGTCCTCCAGGGCAAGTGC  
 TTGTGGAGGAGAGCAAGTCTCAAGAGCGCAGTATTGGATAATCAGGGCTCTCCCTGG  
 AGGCCAGCTGCCCCAGGGGCTGAGCTGCCACCAGAGGTCTGGACCCCTCACTTAGT  
 TCTTGTATTATTTCTCCATCTCCACCTCCTCATCCAGATAACTTACATTACATTCCC  
 AAGAAAGTTCAGGCCAGATGGAAGGTGTTAGGGAAAGGTGGCTGCCTTTCCCTTGT  
 CCTTATTTAGCGATGCCCGGGCATTTAACACCCACCTGGACTTCAGCAGAGTGGTCCG  
 GGGCGAACAGCCATGGGACGGTCACCCAGCAGTGCCTGGCTCTGGTGGCTGCGGTGCG  
 CACGGGAGAGCAGGCCCTCAGCTGGAAAGGCCAGGCCCTGGAGCTGCCTCTTCAGTTT  
 GTGGCAGTTTAGTTTTGTTTTTTTTTTTTTAATCAAAAAAACATTTTTAAAAAA  
 AAAGCTTGAAGGAGGAGCAAGTCTCAAGAGCGCAGTATTGGTGGAGCTTCCCTGAGCAAAG  
 GACACTAACGCCAGTGAAGTGGAGTCTCAGGGCAGGGTGGCAGTTCCCTGAGCAAAG  
 CAGCCAGACGTTGAAGTGTGTTCCAGGAGTTCTATTGTTCTGGGAGGGTGTCTCCGGA  
 TCTGGTGTGACCTTGGTCCAGGAGTTCTATTGTTCTGGGAGGGTGTCTCCGGA  
 GTTTTTGGGTTTTGGTGTCTGTTCTTCTCCATGTGTCTGGCAGGCACT  
 CATTCTGTGGCTGCGCCAGAGGGAAATGTTCTGGAGCTGCCAAGGAGGGAGGAGACTC  
 GGGTTGGCTAATCCCCGGATGAACGGTGCTCCATTGCACCTCCCTCCTGCGCTGCC  
 CTGCCTCTCCACGCACAGTGTAAAGGAGCCAAGAGGAGCCACTCGCCAGACTTGT  
 CCCACCTCTGCGGCATGGGTGTCCAGTGCACCGCTGGCCTCCGCTGCTTCCATCA  
 GCCCTGTCGCCACCTGGTCTTCATGAAGAGCAGACACTTAGAGGCTGGTGGGAATGGG  
 GAGGTGCCCCCTGGGAGGGCAGGCAGGGTTCCAAGCCGGTCCCTGGCGCTGG

**FIGURE 87B**

AGTGCACACAGCCCAGTCGGCACCTGGTGGCTGGAAGCCAACCTGCTTAGATCACTCGG  
GTCCCCACCTTAGAAGGGTCCCCGCCCTAGATCAATCACGTGGACACTAAGGCACGTTT  
AGAGTCTCTTGCTTAATGATTATGTCCATCCGTCTGTCCGCCATTGTGTTTCTGCG  
TCGTGTCATTGGATATAATCCTCAGAAATAATGCACACTAGCCTCTGACAACCATGAAGC  
AAAAATCCGTTACATGTGGGTCTGAACTTGTAGACTCGGTACAGTATCAAATAAAATCT  
ATAACAGAAAAAAAAAAAAAA

**FIGURE 88**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA35673
><subunit 1 of 1, 546 aa, 0 stop
><MW: 63742, pI: 8.62, NX(S/T): 6
MRQTIIVIKFILIIICYTVYYVHNIKFDVDCTVDIESLTGYRTYCAHPLATLFKILASF
YISLVIFYGLICMYTLWWMLRRSLKKYSFESIREESSYSDIPDVKNDFAFMLHLIDQYDP
LYSKRFAVFLSEVSENKLRLQLNNNEWTLDFKLQRQLTKNAQDKLELHLFMLSGIPDTVFD
LVELEVLKLELIPDVTIPPSIAQLTGLKELWLYHTAAKIEAPALAFRLRENLRALHIKFID
IKEIPLWIYSLKTLEELHLTGNLSAENNRYIVIDGLRELKRLKVLRLKSNLSKLPQVVTD
VGVLQKLSINNEGTKLIVLNSLKKMANLTELELIRCDLERIPHISIFSLHNLQEIDLKDN
NLKTIIEEEIISFQHLHRLTCLKLWYNHAYIPIQIGNLTNERLYLNRNKEKIPQLFYCR
RKLRYLDDSHNNLTFLPADIGLLQNLQNLAITANRIETLPPELFQCRKLRALHLGNNVLQ
SLPSRVGELTNLTQIELRGNRLECLPVELGECPLLKRSGLVVEEDLFNTLPPEVKERLWR
ADKEQA
```

**FIGURE 89**

GCCTGTTGCTGATGCTGCCGTGCGGTACTTGTC  
 ><MET {trans=1-s, dir=f, res=1}  
 ATGGAGCTGGCACTGCAGCGCTCTCCGTCGGTGGTGCTGCTGCCGCTGCTG  
 CTGGGCCTGAACGCAGGAGCTGTCATTGACTGGCCCACAGAGGGAGGGCAAGGAAGTATGG  
 GATTATGTGACGGTCCGCAAGGATGCCTACATGTTCTGGTGGCTTATTATGCCACCAAC  
 TCCTGCAAGAACCTCTCAGAACTGCCCTGGTCATGGCTTCAGGGCGGTCCAGGCAGG  
 TCTAGCACTGGATTGGAAACTTGAGGAAATTGGGCCCTTGACAGTGATCTCAAACCA  
 CGGAAAACCACCTGGCTCCAGGCTGCCAGTCTCCTATTGTGGATAATCCGTGGCACT  
 GGGTTCAGTTATGTGAATGGTAGTGGTGCTATGCCAAGGACCTGGCTATGGTGGCTTCA  
 GACATGATGGTCTCCTGAAGACCTCTTCAGTGCCACAAAGAATTCCAGACAGTTCCA  
 TTCTACATTTCTCAGAGTCCTATGGAGGAAAATGGCAGCTGGCATTGGTAGAGCTT  
 TATAAGGCCATTCAAGCGAGGGACCACATCAAGTGCAACTTGCAGGGGTTGCCTGGGTGAT  
 TCCTGGATCTCCCTGTTGATTGGTGCCTCCTGGGACCTTACCTGTACAGCATGTCT  
 CTTCTCGAAGACAAGGTCTGGCAGAGGTGCTAAGGTTGCAGAGCAAGTACTGAATGCC  
 GTAAATAAGGGGCTCTACAGAGAGGCCACAGAGCTGGGGAAAGCAGAAATGATCATT  
 GAACAGAACACAGATGGGTGAACCTCTATAACATCTTAACAAAGCACTCCACGTCT  
 ACAATGGAGTCGAGTCTAGAATTCACACAGAGCCACCTAGTTGTCTTCAGCGCCAC  
 GTGAGACACCTACAACGAGATGCCCTAACGCCAGTCATTAGCATTGGACAGTTGCTGGAGGCAGGG  
 ATCAACGTGACGGTGTATAATGGACAGCTGGATCTCATCGTAGATACCATGGGTAGGAG  
 GCCTGGGTGCGGAAACTGAAGTGGCCAGAACTGCCCTAAATTCAAGTCAGCTGAAGTGGAAAG  
 GCCCTGTACAGTGACCCCTAAATCTTGGAAACATCTGCTTGTCAAGTCCTACAAGAAC  
 CTTGCTTCTACTGGATTCTGAAAGCTGGTCAATGGTCCCTCTGACCAAGGGGACATG  
 GCTCTGAAGATGATGAGACTGGTACTCAGCAAGAATAGGATGGATGGGGCTGGAGATGA  
 GCTGGTTGGCCTGGGCACAGAGCTGAGCTGAGGCCGCTGAAGCTGTAGGAAGCGCCA  
 TTCTCCCTGTATCTAAGTGGGCTGTGATCAAGAAGGTTCTGACCAGCTCTGCAGAGG  
 ATAAAATCATTGTCTGGAGGCAATTGGAAATTATTCTGCTTCTTAAAAAACCTAA  
 GATTTTTAAAAAATTGATTGTTGATCAAAATAAAGGATGATAATAGATATTAA

**FIGURE 90**

&gt;&lt;signal peptide&gt;

MELALRRSPVPRWLLLLPLLLGLNA

&gt;&lt;start mature protein&gt;

GAVIDWPTEEGKEVW

&gt;&lt;homology to peptidases 40-end&gt;

DYVTVRKDAYMFWWLYYATNSCK

&gt;&lt;potential N-glycosylation site&gt;

NFSELPLVMWLQGGPGGSSTGFGNFEIGPLSDLKPRKTTWLQAASLLFVDNPVGT  
GFSYV

&gt;&lt;potential N-glycosylation site&gt;

NGSGAYAKDLAMVASDMMVLLKTFFSCHKEFQTVPFYIFSESYGGKMAAGIGLELY  
KAIQRGTIKCNFAGVALGDSWISPVDSVLSWGPYLYSMSLLEDKGLAEVSKVAEQVL  
NAVNKGLYCREATELGKAEMIIIQEQTGVNFYNILTKSTPTSTMESLEFTQSHLVCL  
CQRHVRHLQRDALSQLMNGPIRKKLIIPEDQSWGGQATNVFVNMEEDFMKPVISIV  
DELLEAGI

&gt;&lt;potential N-glycosylation site&gt;

NVTVYNGQLDLIVDTMGQEAWVRKLKWPELPKFSQLWKALYSDPKSLETSAFVKS  
YKNLAFYWILKAGHMVPSDQGDMALKMMRLVTQQE

**FIGURE 91**

GGCCGCGGGAGAGGGAGGCC  
><MET {trans=1-s, dir=f, res=1}  
ATGGGCGCGCGGGCGCTGCTGCTGGCGCTGCTGGCTCGGGCTGGACTCAGGAAG  
CCGGAGTCGCAAGGAGGCGCGCCGTATCAGGACCATGCGGCCGACGGGTATCACGTCG  
CGCATCGTGGGTGGAGAGGACGCCGAACTCGGCGTTGGCGTGGCAGGGAGCCTGCGC  
CTGTGGGATTCCCACGTATGCGGAGTGAGCCTGCTCAGCCACCGCTGGCACTCACGGCG  
GCGCACTGCTTGAAACCTATAGTGCACCTAGTGATCCCTCCGGTGGATGGTCCAGTT  
GGCCAGCTGACTTCCATGCCATCCTCTGGAGCCTGCAGGCCTACTACACCCGTTACTTC  
GTATCGAATATCTATCTGAGCCCTCGCTACCTGGGAATTCACCTATGACATTGCCTTG  
GTGAAGCTGTCTGCACCTGTACACTAAACACATCCAGGCCATCTGTCTCCAGGCC  
TCCACATTTGAGTTGAGAACCGGACAGACTGCTGGGTGACTGGCTGGGGTACATCAA  
GAGGATGAGGCACTGCCATCTCCCCACACCCCTCCAGGAAGTTCAGGTGCCATATAAAC  
AACTCTATGTGCAACCACCTCTCCTCAAGTACAGTTCCGCAAGGACATCTTGGAGAC  
ATGGTTTGTGCTGGCAACGCCAACGGGGAGGATGCCTGCTCGGTGACTCAGGTGGA  
CCCTGGCCTGTAACAAGAATGGACTGTGGTATCAGATTGGAGTCGTGAGCTGGGGAGTG  
GGCTGTGGTCGCCAATCGGCCGGTGTACACCAATATGCCACCACTTGGAGTGG  
ATCCAGAAGCTGATGCCAGAGTGGCATGTCAGGCCAGACCCCTGGCCACTACTC  
TTTCCCTCTGGCTCTCCACTCCTGGGGCGGTCTGAGCCTACCTGAGGCC  
TGCAGCCTGGGCCACTGCCAGTCAGGCCGGTCTCTGTCTTGGTAATAA  
ACACATTCCAGTTGATGCCCTGCAGGGCATTCTCAAAAAAAAAAAAAAAA  
A

**FIGURE 92**

><signal peptide>

MGARGALLALLLARAGL

><start mature protein>

RKPESQEAAPLSGPCGRRVITSRIVGGEDAELGRWPWQGSLRLWDHVCGVSLLSHRWA

><Serine proteases, trypsin family, histidine active site 'LTAAHC'>

LTAAHCFETYSDLSDPSGWMVQFGQLTSMPSFWSLQAYYTRYFVSNIYLSPRYLGNS  
PYDIALVKLSAPVTYTKHIQPICLQASTFEFE

><potential N-glycosylation site>

NRTDCWVTGWGYIKEDEALPSPHTLQEJVQVII

><potential N-glycosylation site>

NNSMCNHLFLKYSFRKDIFGDMVCAGNAQGGKDACFGDSGGPLACNKNGLWYQIG  
VVSWGVGCGRPNRPGVYT

><potential N-glycosylation site>

NISHHFEWIQKLMAQSGMSQPDPSWPLLFFPLLWALPLLGPV

**FIGURE 93**

```

CCCACGCGTCCGGAGCGGTGGAAAGGGCAGA
<MET {trans=1-s, dir=f, res=1}
ATGGGACTCCAAGCCTGCCCTAGGGCTTTGCCCTCATCCTCTGGCAAATGCAGT
TACAGCCGGAGCCGACCAGCGAGGACGCTGCCCTAGGCTGGGTGCCCTGGCCGT
GCGGACCCCTGAGGAAGAGCTGAGTCTCACCTTGCCCTGAGACAGCAGAATGTGGAAAGA
CTCTCGGAGCTGGTGCAGGCTGTCGGATCCCAGCTCCTCAATACGGAAAATACCTG
ACCCTAGAGAATGTGGCTGATCTGGTGAGGCCATCCCCACTGACCCTCACACGGTGCAA
AAATGGCTTGGCAGCCGGAGCAGAACAGTGCATTCTGTGATCACACAGGACTTCTG
ACTTGCTGGCTGAGCATCCGACAAGCAGAGCTGCTGCTCCCTGGGCTGAGTTCATCAC
TATGTGGGAGGACCTACGGAAACCCATGTTGTAAGGTCCCCACATCCCTACCAGCTTCCA
CAGGCCTTGGCCCCCATGTGGACTTGTTGGGGACTGCACCGTTTCCCCAACATCA
TCCCTGAGGCAACGCTTGAGCCGAGGTGACAGGGACTGTAGGCCTGCATCTGGGGTA
ACCCCCCTGTGATCCGTAAGCGATAACAACCTGACCTCACAAAGACGTGGCTCTGGCACC
AGCAATAACAGCCAAGCCTGTGCCAGTCCCTGGAGCAGTATTCCATGACTCAGACCTG
GCTCAGTTCATGCGCTCTCGGTGGCAACTTGACATCAGGCATCAGTAGCCGTGTG
GTTGGACAACAGGGCCGGGCCGGGCGGATTGAGGCCAGTCTAGATGTGCAGTACCTG
ATGAGTGCTGGTCCAACATCTCACCTGGGTCTACAGTAGCCCTGGCCGGATGAGGA
CAGGAGCCCTTCTGCAGTGGCTATGCTCAGTAATGAGTCAGCCCTGCCACATGTG
CATACTGTGAGCTATGGAGATGATGAGGACTCCCTCAGCAGCGCTACATCCAGCGGGTC
AACACTGAGCTCATGAAGGCTGCCGCTCGGGGCTCACCCCTGCTCTCGCCTCAGGTGAC
AGTGGGGCCGGGTGTTGGTCTGTCCTCTGGAAAGACACCAGTCCGCCCTACCTTCCCTGCC
TCCAGCCCCATGTCACACAGTGGGAGGCACATCCCTCAGGAACCTTCCATCACA
AATGAAATTGTTGACTATATCAGTGGTGGCTTCAGCAATGTGTTCCACGGCCTTCA
TACCAAGGAGGAGCTGTAACGAAGTTCTGAGCTCTAGCCCCCACCTGCCACATCCAGT
TACTTCAATGCCAGTGGCGTGCCTACCCAGATGTGGCTGCACTTCTGATGGCTACTGG
GTGGTCAGCAACAGAGTGCCTATCCATGGGTGTCGGAACCTCGCCCTACTCCAGT
TTTGGGGGATCCTATCCTGATCAATGAGCACAGGATCCTAGTGGCCGCCCCCTTT
GGCTTCTCAACCCAAGGCTCTACAGCAGCATGGGCAGGTCTTTGATGTAACCGT
GGCTGCCATGAGTCCTGTGGATGAAAGAGGTAGAGGGCCAGGGTTCTGCTCTGGTCT
GGCTGGGATCCTGTAACAGGCTGGGAACACCAACTTCCAGCTTGCTGAAGACTCTAC
TCAACCCCTGACCCCTTCTATCAGGAGAGATGGCTTGTCCCTGCCCTGAAGCTGGCAG
TTCAGTCCCTATTCTGCCCTGTTGGAAGCCCTGCTGAACCCCTCAACTATTGACTGCTGC
AGACAGCTTATCTCCCTAACCTGAAATGCTGTGAGCTTGACTCCAACCCCTACC
ATGCTCCATCATACTCAGGTCTCCCTACTCCTGCCTTAGATTCTCAATAAGATGCTGTA
ACTAGCATTGTTGAATGCCCTCCCTCCGATCTCATCTTCTCTTCAATTCCGCTT
TTCCAAAGGGTGTATACAGACTCTGTGCACTATTCACTGATATTCAATTCCCAATT
ACTGCAAGGAGACCTACTGTACCGTTACTCTTCCACCTGACATCCAGAAACAA
TGGCCTCCAGTGCATACTCTCAATCTTGTCTTATGGCCTTCCATCATAGTTGCCAC
TCCCTCTCTTACTTAGCTCCAGGTCTAACCTCTGACTACTCTGTCTTCCCTCT
CATCAATTCTGCTTCTCATGGAATGCTGACCTTCATTGCTCCATTGAGATTTG
TCTTCTCAGTTACTCATTGTCCCTGGAACAAATCACTGACATCTACAACCATTACCAT
CTCACTAAAGACTTCTATCCAATAATGATTGATACTCAAATGAAAAAA

```

**FIGURE 94**

><signal peptide>

MGLQACLLGLFALILS

><start mature protein>

GKCSYSPEPDQRRTLPPGVSLGRADPEEELSLTFALRQQNVERLSELVQAVSDPSSP  
QYGKYLTL ENVADLVRPSPLTLHTVQKWLLAAGAQKCHSVITQDFLTCWLSIRQAE  
LLPGAEFHYYVGGPTETHVVRSPHPYQLPQALAPHVDFVGGLHRFPPTSSLRQRPEPQ  
VTGTVGLHLGVTPSVIRKRY

><potential N-glycosylation site>

NLTSQDVGSCTS

><potential N-glycosylation site>

NNSQACAQFLEQYFHDSDLAQFMRLF GGNAHQASVARVVGQQGRGRAGIEASLDV  
QYLMSAGA

><potential N-glycosylation site>

NISTWVYSSPGRHEGQEPFLQWLMLLS

><potential N-glycosylation site>

NESALPHVHTSYGDDEDLSSAYIQRVNTELMKAAARGLTLLFASGDSGAGCWSVS  
GRHQFRPTFPASSPYVTTGGTSFQEPFLITNEIVDYISGGGFSNVPRPSYQEEAVTKF  
LSSSPHLPPSSYF

><potential N-glycosylation site>

NASGRAYPDVAALSDGYWVVSNRVPIPWVSGTSASTPVFGGILSLINEHRILSGRPLL  
GFLNPRLYQQHGAGLFDVTRGCHESCLDEEVEGQGFCSGPGWDPVTGWGTPTSQLC

**FIGURE 95**

GCCGCGCGCTCTCTCCGGGCCACACCTGTCTGAGCGCGCAGCGAGCCGGCCGG  
 GCGGGCTGCTCGCGCGAACAGTGCTCGC  
 ><MET {trans=1-s, dir=f, res=1}>  
 ATGGCAGGGATTCCAGGGCTCCTTCCTCTCTTCTGCTCTGTGCTGTTGGCAA  
 GTGAGCCCTTACAGTGCCCCCTGGAAACCCACTTGGCCTGCATACCGCCTCCCTGTC  
 TTGCCCCAGTCTACCCCTCAATTAGCCAAGCCAGACTTGGAGCCGAAGCAAATTAGAA  
 GTATCTTCTCATGTGGACCCCAGTGTATAAGGAACTCCACTGCCACTTACGAAGAG  
 GCCAAGCAATATCTGTCTTATGAAACGCTCTATGCCAATGGCAGCCGACAGAGACGCAG  
 GTGGGCATCTACATCCTCAGCAGTAGTGGAGATGGGCCAACACCGAGACTCAGGGTCT  
 TCAGGAAAGTCTCGAAGGAAGCAGCAGATTATGGCTATGACAGCAGGTTCAAGCATT  
 GGGAAAGGACTTCCTGCTCAACTACCCTTCTCAACATCAGTGAAGTTATCCACGGGCTGC  
 ACCGGCACCCCTGGTGGCAGAGAACATGTCTCACAGCTGCCACTGCATACACGATGGA  
 AAAACCTATGTGAAAGGAACCCAGAACGCTCGAGTGGCTTCTAAAGCCCAAGTTAAA  
 GATGGTGGTCGAGGGCCAACGACTCCACTTCAGCCATGCCGAGCAGATGAAATTTCAG  
 TGGATCCGGGTGAAACGCACCCATGTGCCAAGGGTTGGATCAAGGGCAATGCCAATGAC  
 ATCGGCATGGATTATGATTATGCCCTCCTGGAACCTAAAAAGCCCCACAAGAGAAAATT  
 ATGAAGATTGGGGTGAGCCCTCCTGCTAACGAGCTGCCAGGGGGCAGAATTCACTTCT  
 GGTTATGACAATGACCGACCAGGAATTGGTGTATCGCTCTGTGACGTCAAAGACGAG  
 ACCTATGACTTGCTCTACCAGCAATGCGATGCCAGCCAGGGGCCAGCGGGCTGGGTC  
 TATGTGAGGATGTGGAAGAGACAGCAGCAGAAGTGGAGCGAAAAATTATTGGCATT  
 TCAGGGCACCAGTGGTGGACATGAATGGTCCCCACAGGATTCAACGTGGCTGTCAGA  
 ATCACTCCTCTCAAATATGCCAGATTGCTATTGGATTAAAGGAAACTACCTGGATTGT  
 AGGGAGGGGTGACACAGTGTCCCTCCTGGCAGCAATTAGGTCTTATGTTCTTATT  
 TAGGAGAGGCCAATTGTTTTGTCAATTGGCGTGCACACGTGTGTGTGTGTGT  
 GTGTGTAAGGTGTCTTATAATCTTACCTATTCTTACAATTGCAAGATGACTGGCTTT  
 ACTATTGAAAATGGTTGTGTATCATATCATATCATTTAAGCAGTTGAAGGCATA  
 CTTTGCAAGAAATAAAAAAAACTGATTGGCAATGAGGAATATTGACAATTAA  
 GTTAATCTCACGTTTGCAAACATTGATTGGGTTATTCACTGAACATTGTTCAAAGAT  
 TTATATTAAATATTGGCATACAAGAGATATGAAAAA

**FIGURE 96**

&gt;&lt;signal peptide&gt;

MAGIPGLLFLFFLLCAVG

&gt;&lt;start mature protein&gt;

QVSPYSAPWKPTWPAYRLPVVLPQSTLNLA  
KPDFGAEAKLEVSSSCGPQCHKGTPLP  
TYEEAKQYLSYETLYA

&gt;&lt;potential N-glycosylation site&gt;

NGSRTETQVGIYILSSSGDGAQHRDSGSSGKSRRKRQIYGYDSRFSIFGKD  
FLLNYPFS  
TSVKLSTGCTGTLVAEKHV

&gt;&lt;serine proteases, trypsin family, histidine active site 'LTAH'&gt;

LTAHCIHDGKTYVKGTQKLRVGFLPKFKDGGRGA

&gt;&lt;potential N-glycosylation site&gt;

NDSTSAMPEQMKFQWIRVKRTHVPKGWIKGNANDIGMDYDYALLELKKPHKRKF  
M  
KIGVSPPAKQLPGGRIHFSGYDNDRPGNLVYRFCDVKDETYDLLYQQCDAQPGASGS  
GVYVRMWKRQQQKWERKIIGIFSGHQWVDMNGSPQDFNVAVRITPLKYAQICYWI  
GNYLDCREG

## **FIGURE 97**

GCATGCCCTGGTCTCTCGAGCCTGCTGCCGTCCCCCCCCACCA  
><MET {trans=1-s, dir=f, res=1}  
ATGGTGGTTCTGGAGCCCCCAGCCCTGGTGGGGCTGTCGGCACCTCACCTCC  
CTGCTGCTGCTGGCGTCAGCCATCCTCAATGCGGCCAGGATACTGTTCCCCAGCC  
TGTGGGAAGCCCCAGCAGCTGAACC GGTTGTGGCGGCGAGGACAGCACTGACAGCGAG  
TGGCCCTGGATCGTGAGCATCCAGAAGAATGGGACCCACCACTGCGCAGGTTCTGCTC  
ACCAGCCGCTGGGTGATCACTGCTGCCACTGTTCAAGGACAACCTGAACAAACCATAC  
CTGTTCTCTGTGCTGGGGCCTGGCAGCTGGGAACCTGGCTCTGGTCCAGAAG  
GTGGGTGTTGCCTGGTGGAGCCCCACCTGTGTATTCTGGAAGGAAGGTGCCTGTGCA  
GACATTGCCCTGGTGCCTCGAGCGCTCCATACAGTTCTCAGAGCGGGCTGCCATC  
TGCCTACCTGATGCCCTATCCACCTCCCTCAAACACCCACTGCTGGATCTCAGGCTGG  
GGGAGCATCCAAGATGGAGTTCCCTGCCAACCCCTCAGACCCCTGCAGAAGCTGAAGGTT  
CCTATCATCGACTCGGAAGTCTGCAGCCATCTGTACTGGCGGGAGCAGGACAGGGACCC  
ATCACTGAGGACATGCTGTGCCGGCTACTGGAGGGGGAGCAGGATGCTGTCTGGC  
GAECTCCGGGGCCCCCTCATGTGCCAGGTGGACGGCGCTGGCTGCTGCCGGCATCATC  
AGCTGGGCGAGGGCTGTGCCAGCGCAACAGGCCGGGTCTACATCAGCCTCTGCG  
CACCGCTCTGGTGGAGAAGATCGTCAAGGGTGCAGCTCCGGCGCTCAGGG  
GGTGGGCCCTCAGGGCACCGAGCCAGGGCTCTGGGCCGCCGCGCTCTAGGGCGCA  
GCGGGACCGCGGGCTGGATCTGAAAGGCGCCAGATCCACATCTGGATCTGGATCTGCG  
GCGGCCTCGGGCGGTTCCCCCGCGTAATAGGCTCATCTACCTCTACCTCTGGGGCC  
CGGACGGCTGCTCGGAAAGGAAACCCCTCCCCGACCCGCCGACGGCTCAGGGCCCC  
CTCCAAGGCATCAGGCCCGCCAACGGCCTCATGTCCCCGCCACGACTCCGGCCC  
CGCCCCCGGGCCCCAGCGCTTTGTGTATAATGTTAATGATTGTTAGGTATTGT  
AACCTGCCACATATCTTATTATTCTCCAATTCAATAAATTATTATTCTCCAAAA  
AAAAAA

**FIGURE 98**

><signal peptide>

MVVSGAPPALGGGCLGTFTSLLLLASTAILNA

><start mature peptide>

ARIPVPPACGKPQQQLNRRVVGGEDSTDSEWPWIVSIQK

><potential N-glycosylation site>

NGTHHCAGSLLTSRWV

><Serine proteases active site ITAAHC>

ITAAHCFKDNLNKPYLFSVLLGAWQLGNPGSRSQKVGVAWVEPHPVYSWKEGACA  
DIALVRLERSIQFSERVLPICLPDASIHLPPNTHCWISGWGSIQDGVPPLPHPQTLQKLKV  
PIIDSEVCYSHLYWRGAGQGPITEDMLCAGYLEGERDACLGDSGGPLMCQVDGAWLL  
AGIISWGEGCAERNRPGVYISLSAHRSWVEKIVQGVQLRGRAQGGGALRAPSGSGA  
AARS

**FIGURE 99**

```

GACGGCTGGCCACC
><MET {trans=1-s, dir=f, res=1}
ATGCACGGCTCCTGCAGTTCTGATGCTTCTGCTGCCGCTACTGCTACTGCTGGTGGCC
ACCACAGGCCCGTTGGAGCCCTCACAGATGAGGAGAACGTTGATGGTGGAGCTGCAC
AACCTCTACCGGGCCAGGTATCCCCACGGCCTCACAGACATGCTGCACATGAGATGGGAC
GAGGAGCTGGCCGCCTCGCCAAGGCCTACGCACGGCAGTGCCTGTGGGCCACAACAAG
GAGCGCGGGCGCCGCGAGAATCTGTCGCCATCACAGACGAGGGCATGGACGTGCCG
CTGGCCATGGAGGAGTGGCACCAAGCGAGCTGAGCACTACAACCTCAGGCCGCCACCTGC
AGCCCAGGCCAGATGTGGCCACTACACGCAGGTGGTATGGCCAAGACAGAGAGGATC
GGCTGTGGTCCCACCTCTGTGAGAAGCTCAGGGTGTGAGGAGACCAACATCGAATT
CTGGTGTGCAACTATGAGCCTCCGGGAACGTGAAGGGAAACGGCCCTACCAGGAGGG
ACTCCGTGCTCCAATGCCCCTGGCTACCACTGCAAGAACTCCCTCTGTGAACCCATC
GGAAGCCCGGAAGATGCTCAGGATTGCGCTTACCTGGTAACTGAGGCCCATCCTCCGG
GCGACTGAAGCATCAGACTCTAGGAAAATGGTACTCCTCTCCCTAGCAACGGGATT
CCGGCTTCTGGTAACAGAGGTCTCAGGCCCTGGCAACCAAGGCTCTGCCTGCTGTG
GAAACCCAGGCCCAACTCCTTAGCAACGAAAGACCCGCCCTCATGGCAACAGAGGCT
CCACCTGCGTAACAAC TGAGGTCCCTCATTTGGCAGCTCACAGCCTGCCCTCTG
GATGAGGAGCCAGTTACCTCCCCAAATGACCCATGTTCTATCCAAAATCAGCAGAC
AAAGTGACAGACAAAACAAAAGTGCCTCTAGGAGGCCAGAGAACTCTCTGGACCCAAAG
ATGTCCTGACAGGGCAAGGAACCTCTACCCATGCCAGGAGGCTGAGGCTGAG
GCTGAGTTGCCCTTCCAGTGAGGTCTGGCTCAGTTTCCAGGCCAGGACAAGCCA
GGTAGCTGCAGGCCACACTGGACCACACGGGCACACCTCCAAGTCCCTGCCAAT
TCCCCAATACCTCTGCCACCGCTAATGCCACGGTGGCGTGCCTGCTGAGTCG
TCCTGCCAGGTGCAGAGGCCCTGACAAGCCTAGCGTTGTGTCAGGGCTGAACCTGGG
CCTGGCATGTTGGGCCCTCCTGGACTACTGCTCCTGCCCTCTGGTGTGGCT
GGAATCTCTGAATGGGATACCACCTCAAAGGGTGAAGAGGTCACTGTCCTCTGTCA
TTCCCCACCCCTGCCCCAGCCCTAAACAAGATACTCTGGTTAAGGCCCTCCGGAAAGG
GAAAGGCTACGGGCATGTGCCCTCATCACACCATCCCTGGAGGCACAAGGCTGGCT
GGCTGCGAGCTCAGGAGGCCCTGAGGACTGCACACCGGGCCACACCTCTCCGCC
TCCCTCTGAGTCCTGGGGTGGGAGGATTGAGGGAGCTCACTGCCAACCTGGGCTGG
GCTGCTGCCACACAGCATGTGCGCTCTCCCTGAGTGCCTGTTAGCTGGGATGGG
TTCCTAGGGGCAGATGAAGGACAAGCCCCACTGGAGTGGGTCTTGAGTGGGGAGGC
AGGGACGAGGGAAGGAAAGTAACCTGACTCTCAAAAAACCTGTCCAACCTGTGAA
A

```

## FIGURE 100

><signal peptide>

MHGSCSFLMLLLPLLLLLVATT

><start of mature peptide, extracellular domain>

GPVGALTDEEKRLMVELHNL YRAQVSPTASDMLHMRWDEELAAFAKAYARQCVW  
GHNKERGRRGENLFAITDEGMDVPLAMEEWHHEREHY

><potential N-glycosylation site>

NLSAATCSPGQMC

><GHYTQVVWAKT Extracellular proteins SCP/Tpx-1/Ag5/PR-1/Sc7 signature 1 - CRISP  
signature>

GHYTQVVWAKTERIGCGSHFCEKLQGVETNIEL

><LLVCNYEPPGNV Extracellular proteins SCP/Tpx-1/Ag5/PR-1/Sc7 signature 2 -CRISP  
signature>

LVCNYEPPGNVKGKR PYQE GTPCSQCPSGYHCKNSLCEPIGS PEDA QDLPYL VTEAPSFR  
ATEASDSRKMGTPSSLATGIPAFLVTEVSGSLATKALPAVETQAPTS LATKDPPSMATEA  
PPCVTTEVPSILAAHSLPSLDEEPVTFPKSTHVPIP KSADKVTDKT KVP SRSPENS LDPK  
MSLTGARELLPHAQEEAEAEALPPSSEV LASVFP AQDKPGELQATLDHTGHTSSKSLPN  
FP

><potential N-glycosylation site>

NTSATA

><potential N-glycosylation site>

NATGGRALALQSSLPGAEGPDKPSVVSGLNS

><potential glycosylphosphatidylinositol attachment site>

GPGHVVWGPLLGLLLLPPPLVLAGIF

## **FIGURE 101A**

GTAACTGAAGTCAGGCTTTCAATTGGGAAGCCCCCTAACAGAACATCGGTCAATTCTCCA  
 AGTT  
 ><MET {trans=1-s, dir=f, res=1}  
 ATGGTGGACGTACTTCTGTTCTCCCTCTGCTTGCCTTTCACATTAGCAGACCGGAC  
 TTAAGTCACAACAGATTATCTTCATCAAGGCAAGTCCATGAGCCACCTCAAAGCCTT  
 CGAGAAGTGAAGACTGAACAACAATGAATTGGAGACCATTCCAATCTGGGACCAGTCTCG  
 GCAAATATTACACTTCTCTGGCTGGAAACAGGATTGTTGAAATACTCCCTGAACAT  
 CTGAAAGAGTTCAGTCCTTGAAACTTGGACCTTAGCAGCAACAATATTCAGAGCTC  
 CAAACTGCATTCCAGCCTACAGCTCAAATATCTGTATCTCAACAGCAACCGAGTCACA  
 TCAATGGAACCTGGGTATTTGACAATTGGCAACACACTCCTGTGTTAAAGCTGAAC  
 AGGAACCGAACATCTCAGCTATCCCACCCAAAGATGTTAAACTGCCCAACTGCAACATCTC  
 GAATTGAAACGAAACAAGATTAAGGAAATGGAGTAACGAAACTTATGGATGGAGCTTTGG  
 GGGCTGAGCAACATGGAAATTTGCAGCTGGACCATAACAACCTAACAGAGATTACCAAA  
 GGCTGGCTTACGGCTGCTGATGCTGCAGGAACCTCATCTCAGCCAAATGCCATCAAC  
 AGGATCAGCCCTGATGCCTGGAGTTCTGCCAGAACGCTCAGTGAGCTGGACCTAACTTCA  
 AATCACTTATCAAGGTTAGATGATTCAAGCTCCTGGCCTAACGTTAACAAACACTG  
 CACATTGGGAAACAACAGAGTCAGCTACATTGCTGATTGTCCTCCGGGGCTTCCAGT  
 TTAAAGACTTTGGATCTGAAGAACAAATGAAATTCTGGACTATTGAAGACATGAATGGT  
 GCTTTCTCTGGGCTTGACAAACTGAGGCGACTGATACTCCAAGGAAATCGGATCGTTCT  
 ATTACTAAAAAGCCTTCACTGGTTGGATGCTGATTGGAGCATCTAGACCTGAGTGACAAC  
 GCAATCATGTCTTACAAGGCAATGCATTTCACAAATGAAGAAACTGCAACAAATTGCAT  
 TTAAATACATCAAGCCTTGTGCGATTGCCAGCTAAATGGCTCCCACAGTGGTGGCG  
 GAAAACAACTTTCAGAGCTTGTAAATGCCAGTTGTGCTGATGATTGGAGCATCTAGACCTGAGTGACAAC  
 AGAACATTTTGCTGTTAGCCCAGATGGCTTGTGATGATTGGAGCATCTAGACCTGAGTGACAAC  
 ATCACGGTTAGCCAGAACACAGTCGGCAATAAAAGGTTCAATTGAGTTCATCTGC  
 TCAGCTGCCAGCAGCAGTGATTCCCCAATGACTTTGCTTGGAAAAAAAGACAATGAAC  
 CTGCATGATGCTGAAATGGAAAATTATGCACACCTCCGGGCCAACGGTGGCGAGGTGATG  
 GAGTATACCACCATCCTCGGCTGCGAGGTGGAATTGCCAGTGAGGGAAATATCAG  
 TGTGTCATCTCAAATCACTTGGTCATCCTACTCTGTCAAAGCCAAGCTTACAGTAAAT  
 ATGCTCCCTCATTCAACCAAGACCCCCATGGATCTCACCCTCGAGCTGGGGCATGGCA  
 CGCTTGGAGTGTGCTGCTGGGGCACCCAGCCCCCAGATAGCCTGGCAGAAGGATGGG  
 GGCACAGACTTCCCAGCTGCACGGGAGAGACGCATGCTGATGCCCGAGGATGACGTG  
 TTCTTATCGTGGATGTAAGATAGAGGACATTGGGTATACAGCTGCACAGCTCAGAAC  
 AGTGCAGGAAGTATTCAGCAAATGCAACTCTGACTGTCTAGAAACACCATCTTTG  
 CGGCCACTGTTGGACCGAACTGTAACCAAGGGAGAAACAGCCGTCTACAGTGCATTGCT  
 GGAGGAAGCCCTCCCCCTAAACTGAACCTGGACCAAAAGATGATAGGCCATTGGTGGTAACC  
 GAGAGGCACCTTTGCGAGCAGGCAATCAGCTCTGATTATTGTGGACTCAGATGTCAGT  
 GATGCTGGAAATACACATGTGAGATGTCTAACACCCCTGGCACTGAGAGAGGAAACGTG  
 CGCCTCAGTGTGATCCCCACTCCAACCTCGCACTCCCTCAGATGACAGCCCCATCGTTA  
 GACGATGACGGATGGCACTGTGGGTGTCGTGATCATAGCCGTGGTTGCTGTGGTG  
 GGCACGTCACTCGTGTGGGTGTCATCATATACCACACAAGGGGGAGGAATGAAGATTGC  
 AGCATTACCAACACAGATGAGACCAACTGCCAGCAGATATTCTAGTTATTGTCATCT  
 CAGGGACGTTAGCTGACAGGCAGGATGGGTACGTGCTTCAGAAAGTGGAAAGCACCAC  
 CAGTTGTCACATCTCAGGTGCTGGATTTCACACAACTGACAGTAGTGGAC  
 TGCCATATTGACAATAGCAGTGAAGCTGATGTGGAAAGCTGCCACAGATCTGTTCTTGT  
 CCGTTTTGGGATCCACAGGCCCTATGTATTGAAAGGGAAATGTGTATGGCTCAGATCCT  
 TTTGAAACATATCATAACAGGTTGCACTGACAGGCAGGATGGGTACGTGCTTCAGAAAGTGGAAAGCACCAC  
 GAGGCCAGTTACATAAAGAAAAAGGAGTGCTACCCATGTTCTCATCCTTCAGAAGAATCC  
 TGCAGACGGAGCTCAGTAATATATCGTGGCCTTCACATGTGAGGAAGCTACTAACACT  
 AGTTACTCTCACAATGAAGGACCTGGAATGAAAAATCTGTGCTAAACAAGTCCTTTA  
 GATTTAGTGCAAATCCAGAGGCCAGCGTGGTTGCCTCGAGTAATTCTCATGGTAC  
 TTTGGAAAAGCTCTCAGGAGACCTCACCTAGATGCCTATTCAAGCTTGGACAGCCATCA

**FIGURE 101B**

GATTGTCAGCCAAGAGCCTTTAT TGAAAGCTCATTCTCCCCAGACTGGACTCTGGG  
TCAGAGGAAGATGGGAAAGAAAGGACAGATTTCAGGAAGAAAATCACATTGTACCTT  
AAACAGACTTAGAAAAC TACAGGACTCCAAATTTCAAGTCTTATGACTGGACACATAG  
ACTGAATGAGACCAAAGAAAAGCTTAACATACTACCTCAAGTGAAC TTTATTAAAAG  
AGAGAGAATCTATGTTTTAAATGGAGTTATGAATTAAAAGGATAAAATGCTTA  
TTTATACAGATGAACCAAATTACAAAAAGTTATGAAAATT TTATACGGAAATGATGC  
TCATATAAGAACATACCTTTAAACTATTTTAACTTTGTTTATGCAAAAAGTATCTT  
ACGTAATTAAATGATATAATCATGATTATTTATGTATTTTATAATGCCAGATTCTT  
TTTATGGAAAATGAGTTACTAAAGCATTTAAATAACCTGCCTGTACCATT TAA  
ATAGAAGTTACTTCATTATTTGCACATTATTTAATAAAAATGTGTCAATTGAA

**FIGURE 102**

MVDVLLLFSLCLLFHISRPDLSHNRLSFIKASSMSHLQSLREVKLNNNELETIPNLGPVS  
ANITLLSLAGNRIVEILPEHLKEFQSLETLDLSSNNISELQTAFPALQLKYLYLNSNRVT  
SMEPGYFDNLANTLLVLKLNRRNRIASIPPKMFKLPQLQHLELRNPKIKNVDGLTFQGLGA  
LKSLKMQRNGVTKLMGAFWGLSNMEILQLDHNNLTEITKGWLYGLLMLQELHLSQNAIN  
RISPDAWEFCQKLSLELDLTFNHLSRLDDSSFLGLSLLNTLHIGNNRVSYIADCAFRLSS  
LKTLDLKNNIEISWTIEDMNGAFSGLDKLRRLILQGNRIRSITKKAFTGLDALEHLDLSDN  
AIMSLQGNAFSQMKKLQQLHLNTSSLLCDCQLKWLPQWVAENNQSFVNASCAPQLLKG  
RSIFAVSPDGVCDDFPKPQITVQPETQSAIKGSNLSFICSAASSSDSPMTFAWKKDNEL  
LHDAEMENYAHLRAQGGEVMEYTTILRLREVEFASEGKYQCVISNHFGSSYSVKAKLTVN  
MLPSFTKTPMDLTIRAGAMARLECAAVGHPPAPQIAWQKDGGTDFPAARERRMHVPEDDV  
FFIVDVKIEDIGVYNSCTAQNSAGSIISANATLVLETPSFLRPLLDRTVKGETAVLQCIAG  
GGSPPPKNWTKDDSPVVTERHFFAAGNQLLIVDSDVSDAGKYTCEMSNTLGTERGNV  
RLSVIPTPTCDSPQMTAPSLODDGWATVGVIIAVVCCVVGTSLVWVVIYHTRRRNEDC  
SITNTDETNLPADIPSYLSSQGTIADRQDGYSSESQSHHQFVTSSGAGFFLPQHDSSGT  
CHIDNSSEADVEAATDLCFLCPFLGSTGPMYLKGNVYGSDFPFETYHTGCSPDPRTVLMHY  
EPSYIKKKECYPCHPSEESCERSFSNISWPShVRKLLNTSYSHNEGPGMKNLCLNKSSL  
DFSANPEPASVASSNSFMGTFGKALRRPHLDAYSSFGQPSDCQPRAFYLKAHSSPDLDG  
SEEDGKERTDFQEENHICTFKQTLENYRTPNFQSYLDT

**FIGURE 103**

GGGGAGAGGAATTGACCATGTAAAAGGAGACTTTTTTGGTGGTGGCTGTTGG  
 TGCCTTGCAAAATGAAGGATGCAGGACGCAGCTTCTCCTGGAACCGAACGCAATGGAT  
 AACTGATTGTGCAAGAGAGAAGAACGAAGCTTTCTGTGAGCCCTGGATCTTA  
 ACACAAATGTGTATATGTGACACAGGGAGCATTCAAGAATGAAATAACCAGAGTTAGA  
 CCCGCGGGGGTGGTGTCTGACATAATAAATAATCTAAAGCAGCTGTCCTCCCTCC  
 CCACCCCCAAAAAAAAGGATGATTGGAAATGAAGAACCGAGGATTACAAAGAAAAAGT  
 ATGTTCATTTCTCTATAAAGGAGAAAGTGAGCCAAGGAGATATTTGGAATGAAAG  
 TTTGGGGCTTTTAGTAAAGTAAAGAACCTGGTGTGGTGGTTCCCTTCTTTGAA  
 TTTCCCACAAGAGGAGAGGAAATTAAATAATACATCTGCAAAGAAATTTCAGAGAAGAAAA  
 GTTGACCGCGGGCAGATTGAGGCATTGATTGGGGAGAGAACCCAGCAGAGCACAGTTGGA  
 TTTGTGCCTATGTTGACTAAAATTGACGGATAATTGCAAGTTGGATTTCTTCATCAACC  
 TCCTTTTTAAATTTATTCTCTGGTATCAAGATCATGCGTTCTTGTGTTCTT  
 AACCACTGGATTTCATCTGGATGTTGCTGTGATCAGTCTGAAATACAACACTGTTGAAT  
 TCCAGAAGGACCAACACCAAGATAAATTATGA  
 ><MET {trans=1-s, dir=f, res=1}  
 ATGTTGAACAAGATGACCTTACATCCACAGCAGATAATGATAGGTCTAGGTTAACAGG  
 GCCCTATTGACCCCCCTGCTTGTGGTGTGGCTCTTCAACTTCTTGTGGTGGCTGGT  
 CTGGTGCAGGGCTCAGACCTGCCCTCTGTGTGCTCTGCAGCAACCAGTCAGCAAGGTG  
 ATTTGTGTTCGAAAAACCTCGCTGAGGTTCCGGATGGCATCTCCACCAACACAGGCTG  
 CTGAACCTCCATGAGAACCAAATCCAGATCATCAAAGTGAACAGCTTCAAGCAGTGTGAGG  
 CACTTGGAAATCCTACAGTTGAGTAGGAACCATATCAGAACCAATTGAAATTGGGGCTTC  
 AATGGTCTGGCGAACCTCAACACTCTGAACTCTTGACAATCGTCTTACTACCATCCG  
 AATGGAGCTTGTATACTTGTCTAAACTGAAGGAGCTCTGGTGTGCAAACACCCATT  
 GAAAGCATCCCTCTTATGCTTTAACAGAAATTCTTGTGCGCCGACTAGACTAGGG  
 GAATTGAAAAGACTTCATACATCTCAGAACGGTGCCTTGAAGGTCTGTCCAACATTGAGG  
 TATTTGAACCTTGCCATGTGCAACCTTCGGAAATCCCTAACCTCACACCGCTCATAAAA  
 CTAGATGAGCTGGATCTTCTGGAAATCATTATCTGCCATCAGGCCTGGCTCTTCCAG  
 GGTTGATGCACCTTCAAAAATGTGGATGATACAGTCCCAGATTCAAGTGATTGAACGG  
 AATGCCTTGACAACCTCAGTCACTAGTGGAGATCAACCTGGCACACAATACTAACA  
 TTACTGCCTCATGACCTTCACTCCCTGCATCATCTAGAGCGGATACATTACATCAC  
 AACCCCTGGAACCTGTAACCTGTGACATACTGTGGCTCAGCTGGGATAAAAGACATGGCC  
 CCCTCGAACACAGCTTGTGTGCCGGTGTAAACACTCCTCCAACTAAAGGGGAGGTAC  
 ATTGGAGAGCTGACCAGAATTACTTCACATGCTATGCTCCGGTGATTGTGGAGCCCCCT  
 GCAGACCTCAATGTCACTGAAGGCATGGCAGCTGAGCTGAAATGTCGGGCCTCCACATCC  
 CTGACATCTGTATCTGGATTACTCCAATGGAACAGTCATGACACATGGGCGTACAAA  
 GTGCGGATAGCTGTGCTCAGTGATGGTACGTTAACATTCAAAATGTAAGTGTGCAAGAT  
 ACAGGCATGTACACATGTATGGTAGTAATTCCGGTGGAAATACTACTGCTTCAGCCACC  
 CTGAATGTTACTGCAGCAACCAACTACTCCTTCTCTTCAACCGTCACAGTAGAG  
 ACTATGGAACCGTCTCAGGATGAGGCACGGACCACAGATAACAATGTGGGTCCCACTCCA  
 GTGGTCAGTGGGAGACCACCAATGTGACCACCTCTCACACCACAGAGCACAGGTG  
 ACAGAGAAAACCTTCAACATCCAGTGACTGATATAAACAGTGGGATCCCAGGAATTGAT  
 GAGGTGATGAAGACTACCAAAATCATCATTGGGTGTTTGTGGCATCACACTCATGGCT  
 GCAGTGATGCTGGTCAATTCTACAAGATGAGGAAGCAGCACCACGGCAAAACCATCAC  
 GCCCAACAAGGACTGTTGAAATTATAATGTGGATGAGATTACGGGAGACACACCC  
 ATGGAAAGCCACCTGCCATGCCATGCTATGAGCATGAGCACCTAAATCACTATAACTCA  
 TACAAATCTCCCTCAACCACACAAACACAGTTAACACAATAATTCAATACACAGTTCA  
 GTGCATGAACCGTTATTGATCCGAATGAACTCTAAAGACAATGTACAAGAGACTCAAATC  
 TAAAACATTACAGAGTACAAAAACAAACATCAAAAAAAAGACAGTTATTAAAAAA  
 TGACACAAATGACTGGCTAAATCTACTGTTCAAAAAAGTGTCTTACAAAAAAACAAA  
 AAAGAAAAGAAATTATTAAAAATTCTATTGTGATCTAAAGCAGACAAAAAA

**FIGURE 104**

&gt;&lt;signal peptide&gt;

MLNKMTLHPQQIMIGPRFNRALFDPLLVVLLALQLLVVAGLVRA

&gt;&lt;start mature peptide, extracellular domain&gt;

QTCPSVCSCSNQFSKVICVRKNLREVPDGISTNTRL

&gt;&lt;start leucine rich repeat domains&gt;

LNLHENQIQIIVNSFKHLRHEILQLSRNHIRTIEIGAFNGLANLNTLEFDNRLTTIPN  
GAFVYLSKLKELWLRNNPIESIPSYAFNRIPSLRRLDLGELKRLSYISEGAFEGLSNLRY  
LNLCAMCNLREIPNLTPLIKLDELDLSGNHLSAIRPGSFQGLMHLQKLWMIQSQIQVIER  
NAFDNLQSLVEINLAHNNLTLLPHDLFTPPLHHLERIHLHHNPWCNCIDLWLSWWIK  
DMAPSNTACCARCNTPPNLKGRYIGELDQNYFTCYAPVIVEPPADLNVTGMAAEELK  
CRASTSLSVSWITPNGTVMTGAYKVRIAVLSDGTLNFTNVTVQDTGMYTCMVSN  
SVGNTTASATLNTAATTPFSYFSTVTVETMEPSQDEARTTDNNVGPTPVVDWE

&gt;&lt;end leucine rich repeat domains&gt;

TTNVTTSLTPQSTRSTEKTFTIPVTDINSGIPGIDE

&gt;&lt;start transmembrane domain&gt;

VMKTTKIIIGCFVAITLMAAVMLVI

&gt;&lt;start intracellular domain&gt;

FYKMRKQHHRQNHHAPTRTVEIINVDEITGDTPMESHPMPAIEHEHLNHYN SYKS  
PFNHTTVNTINSIHSSVHEPLLIRMNSKDNVQETQI

**FIGURE 105A**

AGCCGACGCTGCTCAAGCTGCAACTCTGTTGCAGTTGGCAGTTCTTTCGGTTCCCTCCTG  
 CTGTTGGGGCATGAAAGGGCTCGCCGCCGGAGTAAAAGAAGGAATTGACCGGGCAGCG  
 CGAGGGAGGAGCGCAGCGACCGCGAGGGCGGGCGTGCACCCCTCGCTGGAAGTTGTGC  
 CGGGCCCCGAGCGCGCCGGCTGGAGCTCGGGTAGAGACCTAGGCCGCTGACCGCGAT  
 GAGCGCGCCGAGCCTCCGTGCGCGCCGGGGTTGGGCTGCTGCTGCGCGGTGCTGG  
 GGCGCGCTGGCGGTCCGACAGCGCGGTGCGGGGAACCTGGGAGCCCTCTGGGGTAGCC  
 GCCGAGCGCCCAGCCCCACTACCTGCCGCTGCCCTCGGGGACCTGCTGGACTGCAGTCGTA  
 GCGGCTAGCGCGTCTCCGAGCCACTCCGCTGGGCGCTCGGCTGGACTTAAGTCACA  
 ACAGATTATCTTCATCAAGGCAAGTTCCATGAGCCACCTCAAAGCCTCGAGAAGTGAAA  
 CTGAAACAACATGAATTGGAGACCATTCCAATCTGGGACCAGTCTCGGCAAATATTACACT  
 TCTCTCCTGGCTGAAACAGGATTGTTGAAATACTCCCTGAACATCTGAAAGAGTTCACT  
 CCCTGAAACTTGGACCTTAGCAGCAACAATATTCAAGAGCTCCAAACTGCATTCCAGCC  
 CTACAGCTCAAATATCTGTATCTAACAGCAACCGAGTCACATCAATGGAACCTGGTATTT  
 TGACAATTGGCCAACACACTCCTTGTGTTAAAGCTGAACAGGAACCGAATCTCAGCTATCC  
 CACCCAAGATGTTAAACTGCCAACTGCAACATCTGAATTGAACCGAAACAGATTAAA  
 AATGTAGATGGACTGACATTCCAAGGCCTGGTCTGAAGTCTCTGAAAATGCAAAGAAAA  
 TGGAGTAACGAAACTTATGGATGGAGCTTTGGGGCTGAGCAACATGGAATTGGCAGC  
 TGGACCATAACAACCTAACAGAGATTACCAAAGGCTGGTTACGGCTGCTGATGCTGCAG  
 GAACTTCATCTCAGCCAAATGCCATCAACAGGATCAGCCCTGATGCTGGAGTTCTGCCA  
 GAAGCTCAGTGAGCTGGACCTAACCTTCAATTCAAGGTTAGATGATTCAAGCTTCC  
 TTGGCCTAAGCTTAAACTAACACTGCACATTGGGAAACAACAGAGTCAGCTACATTGCTGAT  
 TGTGCTTCCGGGGCTTCCAGTTAAAGACTTGGATCTGAAGAACAAATGAAATTCTG  
 GACTATTGAAGACATGAATGGTCTTCTGGGCTTGACAAACTGAGGGCAGTGATACTCC  
 AAGGAAATCGGATCCGTTCTATTACTAAAAAGCCTTCACTGGGTTGGATGCATTGGAGC  
 ATCTAGACCTGAGTGACAACGCAATCATGTCCTTACAAGGCAATGCATTTCACAAATGAAGAA  
 ACTGCAACAAATTGCAATTAAATACATCAAGCCTTGTGCGATTGCCAGCTAAATGGCTCC  
 CACAGTGGGTGGCGAAAACAACCTTCAGAGCTTGTAAATGCCAGTTGTGCTGGCCATCCTCAG  
 CTGCTAAAGGAAGAAGCATTGGCTTAGGCCAGATGGCTTGTGATGATTTC  
 CAAACCCCAGATCACGGTTAGCCAGAAACACAGTCGGCAATAAAAGGTTCCAATTGAGTT  
 TCATCTGCTCAGCTGCCAGCAGCAGTGATTCCCCAATGACTTTGCTGGAAAAAGACAAT  
 GAACTACTGCATGATGCTGAAATGGAAAATTATGCACACCTCCGGGCCAAGGTGGCGAGGT  
 GATGGAGTATACCAACCATCCTCGGCTGCGGAGGTGGAAATTGCCAGTGAGGGAAATATC  
 AGTGTGTCATCTCAATCACTTGGTTCATCCTACTCTGTCAAAGCCAAGCTTACAGTAAAT  
 ATGCTTCCCTATTCAACCAAGACCCCCATGGATCTCACCATCGAGCTGGGCCATGGCAG  
 CTTGGAGTGTGCTGTGGGGCACCAGCCCCCAGATAGCCTGGCAGAAGGATGGGGCA  
 CAGACTTCCAGCTGCACGGAGAGACGCATGCTGATGCCAGGATGACGTGTTCTT  
 ATCGTGGATGTGAAGATAGAGGACATTGGGTATACAGCTGCACAGCTCAGAACAGTGCAG  
 AAGTATTCAGCAAATGCAACTCTGACTGTCCTAGAAACACCATATTGGGCCACTGT  
 TGGACCGAACTGTAACCAAGGGAGAAACAGCGTCTACAGTGCATTGCTGGAGGAAGCCT  
 CCCCCCTAAACTGAACTGGACCAAAGATGATAGCCATTGGTGTAAACCGAGAGGCACCTTT  
 TGCAGCAGGCAATCAGCTCTGATTATTGTTGACTCAGATGTCAGTGATGCTGGAAATACA  
 CATGTGAGATGTCTAACACCCCTGGCACTGAGAGAGGAAACGTGCGCCTCAGTGTGATCCCC  
 ACTCCAACCTGCGACTCCCTCAGATGACAGCCCCATCGTAGACGATGACGGATGGCCAC  
 TGTGGGTGTCGTGATCATGCCGGTTGCTGTGTTGGCACGTCACTCGTGTGGGTGG  
 TCATCATATACCAACACAAGGCGGAGGAATGAAGATTGCAAGCATTACCAACACAGATGAGACC  
 AACCTGCCAGCAGATATTCTAGTTATTGTCATCTCAGGGAAACGTTAGCTGACAGGCAGGA  
 TGGGTACGTGCTTCAGAAAGTGGAAAGCCACCACAGTTGTCACATCTCAGGTGCTGGAT  
 TTTCTTACCAACATGACAGTAGTGGACCTGCCATATTGACAATAGCAGTGAAGCTGAT  
 GTGGAAGCTGCCACAGATCTGTTCTTGTCCGTTGGATCCACAGGCCCTATGTATTT  
 GAAGGGAAATGTGTATGGCTCAGATCCTTGTGAAACATATCATAACAGGTTGCACTGCTGACC  
 CAAGAACAGTTAATGGACCACTATGAGCCAGTTACATAAAGAAAAAGGAGTGCTACCCA  
 TGTTCTCATCCTTCAGAAGAATCCTGCGAACGGAGCTCAGTAATATATCGTGGCCTTCACA  
 TGTGAGGAAGCTACTAACACTAGTTACTCTCACAAATGAAGGACCTGGAATGAAAAATCTGT  
 GTCTAAACAAGTCTCTTGTGAAATCCAGAGGCCAGCGTGGCTGCTCGAGT  
 AATTCTTCATGGGTACCTTGGAAAAGCTCTCAGGAGACCTCACCTAGATGCCATTCAAG

**FIGURE 105B**

CTTTGGACAGCCATCAGATTGTCAGCCAAGAGCCTTTATTGAAAGCTCATTCTTCCCCAG  
ACTTGGACTCTGGGTCAAGAGGAAGATGGGAAAGAAGGACAGATTTCAAGGAAAGAAAATCAC  
ATTGTACCTTAAACAGACTTAGAAAACATACAGGACTCCAAATTCAGTCTATGACTT  
GGACACATAGACTGAATGAGACCAAAGGAAAGCTAACATACTACCTCAAGTGAACCTTTA  
TTTAAAAGAGAGAGAATCTTATGTTTTAAATGGAGTTATGAATTAAAAGGATAAAAAT  
GCTTTATTTATACAGATGAACCAAATTACAAAAAGTTATGAAAATTTTATACGGGAATG  
ATGCTCATATAAGAATAACCTTTAAACTATTTTAACTTGTTTATGCACAAAAAGTATC  
TTACGTAAATTAAATGATATAAATCATGATTATTTATGTATTTATAATGCCAGATTCTT  
TTTATGGAAAATGAGTTACTAAAGCATTAAATAACCTGCCTGTACCATTAAAT  
AGAAGTTACTTCATTATTTGCACATTATTTAATAAAATGTGCAATTGAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAA

**FIGURE 106**

```
></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA37140
><subunit 1 of 1, 1119 aa, 1 stop
><MW: 123434, pI: 6.09, NX(S/T): 12
MSAPSLRARAAGLGLLLCAVLGRAGRSDGGRRGELQPSGVAAERPCPTTCRCLGDLLDC
SRKRLARLPEPLPSWVARLDLSHNRLSFIKASSMSHLQSLREVKLNNNELETIPNLGPVS
ANITLLSLAGNRIVEILPEHLKEFQSLETLDLSSNNISELQTAFPALQLKYLYLNSNRVT
SMEPGYFDNLANTLLVLKLNRRNISAIPPKMFKLPQLQHLELNRNKIKNVDGLTFQGLGA
LKSLKMQRNGVTKLMGAFWGLSNMEILQLDHNNLTEITKGWLYGLLMLQELHLSQNAIN
RISPDAWEFCQKLSLEDDLTFNHLSRLDDSSFLGLSLLNTLHIGNNRVSYIADCAFRLSS
LKTLDLKNNEISWTIEDMNGAFSGLDKLRRRLILQGNRIRSIKKAFTGLDALEHLDLSDN
AIMSLQGNAFSQMKKLQQLHLNTSSLCDCQLKWLPQWVAENNQSFVNASCAPHQPLLKG
RSIFAVSPDGFWCDDFPKPQITVQPETQSAIKGSNLSFICSAASSSDSPMTFAWKKDNE
LHDAEMENYAHLRAGGEGVMEMYTTILRLREVEFASEGKYQCVISNHFGSSYSVKAKLTVN
MLPSFTKTPMDLTIRAGAMARLECAAVGHPAPQIAWQKDGGTDFPAARERRMHVMPEDDV
FFIVDVKIEDIGVYSCTAQNSAGGSISANATLVLETPSFLRPLLDRTVTKGETAVLQCIA
GGSPPPKNWTKDDSPVVTERHFFAAGNQLLIIVDSDVSDAGKYTCMSNTLGTTERGNV
RLSVIPTPTCDSPQMTAPSLLDDGWATGVVIIIAVVCCVVGTSLVVVIIYHTRRRNEDC
SITNTDETNLPADIPSYLSQGTTLADRQDGYSSESQSHHQFVTSSGAGFFLPQHDSSGT
CHIDNSSEADVEAATDLFLCPFLGSTGPMYLKGNVYGSDFETYHTGCSPDPRTVLMHDY
EPSYIKKKECYPSCHPSEESCERSFSNISWPSHVRKLLNTSYSHNEGPGMKNLCLNKSSL
DFSANPEPASVASSNSFMGTFGKALRRPHLDAYSSFGQPSDCQPRAFYLAHSSPDLDSG
SEEDGKERTDFQEENHICTFKQTLENYRTPNFQSYDLDT
```

**FIGURE 107A**

CAAAAC TTGCGTCGCCGGAGAGGCCAGCTGACTTGAATGGAAGGAGCCGAGCCGCCGG  
 GCGCAGCTGAGACTGGGGAGCGCGTCTGGCTGTGGCGCCGCTCGCGCCGGCGCAG  
 CAGGGAAAGGGAAAGCTGTGGCTGCCCTGCTCCACGAGGCGCCACTGGTGTGAACCAGGAGA  
 GCCCTGGGTGGTCCCCTCCCTTATCCCTCCTTATAGAAACCTCCACACTGGGAAGGC  
 AGCGGCAGGCAGGAGGGCTCATGGTGAGCAAGGAGGCCGCTGATCTGCAGGCCACAGCA  
 TTCCGAGTTACAGATTTCACAGATACCAAATGGAAGGCAGGAGGCAGAACAGCCTGCC  
 GGTTCCATCAGCCCTGGCGCCAGGCAGTCAGCTCGGCACCCCCCTGCAGGCACCATGCC  
 CAGAGCCGGGTGCTGCTCCTGCTGCTGCCACAGCTGCACCTGGGACCTGTGCT  
 TGCGTGAGGGCCCCAGGATTGGCGAAGTGGCGGCCACAGCCTGAGGCCGAAGAGAACG  
 AATTGCGGAGGAGGAGGCCGTGGTACTGAGCCCTGAGGAGGCCGGCTGGCCAGCC  
 GCGGTCA GCTGCCCGAGACTGTGCCTTTCCAGGAGGGCTGTGGACTGTGGCGGTAT  
 TGACCTGCGTGAGTTCCGGGGACCTGCCTGAGCACACCAACCACCTATCTGCAGAAC  
 ACCAGCTGAAAAGATCTACCCCTGAGGAGCTCTCCGGCTGCACCGGCTGGAGACACTGAAC  
 CTGCAAAACAACGCCCTGACTTCCGAGGGCTCCAGAGAACGGCTTGAGCATCTGACCAA  
 CCTCAATTACCTGTACTTGGCCAATAACAAGCTGACCTGGCACCCGCTTCTGCCAAACG  
 CCCTGATCAGTGTGGACTTGCTGCCA ACTATCTCACCAAGATCTATGGGCTCACCTTGGC  
 CAGAAGCCAAACTTGAGGTCTGTGTACCTGCACAACAAGCTGGCAGACGCCGGCTGCC  
 GGACAAACATGTTCAACGGCTCCAGCAACGTCGAGGTCTCATCCTGTCAGCAACTTCTGC  
 GCCACGTGCCAAGCACCTGCCCTGCCCTGTACAAGCTGCACCTCAAGAACACAAGCTG  
 GAGAAGATCCCCCGGGGGCTTCAGCGAGCTGAGCAGCCTGCGAGCTATACTGCAGAA  
 CAACTACCTGACTGACCGAGGGCTGGACAACAGAGAACCTCTGGAAAGCTCTCCAGGCTGGAGT  
 ACCTGGATCTGTCAGCAACAACCTGTCTCGGGTCCCAGCTGGCTGCCGCGAGCCTGGT  
 CTGCTGCACTTGGAGAAGAACGCCATCCGGAGCGTGGACGCGAATGTGCTGACCCCATCCG  
 CAGCCTGGAGTACCTGCTGTCAGCAACCAGCTGCCAGGGAGCAGGGCATCCACCCACTGG  
 CCTTCCAGGGCTCAAGCGTTGCACACGGTGCACCTGTACAACAACAGCGCTGGAGCGCGTG  
 CCCAGTGGCCTGCCCTGCCCGCGCACCCCTCATGATCCTGCACAACCAGATCACAGGCAT  
 TGGCCCGAAGACTTTGCCACCA CCTACTTCTGGAGGAGCTAACCTCAGCTACAACCGCA  
 TCACCA GCCCACAGGTGCACCGCGACGCCCTCCGCAAGCTGCCCTGCTGCCCTGCTGGAC  
 CTGTCGGCAACCGGCTGCACACGCTGCCACCTGGCTGCCCTGAAATGTCCATGTGCTGAA  
 GGTCAAGCGCAATGAGCTGGCTGCCCTGGCACGAGGGCGCTGGCGGGCATGGCTAGCTGC  
 GTGAGCTGTACCTCACCAGCAACCGACTGCCAGCCGAGCCCTGGGCCCCGTGCCCTGGTG  
 GACCTGCCCATCTGCAGCTGGACATGCCGGAATCAGCTCACAGAGATCCCCGAGGG  
 GCTCCCCGAGTCACTTGAGTACCTGTACCTGCAGAACACAAGATTAGTGCAGCTGGCGCCA  
 ATGCCCTGACTCCACGCCAACCTCAAGGGATCTTCTCAGGTTAACAAAGCTGGCTGTG  
 GGCTCCGTGGACAGTGCCTCCGGAGGCTGAAGCACCTGCAGGTCTGGACATTGAAGG  
 CAACTTAGAGTTGGTGACATTCCAAGGACCGTGGCGCTGGGAAGGAAAGGAGGAGG  
 AGGAAGAGGAGGAGGAGGAGGAAGAGGAACAAAGATAGTACAAGGTGATGCAGATGTGACC  
 TAGGATGATGGACCGCCGGACTTTCTGCAGCACACGCCGTGTGCTGTGAGCCCCCAC  
 TCTGCCGTGCTCACACAGACACACCCAGCTGCACACATGAGGCATCCACATGACACGGGCT  
 GACACAGTCTCATATCCCCACCCCTCCAGGCCGTGCCCACGCCAGACACATGCACACA  
 CATCACACCCCTCAAACACCCAGCTCAGCCACACACAACCTACCCCTCAAACCCACAGTCTC  
 TGTACACACCCACTACCGCTGCCACGCCCTCTGAATCATGCAGGGAGGGCTGCCCTG  
 CCTGGCACACACAGGCCACCCATTCCCTCCCCCTGCTGACATGTGATGCGTATGCATACACA  
 CCACACACACACATGCACAAGTCATGTGCGAACAGCCCTCCAAAGGCTATGCCACAGACA  
 GCTCTGCCAGCCAGAATGCCATAGCAGCTGCCGTGCCCTGTCCATCTGTCCGT  
 CGTCCCTGGAGAAGACACAAGGTATCCATGCTCTGTGGCCAGGTGCCCTGCCACCCCTGG  
 AACTCACAAAAGCTGGCTTTATTCCCTCCATCCTATGGGGACAGGAGGCCTCAGGACTG  
 CTGGCCTGGCCTGGCCACCCCTGCTCCAGGTGCTGGGCAGTCACCTGCTAACAGACTCC  
 TCCCTGCCACGCCCTGGCAGGACACAGGCACCTTCCAATGGGAAGGCCAGTGGAGGCAGG  
 ATGGGAGAGCCCCCTGGGTGCTGCTGGGGCTTGGGGCAGGAGTGAAGCAGAGGTGATGGGG

**FIGURE 107B**

CTGGGCTGAGCCAGGGAGGAAGGACCCAGCTGCACCTAGGAGACACCTTGTCTTCAGGCC  
TGTGGGGGAAGTTCCGGGTGCCTTATTTTATTCTTCTAAGGAAAAAAATGATAAAAAA  
TCTCAAAGCTGATTTCTTGTATAGAAAAACTAATATAAAAGCATTATCCCTATCCCTGC  
AAAAAAAAAA

**FIGURE 108**

Met Glu Gly Glu Glu Ala Glu Gln Pro Ala Trp Phe His Gln Pro Trp  
 Arg Pro Gly Ala Ser Asp Ser Ala Pro Pro Ala Gly Thr Met Ala Gln  
 Ser Arg Val Leu Leu Leu Leu Leu Pro Pro Gln Leu His Leu  
 Gly Pro Val Leu Ala Val Arg Ala Pro Gly Phe Gly Arg Ser Gly Gly  
 His Ser Leu Ser Pro Glu Glu Asn Glu Phe Ala Glu Glu Glu Pro Val  
 Leu Val Leu Ser Pro Glu Glu Pro Gly Pro Gly Pro Ala Ala Val Ser  
 Cys Pro Arg Asp Cys Ala Cys Ser Gln Glu Gly Val Val Asp Cys Gly  
 Gly Ile Asp Leu Arg Glu Phe Pro Gly Asp Leu Pro Glu His Thr Asn  
 His Leu Ser Leu Gln Asn Asn Gln Leu Glu Lys Ile Tyr Pro Glu Glu  
 Leu Ser Arg Leu His Arg Leu Glu Thr Leu Asn Leu Gln Asn Asn Arg  
 Leu Thr Ser Arg Gly Leu Pro Glu Lys Ala Phe Glu His Leu Thr Asn  
 Leu Asn Tyr Leu Tyr Leu Ala Asn Asn Lys Leu Thr Leu Ala Pro Arg  
 Phe Leu Pro Asn Ala Leu Ile Ser Val Asp Phe Ala Ala Asn Tyr Leu  
 Thr Lys Ile Tyr Gly Leu Thr Phe Gly Gln Lys Pro Asn Leu Arg Ser  
 Val Tyr Leu His Asn Asn Lys Leu Ala Asp Ala Gly Leu Pro Asp Asn  
 Met Phe Asn Gly Ser Ser Asn Val Glu Val Leu Ile Leu Ser Ser Asn  
 Phe Leu Arg His Val Pro Lys His Leu Pro Pro Ala Leu Tyr Lys Leu  
 His Leu Lys Asn Asn Lys Leu Glu Lys Ile Pro Pro Gly Ala Phe Ser  
 Glu Leu Ser Ser Leu Arg Glu Leu Tyr Leu Gln Asn Asn Tyr Leu Thr  
 Asp Glu Gly Leu Asp Asn Glu Thr Phe Trp Lys Leu Ser Ser Leu Glu  
 Tyr Leu Asp Leu Ser Ser Asn Asn Leu Ser Arg Val Pro Ala Gly Leu  
 Pro Arg Ser Leu Val Leu Leu His Leu Glu Lys Asn Ala Ile Arg Ser  
 Val Asp Ala Asn Val Leu Thr Pro Ile Arg Ser Leu Glu Tyr Leu Leu  
 Leu His Ser Asn Gln Leu Arg Glu Gln Gly Ile His Pro Leu Ala Phe  
 Gln Gly Leu Lys Arg Leu His Thr Val His Leu Tyr Asn Asn Ala Leu  
 Glu Arg Val Pro Ser Gly Leu Pro Arg Arg Val Arg Thr Leu Met Ile  
 Leu His Asn Gln Ile Thr Gly Ile Gly Arg Glu Asp Phe Ala Thr Thr  
 Tyr Phe Leu Glu Glu Leu Asn Leu Ser Tyr Asn Arg Ile Thr Ser Pro  
 Gln Val His Arg Asp Ala Phe Arg Lys Leu Arg Leu Leu Arg Ser Leu  
 Asp Leu Ser Gly Asn Arg Leu His Thr Leu Pro Pro Gly Leu Pro Arg  
 Asn Val His Val Leu Lys Val Lys Arg Asn Glu Leu Ala Ala Leu Ala  
 Arg Gly Ala Leu Ala Gly Met Ala Gln Leu Arg Glu Leu Tyr Leu Thr  
 Ser Asn Arg Leu Arg Ser Arg Ala Leu Gly Pro Arg Ala Trp Val Asp  
 Leu Ala His Leu Gln Leu Leu Asp Ile Ala Gly Asn Gln Leu Thr Glu  
 Ile Pro Glu Gly Leu Pro Glu Ser Leu Glu Tyr Leu Tyr Leu Gln Asn  
 Asn Lys Ile Ser Ala Val Pro Ala Asn Ala Phe Asp Ser Thr Pro Asn  
 Leu Lys Gly Ile Phe Leu Arg Phe Asn Lys Leu Ala Val Gly Ser Val  
 Val Asp Ser Ala Phe Arg Arg Leu Lys His Leu Gln Val Leu Asp Ile  
 Glu Gly Asn Leu Glu Phe Gly Asp Ile Ser Lys Asp Arg Gly Arg Leu  
 Gly Lys Glu Lys Glu Glu

**FIGURE 109**

GGGAGGGGGCTCCGGCGCCGCGCAGCACCTGCTCCGGCGCGCCCTGCCGCTGTC  
 CTCCGGAGCGGCAGCAGTAGCCGGCGAGGGCTGGGGTCTCGAGACTCTCAG  
 AGGGCGCCTCCCATCGCGCCCACCACCCAAACCTGTTCTCGCGCCACTGCGCTGC  
 GCCCAGGACCCGCTGCCAACATGGATTCTCCTGGCGCTGGCTGGTATCCTCGCT  
 CTACCTGCAGGCAGGCCGAGTCGACGGAGGTGGCCAGGCAAATAGTGTATCGAT  
 TGGCCTATGTCGTTATGGTGGGAGGATTGACTGCTGCTGGGCTGGCTGCCAGTCTTG  
 GGGACAGTGTCAAGCCTGTGTGCCAACACAGATGCAAACATGGTAATGTATCGGGCAA  
 CAAGTGCAAGTGTATCCTGGTTATGCTGAAAAACCTGTAATCAAGATCTAAATGAGTG  
 TGGCCTGAAGCCCCGGCCCTGTAAGCACAGGTGCATGAAACACTTACGGCAGCTACAAGTG  
 CTACTGTCACGGATATATGCTCATGCCGATGGTCTGCTCAAGTGCCCTGACCTG  
 CTCCATGGCAAACGTCAAGTGTAGTGGCTGTGATGTTAAAGGACAAATACGGTGCCAGTG  
 CCCATCCCCCTGGCCTGCACCTGGCTCCTGATGGGAGGACCTGTTAGATGTTGATGAATG  
 TGCTACAGGAAGAGCCTCCTGCCCTAGATTAGGCAATGTCACACTTTGGGAGCTA  
 CATCTGCAAGTGTATAAAGGCTCGATCTCATGTATATTGGAGGCAAATATCAATGTCA  
 TGACATAGACGAATGCTCACTGGTCAGTATCAGTGCAGCAGCTTGCTCGATGTTATAA  
 CGTACGTGGGCTCCTACAAGTCAAATGTAAGAAGGATACCAGGGTGTGACTGACTTG  
 TGTGTATATCCAAAAGTTATGATTGAACTTCAGTCCAATTATGTAACAAAGGGAAA  
 TGGTACCATTTAAAGGGTACACAGGAATAATAATTGGATTCCGTGATGTTGGAAGTAC  
 TTGGTGGCCTCGAAGACACCATATATTCCCTATCATTACCAACAGGCCTACTTCTAA  
 GCCAACACAAGACCTACACCAAAAGCCAACACCAATTCTACTCCACCAACCAACCA  
 CCTGCCAACAGAGCTCAGAACACCTCTACCACCTACAACCCAGAAAGGCCAACCA  
 ACTGACAACATAGCACCAGCTGCCAGTACACCTCAGGAGGGATTACAGTTGACAACAG  
 GGTACAGACAGACCCCTCAGAAACCCAGAGGAGATGTTGCTAGTGTCTGGTACACAGTTG  
 TAATTGGACCATGGACTTGTGGATGGATCAGGGAGAAAGACAATGACTTGCACTGGGA  
 ACCAACAGGGACCCAGCAGGTGACAATATCTGACAGTGTGGCAGCCAAGGCCAGG  
 GGGAAAAGCTGCACGCTGGCTACCTCTGGCCCTCATGCATTAGGGACCTGTG  
 CCTGTCATTAGGACAAGGTGACGGGCTGCACTCTGGCACACTCCAGGTGTTGAG  
 AAAACACGGTGCCACGGAGCAGCCCTGTGGGGAGAAATGGTGGCCATGGCTGGAGGCA  
 AACACAGATCACCTGCGAGGGCTGACATCAAGAGCAATCACAAAGATGATTAAAGGG  
 TTGGAAAAAAAGATCTATGATGGAAAATTAAAGGAACGGGATTATTGAGCCTGGAGAAG  
 AGAAGACTGAGGGGCAAACCAATTGATGGTTCAAGTATATGAAGGGTTGGCACAGAGAG  
 GGTGGCGACCAGCTGTTCTCCATATGCACAAAGAATAGAACAGAGGAAACTGGCTTAGA  
 CTAGAGTATAAGGGAGCATTCTGGCAGGGCCATTGTTAGAATACTTCATAAAAAAAG  
 AAGTGTGAAAATCTCAGTATCTCTCTTTCTAAAAAATTAGATAAAATTGTCTAT  
 TTAAGATGGTTAAAGATGTTCTACCCAAAGGAAAAGTAACAAATTATAGAATTCCAAA  
 AGATGTTTGATCCTACTAGTAGTATGCAAGTGAAAATCTTAACTAAATAATTGGAC  
 AAGGCTTAATTAGGCACTTCCCTCTGACCTCTAAATGGAGAGGGATTGAAAGGGGAAG  
 AGCCCACCAATGCTGAGCTCACTGAAATATCTCTCCCTATGGCAATCCTAGCAGTATT  
 AAAGAAAAAAGGAAACTATTATCCAAATGAGAGTATGATGGACAGATATTAGTATC  
 TCAGTAATGCTCTAGTGTGGCGGTGGTTCAATGTTCTCATGGTAAAGGTATAAGCC  
 TTTCATTGTCATGGATGATGTTCAGATTTTTTTTAAGAGATCCTCAAGGA  
 ACACAGTTCAGAGAGATTTCATGGGTGCATTCTCTCTGCTCGTGTGACAAGTTAT  
 CTTGGCTGCTGAGAAAGAGTGCCCTGCCAACACGGGAGACCTTCTCACCTCATCA  
 GTATGATTAGTCTCTTATCAATTGGACTCTCCAGGTTCCACAGAACAGTAATATT  
 TTTGAACAATAGGTACAATAGAAGGTCTCTGTCATTAACTGGTAAAGGCAGGGCTGG  
 AGGGGAAAATAATCATTAAGCCTTGAGTAACGGCAGAATATATGGCTGTAGATCCAT  
 TTTTAATGGTCATTCCTTATGGTCATATAACTGACAGTGAAGATGAAAGGGAAA  
 ATAAATGAAAATTTCAGTTGCAATGATAACATTGCACTAAACTGATGAAAGAAG  
 TTATCCAAAGTACTGTATAACATCTGTTATTATTAATGTTCTAAAATAAAAATG  
 TTAGTGGTTTCCAAATGGCTAATAAAAACAATTATGTAAATAAAACACTGTTAGT  
 AAT

**FIGURE 110**

```
><signal peptide>
MDFLLALVLVSSLYLQA
><start mature protein>
AAEFDGRWPRQIVSSIGLCRYGGRIDCCWGWARQSWGQCQPV
><EGF-like repeats, 60-253>
COPRCKHGE CIGPNKCKCHPGYAGKTCNQDLNECGLKPRPC KHRCMNTYGSYKCYCLNGYML
MPDGSCSSALTCSMANCQYGCDVVKGQIRCQCPSPGLHLAPDGRTCDVDECATGRASCPRF
RQCVNTFGSYICKCHKGFDL MYIGGKYQCHDIDECSLGQYQCSSFARCYNVRGSYKCKCKEG
YQGDGLTCVYIPKVMIEPSGPIHVPKG
><potential N-glycosylation site>
NGTILKGDTGNNNWIPDVGSTWWPPKTPYIPPIITNRPTSKPTTRPTPKPTPIPTPPPPPPL
PTELRTPLPPTPERPTTGLTTIAPAASSTPPGGITVDNRVQTDPQKPRGDVFSLVHSCNFD
HGLCGWIKEKDNDLHWEPIRD PAGGQYLTVSAAKAPGGKAARLVLPLGRLMHSDLCLSFRH
KVTGLHSGTLQVFVRKHGAHGAALWGRNGGHGWRQTQITLRGADIKSESQR
```

**FIGURE 111**

CTTCTTGAAAAGGATTATCACCTGATCAGGTCTCTGCATTTGCCCTTAGATTGTGA  
AATGTGGCTCAAGGTCTCACACTTCCCTTGCAACAGGTGCTGCTCGGGGCTGA  
AGGTGACAGTGCCATCACACACTGTCCATGGCGTCAGAGGTCAAGGCCCTACCTACCCGTC  
CACTATGGCTTCCACACTCCAGCATCAGACATCCAGATCATATGGCTATTGAGAGACCCCA  
ACAATGCCCAAATACTTACTGGGCTCTGTGAATAAGTCTGTGGTCTGACTTGAATACC  
AACACAAGTTACCATGATGCCACCCAATGCATCTGCTTATCAACCCACTGCAGTCCCT  
GATGAAGGCAATTACATCGTGAAGGTCAACATTCAAGGAAATGGAACCTATCTGCCAGTCA  
GAAGATACAAGTCACGGTGTGATGATCCTGTCACAAAGCCAGTGGTGCAGATTCACTCCCT  
CTGGGCTGTGGAGTATGTGGGAACATGACCTGACATGCCATGTGGAAGGGGCACTCGG  
CTAGCTTACCAATGGCTAAAAAATGGGAGACCTGTCCACACCAGCTCCACCTACTCCTTT  
TCCCCAAAACAATACCCCTCATATTGCTCAGTAACCAAGGAAGACATTGGAAATTACAGCT  
GCCTGGTGAGGAACCTGTCAGTGAAATGGAAAGTGATATCATTATGCCCATCATATATT  
GGACCTTATGGACTTCAAGTGAATTCTGATAAAGGGCTAAAGTAGGGGAAGTGTACTGT  
TGACCTTGGAGAGGCCATCCTATTGATTGTTCTGCTGATTCTCATCCCCAACACCTACT  
CCTGGATTAGGAGGACTGACAATACTACATATATCATTAAGCATGGCCTCGCTTAGAAGTT  
GCATCTGAGAAAGTAGCCCAGAAGACAATGGACTATGTGTGCTGTGCTTACAACAACATAAC  
CGGCAGGCAAGATGAAACTCATTCACAGTTACATCACTTCCGTAGGACTGGAGAAGCTTG  
CACAGAAAGGAAATCATGTACCTTAGCAAGTATAACTGGAATATCACTATTTTGATT  
ATATCCATGTCTTCTTCTTCTATGGAAAAAATATCAACCCCTACAAAGTTATAAAACAGAA  
ACTAGAAGGCAGGCCAGAAACAGAATACAGGAAGCTCAAACATTTCAGGCCATGAAGATG  
CTCTGGATGACTTCGGAATATATGAATTGTTGCTTCCAGATGTTCTGGTGTTCAGG  
ATTCCAAGCAGGTCTGTTCCAGCCTCTGATTGTGATCGGGGCAAGATTGCACAGTACAGT  
GTATGAAGTTATTCAAGCACATCCCTGCCAGCAGCAAGACCATTCCAGAGTGAACTTCATGG  
GCTAACACGTACATTCAAGTGAAGAAACATTAAAGGAAAACAGTGGAAAAGT  
ATATTAATCTGGAATCAGTGAAGAAACCAGGACCAACACCTTACTCATTATCCTTACA  
TGCAGAATAGAGGCATTATGCAAATTGAACTGCAGGTTTCAGCATATACACAATGTCTT  
GTGCAACAGAAAACATGTTGGGAAATATTCCCTCAGTGGAGAGTCGTTCTCATGCTGACGG  
GGAGAACGAAAGTGACAGGGTTCTCATAAGTTGTATGAAATATCTCACAAACCTCA  
ATTAGTTCTACTCTACACTTCACTATCATCAACACTGAGACTATCCTGTCTCACCTACAAA  
TGTGGAAACTTACATTGTTGATTTCACTTCAATTAACTTCTATCTTGTATTTGACAA  
TTAAGAATGCTAAATTATGTTCAATTAACTTCAATTAACTTCTATCTTGTATTTGACAA  
CAAAGTAATAAGGATGGTTGTCACAAAACAAACTATGCCCTCTTTTTCAATCACC  
AGTAGTATTGGAGAAGACTGTGAACACTTAAGGAAATGACTATTAAAGTCTTATTGTTA  
TTTTTTCAAGGAAAGATGGATTCAAATAATTCTGTTTGCTTTAAAAA

**FIGURE 112**

Met Trp Leu Lys Val Phe Thr Thr Phe Leu Ser Phe Ala Thr Gly Ala Cys Ser Gly Leu Lys Val Thr Val Pro Ser His Thr Val His Gly Val Arg Gly Gln Ala Leu Tyr Leu Pro Val His Tyr Gly Phe His Thr Pro Ala Ser Asp Ile Gln Ile Ile Trp Leu Phe Glu Arg Pro His Thr Met Pro Lys Tyr Leu Leu Gly Ser Val Asn Lys Ser Val Val Pro Asp Leu Glu Tyr Gln His Lys Phe Thr Met Met Pro Pro Asn Ala Ser Leu Leu Ile Asn Pro Leu Gln Phe Pro Asp Glu Gly Asn Tyr Ile Val Lys Val Asn Ile Gln Gly Asn Gly Thr Leu Ser Ala Ser Gln Lys Ile Gln Val Thr Val Asp Asp Pro Val Thr Lys Pro Val Val Gln Ile His Pro Pro Ser Gly Ala Val Glu Tyr Val Gly Asn Met Thr Leu Thr Cys His Val Glu Gly Gly Thr Arg Leu Ala Tyr Gln Trp Leu Lys Asn Gly Arg Pro Val His Thr Ser Ser Thr Tyr Ser Phe Ser Pro Gln Asn Asn Thr Leu His Ile Ala Pro Val Thr Lys Glu Asp Ile Gly Asn Tyr Ser Cys Leu Val Arg Asn Pro Val Ser Glu Met Glu Ser Asp Ile Ile Met Pro Ile Ile Tyr Tyr Gly Pro Tyr Gly Leu Gln Val Asn Ser Asp Lys Gly Leu Lys Val Gly Glu Val Phe Thr Val Asp Leu Gly Glu Ala Ile Leu Phe Asp Cys Ser Ala Asp Ser His Pro Pro Asn Thr Tyr Ser Trp Ile Arg Arg Thr Asp Asn Thr Thr Tyr Ile Ile Lys His Gly Pro Arg Leu Glu Val Ala Ser Glu Lys Val Ala Gln Lys Thr Met Asp Tyr Val Cys Cys Ala Tyr Asn Asn Ile Thr Gly Arg Gln Asp Glu Thr His Phe Thr Val Ile Ile Thr Ser Val Gly Leu Glu Lys Leu Ala Gln Lys Gly Lys Ser Leu Ser Pro Leu Ala Ser Ile Thr Gly Ile Ser Leu Phe Leu Ile Ile Ser Met Cys Leu Leu Phe Leu Trp Lys Lys Tyr Gln Pro Tyr Lys Val Ile Lys Gln Lys Leu Glu Gly Arg Pro Glu Thr Glu Tyr Arg Lys Ala Gln Thr Phe Ser Gly His Glu Asp Ala Leu Asp Asp Phe Gly Ile Tyr Glu Phe Val Ala Phe Pro Asp Val Ser Gly Val Ser Arg Ile Pro Ser Arg Ser Val Pro Ala Ser Asp Cys Val Ser Gly Gln Asp Leu His Ser Thr Val Tyr Glu Val Ile Gln His Ile Pro Ala Gln Gln Asp His Pro Glu

**FIGURE 113**

GCAAGCGGCGAA  
 ><MET {trans=1-s, dir=f, res=1}  
 ATGGCGCCCTCGGGAGTCCTGCAGTCCCCCTGGCAGTCCTGGTGCTGTTGCTTGGGT  
 GCTCCCTGGACGCACGGCGGCCGAGCAACGTTCGCGTCATACGGACGAGAACTGGAGA  
 GAACTGCTGGAAGGAGACTGGATGATAGAATTATGCCCGTGGTGCCTGCTTGTCAA  
 AATCTCAACCGGAATGGGAAAGTTTGCTGAATGGGGAGAAGATCTGAGGTTAATATT  
 GCGAAAGTAGATGTCACAGAGCAGGCCAGGACTGAGTGGACGGTTATCATAACTGCTCTT  
 CCTACTATTTATCATTGAAAGATGGTGAATTAGGCGCTATCAGGGTCCAAGGACTAAG  
 AAGGACTTCATAAACTTATAAGTGATAAAGAGTGGAAAGAGTATTGAGCCGTTCATCA  
 TGGTTGGTCCAGGTTCTGTTGATGAGTAGTATGTCAGCACTCTTCAGCTATCTATG  
 TGGATCAGGACGTGCCATAACTACTTATTGAAGACCTTGGATTGCCAGTGTGGGATCA  
 TATACTGTTTGCTTGTAGCAACTCTGTTCCGGACTGTTATTAGGACTCTGTATGATA  
 TTTGTGGCAGATTGCCTTGTCTTCAAAAAGGCGCAGACCACAGCCATACCCATACCC  
 TCAAAAAAATTATTATCAGAATCTGCACAACCTTGAAAAAGTGGAGGAGAACAGAG  
 GCGGATGAAGAAGATGTTCAGAAGAAGAAGCTGAAAGTAAAGAAGGAACAAACAAAGAC  
 TTTCCACAGAATGCCATAAGACAACGCTCTGGTCCATCATTGCCACAGATAATCC  
 TAGTTAAATTATAGTTATCTTAATATTATGATTGATAAAACAGAAGATTGATCAT  
 TTTGTTGGTTGAAGTGAACCTGACTTTTGATATTGAGGGTTCACTAGTCTAGATTG  
 TCATTAATGAAAGACTCACATTGAAACATAAAAGCACTAGGTATAAGTTGAAAT  
 ATGATTAAGCACAGTATGATGGTTAAATAGTTCTAATTGAAATCGTCCAA  
 GCAATAAGATTATGATATTGTTAAATAATAACCTATTCAAGTCTGAGTTGAAAAA  
 TTTACATTCCCAAGTATTGCATTATTGAGGTATTAAAGAAGATTATTGAGGAAAT  
 ATTCTCATTTGATATAATTCTCTGTTCACTGTGTGAAAAAAAGAAGATATTCCC  
 ATAAATGGGAAGTTGCCATTGCTCAAGAAATGTGTATTCACTGACAATTCTGTGGT  
 CTTTTAGAGGTATATTCCAAAATTCTGTATTAGTTAGGTTATGCAACTAATAAAAC  
 TACCTTACATTAATTAAATTACAGTTCTACACATGGTAATACAGGATATGCTACTGATT  
 TAGGAAGTTTAAGTTCATGGTATTCTCTGATTCCAACAAAGTTGATTCTCTGT  
 ATTGTTCTTACTATGGTTACATTGTTATTGAAATTGGATGATAATTCTTG  
 GAAACATTGTTATGTTAGTAAACAGTATTGTTGTTCAAACACTGAAGTTACT  
 GAGAGATCCATCAAATTGAAACAACTGTTGAATTAAATTGAGGCACTTTTCAGA  
 TTTTACATCATCTGCTGAACCTCAACTGAAATTGTTTTCTCTGGATGTG  
 AAGGTGAACATCCTGATTGCTGATGTGAAAAAGCCTGGTATTACATTTGAA  
 AATTCAAAGAAGCTTAATATAAAAGTTGCAATTCTACTCAGGAAAAAGCATCTTCTGT  
 TATGTCTTAAATGTATTGTCCTCATATACAGAAAGTTCTAATTGATTTCAGTCT  
 GTAATGCTTGATGTTAAAATAACATTGTTATTGTTAAAAGACAAACTTCATA  
 TTATCCTGTGTTCTTCTGACTGGTAATTGTTGAGGATTTCACAGGTAAAGTCAGT  
 AGGATGGAACATTAGTGTATTCTACTCCTAAAGAGCTAGAATACATAGTTTCACC  
 TTAAGAAGGGGGAAATCATAAATACAATGAATCAACTGACCAATTACGTAGACAA  
 TTTCTGTAATGCCCCCTCTTCTAGGCTCTGTTGTTGAATTGAGGATTACAG  
 TATCGTAATATACAAGTTCTTAAAGCCCTCTCCTTGAATTAAATATTGTACCA  
 TTAAAGAGTTGGATGTGAACTTGTGATGCCTTAGAAAATATCCTAAGCACAAATAA  
 ACCTTCTAACCACTCATTAAAGCTGAAAAAAAAAAAAAA

**FIGURE 114**

MAPSGSLAVPLAVLVLLLWGAPWTHGRRSNVRVITDENWRELLEGDWMIIFYAPWCPACQ  
NLQPEWESFAEWGEDLEVNIAKVDVTEQPGLSGRFIITALPTIYHCKDGEFRRYQGPRTK  
KDFINFISDKEKSIEPVSSWFGPGSVLMSMSALFQLSMWIRTCHNYFIEDLGLPVWGS  
YTVFALATLFSGLLLGLCMIFVADCLCPSKRRRPQYPYPSKKLLSESAQPLKKVEEEQE  
ADEEDVSEEEAESKEGTNKDFPQNAIRQRSLGPSLATDKS

**FIGURE 115**

GCAGTGTCCAGCTGGAGACCGTGATAATTGTTAACTAATTCAACAAACGGGACCC  
TTCTGTGTGCCAGAAACCGCAAGCAGTGTCAACCAGTGGGACAGGGGGATTGGAAGAG  
CGGGAAAGGTCTGGCCCAGAGCAGTGTGACACTTCCTCTGTGACC  
><MET {trans=1-s, dir=f, res=1}  
ATGAAACTCTGGGTGTCATTGCTGATGGCCTGGTTGGTGCCTGAGCTGTGTCAG  
GCCGAATTCTCACCTTATTGGGCACATGACTGACCTGATTTATGCAGAGAAAGAGCTG  
GTGCAGTCTCTGAAAGAGTACATCCTGTGGAGGAAGCCAAGCTTCCAAGATTAAGAGC  
TGGGCAACAAAATGGAAGCCTTGACTIONCAAGTCAGCTGCTGATGCTGAGGGCTACCTG  
GTCACCCCTGTGAATGCCTACAAACTGGTGAAGCGCTAACACAGACTGGCCTGCGCTG  
GAGGACCTTGTCTGCAGGACTCAGCTCAGGTTTATGCCAACCTCTGTGAGCGG  
CAGTTCTCCCCACTGATGAGGACGAGATAGGAGCTGCAAAGCCCTGATGAGACTTCAG  
GACACATACAGGCTGGACCAGGCACAATTCCAGAGGGAACTTCCAGGAACCAAGTAC  
CAGGCAATGCTGAGTGTGGATGACTGCTTGGATGGCCGCTCGGCCTACAATGAAGGG  
GACTATTATCATACGGTGTGGATGGAGCAGGTGCTAAAGCAGCTTGATGCCGGGAG  
GAGGCCACCAACCAAGTCACAGGTGCTGGACTACCTCAGCTATGCTGCTCCAGTTG  
GGTGAATGCAACCGTGCCTGGAGCTCACCCGCCCTGCTCTCCCTGACCCAAGCCAC  
GAACGAGCTGGAGGGAACTGCGGTACTTGAGCAGTTGGAGGAAGAGAGAGAAAAAA  
ACGTTAACAAATCAGACAGAAGCTGAGCTAGCAACCCAGAAGGCATCTATGAGAGGCCT  
GTGGACTACCTGCCTGAGAGGGATTTACGAGAGCCCTGCTGCTGGGAGGGTGTCAAA  
CTGACACCCCGTAGACAGAAGAGGCTTTCTGTAGGTACCAACATGGCAACAGGGCCCCA  
CAGCTGCTATTGCCCTTCAAAGAGGAGGACGAGTGGACAGCCGCACATGTCAGG  
TACTACGATGTCATGTCATGAGGAAATCGAGAGGATCAAGGAGATCGCAAACCTAAA  
CTTGCACGAGCCACCGTCTGTGATCCAAGACAGGAGCTCTACTGTCGCCAGCTACCGG  
GTTTCAAAGCTCCTGGCTAGAGGAAGATGATGACCCCTGTTGGCCGAGTAAATCGT  
CGGATGCAGCATATCACAGGTTAACAGTAAAGACTGCAGAATTGTTACAGGTGCAAAT  
TATGGAGTGGGAGGACAGTATGAACCGCACTCGACTTCTCTAGGCACCTTGACAGC  
GGCCTCAAAACAGAGGGAAATAGGTTAGCGACGTTCTTAACATGAGTGTAGAA  
GCTGGTGGTGCCACCGTCTCCCTGATCTGGGCTGCAATTGGCTAAGAAGGGTACA  
GCTGTGTTCTGGTACAACCTCTGCGAGGGGGAGGTGACTACCGAACAGACATGCT  
GCCTGCCCTGTGCTTGTGGCTGCAAGTGGGCTCCAATAAGTGGTCCATGAACGAGGA  
CAGGAGTTCTTGAGACCTTGTGGATCAACAGAAGTTGACTGACATCCTTCTGTCTTC  
CCCTCCTGGCTTCAAGCCATGTCAACGTGACAGACACCTTGATGTTCTTGTAT  
GTTCTATCAGGCTGATTTGGAGAAATGAATGTTGTCTGGAGCAGAGGGAGACCATA  
CTAGGGCGACTCCTGTGTGACTGAAGTCCAGCCCTTCCATTGAGCCTGTGCCATCCCTG  
GCCCAAGGCTAGGATCAAAGTGGCTGCAGCAGAGTTAGCTGTCTAGCGCTAGCAAGGT  
GCCTTGTACCTCAGGTGTTTAGGTGTGAGATGTTCAGTGAACCAAAGTCTGATACC  
TTGTTTACATGTTGTTTATGGCATTCTATCTATTGTGGCTTACCAAAAAATAAAA  
TGTCCCTACCAAGAAAAAA

**FIGURE 116**

<ptide>  
VSALLMAWFGVLS  
<t mature protein>  
QAEFFTSIGHMTDLIYAEKELVQSLKEYILVEEAKLSKIKSWANKMEALTSKSAADAE  
GYLAHPVNAYKLVKRLNTDWPALEDLVLQDSAAGFIA  
><N-glycosylation site.>  
NLSVQRQFFPTDEDEIGAAKALMRLQDTYRLDPGTISRGELPGTKYQAMLSVDDCF  
GMGRSAYNEGYYHTVLWMEQVLKQLDAGEEATTKSQVLDY  
><potential Leucine zipper 213-234>  
LSYAVFQLGDLHRALELTRLLSLDPSHERAGGNLRYFEQLLEEEREKTLT  
><N-glycosylation site.>  
NQTEAELATPEGIYERPVDPYLPERDVYESLCRGEVKLTPRRQKRLFCRYHHGNRAP  
QLLIAPFKEEDEWDSPHIVRYYDVMSEEEIERIKEIAPKKLARATVRDPKTGVLTVAS  
YRVSKSSWLEEDDPVVARVNRRMQHITGLTVKTAELLQVANYGVGGQYEPHFDFSR  
RRPFDSGLKTEGNRLATFLNYMSDVEAGGATVFPDLGAAIWPKKGTAVFWYNLLRS  
GEGDYRTRHAACPVLVGCKWVSNKWFHERGQEFLRPCGSTEVD

## FIGURE 11.7

GCAGTATTGAGTTTACTCCTCCTTTAGTGGAAAGACAGACCATAATCCAGTGTGAG  
TGAAATTGATTGTTCATTTATTACCGTTTGGCTGGGGTAGTTCCGACACCTTCACAGT  
TGAAGAGCAGGCAGAAGGAGTTGTGAAGACAGGACAATCTTCTTGGGGATGCTGGTCTGGA  
AGCCAGCGGGCTTGCTCTGTCTTGGCCTCATTGACCCCAGGTCTCTGGTTAAAAGTCAA  
AGCCTACTACTGGCCTGGTGCCCATCAATCCATTGATCCTTGAGGCTGTGCCCCGGCAC  
CCACCTGGCAGGGCTTACACCAGCGACTGAGCTCCCTGTTGGCTCTGCTGCCAGCGC  
TTCCCCTCATCTTAGGCTGTCTGGGTGCAGCCTGAGCCTCCTGCCGGTTCCCTGGATC  
CAGGGGGAGGGAGAAGATCCCTGTGTCGAGGCTGTAGGGGAGCGAGGAGGGCACAGAAC  
AGATTGAGAGCTCGGCTAGACCAAAGTGTGAAGACTTCAAACCCGGATTGTCCCCTACT  
ACAGGGACCCCAACAAGCCCTACAAGAAGGTGCTCAGGACTCGGTACATCCAGACAGAGCTG  
GGCTCCCGTGAGCGGTTGCTGGGTGCTGACCTCCCGAGCTACACTGTCCACTTTGGC  
CGTGGCTGTGAACCGTACGGTGGCCCATCACTTCCCTCGGTTACTCTACTTCAGGGCAGC  
GGGGGGCCCGGGCTCCAGCAGGGATGCAAGGTGGTCTCATGGGGATGAGCGGGCCCTGG  
CTCATGTCAGAGACCCCTGCCACCTTCACACACACTTGGGGCGACTACGACTGGTTCTT  
CATCATGCAAGGATGACACATATGTGCAAGGCCCCCGCTGGCAGCCCTGCTGCCACCTCA  
GCATCAACCAAGACACTGTACTTAGGCCGGCAGAGGAGTTCAATTGGCGCAGGGCAGCAGGCC  
CGGTACTGTATGGGGCTTGGCTACCTGTTGTCACGGAGTCTCTGCTCGTCTGCC  
ACATCTGGATGGCTGCCAGGGAGACATTCTAGTGCCGTCTGACGAGTGGCTGGACGCT  
GCCTCATTGACTCTCTGGCGTGGCTGTCTCACAGCACCCAGGGCAGCAGTATCGCTCA  
TTTGAACCTGGCAAAATAGGGACCTGAGAAGGAAGGGAGCTCGGCTTCTGAGTGCCTT  
CGCCGTGCACCCCTGTCTCGAAGGTACCCCATGTACCGGCTCCACAAACGCTCAGCGCTC  
TGGAGTTGGAGCGGGCTTACAGTGAATAGAACAACTGCAGGCTCAGATCCGAAACCTGACC  
GTGCTGACCCCCGAAGGGAGGCAGGGCTGAGCTGGCCGTTGGCTCCCTGCTCCTTCA  
ACCACACTCTCGCTTGAGGTGCTGGCTGGACTACTTCACAGAGCAGCACACCTTCTCCT  
GTGCAAGATGGGCTCCAAGTGCCACTACAGGGGCTAGCAGGGCGGACGTGGTGTGCG  
TTGGAGACTGCCCTGGAGCAGCTCAATCGCGCTATCAGCCCCGCTGCGCTTCCAGAAC  
GCGACTGCTCAACGGCTATCGCGCTTCCAGCAGGGCATGGAGTACACCCCTGGACC  
TGCTGTTGAATGTGTGACACAGCGTGGCACCAGGGGGCCCTGGCTCGCAGGGTCA  
CTGCGGCCACTGAGCGGGTGGAAATCCTACCTATGCCCTATGTCAGTGGCCACCCGAGT  
GCAGCTGGTGTGCCACTCCTGGCTGAGCTGCTGCAGCCCCGGCTTCCCTGAGGGT  
TTGCAGCCAATGTCCTGGAGCCACGAGAACATGCATTGCTACCCCTGTTGCTGGTCA  
CCACGAGAAGGTGGCCGTGGAGCTCCAGACCCATTCTGGGGTAAGGCTGCAGCGGA  
GTTAGAGCGACGGTACCCCTGGGACGAGGCTGGCCTGGCTCGTGTGCGAGCAGAGGCC  
CCCAGGTGCGACTCATGGACGTTGCTCGAAGAAGCACCCTGTGGACACTCTCTTCTC  
ACCACCGTGTGGACAAGGCCTGGGGCGAAGTCCTCAACCGCTGTCGATGAATGCCATCTC  
TGGCTGGCAGGCCTCTTCCAGTCCATTCCAGGAGTTCAATCCTGCCCTGTCACCACAGA  
GATCACCCCCAGGGCCCCCGGGGCTGGCCCTGACCCCCCTCCCTGGTGTGACCCCC  
TCCCGGGGGCTCCTATAGGGGGAGATTGACGGCAGGCTCTGCGGAGGGCTGCTTCTA  
CAACGCTGACTACCTGGCGGCCGAGCCCCGGCTGGCAGGTGAACCTGGCAGGCCAGGAAGAGG  
AGGAAGCCCTGGAGGGCTGGAGGTGATGGATGTTCTCCGGTTCTCAGGGCTCCACCTC  
TTTCGGGCCGTAGAGCCAGGGCTGGTGCAGAAGTTCTCCCTGCGAGACTGCAGCCCACGGCT  
CAGTGAAGAACTCTACCAACCGCTGCCGCTCAGCAACCTGGAGGGCTAGGGGGCGTGGCC  
AGCTGGCTATGGCTCTTGTGAGCAGGACAGGCCAATAGCACTTAGCCCGCTGGGGGCC  
TAACCTCATTACCTTCCCTTGCTGCCAGCCCCAGGAAGGGCAAGGCAAGATGGTGGAC  
AGATAGAGAATTGTTGCTGTATTTAAATGAAAATGTTATTAAACATGTCTCTGCC

**FIGURE 118**

><signal peptide>  
MRLSSLLALLRPALP  
><start mature protein>  
LILGLSLGCSLSLLRVSWIQGEGEDPCVEAVGERGGPQNPDZRARLDQSDEDFKPRIVPY  
YRDPNPKPYKKVLRTRYIQTTELGSRERLLVAVLTSRATLSTLAVAV  
><potential N-glycosylation site>  
NRTVAHHFPRLLYFTGQRGARAPAGMQVVSHGDERPAWLMSETLRHLHTHFGADYD  
><homology to radical fringe -177-241>  
WFFIMQDDTYVQAPRLAALAGHLSINQDLYLGRAEEFIGAGEQARYCHGGFGYLLSRSSLR  
LRPHLDGCRGDILSARPDEWLGRCLIDSLGVGCVSQHQGQQYRSFELAKNRDPEKEGSSAFL  
SAFAVHPVSEGTLMYRLHKRFSALELERAYSEIEQLQAQIR  
><potential N-glycosylation site>  
NLTVLTPEGEAGLSWPVGLPAPFTPNSRFEVLGWDYFTEQHTFSCADGAPKCPLQGASRADV  
GDALETALEQLNRRYQPRLRFQKQRLLNGYRRFDPARGMETYLDLLLECVTQRGHRRALARR  
VSLLRPLSRVEILPMPYVTEATRVQLVPLLVAEAAAAPAFLEAFAANVLEPREHALLTL  
VYGPREGGRGAPDPFLGVKA  
AAAELERRYPGTRLAWLAVRAEAPSQVRLMDVVSKKHPVD  
FFLTTWTRPGPEVLRCRMNAISGWQAFFPVHFQEFNPALSPQRSPPGPPGAGPDPPSPG  
ADPSRGAPIGGRFDRQASAEGCFYNADYLAA  
RARLAVNWQARKRRKPLEGLEVMDVFLRFSG  
LHLFRAVEPGLVQKFSLRDCSPRLSEELYHRCRLSNLEG  
LGGRAQLAMALFEQE  
QANST

**FIGURE 119**

CGGAGTGGTGCGCCAACGTGAGAGGAACCCGTGCGCGCTGCCTTCCTGTCCCCAAGCC  
GTTCTAGACGCCGGAAAAATGCTTCTGAAAGCAGCTCCTTTGAAGGGTGTATGCTTGG  
AAGCATTTCTGTGCTTGATCACTATGCTAGGACACATTAGGATTGGTATGGAAATAGAA  
TGCACCACCATGAGCATCATCACCTACAAGCTCTAACAAAGAAGATATCTGAAAATTCA  
GAGGATGAGCGCATGGAGCTCAGTAAGAGCTTCGAGTATACTGTATTATCCTGTAAAACC  
CAAAGATGTGAGTCTTGGGCTGCAGTAAGAGACTGGACCAAACACTGTGACAAAGCAG  
AGTTCTCAGTTCTGAAAATGTTAAAGTGTGAGTCATTAATATGGACACAAATGACATG  
TGGTTAATGATGAGAAAAGCTTACAAATACGCCCTTGATAAGTATAGAGACCAATACAAC  
GTTCTCCTTGCACGCCCACTACGTTGCTATCATTGAAAACCTAAAGTATTTTGTAA  
AAAAGGATCCATCACAGCCTTCTATCTAGGCCACACTATAAAATCTGGAGACCTTGAATAT  
GTGGGTATGGAAGGAGGAATTGTCTTAAGTGTAGAATCAATGAAAAGACTTAACAGCCTCT  
CAATATCCCAGAAAAGTGTCTGAACAGGGAGGGATGATTGGAAGATATCTGAAGATAAAC  
AGCTAGCAGTTGCCTGAAATATGCTGGAGTATTGAGAAAATGCAGAAGATGCTGATGGA  
AAAGATGTATTAATACCAAATCTGTTGGCTTCTATTAAAGAGGCAATGACTTACACCC  
CAACCAGGTAGTAGAAGGCTGTTGTCAGATATGGCTGTTACTTTAATGGACTGACTCAA  
ATCAGATGCATGTGATGATGTATGGGTATACCGCCTTAGGGCATTGGGATATTTCAAT  
GATGCATTGGTTTCTTACCTCAAATGGTCTGACAATGACTGAGAAGTGGTAGAAAAGCG  
TGAATATGATCTTGTATAGGACGTGTGTCATTATTTGAGTAGTAACATACATATCAA  
TACAGCTGTATGTTCTTTCTTCTAATTGGTGGCACTGGTATAACCACACATTAAAG  
TCAGTAGTACATTTAAATGAGGGTGGTTTTCTTTAAAACACATGAACATTGAAATG  
TGTTGGAAAGAAGTGTGTTAAGAATAATAATTGGCAAATAACTATTAATAAAATTATAT  
GTGATAAAATTCTAAATTATGAACATTAGAAATCTGTGGGCACATATTTGCTGATTGGTT  
AAAAAAATTAAACAGGTCTTAGCGTTCTAAGATATGCAAATGATATCTCTAGTTGTGAATT  
TGTGATTAAGTAAAACCTTAGCTGTGTGTTCCCTTACTCTAATACTGATTATGTTCT  
AAGCCTCCCCAAGTTCCAATGGATTGCCTCTCAAAATGTACAACTAAGCAACTAAAGAAA  
ATTAAAGTGAAGTTGAAAAT

**FIGURE 120**

&gt;&lt;signal peptide&gt;

MLSESSSFLKGVMLGSIFCALITMLGHIRIGHG

&gt;&lt;start mature protein&gt;

NRMHHHEHHHLQAPNKEDILKISEDERMELSKSFRVYCILVKPKDVSLWAAVKETWT  
TKHCDKAEFFSSENVKFESINMDTNDMWLMMRKAYKYAFDKYRDQYNWFFLARP  
TTFAIENLKYFLLKKDPSQPFYLGHТИKSGDLEYVGMEGGIVLSVESMKRLNSLLNIP  
EKCPEQGGMIWKISEDKQLAVCLKYAGVFAENAEDADGKDVFNTKSVGLSIKEAMT  
YHPNQVVEGCCSDMAVTFNGLTPNQMHVMMYGVYRLRAFGHIFNDALVFLPP

&gt;&lt;potential N-glycosylation site&gt;

NGSDND

**FIGURE 121**

CCACCGCGTCCGATCTTACCAACAAACACTCCTGAGGAGAAAGAAAGAGAGGGAGGGAGAG  
AAAAAGAGAGAGAGAGAAACAAAAACCAAAGAGAGAGAAAAATGAATTCATCTAAATCAT  
CTGAAACACAATGCACAGAGAGAGGATGCTCTCTCCAAATGTTCTATGGACTGTTGCT  
GGGATCCCCATCCTATTCTCAGTGCCTGTTCATCACCAGATGTGTTGACATTCGCAT  
CTTCAAACCTGTGATGAGAAAAAGTTCAGCTACCTGAGAATTCACAGAGCTCCTGCT  
ACAATTATGGATCAGGTTCACTGAGAACATTGTTGTCATTGAACGGAAATTTCAATCC  
AGCTGCTACTTCTTCTACTGACACCATTCCCTGGCGTTAAGTTAAAGAACTGCTCAGC  
CATGGGGCTCACCTGGTGGTTATCAACTCACAGGAGGAGCAGGAATTCCCTTACAAGA  
AACCTAAAATGAGAGAGTTTTATTGGACTGTCAGACCAGGTTGTCAGGGTCAGGGCAA  
TGGGTGGACGGCACACCTTGACAAAGTCTGAGCTCTGGATGTAGGGAGGCCAACAA  
CATAGCTACCCCTGGAGGACTGTGCCACCATGAGAGACTCTCAAACCCAAGGCAAAATTGGA  
ATGATGTAACCTGTTCTCAATTATTTGGATTGTGAAATGGTAGGAATAATCCTTG  
AACAAAGGAAATCTTTAAGAACAGAAGGCACAACCAAATGTGAAAGAAGGAAGAGCA  
AGAACATGGCCACACCCACCGCCCCACCGAGAAATTGTCGCTGAACCTCAAAGGACTTC  
ATAAGTATTGTTACTCTGATAACAAATAAGTAGTTAAATGTTAAAAAAAAAAAAAAA  
AAA  
AAAAA

**FIGURE 122**

><subunit 1 of 1, 219 aa, 0 stop  
><MW: 25072, pI: 5.16, NX(S/T): 3  
MNSSKSSETQCTERGCFSQMFLWTVAGIPILFLSACFITRCVVTFRIFQTCDEKKFQLPEN  
FTELSCYNYGSGSVKNCCPLNWEYFQSSCYFFSTDТИSWALSLKNCSAMGAHLVVINSQEEQ  
EFLSYKKPKMREFFIGLSDQVVEGQWQWVDGTPLTKSLSFWDVGEPNNIATLEDATMRDSS  
NPRQNWNDVTCFLNYFRICEMVGINPLNKGKSL



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  C12N 15/12, 15/18, 15/52, C07K 14/47, 14/705, C12N 15/62, C07K 16/18, 16/28		A3	(11) International Publication Number: <b>WO 99/14328</b>
			(43) International Publication Date: 25 March 1999 (25.03.99)
(21) International Application Number: PCT/US98/19330			60/066,770 24 November 1997 (24.11.97) US 60/066,511 24 November 1997 (24.11.97) US 60/066,453 24 November 1997 (24.11.97) US 60/066,840 25 November 1997 (25.11.97) US
(22) International Filing Date: 16 September 1998 (16.09.98)			
(30) Priority Data:			(71) Applicant (for all designated States except US): GENENTECH, INC. [US/US]; One DNA Way, South San Francisco, CA 94080 (US).
60/059,115 17 September 1997 (17.09.97) US 60/059,184 17 September 1997 (17.09.97) US 60/059,122 17 September 1997 (17.09.97) US 60/059,117 17 September 1997 (17.09.97) US 60/059,113 17 September 1997 (17.09.97) US 60/059,121 17 September 1997 (17.09.97) US 60/059,119 17 September 1997 (17.09.97) US 60/059,263 18 September 1997 (18.09.97) US 60/059,266 18 September 1997 (18.09.97) US 60/062,125 15 October 1997 (15.10.97) US 60/062,287 17 October 1997 (17.10.97) US 60/062,285 17 October 1997 (17.10.97) US 60/063,486 21 October 1997 (21.10.97) US 60/062,816 24 October 1997 (24.10.97) US 60/062,814 24 October 1997 (24.10.97) US 60/063,127 24 October 1997 (24.10.97) US 60/063,120 24 October 1997 (24.10.97) US 60/063,121 24 October 1997 (24.10.97) US 60/063,045 24 October 1997 (24.10.97) US 60/063,128 24 October 1997 (24.10.97) US 60/063,329 27 October 1997 (27.10.97) US 60/063,327 27 October 1997 (27.10.97) US 60/063,549 28 October 1997 (28.10.97) US 60/063,541 28 October 1997 (28.10.97) US 60/063,550 28 October 1997 (28.10.97) US 60/063,542 28 October 1997 (28.10.97) US 60/063,544 28 October 1997 (28.10.97) US 60/063,564 28 October 1997 (28.10.97) US 60/063,734 29 October 1997 (29.10.97) US 60/063,738 29 October 1997 (29.10.97) US 60/063,704 29 October 1997 (29.10.97) US 60/063,435 29 October 1997 (29.10.97) US 60/064,215 29 October 1997 (29.10.97) US 60/063,735 29 October 1997 (29.10.97) US 60/063,732 29 October 1997 (29.10.97) US 60/064,103 31 October 1997 (31.10.97) US 60/063,870 31 October 1997 (31.10.97) US 60/064,248 3 November 1997 (03.11.97) US 60/064,809 7 November 1997 (07.11.97) US 60/065,186 12 November 1997 (12.11.97) US 60/065,846 17 November 1997 (17.11.97) US 60/065,693 18 November 1997 (18.11.97) US 60/066,120 21 November 1997 (21.11.97) US 60/066,364 21 November 1997 (21.11.97) US 60/066,772 24 November 1997 (24.11.97) US 60/066,466 24 November 1997 (24.11.97) US			
(72) Inventors; and			(75) Inventors/Applicants (for US only): WOOD, William, I. [US/US]; 1400 Tarrytown Street, San Mateo, CA 94402 (US). GURNEY, Austin, L. [US/US]; One Debbie Lane, Belmont, CA 94002 (US). GODDARD, Audrey [CA/US]; 110 Congo Street, San Francisco, CA 94131 (US). PENNICA, Diane [US/US]; 2417 Hale Drive, Burlingame, CA 94010 (US). CHEN, Jian [CN/US]; 1860 Ogden Drive #14, Burlingame, CA 94010 (US). YUAN, Jean [CN/US]; 176 West 37th Avenue, San Mateo, CA 94403 (US).
(74) Agents: DREGER, Walter, H. et al.; Flehr, Hohbach, Test, Albritton & Herbert LLP, Suite 3400, 4 Embarcadero Center, San Francisco, CA 94111-4187 (US).			
(81) Designated States:			AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(88) Date of publication of the international search report:			15 June 2000 (15.06.00)
(54) Title: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME			
(57) Abstract			
<p>The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptides molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International Application No

PCT, US 98/19330

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 6	C12N15/12	C12N15/18	C12N15/52	C07K14/47	C07K14/705
	C12N15/62	C07K16/18	C07K16/28		

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL - EMROD [Online]            Entry Cg48852, Acc.no. U48852,            18 March 1996 (1996-03-18)            CHEN H. ET AL.: "Cricetulus griseus HT            protein mRNA, complete cds."            XP002095039            the whole document</p> <p>---</p>	1,5-11
X	<p>DATABASE EMBL - EMEST15 [Online]            Entry Hsaa42749, Acc.no. AA242749,            19 March 1997 (1997-03-19)            HILLIER L. ET AL.: "zr65g02.s1 Soares            NhHMPu S1 Homo sapiens cDNA clone 668306            3' similar to TR:G1216486 G1216486 HT            PROTEIN."            XP002095040            the whole document</p> <p>---</p> <p>-/-</p>	1,5



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

1 March 1999

Date of mailing of the international search report

13.07.99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/19330

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KLEIN R D ET AL: "Selection for genes encoding secreted proteins and receptors" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, no. 93, July 1996 (1996-07), page 7108 7108 XP002077277 abstract; figure 1B ---	
A	REVELLE B M ET AL: "SINGLE AMINO ACID RESIDUES IN THE E- AND P-SELECTIN EPIDERMAL GROWTH FACTOR DOMAINS CAN DETERMINE CARBOHYDRATE BINDING SPECIFICITY" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 27, 5 July 1996 (1996-07-05), pages 16160-16170, XP000644685 the whole document -----	

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/19330

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 39, and 38 in as far as it relates to *in vivo* use, are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See Additional sheet.

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Claims 1-18, all partially.

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: Invention 1: claims 1-18 all partially

The isolated native protein designated PRO211 or a protein with at least 80% homology thereto, nucleic acid encoding it, vector comprising said nucleic acid, host cell comprising said vector, process for the production of said protein using said host, chimeric peptide comprising said protein, and an antibody against said peptide.

2. Claims: Inventions 2-59: claims 1-18 all partially

Inventions 2-59: Idem as subject 1 but limited to each of the designated proteins, where invention 2 is limited to PRO217, invention 3 is limited to PRO230, invention 4 is limited to PRO232, invention 5 is limited to PRO187, invention 6 is limited to PRO265, invention 7 is limited to PRO219, invention 8 is limited to PRO246, invention 9 is limited to PRO533, invention 10 is limited to PRO245, invention 11 is limited to PRO220, invention 12 is limited to PRO221, invention 13 is limited to PRO227, invention 14 is limited to PRO258, invention 15 is limited to PRO266, invention 16 is limited to PRO269, invention 17 is limited to PRO287, invention 18 is limited to PRO214, invention 19 is limited to PRO317, invention 20 is limited to PRO301, invention 21 is limited to PRO224, invention 22 is limited to PRO222, invention 23 is limited to PRO234, invention 24 is limited to PRO231, invention 25 is limited to PRO229, invention 26 is limited to PRO238, invention 27 is limited to PRO233, invention 28 is limited to PRO223, invention 29 is limited to PRO235, invention 30 is limited to PRO236, invention 31 is limited to PRO262, invention 32 is limited to PRO239, invention 33 is limited to PRO257, invention 34 is limited to PRO260, invention 35 is limited to PRO263, invention 36 is limited to PRO270, invention 37 is limited to PRO271, invention 38 is limited to PRO272, invention 39 is limited to PRO294, invention 40 is limited to PRO295, invention 41 is limited to PRO293, invention 42 is limited to PRO247,

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

invention 43 is limited to PR0302,  
invention 44 is limited to PR0303,  
invention 45 is limited to PR0304,  
invention 46 is limited to PR0307,  
invention 47 is limited to PR0343,  
invention 48 is limited to PR0328,  
invention 49 is limited to PR0335,  
invention 50 is limited to PR0331,  
invention 51 is limited to PR0326,  
invention 52 is limited to PR0332,  
invention 53 is limited to PR0334,  
invention 54 is limited to PR0346,  
invention 55 is limited to PR0268,  
invention 56 is limited to PR0330,  
invention 57 is limited to PR0339,  
invention 58 is limited to PR0310,  
invention 59 is limited to PR0244.

For the sake of conciseness, the first subject matter is explicitly defined, the other subject matters are defined by analogy thereto.

3. Claims: Invention 60: claims 1-18 partially,  
and claims 19-39 completely.

The isolated native protein designated PR0228 or a protein with at least 80% homology thereto, nucleic acid encoding it, vector comprising said nucleic acid, host cell comprising said vector, process for the production of said protein using said host, chimeric peptide comprising said protein, and an antibody against said peptide. Also method of inducing apoptosis of tumour cells using said protein.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 206

Continuation of Box 3.

Although claims 39, and 38 in as far as it relates to in vivo use, are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----